KR20080068117A - Novel pyridopyrazines and their use as modulators of kinases - Google Patents

Novel pyridopyrazines and their use as modulators of kinases Download PDF

Info

Publication number
KR20080068117A
KR20080068117A KR1020087014068A KR20087014068A KR20080068117A KR 20080068117 A KR20080068117 A KR 20080068117A KR 1020087014068 A KR1020087014068 A KR 1020087014068A KR 20087014068 A KR20087014068 A KR 20087014068A KR 20080068117 A KR20080068117 A KR 20080068117A
Authority
KR
South Korea
Prior art keywords
alkyl
nhc
heterocyclyl
group
heteroaryl
Prior art date
Application number
KR1020087014068A
Other languages
Korean (ko)
Other versions
KR101400905B1 (en
Inventor
에크하르트 클라우스
이레네 자이펠트
에크하르트 귄터
엠마누엘 폴리메로포울로스
미하엘 체흐
틸만 슈스터
Original Assignee
아에테르나 젠타리스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05024693A external-priority patent/EP1785423A1/en
Application filed by 아에테르나 젠타리스 게엠베하 filed Critical 아에테르나 젠타리스 게엠베하
Publication of KR20080068117A publication Critical patent/KR20080068117A/en
Application granted granted Critical
Publication of KR101400905B1 publication Critical patent/KR101400905B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Abstract

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), their preparation and use as medicaments, in particular for the treatment of malignant and other disorders involving pathological cell proliferations.

Description

신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도{Novel pyridopyrazines and their use as modulators of kinases}Novel pyridopyrazines and their use as modulators of kinases

본 발명은 피리도[2,3-b]피라진 형태의 키나제 조절제 및 이의 제조 방법 및 잘못 지시된 세포 신호전달 프로세스의 조절을 위한, 특히 티로신 키나제, 세린/트레오닌 키나제 및 지질 키나제의 기능에 영향을 주기 위한, 및 악성 또는 양성 종양종 및 병리학적 세포 증식을 기초로 하는 다른 장애, 예를 들면, 재협착, 건선, 아테롬성 동맥경화증 및 간경화의 치료를 위한 약제로서의 용도에 관한 것이다. The present invention affects the function of tyrosine kinases, serine / threonine kinases and lipid kinases, particularly for the control of kinase modulators in the form of pyrido [2,3-b] pyrazine and methods for their preparation and for misdirected cellular signaling processes. The present invention relates to a cycle and to use as a medicament for the treatment of malignant or benign tumors and other disorders based on pathological cell proliferation, such as restenosis, psoriasis, atherosclerosis and cirrhosis of the liver.

단백질 키나제의 활성화는 세포 신호전달 프로세스에서 중추적 이벤트이다. 이상 키나제 활성화는 다양한 병리학적 상태에서 관찰된다. 키나제의 표적화 억제는 이에 따라 근본적 치료학적 목적이다. Activation of protein kinases is a pivotal event in cellular signaling processes. Aberrant kinase activation is observed in various pathological conditions. Targeting inhibition of kinases is thus a fundamental therapeutic goal.

단백질의 인산화는 일반적으로 세포외 신호에 의해 초기화되고, 다양한 세포 이벤트, 예를 들면, 대사 프로세스, 세포 성장, 세포 이동, 세포 분화, 막 전달 및 아폽토시스를 조절하기 위한 일반적인 기작을 나타낸다. 키나제 단백질 패밀리는 단백질 인산화에 기인한다. 이들은 포스페이트의 특이 기질 단백질로의 이동을 촉 매한다. 기질 특이성에 기초하여, 키나제는 3개의 주요 부류, 티로신 키나제, 세린/트레오닌 키나제 및 지질 키나제로 분류된다. 수용체 티로신 키나제 및 세포질 티로신, 세린/트레오닌 및 지질 키나제 둘 다는 세포 신호전달에서 중요한 단백질이다. 이들 단백질의 과발현 또는 변성은 병리학적 세포 증식에 기초한 장애에서 중요한 부분이다. 이는 대사 장애, 연결 조직 및 혈관의 장애, 및 악성 및 양성 종양종을 포함한다. 종양 초기화 및 발달에서, 이들은 종종 종양유전자로서, 즉 이상 조직적 활성 키나제 단백질로서 발생한다. 이러한 과도한 키나제 활성화의 결과는, 예를 들면, 조절되지 않은 세포 성장 및 감소된 세포사이다. 종양-유도된 성장 인자의 자극은 또한 키나제의 과자극의 원인일 수 있다. 키나제 조절제의 발달은 이에 따라 특히 키나제에 의해 영향을 받는 모든 발병 프로세스에서 중요하다. Phosphorylation of proteins is generally initiated by extracellular signals and represents a general mechanism for regulating various cellular events such as metabolic processes, cell growth, cell migration, cell differentiation, membrane delivery and apoptosis. The kinase protein family is due to protein phosphorylation. They catalyze the transfer of phosphates to specific substrate proteins. Based on substrate specificity, kinases are classified into three major classes, tyrosine kinases, serine / threonine kinases and lipid kinases. Receptor tyrosine kinases and cytoplasmic tyrosine, serine / threonine and lipid kinases are both important proteins in cellular signaling. Overexpression or degeneration of these proteins is an important part of disorders based on pathological cell proliferation. This includes metabolic disorders, disorders of connective tissue and blood vessels, and malignant and benign tumors. In tumor initialization and development, they often occur as oncogenes, i.e. as aberrant systemically active kinase proteins. The result of such excessive kinase activation is, for example, unregulated cell growth and reduced cell death. Stimulation of tumor-induced growth factors may also be a cause of kinase hyperstimulation. The development of kinase modulators is thus important, especially in all pathogenic processes affected by kinases.

ras-Raf-Mek-Erk 및 PI3K-Akt 신호전달 캐스케이드는 세포 성장, 세포 증식, 아폽토시스, 부착, 이동 및 글루코스 대사에서 중추적 역할을 한다. 따라서, 장애, 예를 들면, 암, 신경변성 및 염증성 장애의 발병기전에서 기본적인 관련성은 ras-Raf-Mek-Erk 및 PI3K-Akt 신호경로 둘 다에서 증명된다. 따라서, 이들 신호 캐스케이드의 개별적인 성분은 다양한 질환 프로세스에서 개입하여 중요한 치료학적 발병 지점을 구성한다[참조: Weinstein-Oppenheimer C.R. et al 2000, Chang F. et al 2003, Katso R. et al 2001 and Lu Y. et al 2003]. The ras-Raf-Mek-Erk and PI3K-Akt signaling cascades play a pivotal role in cell growth, cell proliferation, apoptosis, adhesion, migration and glucose metabolism. Thus, a fundamental relevance in the pathogenesis of disorders such as cancer, neurodegeneration and inflammatory disorders is demonstrated in both ras-Raf-Mek-Erk and PI3K-Akt signaling pathways. Thus, the individual components of these signal cascades intervene in a variety of disease processes to constitute an important therapeutic point of occurrence. See Weinstein-Oppenheimer C.R. et al 2000, Chang F. et al 2003, Katso R. et al 2001 and Lu Y. et al 2003].

2개의 신호경로의 분자 및 생화학적 특성은 먼저 하기에 개별적으로 기재될 수 있다 The molecular and biochemical properties of the two signal pathways can first be described separately below.

다수의 성장 인자, 사이토킨 및 종양유전자는 이의 성장-촉진 신호를 G-단백질-결합된 ras의 활성화를 통해 도입하고, 이는 세린-트레오닌 키나제 Raf의 활성화 및 미토겐-활성화된 단백질 키나제 키나제 1 및 2(MAPKK1/2 또는 Mek1/2)의 활성화를 야기하고, 인산화 및 세포외 신호-조절된 키나제(Erk1 및 2)로 공지된 MAPK 1 및 2의 활성화를 야기한다. 다른 신초 경로와 비교하여, ras-Raf-Mek-Erk 신호경로는 리간드, 티로신 키나제 수용체, G 단백질, 키나제 및 핵 전사 인자를 포함하는 다수의 원종양유전자와 관련된다. 티로신-키나제, 예를 들면, EGFR[참조: Mendelsohn J. et al., 2000]는 종양 프로세스의 과정에서, 과발현 및 돌연변이에 의해 야기되어, 다운스트림 ras-Raf-Mek-Erk 신호경로에 대한 종종 구조적 활성 신호를 매재한다. Ras 돌연변이는 모든 사람 종양의 30%를 돌연변이하고[참조: Khleif S.N. et al., 1999, Marshall C., 1999], 췌장 암종에서 90%의 가장 높게 발생된다[참조: Friess H. et al., 1996, Sirivatanauksorn V. et al., 1998]. c-Raf의 경우, 조절되지 않은 발현 및/또는 활성화는 다양한 종양에서 기술된다[참조: Hoshino R. et al., 1999, McPhillips F. et al., 2001]. B-Raf 지점 돌연변이는 모든 사람 악성 흑색종의 66%, 난소 암종의 14% 및 결장 암종의 12%에서 검출된다[참조: Davies H. et al., 2002]. 따라서, Erk1/2가 다수의 세포 프로세스의 기본 단계, 예를 들면, 세포 성장, 세포 증식 및 세포 분화에 관련되어 있다는 것을 놀랍운 것이 아니다[참조: Lewis T.S. et al., 1998, Chang F. et al., 2003]. Many growth factors, cytokines and oncogenes introduce their growth-promoting signals through activation of G-protein-bound ras, which activates serine-threonine kinase Raf and mitogen-activated protein kinase kinases 1 and 2 Causing activation of (MAPKK1 / 2 or Mek1 / 2) and the activation of MAPK 1 and 2, known as phosphorylation and extracellular signal-regulated kinases (Erk1 and 2). In comparison to other shoot pathways, the ras-Raf-Mek-Erk signaling pathway is associated with a number of proto-oncogenes including ligands, tyrosine kinase receptors, G proteins, kinases and nuclear transcription factors. Tyrosine-kinases, such as EGFR (Mendelsohn J. et al., 2000), are often caused by overexpression and mutations in the course of tumor processes, often for downstream ras-Raf-Mek-Erk signaling pathways. Embed a structural activity signal. Ras mutations mutated 30% of all human tumors [Kleif S.N. et al., 1999, Marshall C., 1999], the highest incidence of 90% in pancreatic carcinoma (Friess H. et al., 1996, Sirivatanauksorn V. et al., 1998). In the case of c-Raf, unregulated expression and / or activation is described in various tumors (Hosino R. et al., 1999, McPhillips F. et al., 2001). B-Raf point mutations are detected in 66% of all human malignant melanoma, 14% of ovarian carcinoma and 12% of colon carcinoma (Davies H. et al., 2002). Thus, it is not surprising that Erk1 / 2 is involved in the basic stages of many cellular processes, such as cell growth, cell proliferation and cell differentiation. See Lewis T.S. et al., 1998, Chang F. et al., 2003].

또한, Raf 키나제의 원소는 또한 Mek-Erk-의존, 항-세포사 작용을 갖고, 이의 분자 단계는 아직 충분히 기술되지 않았다. Mek-Erk-의존 Raf 활성에 대해 기 술된 가능한 상호작용 파트너는 Ask1, Bcl-2, Akt 및 Bag1이다[참조: Chen J et al., 2001, Troppmaier J. et al., 2003, Rapp U.R. et al., 2004, Gotz R. et al., 2005]. Mek-Erk-의존 및 Mek-Erk-의존 신호전달 기작 둘 다는 업스트림 ras 및 Raf 자극의 활성화를 조절하는 것으로 추정된다. In addition, the elements of Raf kinases also have Mek-Erk-dependent, anti-cell death, whose molecular steps have not been fully described yet. Possible interaction partners described for Mek-Erk-dependent Raf activity are Ask1, Bcl-2, Akt and Bag1. See Chen J et al., 2001, Troppmaier J. et al., 2003, Rapp U.R. et al., 2004, Gotz R. et al., 2005]. Both Mek-Erk-dependent and Mek-Erk-dependent signaling mechanisms are presumed to regulate the activation of upstream ras and Raf stimuli.

포스파티딜이노시톨 3-키나제(PI3Ks)의 동종효소는 기본적으로 지질 키나제로서 작용하고, 제2 전령 지질 PtdIns(포스파티딜이노시톨)에서 PtdIns(3)P, PtdIns(3,4)P2, PtdIns(3,4,5)P3 포스파티딜이노시톨 포스페이트로의 D3인산화를 촉매한다. 부류 I의 PI3Ks는 촉매적 아단위(p110알파, 베타, 감마, 델타) 및 조절 아단위(p85알파, 베타 또는 p101감마)의 구조적 관점에서 구성된다. 또한, 부류 II(PI3K-C2알파, PI3K-C2베타) 및 부류 III(Vps34p) 효소는 PI3 키나제의 패밀리를 갖는다[참조: Wymann M.P. et al., 1998, VanHaesebroeck B. et al., 2001]. PI3K에 의해 유도되는 PIP 상승은 먼저 증식성 ras-Raf-Mek-Erk 신호경로를 ras의 커프링을 통해 활성화시키고[참조: Rodriguez-Viciana P. et al., 1994], 부차적으로 Akt를 세포 막으로 동원하고, 후속적으로 당해 키나제를 과발현시켜 항-세포사 신호경로를 자극한다[참조: Alessi D.R. et al., 1996, Chang H.W. et al., 1997, Moore S.M. et al., 1998]. 따라서, PI3Ks의 활성화는 종양 발달의 적어도 2개의 중요한 기작, 특히 세포 성장 및 세포 분화의 활성화, 및 아폽토시스의 억제을 수행한다. 또한, PI3Ks는 또한 단백질-포스포릴화 특성을 갖고[참조: Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, VanHaesebroeck B. et al., 1999], 이는 예를 들면, 본질적으로 PI3Ks를 조절하는 세린 자동인산화를 유 도할 수 있다. 또한 PI3Ks는 심장 수축의 조절에서 키나제-의존, 조절 효과기 특성인 것이 공지되어 있다[참조: Crackower M.A. et al., 2002, Patrucco etal., 2004]. 또한, PI3K델타 및 PI3K감마가 특이적으로 조혈 세포에서 발현되고, 이에 따라 염증성 장애, 예를 들면, 류마티스, 천식 및 알레르기의 치료에서 및 B 및 T 세포 림프종의 치료에서 동종효소-특이적 PI3K델타 및 PI3K감마 억제제에 대한 발병의 잠재적 지점인 것이 증명되었다[참조: Okkenhaug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005]. 최근 원종양유전자로서 확인된[참조: Shayesteh L. et al., 1999, Ma Y.Y. et al., 2000, Samuels Y. et al., 2004, Campbell I.G. et al., 2004, Levine D.A., 2005] PI3K알파는 종양 장애의 치료에서 중요한 표적이다. 활성 성분 발달에 대한 표적으로서 PI3K 종의 중요성이 이에 따라 극도로 넓어진다[참조: Chang F. & Lee J.T. et al, 2003].Homozymes of phosphatidylinositol 3-kinase (PI3Ks) basically act as lipid kinases, and PtdIns (3) P, PtdIns (3,4) P2, PtdIns (3,4,) in the second messenger lipid PtdIns (phosphatidyl inositol) 5) Catalyzes D3 phosphorylation to P3 phosphatidylinositol phosphate. Class I PI3Ks are constructed from the structural point of view of catalytic subunits (p110 alpha, beta, gamma, delta) and regulatory subunits (p85 alpha, beta or p101 gamma). In addition, Class II (PI3K-C2alpha, PI3K-C2beta) and Class III (Vps34p) enzymes have a family of PI3 kinases. See Wymann M.P. et al., 1998, Van Haesebroeck B. et al., 2001]. PIP elevation induced by PI3K first activates the proliferative ras-Raf-Mek-Erk signaling pathway through ras cuffing (Rodrigue-Viciana P. et al., 1994), and secondary Akt to cell membranes. And subsequently overexpress this kinase to stimulate anti-cell death signaling pathways. See Alessi DR. et al., 1996, Chang H.W. et al., 1997, Moore S.M. et al., 1998]. Thus, activation of PI3Ks performs at least two important mechanisms of tumor development, in particular activation of cell growth and cell differentiation, and inhibition of apoptosis. In addition, PI3Ks also have protein-phosphorylation properties (Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, VanHaesebroeck B. et al., 1999). This may lead to, for example, serine autophosphorylation, which essentially regulates PI3Ks. It is also known that PI3Ks are kinase-dependent, regulatory effector properties in the regulation of heart contraction. See Crackower M.A. et al., 2002, Patrucco et al., 2004]. In addition, PI3Kdelta and PI3Kgamma are specifically expressed in hematopoietic cells, thus homozyme-specific PI3Kdelta in the treatment of inflammatory disorders such as rheumatoid, asthma and allergy and in the treatment of B and T cell lymphomas. And a potential point of onset for PI3Kgamma inhibitors (Okkenhaug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005). Recently identified as a proto-oncogene [Shayesteh L. et al., 1999, Ma Y.Y. et al., 2000, Samuels Y. et al., 2004, Campbell I.G. et al., 2004, Levine D.A., 2005] PI3Kalpha is an important target in the treatment of tumor disorders. The importance of the PI3K species as a target for active ingredient development thus broadens accordingly. Chang F. & Lee J.T. et al, 2003].

PI3K-관련 키나제(PIKKs)가 동등하게 중요하고, 이는 세린/트레오닌 키나제 mTOR, ATM, ATR, h-SMG-1 및 DNA-PK를 포함한다[참조: Chiang G.G. et al 2004]. 이의 촉매적 도메인은 PI3Ks의 촉매적 도메인과 높은 서열 상동성을 갖는다. PI3K-related kinases (PIKKs) are equally important, including serine / threonine kinase mTOR, ATM, ATR, h-SMG-1 and DNA-PK. See Chiang G.G. et al 2004]. Its catalytic domain has high sequence homology with the catalytic domain of PI3Ks.

또한, 종양 억제인자 단백질 PTEN의 손실[참조: Li J. et al., 1997, Steck P.A. et al., 1997]은, PI3K에 의해 초기화된 인산화의 역전 기능을 하고, Akt의 과활성 및 이의 다운스트림 캐스케이드 성분을 야기하고, 이에 따라, 종양 치료용 표적 분자로서 PI3K의 인과적 중요성을 강조한다. In addition, loss of the tumor suppressor protein PTEN [Li J. et al., 1997, Steck P.A. et al., 1997], invert the function of phosphorylation initiated by PI3K and cause overactivity of Akt and its downstream cascade components, thus highlighting the causal importance of PI3K as a target molecule for tumor treatment. do.

ras-Raf-Mek-Erk 및 PI3K-Akt 신호경로의 개별적인 성분의 다양한 억제제는 이미 공개되어 있고 특허되어 있다. Various inhibitors of the individual components of the ras-Raf-Mek-Erk and PI3K-Akt signaling pathways are already published and patented.

키나제-억제제, 특히 ras-Raf-Mek-Erk 및 PI3K-Akt 경로에 대한 분야의 현재 발달 상태는 문헌에 평가되어 있다[참조: the reviews by J.S. Sebolt-Leopold et al., 2004, and R. Wetzker et al., 2004]. 당해 문헌은 저분자량 ras-Raf-Mek-Erk 및 PI3K 억제제의 합성 및 용도를 기재하는 특허의 광범위한 리스트를 포함한다. Current developments in the field of kinase-inhibitors, particularly the ras-Raf-Mek-Erk and PI3K-Akt pathways, have been assessed in the reviews by the reviews by J.S. Sebolt-Leopold et al., 2004, and R. Wetzker et al., 2004]. This document contains an extensive list of patents describing the synthesis and use of low molecular weight ras-Raf-Mek-Erk and PI3K inhibitors.

키나제 억제제 Bay 43-9006(WO 99/32111, WO 03/068223)는 이미 임상 시험에서 세린/트레오닌 키나제 및 티로신 키나제, 예를 들면, Raf, VEGFR2/3, Flt-3, PDGFR, c-Kit 및 추가 키나제의 비교적 비특이 억제 패턴을 나타낸다. 혈관형성(예를 들면, 신장 세포 암종의 경우)에 의해 유도된 진행 종양 장애에서 뿐만 아니라 높은 B-Raf 돌연변이 속도를 갖는 흑색종의 경우에 이러한 억제제에 상당히 영향을 미친다. Bay 43-9006의 임상적 작용은 현재 또한 예를 들면, 도세탁셀과 배합한 무반응 고형 종양을 갖는 환자에서 측정되었다. 지금까지, 온화한 부작용 및 전도유망한 항-종양 효과가 기재되어 있다. PI3K-Akt 신호경로에서 키나제의 억제는 Bay 43-9006에 기재되거나 나타나지 않았다.Kinase inhibitors Bay 43-9006 (WO 99/32111, WO 03/068223) have already been tested in clinical trials for serine / threonine kinases and tyrosine kinases such as Raf, VEGFR2 / 3, Flt-3, PDGFR, c-Kit and A relatively nonspecific inhibition pattern of additional kinases. It significantly affects these inhibitors in melanoma with high B-Raf mutation rates as well as in advanced tumor disorders induced by angiogenesis (eg for renal cell carcinoma). The clinical action of Bay 43-9006 has now also been measured in patients with unresponsive solid tumors, for example in combination with docetaxel. To date, mild side effects and promising anti-tumor effects have been described. Inhibition of kinases in the PI3K-Akt signaling pathway was not described or shown in Bay 43-9006.

Mek1/2 억제제PD0325901(WO 02/06213)는 현재 I기 임상 시험 중이다. 전구체 물질 CI-1040(WO 00/35435, WO 00/37141)은 이의 높은 Mek 특이성 및 표적 친화도에 의해 인지되었다. 그러나, 이들 화합물은 I/II기 연구에서 대사적으로 불안정한 것으로 밝혀졌다. 현재 후임의 물질 PD0325901에 대한 임상 데이타는 여전히 시행중이다. 그러나, Erk1 또는 Erk2와의 상호작용과 PI3K-Akt 신호경로를 억제하는 작용 또는 이의 동시 조절은 이러한 Mek 억제제에 대해 공개되거나 나타난 적이 없다. Mek1 / 2 inhibitor PD0325901 (WO 02/06213) is currently in Phase I clinical trial. Precursor material CI-1040 (WO 00/35435, WO 00/37141) was recognized by its high Mek specificity and target affinity. However, these compounds have been found to be metabolically labile in phase I / II studies. Clinical data for the successor substance PD0325901 is still in force. However, the interaction with Erk1 or Erk2 and the inhibition or PI regulation of PI3K-Akt signaling pathways have not been disclosed or shown for these Mek inhibitors.

지금까지 공개된 PI3K 억제제는 여전히 임상전 시험중이다. ICOS는 높은 PI3K델타 동종효소 특이성을 갖는 PI3K 억제제 IC87114를 나타낸다(WO 01/81346). PI103(WO 04/017950)(Yamanouchi/Piramed)는 선택도 대 PI3K알파 이소형을 기재하고 있다. 그러나, 연구에서 높게 나타난 분야는 PI3K 억제제의 조기 발달에 존재한다[참조: review of R. Wetzker et al., 2004].The PI3K inhibitors disclosed so far are still in preclinical trials. ICOS represents PI3K inhibitor IC87114 with high PI3Kdelta isoenzyme specificity (WO 01/81346). PI103 (WO 04/017950) (Yamanouchi / Piramed) describes selectivity versus PI3Kalpha isoform. However, a high field in the study exists in the early development of PI3K inhibitors (review of R. Wetzker et al., 2004).

Jnk 또는 p38의 SAPK 신호경로의 억제제는 문헌에 기재되어 있다[참조: Gum R.J., 1998, Bennett B.L. et al 2001, Davies S.P. et al 2000]. 그러나, PI3K을 억제하는 작용 또는 Erk1 또는 Erk2의 특이 억제 또는 그외의 SAPKs, Erk1, Erk2, 또는 PI3K의 특이 억제는 이들 SAPK 억제제에 대해 나타난 적이 없다.Inhibitors of the SAPK signaling pathway of Jnk or p38 have been described in Gum R.J., 1998, Bennett B.L. et al 2001, Davies S.P. et al 2000]. However, no action to inhibit PI3K or specific inhibition of Erk1 or Erk2 or other specific inhibition of SAPKs, Erk1, Erk2, or PI3K has been shown for these SAPK inhibitors.

6- 또는 7-치환된 피리도[2,3-b]피라진 유도체는 약리학적 활성 화합물로서 및 합성 단위로서 약제학적 화학에서의 광범위한 농도가 밝혀졌다. 6- or 7-substituted pyrido [2,3-b] pyrazine derivatives have been found to have broad concentrations in pharmaceutical chemistry as pharmacologically active compounds and as synthetic units.

예를 들면, WO 04/104002 및 WO 04/104003은 우레아, 티오우레아, 아미딘 또는 구아니딘 그룹에 의해 6- 또는 7-치환될 수 있는 피리도[2,3-b]피라진을 기재한다. 이들 화합물은 키나제, 특히 티로신 및 세린/트레오닌 키나제의 억제제 또는 조절제로서 특징을 갖고, 약제로서의 용도가 보고되어 있다. 대조적으로, 단독으로 또는 티로신 및 세린/트레오닌 키나제와 배합한 이들 화합물의 지질 키나제로서의 용도는 기재되어 있지 않다. For example, WO 04/104002 and WO 04/104003 describe pyrido [2,3-b] pyrazine which can be 6- or 7-substituted by urea, thiourea, amidine or guanidine groups. These compounds are characterized as inhibitors or modulators of kinases, in particular tyrosine and serine / threonine kinases, and their use as a medicament has been reported. In contrast, the use of these compounds as lipid kinases, alone or in combination with tyrosine and serine / threonine kinases, is not described.

또한, WO 99/17759는 6-위치에서 특히 알킬-, 아릴- 및 헤테로아릴-치환된 카바메이트를 갖는 피리도[2,3-b]피라진을 기재한다. 이들 화합물은 세린-트레오 닌 단백질 키나제의 작용을 조절하기 위한 용도를 의도한다. WO 99/17759 also describes pyrido [2,3-b] pyrazine with the alkyl-, aryl- and heteroaryl-substituted carbamate in the 6-position. These compounds are intended for use to modulate the action of serine-threonine protein kinases.

WO 05/007099(Kawakami et al.)는 특히 우레아-치환된 피리도[2,3-b]피라진를 세린/트레오닌 키나제 PKB의 억제제로서 기재한다. 그러나, 이 출원은 추가로 R 라디칼를 한정하지 않았고, 여기서, 우레아에 치환 범위는 기재되어야 하지만, 우레아의 치환 범위는 명백히 나타내지 않았다. 이들 화합물의 경우, 암 장애의 치료에서 용도는 보고되어 있다. 그러나, 이들 생물학적 특성을 갖는 우레아-치환된 피리도피라진의 구체적인 실시가 제공되어 있지 않다. 또한, 이에 기재된 피리도피라진은 본 발명의 피리도[2,3-b]피라진과 구조적으로 상당히 상이하다. WO 05/007099 (Kawakami et al.) Describes in particular urea-substituted pyrido [2,3-b] pyrazine as an inhibitor of serine / threonine kinase PKB. However, this application did not further limit the R radicals, where the range of substitution for urea should be described, but the range of substitution of urea was not explicitly indicated. For these compounds, their use in the treatment of cancer disorders has been reported. However, no specific implementation of urea-substituted pyridopyrazines having these biological properties is provided. In addition, the pyridopyrazine described herein is significantly different in structure from the pyrido [2,3-b] pyrazine of the present invention.

6- 및 7-우레아-치환된 피리도[2,3-b]피라진의 추가 실시는 WO 05/056547(Bemis et al.)에 보고되어 있다. 그러나, 이 특허의 화합물은 2- 또는 3-위치에서 추가의 카보닐, 설폭시, 설폰 또는 이민 치환을 갖고, 본원에 기재된 본 발명의 피리도[2,3-b]피라진과 구조적으로 현저히 상이함을 의미한다. WO 05/056547에 보고된 피리도피라진은 단백질 키나제, 특히 GSK-3, Syk 및 JAK-3의 억제제로서 기재되어 있다. 이러한 화합물의 경우, 보고된 용도는 증식성 장애의 치료에서 용도를 포함한다. 단독으로 또는 세린/트레오닌 키나제와 배합한 지질 키나제의 조절제로서 이들 화합물의 용도가 기재되어 있다. Further implementations of 6- and 7-urea-substituted pyrido [2,3-b] pyrazine are reported in WO 05/056547 (Bemis et al.). However, the compounds of this patent have further carbonyl, sulfoxy, sulfone or imine substitutions in the 2- or 3-position and are structurally significantly different from the pyrido [2,3-b] pyrazine of the invention described herein. It means. Pyridopyrazines reported in WO 05/056547 are described as inhibitors of protein kinases, in particular GSK-3, Syk and JAK-3. For such compounds, reported uses include the use in the treatment of proliferative disorders. The use of these compounds is described alone or as modulators of lipid kinases, in combination with serine / threonine kinases.

WO 04/005472(White et al.)는 특히 항균성 물질로서 박테리아의 성장을 억제하는 6-카바메이트-치환된 피리도[2,3-b]피라진을 기재하고 있다. 항종양 작용이 기재되어 있지 않다. WO 04/005472 (White et al.) Describes 6-carbamate-substituted pyrido [2,3-b] pyrazine which inhibits the growth of bacteria, in particular as an antimicrobial substance. Antitumor action is not described.

추가적으로 또한 우레아 또는 카바메이트 치환을 6- 또는 7-위치에서 가질 수 있는, 페닐 환에 특정 알킬피롤리딘, 알킬피페리딘 또는 알킬설폰아미드 라디칼를 갖는 특정한 디페닐퀴녹살린 및 -피리도[2,3-b]피라진은 WO 03/084473(Barnett et al.), WO 03/086394(Bilodeau et al.) 및 WO 03/086403(Lindsley et al.)에 세린/트레오닌 키나제 Akt 활성의 억제제로서 기재되어 있다. 이들 화합물의 경우, 암 장애를 치료하기 위한 용도가 보고되었다. 이에 기재된 피리도[2,3-b]피라진 실시 화합물의 경우, 생물학적 작용의 한정된 지시가 명시되어 있지 않다. 또한, 본 발명에 기재된 본 발명의 피리도[2,3-b]피라진과 구조적으로 현저하게 상이하다. Additionally, certain diphenylquinoxalines and -pyrido [2, with specific alkylpyrrolidine, alkylpiperidine or alkylsulfonamide radicals in the phenyl ring, which may also have a urea or carbamate substitution at the 6- or 7-position; 3-b] pyrazine has been described in WO 03/084473 (Barnett et al.), WO 03/086394 (Bilodeau et al.) And WO 03/086403 (Lindsley et al.) As inhibitors of serine / threonine kinase Akt activity. have. For these compounds, their use for treating cancer disorders has been reported. For the pyrido [2,3-b] pyrazine working compounds described herein, no limited indication of biological action is specified. It is also structurally significantly different from the pyrido [2,3-b] pyrazine of the present invention described in the present invention.

또한, WO 03/024448(Delorme et al.)은 또한 카바메이트를 추가의 치환체로서 함유하고, 세포 증식 장애의 치료용으로 히스톤 데아세틸라제 억제제로서 사용될 수 있는 아미드- 및 아크릴아미드-치환된 피리도[2,3-b]피라진을 기재하고 있다.In addition, WO 03/024448 (Delorme et al.) Also contains carbamate as an additional substituent, and amide- and acrylamide-substituted pyrido can be used as a histone deacetylase inhibitor for the treatment of cell proliferative disorders. [2,3-b] pyrazine is described.

추가로 문헌[참조: C. Temple, Jr.; J. Med. Chem. 1990, 3044-3050]에는 6-에틸 카바메이트-치환된 피리도[2,3-b]피라진 유도체의 합성을 지개하는 실시가 사용된다. 항종양 작용은 기재되지 않았고 분명하지 않다.See also, C. Temple, Jr .; J. Med. Chem. 1990, 3044-3050, uses a practice to delay the synthesis of 6-ethyl carbamate-substituted pyrido [2,3-b] pyrazine derivatives. Antitumor action is not described and not clear.

6-에틸 카바메이트-치환된 피리도[2,3-b]피라진의 추가 유도체의 합성은 문헌에 기재되어 있다[참조: R. D. Elliott (J. Org. Chem. 1968, 2393-2397]. 이들 화합물의 생물학적 작용은 기재되지 않았고 분명하지 않다. The synthesis of additional derivatives of 6-ethyl carbamate-substituted pyrido [2,3-b] pyrazine is described in the literature (RD Elliott ( J. Org. Chem. 1968, 2393-2397). The biological action of is not described and is not clear.

문헌[참조: C.Temple, Jr. J. Med. Chem.1968,1216-1218]은 잠재적 활성 항말라리아 성분으로서 6-에틸 카바메이트-치환된 피리도[2,3-b]피라진의 합성 및 연 구를 기재하고 있다. 항종양 작용은 기재되지 않았고 분명하지 않다.See C. Temple, Jr. J. Med. Chem. 1968,1216-1218 describe the synthesis and study of 6-ethyl carbamate-substituted pyrido [2,3-b] pyrazine as a potential active antimalarial component. Antitumor action is not described and not clear.

발명의 설명Description of the Invention

본 발명은 따라서 수용체 티로신 키나제, 세포질 티로신 키나제, 세린/트레오닌 키나제 및 지질 키나제의 조절제로서 적합한 신규한 화합물의 제공을 지시한다. 잘못 조절된 신호전달 캐스케이드 - 예를 들면, Raf-Mek-Erk 또는 PI3K-Akt의 경우 -에서 연속으로 존재하는 모든 키나제가 종양발생 키나제로서 또는 구조적 활성 효소로서 존재할 필요는 없기 때문에, 본 발명은 또한 불활성 키나제를 치료학적 표적 단백질로서 고려하고, 즉, 신규한 화합물은 활성 및 비활성 키나제 둘 다에 결합하여 신호전달에 영향을 줄 수 있다.The present invention thus directs the provision of novel compounds suitable as modulators of receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine / threonine kinases and lipid kinases. The present invention also contemplates that not all kinases present in succession in a misregulated signaling cascade-for example Raf-Mek-Erk or PI3K-Akt-need to be present as oncogenic kinases or as structurally active enzymes. Inactive kinases are considered as therapeutic target proteins, ie, novel compounds can bind to and affect signaling by both active and inactive kinases.

본 발명은 또한 수용체 티로신 키나제, 세포질 티로신 키나제, 세린/트레오닌 키나제 및 지질 키나제의 조절제로서 하나의 개별적인 키나제 또는 2개 이상의 키나제, 특히 Erk1/2 및 PI3K, 하나의 신호전달 캐스케이드 또는 상이한 신호전달 캐스케이드, 특히 ras-Raf-Mek-Erk 및 PI3K-Akt에 영향을 주는 특징을 갖는 신규한 화합물의 제공을 지시한다. 단지 하나의 신호전달경로에서 치료학적 발병과 비교한 이중 기작, 즉, 2개 이상의 신호전달 캐스케이드의 동시 억제는, 부가적인 효과로 인해, 키나제에 의해 영향을 받는 모든 발병 프로세스의 치료에서 효과를 증가시킬 수 있다. The invention also relates to one individual kinase or two or more kinases, in particular Erk1 / 2 and PI3K, one signaling cascade or a different signaling cascade, as modulators of receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine / threonine kinases and lipid kinases, In particular, it is directed to the provision of novel compounds having characteristics affecting ras-Raf-Mek-Erk and PI3K-Akt. Dual mechanisms, ie, simultaneous inhibition of two or more signaling cascades, compared to therapeutic onset in only one signaling pathway, increase the effect in the treatment of all onset processes affected by kinases, due to additional effects. You can.

놀랍게도, 예를 들면, 우레아 또는 티오우레아 잔기에 의해 6- 또는 7-치환된 피리도[2,3-b]피라진의 그룹으로부터의 신규한 화합물이 잘못 지시된 세포 신호 전달 프로세스를 조절하기 위한, 특히 수용체 티로신 키나제, 세포질 티로신 키나제, 세린/트레오닌 키나제 및 지질 키나제의 작용에 영향을 주기 위한, 및 예를 들면, 유방, 전립샘, 폐, 피부, 난소의 악성 또는 양성 종양 장애, 및 세포 증식를 기초로하는 다른 장애를 치료하기 위한 약제를 제조하는데 적합하다는 것이 밝혀졌다. Surprisingly, for example, a novel compound from the group of pyrido [2,3-b] pyrazine 6- or 7-substituted by urea or thiourea residues can be used to modulate a cell signaling process that is misdirected. In particular for affecting the action of receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine / threonine kinases and lipid kinases, and based on, for example, malignant or benign tumor disorders of the breast, prostate, lung, skin, ovary, and cell proliferation Has been found to be suitable for the manufacture of a medicament for treating other disorders.

본 발명의 제1 양태는 화학식 I의 피리도[2,3-b]피라진의 그룹의 신규한 화합물을 기재한다.A first aspect of the invention describes a novel compound of the group of pyrido [2,3-b] pyrazine of formula (I).

Figure 112008041801646-PCT00001
Figure 112008041801646-PCT00001

상기 화학식 I에서, In Formula I,

(A) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:(A) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted aryl" wherein "substituted aryl" is substituted by one or more substituents identically or differently selected from the group consisting of: :

(a) "알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, NHX1, N(알킬)2, NHC(O)알킬, NHC(O)사이클로알킬, NHC(O)헤테로사이클릴, NHC(O)아릴, NHC(O)헤테로아릴, NHC(O)아릴알킬, NHC(O)헤테로아릴알킬, NHS(O2)알킬, NHS(O2)사이클로알킬, NHS(O2)헤테로사이클릴, NHS(O2)아릴, NHS(O2)헤테로아릴, NHS(O2)아릴알킬, NHS(O2)헤테로아릴알킬, S알킬, S아릴, S헤테로아릴, OX2, OC(O)알킬, OC(O)사이클로알킬, OC(O)헤테로사이클릴, OC(O)아릴, OC(O)헤테로아릴, OC(O)아릴알킬, OC(O)헤테로아릴알킬, OS(O2)알킬, OS(O2)사이클로알킬, OS(O2)헤테로사이클릴, OS(O2)아릴, OS(O2)헤테로아릴, OS(O2)아릴알킬, OS(O2)헤테로아릴알킬, C(O)알킬, C(O)아릴, C(O)헤테로아릴, C(O)OX3, C(O)NHX4, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, S(O)알킬, S(O)아릴, S(O2)알킬, S(O2)아릴, S(O2)NH알킬, S(O2)NH아릴, S(O2)NH헤테로아릴, S(O2)NH아릴알킬, S(O2)O알킬, S(O2)O아릴, S(O2)O아릴알킬"(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, NHX1, N (alkyl) 2 , NHC (O) alkyl, NHC (O) cycloalkyl, NHC (O) heterocyclyl, NHC (O ) Aryl, NHC (O) heteroaryl, NHC (O) arylalkyl, NHC (O) heteroarylalkyl, NHS (O 2 ) alkyl, NHS (O 2 ) cycloalkyl, NHS (O 2 ) heterocyclyl, NHS (O 2 ) aryl, NHS (O 2 ) heteroaryl, NHS (O 2 ) arylalkyl, NHS (O 2 ) heteroarylalkyl, Salkyl, Saryl, Sheteroaryl, OX 2, OC (O) alkyl, OC (O) cycloalkyl, OC (O) heterocyclyl, OC (O) aryl, OC (O) heteroaryl, OC (O) arylalkyl, OC (O) heteroarylalkyl, OS (O 2 ) alkyl, OS (O 2 ) cycloalkyl, OS (O 2 ) heterocyclyl, OS (O 2 ) aryl, OS (O 2 ) heteroaryl, OS (O 2 ) arylalkyl, OS (O 2 ) heteroarylalkyl, C ( O) alkyl, C (O) aryl, C (O) heteroaryl, C (O) OX3, C (O) NHX4, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , S (O) alkyl, S (O) aryl, S (O 2 ) alkyl, S (O 2 ) aryl, S (O 2 ) NH alkyl, S (O 2 ) NH aryl, S (O 2 ) NH heteroaryl, S (O 2 ) NH arylalkyl, S (O 2 ) O alkyl, S (O 2 ) O aryl, S (O 2 ) Oarylalkyl "

여기서, X1, X2, X3, X4는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Wherein X 1, X 2, X 3, X 4 are each independently selected from the group consisting of: “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl Alkyl "

단, 치환체 그룹(a)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "(C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, N3, NH사이클로알킬, NH사이클로알킬알킬, NH헤테로아릴, NH헤테로아릴알킬, NH아릴알킬, NH헤테로사이클릴, NH헤테로사이클릴알킬, NX5X6, S사이클로알킬, S사이클로알킬알킬, S아 릴, S아릴알킬, S헤테로아릴, S헤테로아릴알킬, S헤테로사이클릴, S헤테로사이클릴알킬, O사이클로알킬, O사이클로알킬알킬, O아릴알킬, O헤테로아릴, O헤테로아릴알킬, O헤테로사이클릴, O헤테로사이클릴알킬, O(X7-O)pX8 (p = 1, 2, 3, 4, 5), OP(O)(OX9)(OX10), C(O)OX11, C(O)NH2, C(O)NHX12, C(O)NX13X14, S(O2)X15, P(O)(OH)2, P(O)(OX16)(OX17), Si(X18)(X19)(X20), OSi(X21)(X22)(X23), OC(O)OX24, OC(O)NHX25, OC(O)NX26X27, NHC(O)OX28, NHC(O)NHX29, NHC(O)NX30X31, NX32C(O)OX33, NX34C(O)NHX35, NX36C(O)NX37X38, OS(O2)X39, NHC(O)X40, NX41C(O)X42, C(O)X43, OC(O)X44, S(O)X45, S(O2)NHX46, S(O2)NX47X48, S(O2)OX49, O(X50-O)p-H (p = 1, 2, 3, 4, 5)"(i) "(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , NHcycloalkyl, NHcyclo Alkylalkyl, NH heteroaryl, NH heteroarylalkyl, NHarylalkyl, NH heterocyclyl, NH heterocyclylalkyl, NX5X6, Scycloalkyl, Scycloalkylalkyl, Saryl, Sarylalkyl, S heteroaryl, S heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, Ocycloalkyl, Ocycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O (X7-O) p X8 (p = 1, 2, 3, 4, 5), OP (O) (OX9) (OX10), C (O) OX11, C (O) NH 2 , C (O) NHX12 , C (O) NX13X14, S (O 2 ) X15, P (O) (OH) 2 , P (O) (OX16) (OX17), Si (X18) (X19) (X20), OSi (X21) ( X22) (X23), OC (O) OX24, OC (O) NHX25, OC (O) NX26X27, NHC (O) OX28, NHC (O) NHX29, NHC (O) NX30X31, NX32C (O) OX33, NX34C ( O) NHX35, NX36C (O) NX37X38, OS (O 2 ) X39, NHC (O) X40, NX41C (O) X42, C (O) X43, OC (O) X44, S (O) X45, S (O 2 ) NHX46, S (O 2 ) NX47X48, S (O 2 ) OX49, O (X50-O) p -H (p = 1, 2, 3, 4, 5) "

추가로 단, "N(알킬)2"는 다음 치환체 그룹(b)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further provided that "N (alkyl) 2 " is further substituted by one or more substituents selected from the following substituent groups (b);

여기서, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X13, X14 및/또는 X26, X27 및/또는 X30, X31 및/또는 X37, X38 및/또는 X47, X48은 또 한 함께 "헤테로사이클릴"을 형성할 수 있고,Where X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50 are each independently composed of Selected from the group: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein the alternative X13, X14 and / or X26, X27 and / or X30, X31 and / or X37, X38 and / or X47, X48 may also together form a "heterocyclyl",

추가로 단, Z3 또는 Z4 라디칼 중 하나가 "헤테로사이클릴알킬"에 의해 치환된 "치환된 아릴"인 경우, 나머지 Z3 또는 Z4 라디칼은 각각의 경우 "치환되거나 치환되지 않은 아릴"이 아니고,Further provided that if one of the Z3 or Z4 radicals is "substituted aryl" substituted by "heterocyclylalkyl", then the remaining Z3 or Z4 radicals are in each case not "substituted or unsubstituted aryl",

여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(b) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX51, NX52X53, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X54, C(O)OX55, C(O)NHX56, C(O)NX57X58, OX59, O(X60-O)rH (r = 1, 2, 3, 4, 5), O(X61-O)rX62 (r = 1, 2, 3, 4, 5), OC(O)X63, OC(O)OX64, OC(O)NHX65, OC(O)NX66X67, OP(O)(OX68)(OX69), OSi(X70)(X71)(X72), OS(O2)X73, NHC(O)X74, NX75C(O)X76, NHC(O)OX77, NHC(O)NHX78, NHC(O)NX79X80, NX81C(O)OX82, NX83C(O)NHX84, NX85C(O)NX86X87, NHS(O2)X88, NX89S(O2)X90, SX91, S(O)X92, S(O2)X93, S(O2)NHX94, S(O2)NX95X96, S(O2)OX97, P(O)(OX98)(OX99), Si(X100)(X101)(X102)"(b) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX51, NX52X53, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X54, C (O) OX55, C (O) NHX56, C (O) NX57X58, OX59, O (X60-O) r H (r = 1, 2, 3, 4, 5), O (X61-O) r X62 (r = 1, 2, 3, 4, 5), OC (O) X63, OC (O) OX64, OC (O) NHX65 , OC (O) NX66X67, OP (O) (OX68) (OX69), OSi (X70) (X71) (X72), OS (O 2 ) X73, NHC (O) X74, NX75C (O) X76, NHC ( O) OX77, NHC (O) NHX78, NHC (O) NX79X80, NX81C (O) OX82, NX83C (O) NHX84, NX85C (O) NX86X87, NHS (O 2 ) X88, NX89S (O 2 ) X90, SX91, S (O) X92, S (O 2 ) X93, S (O 2 ) NHX94, S (O 2 ) NX95X96, S (O 2 ) OX97, P (O) (OX98) (OX99), Si (X100) ( X101) (X102) "

여기서, X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X57, X58 및/또는 X66, X67 및/또는 X79, X80 및/또는 X86, X87 및/또는 X95, X96은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Where X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X57, X58 and / or X66, X67 and / or X79, X80 and / or X86, X87 and / or X95, X96 together may also refer to" heterocyclyl " Can form,

여기서, 임의로, 치환체 그룹(b)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX103, NX104X105, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X106, C(O)OX107, C(O)NHX108, C(O)NX109X110, OX111, O(X112-O)sH (s = 1, 2, 3, 4, 5), O(X113-O)sX114 (s = 1, 2, 3, 4, 5), OC(O)X115, OC(O)OX116, OC(O)NHX117, OC(O)NX118X119, OP(O)(OX120)(OX121), OSi(X122)(X123)(X124), OS(O2)X125, NHC(O)X126, NX127C(O)X128, NHC(O)OX129, NHC(O)NHX130, NHC(O)NX131X132, NX133C(O)OX134, NX135C(O)NHX136, NX137C(O)NX138X139, NHS(O2)X140, NX141S(O2)X142, SX143, S(O)X144, S(O2)X145, S(O2)NHX146, S(O2)NX147X148, S(O2)OX149, P(O)(OX150)(OX151), Si(X152)(X153)(X154)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX 103, NX104X105, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X106, C (O) OX107, C (O) NHX108, C (O) NX109X110, OX111, O (X112-O) s H (s = 1, 2, 3, 4, 5), O (X113-O) s X114 (s = 1, 2, 3, 4, 5), OC (O) X115, OC (O) OX116, OC (O) NHX117 , OC (O) NX118X119, OP (O) (OX120) (OX121), OSi (X122) (X123) (X124), OS (O 2 ) X125, NHC (O) X126, NX127C (O) X128, NHC ( O) OX129, NHC (O) NHX130, NHC (O) NX131X132, NX133C (O) OX134, NX135C (O) NHX136, NX137C (O) NX138X139, NHS (O 2 ) X140, NX141S (O 2 ) X142, SX143, S (O) X144, S (O 2 ) X145, S (O 2 ) NHX146, S (O 2 ) NX147X148, S (O 2 ) OX149, P (O) (OX150) (OX151), Si (X152) ( X153) (X154) "

여기서, X103, X104, X105, X106, X107, X108, X109, X110, X111, X112, X113, X114, X115, X116, X117, X118, X119, X120, X121, X122, X123, X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, X149, X150, X151, X152, X153, X154는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X109, X110 및/또는 X118, X119 및/또는 X131, X132 및/또는 X138, X139 및/또는 X147, X148은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where X103, X104, X105, X106, X107, X108, X109, X110, X111, X112, X113, X114, X115, X116, X117, X118, X119, X120, X121, X122, X123, X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, X149, X150, X151, X152, X153, X154 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X109, X110 and / or X118, X119 and / or X131, X132 and / or X138, X139 and / or X147, X148 may also be referred to as" heterocyclyl " Can form,

여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX155, NX156X157, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X158, C(O)OX159, C(O)NHX160, C(O)NX161X162, OX163, O(X164-O)tH (t = 1, 2, 3, 4, 5), O(X165-O)tX166 (t = 1, 2, 3, 4, 5), OC(O)X167, OC(O)OX168, OC(O)NHX169, OC(O)NX170X171, OP(O)(OX172)(OX173), OSi(X174)(X175)(X176), OS(O2)X177, NHC(O)X178, NX179C(O)X180, NHC(O)OX181, NHC(O)NHX182, NHC(O)NX183X184, NX185C(O)OX186, NX187C(O)NHX188, NX189C(O)NX190X191, NHS(O2)X192, NX193S(O2)X194, SX195, S(O)X196, S(O2)X197, S(O2)NHX198, S(O2)NX199X200, S(O2)OX201, P(O)(OX202)(OX203), Si(X204)(X205)(X206)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX155, NX156X157, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X158, C (O) OX159, C (O) NHX160, C (O) NX161X162, OX163, O (X164-O) t H (t = 1, 2, 3, 4, 5), O (X165-O) t X166 (t = 1, 2, 3, 4, 5), OC (O) X167, OC (O) OX168, OC (O) NHX169 , OC (O) NX170X171, OP (O) (OX172) (OX173), OSi (X174) (X175) (X176), OS (O 2 ) X177, NHC (O) X178, NX179C (O) X180, NHC ( O) OX181, NHC (O) NHX182, NHC (O) NX183X184, NX185C (O) OX186, NX187C (O) NHX188, NX189C (O) NX190X191, NHS (O 2 ) X192, NX193S (O 2 ) X194, SX195, S (O) X196, S (O 2 ) X197, S (O 2 ) NHX198, S (O 2 ) NX199X200, S (O 2 ) OX201, P (O) (OX202) (OX203), Si (X204) ( X205) (X206) "

여기서, X155, X156, X157, X158, X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X175, X176, X177, X178, X179, X180, X181, X182, X183, X184, X185, X186, X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X161, X162 및/또는 X170, X171 및/또는 X183, X184 및/또는 X190, X191 및/또는 X199, X200은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where X155, X156, X157, X158, X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X175, X176, X177, X178, X179, X180, X181, X182, X183, X184, X185, X186, X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X161, X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 together may also refer to" heterocyclyl " Can form,

또는 Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고: Or one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted aryl" wherein "substituted aryl" is substituted by one or more substituents identically or differently selected from the group consisting of:

(c) "(C9-C30)알킬, NX207X208, NH(C9-C30)알킬, NHC(O)사이클로알킬알킬, NHC(O)헤테로사이클릴알킬, NHC(O)(C9-C30)알킬, NX209C(O)X210, NX211C(O)(C9-C30)알킬, NHC(O)OX212, NX213C(O)OX214, NHC(O)NHX215, NHC(O)NX216X217, NX218C(O)NHX219, NX220C(O)NX221X222, NHS(O2)사이클로알킬알킬, NHS(O2)헤테로사이클릴알킬, NX223S(O2)X224, O(C9-C30)알킬, S사이클로알킬, S헤테로사이클릴, S아릴알킬, S헤테로아릴알킬, S사이클로알킬알킬, S헤테로사이클릴알킬, S(C9-C30)알킬, OC(O)사이클로알킬알킬, OC(O)헤테로사이클릴알킬, OC(O)(C9-C30)알킬, OS(O2)사이클로알킬알킬, OS(O2)헤테로사이클릴알킬, OS(O2)(C9-C30)알킬, OC(O)OX225, OC(O)NHX226, OC(O)NX227X228, OP(O)(OX229)(OX230), C(O)사이클로알킬, C(O)헤테로사이클릴, C(O)아릴알킬, C(O)헤테로아릴알킬, C(O)사이클로알킬알킬, C(O)헤테로사이클릴알킬, C(O)(C9-C30)알킬, C(O)O(C9-C30)알킬, C(O)NH(C9-C30)알킬, C(O)NX231X232, C(O)NHOX233, C(O)NX234-OX235, C(O)NHNX236X237, C(O)NX238NX239X240, S(O)사이클로알킬, S(O)헤테로사이클릴, S(O)헤테로아릴, S(O)아릴알킬, S(O)헤테로아릴알킬, S(O)사이클로알킬알킬, S(O)헤테로사이클릴알킬, S(O)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)헤테로사이클릴, S(O2)헤테로아릴, S(O2)아릴알킬, S(O2)헤테로아릴알킬, S(O2)사이클로알킬알킬, S(O2)헤테로사이클릴알킬, S(O2)(C9-C30)알킬, S(O2)NH사이클로알킬, S(O2)NH헤테로사이클릴, S(O2)NH헤테로아릴알킬, S(O2)NH사이클로알킬알킬, S(O2)NH헤테로사이클릴알킬, S(O2)NH(C9-C30)알킬, S(O2)O사이클로알킬, S(O2)O헤테로사이클릴, S(O2)O헤테로아릴, S(O2)O헤테로아릴알킬, S(O2)O사이클로알킬알킬, S(O2)O헤테로사이클릴알킬, S(O2)O(C9-C30)알킬, P(O)(OH)2, P(O)(OX241)(OX242), Si(X243)(X244)(X245), OSi(X246)(X247)(X248)"(c) "(C 9 -C 30 ) alkyl, NX207X208, NH (C 9 -C 30 ) alkyl, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NHC (O) (C 9- C 30 ) alkyl, NX209C (O) X210, NX211C (O) (C 9 -C 30 ) alkyl, NHC (O) OX212, NX213C (O) OX214, NHC (O) NHX215, NHC (O) NX216X217, NX218C ( O) NHX219, NX220C (O) NX221X222, NHS (O 2 ) cycloalkylalkyl, NHS (O 2 ) heterocyclylalkyl, NX223S (O 2 ) X224, O (C 9 -C 30 ) alkyl, Scycloalkyl, S heterocyclyl, Sarylalkyl, S heteroarylalkyl, Scycloalkylalkyl, S heterocyclylalkyl, S (C 9 -C 30 ) alkyl, OC (O) cycloalkylalkyl, OC (O) heterocyclyl Alkyl, OC (O) (C 9 -C 30 ) alkyl, OS (O 2 ) cycloalkylalkyl, OS (O 2 ) heterocyclylalkyl, OS (O 2 ) (C 9 -C 30 ) alkyl, OC ( O) OX225, OC (O) NHX226, OC (O) NX227X228, OP (O) (OX229) (OX230), C (O) cycloalkyl, C (O) heterocyclyl, C (O) arylalkyl, C (O) heteroarylalkyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O) (C 9 -C 30 ) alkyl, C (O) O (C 9 -C 30 ) alkyl, C (O) NH (C 9 -C 30 ) alkyl, C (O) NX231X232, C (O) NHOX233, C (O) NX234-OX235, C ( O) NHNX236X237, C (O) NX238NX239X240, S (O) cycloalkyl, S (O) heterocyclyl, S (O) heteroaryl, S (O) arylalkyl, S (O) heteroarylalkyl, S (O ) Cycloalkylalkyl, S (O) heterocyclylalkyl, S (O) (C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) heterocyclyl, S (O 2 ) hetero Aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroarylalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) heterocyclylalkyl, S (O 2 ) (C 9 -C 30 ) Alkyl, S (O 2 ) NH cycloalkyl, S (O 2 ) NH heterocyclyl, S (O 2 ) NH heteroarylalkyl, S (O 2 ) NH cycloalkylalkyl, S (O 2 ) NH heterocyclyl Alkyl, S (O 2 ) NH (C 9 -C 30 ) alkyl, S (O 2 ) Ocycloalkyl, S (O 2 ) O heterocyclyl, S (O 2 ) O heteroaryl, S (O 2 ) O heteroarylalkyl, S (O 2 ) Ocycloalkylalkyl, S (O 2 ) Oheterocyclylalkyl, S (O 2 ) O (C 9 -C 30 ) alkyl, P (O) (OH) 2 , P (O) (OX241) (O X242), Si (X243) (X244) (X245), OSi (X246) (X247) (X248) "

여기서, X207, X208, X209, X210, X211, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X216, X217 및/또는 X221, X222 및/또는 X227, X228 및/또는 X231, X232 및/또는 X236, X237 및/또는 X239, X240은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X207, X208, X209, X210, X211, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, X216, X217 and / or X221, X222 and / or X227, X228 and / or X231, X232 and / or X236, X237 and / or X239, X240 may also together form "heterocyclyl" in each case,

단, 치환체 "N(알킬)2", "C(O)N(알킬)2", "C(O)N(사이클로알킬)2", "C(O)N(아릴)2", "C(O)N(헤테로아릴)2"는 다음 치환체 그룹(i)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Provided that the substituents "N (alkyl) 2 ", "C (O) N (alkyl) 2 ", "C (O) N (cycloalkyl) 2 ", "C (O) N (aryl) 2 ", "C (O) N (heteroaryl) 2 ″ is further substituted by one or more substituents selected from the following substituent groups (i);

추가로 단, Z3 또는 Z4 라디칼 중 하나가 "헤테로사이클릴알킬"에 의해 치환된 "치환된 아릴"인 경우, 나머지 Z3 또는 Z4 라디칼은 각각의 경우 "치환되지 않거나 치환된 아릴"이 아니고,Further provided that if one of the Z3 or Z4 radicals is "substituted aryl" substituted by "heterocyclylalkyl", then the remaining Z3 or Z4 radicals in each case are not "unsubstituted or substituted aryl",

여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX249, NX250X251, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X252, C(O)OX253, C(O)NHX254, C(O)NX255X256, OX257, O(X258-O)uH (u = 1, 2, 3, 4, 5), O(X259-O)uX260 (u = 1, 2, 3, 4, 5), OC(O)X261, OC(O)OX262, OC(O)NHX263, OC(O)NX264X265, OP(O)(OX266)(OX267), OSi(X268)(X269)(X270), OS(O2)X271, NHC(O)X272, NX273C(O)X274, NHC(O)OX275, NHC(O)NHX276, NHC(O)NX277X278, NX279C(O)OX280, NX281C(O)NHX282, NX283C(O)NX284X285, NHS(O2)X286, NX287S(O2)X288, SX289, S(O)X290, S(O2)X291, S(O2)NHX292, S(O2)NX293X294, S(O2)OX295, P(O)(OX296)(OX297), Si(X298)(X299)(X300)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX249, NX250X251, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X252, C (O) OX253, C (O) NHX254, C (O) NX255X256, OX257, O (X258-O) u H (u = 1, 2, 3, 4, 5), O (X259-O) u X260 (u = 1, 2, 3, 4, 5), OC (O) X261, OC (O) OX262, OC (O) NHX263 , OC (O) NX264X265, OP (O) (OX266) (OX267), OSi (X268) (X269) (X270), OS (O 2 ) X271, NHC (O) X272, NX273C (O) X274, NHC ( O) OX275, NHC (O) NHX276, NHC (O) NX277X278, NX279C (O) OX280, NX281C (O) NHX282, NX283C (O) NX284X285, NHS (O 2 ) X286, NX287S (O 2 ) X288, SX289, S (O) X290, S (O 2 ) X291, S (O 2 ) NHX292, S (O 2 ) NX293X294, S (O 2 ) OX295, P (O) (OX296) (OX297), Si (X298) ( X299) (X300) "

여기서, X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X296, X297, X298, X299, X300은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X255, X256 및/또는 X264, X265 및/또는 X277, X278 및/또는 X284, X285 및/또는 X293, X294는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X296, X297, X298, X299, X300 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X255, X256 and / or X264, X265 and / or X277, X278 and / or X284, X285 and / or X293, X294 are also in each case" heterocycle Reels ",

여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals are each independently selected by one or more substituents identically or differently selected from the group consisting of:

(d) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX301, NX302X303, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X304, C(O)OX305, C(O)NHX306, C(O)NX307X308, OX309, O(X310-O)uuH (uu = 1, 2, 3, 4, 5), O(X311-O)uuX312 (uu = 1, 2, 3, 4, 5), OC(O)X313, OC(O)OX314, OC(O)NHX315, OC(O)NX316X317, OP(O)(OX318)(OX319), OSi(X320)(X321)(X322), OS(O2)X323, NHC(O)X324, NX325C(O)X326, NHC(O)OX327, NHC(O)NHX328, NHC(O)NX329X330, NX331C(O)OX332, NX333C(O)NHX334, NX335C(O)NX336X337, NHS(O2)X338, NX339S(O2)X340, SX341, S(O)X342, S(O2)X343, S(O2)NHX344, S(O2)NX345X346, S(O2)OX347, P(O)(OX348)(OX349), Si(X350)(X351)(X352)"(d) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX301, NX302X303, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X304, C (O) OX305, C (O) NHX306, C (O) NX307X308, OX309, O (X310-O) uu H (uu = 1, 2, 3, 4, 5), O (X311-O) uu X312 (uu = 1, 2, 3, 4, 5), OC (O) X313, OC (O) OX314, OC (O) NHX315 , OC (O) NX316X317, OP (O) (OX318) (OX319), OSi (X320) (X321) (X322), OS (O 2 ) X323, NHC (O) X324, NX325C (O) X326, NHC ( O) OX327, NHC (O) NHX328, NHC (O) NX329X330, NX331C (O) OX332, NX333C (O) NHX334, NX335C (O) NX336X337, NHS (O 2 ) X338, NX339S (O 2 ) X340, SX341, S (O) X342, S (O 2 ) X343, S (O 2 ) NHX344, S (O 2 ) NX345X346, S (O 2 ) OX347, P (O) (OX348) (OX349), Si (X350) ( X351) (X352) "

여기서, X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312, X313, X314, X315, X316, X317, X318, X319, X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X332, X333, X334, X335, X336, X337, X338, X339, X340, X341, X342, X343, X344, X345, X346, X347, X348, X349, X350, X351, X352는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X307, X308 및/또는 X316, X317 및/또는 X329, X330 및/또는 X336, X337 및/또는 X345, X346은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312, X313, X314, X315, X316, X317, X318, X319, X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X332, X333, X334, X335, X336, X337, X338, X339, X340, X341, X342, X343, X344, X345, X346, X347, X348, X349, X350, X351, X352 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X307, X308 and / or X316, X317 and / or X329, X330 and / or X336, X337 and / or X345, X346 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(d)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (d) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX353, NX354X355, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X356, C(O)OX357, C(O)NHX358, C(O)NX359X360, OX361, O(X362-O)vH (v = 1, 2, 3, 4, 5), O(X363-O)vX364 (v = 1, 2, 3, 4, 5), OC(O)X365, OC(O)OX366, OC(O)NHX367, OC(O)NX368X369, OP(O)(OX370)(OX371), OSi(X372)(X373)(X374), OS(O2)X375, NHC(O)X376, NX377C(O)X378, NHC(O)OX379, NHC(O)NHX380, NHC(O)NX381X382, NX383C(O)OX384, NX385C(O)NHX386, NX387C(O)NX388X389, NHS(O2)X390, NX391S(O2)X392, SX393, S(O)X394, S(O2)X395, S(O2)NHX396, S(O2)NX397X398, S(O2)OX399, P(O)(OX400)(OX401), Si(X402)(X403)(X404)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX353, NX354X355, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X356, C (O) OX357, C (O) NHX358, C (O) NX359X360, OX361, O (X362-O) v H (v = 1, 2, 3, 4, 5), O (X363-O) v X364 (v = 1, 2, 3, 4, 5), OC (O) X365, OC (O) OX366, OC (O) NHX367 , OC (O) NX368X369, OP (O) (OX370) (OX371), OSi (X372) (X373) (X374), OS (O 2 ) X375, NHC (O) X376, NX377C (O) X378, NHC ( O) OX379, NHC (O) NHX380, NHC (O) NX381X382, NX383C (O) OX384, NX385C (O) NHX386, NX387C (O) NX388X389, NHS (O 2 ) X390, NX391S (O 2 ) X392, SX393 S (O) X394, S (O 2 ) X395, S (O 2 ) NHX396, S (O 2 ) NX397X398, S (O 2 ) OX399, P (O) (OX400) (OX401), Si (X402) ( X403) (X404) "

여기서, X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X375, X376, X377, X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X400, X401, X402, X403, X404는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X359, X360 및/또는 X368, X369 및/또는 X381, X382 및/또는 X388, X389 및/또는 X397, X398은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X375, X376, X377, X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X400, X401, X401 X402, X403, X404 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X359, X360 and / or X368, X369 and / or X381, X382 and / or X388, X389 and / or X397, X398 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체 는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX405, NX406X407, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X408, C(O)OX409, C(O)NHX410, C(O)NX411X412, OX413, O(X414-O)wH (w = 1, 2, 3, 4, 5), O(X415-O)wX416 (w = 1, 2, 3, 4, 5), OC(O)X417, OC(O)OX418, OC(O)NHX419, OC(O)NX420X421, OP(O)(OX422)(OX423), OSi(X424)(X425)(X426), OS(O2)X427, NHC(O)X428, NX429C(O)X430, NHC(O)OX431, NHC(O)NHX432, NHC(O)NX433X434, NX435C(O)OX436, NX437C(O)NHX438, NX439C(O)NX440X441, NHS(O2)X442, NX443S(O2)X444, SX445, S(O)X446, S(O2)X447, S(O2)NHX448, S(O2)NX449X450, S(O2)OX451, P(O)(OX452)(OX453), Si(X454)(X455)(X456)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX405, NX406X407, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X408, C (O) OX409, C (O) NHX410, C (O) NX411X412, OX413, O (X414-O) w H (w = 1, 2, 3, 4, 5), O (X415-O) w X416 (w = 1, 2, 3, 4, 5), OC (O) X417, OC (O) OX418, OC (O) NHX419 , OC (O) NX420X421, OP (O) (OX422) (OX423), OSi (X424) (X425) (X426), OS (O 2 ) X427, NHC (O) X428, NX429C (O) X430, NHC ( O) OX431, NHC (O) NHX432, NHC (O) NX433X434, NX435C (O) OX436, NX437C (O) NHX438, NX439C (O) NX440X441, NHS (O 2 ) X442, NX443S (O 2 ) X444, SX445, S (O) X446, S (O 2 ) X447, S (O 2 ) NHX448, S (O 2 ) NX449X450, S (O 2 ) OX451, P (O) (OX452) (OX453), Si (X454) ( X455) (X456) "

여기서, X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X411, X412및/또는 X420, X421 및/또는 X433, X434 및/또는 X440, X441 및/또는 X449, X450은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X411, X412 and / or X420, X421 and / or X433, X434 and / or X440, X441 and / or X449, X450 are also in each case" heterocycle. " Reels ",

Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of:

(e) 수소;(e) hydrogen;

(f) 할로겐, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;

(g) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX457, NX458X459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X460, C(O)OX461, C(O)NHX462, C(O)NX463X464, OX465, O(X466-O)xH (x = 1, 2, 3, 4, 5), O(X467-O)xX468 (x = 1, 2, 3, 4, 5), OC(O)X469, OC(O)OX470, OC(O)NHX471, OC(O)NX472X473, OP(O)(OX474)(OX475), OSi(X476)(X477)(X478), OS(O2)X479, NHC(O)X480, NX481C(O)X482, NHC(O)OX483, NHC(O)NHX484, NHC(O)NX485X486, NX487C(O)OX488, NX489C(O)NHX490, NX491C(O)NX492X493, NHS(O2)X494, NX495S(O2)X496, SX497, S(O)X498, S(O2)X499, S(O2)NHX500, S(O2)NX501X502, S(O2)OX503, P(O)(OX504)(OX505), Si(X506)(X507)(X508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX457, NX458X459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X460, C (O) OX461, C (O) NHX462, C (O) NX463X464, OX465, O (X466-O) x H (x = 1, 2, 3, 4, 5), O (X467-O) x X468 (x = 1, 2, 3, 4, 5), OC (O) X469, OC (O) OX470, OC (O) NHX471 , OC (O) NX472X473, OP (O) (OX474) (OX475), OSi (X476) (X477) (X478), OS (O 2 ) X479, NHC (O) X480, NX481C (O) X482, NHC ( O) OX483, NHC (O) NHX484, NHC (O) NX485X486, NX487C (O) OX488, NX489C (O) NHX490, NX491C (O) NX492X493, NHS (O 2 ) X494, NX495S (O 2 ) X496, SX497, S (O) X498, S (O 2 ) X499, S (O 2 ) NHX500, S (O 2 ) NX501X502, S (O 2 ) OX503, P (O) (OX504) (OX505), Si (X506) ( X507) (X508) "

여기서, X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X463, X464 및/또는 X472, X473 및/또는 X485, X486 및/또는 X492, X493 및/또는 X501, X502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X463, X464 and / or X472, X473 and / or X485, X486 and / or X492, X493 and / or X501, X502 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX509, NX510X511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X512, C(O)OX513, C(O)NHX514, C(O)NX515X516, OX517, O(X518-O)yH (y = 1, 2, 3, 4, 5), O(X519-O)yX520 (y = 1, 2, 3, 4, 5), OC(O)X521, OC(O)OX522, OC(O)NHX523, OC(O)NX524X525, OP(O)(OX526)(OX527), OSi(X528)(X529)(X530), OS(O2)X531, NHC(O)X532, NX533C(O)X534, NHC(O)OX535, NHC(O)NHX536, NHC(O)NX537X538, NX539C(O)OX540, NX541C(O)NHX542, NX543C(O)NX544X545, NHS(O2)X546, NX547S(O2)X548, SX549, S(O)X550, S(O2)X551, S(O2)NHX552, S(O2)NX553X554, S(O2)OX555, P(O)(OX556)(OX557), Si(X558)(X559)(X560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX509, NX510X511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X512, C (O) OX513, C (O) NHX514, C (O) NX515X516, OX517, O (X518-O) y H (y = 1, 2, 3, 4, 5), O (X519-O) y X520 (y = 1, 2, 3, 4, 5), OC (O) X521, OC (O) OX522, OC (O) NHX523 , OC (O) NX524X525, OP (O) (OX526) (OX527), OSi (X528) (X529) (X530), OS (O 2 ) X531, NHC (O) X532, NX533C (O) X534, NHC ( O) OX535, NHC (O) NHX536, NHC (O) NX537X538, NX539C (O) OX540, NX541C (O) NHX542, NX543C (O) NX544X545, NHS (O 2 ) X546, NX547S (O 2 ) X548, SX549, S (O) X550, S (O 2 ) X551, S (O 2 ) NHX552, S (O 2 ) NX553X554, S (O 2 ) OX555, P (O) (OX556) (OX557), Si (X558) ( X559) (X560) "

여기서, X509, X510, X511, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527, X528, X529, X530, X531, X532, X533, X534, X535, X536, X537, X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X515, X516 및/또는 X524, X525 및/또는 X537, X538 및/또는 X544, X545 및/또는 X553, X554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X509, X510, X511, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527, X528, X529, X530, X531, X532, X533, X534, X535, X536, X537, X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X515, X516 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX561, NX562X563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X564, C(O)OX565, C(O)NHX566, C(O)NX567X568, OX569, O(X570-O)zH (z = 1, 2, 3, 4, 5), O(X571-O)zX572 (z = 1, 2, 3, 4, 5), OC(O)X573, OC(O)OX574, OC(O)NHX575, OC(O)NX576X577, OP(O)(OX578)(OX579), OSi(X580)(X581)(X582), OS(O2)X583, NHC(O)X584, NX585C(O)X586, NHC(O)OX587, NHC(O)NHX588, NHC(O)NX589X590, NX591C(O)OX592, NX593C(O)NHX594, NX595C(O)NX596X597, NHS(O2)X598, NX599S(O2)X600, SX601, S(O)X602, S(O2)X603, S(O2)NHX604, S(O2)NX605X606, S(O2)OX607, P(O)(OX608)(OX609), Si(X610)(X611)(X612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX561, NX562X563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X564, C (O) OX565, C (O) NHX566, C (O) NX567X568, OX569, O (X570-O) z H (z = 1, 2, 3, 4, 5), O (X571-O) z X572 (z = 1, 2, 3, 4, 5), OC (O) X573, OC (O) OX574, OC (O) NHX575 , OC (O) NX576X577, OP (O) (OX578) (OX579), OSi (X580) (X581) (X582), OS (O 2 ) X583, NHC (O) X584, NX585C (O) X586, NHC ( O) OX587, NHC (O) NHX588, NHC (O) NX589X590, NX591C (O) OX592, NX593C (O) NHX594, NX595C (O) NX596X597, NHS (O 2 ) X598, NX599S (O 2 ) X600, SX601, S (O) X602, S (O 2 ) X603, S (O 2 ) NHX604, S (O 2 ) NX605X606, S (O 2 ) OX607, P (O) (OX608) (OX609), Si (X610) ( X611) (X612) "

여기서, X561, X562, X563, X564, X565, X566, X567, X568, X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X611, X612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X567, X568 및/또는 X576, X577 및/또는 X589, X590 및/또는 X596, X597 및/또는 X605, X606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X561, X562, X563, X564, X565, X566, X567, X568, X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X611, X612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X567, X568 and / or X576, X577 and / or X589, X590 and / or X596, X597 and / or X605, X606 are also in each case" heterocycle Reels ",

(h) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX613, NX614X615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X616, C(O)OX617, C(O)NHX618, C(O)NX619X620, OX621, O(X622-O)aH (a = 1, 2, 3, 4, 5), O(X623-O)aX624 (a = 1, 2, 3, 4, 5), OC(O)X625, OC(O)OX626, OC(O)NHX627, OC(O)NX628X629, OP(O)(OX630)(OX631), OSi(X632)(X633)(X634), OS(O2)X635, NHC(O)X636, NX637C(O)X638, NHC(O)OX639, NHC(O)NHX640, NHC(O)NX641X642, NX643C(O)OX644, NX645C(O)NHX646, NX647C(O)NX648X649, NHS(O2)X650, NX651S(O2)X652, SX653, S(O)X654, S(O2)X655, S(O2)NHX656, S(O2)NX657X658, S(O2)OX659, P(O)(OX660)(OX661), Si(X662)(X663)(X664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX613, NX614X615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X616, C (O) OX617, C (O) NHX618, C (O) NX619X620, OX621, O (X622-O) a H (a = 1, 2, 3, 4, 5), O (X623-O) a X624 (a = 1, 2, 3, 4, 5), OC (O) X625, OC (O) OX626, OC (O) NHX627 , OC (O) NX628X629, OP (O) (OX630) (OX631), OSi (X632) (X633) (X634), OS (O 2 ) X635, NHC (O) X636, NX637C (O) X638, NHC ( O) OX639, NHC (O) NHX640, NHC (O) NX641X642, NX643C (O) OX644, NX645C (O) NHX646, NX647C (O) NX648X649, NHS (O 2 ) X650, NX651S (O 2 ) X652, SX653, S (O) X654, S (O 2 ) X655, S (O 2 ) NHX656, S (O 2 ) NX657X658, S (O 2 ) OX659, P (O) (OX660) (OX661), Si (X662) ( X663) (X664) "

여기서, X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631, X632, X633, X634, X635, X636,X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651, X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, X663, X664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X619, X620 및/또는 X628, X629 및/또는 X641, X642 및/또는 X648, X649 및/또는 X657, X658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631, X632, X633, X634, X635, X636, X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651, X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, X663, X664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X619, X620 and / or X628, X629 and / or X641, X642 and / or X648, X649 and / or X657, X658 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX665, NX666X667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X668, C(O)OX669, C(O)NHX670, C(O)NX671X672, OX673, O(X674-O)bH (b = 1, 2, 3, 4, 5), O(X675- O)bX676 (b = 1, 2, 3, 4, 5), OC(O)X677, OC(O)OX678, OC(O)NHX679, OC(O)NX680X681, OP(O)(OX682)(OX683), OSi(X684)(X685)(X686), OS(O2)X687, NHC(O)X688, NX689C(O)X690, NHC(O)OX691, NHC(O)NHX692, NHC(O)NX693X694, NX695C(O)OX696, NX697C(O)NHX698, NX699C(O)NX700X701, NHS(O2)X702, NX703S(O2)X704, SX705, S(O)X706, S(O2)X707, S(O2)NHX708, S(O2)NX709X710, S(O2)OX711, P(O)(OX712)(OX713), Si(X714)(X715)(X716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX665, NX666X667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X668, C (O) OX669, C (O) NHX670, C (O) NX671X672, OX673, O (X674-O) b H (b = 1, 2, 3, 4, 5), O (X675-O) b X676 (b = 1, 2, 3, 4, 5), OC (O) X677, OC (O) OX678, OC (O) NHX679 , OC (O) NX680X681, OP (O) (OX682) (OX683), OSi (X684) (X685) (X686), OS (O 2 ) X687, NHC (O) X688, NX689C (O) X690, NHC ( O) OX691, NHC (O) NHX692, NHC (O) NX693X694, NX695C (O) OX696, NX697C (O) NHX698, NX699C (O) NX700X701, NHS (O 2 ) X702, NX703S (O 2 ) X704, SX705, S (O) X706, S (O 2 ) X707, S (O 2 ) NHX708, S (O 2 ) NX709X710, S (O 2 ) OX711, P (O) (OX712) (OX713), Si (X714) ( X715) (X716) "

여기서, X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X687, X688, X689, X690, X691, X692, X693, X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X671, X672 및/또는 X680, X681 및/또는 X693, X694 및/또는 X700, X701 및/또는 X709, X710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X687, X688, X689, X690, X691, X692, X693, X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X671, X672 and / or X680, X681 and / or X693, X694 and / or X700, X701 and / or X709, X710 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX717, NX718X719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X720, C(O)OX721, C(O)NHX722, C(O)NX723X724, OX725, O(X726-O)cH (c = 1, 2, 3, 4, 5), O(X727-O)cX728 (c = 1, 2, 3, 4, 5), OC(O)X729, OC(O)OX730, OC(O)NHX731, OC(O)NX732X733, OP(O)(OX734)(OX735), OSi(X736)(X737)(X738), OS(O2)X739, NHC(O)X740, NX741C(O)X742, NHC(O)OX743, NHC(O)NHX744, NHC(O)NX745X746, NX747C(O)OX748, NX749C(O)NHX750, NX751C(O)NX752X753, NHS(O2)X754, NX755S(O2)X756, SX757, S(O)X758, S(O2)X759, S(O2)NHX760, S(O2)NX761X762, S(O2)OX763, P(O)(OX764)(OX765), Si(X766)(X767)(X768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX717, NX718X719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X720, C (O) OX721, C (O) NHX722, C (O) NX723X724, OX725, O (X726-O) c H (c = 1, 2, 3, 4, 5), O (X727-O) c X728 (c = 1, 2, 3, 4, 5), OC (O) X729, OC (O) OX730, OC (O) NHX731 , OC (O) NX732X733, OP (O) (OX734) (OX735), OSi (X736) (X737) (X738), OS (O 2 ) X739, NHC (O) X740, NX741C (O) X742, NHC ( O) OX743, NHC (O) NHX744, NHC (O) NX745X746, NX747C (O) OX748, NX749C (O) NHX750, NX751C (O) NX752X753, NHS (O 2 ) X754, NX755S (O 2 ) X756, SX757, S (O) X758, S (O 2 ) X759, S (O 2 ) NHX760, S (O 2 ) NX761X762, S (O 2 ) OX763, P (O) (OX764) (OX765), Si (X766) ( X767) (X768) "

여기서, X717, X718, X719, X720, X721, X722, X723, X724, X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X723, X724 및/또는 X732, X733 및/또는 X745, X746 및/또는 X752, X753 및/또는 X761, X762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X717, X718, X719, X720, X721, X722, X723, X724, X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X723, X724 and / or X732, X733 and / or X745, X746 and / or X752, X753 and / or X761, X762 are also in each case" heterocycle. " Reels ",

(j) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX769, NX770X771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X772, C(O)OX773, C(O)NHX774, C(O)NX775X776, OX777, O(X778-O)dH (d = 1, 2, 3, 4, 5), O(X779-O)dX780 (d = 1, 2, 3, 4, 5), OC(O)X781, OC(O)OX782, OC(O)NHX783, OC(O)NX784X785, OP(O)(OX786)(OX787), OSi(X788)(X789)(X790), OS(O2)X791, NHC(O)X792, NX793C(O)X794, NHC(O)OX795, NHC(O)NHX796, NHC(O)NX797X798, NX799C(O)OX800, NX801C(O)NHX802, NX803C(O)NX804X805, NHS(O2)X806, NX807S(O2)X808, SX809, S(O)X810, S(O2)X811, S(O2)NHX812, S(O2)NX813X814, S(O2)OX815, P(O)(OX816)(OX817), Si(X818)(X819)(X820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX769, NX770X771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X772, C (O) OX773, C (O) NHX774, C (O) NX775X776, OX777, O (X778-O) d H (d = 1, 2, 3, 4, 5), O (X779-O) d X780 (d = 1, 2, 3, 4, 5), OC (O) X781, OC (O) OX782, OC (O) NHX783 , OC (O) NX784X785, OP (O) (OX786) (OX787), OSi (X788) (X789) (X790), OS (O 2 ) X791, NHC (O) X792, NX793C (O) X794, NHC ( O) OX795, NHC (O) NHX796, NHC (O) NX797X798, NX799C (O) OX800, NX801C (O) NHX802, NX803C (O) NX804X805, NHS (O 2 ) X806, NX807S (O 2 ) X808, SX809, S (O) X810, S (O 2 ) X811, S (O 2 ) NHX812, S (O 2 ) NX813X814, S (O 2 ) OX815, P (O) (OX816) (OX817), Si (X818) ( X819) (X820) "

여기서, X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779, X780, X781, X782, X783, X784, X785, X786, X787, X788, X789, X790, X791, X792, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807, X808, X809, X810, X811, X812, X813, X814, X815, X816, X817, X818, X819, X820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X775, X776 및/또는 X784, X785 및/또는 X797, X798 및/또는 X804, X805 및/또는 X813, X814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779, X780, X781, X782, X783, X784, X785, X786, X787, X788, X789, X790, X791, X792, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807, X808, X809, X810, X811, X812, X813, X814, X815, X816, X817, X818, X819, X820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X775, X776 and / or X784, X785 and / or X797, X798 and / or X804, X805 and / or X813, X814 are also in each case" heterocycle Reels ";

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX821, NX822X823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X824, C(O)OX825, C(O)NHX826, C(O)NX827X828, OX829, O(X830-O)eH (e = 1, 2, 3, 4, 5), O(X831-O)eX832 (e = 1, 2, 3, 4, 5), OC(O)X833, OC(O)OX834, OC(O)NHX835, OC(O)NX836X837, OP(O)(OX838)(OX839), OSi(X840)(X841)(X842), OS(O2)X843, NHC(O)X844, NX845C(O)X846, NHC(O)OX847, NHC(O)NHX848, NHC(O)NX849X850, NX851C(O)OX852, NX853C(O)NHX854, NX855C(O)NX856X857, NHS(O2)X858, NX859S(O2)X860, SX861, S(O)X862, S(O2)X863, S(O2)NHX864, S(O2)NX865X866, S(O2)OX867, P(O)(OX868)(OX869), Si(X870)(X871)(X872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX821, NX822X823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X824, C (O) OX825, C (O) NHX826, C (O) NX827X828, OX829, O (X830-O) e H (e = 1, 2, 3, 4, 5), O (X831-O) e X832 (e = 1, 2, 3, 4, 5), OC (O) X833, OC (O) OX834, OC (O) NHX835 , OC (O) NX836X837, OP (O) (OX838) (OX839), OSi (X840) (X841) (X842), OS (O 2 ) X843, NHC (O) X844, NX845C (O) X846, NHC ( O) OX847, NHC (O) NHX848, NHC (O) NX849X850, NX851C (O) OX852, NX853C (O) NHX854, NX855C (O) NX856X857, NHS (O 2 ) X858, NX859S (O 2 ) X860, SX861, S (O) X862, S (O 2 ) X863, S (O 2 ) NHX864, S (O 2 ) NX865X866, S (O 2 ) OX867, P (O) (OX868) (OX869), Si (X870) ( X871) (X872) "

여기서, X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839, X840, X841, X842, X843, X844, X845, X846, X847, X848, X849, X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X827, X828 및/또는 X836, X837 및/또는 X849, X850 및/또는 X856, X857 및/또는 X865, X866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839, X840, X841, X842, X843, X844, X845, X846, X847, X848, X849, X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X827, X828 and / or X836, X837 and / or X849, X850 and / or X856, X857 and / or X865, X866 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX873, NX874X875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X876, C(O)OX877, C(O)NHX878, C(O)NX879X880, OX881, O(X882-O)fH (f = 1, 2, 3, 4, 5), O(X883-O)fX884 (f = 1, 2, 3, 4, 5), OC(O)X885, OC(O)OX886, OC(O)NHX887, OC(O)NX888X889, OP(O)(OX890)(OX891), OSi(X892)(X893)(X894), OS(O2)X895, NHC(O)X896, NX897C(O)X898, NHC(O)OX899, NHC(O)NHX900, NHC(O)NX901X902, NX903C(O)OX904, NX905C(O)NHX906, NX907C(O)NX908X909, NHS(O2)X910, NX911S(O2)X912, SX913, S(O)X914, S(O2)X915, S(O2)NHX916, S(O2)NX917X918, S(O2)OX919, P(O)(OX920)(OX921), Si(X922)(X923)(X924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX873, NX874X875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X876, C (O) OX877, C (O) NHX878, C (O) NX879X880, OX881, O (X882-O) f H (f = 1, 2, 3, 4, 5), O (X883-O) f X884 (f = 1, 2, 3, 4, 5), OC (O) X885, OC (O) OX886, OC (O) NHX887 , OC (O) NX888X889, OP (O) (OX890) (OX891), OSi (X892) (X893) (X894), OS (O 2 ) X895, NHC (O) X896, NX897C (O) X898, NHC ( O) OX899, NHC (O) NHX900, NHC (O) NX901X902, NX903C (O) OX904, NX905C (O) NHX906, NX907C (O) NX908X909, NHS (O 2 ) X910, NX911S (O 2 ) X912, SX913, S (O) X914, S (O 2 ) X915, S (O 2 ) NHX916, S (O 2 ) NX917X918, S (O 2 ) OX919, P (O) (OX920) (OX921), Si (X922) ( X923) (X924) "

여기서, X873, X874, X875, X876, X877, X878, X879, X880, X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X879, X880 및/또는 X888, X889 및/또는 X901, X902 및/또는 X908, X909 및/또는 X917, X918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X873, X874, X875, X876, X877, X878, X879, X880, X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X879, X880 and / or X888, X889 and / or X901, X902 and / or X908, X909 and / or X917, X918 are also in each case" heterocycle Reels ",

(k) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX925, NX926X927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X928, C(O)OX929, C(O)NHX930, C(O)NX931X932, OX933, O(X934-O)gH (g = 1, 2, 3, 4, 5), O(X935-O)gX936 (g = 1, 2, 3, 4, 5), OC(O)X937, OC(O)OX938, OC(O)NHX939, OC(O)NX940X941, OP(O)(OX942)(OX943), OSi(X944)(X945)(X946), OS(O2)X947, NHC(O)X948, NX949C(O)X950, NHC(O)OX951, NHC(O)NHX952, NHC(O)NX953X954, NX955C(O)OX956, NX957C(O)NHX958, NX959C(O)NX960X961, NHS(O2)X962, NX963S(O2)X964, SX965, S(O)X966, S(O2)X967, S(O2)NHX968, S(O2)NX969X970, S(O2)OX971, P(O)(OX972)(OX973), Si(X974)(X975)(X976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX925, NX926X927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X928, C (O) OX929, C (O) NHX930, C (O) NX931X932, OX933, O (X934-O) g H (g = 1, 2, 3, 4, 5), O (X935-O) g X936 (g = 1, 2, 3, 4, 5), OC (O) X937, OC (O) OX938, OC (O) NHX939 , OC (O) NX940X941, OP (O) (OX942) (OX943), OSi (X944) (X945) (X946), OS (O 2 ) X947, NHC (O) X948, NX949C (O) X950, NHC ( O) OX951, NHC (O) NHX952, NHC (O) NX953X954, NX955C (O) OX956, NX957C (O) NHX958, NX959C (O) NX960X961, NHS (O 2 ) X962, NX963S (O 2 ) X964, SX965, S (O) X966, S (O 2 ) X967, S (O 2 ) NHX968, S (O 2 ) NX969X970, S (O 2 ) OX971, P (O) (OX972) (OX973), Si (X974) ( X975) (X976) "

여기서, X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943, X944, X945, X946, X947, X948, X949, X950, X951, X952, X953, X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X931, X932 및/또는 X940, X941 및/또는 X953, X954 및/또는 X960, X961 및/또는 X969, X970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943, X944, X945, X946, X947, X948, X949, X950, X951, X952, X953, X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X931, X932 and / or X940, X941 and / or X953, X954 and / or X960, X961 and / or X969, X970 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX977, NX978X979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X980, C(O)OX981, C(O)NHX982, C(O)NX983X984, OX985, O(X986-O)hH (h = 1, 2, 3, 4, 5), O(X987- O)hX988 (h = 1, 2, 3, 4, 5), OC(O)X989, OC(O)OX990, OC(O)NHX991, OC(O)NX992X993, OP(O)(OX994)(OX995), OSi(X996)(X997)(X998), OS(O2)X999, NHC(O)X1000, NX1001C(O)X1002, NHC(O)OX1003, NHC(O)NHX1004, NHC(O)NX1005X1006, NX1007C(O)OX1008, NX1009C(O)NHX1010, NX1011C(O)NX1012X1013, NHS(O2)X1014, NX1015S(O2)X1016, SX1017, S(O)X1018, S(O2)X1019, S(O2)NHX1020, S(O2)NX1021X1022, S(O2)OX1023, P(O)(OX1024)(OX1025), Si(X1026)(X1027)(X1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX977, NX978X979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X980, C (O) OX981, C (O) NHX982, C (O) NX983X984, OX985, O (X986-O) h H (h = 1, 2, 3, 4, 5), O (X987-O) h X988 (h = 1, 2, 3, 4, 5), OC (O) X989, OC (O) OX990, OC (O) NHX991 , OC (O) NX992X993, OP (O) (OX994) (OX995), OSi (X996) (X997) (X998), OS (O 2 ) X999, NHC (O) X1000, NX1001C (O) X1002, NHC ( O) OX1003, NHC (O) NHX1004, NHC (O) NX1005X1006, NX1007C (O) OX1008, NX1009C (O) NHX1010, NX1011C (O) NX1012X1013, NHS (O 2 ) X1014, NX1015S (O 2 ) X1016, SX1016, SX1016 S (O) X1018, S (O 2 ) X1019, S (O 2 ) NHX1020, S (O 2 ) NX1021X1022, S (O 2 ) OX1023, P (O) (OX1024) (OX1025), Si (X1026) ( X1027) (X1028) "

여기서, X977, X978, X979, X980, X981, X982, X983, X984, X985, X986, X987, X988, X989, X990, X991, X992, X993, X994, X995, X996, X997, X998, X999, X1000, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X1011, X1012, X1013, X1014, X1015, X1016, X1017, X1018, X1019, X1020, X1021, X1022, X1023, X1024, X1025, X1026, X1027, X1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X983, X984 및/또는 X992, X993 및/또는 X1005, X1006 및/또는 X1012, X1013 및/또는 X1021, X1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X977, X978, X979, X980, X981, X982, X983, X984, X985, X986, X987, X988, X989, X990, X991, X992, X993, X994, X995, X996, X997, X998, X999, X1000, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X1011, X1012, X1013, X1014, X1015, X1016, X1017, X1018, X1019, X1020, X1021, X1022, X1023, X1024, X1024 X1026, X1027, X1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X983, X984 and / or X992, X993 and / or X1005, X1006 and / or X1012, X1013 and / or X1021, X1022 are also in each case" heterocycle Reels ",

(l) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1029, NX1030X1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1032, C(O)OX1033, C(O)NHX1034, C(O)NX1035X1036, OX1037, O(X1038-O)iH (i = 1, 2, 3, 4, 5), O(X1039-O)iX1040 (i = 1, 2, 3, 4, 5), OC(O)X1041, OC(O)OX1042, OC(O)NHX1043, OC(O)NX1044X1045, OP(O)(OX1046)(OX1047), OSi(X1048)(X1049)(X1050), OS(O2)X1051, NHC(O)X1052, NX1053C(O)X1054, NHC(O)OX1055, NHC(O)NHX1056, NHC(O)NX1057X1058, NX1059C(O)OX1060, NX1061C(O)NHX1062, NX1063C(O)NX1064X1065, NHS(O2)X1066, NX1067S(O2)X1068, SX1069, S(O)X1070, S(O2)X1071, S(O2)NHX1072, S(O2)NX1073X1074, S(O2)OX1075, P(O)(OX1076)(OX1077), Si(X1078)(X1079)(X1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1029, NX1030X1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1032, C (O) OX1033, C (O) NHX1034, C (O) NX1035X1036, OX1037, O (X1038-O) i H (i = 1, 2, 3, 4, 5), O (X1039-O) i X1040 (i = 1, 2, 3, 4, 5), OC (O) X1041, OC (O) OX1042, OC (O) NHX1043 , OC (O) NX1044X1045, OP (O) (OX1046) (OX1047), OSi (X1048) (X1049) (X1050), OS (O 2 ) X1051, NHC (O) X1052, NX1053C (O) X1054, NHC ( O) OX1055, NHC (O) NHX1056, NHC (O) NX1057X1058, NX1059C (O) OX1060, NX1061C (O) NHX1062, NX1063C (O) NX1064X1065, NHS (O 2 ) X1066, NX1067S (O 2 ) X1068, SX1069 S (O) X1070, S (O 2 ) X1071, S (O 2 ) NHX1072, S (O 2 ) NX1073X1074, S (O 2 ) OX1075, P (O) (OX1076) (OX1077), Si (X1078) ( X1079) (X1080) "

여기서, X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051, X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, X1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1035, X1036 및/또는 X1044, X1045 및/또는 X1057, X1058 및/또는 X1064, X1065 및/또는 X1073, X1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051, X1052 X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077 X1078, X1079, X1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1035, X1036 and / or X1044, X1045 and / or X1057, X1058 and / or X1064, X1065 and / or X1073, X1074 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1081, NX1082X1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1084, C(O)OX1085, C(O)NHX1086, C(O)NX1087X1088, OX1089, O(X1090-O)jH (j = 1, 2, 3, 4, 5), O(X1091-O)jX1092 (j = 1, 2, 3, 4, 5), OC(O)X1093, OC(O)OX1094, OC(O)NHX1095, OC(O)NX1096X1097, OP(O)(OX1098)(OX1099), OSi(X1100)(X1101)(X1102), OS(O2)X1103, NHC(O)X1104, NX1105C(O)X1106, NHC(O)OX1107, NHC(O)NHX1108, NHC(O)NX1109X1110, NX1111C(O)OX1112, NX1113C(O)NHX1114, NX1115C(O)NX1116X1117, NHS(O2)X1118, NX1119S(O2)X1120, SX1121, S(O)X1122, S(O2)X1123, S(O2)NHX1124, S(O2)NX1125X1126, S(O2)OX1127, P(O)(OX1128)(OX1129), Si(X1130)(X1131)(X1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1081, NX1082X1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1084, C (O) OX1085, C (O) NHX1086, C (O) NX1087X1088, OX1089, O (X1090-O) j H (j = 1, 2, 3, 4, 5), O (X1091-O) j X1092 (j = 1, 2, 3, 4, 5), OC (O) X1093, OC (O) OX1094, OC (O) NHX1095 , OC (O) NX1096X1097, OP (O) (OX1098) (OX1099), OSi (X1100) (X1101) (X1102), OS (O 2 ) X1103, NHC (O) X1104, NX1105C (O) X1106, NHC ( O) OX1107, NHC (O) NHX1108, NHC (O) NX1109X1110, NX1111C (O) OX1112, NX1113C (O) NHX1114, NX1115C (O) NX1116X1117, NHS (O 2 ) X1118, NX1119S (O 2 ) X1120, SX112 S (O) X1122, S (O 2 ) X1123, S (O 2 ) NHX1124, S (O 2 ) NX1125X1126, S (O 2 ) OX1127, P (O) (OX1128) (OX1129), Si (X1130) ( X1131) (X1132) "

여기서, X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1104, X1105, X1106, X1107, X1108, X1109, X1110, X1111, X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131, X1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1087, X1088 및/또는 X1096, X1097 및/또는 X1109, X1110 및/또는 X1116, X1117 및/또는 X1125, X1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1104 X1105, X1106, X1107, X1108, X1109, X1110, X1111, X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1128, X1128 X1130, X1131, X1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1087, X1088 and / or X1096, X1097 and / or X1109, X1110 and / or X1116, X1117 and / or X1125, X1126 are also in each case" heterocycle Reels ",

(m) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사 이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)X1133, C(O)OX1134, C(O)NX1135X1136, S(O2)X1137, S(O2)OX1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) X1133, C (O) OX1134, C (O) NX1135X1136, S (O 2 ) X1137, S (O 2 ) OX1138 "

여기서, X1133, X1134, X1135, X1136, X1137, X1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1135, X1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein X1133, X1134, X1135, X1136, X1137, X1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, X1135, X1136 together may also form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1139, NX1140X1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1142, C(O)OX1143, C(O)NHX1144, C(O)NX1145X1146, OX1147, O(X1148-O)kH (k = 1, 2, 3, 4, 5), O(X1149-O)kX1150 (k = 1, 2, 3, 4, 5), OC(O)X1151, OC(O)OX1152, OC(O)NHX1153, OC(O)NX1154X1155, OP(O)(OX1156)(OX1157), OSi(X1158)(X1159)(X1160), OS(O2)X1161, NHC(O)X1162, NX1163C(O)X1164, NHC(O)OX1165, NHC(O)NHX1166, NHC(O)NX1167X1168, NX1169C(O)OX1170, NX1171C(O)NHX1172, NX1173C(O)NX1174X1175, NHS(O2)X1176, NX1177S(O2)X1178, SX1179, S(O)X1180, S(O2)X1181, S(O2)NHX1182, S(O2)NX1183X1184, S(O2)OX1185, P(O)(OX1186)(OX1187), Si(X1188)(X1189)(X1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1139, NX1140X1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1142, C (O) OX1143, C (O) NHX1144, C (O) NX1145X1146, OX1147, O (X1148-O) k H (k = 1, 2, 3, 4, 5), O (X1149-O) k X1150 (k = 1, 2, 3, 4, 5), OC (O) X1151, OC (O) OX1152, OC (O) NHX1153 , OC (O) NX1154X1155, OP (O) (OX1156) (OX1157), OSi (X1158) (X1159) (X1160), OS (O 2 ) X1161, NHC (O) X1162, NX1163C (O) X1164, NHC ( O) OX1165, NHC (O) NHX1166, NHC (O) NX1167X1168, NX1169C (O) OX1170, NX1171C (O) NHX1172, NX1173C (O) NX1174X1175, NHS (O 2 ) X1176, NX1177S (O 2 ) X1178, SX1178 S (O) X1180, S (O 2 ) X1181, S (O 2 ) NHX1182, S (O 2 ) NX1183X1184, S (O 2 ) OX1185, P (O) (OX1186) (OX1187), Si (X1188) ( X1189) (X1190) "

여기서, X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181, X1182, X1183, X1184, X1185, X1186, X1187, X1188, X1189, X1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1145, X1146 및/또는 X1154, X1155 및/또는 X1167, X1168 및/또는 X1174, X1175 및/또는 X1183, X1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1162 X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181, X1182, X1183, X1184, X1185, X1186, X1186, X1186 X1188, X1189, X1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1145, X1146 and / or X1154, X1155 and / or X1167, X1168 and / or X1174, X1175 and / or X1183, X1184 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1191, NX1192X1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1194, C(O)OX1195, C(O)NHX1196, C(O)NX1197X1198, OX1199, O(X1200-O)lH (l = 1, 2, 3, 4, 5), O(X1201-O)lX1202 (l = 1, 2, 3, 4, 5), OC(O)X1203, OC(O)OX1204, OC(O)NHX1205, OC(O)NX1206X1207, OP(O)(OX1208)(OX1209), OSi(X1210)(X1211)(X1212), OS(O2)X1213, NHC(O)X1214, NX1215C(O)X1216, NHC(O)OX1217, NHC(O)NHX1218, NHC(O)NX1219X1220, NX1221C(O)OX1222, NX1223C(O)NHX1224, NX1225C(O)NX1226X1227, NHS(O2)X1228, NX1229S(O2)X1230, SX1231, S(O)X1232, S(O2)X1233, S(O2)NHX1234, S(O2)NX1235X1236, S(O2)OX1237, P(O)(OX1238)(OX1239), Si(X1240)(X1241)(X1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1191, NX1192X1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1194, C (O) OX1195, C (O) NHX1196, C (O) NX1197X1198, OX1199, O (X1200-O) l H (l = 1, 2, 3, 4, 5), O (X1201-O) l X1202 (l = 1, 2, 3, 4, 5), OC (O) X1203, OC (O) OX1204, OC (O) NHX1205 , OC (O) NX1206X1207, OP (O) (OX1208) (OX1209), OSi (X1210) (X1211) (X1212), OS (O 2 ) X1213, NHC (O) X1214, NX1215C (O) X1216, NHC ( O) OX1217, NHC (O) NHX1218, NHC (O) NX1219X1220, NX1221C (O) OX1222, NX1223C (O) NHX1224, NX1225C (O) NX1226X1227, NHS (O 2 ) X1228, NX1229S (O 2 ) X1230, SX123 S (O) X1232, S (O 2 ) X1233, S (O 2 ) NHX1234, S (O 2 ) NX1235X1236, S (O 2 ) OX1237, P (O) (OX1238) (OX1239), Si (X1240) ( X1241) (X1242) "

여기서, X1191, X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237, X1238, X1239, X1240, X1241, X1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1197, X1198 및/또는 X1206, X1207 및/또는 X1219, X1220 및/또는 X1226, X1227 및/또는 X1235, X1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1191, X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1214 X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237, X1238, X1239, X1240, X1241, X1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1197, X1198 and / or X1206, X1207 and / or X1219, X1220 and / or X1226, X1227 and / or X1235, X1236 are also in each case" heterocycle Reels ",

또는or

(B) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "치환된 헤테로아릴"이고, 여기서, "치환된 헤테로아릴"은 다음으로 이루어진 그룹으로부터 선택된 하나 이상의 치환체에 의해 치환되고:(B) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted heteroaryl" wherein "substituted heteroaryl" is substituted by one or more substituents selected from the group consisting of:

(a) "알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, NHV1, N(알킬)2, NHC(O)알킬, NHC(O)사이클로알킬, NHC(O)헤테로사이클릴, NHC(O)아릴, NHC(O)헤테로아릴, NHC(O)아릴알킬, NHC(O)헤테로아릴알킬, NHS(O2)알킬, NHS(O2)사이클로알킬, NHS(O2)헤테로사이클릴, NHS(O2)아릴, NHS(O2)헤테로아릴, NHS(O2)아릴알킬, NHS(O2)헤테로아릴알킬, S알킬, S아릴, S헤테로아릴, O알킬, O사이클로알킬, O사이클로알킬알킬, O아릴, O아릴알킬, O헤테로아릴, O-헤테로아릴알킬, O헤테로사이클릴알킬, OC(O)알킬, OC(O)사이클로알킬, OC(O)헤테로사이클릴, OC(O)아릴, OC(O)헤테로아릴, OC(O)아릴알킬, OC(O)헤테로아릴알킬, OS(O2)알킬, OS(O2)사이클로알킬, OS(O2)헤테로사이클릴, OS(O2)아릴, OS(O2)헤테로아릴, OS(O2)아릴알킬, OS(O2)헤테로아릴알킬, C(O)알킬, C(O)아릴, C(O)헤테로아릴, C(O)OV2, C(O)NHV3, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, S(O2)NH알킬, S(O2)NH아릴, S(O2)NH헤테로아릴, S(O2)NH아릴알킬, S(O2)O알킬, S(O2)O아릴, S(O2)O 아릴알킬"(a) “alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, NHV 1, N (alkyl) 2 , NHC (O) alkyl, NHC (O) cycloalkyl, NHC (O) heterocyclyl, NHC (O ) Aryl, NHC (O) heteroaryl, NHC (O) arylalkyl, NHC (O) heteroarylalkyl, NHS (O 2 ) alkyl, NHS (O 2 ) cycloalkyl, NHS (O 2 ) heterocyclyl, NHS (O 2 ) aryl, NHS (O 2 ) heteroaryl, NHS (O 2 ) arylalkyl, NHS (O 2 ) heteroarylalkyl, Salkyl, Saryl, Sheteroaryl, Oalkyl, Ocycloalkyl, Ocyclo Alkylalkyl, Oaryl, Oarylalkyl, Oheteroaryl, O-heteroarylalkyl, Oheterocyclylalkyl, OC (O) alkyl, OC (O) cycloalkyl, OC (O) heterocyclyl, OC (O ) Aryl, OC (O) heteroaryl, OC (O) arylalkyl, OC (O) heteroarylalkyl, OS (O 2 ) alkyl, OS (O 2 ) cycloalkyl, OS (O 2 ) heterocyclyl, OS (O 2 ) aryl, OS (O 2 ) heteroaryl, OS (O 2 ) arylalkyl, OS (O 2 ) heteroarylalkyl, C (O) alkyl, C (O) aryl, C (O) heteroaryl, C (O) OV2, C (O) NHV 3, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2, S (O 2 ) NH Alkyl, S (O2) NHaryl, S (O2) NH heteroaryl, S (O 2 ) NH arylalkyl, S (O 2 ) Oalkyl, S (O 2 ) Oaryl, S (O 2 ) O arylalkyl "

여기서, V1, V2, V3은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Wherein V 1, V 2, V 3 are each independently selected from the group consisting of: “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl”

단, 치환체 그룹(a)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "(C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, N3, NH사이클로알킬, NH사이클로알킬알킬, NH헤테로아릴, NH헤테로아릴알킬, NH아릴알킬, NH헤테로사이클릴, NH헤테로사이클릴알킬, NV4V5, S사이클로알킬, S사이클로알킬알킬, S아릴, S아릴알킬, S헤테로아릴, S헤테로아릴알킬, S헤테로사이클릴, S헤테로사이클릴알킬, O사이클로알킬, O사이클로알킬알킬, O아릴알킬, O헤테로아릴, O헤테로아릴알킬, O헤테로사이클릴, O헤테로사이클릴알킬, O(V6-O)pH (p = 1, 2, 3, 4, 5), O(V7-O)pV8 (p = 1, 2, 3, 4, 5), OP(O)(OV9)(OV10), C(O)OV11, C(O)NH2, C(O)NHV12, C(O)NV13V14, S(O2)V15, P(O)(OH)2, P(O)(OV16)(OV17), Si(V18)(V19)(V20), OSi(V21)(V22)(V23), OC(O)OV24, OC(O)NHV25, OC(O)NV26V27, NHC(O)OV28, NHC(O)NHV29, NHC(O)NV30V31, NV32C(O)OV33, NV34C(O)NHV35, NV36C(O)NV37V38, NV39S(O2)V40, NHS(O2)V41, OS(O2)V42, NHC(O)V43, NV44C(O)V45, C(O)V46, OC(O)V47, S(O)V48, S(O2)NHV49, S(O2)NV50V51, S(O2)OV52"(i) "(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , NHcycloalkyl, NHcyclo Alkylalkyl, NH heteroaryl, NH heteroarylalkyl, NH arylalkyl, NH heterocyclyl, NH heterocyclylalkyl, NV4V5, Scycloalkyl, Scycloalkylalkyl, Saryl, Sarylalkyl, S heteroaryl, S Heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, Ocycloalkyl, Ocycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O ( V6-O) p H (p = 1, 2, 3, 4, 5), O (V7-O) p V8 (p = 1, 2, 3, 4, 5), OP (O) (OV9) ( OV10), C (O) OV11, C (O) NH2, C (O) NHV12, C (O) NV13V14, S (O 2 ) V15, P (O) (OH) 2 , P (O) (OV16) (OV17), Si (V18) (V19) (V20), OSi (V21) (V22) (V23), OC (O) OV24, OC (O) NHV25, OC (O) NV26V27, NHC (O) OV28, NHC (O) NHV29, NHC (O) NV30V31, NV32C (O) OV33, NV34C (O) NHV35, NV36C (O) NV37V38, NV39S (O 2 ) V40, NHS (O 2 ) V41, OS (O 2 ) V42, NHC (O) V43, NV44C (O) V45, C (O) V46, OC (O ) V47, S (O) V48, S (O 2 ) NHV49, S (O 2 ) NV50V51, S (O 2 ) OV52 "

추가로 단, "N(알킬)2"는 다음 치환체 그룹(b)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further provided that "N (alkyl) 2 " is further substituted by one or more substituents selected from the following substituent groups (b);

여기서, V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V26, V27, V28, V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43, V44, V45, V46, V47, V48, V49, V50, V51, V52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬" 여기서, 대안적으로, V13, V14 및/또는 V26, V27 및/또는 V30, V31 및/또는 V37, V38 및/또는 V50, V51 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V26, V27, V28, V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43, V44, V45, V46, V47, V48, V49, V50, V51, V52 Each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "Here, alternatively, V13, V14 and / or V26, V27 and / or V30, V31 and / or V37, V38 and / or V50, V51 together may also form" heterocyclyl ",

여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(b) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV53, NV54V55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V56, C(O)OV57, C(O)NHV58, C(O)NV59V60, OV61, O(V62-O)rH (r = 1, 2, 3, 4, 5), O(V63-O)rV64 (r = 1, 2, 3, 4, 5), OC(O)V65, OC(O)OV66, OC(O)NHV67, OC(O)NV68V69, OP(O)(OV70)(OV71), OSi(V72)(V73)(V74), OS(O2)V75, NHC(O)V76, NV77C(O)V78, NHC(O)OV79, NHC(O)NHV80, NHC(O)NV81V82, NV83C(O)OV84, NV85C(O)NHV86, NV87C(O)NV88V89, NHS(O2)V90, NV91S(O2)V92, SV93, S(O)V94, S(O2)V95, S(O2)NHV96, S(O2)NV97V98, S(O2)OV99, P(O)(OV100)(OV101), Si(V102)(V103)(V104)"(b) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV53, NV54V55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V56, C (O) OV57, C (O) NHV58, C (O) NV59V60, OV61, O (V62-O) r H (r = 1, 2, 3, 4, 5), O (V63-O) r V64 (r = 1, 2, 3, 4, 5), OC (O) V65, OC (O) OV66, OC (O) NHV67 , OC (O) NV68V69, OP (O) (OV70) (OV71), OSi (V72) (V73) (V74), OS (O 2 ) V75, NHC (O) V76, NV77C (O) V78, NHC ( O) OV79, NHC (O) NHV80, NHC (O) NV81V82, NV83C (O) OV84, NV85C (O) NHV86, NV87C (O) NV88V89, NHS (O 2 ) V90, NV91S (O 2 ) V92, SV93, S (O) V94, S (O 2 ) V95, S (O 2 ) NHV96, S (O 2 ) NV97V98, S (O 2 ) OV99, P (O) (OV100) (OV101), Si (V102) ( V103) (V104) "

여기서, V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65, V66, V67, V68, V69, V70, V71, V72, V73, V74, V75, V76, V77, V78, V79, V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V59, V60 및/또는 V68, V69 및/또는 V81, V82 및/또는 V88, V89 및/또는 V97, V98은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65, V66, V67, V68, V69, V70, V71, V72, V73, V74, V75, V76, V77, V78, V79, V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V59, V60 and / or V68, V69 and / or V81, V82 and / or V88, V89 and / or V97, V98 together may also refer to" heterocyclyl " Can form,

여기서, 임의로, 치환체 그룹(b)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV105, NV106V107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V108, C(O)OV109, C(O)NHV110, C(O)NV111V112, OV113, O(V114-O)sH (s = 1, 2, 3, 4, 5), O(V115-O)sV116 (s = 1, 2, 3, 4, 5), OC(O)V117, OC(O)OV118, OC(O)NHV119, OC(O)NV120V121, OP(O)(OV122)(OV123), OSi(V124)(V125)(V126), OS(O2)V127, NHC(O)V128, NV129C(O)V130, NHC(O)OV131, NHC(O)NHV132, NHC(O)NV133V134, NV135C(O)OV136, NV137C(O)NHV138, NV139C(O)NV140V141, NHS(O2)V142, NV143S(O2)V144, SV145, S(O)V146, S(O2)V147, S(O2)NHV148, S(O2)NV149V150, S(O2)OV151, P(O)(OV152)(OV153), Si(V154)(V155)(V156)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV105, NV106V107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V108, C (O) OV109, C (O) NHV110, C (O) NV111V112, OV113, O (V114-O) s H (s = 1, 2, 3, 4, 5), O (V115-O) s V116 (s = 1, 2, 3, 4, 5), OC (O) V117, OC (O) OV118, OC (O) NHV119 , OC (O) NV120V121, OP (O) (OV122) (OV123), OSi (V124) (V125) (V126), OS (O 2 ) V127, NHC (O) V128, NV129C (O) V130, NHC ( O) OV131, NHC (O) NHV132, NHC (O) NV133V134, NV135C (O) OV136, NV137C (O) NHV138, NV139C (O) NV140V141, NHS (O 2 ) V142, NV143S (O 2 ) V144, SV145, S (O) V146, S (O 2 ) V147, S (O 2 ) NHV148, S (O 2 ) NV149V150, S (O 2 ) OV151, P (O) (OV152) (OV153), Si (V154) ( V155) (V156) "

여기서, V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141, V142, V143, V144, V145, V146, V147, V148, V149, V150, V151, V152, V153, V154, V155, V156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V111, V112 및/또는 V120, V121 및/또는 V133, V134 및/또는 V140, V141 및/또는 V149, V150은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141, V142, V143, V144, V145, V146, V147, V148, V149, V150, V151, V152, V153, V154, V155, V156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V111, V112 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 may also together refer to" heterocyclyl " Can form,

여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV157, NV158V159, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V160, C(O)OV161, C(O)NHV162, C(O)NV163V164, OV165, O(V166-O)tH (t = 1, 2, 3, 4, 5), O(V167-O)tV168 (t = 1, 2, 3, 4, 5), OC(O)V169, OC(O)OV170, OC(O)NHV171, OC(O)NV172V173, OP(O)(OV174)(OV175), OSi(V176)(V177)(V178), OS(O2)V179, NHC(O)V180, NV181C(O)V182, NHC(O)OV183, NHC(O)NHV184, NHC(O)NV185V186, NV187C(O)OV188, NV189C(O)NHV190, NV191C(O)NV192V193, NHS(O2)V194, NV195S(O2)V196, SV197, S(O)V198, S(O2)V199, S(O2)NHV200, S(O2)NV201V202, S(O2)OV203, P(O)(OV204)(OV205), Si(V206)(V207)(V208)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV157, NV158V159, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V160, C (O) OV161, C (O) NHV162, C (O) NV163V164, OV165, O (V166-O) t H (t = 1, 2, 3, 4, 5), O (V167-O) t V168 (t = 1, 2, 3, 4, 5), OC (O) V169, OC (O) OV170, OC (O) NHV171 , OC (O) NV172V173, OP (O) (OV174) (OV175), OSi (V176) (V177) (V178), OS (O2) V179, NHC (O) V180, NV181C (O) V182, NHC (O ) OV183, NHC (O) NHV184, NHC (O) NV185V186, NV187C (O) OV188, NV189C (O) NHV190, NV191C (O) NV192V193, NHS (O 2 ) V194, NV195S (O 2 ) V196, SV197, S (O) V198, S (O 2 ) V199, S (O 2 ) NHV200, S (O 2 ) NV201V202, S (O 2 ) OV203, P (O) (OV204) (OV205), Si (V206) (V207 ) (V208) "

여기서, V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194, V195, V196, V197, V198, V199, V200, V201, V202, V203, V204, V205, V206, V207, V208은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V163, V164 및/또는 V172, V173 및/또는 V185, V186 및/또는 V192, V193 및/또는 V201, V202는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194, V195, V196, V197, V198, V199, V200, V201, V202, V203, V204, V205, V206, V207, V208 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V163, V164 and / or V172, V173 and / or V185, V186 and / or V192, V193 and / or V201, V202 together also refer to" heterocyclyl " Can form,

또는 Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "치환된 헤테로아릴"이고, 여기서, "치환된 헤테로아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고: Or one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted heteroaryl" wherein "substituted heteroaryl" is substituted by one or more substituents identically or differently selected from the group consisting of: Being:

(c) "(C9-C30)알킬, NV209V210, NH(C9-C30)알킬, NHC(O)사이클로알킬알킬, NHC(O)헤테로사이클릴알킬, NHC(O)(C9-C30)알킬, NV211C(O)V212, NV213C(O)(C9-C30)알킬, NHC(O)OV214, NV215C(O)OV216, NHC(O)NHV217, NHC(O)NV218V219, NV220C(O)NHV221, NV222C(O)NV223V224, NHS(O2)사이클로알킬알킬, NHS(O2)헤테로사이클릴알킬, NV225S(O2)V226, O헤테로사이클릴, O(C9-C30)알킬, S사이클로알킬, S헤테로사이클릴, S아릴알킬, S헤테로아릴알킬, S사이클로알킬알킬, S헤테로사이클릴 알킬, S(C9-C30)알킬, OC(O)사이클로알킬알킬, OC(O)헤테로사이클릴알킬, OC(O)(C9-C30)알킬, OC(O)OV227, OC(O)NHV228, OC(O)NV229V230, OP(O)(OV231)(OV232), OS(O2)사이클로알킬알킬, OS(O2)헤테로사이클릴알킬, OS(O2)(C9-C30)알킬, C(O)사이클로알킬, C(O)헤테로사이클릴, C(O)아릴알킬, C(O)헤테로아릴알킬, C(O)사이클로알킬알킬, C(O)헤테로사이클릴알킬, C(O)(C9-C30)알킬, C(O)O(C9-C30)알킬, C(O)NH(C9-C30)알킬, C(O)NV233V234, C(O)NHOV235, C(O)NV236-OV237, C(O)NHNV238V239, C(O)NV240NV241V242, S(O)V243, S(O2)V244, S(O2)NH사이클로알킬, S(O2)NH헤테로사이클릴, S(O2)NH헤테로아릴알킬, S(O2)NH사이클로알킬알킬, S(O2)NH헤테로사이클릴알킬, S(O2)NH(C9-C30)알킬, S(O2)O사이클로알킬, S(O2)O헤테로사이클릴, S(O2)O헤테로아릴, S(O2)O헤테로아릴알킬, S(O2)O사이클로알킬알킬, S(O2)O헤테로사이클릴알킬, S(O2)O(C9-C30)알킬, P(O)(OH)2, P(O)(OV245)(OV246), Si(V247)(V248)(V249), OSi(V250)(V251)(V252)"(c) "(C 9 -C 30 ) alkyl, NV209V210, NH (C 9 -C 30 ) alkyl, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NHC (O) (C 9- C 30 ) alkyl, NV211C (O) V212, NV213C (O) (C 9 -C 30 ) alkyl, NHC (O) OV214, NV215C (O) OV216, NHC (O) NHV217, NHC (O) NV218V219, NV220C ( O) NHV221, NV222C (O) NV223V224, NHS (O 2 ) cycloalkylalkyl, NHS (O 2 ) heterocyclylalkyl, NV225S (O 2) V226, O heterocyclyl, O (C 9 -C 30 ) alkyl, Scycloalkyl, Sheterocyclyl, Sarylalkyl, Sheteroarylalkyl, Scycloalkylalkyl, Sheterocyclyl alkyl, S (C 9 -C 30 ) alkyl, OC (O) cycloalkylalkyl, OC (O Heterocyclylalkyl, OC (O) (C 9 -C 30 ) alkyl, OC (O) OV227, OC (O) NHV228, OC (O) NV229V230, OP (O) (OV231) (OV232), OS ( O 2 ) cycloalkylalkyl, OS (O 2) heterocyclylalkyl, OS (O 2 ) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) heterocyclyl, C (O) aryl Alkyl, C (O) heteroarylalkyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O ) (C 9 -C 30 ) alkyl, C (O) O (C 9 -C 30 ) alkyl, C (O) NH (C 9 -C 30 ) alkyl, C (O) NV233V234, C (O) NHOV235, C (O) NV236-OV237, C (O) NHNV238V239, C (O) NV240NV241V242, S (O) V243, S (O 2 ) V244, S (O 2 ) NH cycloalkyl, S (O 2 ) NH heterocycle Reel, S (O 2 ) NH heteroarylalkyl, S (O 2 ) NH cycloalkylalkyl, S (O 2 ) NH heterocyclylalkyl, S (O 2 ) NH (C 9 -C 30 ) alkyl, S ( O 2 ) Ocycloalkyl, S (O 2 ) O heterocyclyl, S (O 2 ) O heteroaryl, S (O 2 ) O heteroarylalkyl, S (O 2 ) Ocycloalkylalkyl, S (O 2 ) O Heterocyclylalkyl, S (O 2 ) O (C 9 -C 30 ) alkyl, P (O) (OH) 2, P (O) (OV245) (OV246), Si (V247) (V248) ( V249), OSi (V250) (V251) (V252) "

여기서, V209, V210, V211, V212, V213, V214, V215, V216, V217, V218, V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229, V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬 알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V218, V219 및/또는 V223, V224 및/또는 V229, V230 및/또는 V233, V234 및/또는 V238, V239 및/또는 V241, V242는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V209, V210, V211, V212, V213, V214, V215, V216, V217, V218, V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229, V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are each independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkyl alkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein, alternatively, V218, V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 together may also form “heterocyclyl”,

단, 치환체 "N(알킬)2", "C(O)N(알킬)2", "C(O)N(사이클로알킬)2", "C(O)N(아릴)2", "C(O)N(헤테로아릴)2"는 다음 치환체 그룹(i)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Provided that the substituents "N (alkyl) 2 ", "C (O) N (alkyl) 2 ", "C (O) N (cycloalkyl) 2 ", "C (O) N (aryl) 2 ", "C (O) N (heteroaryl) 2 ″ is further substituted by one or more substituents selected from the following substituent groups (i);

여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV253, NV254V255, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V256, C(O)OV257, C(O)NHV258, C(O)NV259V260, OV261, O(V262-O)uH (u = 1, 2, 3, 4, 5), O(V263-O)uV264 (u = 1, 2, 3, 4, 5), OC(O)V265, OC(O)OV266, OC(O)NHV267, OC(O)NV268V269, OP(O)(OV270)(OV271), OSi(V272)(V273)(V274), OS(O2)V275, NHC(O)V276, NV277C(O)V278, NHC(O)OV279, NHC(O)NHV280, NHC(O)NV281V282, NV283C(O)OV284, NV285C(O)NHV286, NV287C(O)NV288V289, NHS(O2)V290, NV291S(O2)V292, SV293, S(O)V294, S(O2)V295, S(O2)NHV296, S(O2)NV297V298, S(O2)OV299, P(O)(OV300)(OV301), Si(V302)(V303)(V304)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV253, NV254V255, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V256, C (O) OV257, C (O) NHV258, C (O) NV259V260, OV261, O (V262-O) u H (u = 1, 2, 3, 4, 5), O (V263-O) u V264 (u = 1, 2, 3, 4, 5), OC (O) V265, OC (O) OV266, OC (O) NHV267 , OC (O) NV268V269, OP (O) (OV270) (OV271), OSi (V272) (V273) (V274), OS (O 2 ) V275, NHC (O) V276, NV277C (O) V278, NHC ( O) OV279, NHC (O) NHV280, NHC (O) NV281V282, NV283C (O) OV284, NV285C (O) NHV286, NV287C (O) NV288V289, NHS (O2) V290, NV291S (O2) V292, SV293, S ( O) V294, S (O 2 ) V295, S (O 2 ) NHV296, S (O 2 ) NV297V298, S (O 2 ) OV299, P (O) (OV300) (OV301), Si (V302) (V303) (V304) "

여기서, V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274, V275, V276, V277, V278, V279, V280, V281, V282, V283, V284, V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V259, V260 및/또는 V268, V269 및/또는 V281, V282 및/또는 V288, V289 및/또는 V297, V298은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274, V275, V276, V277, V278, V279, V280, V281, V282, V283, V284, V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V259, V260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 together may also refer to" heterocyclyl " Can form,

여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(d) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV305, NV306V307, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V308, C(O)OV309, C(O)NHV310, C(O)NV311V312, OV313, O(V314-O)vH (v = 1, 2, 3, 4, 5), O(V315-O)vV316 (v = 1, 2, 3, 4, 5), OC(O)V317, OC(O)OV318, OC(O)NHV319, OC(O)NV320V321, OP(O)(OV322)(OV323), OSi(V324)(V325)(V326), OS(O2)V327, NHC(O)V328, NV329C(O)V330, NHC(O)OV331, NHC(O)NHV332, NHC(O)NV333V334, NV335C(O)OV336, NV337C(O)NHV338, NV339C(O)NV340V341, NHS(O2)V342, NV343S(O2)V344, SV345, S(O)V346, S(O2)V347, S(O2)NHV348, S(O2)NV349V350, S(O2)OV351, P(O)(OV352)(OV353), Si(V354)(V355)(V356)"(d) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV305, NV306V307, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V308, C (O) OV309, C (O) NHV310, C (O) NV311V312, OV313, O (V314-O) v H (v = 1, 2, 3, 4, 5), O (V315-O) v V316 (v = 1, 2, 3, 4, 5), OC (O) V317, OC (O) OV318, OC (O) NHV319 , OC (O) NV320V321, OP (O) (OV322) (OV323), OSi (V324) (V325) (V326), OS (O 2 ) V327, NHC (O) V328, NV329C (O) V330, NHC ( O) OV331, NHC (O) NHV332, NHC (O) NV333V334, NV335C (O) OV336, NV337C (O) NHV338, NV339C (O) NV340V341, NHS (O2) V342, NV343S (O2) V344, SV345, S ( O) V346, S (O 2 ) V347, S (O 2 ) NHV348, S (O 2 ) NV349V350, S (O 2 ) OV351, P (O) (OV352) (OV353), Si (V354) (V355) (V356) "

여기서, V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331, V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V311, V312 및/또는 V320, V321 및/또는 V333, V334 및/또는 V340, V341 및/또는 V349, V350은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331, V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V311, V312 and / or V320, V321 and / or V333, V334 and / or V340, V341 and / or V349, V350 may also be referred to as" heterocyclyl " Can form,

여기서, 임의로, 치환체 그룹(d)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (d) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV357, NV358V359, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V360, C(O)OV361, C(O)NHV362, C(O)NV363V364, OV365, O(V366-O)wH (w = 1, 2, 3, 4, 5), O(V367-O)wV368 (w = 1, 2, 3, 4, 5), OC(O)V369, OC(O)OV370, OC(O)NHV371, OC(O)NV372V373, OP(O)(OV374)(OV375), OSi(V376)(V377)(V378), OS(O2)V379, NHC(O)V380, NV381C(O)V382, NHC(O)OV383, NHC(O)NHV384, NHC(O)NV385V386, NV387C(O)OV388, NV389C(O)NHV390, NV391C(O)NV392V393, NHS(O2)V394, NV395S(O2)V396, SV397, S(O)V398, S(O2)V399, S(O2)NHV400, S(O2)NV401V402, S(O2)OV403, P(O)(OV404)(OV405), Si(V406)(V407)(V408)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV357, NV358V359, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V360, C (O) OV361, C (O) NHV362, C (O) NV363V364, OV365, O (V366-O) w H (w = 1, 2, 3, 4, 5), O (V367-O) w V368 (w = 1, 2, 3, 4, 5), OC (O) V369, OC (O) OV370, OC (O) NHV371 , OC (O) NV372V373, OP (O) (OV374) (OV375), OSi (V376) (V377) (V378), OS (O 2 ) V379, NHC (O) V380, NV381C (O) V382, NHC ( O) OV383, NHC (O) NHV384, NHC (O) NV385V386, NV387C (O) OV388, NV389C (O) NHV390, NV391C (O) NV392V393, NHS (O2) V394, NV395S (O2) V396, SV397, S ( O) V398, S (O 2 ) V399, S (O 2 ) NHV400, S (O 2 ) NV401V402, S (O 2 ) OV403, P (O) (OV404) (OV405), Si (V406) (V407) (V408) "

여기서, V357, V358, V359, V360, V361, V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V363, V364 및/또는 V372, V373 및/또는 V385, V386 및/또는 V392, V393 및/또는 V401, V402는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V357, V358, V359, V360, V361, V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V363, V364 and / or V372, V373 and / or V385, V386 and / or V392, V393 and / or V401, V402 together also represent" heterocyclyl " Can form,

여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV409, NV410V411, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V412, C(O)OV413, C(O)NHV414, C(O)NV415V416, OV417, O(V418-O)xH (x = 1, 2, 3, 4, 5), O(V419-O)xV420 (x = 1, 2, 3, 4, 5), OC(O)V421, OC(O)OV422, OC(O)NHV423, OC(O)NV424V425, OP(O)(OV426)(OV427), OSi(V428)(V429)(V430), OS(O2)V431, NHC(O)V432, NV433C(O)V434, NHC(O)OV435, NHC(O)NHV436, NHC(O)NV437V438, NV439C(O)OV440, NV441C(O)NHV442, NV443C(O)NV444V445, NHS(O2)V446, NV447S(O2)V448, SV449, S(O)V450, S(O2)V451, S(O2)NHV452, S(O2)NV453V454, S(O2)OV455, P(O)(OV456a)(OV456b), Si(V456c)(V456d)(V456e)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV 409, NV410V411, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V412, C (O) OV413, C (O) NHV414, C (O) NV415V416, OV417, O (V418-O) x H (x = 1, 2, 3, 4, 5), O (V419-O) x V420 (x = 1, 2, 3, 4, 5), OC (O) V421, OC (O) OV422, OC (O) NHV423 , OC (O) NV424V425, OP (O) (OV426) (OV427), OSi (V428) (V429) (V430), OS (O 2 ) V431, NHC (O) V432, NV433C (O) V434, NHC ( O) OV435, NHC (O) NHV436, NHC (O) NV437V438, NV439C (O) OV440, NV441C (O) NHV442, NV443C (O) NV444V445, NHS (O 2 ) V446, NV447S (O2) V448, SV449, S (O) V450, S (O 2 ) V451, S (O 2 ) NHV452, S (O 2 ) NV453V454, S (O 2 ) OV455, P (O) (OV456a) (OV456b), Si (V456c) (V456d ) (V456e) "

여기서, V409, V410, V411, V412, V413, V414, V415, V416, V417, V418, V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429, V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V415, V416 및/또는 V424, V425 및/또는 V437, V438 및/또는 V444, V445 및/또는 V453, V454는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V409, V410, V411, V412, V413, V414, V415, V416, V417, V418, V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429, V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V415, V416 and / or V424, V425 and / or V437, V438 and / or V444, V445 and / or V453, V454 together also refer to" heterocyclyl " Can form,

및 Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고:And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of:

(e) 수소;(e) hydrogen;

(f) 할로겐, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;

(g) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV457, NV458V459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V460, C(O)OV461, C(O)NHV462, C(O)NV463V464, OV465, O(V466-O)yH (y = 1, 2, 3, 4, 5), O(V467-O)yV468 (y = 1, 2, 3, 4, 5), OC(O)V469, OC(O)OV470, OC(O)NHV471, OC(O)NV472V473, OP(O)(OV474)(OV475), OSi(V476)(V477)(V478), OS(O2)V479, NHC(O)V480, NV481C(O)V482, NHC(O)OV483, NHC(O)NHV484, NHC(O)NV485V486, NV487C(O)OV488, NV489C(O)NHV490, NV491C(O)NV492V493, NHS(O2)V494, NV495S(O2)V496, SV497, S(O)V498, S(O2)V499, S(O2)NHV500, S(O2)NV501V502, S(O2)OV503, P(O)(OV504)(OV505), Si(V506)(V507)(V508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV457, NV458V459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V460, C (O) OV461, C (O) NHV462, C (O) NV463V464, OV465, O (V466-O) y H (y = 1, 2, 3, 4, 5), O (V467-O) y V468 (y = 1, 2, 3, 4, 5), OC (O) V469, OC (O) OV470, OC (O) NHV471 , OC (O) NV472V473, OP (O) (OV474) (OV475), OSi (V476) (V477) (V478), OS (O 2 ) V479, NHC (O) V480, NV481C (O) V482, NHC ( O) OV483, NHC (O) NHV484, NHC (O) NV485V486, NV487C (O) OV488, NV489C (O) NHV490, NV491C (O) NV492V493, NHS (O2) V494, NV495S (O2) V496, SV497, S ( O) V498, S (O 2 ) V499, S (O 2 ) NHV500, S (O 2 ) NV501V502, S (O 2 ) OV503, P (O) (OV504) (OV505), Si (V506) (V507) (V508) "

여기서, V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495, V496, V497, V498, V499, V500, V501, V502, V503, V504, V505, V506, V507, V508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V463, V464 및/또는 V472, V473 및/또는 V485, V486 및/또는 V492, V493 및/또는 V501, V502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495, V496, V497, V498, V499, V500, V501, V502, V503, V504, V505, V506, V507, V508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V463, V464 and / or V472, V473 and / or V485, V486 and / or V492, V493 and / or V501, V502 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV509, NV510V511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V512, C(O)OV513, C(O)NHV514, C(O)NV515V516, OV517, O(V518-O)zH (z = 1, 2, 3, 4, 5), O(V519-O)zV520 (z = 1, 2, 3, 4, 5), OC(O)V521, OC(O)OV522, OC(O)NHV523, OC(O)NV524V525, OP(O)(OV526)(OV527), OSi(V528)(V529)(V530), OS(O2)V531, NHC(O)V532, NV533C(O)V534, NHC(O)OV535, NHC(O)NHV536, NHC(O)NV537V538, NV539C(O)OV540, NV541C(O)NHV542, NV543C(O)NV544V545, NHS(O2)V546, NV547S(O2)V548, SV549, S(O)V550, S(O2)V551, S(O2)NHV552, S(O2)NV553V554, S(O2)OV555, P(O)(OV556)(OV557), Si(V558)(V559)(V560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV509, NV510V511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V512, C (O) OV513, C (O) NHV514, C (O) NV515V516, OV517, O (V518-O) z H (z = 1, 2, 3, 4, 5), O (V519-O) z V520 (z = 1, 2, 3, 4, 5), OC (O) V521, OC (O) OV522, OC (O) NHV523 , OC (O) NV524V525, OP (O) (OV526) (OV527), OSi (V528) (V529) (V530), OS (O 2 ) V531, NHC (O) V532, NV533C (O) V534, NHC ( O) OV535, NHC (O) NHV536, NHC (O) NV537V538, NV539C (O) OV540, NV541C (O) NHV542, NV543C (O) NV544V545, NHS (O 2 ) V546, NV547S (O 2 ) V548, SV549, S (O) V550, S (O 2 ) V551, S (O 2 ) NHV552, S (O 2 ) NV553V554, S (O 2 ) OV555, P (O) (OV556) (OV557), Si (V558) ( V559) (V560) "

여기서, V509, V510, V511, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527, V528, V529, V530, V531, V532, V533, V534, V535, V536, V537, V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V515, V516 및/또는 V524, V525 및/또는 V537, V538 및/또는 V544, V545 및/또는 V553, V554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, V509, V510, V511, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527, V528, V529, V530, V531, V532, V533, V534, V535, V536, V537, V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V515, V516 and / or V524, V525 and / or V537, V538 and / or V544, V545 and / or V553, V554 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV561, NV562V563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V564, C(O)OV565, C(O)NHV566, C(O)NV567V568, OV569, O(V570-O)aH (a = 1, 2, 3, 4, 5), O(V571-O)aV572 (a = 1, 2, 3, 4, 5), OC(O)V573, OC(O)OV574, OC(O)NHV575, OC(O)NV576V577, OP(O)(OV578)(OV579), OSi(V580)(V581)(V582), OS(O2)V583, NHC(O)V584, NV585C(O)V586, NHC(O)OV587, NHC(O)NHV588, NHC(O)NV589V590, NV591C(O)OV592, NV593C(O)NHV594, NV595C(O)NV596V597, (iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV561, NV562V563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V564, C (O) OV565, C (O) NHV566, C (O) NV567V568, OV569, O (V570-O) a H (a = 1, 2, 3, 4, 5), O (V571-O) a V572 (a = 1, 2, 3, 4, 5), OC (O) V573, OC (O) OV574, OC (O) NHV575 , OC (O) NV576V577, OP (O) (OV578) (OV579), OSi (V580) (V581) (V582), OS (O 2 ) V583, NHC (O) V584, NV585C (O) V586, NHC ( O) OV587, NHC (O) NHV588, NHC (O) NV589V590, NV591C (O) OV592, NV593C (O) NHV594, NV595C (O) NV596V597,

NHS(O2)V598, NV599S(O2)V600, SV601, S(O)V602, S(O2)V603, S(O2)NHV604, S(O2)NV605V606, S(O2)OV607, P(O)(OV608)(OV609), Si(V610)(V611)(V612)"NHS (O 2 ) V598, NV599S (O 2 ) V600, SV601, S (O) V602, S (O 2 ) V603, S (O 2 ) NHV604, S (O 2 ) NV605V606, S (O 2 ) OV607, P (O) (OV608) (OV609), Si (V610) (V611) (V612) "

여기서, V561, V562, V563, V564, V565, V566, V567, V568, V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V567, V568 및/또는 V576, V577 및/또는 V589, V590 및/또는 V596, V597 및/또는 V605, V606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V561, V562, V563, V564, V565, V566, V567, V568, V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V567, V568 and / or V576, V577 and / or V589, V590 and / or V596, V597 and / or V605, V606 are also in each case" heterocycle. " Reels ",

(h) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV613, NV614V615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V616, C(O)OV617, C(O)NHV618, C(O)NV619V620, OV621, O(V622-O)bH (b = 1, 2, 3, 4, 5), O(V623-O)bV624 (b = 1, 2, 3, 4, 5), OC(O)V625, OC(O)OV626, OC(O)NHV627, OC(O)NV628V629, OP(O)(OV630)(OV631), OSi(V632)(V633)(V634), OS(O2)V635, NHC(O)V636, NV637C(O)V638, NHC(O)OV639, NHC(O)NHV640, NHC(O)NV641V642, NV643C(O)OV644, NV645C(O)NHV646, NV647C(O)NV648V649, NHS(O2)V650, NV651S(O2)V652, SV653, S(O)V654, S(O2)V655, S(O2)NHV656, S(O2)NV657V658, S(O2)OV659, P(O)(OV660)(OV661), Si(V662)(V663)(V664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV613, NV614V615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V616, C (O) OV617, C (O) NHV618, C (O) NV619V620, OV621, O (V622-O) b H (b = 1, 2, 3, 4, 5), O (V623-O) b V624 (b = 1, 2, 3, 4, 5), OC (O) V625, OC (O) OV626, OC (O) NHV627 , OC (O) NV628V629, OP (O) (OV630) (OV631), OSi (V632) (V633) (V634), OS (O 2 ) V635, NHC (O) V636, NV637C (O) V638, NHC ( O) OV639, NHC (O) NHV640, NHC (O) NV641V642, NV643C (O) OV644, NV645C (O) NHV646, NV647C (O) NV648V649, NHS (O 2 ) V650, NV651S (O 2 ) V652, SV653, S (O) V654, S (O 2 ) V655, S (O 2 ) NHV656, S (O 2 ) NV657V658, S (O 2 ) OV659, P (O) (OV660) (OV661), Si (V662) ( V663) (V664) "

여기서, V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631, V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651, V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V619, V620 및/또는 V628, V629 및/또는 V641, V642 및/또는 V648, V649 및/또는 V657, V658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631, V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651, V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V619, V620 and / or V628, V629 and / or V641, V642 and / or V648, V649 and / or V657, V658 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV665, NV666V667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V668, C(O)OV669, C(O)NHV670, C(O)NV671V672, OV673, O(V674-O)cH (c = 1, 2, 3, 4, 5), O(V675-O)cV676 (c = 1, 2, 3, 4, 5), OC(O)V677, OC(O)OV678, OC(O)NHV679, OC(O)NV680V681, OP(O)(OV682)(OV683), OSi(V684)(V685)(V686), OS(O2)V687, NHC(O)V688, NV689C(O)V690, NHC(O)OV691, NHC(O)NHV692, NHC(O)NV693V694, NV695C(O)OV696, NV697C(O)NHV698, NV699C(O)NV700V701, NHS(O2)V702, NV703S(O2)V704, SV705, S(O)V706, S(O2)V707, S(O2)NHV708, S(O2)NV709V710, S(O2)OV711, P(O)(OV712)(OV713), Si(V714)(V715)(V716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV665, NV666V667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V668, C (O) OV669, C (O) NHV670, C (O) NV671V672, OV673, O (V674-O) c H (c = 1, 2, 3, 4, 5), O (V675-O) c V676 (c = 1, 2, 3, 4, 5), OC (O) V677, OC (O) OV678, OC (O) NHV679 , OC (O) NV680V681, OP (O) (OV682) (OV683), OSi (V684) (V685) (V686), OS (O 2 ) V687, NHC (O) V688, NV689C (O) V690, NHC ( O) OV691, NHC (O) NHV692, NHC (O) NV693V694, NV695C (O) OV696, NV697C (O) NHV698, NV699C (O) NV700V701, NHS (O 2 ) V702, NV703S (O2) V704, SV705, S (O) V706, S (O 2 ) V707, S (O 2 ) NHV708, S (O 2 ) NV709V710, S (O 2 ) OV711, P (O) (OV712) (OV713), Si (V714) (V715 ) (V716) "

여기서, V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V687, V688, V689, V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V712, V713, V714, V715, V716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V671, V672 및/또는 V680, V681 및/또는 V693, V694 및/또는 V700, V701 및/또는 V709, V710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V687, V688, V689, V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V712, V713, V714, V715, V716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V671, V672 and / or V680, V681 and / or V693, V694 and / or V700, V701 and / or V709, V710 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV717, NV718V719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V720, C(O)OV721, C(O)NHV722, C(O)NV723V724, OV725, O(V726-O)dH (d = 1, 2, 3, 4, 5), O(V727-O)dV728 (d = 1, 2, 3, 4, 5), OC(O)V729, OC(O)OV730, OC(O)NHV731, OC(O)NV732V733, OP(O)(OV734)(OV735), OSi(V736)(V737)(V738), OS(O2)V739, NHC(O)V740, NV741C(O)V742, NHC(O)OV743, NHC(O)NHV744, NHC(O)NV745V746, NV747C(O)OV748, NV749C(O)NHV750, NV751C(O)NV752V753, NHS(O2)V754, NV755S(O2)V756, SV757, S(O)V758, S(O2)V759, S(O2)NHV760, S(O2)NV761V762, S(O2)OV763, P(O)(OV764)(OV765), Si(V766)(V767)(V768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV717, NV718V719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V720, C (O) OV721, C (O) NHV722, C (O) NV723V724, OV725, O (V726-O) d H (d = 1, 2, 3, 4, 5), O (V727-O) d V728 (d = 1, 2, 3, 4, 5), OC (O) V729, OC (O) OV730, OC (O) NHV731 , OC (O) NV732V733, OP (O) (OV734) (OV735), OSi (V736) (V737) (V738), OS (O 2 ) V739, NHC (O) V740, NV741C (O) V742, NHC ( O) OV743, NHC (O) NHV744, NHC (O) NV745V746, NV747C (O) OV748, NV749C (O) NHV750, NV751C (O) NV752V753, NHS (O2) V754, NV755S (O2) V756, SV757, S ( O) V758, S (O 2 ) V759, S (O 2 ) NHV760, S (O 2 ) NV761V762, S (O 2 ) OV763, P (O) (OV764) (OV765), Si (V766) (V767) (V768) "

여기서, V717, V718, V719, V720,V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V723, V724 및/또는 V732, V733 및/또는 V745, V746 및/또는 V752, V753 및/또는 V761, V762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V717, V718, V719, V720, V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V723, V724 and / or V732, V733 and / or V745, V746 and / or V752, V753 and / or V761, V762 are also in each case" heterocycle. " Reels ",

(j) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV769, NV770V771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V772, C(O)OV773, C(O)NHV774, C(O)NV775V776, OV777, O(V778-O)eH (e = 1, 2, 3, 4, 5), O(V779-O)eV780 (e = 1, 2, 3, 4, 5), OC(O)V781, OC(O)OV782, OC(O)NHV783, OC(O)NV784V785, OP(O)(OV786)(OV787), OSi(V788)(V789)(V790), OS(O2)V791, NHC(O)V792, NV793C(O)V794, NHC(O)OV795, NHC(O)NHV796, NHC(O)NV797V798, NV799C(O)OV800, NV801C(O)NHV802, NV803C(O)NV804V805, NHS(O2)V806, NV807S(O2)V808, SV809, S(O)V810, S(O2)V811, S(O2)NHV812, S(O2)NV813V814, S(O2)OV815, P(O)(OV816)(OV817), Si(V818)(V819)(V820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV769, NV770V771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V772, C (O) OV773, C (O) NHV774, C (O) NV775V776, OV777, O (V778-O) e H (e = 1, 2, 3, 4, 5), O (V779-O) e V780 (e = 1, 2, 3, 4, 5), OC (O) V781, OC (O) OV782, OC (O) NHV783 , OC (O) NV784V785, OP (O) (OV786) (OV787), OSi (V788) (V789) (V790), OS (O 2 ) V791, NHC (O) V792, NV793C (O) V794, NHC ( O) OV795, NHC (O) NHV796, NHC (O) NV797V798, NV799C (O) OV800, NV801C (O) NHV802, NV803C (O) NV804V805, NHS (O 2 ) V806, NV807S (O 2 ) V808, SV809, S (O) V810, S (O 2 ) V811, S (O 2 ) NHV812, S (O 2 ) NV813V814, S (O 2 ) OV815, P (O) (OV816) (OV817), Si (V818) ( V819) (V820) "

여기서, V769, V770, V771, V772, V773, V774, V775, V776, V777, V778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V791, V792, V793, V794, V795, V796, V797, V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V775, V776 및/또는 V784, V785 및/또는 V797, V798 및/또는 V804, V805 및/또는 V813, V814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V769, V770, V771, V772, V773, V774, V775, V776, V777, V778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V791, V792, V793, V794, V795, V796, V797, V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V775, V776 and / or V784, V785 and / or V797, V798 and / or V804, V805 and / or V813, V814 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV821, NV822V823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V824, C(O)OV825, C(O)NHV826, C(O)NV827V828, OV829, O(V830-O)fH (f = 1, 2, 3, 4, 5), O(V831- O)fV832 (f = 1, 2, 3, 4, 5), OC(O)V833, OC(O)OV834, OC(O)NHV835, OC(O)NV836V837, OP(O)(OV838)(OV839), OSi(V840)(V841)(V842), OS(O2)V843, NHC(O)V844, NV845C(O)V846, NHC(O)OV847, NHC(O)NHV848, NHC(O)NV849V850, NV851C(O)OV852, NV853C(O)NHV854, NV855C(O)NV856V857, NHS(O2)V858, NV859S(O2)V860, SV861, S(O)V862, S(O2)V863, S(O2)NHV864, S(O2)NV865V866, S(O2)OV867, P(O)(OV868)(OV869), Si(V870)(V871)(V872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV821, NV822V823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V824, C (O) OV825, C (O) NHV826, C (O) NV827V828, OV829, O (V830-O) f H (f = 1, 2, 3, 4, 5), O (V831- O) f V832 (f = 1, 2, 3, 4, 5), OC (O) V833, OC (O) OV834, OC (O) NHV835 , OC (O) NV836V837, OP (O) (OV838) (OV839), OSi (V840) (V841) (V842), OS (O 2 ) V843, NHC (O) V844, NV845C (O) V846, NHC ( O) OV847, NHC (O) NHV848, NHC (O) NV849V850, NV851C (O) OV852, NV853C (O) NHV854, NV855C (O) NV856V857, NHS (O 2 ) V858, NV859S (O 2 ) V860, SV861, S (O) V862, S (O 2 ) V863, S (O 2 ) NHV864, S (O 2 ) NV865V866, S (O 2 ) OV867, P (O) (OV868) (OV869), Si (V870) ( V871) (V872) "

여기서, V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859, V860, V861, V862, V863, V864, V865, V866, V867, V868, V869, V870, V871, V872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V827, V828 및/또는 V836, V837 및/또는 V849, V850 및/또는 V856, V857 및/또는 V865, V866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859, V860, V861, V862, V863, V864, V865, V866, V867, V868, V869, V870, V871, V872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V827, V828 and / or V836, V837 and / or V849, V850 and / or V856, V857 and / or V865, V866 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV873, NV874V875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V876, C(O)OV877, C(O)NHV878, C(O)NV879V880, OV881, O(V882-O)gH (g = 1, 2, 3, 4, 5), O(V883-O)gV884 (g = 1, 2, 3, 4, 5), OC(O)V885, OC(O)OV886, OC(O)NHV887, OC(O)NV888V889, OP(O)(OV890)(OV891), OSi(V892)(V893)(V894), OS(O2)V895, NHC(O)V896, NV897C(O)V898, NHC(O)OV899, NHC(O)NHV900, NHC(O)NV901V902, NV903C(O)OV904, NV905C(O)NHV906, NV907C(O)NV908V909, NHS(O2)V910, NV911S(O2)V912, SV913, S(O)V914, S(O2)V915, S(O2)NHV916, S(O2)NV917V918, S(O2)OV919, P(O)(OV920)(OV921), Si(V922)(V923)(V924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV873, NV874V875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V876, C (O) OV877, C (O) NHV878, C (O) NV879V880, OV881, O (V882-O) g H (g = 1, 2, 3, 4, 5), O (V883-O) g V884 (g = 1, 2, 3, 4, 5), OC (O) V885, OC (O) OV886, OC (O) NHV887 , OC (O) NV888V889, OP (O) (OV890) (OV891), OSi (V892) (V893) (V894), OS (O 2 ) V895, NHC (O) V896, NV897C (O) V898, NHC ( O) OV899, NHC (O) NHV900, NHC (O) NV901V902, NV903C (O) OV904, NV905C (O) NHV906, NV907C (O) NV908V909, NHS (O 2 ) V910, NV911S (O 2 ) V912, SV913, S (O) V914, S (O 2 ) V915, S (O 2 ) NHV916, S (O 2 ) NV917V918, S (O 2 ) OV919, P (O) (OV920) (OV921), Si (V922) ( V923) (V924) "

여기서, V873, V874, V875, V876, V877, V878, V879, V880, V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V879, V880 및/또는 V888, V889 및/또는 V901, V902 및/또는 V908, V909 및/또는 V917, V918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V873, V874, V875, V876, V877, V878, V879, V880, V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V879, V880 and / or V888, V889 and / or V901, V902 and / or V908, V909 and / or V917, V918 are also in each case" heterocycle Reels ",

(k) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV925, NV926V927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V928, C(O)OV929, C(O)NHV930, C(O)NV931V932, OV933, O(V934-O)hH (h = 1, 2, 3, 4, 5), O(V935-O)hV936 (h = 1, 2, 3, 4, 5), OC(O)V937, OC(O)OV938, OC(O)NHV939, OC(O)NV940V941, OP(O)(OV942)(OV943), OSi(V944)(V945)(V946), OS(O2)V947, NHC(O)V948, NV949C(O)V950, NHC(O)OV951, NHC(O)NHV952, NHC(O)NV953V954, NV955C(O)OV956, NV957C(O)NHV958, NV959C(O)NV960V961, NHS(O2)V962, NV963S(O2)V964, SV965, S(O)V966, S(O2)V967, S(O2)NHV968, S(O2)NV969V970, S(O2)OV971, P(O)(OV972)(OV973), Si(V974)(V975)(V976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV925, NV926V927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V928, C (O) OV929, C (O) NHV930, C (O) NV931V932, OV933, O (V934-O) h H (h = 1, 2, 3, 4, 5), O (V935-O) h V936 (h = 1, 2, 3, 4, 5), OC (O) V937, OC (O) OV938, OC (O) NHV939 , OC (O) NV940V941, OP (O) (OV942) (OV943), OSi (V944) (V945) (V946), OS (O 2 ) V947, NHC (O) V948, NV949C (O) V950, NHC ( O) OV951, NHC (O) NHV952, NHC (O) NV953V954, NV955C (O) OV956, NV957C (O) NHV958, NV959C (O) NV960V961, NHS (O 2 ) V962, NV963S (O 2 ) V964, SV965, S (O) V966, S (O 2 ) V967, S (O 2 ) NHV968, S (O 2 ) NV969V970, S (O 2 ) OV971, P (O) (OV972) (OV973), Si (V974) ( V975) (V976) "

여기서, V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963, V964, V965, V966, V967, V968, V969, V970, V971, V972, V973, V974, V975, V976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V931, V932 및/또는 V940, V941 및/또는 V953, V954 및/또는 V960, V961 및/또는 V969, V970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963, V964, V965, V966, V967, V968, V969, V970, V971, V972, V973, V974, V975, V976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V931, V932 and / or V940, V941 and / or V953, V954 and / or V960, V961 and / or V969, V970 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV977, NV978V979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V980, C(O)OV981, C(O)NHV982, C(O)NV983V984, OV985, O(V986-O)iH (i = 1, 2, 3, 4, 5), O(V987-O)iV988 (i = 1, 2, 3, 4, 5), OC(O)V989, OC(O)OV990, OC(O)NHV991, OC(O)NV992V993, OP(O)(OV994)(OV995), OSi(V996)(V997)(V998), OS(O2)V999, NHC(O)V1000, NV1001C(O)V1002, NHC(O)OV1003, NHC(O)NHV1004, NHC(O)NV1005V1006, NV1007C(O)OV1008, NV1009C(O)NHV1010, NV1011C(O)NV1012V1013, NHS(O2)V1014, NV1015S(O2)V1016, SV1017, S(O)V1018, S(O2)V1019, S(O2)NHV1020, S(O2)NV1021V1022, S(O2)OV1023, P(O)(OV1024)(OV1025), Si(V1026)(V1027)(V1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV977, NV978V979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V980, C (O) OV981, C (O) NHV982, C (O) NV983V984, OV985, O (V986-O) i H (i = 1, 2, 3, 4, 5), O (V987-O) i V988 (i = 1, 2, 3, 4, 5), OC (O) V989, OC (O) OV990, OC (O) NHV991 , OC (O) NV992V993, OP (O) (OV994) (OV995), OSi (V996) (V997) (V998), OS (O2) V999, NHC (O) V1000, NV1001C (O) V1002, NHC (O OV1003, NHC (O) NHV1004, NHC (O) NV1005V1006, NV1007C (O) OV1008, NV1009C (O) NHV1010, NV1011C (O) NV1012V1013, NHS (O2) V1014, NV1015S (O2) V1016, SV1017, S (O ) V1018, S (O 2 ) V1019, S (O 2 ) NHV1020, S (O 2 ) NV1021V1022, S (O 2 ) OV1023, P (O) (OV1024) (OV1025), Si (V1026) (V1027) ( V1028) "

여기서, V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1025, V1026, V1027, V1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V983, V984 및/또는 V992, V993 및/또는 V1005, V1006 및/또는 V1012, V1013 및/또는 V1021, V1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1024 V1026, V1027, V1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V983, V984 and / or V992, V993 and / or V1005, V1006 and / or V1012, V1013 and / or V1021, V1022 are also in each case" heterocycle Reels ",

(l) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1029, NV1030V1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1032, C(O)OV1033, C(O)NHV1034, C(O)NV1035V1036, OV1037, O(V1038-O)jH (j = 1, 2, 3, 4, 5), O(V1039-O)jV1040 (j = 1, 2, 3, 4, 5), OC(O)V1041, OC(O)OV1042, OC(O)NHV1043, OC(O)NV1044V1045, OP(O)(OV1046)(OV1047), OSi(V1048)(V1049)(V1050), OS(O2)V1051, NHC(O)V1052, NV1053C(O)V1054, NHC(O)OV1055, NHC(O)NHV1056, NHC(O)NV1057V1058, NV1059C(O)OV1060, NV1061C(O)NHV1062, NV1063C(O)NV1064V1065, NHS(O2)V1066, NV1067S(O2)V1068, SV1069, S(O)V1070, S(O2)V1071, S(O2)NHV1072, S(O2)NV1073V1074, S(O2)OV1075, P(O)(OV1076)(OV1077), Si(V1078)(V1079)(V1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1029, NV1030V1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1032, C (O) OV1033, C (O) NHV1034, C (O) NV1035V1036, OV1037, O (V1038-O) j H (j = 1, 2, 3, 4, 5), O (V1039-O) j V1040 (j = 1, 2, 3, 4, 5), OC (O) V1041, OC (O) OV1042, OC (O) NHV1043 , OC (O) NV1044V1045, OP (O) (OV1046) (OV1047), OSi (V1048) (V1049) (V1050), OS (O 2 ) V1051, NHC (O) V1052, NV1053C (O) V1054, NHC ( O) OV1055, NHC (O) NHV1056, NHC (O) NV1057V1058, NV1059C (O) OV1060, NV1061C (O) NHV1062, NV1063C (O) NV1064V1065, NHS (O2) V1066, NV1067S (O2) V1068, SV1069, S ( O) V1070, S (O 2 ) V1071, S (O 2 ) NHV1072, S (O 2 ) NV1073V1074, S (O 2 ) OV1075, P (O) (OV1076) (OV1077), Si (V1078) (V1079) (V1080) "

여기서, V1029, V1030, V1031, V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051, V1052, V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1077, V1078, V1079, V1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1035, V1036 및/또는 V1044, V1045 및/또는 V1057, V1058 및/또는 V1064, V1065 및/또는 V1073, V1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1029, V1030, V1031, V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051, V1052 V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1076, V1076 V1078, V1079, V1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V1035, V1036 and / or V1044, V1045 and / or V1057, V1058 and / or V1064, V1065 and / or V1073, V1074 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1081, NV1082V1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1084, C(O)OV1085, C(O)NHV1086, C(O)NV1087V1088, OV1089, O(V1090-O)kH (k = 1, 2, 3, 4, 5), O(V1091-O)kV1092 (k = 1, 2, 3, 4, 5), OC(O)V1093, OC(O)OV1094, OC(O)NHV1095, OC(O)NV1096V1097, OP(O)(OV1098)(OV1099), OSi(V1100)(V1101)(V1102), OS(O2)V1103, NHC(O)V1104, NV1105C(O)V1106, NHC(O)OV1107, NHC(O)NHV1108, NHC(O)NV1109V1110, NV1111C(O)OV1112, NV1113C(O)NHV1114, NV1115C(O)NV1116V1117, NHS(O2)V1118, NV1119S(O2)V1120, SV1121, S(O)V1122, S(O2)V1123, S(O2)NHV1124, S(O2)NV1125V1126, S(O2)OV1127, P(O)(OV1128)(OV1129), Si(V1130)(V1131)(V1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1081, NV1082V1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1084, C (O) OV1085, C (O) NHV1086, C (O) NV1087V1088, OV1089, O (V1090-O) k H (k = 1, 2, 3, 4, 5), O (V1091-O) k V1092 (k = 1, 2, 3, 4, 5), OC (O) V1093, OC (O) OV1094, OC (O) NHV1095 , OC (O) NV1096V1097, OP (O) (OV1098) (OV1099), OSi (V1100) (V1101) (V1102), OS (O 2 ) V1103, NHC (O) V1104, NV1105C (O) V1106, NHC ( O) OV1107, NHC (O) NHV1108, NHC (O) NV1109V1110, NV1111C (O) OV1112, NV1113C (O) NHV1114, NV1115C (O) NV1116V1117, NHS (O2) V1118, NV1119S (O2) V1120, SV1121, S112 (S) O) V1122, S (O 2 ) V1123, S (O 2 ) NHV1124, S (O 2 ) NV1125V1126, S (O 2 ) OV1127, P (O) (OV1128) (OV1129), Si (V1130) (V1131) (V1132) "

여기서, V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105, V1106, V1107, V1108, V1109, V1110, V1111, V1112, V1113, V1114, V1115, V1116, V1117, V1118, V1119, V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1129, V1130, V1131, V1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1087, V1088 및/또는 V1096, V1097 및/또는 V1109, V1110 및/또는 V1116, V1117 및/또는 V1125, V1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1104 V1105, V1106, V1107, V1108, V1109, V1110, V1111, V1112, V1113, V1114, V1115, V1116, V1117, V1118, V1119, V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1128, V1128, V1128 V1130, V1131, V1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V1087, V1088 and / or V1096, V1097 and / or V1109, V1110 and / or V1116, V1117 and / or V1125, V1126 are also in each case" heterocycle. " Reels ",

(m) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)V1133, C(O)OV1134, C(O)NV1135V1136, S(O2)V1137, S(O2)OV1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) V1133 , C (O) OV1134, C (O) NV1135V1136, S (O 2 ) V1137, S (O 2 ) OV1138 "

여기서, V1133, V1134, V1135, V1136, V1137, V1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1135, V1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein V1133, V1134, V1135, V1136, V1137, V1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, V1135, V1136 together may also form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1139, NV1140V1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1142, C(O)OV1143, C(O)NHV1144, C(O)NV1145V1146, OV1147, O(V1148-O)lH (l = 1, 2, 3, 4, 5), O(V1149-O)lV1150 (l = 1, 2, 3, 4, 5), OC(O)V1151, OC(O)OV1152, OC(O)NHV1153, OC(O)NV1154V1155, OP(O)(OV1156)(OV1157), OSi(V1158)(V1159)(V1160), OS(O2)V1161, NHC(O)V1162, NV1163C(O)V1164, NHC(O)OV1165, NHC(O)NHV1166, NHC(O)NV1167V1168, NV1169C(O)OV1170, NV1171C(O)NHV1172, NV1173C(O)NV1174V1175, NHS(O2)V1176, NV1177S(O2)V1178, SV1179, S(O)V1180, S(O2)V1181, S(O2)NHV1182, S(O2)NV1183V1184, S(O2)OV1185, P(O)(OV1186)(OV1187), Si(V1188)(V1189)(V1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1139, NV1140V1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1142, C (O) OV1143, C (O) NHV1144, C (O) NV1145V1146, OV1147, O (V1148-O) l H (l = 1, 2, 3, 4, 5), O (V1149-O) l V1150 (l = 1, 2, 3, 4, 5), OC (O) V1151, OC (O) OV1152, OC (O) NHV1153 , OC (O) NV1154V1155, OP (O) (OV1156) (OV1157), OSi (V1158) (V1159) (V1160), OS (O 2 ) V1161, NHC (O) V1162, NV1163C (O) V1164, NHC ( O) OV1165, NHC (O) NHV1166, NHC (O) NV1167V1168, NV1169C (O) OV1170, NV1171C (O) NHV1172, NV1173C (O) NV1174V1175, NHS (O2) V1176, NV1177S (O2) V1178, SV1179, S (11) O) V1180, S (O 2 ) V1181, S (O 2 ) NHV1182, S (O 2 ) NV1183V1184, S (O 2 ) OV1185, P (O) (OV1186) (OV1187), Si (V1188) (V1189) (V1190) "

여기서, V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1161, V1162, V1163, V1164, V1165, V1166, V1167, V1168, V1169, V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1186, V1187, V1188, V1189, V1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1145, V1146 및/또는 V1154, V1155 및/또는 V1167, V1168 및/또는 V1174, V1175 및/또는 V1183, V1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1161, V1162, V1162 V1163, V1164, V1165, V1166, V1167, V1168, V1169, V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1186, V1187 V1188, V1189, V1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V1145, V1146 and / or V1154, V1155 and / or V1167, V1168 and / or V1174, V1175 and / or V1183, V1184 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1191, NV1192V1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1194, C(O)OV1195, C(O)NHV1196, C(O)NV1197V1198, OV1199, O(V1200-O)mH (m = 1, 2, 3, 4, 5), O(V1201-O)mV1202 (m = 1, 2, 3, 4, 5), OC(O)V1203, OC(O)OV1204, OC(O)NHV1205, OC(O)NV1206V1207, OP(O)(OV1208)(OV1209), OSi(V1210)(V1211)(V1212), OS(O2)V1213, NHC(O)V1214, NV1215C(O)V1216, NHC(O)OV1217, NHC(O)NHV1218, NHC(O)NV1219V1220, NV1221C(O)OV1222, NV1223C(O)NHV1224, NV1225C(O)NV1226V1227, NHS(O2)V1228, NV1229S(O2)V1230, SV1231, S(O)V1232, S(O2)V1233, S(O2)NHV1234, S(O2)NV1235V1236, S(O2)OV1237, P(O)(OV1238)(OV1239), Si(V1240)(V1241)(V1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1191, NV1192V1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1194, C (O) OV1195, C (O) NHV1196, C (O) NV1197V1198, OV1199, O (V1200-O) m H (m = 1, 2, 3, 4, 5), O (V1201-O) m V1202 (m = 1, 2, 3, 4, 5), OC (O) V1203, OC (O) OV1204, OC (O) NHV1205 , OC (O) NV1206V1207, OP (O) (OV1208) (OV1209), OSi (V1210) (V1211) (V1212), OS (O 2 ) V1213, NHC (O) V1214, NV1215C (O) V1216, NHC ( O) OV1217, NHC (O) NHV1218, NHC (O) NV1219V1220, NV1221C (O) OV1222, NV1223C (O) NHV1224, NV1225C (O) NV1226V1227, NHS (O2) V1228, NV1229S (O2) V1230, SV1231, S (123) O) V1232, S (O 2 ) V1233, S (O 2) NHV1234, S (O 2) NV1235V1236, S (O 2) OV1237, P (O) (OV1238) (OV1239), Si (V1240) (V1241) (V1242) "

여기서, V1191, V1192, V1193, V1194, V1195, V1196, V1197, V1198, V1199, V1200, V1201, V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V1211, V1212, V1213, V1214, V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1235, V1236, V1237, V1238, V1239, V1240, V1241, V1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알 킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1197, V1198 및/또는 V1206, V1207 및/또는 V1219, V1220 및/또는 V1226, V1227 및/또는 V1235, V1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1191, V1192, V1193, V1194, V1195, V1196, V1197, V1198, V1199, V1200, V1201, V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V1211, V1212, V1213, V1214, V1214 V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1235, V1236, V1237, V1238, V1239 V1240, V1241, V1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, V1197, V1198 and / or V1206, V1207 and / or V1219, V1220 and / or V1226, V1227 and / or V1235, V1236 are also in each case" hetero " Cyclyl ",

또는or

(C) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "치환된 알킬", 여기서, "치환된 알킬"은 다음으로 이루어진 그룹으로부터 선택된 하나 이상의 치환체에 의해 치환되고:(C) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently substituted by "substituted alkyl" wherein "substituted alkyl" is substituted by one or more substituents selected from the group consisting of:

(a) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1, NW2W3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W4, C(O)OW5, C(O)NHW6, C(O)NW7W8, OW9, O(W10-O)rH (r = 1, 2, 3, 4, 5), O(W11-O)rW12 (r = 1, 2, 3, 4, 5), OC(O)W13, OC(O)OW14, OC(O)NHW15, OC(O)NW16W17, OP(O)(OW18)(OW19), OSi(W20)(W21)(W22), OS(O2)W23, NHC(O)W24, NW25C(O)W26, NHC(O)OW27, NHC(O)NHW28, NHC(O)NW29W30, NW31C(O)OW32, NW33C(O)NHW34, NW35C(O)NW36W37, NHS(O2)W38, NW39S(O2)W40, SW41, S(O)W42, S(O2)W43, S(O2)NHW44, S(O2)NW45W46, S(O2)OW47, P(O)(OW48)(OW49), Si(W50)(W51)(W52)"(a) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW 1 , NW 2 W 3 , NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W4, C (O) OW5, C (O) NHW6, C (O) NW7W8, OW9, O (W10-O) r H (r = 1, 2, 3, 4, 5), O (W11-O) r W12 (r = 1, 2, 3, 4, 5), OC (O) W13, OC (O) OW14, OC (O) NHW15 , OC (O) NW16W17, OP (O) (OW18) (OW19), OSi (W20) (W21) (W22), OS (O 2 ) W23, NHC (O) W24, NW25C (O) W26, NHC ( O) OW27, NHC (O) NHW28, NHC (O) NW29W30, NW31C (O) OW32, NW33C (O) NHW34, NW35C (O) NW36W37, NHS (O 2 ) W38, NW39S (O 2 ) W40, SW41, S (O) W42, S (O 2 ) W43, S (O 2 ) NHW44, S (O 2 ) NW45W46, S (O 2 ) OW47, P (O) (OW48) (OW49), Si (W50) ( W51) (W52) "

여기서, W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W11, W12, W13, W14, W15, W16, W17, W18, W19, W20, W21, W22, W23, W24, W25, W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42,W43, W44, W45, W46, W47, W48, W49, W50, W51, W52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W7, W8 및/또는 W16, W17 및/또는 W29, W30 및/또는 W36, W37 및/또는 W45, W46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W11, W12, W13, W14, W15, W16, W17, W18, W19, W20, W21, W22, W23, W24, W25, W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W7, W8 and / or W16, W17 and / or W29, W30 and / or W36, W37 and / or W45, W46 are also in each case" heterocycle. " Reels ",

단, "C(O)NH아릴", "C(O)NH헤테로아릴", "C(O)NH사이클로알킬", "C(O)NH헤테로사이클릴"은 다음 치환 그룹(i)로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Provided that "C (O) NHaryl", "C (O) NH heteroaryl", "C (O) NH cycloalkyl", "C (O) NH heterocyclyl" are selected from the following substitution groups (i) Further substituted by one or more substituents;

여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (a) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW53, NW54W55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W56, C(O)OW57, C(O)NHW58, C(O)NW59W60, OW61, O(W62-O)sH (s = 1, 2, 3, 4, 5), O(W63-O)tW64 (t = 1, 2, 3, 4, 5), OC(O)W65, OC(O)OW66, OC(O)NHW67, OC(O)NW68W69, OP(O)(OW70)(OW71), OSi(W72)(W73)(W74), OS(O2)W75, NHC(O)W76, NW77C(O)W78, NHC(O)OW79, NHC(O)NHW80, NHC(O)NW81W82, NW83C(O)OW84, NW85C(O)NHW86, NW87C(O)NW88W89, NHS(O2)W90, NW91S(O2)W92, SW93, S(O)W94, S(O2)W95, S(O2)NHW96, S(O2)NW97W98, S(O2)OW99, P(O)(OW100)(OW101), Si(W102)(W103)(W104)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW53, NW54W55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W56, C (O) OW57, C (O) NHW58, C (O) NW59W60, OW61, O (W62-O) s H (s = 1, 2, 3, 4, 5), O (W63-O) t W64 (t = 1, 2, 3, 4, 5), OC (O) W65, OC (O) OW66, OC (O) NHW67 , OC (O) NW68W69, OP (O) (OW70) (OW71), OSi (W72) (W73) (W74), OS (O 2 ) W75, NHC (O) W76, NW77C (O) W78, NHC ( O) OW79, NHC (O) NHW80, NHC (O) NW81W82, NW83C (O) OW84, NW85C (O) NHW86, NW87C (O) NW88W89, NHS (O 2 ) W90, NW91S (O 2 ) W92, SW93, S (O) W94, S (O 2 ) W95, S (O 2 ) NHW96, S (O 2 ) NW97W98, S (O 2 ) OW99, P (O) (OW100) (OW101), Si (W102) ( W103) (W104) "

여기서, W53, W54, W55, W56, W57, W58, W59, W60, W61, W62, W63, W64, W65, W66, W67, W68, W69, W70, W71, W72, W73, W74, W75, W76, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88,W89, W90, W91, W92, W93, W94, W95, W96, W97, W98, W99, W100, W101, W102, W103, W104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W59, W60 및/또는 W68, W69 및/또는 W81, W82 및/또는 W88, W89 및/또는 W97, W98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W53, W54, W55, W56, W57, W58, W59, W60, W61, W62, W63, W64, W65, W66, W67, W68, W69, W70, W71, W72, W73, W74, W75, W76, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88, W89, W90, W91, W92, W93, W94, W95, W96, W97, W98, W99, W100, W101, W102, W103, W104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W59, W60 and / or W68, W69 and / or W81, W82 and / or W88, W89 and / or W97, W98 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW105, NW106W107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W108, C(O)OW109, C(O)NHW110, C(O)NW111W112, OW113, O(W114-O)tH (t = 1, 2, 3, 4, 5), O(W115-O)tW116 (t = 1, 2, 3, 4, 5), OC(O)W117, OC(O)OW118, OC(O)NHW119, OC(O)NW120W121, OP(O)(OW122)(OW123), OSi(W124)(W125)(W126), OS(O2)W127, NHC(O)W128, NW129C(O)W130, NHC(O)OW131, NHC(O)NHW132, NHC(O)NW133W134, NW135C(O)OW136, NW137C(O)NHW138, NW139C(O)NW140W141, NHS(O2)W142, NW143S(O2)W144, SW145, S(O)W146, S(O2)W147, S(O2)NHW148, S(O2)NW149W150, S(O2)OW151, P(O)(OW152)(OW153), Si(W154)(W155)(W156)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW105, NW106W107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W108, C (O) OW109, C (O) NHW110, C (O) NW111W112, OW113, O (W114-O) t H (t = 1, 2, 3, 4, 5), O (W115-O) t W116 (t = 1, 2, 3, 4, 5), OC (O) W117, OC (O) OW118, OC (O) NHW119 , OC (O) NW120W121, OP (O) (OW122) (OW123), OSi (W124) (W125) (W126), OS (O 2 ) W127, NHC (O) W128, NW129C (O) W130, NHC ( O) OW131, NHC (O) NHW132, NHC (O) NW133W134, NW135C (O) OW136, NW137C (O) NHW138, NW139C (O) NW140W141, NHS (O 2 ) W142, NW143S (O 2 ) W144, SW145, S (O) W146, S (O 2 ) W147, S (O 2 ) NHW148, S (O 2 ) NW149W150, S (O 2 ) OW151, P (O) (OW152) (OW153), Si (W154) ( W155) (W156) "

여기서, W105, W106, W107, W108, W109, W110, W111, W112,W113, W114, W115, W116, W117, W118, W119, W120, W121, W122, W123, W124, W125, W126, W127, W128, W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152, W153, W154, W155, W156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W111, W112 및/또는 W120, W121 및/또는 W133, W134 및/또는 W140, W141 및/또는 W149, W150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W105, W106, W107, W108, W109, W110, W111, W112, W113, W114, W115, W116, W117, W118, W119, W120, W121, W122, W123, W124, W125, W126, W127, W128, W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152, W153, W154, W155, W156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W111, W112 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 are also in each case" heterocycle. " Reels ",

또는 Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "(C9-C30)알킬" Or one of the Z3, Z4 radicals or both the Z3, Z4 radicals is independently "(C 9 -C 30 ) alkyl"

여기서, "(C9-C30)알킬"은 독립적으로 임의로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein “(C 9 -C 30 ) alkyl” may be independently substituted by one or more substituents, optionally selected the same or different from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW157, NW158W159, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W160, C(O)OW161, C(O)NHW162, C(O)NW163W164, OW165, O(W166-O)uH (u = 1, 2, 3, 4, 5), O(W167-O)uW168 (u = 1, 2, 3, 4, 5), OC(O)W169, OC(O)OW170, OC(O)NHW171, OC(O)NW172W173, OP(O)(OW174)(OW175), OSi(W176)(W177)(W178), OS(O2)W179, NHC(O)W180, NW181C(O)W182, NHC(O)OW183, NHC(O)NHW184, NHC(O)NW185W186, NW187C(O)OW188, NW189C(O)NHW190, NW191C(O)NW192W193, NHS(O2)W194, NW195S(O2)W196, SW197, S(O)W198, S(O2)W199, S(O2)NHW200, S(O2)NW201W202, S(O2)OW203, P(O)(OW204)(OW205), Si(W206)(W207)(W208)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW157, NW158W159, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W160, C (O) OW161, C (O) NHW162, C (O) NW163W164, OW165, O (W166-O) u H (u = 1, 2, 3, 4, 5), O (W167-O) u W168 (u = 1, 2, 3, 4, 5), OC (O) W169, OC (O) OW170, OC (O) NHW171 , OC (O) NW172W173, OP (O) (OW174) (OW175), OSi (W176) (W177) (W178), OS (O 2 ) W179, NHC (O) W180, NW181C (O) W182, NHC ( O) OW183, NHC (O) NHW184, NHC (O) NW185W186, NW187C (O) OW188, NW189C (O) NHW190, NW191C (O) NW192W193, NHS (O 2 ) W194, NW195S (O 2 ) W196, SW197, S (O) W198, S (O 2 ) W199, S (O 2 ) NHW200, S (O 2 ) NW201W202, S (O 2 ) OW203, P (O) (OW204) (OW205), Si (W206) ( W207) (W208) "

여기서, W157, W158, W159, W160, W161, W162, W163, W164, W165, W166, W167, W168, W169, W170, W171, W172, W173, W174, W175, W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W163, W164 및/또는 W172, W173 및/또는 W185, W186 및/또는 W192, W193 및/또는 W201, W202는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W157, W158, W159, W160, W161, W162, W163, W164, W165, W166, W167, W168, W169, W170, W171, W172, W173, W174, W175, W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW209, NW210W211, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W212, C(O)OW213, C(O)NHW214, C(O)NW215W216, OW217, O(W218-O)vH (v = 1, 2, 3, 4, 5), O(W219-O)vW220 (v = 1, 2, 3, 4, 5), OC(O)W221, OC(O)OW222, OC(O)NHW223, OC(O)NW224W225, OP(O)(OW226)(OW227), OSi(W228)(W229)(W230), OS(O2)W231, NHC(O)W232, NW233C(O)W234, NHC(O)OW235, NHC(O)NHW236, NHC(O)NW237W238, NW239C(O)OW240, NW241C(O)NHW242, NW243C(O)NW244W245, NHS(O2)W246, NW247S(O2)W248, SW249, S(O)W250, S(O2)W251, S(O2)NHW252, S(O2)NW253W254, S(O2)OW255, P(O)(OW256)(OW257), Si(W258)(W259)(W260)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW209, NW210W211, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W212, C (O) OW213, C (O) NHW214, C (O) NW215W216, OW217, O (W218-O) v H (v = 1, 2, 3, 4, 5), O (W219-O) v W220 (v = 1, 2, 3, 4, 5), OC (O) W221, OC (O) OW222, OC (O) NHW223 , OC (O) NW224W225, OP (O) (OW226) (OW227), OSi (W228) (W229) (W230), OS (O 2 ) W231, NHC (O) W232, NW233C (O) W234, NHC ( O) OW235, NHC (O) NHW236, NHC (O) NW237W238, NW239C (O) OW240, NW241C (O) NHW242, NW243C (O) NW244W245, NHS (O 2 ) W246, NW247S (O 2 ) W248, SW249, S (O) W250, S (O 2 ) W251, S (O 2 ) NHW252, S (O 2 ) NW253W254, S (O 2 ) OW255, P (O) (OW256) (OW257), Si (W258) ( W259) (W260) "

여기서, W209, W210, W211, W212, W213, W214, W215, W216, W217, W218, W219, W220, W221, W222, W223, W224, W225, W226, W227, W228, W229, W230, W231, W232, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W215, W216 및/또는 W224, W225 및/또는 W237, W238 및/또는 W244, W245 및/또는 W253, W254는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W209, W210, W211, W212, W213, W214, W215, W216, W217, W218, W219, W220, W221, W222, W223, W224, W225, W226, W227, W228, W229, W230, W231, W232, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 are also in each case" heterocycle. " Reels ",

Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of:

(b) 수소;(b) hydrogen;

(c) 할로겐, F, Cl, Br, I;(c) halogen, F, Cl, Br, I;

(d) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(d) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW457, NW458W459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W460, C(O)OW461, C(O)NHW462, C(O)NW463W464, OW465, O(W466-O)xH (x = 1, 2, 3, 4, 5), O(W467-O)xW468 (x = 1, 2, 3, 4, 5), OC(O)W469, OC(O)OW470, OC(O)NHW471, OC(O)NW472W473, OP(O)(OW474)(OW475), OSi(W476)(W477)(W478), OS(O2)W479, NHC(O)W480, NW481C(O)W482, NHC(O)OW483, NHC(O)NHW484, NHC(O)NW485W486, NW487C(O)OW488, NW489C(O)NHW490, NW491C(O)NW492W493, NHS(O2)W494, NW495S(O2)W496, SW497, S(O)W498, S(O2)W499, S(O2)NHW500, S(O2)NW501W502, S(O2)OW503, P(O)(OW504)(OW505), Si(W506)(W507)(W508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW457, NW458W459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W460, C (O) OW461, C (O) NHW462, C (O) NW463W464, OW465, O (W466-O) x H (x = 1, 2, 3, 4, 5), O (W467-O) x W468 (x = 1, 2, 3, 4, 5), OC (O) W469, OC (O) OW470, OC (O) NHW471 , OC (O) NW472W473, OP (O) (OW474) (OW475), OSi (W476) (W477) (W478), OS (O 2 ) W479, NHC (O) W480, NW481C (O) W482, NHC ( O) OW483, NHC (O) NHW484, NHC (O) NW485W486, NW487C (O) OW488, NW489C (O) NHW490, NW491C (O) NW492W493, NHS (O 2 ) W494, NW495S (O 2 ) W496, SW497, S (O) W498, S ( O 2) W499, S (O 2) NHW500, S (O 2) NW501W502, S (O 2) OW503, P (O) (OW504) (OW505), Si (W506) ( W507) (W508) "

여기서, W457, W458, W459, W460, W461, W462, W463, W464, W465, W466, W467, W468, W469, W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W480, W481, W482, W483, W484, W485, W486, W487, W488, W489, W490, W491, W492, W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W463, W464 및/또는 W472, W473 및/또는 W485, W486 및/또는 W492, W493 및/또는 W501, W502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W457, W458, W459, W460, W461, W462, W463, W464, W465, W466, W467, W468, W469, W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W480, W481, W482, W483, W484, W485, W486, W487, W488, W489, W490, W491, W492, W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W463, W464 and / or W472, W473 and / or W485, W486 and / or W492, W493 and / or W501, W502 are also in each case a" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW509, NW510W511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W512, C(O)OW513, C(O)NHW514, C(O)NW515W516, OW517, O(W518-O)yH (y = 1, 2, 3, 4, 5), O(W519-O)yW520 (y = 1, 2, 3, 4, 5), OC(O)W521, OC(O)OW522, OC(O)NHW523, OC(O)NW524W525, OP(O)(OW526)(OW527), OSi(W528)(W529)(W530), OS(O2)W531, NHC(O)W532, NW533C(O)W534, NHC(O)OW535, NHC(O)NHW536, NHC(O)NW537W538, NW539C(O)OW540, NW541C(O)NHW542, NW543C(O)NW544W545, NHS(O2)W546, NW547S(O2)W548, SW549, S(O)W550, S(O2)W551, S(O2)NHW552, S(O2)NW553W554, S(O2)OW555, P(O)(OW556)(OW557), Si(W558)(W559)(W560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW509, NW510W511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W512, C (O) OW513, C (O) NHW514, C (O) NW515W516, OW517, O (W518-O) y H (y = 1, 2, 3, 4, 5), O (W519-O) y W520 (y = 1, 2, 3, 4, 5), OC (O) W521, OC (O) OW522, OC (O) NHW523 , OC (O) NW524W525, OP (O) (OW526) (OW527), OSi (W528) (W529) (W530), OS (O 2 ) W531, NHC (O) W532, NW533C (O) W534, NHC ( O) OW535, NHC (O) NHW536, NHC (O) NW537W538, NW539C (O) OW540, NW541C (O) NHW542, NW543C (O) NW544W545, NHS (O 2 ) W546, NW547S (O 2 ) W548, SW549, S (O) W550, S (O 2 ) W551, S (O 2 ) NHW552, S (O 2 ) NW553W554, S (O 2 ) OW555, P (O) (OW556) (OW557), Si (W558) ( W559) (W560) "

여기서, W509, W510, W511, W512, W513, W514, W515, W516, W517, W518, W519, W520, W521, W522, W523, W524, W525, W526, W527, W528, W529, W530, W531, W532, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552, W553, W554, W555, W556, W557, W558, W559, W560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W515, W516 및/또는 W524, W525 및/또는 W537, W538 및/또는 W544, W545 및/또는 W553, W554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W509, W510, W511, W512, W513, W514, W515, W516, W517, W518, W519, W520, W521, W522, W523, W524, W525, W526, W527, W528, W529, W530, W531, W532, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552, W553, W554, W555, W556, W557, W558, W559, W560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W515, W516 and / or W524, W525 and / or W537, W538 and / or W544, W545 and / or W553, W554 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW561, NW562W563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W564, C(O)OW565, C(O)NHW566, C(O)NW567W568, OW569, O(W570-O)zH (z = 1, 2, 3, 4, 5), O(W571- O)zW572 (z = 1, 2, 3, 4, 5), OC(O)W573, OC(O)OW574, OC(O)NHW575, OC(O)NW576W577, OP(O)(OW578)(OW579), OSi(W580)(W581)(W582), OS(O2)W583, NHC(O)W584, NW585C(O)W586, NHC(O)OW587, NHC(O)NHW588, NHC(O)NW589W590, NW591C(O)OW592, NW593C(O)NHW594, NW595C(O)NW596W597, NHS(O2)W598, NW599S(O2)W600, SW601, S(O)W602, S(O2)W603, S(O2)NHW604, S(O2)NW605W606, S(O2)OW607, P(O)(OW608)(OW609), Si(W610)(W611)(W612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW561, NW562W563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W564, C (O) OW565, C (O) NHW566, C (O) NW567W568, OW569, O (W570-O) z H (z = 1, 2, 3, 4, 5), O (W571-O) z W572 (z = 1, 2, 3, 4, 5), OC (O) W573, OC (O) OW574, OC (O) NHW575 , OC (O) NW576W577, OP (O) (OW578) (OW579), OSi (W580) (W581) (W582), OS (O 2 ) W583, NHC (O) W584, NW585C (O) W586, NHC ( O) OW587, NHC (O) NHW588, NHC (O) NW589W590, NW591C (O) OW592, NW593C (O) NHW594, NW595C (O) NW596W597, NHS (O 2 ) W598, NW599S (O 2 ) W600, SW601, S (O) W602, S (O 2 ) W603, S (O 2 ) NHW604, S (O 2 ) NW605W606, S (O 2 ) OW607, P (O) (OW608) (OW609), Si (W610) ( W611) (W612) "

여기서, W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576, W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W611, W612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W567, W568 및/또는 W576, W577 및/또는 W589, W590 및/또는 W596, W597 및/또는 W605, W606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576, W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W611, W612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W567, W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 are also in each case" heterocycle Reels ",

(e) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(e) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW613, NW614W615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W616, C(O)OW617, C(O)NHW618, C(O)NW619W620, OW621, O(W622-O)aH (a = 1, 2, 3, 4, 5), O(W623-O)aW624 (a = 1, 2, 3, 4, 5), OC(O)W625, OC(O)OW626, OC(O)NHW627, OC(O)NW628W629, OP(O)(OW630)(OW631), OSi(W632)(W633)(W634), OS(O2)W635, NHC(O)W636, NW637C(O)W638, NHC(O)OW639, NHC(O)NHW640, NHC(O)NW641W642, NW643C(O)OW644, NW645C(O)NHW646, NW647C(O)NW648W649, NHS(O2)W650, NW651S(O2)W652, SW653, S(O)W654, S(O2)W655, S(O2)NHW656, S(O2)NW657W658, S(O2)OW659, P(O)(OW660)(OW661), Si(W662)(W663)(W664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW613, NW614W615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W616, C (O) OW617, C (O) NHW618, C (O) NW619W620, OW621, O (W622-O) a H (a = 1, 2, 3, 4, 5), O (W623-O) a W624 (a = 1, 2, 3, 4, 5), OC (O) W625, OC (O) OW626, OC (O) NHW627 , OC (O) NW628W629, OP (O) (OW630) (OW631), OSi (W632) (W633) (W634), OS (O 2 ) W635, NHC (O) W636, NW637C (O) W638, NHC ( O) OW639, NHC (O) NHW640, NHC (O) NW641W642, NW643C (O) OW644, NW645C (O) NHW646, NW647C (O) NW648W649, NHS (O 2 ) W650, NW651S (O 2 ) W652, SW653, S (O) W654, S (O 2 ) W655, S (O 2 ) NHW656, S (O 2 ) NW657W658, S (O 2 ) OW659, P (O) (OW660) (OW661), Si (W662) ( W663) (W664) "

여기서, W613, W614, W615, W616, W617, W618, W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636, W637, W638, W639, W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W619, W620 및/또는 W628, W629 및/또는 W641, W642 및/또는 W648, W649 및/또는 W657, W658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W613, W614, W615, W616, W617, W618, W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636, W637, W638, W639, W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W619, W620 and / or W628, W629 and / or W641, W642 and / or W648, W649 and / or W657, W658 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW665, NW666W667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W668, C(O)OW669, C(O)NHW670, C(O)NW671W672, OW673, O(W674-O)bH (b = 1, 2, 3, 4, 5), O(W675-O)bW676 (b = 1, 2, 3, 4, 5), OC(O)W677, OC(O)OW678, OC(O)NHW679, OC(O)NW680W681, OP(O)(OW682)(OW683), OSi(W684)(W685)(W686), OS(O2)W687, NHC(O)W688, NW689C(O)W690, NHC(O)OW691, NHC(O)NHW692, NHC(O)NW693W694, NW695C(O)OW696, NW697C(O)NHW698, NW699C(O)NW700W701, NHS(O2)W702, NW703S(O2)W704, SW705, S(O)W706, S(O2)W707, S(O2)NHW708, S(O2)NW709W710, S(O2)OW711, P(O)(OW712)(OW713), Si(W714)(W715)(W716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW665, NW666W667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W668, C (O) OW669, C (O) NHW670, C (O) NW671W672, OW673, O (W674-O) b H (b = 1, 2, 3, 4, 5), O (W675-O) b W676 (b = 1, 2, 3, 4, 5), OC (O) W677, OC (O) OW678, OC (O) NHW679 , OC (O) NW680W681, OP (O) (OW682) (OW683), OSi (W684) (W685) (W686), OS (O 2 ) W687, NHC (O) W688, NW689C (O) W690, NHC ( O) OW691, NHC (O) NHW692, NHC (O) NW693W694, NW695C (O) OW696, NW697C (O) NHW698, NW699C (O) NW700W701, NHS (O 2 ) W702, NW703S (O 2 ) W704, SW705, S (O) W706, S (O 2 ) W707, S (O 2 ) NHW708, S (O 2 ) NW709W710, S (O 2 ) OW711, P (O) (OW712) (OW713), Si (W714) ( W715) (W716) "

여기서, W665, W666, W667, W668, W669, W670, W671, W672, W673, W674, W675, W676, W677, W678, W679, W680, W681, W682, W683, W684, W685, W686, W687, W688, W689, W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, W700, W701, W702, W703, W704, W705, W706, W707, W708, W709, W710, W711, W712, W713, W714, W715, W716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W671, W672 및/또는 W680, W681 및/또는 W693, W694 및/또는 W700, W701 및/또는 W709, W710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W665, W666, W667, W668, W669, W670, W671, W672, W673, W674, W675, W676, W677, W678, W679, W680, W681, W682, W683, W684, W685, W686, W687, W688, W689, W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, W700, W701, W702, W703, W704, W705, W706, W707, W708, W709, W710, W711, W712, W713, W714, W715, W716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W671, W672 and / or W680, W681 and / or W693, W694 and / or W700, W701 and / or W709, W710 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW717, NW718W719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W720, C(O)OW721, C(O)NHW722, C(O)NW723W724, OW725, O(W726-O)cH (c = 1, 2, 3, 4, 5), O(W727-O)cW728 (c = 1, 2, 3, 4, 5), OC(O)W729, OC(O)OW730, OC(O)NHW731, OC(O)NW732W733, OP(O)(OW734)(OW735), OSi(W736)(W737)(W738), OS(O2)W739, NHC(O)W740, NW741C(O)W742, NHC(O)OW743, NHC(O)NHW744, NHC(O)NW745W746, NW747C(O)OW748, NW749C(O)NHW750, NW751C(O)NW752W753, NHS(O2)W754, NW755S(O2)W756, SW757, S(O)W758, S(O2)W759, S(O2)NHW760, S(O2)NW761W762, S(O2)OW763, P(O)(OW764)(OW765), Si(W766)(W767)(W768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW717, NW718W719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W720, C (O) OW721, C (O) NHW722, C (O) NW723W724, OW725, O (W726-O) c H (c = 1, 2, 3, 4, 5), O (W727-O) c W728 (c = 1, 2, 3, 4, 5), OC (O) W729, OC (O) OW730, OC (O) NHW731 , OC (O) NW732W733, OP (O) (OW734) (OW735), OSi (W736) (W737) (W738), OS (O 2 ) W739, NHC (O) W740, NW741C (O) W742, NHC ( O) OW743, NHC (O) NHW744, NHC (O) NW745W746, NW747C (O) OW748, NW749C (O) NHW750, NW751C (O) NW752W753, NHS (O 2 ) W754, NW755S (O 2 ) W756, SW757, S (O) W758, S (O 2 ) W759, S (O 2 ) NHW760, S (O 2 ) NW761W762, S (O 2 ) OW763, P (O) (OW764) (OW765), Si (W766) ( W767) (W768) "

여기서, W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740, W741, W742, W743, W744, W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756, W757, W758, W759, W760, W761, W762, W763, W764, W765, W766, W767, W768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W723, W724 및/또는 W732, W733 및/또는 W745, W746 및/또는 W752, W753 및/또는 W761, W762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Here, W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740, W741, W742, W743, W744, W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756, W757, W758, W759, W760, W761, W762, W763, W764, W765, W766, W767, W768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 are also in each case a" heterocycle. " Reels ";

(f) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(f) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

"알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW769, NW770W771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W772, C(O)OW773, C(O)NHW774, C(O)NW775W776, OW777, O(W778-O)dH (d = 1, 2, 3, 4, 5), O(W779-O)dW780 (d = 1, 2, 3, 4, 5), OC(O)W781, OC(O)OW782, OC(O)NHW783, OC(O)NW784W785, OP(O)(OW786)(OW787), OSi(W788)(W789)(W790), OS(O2)W791, NHC(O)W792, NW793C(O)W794, NHC(O)OW795, NHC(O)NHW796, NHC(O)NW797W798, NW799C(O)OW800, NW801C(O)NHW802, NW803C(O)NW804W805, NHS(O2)W806, NW807S(O2)W808, SW809, S(O)W810, S(O2)W811, S(O2)NHW812, S(O2)NW813W814, S(O2)OW815, P(O)(OW816)(OW817), Si(W818)(W819)(W820)""Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , NHW769, NW770W771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H , P (O) (OH) 2 , C (O) W772, C (O) OW773, C (O) NHW774, C (O) NW775W776, OW777, O (W778-O) d H (d = 1, 2 , 3, 4, 5), O (W779-O) d W780 (d = 1, 2, 3, 4, 5), OC (O) W781, OC (O) OW782, OC (O) NHW783, OC ( O) NW784W785, OP (O) (OW786) (OW787), OSi (W788) (W789) (W790), OS (O 2 ) W791, NHC (O) W792, NW793C (O) W794, NHC (O) OW795 , NHC (O) NHW796, NHC (O) NW797W798, NW799C (O) OW800, NW801C (O) NHW802, NW803C (O) NW804W805, NHS (O 2 ) W806, NW807S (O 2 ) W808, SW809, S (O ) W810, S (O 2 ) W811, S (O 2 ) NHW812, S (O 2 ) NW813W814, S (O 2 ) OW815, P (O) (OW816) (OW817), Si (W818) (W819) ( W820) "

여기서, W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W791, W792, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W811, W812, W813, W814, W815, W816, W817, W818, W819, W820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W775, W776 및/또는 W784, W785 및/또는 W797, W798 및/또는 W804, W805 및/또는 W813, W814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W791, W792, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W811, W812, W813, W814, W815, W816, W817, W818, W819, W820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W775, W776 and / or W784, W785 and / or W797, W798 and / or W804, W805 and / or W813, W814 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW821, NW822W823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W824, C(O)OW825, C(O)NHW826, C(O)NW827W828, OW829, O(W830-O)eH (e = 1, 2, 3, 4, 5), O(W831-O)eW832 (e = 1, 2, 3, 4, 5), OC(O)W833, OC(O)OW834, OC(O)NHW835, OC(O)NW836W837, OP(O)(OW838)(OW839), OSi(W840)(W841)(W842), OS(O2)W843, NHC(O)W844, NW845C(O)W846, NHC(O)OW847, NHC(O)NHW848, NHC(O)NW849W850, NW851C(O)OW852, NW853C(O)NHW854, NW855C(O)NW856W857, NHS(O2)W858, NW859S(O2)W860, SW861, S(O)W862, S(O2)W863, S(O2)NHW864, S(O2)NW865W866, S(O2)OW867, P(O)(OW868)(OW869), Si(W870)(W871)(W872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW821, NW822W823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W824, C (O) OW825, C (O) NHW826, C (O) NW827W828, OW829, O (W830-O) e H (e = 1, 2, 3, 4, 5), O (W831-O) e W832 (e = 1, 2, 3, 4, 5), OC (O) W833, OC (O) OW834, OC (O) NHW835 , OC (O) NW836W837, OP (O) (OW838) (OW839), OSi (W840) (W841) (W842), OS (O 2 ) W843, NHC (O) W844, NW845C (O) W846, NHC ( O) OW847, NHC (O) NHW848, NHC (O) NW849W850, NW851C (O) OW852, NW853C (O) NHW854, NW855C (O) NW856W857, NHS (O 2 ) W858, NW859S (O 2 ) W860, SW861, S (O) W862, S (O 2 ) W863, S (O 2 ) NHW864, S (O 2 ) NW865W866, S (O 2 ) OW867, P (O) (OW868) (OW869), Si (W870) ( W871) (W872) "

여기서, W821, W822, W823, W824, W825, W826, W827, W828, W829, W830, W831, W832, W833, W834, W835, W836, W837, W838, W839, W840, W841, W842, W843, W844, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W827, W828 및/또는 W836, W837 및/또는 W849, W850 및/또는 W856, W857 및/또는 W865, W866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Here, W821, W822, W823, W824, W825, W826, W827, W828, W829, W830, W831, W832, W833, W834, W835, W836, W837, W838, W839, W840, W841, W842, W843, W844, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W827, W828 and / or W836, W837 and / or W849, W850 and / or W856, W857 and / or W865, W866 are also in each case a" heterocycle. " Reels ";

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW873, NW874W875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W876, C(O)OW877, C(O)NHW878, C(O)NW879W880, OW881, O(W882-O)fH (f = 1, 2, 3, 4, 5), O(W883-O)fW884 (f = 1, 2, 3, 4, 5), OC(O)W885, OC(O)OW886, OC(O)NHW887, OC(O)NW888W889, OP(O)(OW890)(OW891), OSi(W892)(W893)(W894), OS(O2)W895, NHC(O)W896, NW897C(O)W898, NHC(O)OW899, NHC(O)NHW900, NHC(O)NW901W902, NW903C(O)OW904, NW905C(O)NHW906, NW907C(O)NW908W909, NHS(O2)W910, NW911S(O2)W912, SW913, S(O)W914, S(O2)W915, S(O2)NHW916, S(O2)NW917W918, S(O2)OW919, P(O)(OW920)(OW921), Si(W922)(W923)(W924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW873, NW874W875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W876, C (O) OW877, C (O) NHW878, C (O) NW879W880, OW881, O (W882-O) f H (f = 1, 2, 3, 4, 5), O (W883-O) f W884 (f = 1, 2, 3, 4, 5), OC (O) W885, OC (O) OW886, OC (O) NHW887 , OC (O) NW888W889, OP (O) (OW890) (OW891), OSi (W892) (W893) (W894), OS (O 2 ) W895, NHC (O) W896, NW897C (O) W898, NHC ( O) OW899, NHC (O) NHW900, NHC (O) NW901W902, NW903C (O) OW904, NW905C (O) NHW906, NW907C (O) NW908W909, NHS (O 2 ) W910, NW911S (O 2 ) W912, SW913, S (O) W914, S (O 2 ) W915, S (O 2 ) NHW916, S (O 2 ) NW917W918, S (O 2 ) OW919, P (O) (OW920) (OW921), Si (W922) ( W923) (W924) "

여기서, W873, W874, W875, W876, W877, W878, W879, W880, W881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W896, W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W911, W912, W913, W914, W915, W916, W917, W918, W919, W920, W921, W922, W923, W924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W879, W880 및/또는 W888, W889 및/또는 W901, W902 및/또는 W908, W909 및/또는 W917, W918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W873, W874, W875, W876, W877, W878, W879, W880, W881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W896, W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W911, W912, W913, W914, W915, W916, W917, W918, W919, W920, W921, W922, W923, W924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W879, W880 and / or W888, W889 and / or W901, W902 and / or W908, W909 and / or W917, W918 are also in each case" heterocycle. " Reels ",

(g) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(g) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein optionally, Said substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW925, NW926W927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W928, C(O)OW929, C(O)NHW930, C(O)NW931W932, OW933, O(W934-O)gH (g = 1, 2, 3, 4, 5), O(W935-O)gW936 (g = 1, 2, 3, 4, 5), OC(O)W937, OC(O)OW938, OC(O)NHW939, OC(O)NW940W941, OP(O)(OW942)(OW943), OSi(W944)(W945)(W946), OS(O2)W947, NHC(O)W948, NW949C(O)W950, NHC(O)OW951, NHC(O)NHW952, NHC(O)NW953W954, NW955C(O)OW956, NW957C(O)NHW958, NW959C(O)NW960W961, NHS(O2)W962, NW963S(O2)W964, SW965, S(O)W966, S(O2)W967, S(O2)NHW968, S(O2)NW969W970, S(O2)OW971, P(O)(OW972)(OW973), Si(W974)(W975)(W976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW925, NW926W927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W928, C (O) OW929, C (O) NHW930, C (O) NW931W932, OW933, O (W934-O) g H (g = 1, 2, 3, 4, 5), O (W935-O) g W936 (g = 1, 2, 3, 4, 5), OC (O) W937, OC (O) OW938, OC (O) NHW939 , OC (O) NW940W941, OP (O) (OW942) (OW943), OSi (W944) (W945) (W946), OS (O 2 ) W947, NHC (O) W948, NW949C (O) W950, NHC ( O) OW951, NHC (O) NHW952, NHC (O) NW953W954, NW955C (O) OW956, NW957C (O) NHW958, NW959C (O) NW960W961, NHS (O 2 ) W962, NW963S (O 2 ) W964, SW965, S (O) W966, S (O 2 ) W967, S (O 2 ) NHW968, S (O 2 ) NW969W970, S (O 2 ) OW971, P (O) (OW972) (OW973), Si (W974) ( W975) (W976) "

여기서, W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941, W942, W943, W944, W945, W946, W947, W948, W949, W950, W951, W952, W953, W954, W955, W956, W957, W958, W959, W960, W961, W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W972, W973, W974, W975, W976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W931, W932 및/또는 W940, W941 및/또는 W953, W954 및/또는 W960, W961 및/또는 W969, W970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941, W942, W943, W944, W945, W946, W947, W948, W949, W950, W951, W952, W953, W954, W955, W956, W957, W958, W959, W960, W961, W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W972, W973, W974, W975, W976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W931, W932 and / or W940, W941 and / or W953, W954 and / or W960, W961 and / or W969, W970 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW977, NW978W979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W980, C(O)OW981, C(O)NHW982, C(O)NW983W984, OW985, O(W986-O)hH (h = 1, 2, 3, 4, 5), O(W987-O)hW988 (h = 1, 2, 3, 4, 5), OC(O)W989, OC(O)OW990, OC(O)NHW991, OC(O)NW992W993, OP(O)(OW994)(OW995), OSi(W996)(W997)(W998), OS(O2)W999, NHC(O)W1000, NW1001C(O)W1002, NHC(O)OW1003, NHC(O)NHW1004, NHC(O)NW1005W1006, NW1007C(O)OW1008, NW1009C(O)NHW1010, NW1011C(O)NW1012W1013, NHS(O2)W1014, NW1015S(O2)W1016, SW1017, S(O)W1018, S(O2)W1019, S(O2)NHW1020, S(O2)NW1021W1022, S(O2)OW1023, P(O)(OW1024)(OW1025), Si(W1026)(W1027)(W1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW977, NW978W979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W980, C (O) OW981, C (O) NHW982, C (O) NW983W984, OW985, O (W986-O) h H (h = 1, 2, 3, 4, 5), O (W987-O) h W988 (h = 1, 2, 3, 4, 5), OC (O) W989, OC (O) OW990, OC (O) NHW991 , OC (O) NW992W993, OP (O) (OW994) (OW995), OSi (W996) (W997) (W998), OS (O 2 ) W999, NHC (O) W1000, NW1001C (O) W1002, NHC ( O) OW1003, NHC (O) NHW1004, NHC (O) NW1005W1006, NW1007C (O) OW1008, NW1009C (O) NHW1010, NW1011C (O) NW1012W1013, NHS (O 2 ) W1014, NW1015S (O 2 ) W1016, SW1016 S (O) W1018, S (O 2 ) W1019, S (O 2 ) NHW1020, S (O 2 ) NW1021W1022, S (O 2 ) OW1023, P (O) (OW1024) (OW1025), Si (W1026) ( W1027) (W1028) "

여기서, W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988, W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001, W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W1011, W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, W1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W983, W984 및/또는 W992, W993 및/또는 W1005, W1006 및/또는 W1012, W1013 및/또는 W1021, W1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988, W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001, W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W1011, W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1024 W1026, W1027, W1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022 are also in each case" heterocycle Reels ",

(h) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(h) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein optionally, Said substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1029, NW1030W1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1032, C(O)OW1033, C(O)NHW1034, C(O)NW1035W1036, OW1037, O(W1038-O)iH (i = 1, 2, 3, 4, 5), O(W1039-O)iW1040 (i = 1, 2, 3, 4, 5), OC(O)W1041, OC(O)OW1042, OC(O)NHW1043, OC(O)NW1044W1045, OP(O)(OW1046)(OW1047), OSi(W1048)(W1049)(W1050), OS(O2)W1051, NHC(O)W1052, NW1053C(O)W1054, NHC(O)OW1055, NHC(O)NHW1056, NHC(O)NW1057W1058, NW1059C(O)OW1060, NW1061C(O)NHW1062, NW1063C(O)NW1064W1065, NHS(O2)W1066, NW1067S(O2)W1068, SW1069, S(O)W1070, S(O2)W1071, S(O2)NHW1072, S(O2)NW1073W1074, S(O2)OW1075, P(O)(OW1076)(OW1077), Si(W1078)(W1079)(W1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1029, NW1030W1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1032, C (O) OW1033, C (O) NHW1034, C (O) NW1035W1036, OW1037, O (W1038-O) i H (i = 1, 2, 3, 4, 5), O (W1039-O) i W1040 (i = 1, 2, 3, 4, 5), OC (O) W1041, OC (O) OW1042, OC (O) NHW1043 , OC (O) NW1044W1045, OP (O) (OW1046) (OW1047), OSi (W1048) (W1049) (W1050), OS (O 2 ) W1051, NHC (O) W1052, NW1053C (O) W1054, NHC ( O) OW1055, NHC (O) NHW1056, NHC (O) NW1057W1058, NW1059C (O) OW1060, NW1061C (O) NHW1062, NW1063C (O) NW1064W1065, NHS (O 2 ) W1066, NW1067S (O 2 ) W1068, SW1069 S (O) W1070, S (O 2 ) W1071, S (O 2 ) NHW1072, S (O 2 ) NW1073W1074, S (O 2 ) OW1075, P (O) (OW1076) (OW1077), Si (W1078) ( W1079) (W1080) "

여기서, W1029, W1030, W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051, W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1035, W1036 및/또는 W1044, W1045 및/또는 W1057, W1058 및/또는 W1064, W1065 및/또는 W1073, W1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W1029, W1030, W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051, W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1076 W1078, W1079, W1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W1035, W1036 and / or W1044, W1045 and / or W1057, W1058 and / or W1064, W1065 and / or W1073, W1074 are also in each case a" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1081, NW1082W1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1084, C(O)OW1085, C(O)NHW1086, C(O)NW1087W1088, OW1089, O(W1090-O)jH (j = 1, 2, 3, 4, 5), O(W1091-O)jW1092 (j = 1, 2, 3, 4, 5), OC(O)W1093, OC(O)OW1094, OC(O)NHW1095, OC(O)NW1096W1097, OP(O)(OW1098)(OW1099), OSi(W1100)(W1101)(W1102), OS(O2)W1103, NHC(O)W1104, NW1105C(O)W1106, NHC(O)OW1107, NHC(O)NHW1108, NHC(O)NW1109W1110, NW1111C(O)OW1112, NW1113C(O)NHW1114, NW1115C(O)NW1116W1117, NHS(O2)W1118, NW1119S(O2)W1120, SW1121, S(O)W1122, S(O2)W1123, S(O2)NHW1124, S(O2)NW1125W1126, S(O2)OW1127, P(O)(OW1128)(OW1129), Si(W1130)(W1131)(W1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1081, NW1082W1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1084, C (O) OW1085, C (O) NHW1086, C (O) NW1087W1088, OW1089, O (W1090-O) j H (j = 1, 2, 3, 4, 5), O (W1091-O) j W1092 (j = 1, 2, 3, 4, 5), OC (O) W1093, OC (O) OW1094, OC (O) NHW1095 , OC (O) NW1096W1097, OP (O) (OW1098) (OW1099), OSi (W1100) (W1101) (W1102), OS (O 2 ) W1103, NHC (O) W1104, NW1105C (O) W1106, NHC ( O) OW1107, NHC (O) NHW1108, NHC (O) NW1109W1110, NW1111C (O) OW1112, NW1113C (O) NHW1114, NW1115C (O) NW1116W1117, NHS (O 2 ) W1118, NW1119S (O 2 ) W1120, SW112 S (O) W1122, S (O 2 ) W1123, S (O 2 ) NHW1124, S (O 2 ) NW1125W1126, S (O 2 ) OW1127, P (O) (OW1128) (OW1129), Si (W1130) ( W1131) (W1132) "

여기서, W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092, W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1104, W1105, W1106, W1107, W1108, W1109, W1110, W1111, W1112, W1113, W1114, W1115, W1116, W1117, W1118, W1119, W1120, W1121, W1122, W1123, W1124, W1125, W1126, W1127, W1128, W1129, W1130, W1131, W1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1087, W1088 및/또는 W1096, W1097 및/또는 W1109, W1110 및/또는 W1116, W1117 및/또는 W1125, W1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092, W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1103 W1105, W1106, W1107, W1108, W1109, W1110, W1111, W1112, W1113, W1114, W1115, W1116, W1117, W1118, W1119, W1120, W1121, W1122, W1123, W1124, W1125, W1126, W1127, W1128, 29 W1130, W1131, W1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W1087, W1088 and / or W1096, W1097 and / or W1109, W1110 and / or W1116, W1117 and / or W1125, W1126 are also in each case" heterocycle. " Reels ",

(j) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(j) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)W1133, C(O)OW1134, C(O)NW1135W1136, S(O2)W1137, S(O2)OW1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) W1133 , C (O) OW1134, C (O) NW1135W1136, S (O 2 ) W1137, S (O 2 ) OW1138 "

여기서, W1133, W1134, W1135, W1136, W1137, W1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1135, W1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein W1133, W1134, W1135, W1136, W1137, W1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, W1135, W1136 together may also form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1139, NW1140W1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1142, C(O)OW1143, C(O)NHW1144, C(O)NW1145W1146, OW1147, O(W1148-O)kH (k = 1, 2, 3, 4, 5), O(W1149-O)kW1150 (k = 1, 2, 3, 4, 5), OC(O)W1151, OC(O)OW1152, OC(O)NHW1153, OC(O)NW1154W1155, OP(O)(OW1156)(OW1157), OSi(W1158)(W1159)(W1160), OS(O2)W1161, NHC(O)W1162, NW1163C(O)W1164, NHC(O)OW1165, NHC(O)NHW1166, NHC(O)NW1167W1168, NW1169C(O)OW1170, NW1171C(O)NHW1172, NW1173C(O)NW1174W1175, NHS(O2)W1176, NW1177S(O2)W1178, SW1179, S(O)W1180, S(O2)W1181, S(O2)NHW1182, S(O2)NW1183W1184, S(O2)OW1185, P(O)(OW1186)(OW1187), Si(W1188)(W1189)(W1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1139, NW1140W1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1142, C (O) OW1143, C (O) NHW1144, C (O) NW1145W1146, OW1147, O (W1148-O) k H (k = 1, 2, 3, 4, 5), O (W1149-O) k W1150 (k = 1, 2, 3, 4, 5), OC (O) W1151, OC (O) OW1152, OC (O) NHW1153 , OC (O) NW1154W1155, OP (O) (OW1156) (OW1157), OSi (W1158) (W1159) (W1160), OS (O 2 ) W1161, NHC (O) W1162, NW1163C (O) W1164, NHC ( O) OW1165, NHC (O) NHW1166, NHC (O) NW1167W1168, NW1169C (O) OW1170, NW1171C (O) NHW1172, NW1173C (O) NW1174W1175, NHS (O 2 ) W1176, NW1177S (O2) W1178, SW1179 (O) W1180, S (O 2 ) W1181, S (O 2 ) NHW1182, S (O 2 ) NW1183W1184, S (O 2 ) OW1185, P (O) (OW1186) (OW1187), Si (W1188) (W1189 ) (W1190) "

여기서, W1139, W1140, W1141, W1142, W1143, W1144, W1145, W1146, W1147, W1148, W1149, W1150, W1151, W1152, W1153, W1154, W1155, W1156, W1157, W1158, W1159, W1160, W1161, W1162, W1163, W1164, W1165, W1166, W1167, W1168, W1169, W1170, W1171, W1172, W1173, W1174, W1175, W1176, W1177, W1178, W1179, W1180, W1181, W1182, W1183, W1184, W1185, W1186, W1187, W1188, W1189, W1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알 킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1145, W1146 및/또는 W1154, W1155 및/또는 W1167, W1168 및/또는 W1174, W1175 및/또는 W1183, W1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W1139, W1140, W1141, W1142, W1143, W1144, W1145, W1146, W1147, W1148, W1149, W1150, W1151, W1152, W1153, W1154, W1155, W1156, W1157, W1158, W1159, W1160, W1161, W1162, W1163, W1164, W1165, W1166, W1167, W1168, W1169, W1170, W1171, W1172, W1173, W1174, W1175, W1176, W1177, W1178, W1179, W1180, W1181, W1182, W1183, W1184, W1185, W1186, W1186, W1188, W1189, W1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, W1145, W1146 and / or W1154, W1155 and / or W1167, W1168 and / or W1174, W1175 and / or W1183, W1184 are also in each case" hetero " Cyclyl ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1191, NW1192W1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1194, C(O)OW1195, C(O)NHW1196, C(O)NW1197W1198, OW1199, O(W1200-O)lH (l = 1, 2, 3, 4, 5), O(W1201-O)lW1202 (l = 1, 2, 3, 4, 5), OC(O)W1203, OC(O)OW1204, OC(O)NHW1205, OC(O)NW1206W1207, OP(O)(OW1208)(OW1209), OSi(W1210)(W1211)(W1212), OS(O2)W1213, NHC(O)W1214, NW1215C(O)W1216, NHC(O)OW1217, NHC(O)NHW1218, NHC(O)NW1219W1220, NW1221C(O)OW1222, NW1223C(O)NHW1224, NW1225C(O)NW1226W1227, NHS(O2)W1228, NW1229S(O2)W1230, SW1231, S(O)W1232, S(O2)W1233, S(O2)NHW1234, S(O2)NW1235W1236, S(O2)OW1237, P(O)(OW1238)(OW1239), Si(W1240)(W1241)(W1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1191, NW1192W1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1194, C (O) OW1195, C (O) NHW1196, C (O) NW1197W1198, OW1199, O (W1200-O) l H (l = 1, 2, 3, 4, 5), O (W1201-O) l W1202 (l = 1, 2, 3, 4, 5), OC (O) W1203, OC (O) OW1204, OC (O) NHW1205 , OC (O) NW1206W1207, OP (O) (OW1208) (OW1209), OSi (W1210) (W1211) (W1212), OS (O 2 ) W1213, NHC (O) W1214, NW1215C (O) W1216, NHC ( O) OW1217, NHC (O) NHW1218, NHC (O) NW1219W1220, NW1221C (O) OW1222, NW1223C (O) NHW1224, NW1225C (O) NW1226W1227, NHS (O 2 ) W1228, NW1229S (O 2 ) W1230, SW123 S (O) W1232, S (O 2 ) W1233, S (O 2 ) NHW1234, S (O 2 ) NW1235W1236, S (O 2 ) OW1237, P (O) (OW1238) (OW1239), Si (W1240) ( W1241) (W1242) "

여기서, W1191, W1192, W1193, W1194, W1195, W1196, W1197, W1198, W1199, W1200, W1201, W1202, W1203, W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1238, W1239, W1240, W1241, W1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1197, W1198 및/또는 W1206, W1207 및/또는 W1219, W1220 및/또는 W1226, W1227 및/또는 W1235, W1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W1191, W1192, W1193, W1194, W1195, W1196, W1197, W1198, W1199, W1200, W1201, W1202, W1203, W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1214 W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1238, W1240, W1241, W1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W1197, W1198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 are also in each case a" heterocycle. " Reels ",

또는or

(A) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(A) one of the Z3, Z4 radicals or both Z3, Z4 radicals is each independently selected from the group consisting of:

(1) "NZ10Z11, OZ12, SZ13"(1) "NZ10Z11, OZ12, SZ13"

여기서, Z10, Z11 라디칼 중 하나 또는 Z10, Z11 라디칼 및 Z12, Z13 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein one of Z10, Z11 radicals or both Z10, Z11 radicals and Z12, Z13 radicals are each independently selected from the group consisting of:

(a) "수소, 알킬, 사이클로알킬, 사이클로알킬알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 헤테로사이클릴, 헤테로사이클릴알킬"(a) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"

단, Z10, Z11 라디칼 둘 다는 동시에 수소가 아니고;Provided that both Z10 and Z11 radicals are not simultaneously hydrogen;

추가로 단, Z12 라디칼은 수소가 아니고;Further provided that the Z12 radical is not hydrogen;

추가로 단, 치환체 그룹(a)의 상기한 치환체는, 이들이 수소가 아닌 경우, 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Further provided that the aforementioned substituents of substituent group (a) are further substituted by one or more substituents, each of which is independently the same or differently selected from the group consisting of:

(i) "(C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, N3, NH사이클로알킬, NH사이클로알킬알킬, NH헤테로아릴, NH헤테로아릴알킬, NH아릴알킬, NH헤테로사이클릴, NH헤테로사이클릴알킬, NQ1Q2, S사이클로알킬, S사이클로알킬알킬, S아릴, S아릴알킬, S헤테로아릴, S헤테로아릴알킬, S헤테로사이클릴, S헤테로사이클릴알킬, O사이클로알킬, O사이클로알킬알킬, O아릴알킬, O헤테로아릴, O헤테로아릴알킬, O헤테로사이클릴, O헤테로사이클릴알킬, O(Q3-O)pH (p = 1, 2, 3, 4, 5), O(Q4-O)pQ5 (p = 1, 2, 3, 4, 5), OP(O)(OQ6)(OQ7), C(O)OQ8, C(O)NH2, C(O)NHQ9, C(O)NQ10Q11, S(O2)Q12, P(O)(OH)2, P(O)(OQ13)(OQ14), Si(Q15)(Q16)(Q17), OSi(Q18)(Q19)(Q20), OC(O)OQ21, OC(O)NHQ22, OC(O)NQ23Q24, NHC(O)OQ25, NHC(O)NHQ26, NHC(O)NQ27Q28, NQ29C(O)OQ30, NQ31C(O)NHQ32, NQ33C(O)NQ34Q35, NQ36S(O2)Q37, NHS(O2)Q38, OS(O2)Q39, NHC(O)Q40, NQ41C(O)Q42, C(O)Q43, OC(O)Q44, S(O)Q45, S(O2)NHQ46, S(O2)NQ47Q48, S(O2)OQ49"(i) "(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , NHcycloalkyl, NHcyclo Alkylalkyl, NH heteroaryl, NH heteroarylalkyl, NH arylalkyl, NH heterocyclyl, NH heterocyclylalkyl, NQ1Q2, Scycloalkyl, Scycloalkylalkyl, Saryl, Sarylalkyl, S heteroaryl, S Heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, Ocycloalkyl, Ocycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O ( Q3-O) p H (p = 1, 2, 3, 4, 5), O (Q4-O) p Q5 (p = 1, 2, 3, 4, 5), OP (O) (OQ6) ( OQ7), C (O) OQ8, C (O) NH2, C (O) NHQ9, C (O) NQ10Q11, S (O 2 ) Q12, P (O) (OH) 2, P (O) (OQ13) (OQ14), Si (Q15) (Q16) (Q17), OSi (Q18) (Q19) (Q20), OC (O) OQ21, OC (O) NHQ22, OC (O) NQ23Q24, NHC (O) OQ25, NHC (O) NHQ26, NHC (O) NQ27Q28, NQ29C (O) OQ30, NQ31C (O) NHQ32 , NQ33C (O) NQ34Q35, NQ36S (O2) Q37, NHS (O2) Q38, OS (O2) Q39, NHC (O) Q40, NQ41C (O) Q42, C (O) Q43, OC (O) Q44, S (O) Q45, S (O 2 ) NHQ46, S (O 2 ) NQ47Q48, S (O 2 ) OQ49 "

추가로 단, "N(알킬)2"는 다음 치환체 그룹(ii)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further provided that "N (alkyl) 2 " is further substituted by one or more substituents selected from the following substituent groups (ii);

여기서, Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q10, Q11 및/또는 Q23, Q24 및/또는 Q27, Q28 및/또는 Q34, Q35 및/또는 Q47, Q48은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 Each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", Where, alternatively, Q10, Q11 and / or Q23, Q24 and / or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 may also together form" heterocyclyl "in each case There is,

여기서, 임의로, 치환체 그룹(a) 및/또는 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (a) and / or substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ50, NQ51Q52, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q53, C(O)OQ54, C(O)NHQ55, C(O)NQ56Q57, OQ58, O(Q59-O)rH (r = 1, 2, 3, 4, 5), O(Q60-O)rQ61 (r = 1, 2, 3, 4, 5), OC(O)Q62, OC(O)OQ63, OC(O)NHQ64, OC(O)NQ65Q66, OP(O)(OQ67)(OQ68), OSi(Q69)(Q70)(Q71), OS(O2)Q72, NHC(O)Q73, NQ74C(O)Q75, NHC(O)OQ76, NHC(O)NHQ77, NHC(O)NQ78Q79, NQ80C(O)OQ81, NQ82C(O)NHQ83, NQ84C(O)NQ85Q86, NHS(O2)Q87, NQ88S(O2)Q89, SQ90, S(O)Q91, S(O2)Q92, S(O2)NHQ93, S(O2)NQ94Q95, S(O2)OQ96, P(O)(OQ97)(OQ98), Si(Q99)(Q100)(Q101)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ50, NQ51Q52, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q53, C (O) OQ54, C (O) NHQ55, C (O) NQ56Q57, OQ58, O (Q59-O) r H (r = 1, 2, 3, 4, 5), O (Q60-O) r Q61 (r = 1, 2, 3, 4, 5), OC (O) Q62, OC (O) OQ63, OC (O) NHQ64 , OC (O) NQ65Q66, OP (O) (OQ67) (OQ68), OSi (Q69) (Q70) (Q71), OS (O 2 ) Q72, NHC (O) Q73, NQ74C (O) Q75, NHC ( O) OQ76, NHC (O) NHQ77, NHC (O) NQ78Q79, NQ80C (O) OQ81, NQ82C (O) NHQ83, NQ84C (O) NQ85Q86, NHS (O2) Q87, NQ88S (O2) Q89, SQ90, S ( O) Q91, S (O 2 ) Q92, S (O 2 ) NHQ93, S (O 2 ) NQ94Q95, S (O 2 ) OQ96, P (O) (OQ97) (OQ98), Si (Q99) (Q100) (Q101) "

여기서, Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71, Q72, Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q56, Q57 및/또는 Q65, Q66 및/또는 Q78, Q79 및/또는 Q85, Q86 및/또는 Q94, Q95는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71, Q72, Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or Q94, Q95 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ102, NQ103Q104, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q105, C(O)OQ106, C(O)NHQ107, C(O)NQ108Q109, OQ110, O(Q111-O)sH (s = 1, 2, 3, 4, 5), O(Q112-O)sQ113 (s = 1, 2, 3, 4, 5), OC(O)Q114, OC(O)OQ115, OC(O)NHQ116, OC(O)NQ117Q118, OP(O)(OQ119)(OQ120), OSi(Q121)(Q122)(Q123), OS(O2)Q124, NHC(O)Q125, NQ126C(O)Q127, NHC(O)OQ128, NHC(O)NHQ129, NHC(O)NQ130Q131, NQ132C(O)OQ133, NQ134C(O)NHQ135, NQ136C(O)NQ137Q138, NHS(O2)Q139, NQ140S(O2)Q141, SQ142, S(O)Q143, S(O2)Q144, S(O2)NHQ145, S(O2)NQ146Q147, S(O2)OQ148, P(O)(OQ149)(OQ150), Si(Q151)(Q152)(Q153)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ102, NQ103Q104, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q105, C (O) OQ106, C (O) NHQ107, C (O) NQ108Q109, OQ110, O (Q111-O) s H (s = 1, 2, 3, 4, 5), O (Q112-O) s Q113 (s = 1, 2, 3, 4, 5), OC (O) Q114, OC (O) OQ115, OC (O) NHQ116 , OC (O) NQ117Q118, OP (O) (OQ119) (OQ120), OSi (Q121) (Q122) (Q123), OS (O 2 ) Q124, NHC (O) Q125, NQ126C (O) Q127, NHC ( O) OQ128, NHC (O) NHQ129, NHC (O) NQ130Q131, NQ132C (O) OQ133, NQ134C (O) NHQ135, NQ136C (O) NQ137Q138, NHS (O2) Q139, NQ140S (O2) Q141, SQ142, S ( O) Q143, S (O 2 ) Q144, S (O 2 ) NHQ145, S (O 2 ) NQ146Q147, S (O 2 ) OQ148, P (O) (OQ149) (OQ150), Si (Q151) (Q152) (Q153) "

여기서, Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111, Q112, Q113, Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q108, Q109 및/또는 Q117, Q118 및/또는 Q130, Q131 및/또는 Q137, Q138 및/또는 Q146, Q147은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111, Q112, Q113, Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q108, Q109 and / or Q117, Q118 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 are also in each case" heterocycle Reels ",

(b) "(C9-C30)알킬, C(O)Q154, C(O)OQ155, C(O)NQ156Q157, S(O2)Q158, S(O2)OQ159"(b) "(C 9 -C 30 ) alkyl, C (O) Q154, C (O) OQ155, C (O) NQ156Q157, S (O 2 ) Q158, S (O 2 ) OQ159"

여기서, Q154, Q155, Q156, Q157, Q158, Q159는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q156, Q157은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein Q154, Q155, Q156, Q157, Q158, Q159 are each independently selected from the group consisting of: "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, Heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q156, Q157 together may also form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(b)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ160, NQ161Q162, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q163, C(O)OQ164, C(O)NHQ165, C(O)NQ166Q167, OQ168, O(Q169-O)tH (t = 1, 2, 3, 4, 5), O(Q170-O)tQ171 (t = 1, 2, 3, 4, 5), OC(O)Q172, OC(O)OQ173, OC(O)NHQ174, OC(O)NQ175Q176, OP(O)(OQ177)(OQ178), OSi(Q179)(Q180)(Q181), OS(O2)Q182, NHC(O)Q183, NQ184C(O)Q185, NHC(O)OQ186, NHC(O)NHQ187, NHC(O)NQ188Q189, NQ190C(O)OQ191, NQ192C(O)NHQ193, NQ194C(O)NQ195Q196, NHS(O2)Q197, NQ198S(O2)Q199, SQ200, S(O)Q201, S(O2)Q202, S(O2)NHQ203, S(O2)NQ204Q205, S(O2)OQ206, P(O)(OQ207)(OQ208), Si(Q209)(Q210)(Q211)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ160, NQ161Q162, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q163, C (O) OQ164, C (O) NHQ165, C (O) NQ166Q167, OQ168, O (Q169-O) t H (t = 1, 2, 3, 4, 5), O (Q170-O) t Q171 (t = 1, 2, 3, 4, 5), OC (O) Q172, OC (O) OQ173, OC (O) NHQ174 , OC (O) NQ175Q176, OP (O) (OQ177) (OQ178), OSi (Q179) (Q180) (Q181), OS (O 2 ) Q182, NHC (O) Q183, NQ184C (O) Q185, NHC ( O) OQ186, NHC (O) NHQ187, NHC (O) NQ188Q189, NQ190C (O) OQ191, NQ192C (O) NHQ193, NQ194C (O) NQ195Q196, NHS (O2) Q197, NQ198S (O2) Q199, SQ200, S ( O) Q201, S (O 2 ) Q202, S (O 2 ) NHQ203, S (O 2 ) NQ204Q205, S (O 2 ) OQ206, P (O) (OQ207) (OQ208), Si (Q209) (Q210) (Q211) "

여기서, Q160,Q161, Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208, Q209, Q210, Q211은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬" 여기서, 대안적으로, Q166, Q167 및/또는 Q175, Q176 및/또는 Q188, Q189 및/또는 Q195, Q196 및/또는 Q204, Q205는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q160, Q161, Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208, Q209, Q210, Q211 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl "wherein, alternatively, Q166, Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204, Q205 are also in each case" heterocyclyl ", And

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ212, NQ213Q214, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q215, C(O)OQ216, C(O)NHQ217, C(O)NQ218Q219, OQ220, O(Q221-O)uH (u = 1, 2, 3, 4, 5), O(Q222-O)uQ223 (u = 1, 2, 3, 4, 5), OC(O)Q224, OC(O)OQ225, OC(O)NHQ226, OC(O)NQ227Q228, OP(O)(OQ229)(OQ230), OSi(Q231)(Q232)(Q233), OS(O2)Q234, NHC(O)Q235, NQ236C(O)Q237, NHC(O)OQ238, NHC(O)NHQ239, NHC(O)NQ240Q241, NQ242C(O)OQ243, NQ244C(O)NHQ245, NQ246C(O)NQ247Q248, NHS(O2)Q249, NQ250S(O2)Q251, SQ252, S(O)Q253, S(O2)Q254, S(O2)NHQ255, S(O2)NQ256Q257, S(O2)OQ258, P(O)(OQ259)(OQ260), Si(Q261)(Q262)(Q263)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ212, NQ213Q214, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q215, C (O) OQ216, C (O) NHQ217, C (O) NQ218Q219, OQ220, O (Q221-O) u H (u = 1, 2, 3, 4, 5), O (Q222-O) u Q223 (u = 1, 2, 3, 4, 5), OC (O) Q224, OC (O) OQ225, OC (O) NHQ226 , OC (O) NQ227Q228, OP (O) (OQ229) (OQ230), OSi (Q231) (Q232) (Q233), OS (O 2 ) Q234, NHC (O) Q235, NQ236C (O) Q237, NHC ( O) OQ238, NHC (O) NHQ239, NHC (O) NQ240Q241, NQ242C (O) OQ243, NQ244C (O) NHQ245, NQ246C (O) NQ247Q248, NHS (O2) Q249, NQ250S (O2) Q251, SQ252, S ( O) Q253, S (O 2 ) Q254, S (O 2 ) NHQ255, S (O 2 ) NQ256Q257, S (O 2 ) OQ258, P (O) (OQ259) (OQ260), Si (Q261) (Q262) (Q263) "

여기서, Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229, Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q218, Q219 및/또는 Q227, Q228 및/또는 Q240, Q241 및/또는 Q247, Q248 및/또는 Q256, Q257은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229, Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q218, Q219 and / or Q227, Q228 and / or Q240, Q241 and / or Q247, Q248 and / or Q256, Q257 are also in each case" heterocycle. " Reels ";

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ264, NQ265Q266, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q267, C(O)OQ268, C(O)NHQ269, C(O)NQ270Q271, OQ272, O(Q273-O)vH (v = 1, 2, 3, 4, 5), O(Q274-O)vQ275 (v = 1, 2, 3, 4, 5), OC(O)Q276, OC(O)OQ277, OC(O)NHQ278, OC(O)NQ279Q280, OP(O)(OQ281)(OQ282), OSi(Q283)(Q284)(Q285), OS(O2)Q286, NHC(O)Q287, NQ288C(O)Q289, NHC(O)OQ290, NHC(O)NHQ291, NHC(O)NQ292Q293, NQ294C(O)OQ295, NQ296C(O)NHQ297, NQ298C(O)NQ299Q300, NHS(O2)Q301, NQ302S(O2)Q303, SQ304, S(O)Q305, S(O2)Q306, S(O2)NHQ307, S(O2)NQ308Q309, S(O2)OQ310, P(O)(OQ311)(OQ312), Si(Q313)(Q314)(Q315)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ264, NQ265Q266, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q267, C (O) OQ268, C (O) NHQ269, C (O) NQ270Q271, OQ272, O (Q273-O) v H (v = 1, 2, 3, 4, 5), O (Q274-O) v Q275 (v = 1, 2, 3, 4, 5), OC (O) Q276, OC (O) OQ277, OC (O) NHQ278 , OC (O) NQ279Q280, OP (O) (OQ281) (OQ282), OSi (Q283) (Q284) (Q285), OS (O 2 ) Q286, NHC (O) Q287, NQ288C (O) Q289, NHC ( O) OQ290, NHC (O) NHQ291, NHC (O) NQ292Q293, NQ294C (O) OQ295, NQ296C (O) NHQ297, NQ298C (O) NQ299Q300, NHS (O2) Q301, NQ302S (O2) Q303, SQ304, S (304) O) Q305, S (O 2 ) Q306, S (O 2 ) NHQ307, S (O 2 ) NQ308Q309, S (O 2 ) OQ310, P (O) (OQ311) (OQ312), Si (Q313) (Q314) (Q315) "

여기서, Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271, Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286,Q287, Q288, Q289, Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q311, Q312, Q313, Q314, Q315는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤 테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q270, Q271 및/또는 Q279, Q280 및/또는 Q292, Q293 및/또는 Q299, Q300 및/또는 Q308, Q309는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271, Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289, Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q311, Q312, Q313, Q314 and Q315 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q270, Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Q309 are also in each case" hetero Cyclyl ",

또는 Z10, Z11 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z10, Z11 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: Or one of the Z10, Z11 radicals is independently selected from the group consisting of, or neither of the Z10, Z11 radicals is independently selected from the group consisting of:

(c) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 헤테로사이클릴, 헤테로사이클릴알킬, C(O)Q316, C(O)OQ317, C(O)NQ318Q319, S(O2)Q320, S(O2)OQ321"(c) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, C (O) Q316 , C (O) OQ317, C (O) NQ318Q319, S (O 2 ) Q320, S (O 2 ) OQ321 "

여기서, Q316, Q317, Q318, Q319, Q320, Q321은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q318, Q319는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Wherein Q316, Q317, Q318, Q319, Q320, Q321 are each independently selected from the group consisting of: "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, Heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q318, Q319 can also together form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는, 이들이 수소가 아닌 경우, 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may be substituted by one or more substituents, each of which, independently of one another, is identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ322, NQ323Q324, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q325, C(O)OQ326, C(O)NHQ327, C(O)NQ328Q329, OQ330, O(Q331-O)wH (w = 1, 2, 3, 4, 5), O(Q332-O)wQ333 (w = 1, 2, 3, 4, 5), OC(O)Q334, OC(O)OQ335, OC(O)NHQ336, OC(O)NQ337Q338, OP(O)(OQ339)(OQ340), OSi(Q341)(Q342)(Q343), OS(O2)Q344, NHC(O)Q345, NQ346C(O)Q347, NHC(O)OQ348, NHC(O)NHQ349, NHC(O)NQ350Q351, NQ352C(O)OQ353, NQ354C(O)NHQ355, NQ356C(O)NQ357Q358, NHS(O2)Q359, NQ360S(O2)Q361, SQ362, S(O)Q363, S(O2)Q364, S(O2)NHQ365, S(O2)NQ366Q367, S(O2)OQ368, P(O)(OQ369)(OQ370), Si(Q371)(Q372)(Q373)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ322, NQ323Q324, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q325, C (O) OQ326, C (O) NHQ327, C (O) NQ328Q329, OQ330, O (Q331-O) w H (w = 1, 2, 3, 4, 5), O (Q332-O) w Q333 (w = 1, 2, 3, 4, 5), OC (O) Q334, OC (O) OQ335, OC (O) NHQ336 , OC (O) NQ337Q338, OP (O) (OQ339) (OQ340), OSi (Q341) (Q342) (Q343), OS (O 2 ) Q344, NHC (O) Q345, NQ346C (O) Q347, NHC ( O) OQ348, NHC (O) NHQ349, NHC (O) NQ350Q351, NQ352C (O) OQ353, NQ354C (O) NHQ355, NQ356C (O) NQ357Q358, NHS (O2) Q359, NQ360S (O2) Q361, SQ362, S ( O) Q363, S (O 2 ) Q364, S (O 2 ) NHQ365, S (O 2 ) NQ366Q367, S (O 2 ) OQ368, P (O) (OQ369) (OQ370), Si (Q371) (Q372) (Q373) "

여기서, Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341, Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350, Q351, Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360, Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q328, Q329 및/또는 Q337, Q338 및/또는 Q350, Q351 및/또는 Q357, Q358 및/또는 Q366, Q367은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341, Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350, Q351, Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360, Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q328, Q329 and / or Q337, Q338 and / or Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 may also in each case be" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ374, NQ375Q376, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q377, C(O)OQ378, C(O)NHQ379, C(O)NQ380Q381, OQ382, O(Q383-O)xH (x = 1, 2, 3, 4, 5), O(Q384-O)xQ385 (x = 1, 2, 3, 4, 5), OC(O)Q386, OC(O)OQ387, OC(O)NHQ388, OC(O)NQ389Q390, OP(O)(OQ391)(OQ392), OSi(Q393)(Q394)(Q395), OS(O2)Q396, NHC(O)Q397, NQ398C(O)Q399, NHC(O)OQ400, NHC(O)NHQ401, NHC(O)NQ402Q403, NQ404C(O)OQ405, NQ406C(O)NHQ407, NQ408C(O)NQ409Q410, NHS(O2)Q411, NQ412S(O2)Q413, SQ414, S(O)Q415, S(O2)Q416, S(O2)NHQ417, S(O2)NQ418Q419, S(O2)OQ420, P(O)(OQ421)(OQ422), Si(Q423)(Q424)(Q425)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ374, NQ375Q376, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q377, C (O) OQ378, C (O) NHQ379, C (O) NQ380Q381, OQ382, O (Q383-O) x H (x = 1, 2, 3, 4, 5), O (Q384-O) x Q385 (x = 1, 2, 3, 4, 5), OC (O) Q386, OC (O) OQ387, OC (O) NHQ388 , OC (O) NQ389Q390, OP (O) (OQ391) (OQ392), OSi (Q393) (Q394) (Q395), OS (O 2 ) Q396, NHC (O) Q397, NQ398C (O) Q399, NHC ( O) OQ400, NHC (O) NHQ401, NHC (O) NQ402Q403, NQ404C (O) OQ405, NQ406C (O) NHQ407, NQ408C (O) NQ409Q410, NHS (O2) Q411, NQ412S (O2) Q413, SQ414, S ( O) Q415, S (O 2 ) Q416, S (O 2 ) NHQ417, S (O 2 ) NQ418Q419, S (O 2 ) OQ420, P (O) (OQ421) (OQ422), Si (Q423) (Q424) (Q425) "

여기서, Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381, Q382, Q383, Q384, Q385, Q386, Q387, Q388,Q389, Q390, Q391, Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400, Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q380, Q381 및/또는 Q389, Q390 및/또는 Q402, Q403 및/또는 Q409, Q410 및/또는 Q418, Q419는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381, Q382, Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391, Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400, Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q380, Q381 and / or Q389, Q390 and / or Q402, Q403 and / or Q409, Q410 and / or Q418, Q419 are also in each case" heterocycle. " Reels ";

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ426, NQ427Q428, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q429, C(O)OQ430, C(O)NHQ431, C(O)NQ432Q433, OQ434, O(Q435-O)yH (y = 1, 2, 3, 4, 5), O(Q436-O)yQ437 (y = 1, 2, 3, 4, 5), OC(O)Q438, OC(O)OQ439, OC(O)NHQ440, OC(O)NQ441Q442, OP(O)(OQ443)(OQ444), OSi(Q445)(Q446)(Q447), OS(O2)Q448, NHC(O)Q449, NQ450C(O)Q451, NHC(O)OQ452, NHC(O)NHQ453, NHC(O)NQ454Q455, NQ456aC(O)OQ456b, NQ456cC(O)NHQ456d, NQ456eC(O)NQ456fQ456g, NHS(O2)Q456h, NQ456iS(O2)Q456j, SQ456k, S(O)Q456l, S(O2)Q456m, S(O2)NHQ456n, S(O2)NQ456- OQ456p, S(O2)OQ456q, P(O)(OQ456r)(OQ456s), Si(Q456t)(Q456u)(Q456v)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ426, NQ427Q428, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q429, C (O) OQ430, C (O) NHQ431, C (O) NQ432Q433, OQ434, O (Q435-O) y H (y = 1, 2, 3, 4, 5), O (Q436-O) y Q437 (y = 1, 2, 3, 4, 5), OC (O) Q438, OC (O) OQ439, OC (O) NHQ440 , OC (O) NQ441Q442, OP (O) (OQ443) (OQ444), OSi (Q445) (Q446) (Q447), OS (O 2 ) Q448, NHC (O) Q449, NQ450C (O) Q451, NHC ( O) OQ452, NHC (O) NHQ453, NHC (O) NQ454Q455, NQ456aC (O) OQ456b, NQ456cC (O) NHQ456d, NQ456eC (O) NQ456fQ456g, NHS (O2) Q456h, NQ456iS (O2) Q456j, SQ456k, SQ456k O) Q456l, S (O 2 ) Q456m, S (O 2 ) NHQ456n, S (O 2 ) NQ456- OQ456p, S (O 2 ) OQ456q, P (O) (OQ456r) (OQ456s), Si (Q456t) ( Q456u) (Q456v) "

여기서, Q426, Q427, Q428, Q429, Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451, Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456j, Q456k, Q456l, Q456m, Q456n, Q456-O, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q432, Q433 및/또는 Q441, Q442 및/또는 Q454, Q455 및/또는 Q456f, Q456g 및/또는 Q456-O, Q456p, 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q426, Q427, Q428, Q429, Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451, Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456j, Q456k, Q456l, Q456m, Q456n, Q456-O, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aryl Alkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456-O, Q456p, and in each case Together can form a "heterocyclyl",

Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of:

(d) 수소;(d) hydrogen;

(e) 할로겐, F, Cl, Br, I;(e) halogen, F, Cl, Br, I;

(f) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(f) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ457, NQ458Q459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q460, C(O)OQ461, C(O)NHQ462, C(O)NQ463Q464, OQ465, O(Q466-O)zH (z = 1, 2, 3, 4, 5), O(Q467-O)zQ468 (z = 1, 2, 3, 4, 5), OC(O)Q469, OC(O)OQ470, OC(O)NHQ471, OC(O)NQ472Q473, OP(O)(OQ474)(OQ475), OSi(Q476)(Q477)(Q478), OS(O2)Q479, NHC(O)Q480, NQ481C(O)Q482, NHC(O)OQ483, NHC(O)NHQ484, NHC(O)NQ485Q486, NQ487C(O)OQ488, NQ489C(O)NHQ490, NQ491C(O)NQ492Q493, NHS(O2)Q494, NQ495S(O2)Q496, SQ497, S(O)Q498, S(O2)Q499, S(O2)NHQ500, S(O2)NQ501Q502, S(O2)OQ503, P(O)(OQ504)(OQ505), Si(Q506)(Q507)(Q508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ457, NQ458Q459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q460, C (O) OQ461, C (O) NHQ462, C (O) NQ463Q464, OQ465, O (Q466-O) z H (z = 1, 2, 3, 4, 5), O (Q467-O) z Q468 (z = 1, 2, 3, 4, 5), OC (O) Q469, OC (O) OQ470, OC (O) NHQ471 , OC (O) NQ472Q473, OP (O) (OQ474) (OQ475), OSi (Q476) (Q477) (Q478), OS (O 2 ) Q479, NHC (O) Q480, NQ481C (O) Q482, NHC ( O) OQ483, NHC (O) NHQ484, NHC (O) NQ485Q486, NQ487C (O) OQ488, NQ489C (O) NHQ490, NQ491C (O) NQ492Q493, NHS (O2) Q494, NQ495S (O2) Q496, SQ497, SQ497 O) Q498, S (O 2 ) Q499, S (O 2 ) NHQ500, S (O 2 ) NQ501Q502, S (O 2 ) OQ503, P (O) (OQ504) (OQ505), Si (Q506) (Q507) (Q508) "

여기서, Q457, Q458, Q459, Q460, Q461, Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485, Q486, Q487, Q488, Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505, Q506, Q507, Q508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q463, Q464 및/또는 Q472, Q473 및/또는 Q485, Q486 및/또는 Q492, Q493 및/또는 Q501, Q502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q457, Q458, Q459, Q460, Q461, Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485, Q486, Q487, Q488, Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505, Q506, Q507, Q508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Q502 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ509, NQ510Q511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q512, C(O)OQ513, C(O)NHQ514, C(O)NQ515Q516, OQ517, O(Q518-O)aH (a = 1, 2, 3, 4, 5), O(Q519-O)aQ520 (a = 1, 2, 3, 4, 5), OC(O)Q521, OC(O)OQ522, OC(O)NHQ523, OC(O)NQ524Q525, OP(O)(OQ526)(OQ527), OSi(Q528)(Q529)(Q530), OS(O2)Q531, NHC(O)Q532, NQ533C(O)Q534, NHC(O)OQ535, NHC(O)NHQ536, NHC(O)NQ537Q538, NQ539C(O)OQ540, NQ541C(O)NHQ542, NQ543C(O)NQ544Q545, NHS(O2)Q546, NQ547S(O2)Q548, SQ549, S(O)Q550, S(O2)Q551, S(O2)NHQ552, S(O2)NQ553Q554, S(O2)OQ555, P(O)(OQ556)(OQ557), Si(Q558)(Q559)(Q560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ509, NQ510Q511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q512, C (O) OQ513, C (O) NHQ514, C (O) NQ515Q516, OQ517, O (Q518-O) a H (a = 1, 2, 3, 4, 5), O (Q519-O) a Q520 (a = 1, 2, 3, 4, 5), OC (O) Q521, OC (O) OQ522, OC (O) NHQ523 , OC (O) NQ524Q525, OP (O) (OQ526) (OQ527), OSi (Q528) (Q529) (Q530), OS (O 2 ) Q531, NHC (O) Q532, NQ533C (O) Q534, NHC ( O) OQ535, NHC (O) NHQ536, NHC (O) NQ537Q538, NQ539C (O) OQ540, NQ541C (O) NHQ542, NQ543C (O) NQ544Q545, NHS (O2) Q546, NQ547S (O2) Q548, SQ549, S ( O) Q550, S (O 2 ) Q551, S (O 2 ) NHQ552, S (O 2 ) NQ553Q554, S (O 2 ) OQ555, P (O) (OQ556) (OQ557), Si (Q558) (Q559) (Q560) "

여기서, Q509, Q510, Q511, Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519,Q520, Q521, Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q531, Q532, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q515, Q516 및/또는 Q524, Q525 및/또는 Q537, Q538 및/또는 Q544, Q545 및/또는 Q553, Q554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q509, Q510, Q511, Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519, Q520, Q521, Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q531, Q532, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q515, Q516 and / or Q524, Q525 and / or Q537, Q538 and / or Q544, Q545 and / or Q553, Q554 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ561, NQ562Q563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q564, C(O)OQ565, C(O)NHQ566, C(O)NQ567Q568, OQ569, O(Q570-O)bH (b = 1, 2, 3, 4, 5), O(Q571-O)bQ572 (b = 1, 2, 3, 4, 5), OC(O)Q573, OC(O)OQ574, OC(O)NHQ575, OC(O)NQ576Q577, OP(O)(OQ578)(OQ579), OSi(Q580)(Q581)(Q582), OS(O2)Q583, NHC(O)Q584, NQ585C(O)Q586, NHC(O)OQ587, NHC(O)NHQ588, NHC(O)NQ589Q590, NQ591C(O)OQ592, NQ593C(O)NHQ594, NQ595C(O)NQ596Q597, NHS(O2)Q598, NQ599S(O2)Q600, SQ601, S(O)Q602, S(O2)Q603, S(O2)NHQ604, S(O2)NQ605Q606, S(O2)OQ607, P(O)(OQ608)(OQ609), Si(Q610)(Q611)(Q612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ561, NQ562Q563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q564, C (O) OQ565, C (O) NHQ566, C (O) NQ567Q568, OQ569, O (Q570-O) b H (b = 1, 2, 3, 4, 5), O (Q571-O) b Q572 (b = 1, 2, 3, 4, 5), OC (O) Q573, OC (O) OQ574, OC (O) NHQ575 , OC (O) NQ576Q577, OP (O) (OQ578) (OQ579), OSi (Q580) (Q581) (Q582), OS (O 2 ) Q583, NHC (O) Q584, NQ585C (O) Q586, NHC ( O) OQ587, NHC (O) NHQ588, NHC (O) NQ589Q590, NQ591C (O) OQ592, NQ593C (O) NHQ594, NQ595C (O) NQ596Q597, NHS (O2) Q598, NQ599S (O2) Q600, SQ601, S (601) O) Q602, S (O 2 ) Q603, S (O 2 ) NHQ604, S (O 2 ) NQ605Q606, S (O 2 ) OQ607, P (O) (OQ608) (OQ609), Si (Q610) (Q611) (Q612) "

여기서, Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581, Q582, Q583, Q584, Q585, Q586, Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q609, Q610, Q611, Q612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q567, Q568 및/또는 Q576, Q577 및/또는 Q589, Q590 및/또는 Q596, Q597 및/또는 Q605, Q606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581, Q582, Q583, Q584, Q585, Q586, Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q609, Q610, Q611, Q612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 are also in each case" heterocycle. " Reels ",

(g) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ613, NQ614Q615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q616, C(O)OQ617, C(O)NHQ618, C(O)NQ619Q620, OQ621, O(Q622-O)cH (c = 1, 2, 3, 4, 5), O(Q623-O)cQ624 (c = 1, 2, 3, 4, 5), OC(O)Q625, OC(O)OQ626, OC(O)NHQ627, OC(O)NQ628Q629, OP(O)(OQ630)(OQ631), OSi(Q632)(Q633)(Q634), OS(O2)Q635, NHC(O)Q636, NQ637C(O)Q638, NHC(O)OQ639, NHC(O)NHQ640, NHC(O)NQ641Q642, NQ643C(O)OQ644, NQ645C(O)NHQ646, NQ647C(O)NQ648Q649, NHS(O2)Q650, NQ651S(O2)Q652, SQ653, S(O)Q654, S(O2)Q655, S(O2)NHQ656, S(O2)NQ657Q658, S(O2)OQ659, P(O)(OQ660)(OQ661), Si(Q662)(Q663)(Q664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ613, NQ614Q615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q616, C (O) OQ617, C (O) NHQ618, C (O) NQ619Q620, OQ621, O (Q622-O) c H (c = 1, 2, 3, 4, 5), O (Q623-O) c Q624 (c = 1, 2, 3, 4, 5), OC (O) Q625, OC (O) OQ626, OC (O) NHQ627 , OC (O) NQ628Q629, OP (O) (OQ630) (OQ631), OSi (Q632) (Q633) (Q634), OS (O 2 ) Q635, NHC (O) Q636, NQ637C (O) Q638, NHC ( O) OQ639, NHC (O) NHQ640, NHC (O) NQ641Q642, NQ643C (O) OQ644, NQ645C (O) NHQ646, NQ647C (O) NQ648Q649, NHS (O2) Q650, NQ651S (O2) Q652, SQ653, S ( O) Q654, S (O 2 ) Q655, S (O 2 ) NHQ656, S (O 2 ) NQ657Q658, S (O 2 ) OQ659, P (O) (OQ660) (OQ661), Si (Q662) (Q663) (Q664) "

여기서, Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621, Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641, Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649,Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q619, Q620 및/또는 Q628, Q629 및/또는 Q641, Q642 및/또는 Q648, Q649 및/또는 Q657, Q658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621, Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641, Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q619, Q620 and / or Q628, Q629 and / or Q641, Q642 and / or Q648, Q649 and / or Q657, Q658 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ665, NQ666Q667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q668, C(O)OQ669, C(O)NHQ670, C(O)NQ671Q672, OQ673, O(Q674-O)dH (d = 1, 2, 3, 4, 5), O(Q675-O)dQ676 (d = 1, 2, 3, 4, 5), OC(O)Q677, OC(O)OQ678, OC(O)NHQ679, OC(O)NQ680Q681, OP(O)(OQ682)(OQ683), OSi(Q684)(Q685)(Q686), OS(O2)Q687, NHC(O)Q688, NQ689C(O)Q690, NHC(O)OQ691, NHC(O)NHQ692, NHC(O)NQ693Q694, NQ695C(O)OQ696, NQ697C(O)NHQ698, NQ699C(O)NQ700Q701, NHS(O2)Q702, NQ703S(O2)Q704, SQ705, S(O)Q706, S(O2)Q707, S(O2)NHQ708, S(O2)NQ709Q710, S(O2)OQ711, P(O)(OQ712)(OQ713), Si(Q714)(Q715)(Q716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ665, NQ666Q667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q668, C (O) OQ669, C (O) NHQ670, C (O) NQ671Q672, OQ673, O (Q674-O) d H (d = 1, 2, 3, 4, 5), O (Q675-O) d Q676 (d = 1, 2, 3, 4, 5), OC (O) Q677, OC (O) OQ678, OC (O) NHQ679 , OC (O) NQ680Q681, OP (O) (OQ682) (OQ683), OSi (Q684) (Q685) (Q686), OS (O 2 ) Q687, NHC (O) Q688, NQ689C (O) Q690, NHC ( O) OQ691, NHC (O) NHQ692, NHC (O) NQ693Q694, NQ695C (O) OQ696, NQ697C (O) NHQ698, NQ699C (O) NQ700Q701, NHS (O2) Q702, NQ703S (O2) Q704, SQ705, S ( O) Q706, S (O 2 ) Q707, S (O 2 ) NHQ708, S (O 2 ) NQ709Q710, S (O 2 ) OQ711, P (O) (OQ712) (OQ713), Si (Q714) (Q715) (Q716) "

여기서, Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711, Q712, Q713, Q714, Q715, Q716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q671, Q672 및/또는 Q680, Q681 및/또는 Q693, Q694 및/또는 Q700, Q701 및/또는 Q709, Q710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711, Q712, Q713, Q714, Q715, Q716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q671, Q672 and / or Q680, Q681 and / or Q693, Q694 and / or Q700, Q701 and / or Q709, Q710 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ717, NQ718Q719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q720, C(O)OQ721, C(O)NHQ722, C(O)NQ723Q724, OQ725, O(Q726-O)eH (e = 1, 2, 3, 4, 5), O(Q727-O)eQ728 (e = 1, 2, 3, 4, 5), OC(O)Q729, OC(O)OQ730, OC(O)NHQ731, OC(O)NQ732Q733, OP(O)(OQ734)(OQ735), OSi(Q736)(Q737)(Q738), OS(O2)Q739, NHC(O)Q740, NQ741C(O)Q742, NHC(O)OQ743, NHC(O)NHQ744, NHC(O)NQ745Q746, NQ747C(O)OQ748, NQ749C(O)NHQ750, NQ751C(O)NQ752Q753, NHS(O2)Q754, NQ755S(O2)Q756, SQ757, S(O)Q758, S(O2)Q759, S(O2)NHQ760, S(O2)NQ761Q762, S(O2)OQ763, P(O)(OQ764)(OQ765), Si(Q766)(Q767)(Q768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ717, NQ718Q719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q720, C (O) OQ721, C (O) NHQ722, C (O) NQ723Q724, OQ725, O (Q726-O) e H (e = 1, 2, 3, 4, 5), O (Q727-O) e Q728 (e = 1, 2, 3, 4, 5), OC (O) Q729, OC (O) OQ730, OC (O) NHQ731 , OC (O) NQ732Q733, OP (O) (OQ734) (OQ735), OSi (Q736) (Q737) (Q738), OS (O 2 ) Q739, NHC (O) Q740, NQ741C (O) Q742, NHC ( O) OQ743, NHC (O) NHQ744, NHC (O) NQ745Q746, NQ747C (O) OQ748, NQ749C (O) NHQ750, NQ751C (O) NQ752Q753, NHS (O2) Q754, NQ755S (O2) Q756, SQ757, S ( O) Q758, S (O 2 ) Q759, S (O 2 ) NHQ760, S (O 2 ) NQ761Q762, S (O 2 ) OQ763, P (O) (OQ764) (OQ765), Si (Q766) (Q767) (Q768) "

여기서, Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q723, Q724 및/또는 Q732, Q733 및/또는 Q745, Q746 및/또는 Q752, Q753 및/또는 Q761, Q762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q723, Q724 and / or Q732, Q733 and / or Q745, Q746 and / or Q752, Q753 and / or Q761, Q762 are also in each case" heterocycle. " Reels ",

(h) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ769, NQ770Q771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q772, C(O)OQ773, C(O)NHQ774, C(O)NQ775Q776, OQ777, O(Q778-O)fH (f = 1, 2, 3, 4, 5), O(Q779-O)fQ780 (f = 1, 2, 3, 4, 5), OC(O)Q781, OC(O)OQ782, OC(O)NHQ783, OC(O)NQ784Q785, OP(O)(OQ786)(OQ787), OSi(Q788)(Q789)(Q790), OS(O2)Q791, NHC(O)Q792, NQ793C(O)Q794, NHC(O)OQ795, NHC(O)NHQ796, NHC(O)NQ797Q798, NQ799C(O)OQ800, NQ801C(O)NHQ802, NQ803C(O)NQ804Q805, NHS(O2)Q806, NQ807S(O2)Q808, SQ809, S(O)Q810, S(O2)Q811, S(O2)NHQ812, S(O2)NQ813Q814, S(O2)OQ815, P(O)(OQ816)(OQ817), Si(Q818)(Q819)(Q820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ769, NQ770Q771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q772, C (O) OQ773, C (O) NHQ774, C (O) NQ775Q776, OQ777, O (Q778-O) f H (f = 1, 2, 3, 4, 5), O (Q779-O) f Q780 (f = 1, 2, 3, 4, 5), OC (O) Q781, OC (O) OQ782, OC (O) NHQ783 , OC (O) NQ784Q785, OP (O) (OQ786) (OQ787), OSi (Q788) (Q789) (Q790), OS (O 2 ) Q791, NHC (O) Q792, NQ793C (O) Q794, NHC ( O) OQ795, NHC (O) NHQ796, NHC (O) NQ797Q798, NQ799C (O) OQ800, NQ801C (O) NHQ802, NQ803C (O) NQ804Q805, NHS (O2) Q806, NQ807S (O2) Q808, SQ809, S ( O) Q810, S (O 2 ) Q811, S (O 2 ) NHQ812, S (O 2 ) NQ813Q814, S (O 2 ) OQ815, P (O) (OQ816) (OQ817), Si (Q818) (Q819) (Q820) "

여기서, Q769, Q770, Q771, Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q811, Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q775, Q776 및/또는 Q784, Q785 및/또는 Q797, Q798 및/또는 Q804, Q805 및/또는 Q813, Q814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q769, Q770, Q771, Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q811, Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q775, Q776 and / or Q784, Q785 and / or Q797, Q798 and / or Q804, Q805 and / or Q813, Q814 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ821, NQ822Q823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q824, C(O)OQ825, C(O)NHQ826, C(O)NQ827Q828, OQ829, O(Q830-O)gH (g = 1, 2, 3, 4, 5), O(Q831-O)gQ832 (g = 1, 2, 3, 4, 5), OC(O)Q833, OC(O)OQ834, OC(O)NHQ835, OC(O)NQ836Q837, OP(O)(OQ838)(OQ839), OSi(Q840)(Q841)(Q842), OS(O2)Q843, NHC(O)Q844, NQ845C(O)Q846, NHC(O)OQ847, NHC(O)NHQ848, NHC(O)NQ849Q850, NQ851C(O)OQ852, NQ853C(O)NHQ854, NQ855C(O)NQ856Q857, NHS(O2)Q858, NQ859S(O2)Q860, SQ861, S(O)Q862, S(O2)Q863, S(O2)NHQ864, S(O2)NQ865Q866, S(O2)OQ867, P(O)(OQ868)(OQ869), Si(Q870)(Q871)(Q872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ821, NQ822Q823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q824, C (O) OQ825, C (O) NHQ826, C (O) NQ827Q828, OQ829, O (Q830-O) g H (g = 1, 2, 3, 4, 5), O (Q831-O) g Q832 (g = 1, 2, 3, 4, 5), OC (O) Q833, OC (O) OQ834, OC (O) NHQ835 , OC (O) NQ836Q837, OP (O) (OQ838) (OQ839), OSi (Q840) (Q841) (Q842), OS (O 2 ) Q843, NHC (O) Q844, NQ845C (O) Q846, NHC ( O) OQ847, NHC (O) NHQ848, NHC (O) NQ849Q850, NQ851C (O) OQ852, NQ853C (O) NHQ854, NQ855C (O) NQ856Q857, NHS (O2) Q858, NQ859S (O2) Q860, SQ861, S ( O) Q862, S (O 2 ) Q863, S (O 2 ) NHQ864, S (O 2 ) NQ865Q866, S (O 2 ) OQ867, P (O) (OQ868) (OQ869), Si (Q870) (Q871) (Q872) "

여기서, Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q827, Q828 및/또는 Q836, Q837 및/또는 Q849, Q850 및/또는 Q856, Q857 및/또는 Q865, Q866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q827, Q828 and / or Q836, Q837 and / or Q849, Q850 and / or Q856, Q857 and / or Q865, Q866 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ873, NQ874Q875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q876, C(O)OQ877, C(O)NHQ878, C(O)NQ879Q880, OQ881, O(Q882-O)hH (h = 1, 2, 3, 4, 5), O(Q883-O)hQ884 (h = 1, 2, 3, 4, 5), OC(O)Q885, OC(O)OQ886, OC(O)NHQ887, OC(O)NQ888Q889, OP(O)(OQ890)(OQ891), OSi(Q892)(Q893)(Q894), OS(O2)Q895, NHC(O)Q896, NQ897C(O)Q898, NHC(O)OQ899, NHC(O)NHQ900, NHC(O)NQ901Q902, NQ903C(O)OQ904, NQ905C(O)NHQ906, NQ907C(O)NQ908Q909, NHS(O2)Q910, NQ911S(O2)Q912, SQ913, S(O)Q914, S(O2)Q915, S(O2)NHQ916, S(O2)NQ917Q918, S(O2)OQ919, P(O)(OQ920)(OQ921), Si(Q922)(Q923)(Q924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ873, NQ874Q875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q876, C (O) OQ877, C (O) NHQ878, C (O) NQ879Q880, OQ881, O (Q882-O) h H (h = 1, 2, 3, 4, 5), O (Q883-O) h Q884 (h = 1, 2, 3, 4, 5), OC (O) Q885, OC (O) OQ886, OC (O) NHQ887 , OC (O) NQ888Q889, OP (O) (OQ890) (OQ891), OSi (Q892) (Q893) (Q894), OS (O 2 ) Q895, NHC (O) Q896, NQ897C (O) Q898, NHC ( O) OQ899, NHC (O) NHQ900, NHC (O) NQ901Q902, NQ903C (O) OQ904, NQ905C (O) NHQ906, NQ907C (O) NQ908Q909, NHS (O2) Q910, NQ911S (O2) Q912, SQ913, S ( O) Q914, S (O 2 ) Q915, S (O 2 ) NHQ916, S (O 2 ) NQ917Q918, S (O 2 ) OQ919, P (O) (OQ920) (OQ921), Si (Q922) (Q923) (Q924) "

여기서, Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891, Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923, Q924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q879, Q880 및/또는 Q888, Q889 및/또는 Q901, Q902 및/또는 Q908, Q909 및/또는 Q917, Q918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891, Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923, Q924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q879, Q880 and / or Q888, Q889 and / or Q901, Q902 and / or Q908, Q909 and / or Q917, Q918 are also in each case" heterocycle. " Reels ",

(j) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(j) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ925, NQ926Q927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q928, C(O)OQ929, C(O)NHQ930, C(O)NQ931Q932, OQ933, O(Q934-O)iH (i = 1, 2, 3, 4, 5), O(Q935-O)iQ936 (i = 1, 2, 3, 4, 5), OC(O)Q937, OC(O)OQ938, OC(O)NHQ939, OC(O)NQ940Q941, OP(O)(OQ942)(OQ943), OSi(Q944)(Q945)(Q946), OS(O2)Q947, NHC(O)Q948, NQ949C(O)Q950, NHC(O)OQ951, NHC(O)NHQ952, NHC(O)NQ953Q954, NQ955C(O)OQ956, NQ957C(O)NHQ958, NQ959C(O)NQ960Q961, NHS(O2)Q962, NQ963S(O2)Q964, SQ965, S(O)Q966, S(O2)Q967, S(O2)NHQ968, S(O2)NQ969Q970, S(O2)OQ971, P(O)(OQ972)(OQ973), Si(Q974)(Q975)(Q976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ925, NQ926Q927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q928, C (O) OQ929, C (O) NHQ930, C (O) NQ931Q932, OQ933, O (Q934-O) i H (i = 1, 2, 3, 4, 5), O (Q935-O) i Q936 (i = 1, 2, 3, 4, 5), OC (O) Q937, OC (O) OQ938, OC (O) NHQ939 , OC (O) NQ940Q941, OP (O) (OQ942) (OQ943), OSi (Q944) (Q945) (Q946), OS (O 2 ) Q947, NHC (O) Q948, NQ949C (O) Q950, NHC ( O) OQ951, NHC (O) NHQ952, NHC (O) NQ953Q954, NQ955C (O) OQ956, NQ957C (O) NHQ958, NQ959C (O) NQ960Q961, NHS (O2) Q962, NQ963S (O2) Q964, SQ965, S ( O) Q966, S (O 2 ) Q967, S (O 2 ) NHQ968, S (O 2 ) NQ969Q970, S (O 2 ) OQ971, P (O) (OQ972) (OQ973), Si (Q974) (Q975) (Q976) "

여기서, Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960, Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q931, Q932 및/또는 Q940, Q941 및/또는 Q953, Q954 및/또는 Q960, Q961 및/또는 Q969, Q970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960, Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ977, NQ978Q979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q980, C(O)OQ981, C(O)NHQ982, C(O)NQ983Q984, OQ985, O(Q986-O)jH (j = 1, 2, 3, 4, 5), O(Q987-O)jQ988 (j = 1, 2, 3, 4, 5), OC(O)Q989, OC(O)OQ990, OC(O)NHQ991, OC(O)NQ992Q993, OP(O)(OQ994)(OQ995), OSi(Q996)(Q997)(Q998), OS(O2)Q999, NHC(O)Q1000, NQ1001C(O)Q1002, NHC(O)OQ1003, NHC(O)NHQ1004, NHC(O)NQ1005Q1006, NQ1007C(O)OQ1008, NQ1009C(O)NHQ1010, NQ1011C(O)NQ1012Q1013, NHS(O2)Q1014, NQ1015S(O2)Q1016, SQ1017, S(O)Q1018, S(O2)Q1019, S(O2)NHQ1020, S(O2)NQ1021Q1022, S(O2)OQ1023, P(O)(OQ1024)(OQ1025), Si(Q1026)(Q1027)(Q1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ977, NQ978Q979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q980, C (O) OQ981, C (O) NHQ982, C (O) NQ983Q984, OQ985, O (Q986-O) j H (j = 1, 2, 3, 4, 5), O (Q987-O) j Q988 (j = 1, 2, 3, 4, 5), OC (O) Q989, OC (O) OQ990, OC (O) NHQ991 , OC (O) NQ992Q993, OP (O) (OQ994) (OQ995), OSi (Q996) (Q997) (Q998), OS (O 2 ) Q999, NHC (O) Q1000, NQ1001C (O) Q1002, NHC ( O) OQ1003, NHC (O) NHQ1004, NHC (O) NQ1005Q1006, NQ1007C (O) OQ1008, NQ1009C (O) NHQ1010, NQ1011C (O) NQ1012Q1013, NHS (O2) Q1014, NQ1015S (O2) Q1016, SQ1016, SQ1016 O) Q1018, S (O 2 ) Q1019, S (O 2 ) NHQ1020, S (O 2 ) NQ1021Q1022, S (O 2 ) OQ1023, P (O) (OQ1024) (OQ1025), Si (Q1026) (Q1027) (Q1028) "

여기서, Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001, Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q983, Q984 및/또는 Q992, Q993 및/또는 Q1005, Q1006 및/또는 Q1012, Q1013 및/또는 Q1021, Q1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001, Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1024, Q1024 Q1026, Q1027, Q1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 are also in each case" heterocycle Reels ",

(k) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein optionally, Said substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1029, NQ1030Q1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1032, C(O)OQ1033, C(O)NHQ1034, C(O)NQ1035Q1036, OQ1037, O(Q1038-O)kH (k = 1, 2, 3, 4, 5), O(Q1039-O)kQ1040 (k = 1, 2, 3, 4, 5), OC(O)Q1041, OC(O)OQ1042, OC(O)NHQ1043, OC(O)NQ1044Q1045, OP(O)(OQ1046)(OQ1047), OSi(Q1048)(Q1049)(Q1050), OS(O2)Q1051, NHC(O)Q1052, NQ1053C(O)Q1054, NHC(O)OQ1055, NHC(O)NHQ1056, NHC(O)NQ1057Q1058, NQ1059C(O)OQ1060, NQ1061C(O)NHQ1062, NQ1063C(O)NQ1064Q1065, NHS(O2)Q1066, NQ1067S(O2)Q1068, SQ1069, S(O)Q1070, S(O2)Q1071, S(O2)NHQ1072, S(O2)NQ1073Q1074, S(O2)OQ1075, P(O)(OQ1076)(OQ1077), Si(Q1078)(Q1079)(Q1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1029, NQ1030Q1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1032, C (O) OQ1033, C (O) NHQ1034, C (O) NQ1035Q1036, OQ1037, O (Q1038-O) k H (k = 1, 2, 3, 4, 5), O (Q1039-O) k Q1040 (k = 1, 2, 3, 4, 5), OC (O) Q1041, OC (O) OQ1042, OC (O) NHQ1043 , OC (O) NQ1044Q1045, OP (O) (OQ1046) (OQ1047), OSi (Q1048) (Q1049) (Q1050), OS (O 2 ) Q1051, NHC (O) Q1052, NQ1053C (O) Q1054, NHC ( O) OQ1055, NHC (O) NHQ1056, NHC (O) NQ1057Q1058, NQ1059C (O) OQ1060, NQ1061C (O) NHQ1062, NQ1063C (O) NQ1064Q1065, NHS (O2) Q1066, NQ1067S (O2) Q1068, SQ1069 O) Q1070, S (O 2 ) Q1071, S (O 2 ) NHQ1072, S (O 2 ) NQ1073Q1074, S (O 2 ) OQ1075, P (O) (OQ1076) (OQ1077), Si (Q1078) (Q1079) (Q1080) "

여기서, Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1076, Q1077, Q1078, Q1079, Q1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1035, Q1036 및/또는 Q1044, Q1045 및/또는 Q1057, Q1058 및/또는 Q1064, Q1065 및/또는 Q1073, Q1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1077, Q1077 Q1078, Q1079, Q1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1081, NQ1082Q1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1084, C(O)OQ1085, C(O)NHQ1086, C(O)NQ1087Q1088, OQ1089, O(Q1090-O)lH (l = 1, 2, 3, 4, 5), O(Q1091-O)lQ1092 (l = 1, 2, 3, 4, 5), OC(O)Q1093, OC(O)OQ1094, OC(O)NHQ1095, OC(O)NQ1096Q1097, OP(O)(OQ1098)(OQ1099), OSi(Q1100)(Q1101)(Q1102), OS(O2)Q1103, NHC(O)Q1104, NQ1105C(O)Q1106, NHC(O)OQ1107, NHC(O)NHQ1108, NHC(O)NQ1109Q1110, NQ1111C(O)OQ1112, NQ1113C(O)NHQ1114, NQ1115C(O)NQ1116Q1117, NHS(O2)Q1118, NQ1119S(O2)Q1120, SQ1121, S(O)Q1122, S(O2)Q1123, S(O2)NHQ1124, S(O2)NQ1125Q1126, S(O2)OQ1127, P(O)(OQ1128)(OQ1129), Si(Q1130)(Q1131)(Q1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1081, NQ1082Q1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1084, C (O) OQ1085, C (O) NHQ1086, C (O) NQ1087Q1088, OQ1089, O (Q1090-O) l H (l = 1, 2, 3, 4, 5), O (Q1091-O) l Q1092 (l = 1, 2, 3, 4, 5), OC (O) Q1093, OC (O) OQ1094, OC (O) NHQ1095 , OC (O) NQ1096Q1097, OP (O) (OQ1098) (OQ1099), OSi (Q1100) (Q1101) (Q1102), OS (O 2 ) Q1103, NHC (O) Q1104, NQ1105C (O) Q1106, NHC ( O) OQ1107, NHC (O) NHQ1108, NHC (O) NQ1109Q1110, NQ1111C (O) OQ1112, NQ1113C (O) NHQ1114, NQ1115C (O) NQ1116Q1117, NHS (O2) Q1118, NQ1119S (O2) Q1120, SQ112 O) Q1122, S (O 2 ) Q1123, S (O 2 ) NHQ1124, S (O 2 ) NQ1125Q1126, S (O 2 ) OQ1127, P (O) (OQ1128) (OQ1129), Si (Q1130) (Q1131) (Q1132) "

여기서, Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104, Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121, Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128, Q1129, Q1130, Q1131, Q1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1087, Q1088 및/또는 Q1096, Q1097 및/또는 Q1109, Q1110 및/또는 Q1116, Q1117 및/또는 Q1125, Q1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104 Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121, Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128,11 Q1130, Q1131, Q1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1087, Q1088 and / or Q1096, Q1097 and / or Q1109, Q1110 and / or Q1116, Q1117 and / or Q1125, Q1126 are also in each case" heterocycle. " Reels ",

(l) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)Q1133, C(O)OQ1134, C(O)NQ1135Q1136, S(O2)Q1137, S(O2)OQ1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) Q1133 , C (O) OQ1134, C (O) NQ1135Q1136, S (O 2 ) Q1137, S (O 2 ) OQ1138 "

여기서, Q1133, Q1134, Q1135, Q1136, Q1137, Q1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1135, Q1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein Q1133, Q1134, Q1135, Q1136, Q1137, Q1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q1135, Q1136 together may also form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1139, NQ1140Q1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1142, C(O)OQ1143, C(O)NHQ1144, C(O)NQ1145Q1146, OQ1147, O(Q1148-O)mH (m = 1, 2, 3, 4, 5), O(Q1149-O)mQ1150 (m = 1, 2, 3, 4, 5), OC(O)Q1151, OC(O)OQ1152, OC(O)NHQ1153, OC(O)NQ1154Q1155, OP(O)(OQ1156)(OQ1157), OSi(Q1158)(Q1159)(Q1160), OS(O2)Q1161, NHC(O)Q1162, NQ1163C(O)Q1164, NHC(O)OQ1165, NHC(O)NHQ1166, NHC(O)NQ1167Q1168, NQ1169C(O)OQ1170, NQ1171C(O)NHQ1172, NQ1173C(O)NQ1174Q1175, NHS(O2)Q1176, NQ1177S(O2)Q1178, SQ1179, S(O)Q1180, S(O2)Q1181, S(O2)NHQ1182, S(O2)NQ1183Q1184, S(O2)OQ1185, P(O)(OQ1186)(OQ1187), Si(Q1188)(Q1189)(Q1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1139, NQ1140Q1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1142, C (O) OQ1143, C (O) NHQ1144, C (O) NQ1145Q1146, OQ1147, O (Q1148-O) m H (m = 1, 2, 3, 4, 5), O (Q1149-O) m Q1150 (m = 1, 2, 3, 4, 5), OC (O) Q1151, OC (O) OQ1152, OC (O) NHQ1153 , OC (O) NQ1154Q1155, OP (O) (OQ1156) (OQ1157), OSi (Q1158) (Q1159) (Q1160), OS (O 2 ) Q1161, NHC (O) Q1162, NQ1163C (O) Q1164, NHC ( O) OQ1165, NHC (O) NHQ1166, NHC (O) NQ1167Q1168, NQ1169C (O) OQ1170, NQ1171C (O) NHQ1172, NQ1173C (O) NQ1174Q1175, NHS (O2) Q1176, NQ1177S (O2) Q1178, SQ1178, SQ1178 O) Q1180, S (O 2 ) Q1181, S (O 2 ) NHQ1182, S (O 2 ) NQ1183Q1184, S (O 2 ) OQ1185, P (O) (OQ1186) (OQ1187), Si (Q1188) (Q1189) (Q1190) "

여기서, Q1139, Q1140, Q1141, Q1142, Q1143, Q1144, Q1145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153, Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185, Q1186, Q1187, Q1188, Q1189, Q1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1145, Q1146 및/또는 Q1154, Q1155 및/또는 Q1167, Q1168 및/또는 Q1174, Q1175 및/또는 Q1183, Q1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1139, Q1140, Q1141, Q1142, Q1143, Q1144, Q1145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153, Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1162 Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185, Q1186, Q1188, Q1189 and Q1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1145, Q1146 and / or Q1154, Q1155 and / or Q1167, Q1168 and / or Q1174, Q1175 and / or Q1183, Q1184 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1191, NQ1192Q1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1194, C(O)OQ1195, C(O)NHQ1196, C(O)NQ1197Q1198, OQ1199, O(Q1200-O)nH (n = 1, 2, 3, 4, 5), O(Q1201-O)nQ1202 (n = 1, 2, 3, 4, 5), OC(O)Q1203, OC(O)OQ1204, OC(O)NHQ1205, OC(O)NQ1206Q1207, OP(O)(OQ1208)(OQ1209), OSi(Q1210)(Q1211)(Q1212), OS(O2)Q1213, NHC(O)Q1214, NQ1215C(O)Q1216, NHC(O)OQ1217, NHC(O)NHQ1218, NHC(O)NQ1219Q1220, NQ1221C(O)OQ1222, NQ1223C(O)NHQ1224, NQ1225C(O)NQ1226Q1227, NHS(O2)Q1228, NQ1229S(O2)Q1230, SQ1231, S(O)Q1232, S(O2)Q1233, S(O2)NHQ1234, S(O2)NQ1235Q1236, S(O2)OQ1237, P(O)(OQ1238)(OQ1239), Si(Q1240)(Q1241)(Q1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1191, NQ1192Q1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1194, C (O) OQ1195, C (O) NHQ1196, C (O) NQ1197Q1198, OQ1199, O (Q1200-O) nH (n = 1 , 2, 3, 4, 5), O (Q1201-O) nQ1202 (n = 1, 2, 3, 4, 5), OC (O) Q1203, OC (O) OQ1204, OC (O) NHQ1205, OC (O) NQ1206Q1207, OP (O) (OQ1208) (OQ1209), OSi (Q1210) (Q1211) (Q1212), OS (O 2 ) Q1213, NHC (O) Q1214, NQ1215C (O) Q1216, NHC (O) OQ1217, NHC (O) NHQ1218, NHC (O) NQ1219Q1220, NQ1221C (O) OQ1222, NQ1223C (O) NHQ1224, NQ1225C (O) NQ1226Q1227, NHS (O2) Q1228, NQ1229S (O2) Q1230, SQ1231, SQ1231 Q1232, S (O 2 ) Q1233, S (O 2 ) NHQ1234, S (O 2 ) NQ1235Q1236, S (O 2 ) OQ1237, P (O) (OQ1238) (OQ1239), Si (Q1240) (Q1241) (Q1242 ) "

여기서, Q1191, Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211, Q1212, Q1213, Q1214, Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239, Q1240, Q1241, Q1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1197, Q1198 및/또는 Q1206, Q1207 및/또는 Q1219, Q1220 및/또는 Q1226, Q1227 및/또는 Q1235, Q1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1191, Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211, Q1212, Q1213, Q1214, Q1214 Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239 Q1240, Q1241, Q1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q1197, Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 are also in each case" heterocycle. " Reels ",

And

Z1, Z2 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "수소, NZ14Z15"Z1 and Z2 radicals are each independently selected from the group consisting of: "hydrogen, NZ14Z15"

단, Z1 = H인 경우, Z2 = NZ14Z15이고, Z1 = NZ14Z15인 경우, Z2 = H이고;Provided that when Z1 = H, Z2 = NZ14Z15, and when Z1 = NZ14Z15, Z2 = H;

여기서, Z14, Z15는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z14 and Z15 are each independently selected from the group consisting of:

(a) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(Y1)NZ16Z17, C(=NZ18)Z19, C(Y2)NZ20Y3Z21"(a) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (Y1) NZ16Z17 , C (= NZ18) Z19, C (Y2) NZ20Y3Z21 "

단, Z14, Z15는 동시에 수소 또는 "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"이 아니고,Provided that Z14 and Z15 are simultaneously hydrogen or "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" No,

추가로 단, Z14, Z15 라디칼 중 하나가 수소 또는 "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"인 경우, 나머지 Z14, Z15 라디칼은 각각의 경우 "C(Y1)NZ16Z17", "C(=NZ18)Z19" 또는 "C(Y2)NZ20Y3Z21"이고,Further provided that one of the Z14, Z15 radicals is hydrogen or "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, hetero Arylalkyl ", the remaining Z14, Z15 radicals are in each case" C (Y1) NZ16Z17 "," C (= NZ18) Z19 "or" C (Y2) NZ20Y3Z21 ",

여기서, Y1, Y2, Y3은 각각 독립적으로 "O, S, =NH, =NZ22"로 이루어진 그룹 으로부터 선택되고,Wherein Y1, Y2, Y3 are each independently selected from the group consisting of "O, S, = NH, = NZ22",

여기서, Z16, Z17, Z18, Z19, Z20, Z21, Z22는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z16, Z17, Z18, Z19, Z20, Z21, Z22 are each independently selected from the group consisting of:

(1) 수소(1) hydrogen

(2) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 헤테로사이클릴, 헤테로사이클릴알킬"(2) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"

여기서, 치환 그룹(a) 및/또는 치환 그룹(2)의 상기한 치환체는 임의로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein said substituents of substitution group (a) and / or substitution group (2) may be optionally substituted each independently by one or more substituents, identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU1, NU2U3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U4, C(O)OU5, C(O)NHU6, C(O)NU7U8, OU9, O(U10-O)rH (r = 1, 2, 3, 4, 5), O(U11-O)rU12 (r = 1, 2, 3, 4, 5), OC(O)U13, OC(O)OU14, OC(O)NHU15, OC(O)NU16U17, OP(O)(OU18)(OU19), OSi(U20)(U21)(U22), OS(O2)U23, NHC(O)U24, NU25C(O)U26, NHC(O)OU27, NHC(O)NHU28, NHC(O)NU29U30, NU31C(O)OU32, NU33C(O)NHU34, NU35C(O)NU36U37, NHS(O2)U38, NU39S(O2)U40, SU41, S(O)U42, S(O2)U43, S(O2)NHU44, S(O2)NU45U46, S(O2)OU47, P(O)(OU48)(OU49), Si(U50)(U51)(U52)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU 1, NU2U3, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U4, C (O) OU5, C (O) NHU6, C (O) NU7U8, OU9, O (U10-O) r H (r = 1, 2, 3, 4, 5), O (U11-O) r U12 (r = 1, 2, 3, 4, 5), OC (O) U13, OC (O) OU14, OC (O) NHU15 , OC (O) NU16U17, OP (O) (OU18) (OU19), OSi (U20) (U21) (U22), OS (O 2 ) U23, NHC (O) U24, NU25C (O) U26, NHC ( O) OU27, NHC (O) NHU28, NHC (O) NU29U30, NU31C (O) OU32, NU33C (O) NHU34, NU35C (O) NU36U37, NHS (O2) U38, NU39S (O2) U40, SU41, S ( O) U42, S (O 2 ) U43, S (O 2 ) NHU44, S (O 2 ) NU45U46, S (O 2 ) OU47, P (O) (OU48) (OU49), Si (U50) (U51) (U52) "

여기서, U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11, U12, U13, U14, U15, U16, U17, U18, U19, U20, U21, U22, U23, U24, U25, U26, U27, U28, U29, U30, U31, U32, U33, U34, U35, U36, U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U7, U8 및/또는 U16, U17 및/또는 U29, U30 및/또는 U36, U37 및/또는 U45, U46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11, U12, U13, U14, U15, U16, U17, U18, U19, U20, U21, U22, U23, U24, U25, U26, U27, U28, U29, U30, U31, U32, U33, U34, U35, U36, U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U7, U8 and / or U16, U17 and / or U29, U30 and / or U36, U37 and / or U45, U46 may also in each case be" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU53, NU54U55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U56, C(O)OU57, C(O)NHU58, C(O)NU59U60, OU61, O(U62-O)rH (r = 1, 2, 3, 4, 5), O(U63-O)rU64 (r = 1, 2, 3, 4, 5), OC(O)U65, OC(O)OU66, OC(O)NHU67, OC(O)NU68U69, OP(O)(OU70)(OU71), OSi(U72)(U73)(U74), OS(O2)U75, NHC(O)U76, NU77C(O)U78, NHC(O)OU79, NHC(O)NHU80, NHC(O)NU81U82, NU83C(O)OU84, NU85C(O)NHU86, NU87C(O)NU88U89, NHS(O2)U90, NU91S(O2)U92, SU93, S(O)U94, S(O2)U95, S(O2)NHU96, S(O2)NU97U98, S(O2)OU99, P(O)(OU100)(OU101), Si(U102)(U103)(U104)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU53, NU54U55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U56, C (O) OU57, C (O) NHU58, C (O) NU59U60, OU61, O (U62-O) r H (r = 1, 2, 3, 4, 5), O (U63-O) r U64 (r = 1, 2, 3, 4, 5), OC (O) U65, OC (O) OU66, OC (O) NHU67 , OC (O) NU68U69, OP (O) (OU70) (OU71), OSi (U72) (U73) (U74), OS (O 2 ) U75, NHC (O) U76, NU77C (O) U78, NHC ( O) OU79, NHC (O) NHU80, NHC (O) NU81U82, NU83C (O) OU84, NU85C (O) NHU86, NU87C (O) NU88U89, NHS (O2) U90, NU91S (O2) U92, SU93, S ( O) U94, S (O 2 ) U95, S (O 2 ) NHU96, S (O 2 ) NU97U98, S (O 2 ) OU99, P (O) (OU100) (OU101), Si (U102) (U103) (U104) "

여기서, U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63, U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77, U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99, U100, U101, U102, U103, U104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U59, U60 및/또는 U68, U69 및/또는 U81, U82 및/또는 U88, U89 및/또는 U97, U98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63, U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77, U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99, U100, U101, U102, U103, U104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U59, U60 and / or U68, U69 and / or U81, U82 and / or U88, U89 and / or U97, U98 may also in each case be" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU105, NU106U107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U108, C(O)OU109, C(O)NHU110, C(O)NU111U112, OU113, O(U114-O)sH (s = 1, 2, 3, 4, 5), O(U115-O)sU116 (s = 1, 2, 3, 4, 5), OC(O)U117, OC(O)OU118, OC(O)NHU119, OC(O)NU120U121, OP(O)(OU122)(OU123), OSi(U124)(U125)(U126), OS(O2)U127, NHC(O)U128, NU129C(O)U130, NHC(O)OU131, NHC(O)NHU132, NHC(O)NU133U134, NU135C(O)OU136, NU137C(O)NHU138, NU139C(O)NU140U141, NHS(O2)U142, NU143S(O2)U144, SU145, S(O)U146, S(O2)U147, S(O2)NHU148, S(O2)NU149U150, S(O2)OU151, P(O)(OU152)(OU153), Si(U154)(U155)(U156)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU105, NU106U107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U108, C (O) OU109, C (O) NHU110, C (O) NU111U112, OU113, O (U114-O) s H (s = 1, 2, 3, 4, 5), O (U115-O) s U116 (s = 1, 2, 3, 4, 5), OC (O) U117, OC (O) OU118, OC (O) NHU119 , OC (O) NU120U121, OP (O) (OU122) (OU123), OSi (U124) (U125) (U126), OS (O 2 ) U127, NHC (O) U128, NU129C (O) U130, NHC ( O) OU131, NHC (O) NHU132, NHC (O) NU133U134, NU135C (O) OU136, NU137C (O) NHU138, NU139C (O) NU140U141, NHS (O2) U142, NU143S (O2) U144, SU145, S ( O) U146, S (O 2 ) U147, S (O 2 ) NHU148, S (O 2 ) NU149U150, S (O 2 ) OU151, P (O) (OU152) (OU153), Si (U154) (U155) (U156) "

여기서, U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U111, U112 및/또는 U120, U121 및/또는 U133, U134 및/또는 U140, U141 및/또는 U149, U150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U111, U112 and / or U120, U121 and / or U133, U134 and / or U140, U141 and / or U149, U150 are also in each case" heterocycle. " Reels ",

(3) C(O)Z23, (3) C (O) Z23,

여기서, Z23은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z23 is independently selected from the group consisting of:

(a) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(a) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 치환 그룹(a)의 상기 치환체는 임의로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein said substituents in substitution group (a) may each be optionally substituted independently by one or more substituents selected the same or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU157, NU158U159, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U160, C(O)OU161, C(O)NHU162, C(O)NU163U164, OU165, O(U166-O)tH (t = 1, 2, 3, 4, 5), O(U167-O)tU168 (t = 1, 2, 3, 4, 5), OC(O)U169, OC(O)OU170, OC(O)NHU171, OC(O)NU172U173, OP(O)(OU174)(OU175), OSi(U176)(U177)(U178), OS(O2)U179, NHC(O)U180, NU181C(O)U182, NHC(O)OU183, NHC(O)NHU184, NHC(O)NU185U186, NU187C(O)OU188, NU189C(O)NHU190, NU191C(O)NU192U193, NHS(O2)U194, NU195S(O2)U196, SU197, S(O)U198, S(O2)U199, S(O2)NHU200, S(O2)NU201U202, S(O2)OU203, P(O)(OU204)(OU205), Si(U206)(U207)(U208)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU157, NU158U159, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U160, C (O) OU161, C (O) NHU162, C (O) NU163U164, OU165, O (U166-O) t H (t = 1, 2, 3, 4, 5), O (U167-O) t U168 (t = 1, 2, 3, 4, 5), OC (O) U169, OC (O) OU170, OC (O) NHU171 , OC (O) NU172U173, OP (O) (OU174) (OU175), OSi (U176) (U177) (U178), OS (O 2 ) U179, NHC (O) U180, NU181C (O) U182, NHC ( O) OU183, NHC (O) NHU184, NHC (O) NU185U186, NU187C (O) OU188, NU189C (O) NHU190, NU191C (O) NU192U193, NHS (O2) U194, NU195S (O2) U196, SU197, S ( O) U198, S (O 2 ) U199, S (O 2 ) NHU200, S (O 2 ) NU201U202, S (O 2 ) OU203, P (O) (OU204) (OU205), Si (U206) (U207) (U208) "

여기서, U157, U158, U159, U160, U161, U162, U163, U164, U165, U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181, U182, U183, U184, U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195, U196, U197, U198, U199, U200, U201, U202, U203, U204, U205, U206, U207, U208은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U163, U164 및/또는 U172, U173 및/또는 U185, U186 및/또는 U192, U193 및/또는 U201, U202는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U157, U158, U159, U160, U161, U162, U163, U164, U165, U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181, U182, U183, U184, U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195, U196, U197, U198, U199, U200, U201, U202, U203, U204, U205, U206, U207, U208 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U163, U164 and / or U172, U173 and / or U185, U186 and / or U192, U193 and / or U201, U202 are also in each case a" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU209, NU210U211, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U212, C(O)OU213, C(O)NHU214, C(O)NU215U216, OU217, O(U218-O)uH (u = 1, 2, 3, 4, 5), O(U219-O)uU220 (u = 1, 2, 3, 4, 5), OC(O)U221, OC(O)OU222, OC(O)NHU223, OC(O)NU224U225, OP(O)(OU226)(OU227), OSi(U228)(U229)(U230), OS(O2)U231, NHC(O)U232, NU233C(O)U234, NHC(O)OU235, NHC(O)NHU236, NHC(O)NU237U238, NU239C(O)OU240, NU241C(O)NHU242, NU243C(O)NU244U245, NHS(O2)U246, NU247S(O2)U248, SU249, S(O)U250, S(O2)U251, S(O2)NHU252, S(O2)NU253U254, S(O2)OU255, P(O)(OU256)(OU257), Si(U258)(U259)(U260)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU209, NU210U211, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U212, C (O) OU213, C (O) NHU214, C (O) NU215U216, OU217, O (U218-O) u H (u = 1, 2, 3, 4, 5), O (U219-O) u U220 (u = 1, 2, 3, 4, 5), OC (O) U221, OC (O) OU222, OC (O) NHU223 , OC (O) NU224U225, OP (O) (OU226) (OU227), OSi (U228) (U229) (U230), OS (O 2 ) U231, NHC (O) U232, NU233C (O) U234, NHC ( O) OU235, NHC (O) NHU236, NHC (O) NU237U238, NU239C (O) OU240, NU241C (O) NHU242, NU243C (O) NU244U245, NHS (O2) U246, NU247S (O2) U248, SU249, S ( O) U250, S (O 2 ) U251, S (O 2 ) NHU252, S (O 2 ) NU253U254, S (O 2 ) OU255, P (O) (OU256) (OU257), Si (U258) (U259) (U260) "

여기서, U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U215, U216 및/또는 U224, U225 및/또는 U237, U238 및/또는 U244, U245 및/또는 U253, U254는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, said substituents in substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU261, NU262U263, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U264, C(O)OU265, C(O)NHU266, C(O)NU267U268, OU269, O(U270-O)vH (v = 1, 2, 3, 4, 5), O(U271-O)vU272 (v = 1, 2, 3, 4, 5), OC(O)U273, OC(O)OU274, OC(O)NHU275, OC(O)NU276U277, OP(O)(OU278)(OU279), OSi(U280)(U281)(U282), OS(O2)U283, NHC(O)U284, NU285C(O)U286, NHC(O)OU287, NHC(O)NHU288, NHC(O)NU289U290, NU291C(O)OU292, NU293C(O)NHU294, NU295C(O)NU296U297, NHS(O2)U298, NU299S(O2)U300, SU301, S(O)U302, S(O2)U303, S(O2)NHU304, S(O2)NU305U306, S(O2)OU307, P(O)(OU308)(OU309), Si(U310)(U311)(U312)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU261, NU262U263, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U264, C (O) OU265, C (O) NHU266, C (O) NU267U268, OU269, O (U270-O) v H (v = 1, 2, 3, 4, 5), O (U271-O) v U272 (v = 1, 2, 3, 4, 5), OC (O) U273, OC (O) OU274, OC (O) NHU275 , OC (O) NU276U277, OP (O) (OU278) (OU279), OSi (U280) (U281) (U282), OS (O 2 ) U283, NHC (O) U284, NU285C (O) U286, NHC ( O) OU287, NHC (O) NHU288, NHC (O) NU289U290, NU291C (O) OU292, NU293C (O) NHU294, NU295C (O) NU296U297, NHS (O2) U298, NU299S (O2) U300, SU301, S ( O) U302, S (O 2 ) U303, S (O 2 ) NHU304, S (O 2 ) NU305U306, S (O 2 ) OU307, P (O) (OU308) (OU309), Si (U310) (U311) (U312) "

여기서, U261,U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301, U302, U303, U304, U305, U306, U307, U308, U309, U310, U311, U312는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U267, U268 및/또는 U276, U277 및/또는 U289, U290 및/또는 U296, U297 및/또는 U305, U306은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U261, U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301, U302, U303, U304, U305, U306, U307, U308, U309, U310, U311, U312 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U267, U268 and / or U276, U277 and / or U289, U290 and / or U296, U297 and / or U305, U306 are also in each case a" heterocycle Reels ",

(4) Z16, Z17은 또한 독립적으로 임의로 함께 "헤테로사이클릴"을 형성할 수 있고;(4) Z16, Z17 can also independently optionally form "heterocyclyl";

(5) "C(O)C(O)U313, S(O2)NU314U315"(5) "C (O) C (O) U313, S (O 2 ) NU314U315"

여기서, U313, U314, U315는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein U313, U314 and U315 are each independently selected from the group consisting of:

(I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU316, NU317U318, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U319, C(O)OU320, C(O)NHU321, C(O)NU322U323, OU324, O(U325-O)wH (w = 1, 2, 3, 4, 5), O(U326-O)wU327 (w = 1, 2, 3, 4, 5), OC(O)U328, OC(O)OU329, OC(O)NHU330, OC(O)NU331U332, OP(O)(OU333)(OU334), OSi(U335)(U336)(U337), OS(O2)U338, NHC(O)U339, NU340C(O)U341, NHC(O)OU342, NHC(O)NHU343, NHC(O)NU344U345, NU346C(O)OU347, NU348C(O)NHU349, NU350C(O)NU351U352, NHS(O2)U353, NU354S(O2)U355, SU356, S(O)U357, S(O2)U358, S(O2)NHU359, S(O2)NU360U361, S(O2)OU362, P(O)(OU363)(OU364), Si(U365)(U366)(U367)"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHU316, NU317U318, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U319, C (O) OU320, C (O) NHU321, C (O) NU322U323, OU324, O (U325-O) w H ( w = 1, 2, 3, 4, 5), O (U326-O) w U327 (w = 1, 2, 3, 4, 5), OC (O) U328, OC (O) OU329, OC (O NHU330, OC (O) NU331U332, OP (O) (OU333) (OU334), OSi (U335) (U336) (U337), OS (O 2 ) U338, NHC (O) U339, NU340C (O) U341, NHC (O) OU342, NHC (O) NHU343, NHC (O) NU344U345, NU346C (O) OU347, NU348C (O) NHU349, NU350C (O) NU351U352, NHS (O2) U353, NU354S (O2) U355, SU356, S (O) U357, S (O 2 ) U358, S (O 2 ) NHU359, S (O 2 ) NU360U361, S (O 2 ) OU362, P (O) (OU363) (OU364), Si (U365) ( U366) (U367) "

여기서, U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328, U329, U330, U331, U332, U333, U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344, U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U322, U323 및/또는 U331, U332 및/또는 U344, U345 및/또는 U351, U352 및/또는 U360, U361은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328, U329, U330, U331, U332, U333, U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344, U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U322, U323 and / or U331, U332 and / or U344, U345 and / or U351, U352 and / or U360, U361 may also in each case be" heterocycle. " Reels ",

여기서, 임의로, 치환 그룹(I)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU368, NU369U370, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U371, C(O)OU372, C(O)NHU373, C(O)NU374U375, OU376, O(U377-O)xH (x = 1, 2, 3, 4, 5), O(U378-O)x)xU379 (x = 1, 2, 3, 4, 5), OC(O)U380, OC(O)OU381, OC(O)NHU382, OC(O)NU383U384, OP(O)(OU385)(OU386), OSi(U387)(U388)(U389), OS(O2)U390, NHC(O)U391, NU392C(O)U393, NHC(O)OU394, NHC(O)NHU395, NHC(O)NU396U397, NU398C(O)OU399, NU400C(O)NHU401, NU402C(O)NU403U404, NHS(O2)U405, NU406S(O2)U407, SU408, S(O)U409, S(O2)U410, S(O2)NHU411, S(O2)NU412U413, S(O2)OU414, P(O)(OU415)(OU416), Si(U417)(U418)(U419)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU368, NU369U370, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U371, C (O) OU372, C (O) NHU373, C (O) NU374U375, OU376, O (U377-O) xH (x = 1 , 2, 3, 4, 5), O (U378-O) x ) x U379 (x = 1, 2, 3, 4, 5), OC (O) U380, OC (O) OU381, OC (O) NHU382, OC (O) NU383U384, OP (O) (OU385) (OU386), OSi (U387) (U388) (U389), OS (O 2 ) U390, NHC (O) U391, NU392C (O) U393, NHC (O) OU394, NHC (O) NHU395, NHC (O) NU396U397, NU398C (O) OU399, NU400C (O) NHU401, NU402C (O) NU403U404, NHS (O2) U405, NU406S (O2) U407, SU408, S (O) U409, S (O 2 ) U410, S (O 2 ) NHU411, S (O 2 ) NU412U413, S (O 2 ) OU414, P (O) (OU415) (OU416), Si (U417) (U418 ) (U419) "

여기서, U368, U369, U370, U371, U372, U373, U374, U375, U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U374, U375 및/또는 U383, U384 및/또는 U396, U397 및/또는 U403, U404 및/또는 U412, U413은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U368, U369, U370, U371, U372, U373, U374, U375, U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U374, U375 and / or U383, U384 and / or U396, U397 and / or U403, U404 and / or U412, U413 are also in each case a" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU420, NU421U422, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U423, C(O)OU424, C(O)NHU425, C(O)NU426U427, OU428, O(U429-O)yH (y = 1, 2, 3, 4, 5), O(U430-O)yU431 (y = 1, 2, 3, 4, 5), OC(O)U432, OC(O)OU433, OC(O)NHU434, OC(O)NU435U436, OP(O)(OU437)(OU438), OSi(U439)(U440)(U441), OS(O2)U442, NHC(O)U443, NU444C(O)U445, NHC(O)OU446, NHC(O)NHU447, NHC(O)NU448U449, NU450C(O)OU451, NU452C(O)NHU453, NU454C(O)NU455U456, NHS(O2)U457, NU458S(O2)U459, SU460, S(O)U461, S(O2)U462, S(O2)NHU463, S(O2)NU464U465, S(O2)OU466, P(O)(OU467)(OU468), Si(U469)(U470)(U471)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU420, NU421U422, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U423, C (O) OU424, C (O) NHU425, C (O) NU426U427, OU428, O (U429-O) y H (y = 1, 2, 3, 4, 5), O (U430-O) y U431 (y = 1, 2, 3, 4, 5), OC (O) U432, OC (O) OU433, OC (O) NHU434 , OC (O) NU435U436, OP (O) (OU437) (OU438), OSi (U439) (U440) (U441), OS (O 2 ) U442, NHC (O) U443, NU444C (O) U445, NHC ( O) OU446, NHC (O) NHU447, NHC (O) NU448U449, NU450C (O) OU451, NU452C (O) NHU453, NU454C (O) NU455U456, NHS (O2) U457, NU458S (O2) U459, SU460, S ( O) U461, S (O 2 ) U462, S (O 2 ) NHU463, S (O 2 ) NU464U465, S (O 2 ) OU466, P (O) (OU467) (OU468), Si (U469) (U470) (U471) "

여기서, U420, U421, U422, U423, U424, U425, U426, U427, U428, U429, U430, U431, U432, U433, U434, U435, U436, U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U426, U427 및/또는 U435, U436 및/또는 U448, U449 및/또는 U455, U456 및/또는 U464, U465는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U420, U421, U422, U423, U424, U425, U426, U427, U428, U429, U430, U431, U432, U433, U434, U435, U436, U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U426, U427 and / or U435, U436 and / or U448, U449 and / or U455, U456 and / or U464, U465 are also in each case together a" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU472, NU473U474, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U475, C(O)OU476, C(O)NHU477, C(O)NU478U479, OU480, O(U481-O)zH (z = 1, 2, 3, 4, 5), O(U482-O)zU483 (z = 1, 2, 3, 4, 5), OC(O)U484, OC(O)OU485, OC(O)NHU486, OC(O)NU487U488, OP(O)(OU489)(OU490), OSi(U491)(U492)(U493), OS(O2)U494, NHC(O)U495, NU496C(O)U497, NHC(O)OU498, NHC(O)NHU499, NHC(O)NU500U501, NU502C(O)OU503, NU504C(O)NHU505, NU506C(O)NU507U508, NHS(O2)U509, NU510S(O2)U511, SU512, S(O)U513, S(O2)U514, S(O2)NHU515, S(O2)NU516U517, S(O2)OU518, P(O)(OU519)(OU520), Si(U521)(U522)(U523)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU472, NU473U474, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U475, C (O) OU476, C (O) NHU477, C (O) NU478U479, OU480, O (U481-O) z H (z = 1, 2, 3, 4, 5), O (U482-O) z U483 (z = 1, 2, 3, 4, 5), OC (O) U484, OC (O) OU485, OC (O) NHU486 , OC (O) NU487U488, OP (O) (OU489) (OU490), OSi (U491) (U492) (U493), OS (O 2 ) U494, NHC (O) U495, NU496C (O) U497, NHC ( O) OU498, NHC (O) NHU499, NHC (O) NU500U501, NU502C (O) OU503, NU504C (O) NHU505, NU506C (O) NU507U508, NHS (O2) U509, NU510S (O2) U511, SU512, S ( O) U513, S (O 2 ) U514, S (O 2 ) NHU515, S (O 2 ) NU516U517, S (O 2 ) OU518, P (O) (OU519) (OU520), Si (U521) (U522) (U523) "

여기서, U472, U473, U474, U475, U476, U477, U478, U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U478, U479 및/또는 U487, U488 및/또는 U500, U501 및/또는 U507, U508 및/또는 U516, U517은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U472, U473, U474, U475, U476, U477, U478, U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U478, U479 and / or U487, U488 and / or U500, U501 and / or U507, U508 and / or U516, U517 are also in each case a" heterocycle. " Reels ",

여기서, 대안적으로, U314, U315는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Here, alternatively, U314, U315 may also together form “heterocyclyl”,

And

Z5 라디칼은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z5 radicals are independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHA1, NA2A3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)A4, C(O)OA5, C(O)NHA6, C(O)NA7A8, OA9, O(A10-O)rH (r = 1, 2, 3, 4, 5), O(A11-O)rA12 (r = 1, 2, 3, 4, 5), OC(O)A13, OC(O)OA14, OC(O)NHA15, OC(O)NA16A17, OP(O)(OA18)(OA19), OSi(A20)(A21)(A22), OS(O2)A23, NHC(O)A24, NA25C(O)A26, NHC(O)OA27, NHC(O)NHA28, NHC(O)NA29A30, NA31C(O)OA32, NA33C(O)NHA34, NA35C(O)NA36A37, NHS(O2)A38, NA39S(O2)A40, SA41, S(O)A42, S(O2)A43, S(O2)NHA44, S(O2)NA45A46, S(O2)OA47, P(O)(OA48)(OA49), Si(A50)(A51)(A52)"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHA1, NA2A3, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) A4, C (O) OA5, C (O) NHA6, C (O) NA7A8, OA9, O (A10-O) r H ( r = 1, 2, 3, 4, 5), O (A11-O) r A12 (r = 1, 2, 3, 4, 5), OC (O) A13, OC (O) OA14, OC (O NHA15, OC (O) NA16A17, OP (O) (OA18) (OA19), OSi (A20) (A21) (A22), OS (O 2 ) A23, NHC (O) A24, NA25C (O) A26, NHC (O) OA27, NHC (O) NHA28, NHC (O) NA29A30, NA31C (O) OA32, NA33C (O) NHA34, NA35C (O) NA36A37, NHS (O2) A38, NA39S (O2) A40, SA41, S (O) A42, S (O 2 ) A43, S (O 2 ) NHA44, S (O 2 ) NA45A46, S (O 2 ) OA47, P (O) (OA48) (OA49), Si (A50) ( A51) (A52) "

여기서, A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, A7, A8 및/또는 A16, A17 및/또는 A29, A30 및/또는 A36, A37 및/또는 A45, A46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, A7, A8 and / or A16, A17 and / or A29, A30 and / or A36, A37 and / or A45, A46 may also in each case be" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHA53, NA54A55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)A56, C(O)OA57, C(O)NHA58, C(O)NA59A60, OA61, O(A62-O)sH (s = 1, 2, 3, 4, 5), O(A63-O)tA64 (t = 1, 2, 3, 4, 5), OC(O)A65, OC(O)OA66, OC(O)NHA67, OC(O)NA68A69, OP(O)(OA70)(OA71), OSi(A72)(A73)(A74), OS(O2)A75, NHC(O)A76, NA77C(O)A78, NHC(O)OA79, NHC(O)NHA80, NHC(O)NA81A82, NA83C(O)OA84, NA85C(O)NHA86, NA87C(O)NA88A89, NHS(O2)A90, NA91S(O2)A92, SA93, S(O)A94, S(O2)A95, S(O2)NHA96, S(O2)NA97A98, S(O2)OA99, P(O)(OA100)(OA101), Si(A102)(A103)(A104)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHA53, NA54A55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) A56, C (O) OA57, C (O) NHA58, C (O) NA59A60, OA61, O (A62-O) s H (s = 1, 2, 3, 4, 5), O (A63-O) t A64 (t = 1, 2, 3, 4, 5), OC (O) A65, OC (O) OA66, OC (O) NHA67 , OC (O) NA68A69, OP (O) (OA70) (OA71), OSi (A72) (A73) (A74), OS (O 2 ) A75, NHC (O) A76, NA77C (O) A78, NHC ( O) OA79, NHC (O) NHA80, NHC (O) NA81A82, NA83C (O) OA84, NA85C (O) NHA86, NA87C (O) NA88A89, NHS (O 2 ) A90, NA91S (O 2 ) A92, SA93, S (O) A94, S (O 2 ) A95, S (O 2 ) NHA96, S (O 2 ) NA97A98, S (O 2 ) OA99, P (O) (OA100) (OA101), Si (A102) ( A103) (A104) "

여기서, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, A59, A60 및/또는 A68, A69 및/또는 A81, A82 및/또는 A88, A89 및/또는 A97, A98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHA105, NA106A107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)A108, C(O)OA109, C(O)NHA110, C(O)NA111A112, OA113, O(A114-O)tH (t = 1, 2, 3, 4, 5), O(A115-O)tA116 (t = 1, 2, 3, 4, 5), OC(O)A117, OC(O)OA118, OC(O)NHA119, OC(O)NA120A121, OP(O)(OA122)(OA123), OSi(A124)(A125)(A126), OS(O2)A127, NHC(O)A128, NA129C(O)A130, NHC(O)OA131, NHC(O)NHA132, NHC(O)NA133A134, NA135C(O)OA136, NA137C(O)NHA138, NA139C(O)NA140A141, NHS(O2)A142, NA143S(O2)A144, SA145, S(O)A146, S(O2)A147, S(O2)NHA148, S(O2)NA149A150, S(O2)OA151, P(O)(OA152)(OA153), Si(A154)(A155)(A156)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHA105, NA106A107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) A108, C (O) OA109, C (O) NHA110, C (O) NA111A112, OA113, O (A114-O) t H (t = 1, 2, 3, 4, 5), O (A115-O) t A116 (t = 1, 2, 3, 4, 5), OC (O) A117, OC (O) OA118, OC (O) NHA119 , OC (O) NA120A121, OP (O) (OA122) (OA123), OSi (A124) (A125) (A126), OS (O 2 ) A127, NHC (O) A128, NA129C (O) A130, NHC ( O) OA131, NHC (O) NHA132, NHC (O) NA133A134, NA135C (O) OA136, NA137C (O) NHA138, NA139C (O) NA140A141, NHS (O2) A142, NA143S (O2) A144, SA145, S ( O) A146, S (O 2 ) A147, S (O 2 ) NHA148, S (O 2 ) NA149A150, S (O 2 ) OA151, P (O) (OA152) (OA153), Si (A154) (A155) (A156) "

여기서, A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, A111, A112 및/또는 A120, A121 및/또는 A133, A134 및/또는 A140, A141 및/또는 A149, A150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, A111, A112 and / or A120, A121 and / or A133, A134 and / or A140, A141 and / or A149, A150 are also in each case" heterocycle Reels ",

또는or

(E) Z1, Z2 라디칼 중 하나 또는 Z1, Z2 라디칼 둘 다는 각각 독립적으로 다 음으로 이루어진 그룹으로부터 선택되고:(E) one of the Z1, Z2 radicals or both Z1, Z2 radicals is each independently selected from the group consisting of:

(a) NZ24Z25;(a) NZ24Z25;

단, Z24, Z25 라디칼 중 하나 또는 Z24, Z25 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Provided that either one of the Z24, Z25 radicals or both Z24, Z25 radicals is each independently selected from the group consisting of:

(1) "C(O)C(O)T1, S(O2)NT2T3"(1) "C (O) C (O) T1, S (O 2 ) NT2T3"

여기서, T1, T2, T3은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein T1, T2, T3 are each independently selected from the group consisting of:

(I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT4, NT5T6, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T7, C(O)OT8, C(O)NHT9, C(O)NT10T11, OT12, O(T13-O)pH (p = 1, 2, 3, 4, 5), O(T14-O)pT15 (p = 1, 2, 3, 4, 5), OC(O)T16, OC(O)OT17, OC(O)NHT18, OC(O)NT19T20, OP(O)(OT21)(OT22), OSi(T23)(T24)(T25), OS(O2)T26, NHC(O)T27, NT28C(O)T29, NHC(O)OT30, NHC(O)NHT31, NHC(O)NT32T33, NT34C(O)OT35, NT36C(O)NHT37, NT38C(O)NT39T40, NHS(O2)T41, NT42S(O2)T43, ST44, S(O)T45, S(O2)T46, S(O2)NHT47, S(O2)NT48T49, S(O2)OT50, P(O)(OT51)(OT52), Si(T53)(T54)(T55)"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHT4, NT5T6, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T7, C (O) OT8, C (O) NHT9, C (O) NT10T11, OT12, O (T13-O) p H ( p = 1, 2, 3, 4, 5), O (T14-O) p T15 (p = 1, 2, 3, 4, 5), OC (O) T16, OC (O) OT17, OC (O NHT18, OC (O) NT19T20, OP (O) (OT21) (OT22), OSi (T23) (T24) (T25), OS (O 2 ) T26, NHC (O) T27, NT28C (O) T29, NHC (O) OT30, NHC (O) NHT31, NHC (O) NT32T33, NT34C (O) OT35, NT36C (O) NHT37, NT38C (O) NT39T40, NHS (O 2 ) T41, NT42S (O 2 ) T43, ST44, S (O) T45, S (O 2 ) T46, S (O 2 ) NHT47, S (O 2 ) NT48T49, S (O 2 ) OT50, P (O) (OT51) (OT52), Si (T53 ) (T54) (T55) "

여기서, T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T10, T11 및/또는 T19, T20 및/또는 T32, T33 및/또는 T39, T40 및/또는 T48, T49는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T10, T11 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환 그룹(I)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT56, NT57T58, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T59, C(O)OT60, C(O)NHT61, C(O)NT62T63, OT64, O(T65-O)rH (r = 1, 2, 3, 4, 5), O(T66-O)rT67 (r = 1, 2, 3, 4, 5), OC(O)T68, OC(O)OT69, OC(O)NHT70, OC(O)NT71T72, OP(O)(OT73)(OT74), OSi(T75)(T76)(T77), OS(O2)T78, NHC(O)T79, NT80C(O)T81, NHC(O)OT82, NHC(O)NHT83, NHC(O)NT84T85, NT86C(O)OT87, NT88C(O)NHT89, NT90C(O)NT91T92, NHS(O2)T93, NT94S(O2)T95, ST96, S(O)T97, S(O2)T98, S(O2)NHT99, S(O2)NT100T101, S(O2)OT102, P(O)(OT103)(OT104), Si(T105)(T106)(T107)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT56, NT57T58, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T59, C (O) OT60, C (O) NHT61, C (O) NT62T63, OT64, O (T65-O) r H (r = 1, 2, 3, 4, 5), O (T66-O) r T67 (r = 1, 2, 3, 4, 5), OC (O) T68, OC (O) OT69, OC (O) NHT70 , OC (O) NT71T72, OP (O) (OT73) (OT74), OSi (T75) (T76) (T77), OS (O 2 ) T78, NHC (O) T79, NT80C (O) T81, NHC ( O) OT82, NHC (O) NHT83, NHC (O) NT84T85, NT86C (O) OT87, NT88C (O) NHT89, NT90C (O) NT91T92, NHS (O 2 ) T93, NT94S (O 2 ) T95, ST96, S (O) T97, S (O 2 ) T98, S (O 2 ) NHT99, S (O 2 ) NT100T101, S (O 2 ) OT102, P (O) (OT103) (OT104), Si (T105) ( T106) (T107) "

여기서, T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102, T103, T104, T105, T106, T107은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T62, T63 및/또는 T71, T72 및/또는 T84, T85 및/또는 T91, T92 및/또는 T100, T101은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102, T103, T104, T105, T106, T107 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T62, T63 and / or T71, T72 and / or T84, T85 and / or T91, T92 and / or T100, T101 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT108, NT109T110, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T111, C(O)OT112, C(O)NHT113, C(O)NT114T115, OT116, O(T117-O)sH (s = 1, 2, 3, 4, 5), O(T118-O)sT119 (s = 1, 2, 3, 4, 5), OC(O)T120, OC(O)OT121, OC(O)NHT122, OC(O)NT123T124, OP(O)(OT125)(OT126), OSi(T127)(T128)(T129), OS(O2)T130, NHC(O)T131, NT132C(O)T133, NHC(O)OT134, NHC(O)NHT135, NHC(O)NT136T137, NT138C(O)OT139, NT140C(O)NHT141, NT142C(O)NT143T144, NHS(O2)T145, NT146S(O2)T147, ST148, S(O)T149, S(O2)T150, S(O2)NHT151, S(O2)NT152T153, S(O2)OT154, P(O)(OT155)(OT156), Si(T157)(T158)(T159)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT108, NT109T110, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T111, C (O) OT112, C (O) NHT113, C (O) NT114T115, OT116, O (T117-O) s H (s = 1, 2, 3, 4, 5), O (T118-O) s T119 (s = 1, 2, 3, 4, 5), OC (O) T120, OC (O) OT121, OC (O) NHT122 , OC (O) NT123T124, OP (O) (OT125) (OT126), OSi (T127) (T128) (T129), OS (O 2 ) T130, NHC (O) T131, NT132C (O) T133, NHC ( O) OT134, NHC (O) NHT135, NHC (O) NT136T137, NT138C (O) OT139, NT140C (O) NHT141, NT142C (O) NT143T144, NHS (O 2 ) T145, NT146S (O 2 ) T147, ST148, S (O) T149, S (O 2 ) T150, S (O 2 ) NHT151, S (O 2 ) NT152T153, S (O 2 ) OT154, P (O) (OT155) (OT156), Si (T157) ( T158) (T159) "

여기서, T108, T109, T110, T111, T112, T113, T114, T115, T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139, T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151, T152, T153, T154, T155, T156, T157, T158, T159는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T114, T115 및/또는 T123, T124 및/또는 T136, T137 및/또는 T143, T144 및/또는 T152, T153은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T108, T109, T110, T111, T112, T113, T114, T115, T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139, T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151, T152, T153, T154, T155, T156, T157, T158, T159 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T114, T115 and / or T123, T124 and / or T136, T137 and / or T143, T144 and / or T152, T153 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT160, NT161T162, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T163, C(O)OT164, C(O)NHT165, C(O)NT166T167, OT168, O(T169-O)tH (t = 1, 2, 3, 4, 5), O(T170-O)tT171 (t = 1, 2, 3, 4, 5), OC(O)T172, OC(O)OT173, OC(O)NHT174, OC(O)NT175T176, OP(O)(OT177)(OT178), OSi(T179)(T180)(T181), OS(O2)T182, NHC(O)T183, NT184C(O)T185, NHC(O)OT186, NHC(O)NHT187, NHC(O)NT188T189, NT190C(O)OT191, NT192C(O)NHT193, NT194C(O)NT195T196, NHS(O2)T197, NT198S(O2)T199, ST200, S(O)T201, S(O2)T202, S(O2)NHT203, S(O2)NT204T205, S(O2)OT206, P(O)(OT207)(OT208), Si(T209)(T210)(T211)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT160, NT161T162, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T163, C (O) OT164, C (O) NHT165, C (O) NT166T167, OT168, O (T169-O) t H (t = 1, 2, 3, 4, 5), O (T170-O) t T171 (t = 1, 2, 3, 4, 5), OC (O) T172, OC (O) OT173, OC (O) NHT174 , OC (O) NT175T176, OP (O) (OT177) (OT178), OSi (T179) (T180) (T181), OS (O 2 ) T182, NHC (O) T183, NT184C (O) T185, NHC ( O) OT186, NHC (O) NHT187, NHC (O) NT188T189, NT190C (O) OT191, NT192C (O) NHT193, NT194C (O) NT195T196, NHS (O 2 ) T197, NT198S (O 2 ) T199, ST200, S (O) T201, S (O 2 ) T202, S (O 2 ) NHT203, S (O 2 ) NT204T205, S (O 2 ) OT206, P (O) (OT207) (OT208), Si (T209) ( T210) (T211) "

여기서, T160, T161, T162, T163, T164, T165,T166, T167, T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T211은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T166, T167 및/또는 T175, T176 및/또는 T188, T189 및/또는 T195, T196 및/또는 T204, T205는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where T160, T161, T162, T163, T164, T165, T166, T167, T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T211 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T166, T167 and / or T175, T176 and / or T188, T189 and / or T195, T196 and / or T204, T205 are also in each case" heterocycle. " Reels ";

여기서, 대안적으로, T2, T3 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Here, alternatively, T2, T3 may also together form "heterocyclyl",

Z24, Z25 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z24, Z25 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z24, Z25 radicals is independently selected from the group consisting of, or neither of the Z24, Z25 radicals is independently selected from the group consisting of:

(2) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(2) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환 그룹(2)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of the substitution group (2) may each be further substituted by one or more substituents independently or identically selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT212, NT213T214, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T215, C(O)OT216, C(O)NHT217, C(O)NT218T219, OT220, O(T221-O)uH (u = 1, 2, 3, 4, 5), O(T222-O)uT223 (u = 1, 2, 3, 4, 5), OC(O)T224, OC(O)OT225, OC(O)NHT226, OC(O)NT227T228, OP(O)(OT229)(OT230), OSi(T231)(T232)(T233), OS(O2)T234, NHC(O)T235, NT236C(O)T237, NHC(O)OT238, NHC(O)NHT239, NHC(O)NT240T241, NT242C(O)OT243, NT244C(O)NHT245, NT246C(O)NT247T248, NHS(O2)T249, NT250S(O2)T251, ST252, S(O)T253, S(O2)T254, S(O2)NHT255, S(O2)NT256T257, S(O2)OT258, P(O)(OT259)(OT260), Si(T261)(T262)(T263)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT212, NT213T214, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T215, C (O) OT216, C (O) NHT217, C (O) NT218T219, OT220, O (T221-O) u H (u = 1, 2, 3, 4, 5), O (T222-O) u T223 (u = 1, 2, 3, 4, 5), OC (O) T224, OC (O) OT225, OC (O) NHT226 , OC (O) NT227T228, OP (O) (OT229) (OT230), OSi (T231) (T232) (T233), OS (O 2 ) T234, NHC (O) T235, NT236C (O) T237, NHC ( O) OT238, NHC (O) NHT239, NHC (O) NT240T241, NT242C (O) OT243, NT244C (O) NHT245, NT246C (O) NT247T248, NHS (O 2 ) T249, NT250S (O 2 ) T251, ST252, S (O) T253, S (O 2 ) T254, S (O 2 ) NHT255, S (O 2 ) NT256T257, S (O 2 ) OT258, P (O) (OT259) (OT260), Si (T261) ( T262) (T263) "

여기서, T212, T213, T214,T215, T216, T217, T218, T219, T220, T221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260, T261, T262, T263은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T218, T219 및/또는 T227, T228 및/또는 T240, T241 및/또는 T247, T248 및/또는 T256, T257은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where T212, T213, T214, T215, T216, T217, T218, T219, T220, T221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260, T261, T262, T263 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T218, T219 and / or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 are also in each case" heterocycle. " Reels ";

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT264, NT265T266, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T267, C(O)OT268, C(O)NHT269, C(O)NT270T271, OT272, O(T273-O)vH (v = 1, 2, 3, 4, 5), O(T274-O)vT275 (v = 1, 2, 3, 4, 5), OC(O)T276, OC(O)OT277, OC(O)NHT278, OC(O)NT279T280, OP(O)(OT281)(OT282), OSi(T283)(T284)(T285), OS(O2)T286, NHC(O)T287, NT288C(O)T289, NHC(O)OT290, NHC(O)NHT291, NHC(O)NT292T293, NT294C(O)OT295, NT296C(O)NHT297, NT298C(O)NT299T300, NHS(O2)T301, NT302S(O2)T303, ST304, S(O)T305, S(O2)T306, S(O2)NHT307, S(O2)NT308T309, S(O2)OT310, P(O)(OT311)(OT312), Si(T313)(T314)(T315)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT264, NT265T266, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T267, C (O) OT268, C (O) NHT269, C (O) NT270T271, OT272, O (T273-O) v H (v = 1, 2, 3, 4, 5), O (T274-O) v T275 (v = 1, 2, 3, 4, 5), OC (O) T276, OC (O) OT277, OC (O) NHT278 , OC (O) NT279T280, OP (O) (OT281) (OT282), OSi (T283) (T284) (T285), OS (O 2 ) T286, NHC (O) T287, NT288C (O) T289, NHC ( O) OT290, NHC (O) NHT291, NHC (O) NT292T293, NT294C (O) OT295, NT296C (O) NHT297, NT298C (O) NT299T300, NHS (O 2 ) T301, NT302S (O 2 ) T303, ST304, S (O) T305, S (O 2 ) T306, S (O 2 ) NHT307, S (O 2 ) NT308T309, S (O 2 ) OT310, P (O) (OT311) (OT312), Si (T313) ( T314) (T315) "

여기서, T264, T265, T266, T267, T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282, T283, T284, T285, T286, T287, T288, T289, T290, T291, T292, T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T270, T271 및/또는 T279, T280 및/또는 T292, T293 및/또는 T299, T300 및/또는 T308, T309는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T264, T265, T266, T267, T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282, T283, T284, T285, T286, T287, T288, T289, T290, T291, T292, T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T270, T271 and / or T279, T280 and / or T292, T293 and / or T299, T300 and / or T308, T309 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT316, NT317T318, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T319, C(O)OT320, C(O)NHT321, C(O)NT322T323, OT324, O(T325-O)wH (w = 1, 2, 3, 4, 5), O(T326-O)wT327 (w = 1, 2, 3, 4, 5), OC(O)T328, OC(O)OT329, OC(O)NHT330, OC(O)NT331T332, OP(O)(OT333)(OT334), OSi(T335)(T336)(T337), OS(O2)T338, NHC(O)T339, NT340C(O)T341, NHC(O)OT342, NHC(O)NHT343, NHC(O)NT344T345, NT346C(O)OT347, NT348C(O)NHT349, NT350C(O)NT351T352, NHS(O2)T353, NT354S(O2)T355, ST356, S(O)T357, S(O2)T358, S(O2)NHT359, S(O2)NT360T361, S(O2)OT362, P(O)(OT363)(OT364), Si(T365)(T366)(T367)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT316, NT317T318, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T319, C (O) OT320, C (O) NHT321, C (O) NT322T323, OT324, O (T325-O) w H (w = 1, 2, 3, 4, 5), O (T326-O) w T327 (w = 1, 2, 3, 4, 5), OC (O) T328, OC (O) OT329, OC (O) NHT330 , OC (O) NT331T332, OP (O) (OT333) (OT334), OSi (T335) (T336) (T337), OS (O 2 ) T338, NHC (O) T339, NT340C (O) T341, NHC ( O) OT342, NHC (O) NHT343, NHC (O) NT344T345, NT346C (O) OT347, NT348C (O) NHT349, NT350C (O) NT351T352, NHS (O 2 ) T353, NT354S (O 2 ) T355, ST356, S (O) T357, S (O 2 ) T358, S (O 2 ) NHT359, S (O 2 ) NT360T361, S (O 2 ) OT362, P (O) (OT363) (OT364), Si (T365) ( T366) (T367) "

여기서, T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334, T335, T336, T337, T338, T339, T340,T341, T342, T343, T344, T345, T346, T347, T348, T349, T350, T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T322, T323 및/또는 T331, T332 및/또는 T344, T345 및/또는 T351, T352 및/또는 T360, T361은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334, T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350, T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 may also in each case be" heterocycle. " Reels ",

(b) NZ26Z27 여기서, Z26, Z27 라디칼 중 하나 또는 Z26, Z27 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(b) NZ26Z27 wherein one of the Z26, Z27 radicals or both Z26, Z27 radicals is each independently selected from the group consisting of:

(1) "C(Y4)NZ28Z29, C(=NZ30)Z31"(1) "C (Y4) NZ28Z29, C (= NZ30) Z31"

여기서, Y4는 독립적으로 "O, S, =NH, =NZ32"로 이루어진 그룹으로부터 선택되고,Wherein Y4 is independently selected from the group consisting of "O, S, = NH, = NZ32",

단, only,

Z28, Z29 라디칼 중 적어도 하나 및 Z30, Z31 라디칼 중 적어도 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:At least one of the Z28, Z29 radicals and at least one of the Z30, Z31 radicals is independently selected from the group consisting of:

(I) "알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, C(O)알킬, C(O)아릴, C(O)헤테로아릴"(I) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl, C (O) heteroaryl"

추가로 단, 치환체 그룹(i)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Further provided that the aforementioned substituents in substituent group (i) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "(C9-C30)알킬, 사이클로알킬알킬, 헤테로사이클릴알킬, 아릴알킬, 헤테로아릴알킬, N3, NT368T369, NHC(O)사이클로알킬알킬, NHC(O)헤테로사이클릴알킬, NT370C(O)T371, NHC(O)OT372, NHC(O)NHT373, NHC(O)NT374T375, NT376C(O)OT377, NT378C(O)NHT379, NT380C(O)NT381T382, NHS(O2)사이클로알킬알킬, NHS(O2)헤테로사이클릴알킬, NT383S(O2)T384, OT385, O(T386-O)xT387 (x = 1, 2, 3, 4, 5), O(T388-O)xH (x = 1, 2, 3, 4, 5), OC(O)-사이클로알킬알킬, OC(O)-헤테로사이클릴알킬, OC(O)OT389, OC(O)NHT390, OC(O)NT391T392, OS(O2)사이클로알킬알킬, OS(O2)헤테로사이클릴알킬, -OP(O)(OT393)(OT394), OSi(T395)(T396)(T397), CHO, C(O)사이클로알킬, C(O)헤테로사이클릴, C(O)사이클로알킬알킬, C(O)헤테로사이클릴알킬, C(O)아릴알킬, C(O)헤테로아릴알킬, S 사이클로알킬알킬, S헤테로사이클릴알킬, S아릴알킬, S헤테로아릴알킬, S(O)사이클로알킬, S(O)헤테로사이클릴, S(O)헤테로아릴, S(O)사이클로알킬알킬, S(O)헤테로사이클릴알킬, S(O)아릴알킬, S(O)헤테로아릴알킬, S(O2)사이클로알킬, S(O2)헤테로사이클릴, S(O2)헤테로아릴, S(O2)사이클로알킬알킬, S(O2)헤테로사이클릴알킬, S(O2)아릴알킬, S(O2)헤테로아릴알킬, S(O2)NH사이클로알킬, S(O2)NH헤테로사이클릴, S(O2)NH사이클로알킬알킬, S(O2)NH헤테로사이클릴알킬, S(O2)NH헤테로아릴알킬, S(O2)NT398T399, S(O2)O사이클로알킬, S(O2)O헤테로사이클릴, S(O2)O헤테로아릴, S(O2)O사이클로알킬알킬, S(O2)O헤테로사이클릴알 킬, S(O2)O헤테로아릴알킬, P(O)(OH)2, P(O)(OT400)(OT401), Si(T402)(T403)(T404)"(i) "(C 9 -C 30 ) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, N3, NT368T369, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NT370C (O) T371, NHC (O) OT372, NHC (O) NHT373, NHC (O) NT374T375, NT376C (O) OT377, NT378C (O) NHT379, NT380C (O) NT381T382, NHS (O 2 ) cycloalkylalkyl , NHS (O 2 ) heterocyclylalkyl, NT383S (O2) T384, OT385, O (T386-O) x T387 (x = 1, 2, 3, 4, 5), O (T388-O) x H ( x = 1, 2, 3, 4, 5), OC (O) -cycloalkylalkyl, OC (O) -heterocyclylalkyl, OC (O) OT389, OC (O) NHT390, OC (O) NT391T392, OS (O 2 ) cycloalkylalkyl, OS (O 2) heterocyclylalkyl, —OP (O) (OT393) (OT394), OSi (T395) (T396) (T397), CHO, C (O) cycloalkyl, C (O) heterocyclyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O) arylalkyl, C (O) heteroarylalkyl, S cycloalkylalkyl, S heterocyclylalkyl , Sarylalkyl, Sheteroarylalkyl, S (O) cycloalkyl, S (O) hetero Cyclyl, S (O) heteroaryl, S (O) cycloalkylalkyl, S (O) heterocyclylalkyl, S (O) arylalkyl, S (O) heteroarylalkyl, S (O 2 ) cycloalkyl, S (O2) heterocyclyl, S (O2) heteroaryl, S (O 2 ) cycloalkylalkyl, S (O2) heterocyclylalkyl, S (O2) arylalkyl, S (O2) heteroarylalkyl, S ( O 2 ) NH cycloalkyl, S (O 2 ) NH heterocyclyl, S (O 2 ) NH cycloalkylalkyl, S (O 2 ) NH heterocyclylalkyl, S (O 2 ) NH heteroarylalkyl, S (O 2 ) NT398T399, S (O 2) O-cycloalkyl, S (O 2) O-heterocyclyl, S (O 2) O-heteroaryl, S (O 2) O-cycloalkyl-alkyl, S (O2) O heterocycle rilal attempts. S (O2) O Heteroarylalkyl, P (O) (OH) 2, P (O) (OT400) (OT401), Si (T402) (T403) (T404) "

추가로 단, "N(알킬)2", "C(O)N(알킬)2", "C(O)N(사이클로알킬)2", "C(O)N(아릴)2", "C(O)N(헤테로아릴)2"는 다음 치환체 그룹(ii)로부터의 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further, provided that "N (alkyl) 2 ", "C (O) N (alkyl) 2 ", "C (O) N (cycloalkyl) 2 ", "C (O) N (aryl) 2 ", " C (O) N (heteroaryl) 2 ″ is further substituted by one or more substituents selected from the following substituent group (ii);

여기서, T368, T369, T370, T371, T372, T373, T374, T375, T376, T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T374, T375 및/또는 T381, T382 및/또는 T391, T392 및/또는 T398, T399는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T368, T369, T370, T371, T372, T373, T374, T375, T376, T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cyclo Alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, T374, T375 and / or T381, T382 and / or T391, T392 and And / or T398, T399 may also in each case together form a “heterocyclyl”,

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT405, NT406T407, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T408, C(O)OT409, C(O)NHT410, C(O)NT411T412, OT413, O(T414-O)yH (y = 1, 2, 3, 4, 5), O(T415-O)yT416 (y = 1, 2, 3, 4, 5), OC(O)T417, OC(O)OT418, OC(O)NHT419, OC(O)NT420T421, OP(O)(OT422)(OT423), OSi(T424)(T425)(T426), OS(O2)T427, NHC(O)T428, NT429C(O)T430, NHC(O)OT431, NHC(O)NHT432, NHC(O)NT433T434, NT435C(O)OT436, NT437C(O)NHT438, NT439C(O)NT440T441, NHS(O2)T442, NT443S(O2)T444, ST445, S(O)T446, S(O2)T447, S(O2)NHT448, S(O2)NT449T450, S(O2)OT451, P(O)(OT452)(OT453), Si(T454)(T455)(T456)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT405, NT406T407, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T408, C (O) OT409, C (O) NHT410, C (O) NT411T412, OT413, O (T414-O) y H (y = 1, 2, 3, 4, 5), O (T415-O) y T416 (y = 1, 2, 3, 4, 5), OC (O) T417, OC (O) OT418, OC (O) NHT419 , OC (O) NT420T421, OP (O) (OT422) (OT423), OSi (T424) (T425) (T426), OS (O 2 ) T427, NHC (O) T428, NT429C (O) T430, NHC ( O) OT431, NHC (O) NHT432, NHC (O) NT433T434, NT435C (O) OT436, NT437C (O) NHT438, NT439C (O) NT440T441, NHS (O2) T442, NT443S (O2) T444, ST445, S ( O) T446, S (O 2 ) T447, S (O 2 ) NHT448, S (O 2 ) NT449T450, S (O 2 ) OT451, P (O) (OT452) (OT453), Si (T454) (T455) (T456) "

여기서, T405, T406, T407, T408, T409, T410, T411, T412, T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T411, T412 및/또는 T420, T421 및/또는 T433, T434 및/또는 T440, T441 및/또는 T449, T450은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where T405, T406, T407, T408, T409, T410, T411, T412, T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T411, T412 and / or T420, T421 and / or T433, T434 and / or T440, T441 and / or T449, T450 are also in each case" heterocycle. " Reels ";

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT457, NT458T459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T460, C(O)OT461, C(O)NHT462, C(O)NT463T464, OT465, O(T466-O)zH (z = 1, 2, 3, 4, 5), O(T467-O)zT468 (z = 1, 2, 3, 4, 5), OC(O)T469, OC(O)OT470, OC(O)NHT471, OC(O)NT472T473, OP(O)(OT474)(OT475), OSi(T476)(T477)(T478), OS(O2)T479, NHC(O)T480, NT481C(O)T482, NHC(O)OT483, NHC(O)NHT484, NHC(O)NT485T486, NT487C(O)OT488, NT489C(O)NHT490, NT491C(O)NT492T493, NHS(O2)T494, NT495S(O2)T496, ST497, S(O)T498, S(O2)T499, S(O2)NHT500, S(O2)NT501T502, S(O2)OT503, P(O)(OT504)(OT505), Si(T506)(T507)(T508)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT457, NT458T459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T460, C (O) OT461, C (O) NHT462, C (O) NT463T464, OT465, O (T466-O) z H (z = 1, 2, 3, 4, 5), O (T467-O) z T468 (z = 1, 2, 3, 4, 5), OC (O) T469, OC (O) OT470, OC (O) NHT471 , OC (O) NT472T473, OP (O) (OT474) (OT475), OSi (T476) (T477) (T478), OS (O 2 ) T479, NHC (O) T480, NT481C (O) T482, NHC ( O) OT483, NHC (O) NHT484, NHC (O) NT485T486, NT487C (O) OT488, NT489C (O) NHT490, NT491C (O) NT492T493, NHS (O2) T494, NT495S (O2) T496, ST497, S ( O) T498, S (O 2 ) T499, S (O 2 ) NHT500, S (O 2 ) NT501T502, S (O 2 ) OT503, P (O) (OT504) (OT505), Si (T506) (T507) (T508) "

여기서, T457, T458, T459, T460, T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T463, T464 및/또는 T472, T473 및/또는 T485, T486 및/또는 T492, T493 및/또는 T501, T502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T457, T458, T459, T460, T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T463, T464 and / or T472, T473 and / or T485, T486 and / or T492, T493 and / or T501, T502 are also in each case" heterocycle. " Reels ",

또는 단, Z28, Z29 라디칼 중 적어도 하나 및 Z30, Z31 라디칼 중 적어도 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: Or provided that at least one of the Z28, Z29 radicals and at least one of the Z30, Z31 radicals is independently selected from the group consisting of:

(II) "(C9-C30)알킬, 사이클로알킬알킬, 헤테로사이클릴알킬, 아릴알킬, 헤테로아릴알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴알킬, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(II) "(C 9 -C 30 ) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) arylalkyl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocyclyl, S (O 2 ) heterocyclylalkyl "

여기서, 임의로, 치환 그룹(II)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (II) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT509, NT510T511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T512, C(O)OT513, C(O)NHT514, C(O)NT515T516, OT517, O(T518-O)aH (a = 1, 2, 3, 4, 5), O(T519-O)aT520 (a = 1, 2, 3, 4, 5), OC(O)T521, OC(O)OT522, OC(O)NHT523, OC(O)NT524T525, OP(O)(OT526)(OT527), OSi(T528)(T529)(T530), OS(O2)T531, NHC(O)T532, NT533C(O)T534, NHC(O)OT535, NHC(O)NHT536, NHC(O)NT537T538, NT539C(O)OT540, NT541C(O)NHT542, NT543C(O)NT544T545, NHS(O2)T546, NT547S(O2)T548, ST549, S(O)T550, S(O2)T551, S(O2)NHT552, S(O2)NT553T554, S(O2)OT555, P(O)(OT556)(OT557), Si(T558)(T559)(T560)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT509, NT510T511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T512, C (O) OT513, C (O) NHT514, C (O) NT515T516, OT517, O (T518-O) a H (a = 1, 2, 3, 4, 5), O (T519-O) a T520 (a = 1, 2, 3, 4, 5), OC (O) T521, OC (O) OT522, OC (O) NHT523 , OC (O) NT524T525, OP (O) (OT526) (OT527), OSi (T528) (T529) (T530), OS (O 2 ) T531, NHC (O) T532, NT533C (O) T534, NHC ( O) OT535, NHC (O) NHT536, NHC (O) NT537T538, NT539C (O) OT540, NT541C (O) NHT542, NT543C (O) NT544T545, NHS (O2) T546, NT547S (O2) T548, ST549, S ( O) T550, S (O 2 ) T551, S (O 2 ) NHT552, S (O 2 ) NT553T554, S (O 2 ) OT555, P (O) (OT556) (OT557), Si (T558) (T559) (T560) "

여기서, T509, T510, T511, T512, T513, T514, T515, T516, T517, T518, T519, T520, T521, T522, T523, T524, T525, T526, T527, T528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544, T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557, T558, T559, T560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T515, T516 및/또는 T524, T525 및/또는 T537, T538 및/또는 T544, T545 및/또는 T553, T554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T509, T510, T511, T512, T513, T514, T515, T516, T517, T518, T519, T520, T521, T522, T523, T524, T525, T526, T527, T528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544, T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557, T558, T559, T560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T515, T516 and / or T524, T525 and / or T537, T538 and / or T544, T545 and / or T553, T554 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT561, NT562T563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T564, C(O)OT565, C(O)NHT566, C(O)NT567T568, OT569, O(T570-O)bH (b = 1, 2, 3, 4, 5), O(T571-O)bT572 (b = 1, 2, 3, 4, 5), OC(O)T573, OC(O)OT574, OC(O)NHT575, OC(O)NT576T577, OP(O)(OT578)(OT579), OSi(T580)(T581)(T582), OS(O2)T583, NHC(O)T584, NT585C(O)T586, NHC(O)OT587, NHC(O)NHT588, NHC(O)NT589T590, NT591C(O)OT592, NT593C(O)NHT594, NT595C(O)NT596T597, NHS(O2)T598, NT599S(O2)T600, ST601, S(O)T602, S(O2)T603, S(O2)NHT604, S(O2)NT605T606, S(O2)OT607, P(O)(OT608)(OT609), Si(T610)(T611)(T612)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT561, NT562T563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T564, C (O) OT565, C (O) NHT566, C (O) NT567T568, OT569, O (T570-O) b H (b = 1, 2, 3, 4, 5), O (T571-O) b T572 (b = 1, 2, 3, 4, 5), OC (O) T573, OC (O) OT574, OC (O) NHT575 , OC (O) NT576T577, OP (O) (OT578) (OT579), OSi (T580) (T581) (T582), OS (O 2 ) T583, NHC (O) T584, NT585C (O) T586, NHC ( O) OT587, NHC (O) NHT588, NHC (O) NT589T590, NT591C (O) OT592, NT593C (O) NHT594, NT595C (O) NT596T597, NHS (O2) T598, NT599S (O2) T600, ST601, S ( O) T602, S (O 2 ) T603, S (O 2 ) NHT604, S (O 2 ) NT605T606, S (O 2 ) OT607, P (O) (OT608) (OT609), Si (T610) (T611) (T612) "

여기서, T561, T562, T563, T564, T565, T566, T567, T568, T569, T570, T571, T572, T573, T574, T575, T576, T577, T578, T579, T580, T581, T582, T583, T584, T585, T586, T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T567, T568 및/또는 T576, T577 및/또는 T589, T590 및/또는 T596, T597 및/또는 T605, T606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T561, T562, T563, T564, T565, T566, T567, T568, T569, T570, T571, T572, T573, T574, T575, T576, T577, T578, T579, T580, T581, T582, T583, T584, T585, T586, T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T567, T568 and / or T576, T577 and / or T589, T590 and / or T596, T597 and / or T605, T606 are also in each case a" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT613, NT614T615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T616, C(O)OT617, C(O)NHT618, C(O)NT619T620, OT621, O(T622-O)cH (c = 1, 2, 3, 4, 5), O(T623-O)cT624 (c = 1, 2, 3, 4, 5), OC(O)T625, OC(O)OT626, OC(O)NHT627, OC(O)NT628T629, OP(O)(OT630)(OT631), OSi(T632)(T633)(T634), OS(O2)T635, NHC(O)T636, NT637C(O)T638, NHC(O)OT639, NHC(O)NHT640, NHC(O)NT641T642, NT643C(O)OT644, NT645C(O)NHT646, NT647C(O)NT648T649, NHS(O2)T650, NT651S(O2)T652, ST653, S(O)T654, S(O2)T655, S(O2)NHT656, S(O2)NT657T658, S(O2)OT659, P(O)(OT660)(OT661), Si(T662)(T663)(T664)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT613, NT614T615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T616, C (O) OT617, C (O) NHT618, C (O) NT619T620, OT621, O (T622-O) c H (c = 1, 2, 3, 4, 5), O (T623-O) c T624 (c = 1, 2, 3, 4, 5), OC (O) T625, OC (O) OT626, OC (O) NHT627 , OC (O) NT628T629, OP (O) (OT630) (OT631), OSi (T632) (T633) (T634), OS (O 2 ) T635, NHC (O) T636, NT637C (O) T638, NHC ( O) OT639, NHC (O) NHT640, NHC (O) NT641T642, NT643C (O) OT644, NT645C (O) NHT646, NT647C (O) NT648T649, NHS (O2) T650, NT651S (O2) T652, ST653, S ( O) T654, S (O 2 ) T655, S (O 2 ) NHT656, S (O 2 ) NT657T658, S (O 2 ) OT659, P (O) (OT660) (OT661), Si (T662) (T663) (T664) "

여기서, T613, T614, T615, T616, T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638, T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T619, T620 및/또는 T628, T629 및/또는 T641, T642 및/또는 T648, T649 및/또는 T657, T658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T613, T614, T615, T616, T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638, T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T619, T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 are also in each case" heterocycle. " Reels ",

And

Z28, Z29 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z28, Z29 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고, Z30, Z31 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z30, Z31 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고, Z32 라디칼은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:One of the Z28, Z29 radicals is independently selected from the group consisting of: or neither of the Z28, Z29 radicals is independently selected from the group consisting of, and one of the Z30, Z31 radicals is independently selected from the group consisting of Or none of the Z30, Z31 radicals are independently selected from the group consisting of: and the Z32 radicals are independently selected from the group consisting of:

(III) "수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, C(O)알킬, C(O)아릴, C(O)헤테로아릴"(III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl, C (O) heteroaryl"

여기서, 임의로, 치환체 그룹(III)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (III) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT665, NT666T667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T668, C(O)OT669, C(O)NHT670, C(O)NT671T672, OT673, O(T674-O)dH (d = 1, 2, 3, 4, 5), O(T675-O)dT676 (d = 1, 2, 3, 4, 5), OC(O)T677, OC(O)OT678, OC(O)NHT679, OC(O)NT680T681, OP(O)(OT682)(OT683), OSi(T684)(T685)(T686), OS(O2)T687, NHC(O)T688, NT689C(O)T690, NHC(O)OT691, NHC(O)NHT692, NHC(O)NT693T694, NT695C(O)OT696, NT697C(O)NHT698, NT699C(O)NT700T701, NHS(O2)T702, NT703S(O2)T704, ST705, S(O)T706, S(O2)T707, S(O2)NHT708, S(O2)NT709T710, S(O2)OT711, P(O)(OT712)(OT713), Si(T714)(T715)(T716)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT665, NT666T667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T668, C (O) OT669, C (O) NHT670, C (O) NT671T672, OT673, O (T674-O) d H (d = 1, 2, 3, 4, 5), O (T675-O) d T676 (d = 1, 2, 3, 4, 5), OC (O) T677, OC (O) OT678, OC (O) NHT679 , OC (O) NT680T681, OP (O) (OT682) (OT683), OSi (T684) (T685) (T686), OS (O 2 ) T687, NHC (O) T688, NT689C (O) T690, NHC ( O) OT691, NHC (O) NHT692, NHC (O) NT693T694, NT695C (O) OT696, NT697C (O) NHT698, NT699C (O) NT700T701, NHS (O2) T702, NT703S (O2) T704, ST705, S ( O) T706, S (O 2 ) T707, S (O 2 ) NHT708, S (O 2 ) NT709T710, S (O 2 ) OT711, P (O) (OT712) (OT713), Si (T714) (T715) (T716) "

여기서, T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676, T677, T678, T679, T680, T681, T682, T683, T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699,T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T711, T712, T713, T714, T715, T716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T671, T672 및/또는 T680, T681 및/또는 T693, T694 및/또는 T700, T701 및/또는 T709, T710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676, T677, T678, T679, T680, T681, T682, T683, T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T711, T712, T713, T714, T715, T716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T671, T672 and / or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT717, NT718T719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T720, C(O)OT721, C(O)NHT722, C(O)NT723T724, OT725, O(T726-O)eH (e = 1, 2, 3, 4, 5), O(T727-O)eT728 (e = 1, 2, 3, 4, 5), OC(O)T729, OC(O)OT730, OC(O)NHT731, OC(O)NT732T733, OP(O)(OT734)(OT735), OSi(T736)(T737)(T738), OS(O2)T739, NHC(O)T740, NT741C(O)T742, NHC(O)OT743, NHC(O)NHT744, NHC(O)NT745T746, NT747C(O)OT748, NT749C(O)NHT750, NT751C(O)NT752T753, NHS(O2)T754, NT755S(O2)T756, ST757, S(O)T758, S(O2)T759, S(O2)NHT760, S(O2)NT761T762, S(O2)OT763, P(O)(OT764)(OT765), Si(T766)(T767)(T768)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT717, NT718T719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T720, C (O) OT721, C (O) NHT722, C (O) NT723T724, OT725, O (T726-O) e H (e = 1, 2, 3, 4, 5), O (T727-O) e T728 (e = 1, 2, 3, 4, 5), OC (O) T729, OC (O) OT730, OC (O) NHT731 , OC (O) NT732T733, OP (O) (OT734) (OT735), OSi (T736) (T737) (T738), OS (O 2 ) T739, NHC (O) T740, NT741C (O) T742, NHC ( O) OT743, NHC (O) NHT744, NHC (O) NT745T746, NT747C (O) OT748, NT749C (O) NHT750, NT751C (O) NT752T753, NHS (O2) T754, NT755S (O2) T756, ST757, S ( O) T758, S (O 2 ) T759, S (O 2 ) NHT760, S (O 2 ) NT761T762, S (O 2 ) OT763, P (O) (OT764) (OT765), Si (T766) (T767) (T768) "

여기서, T717, T718, T719, T720, T721, T722, T723, T724, T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T723, T724 및/또는 T732, T733 및/또는 T745, T746 및/또는 T752, T753 및/또는 T761, T762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T717, T718, T719, T720, T721, T722, T723, T724, T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T723, T724 and / or T732, T733 and / or T745, T746 and / or T752, T753 and / or T761, T762 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:Wherein, optionally, the aforementioned substituents of substituent group (ii) are each independently substituted with one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT769, NT770T771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T772, C(O)OT773, C(O)NHT774, C(O)NT775T776, OT777, O(T778-O)fH (f = 1, 2, 3, 4, 5), O(T779- O)fT780 (f = 1, 2, 3, 4, 5), OC(O)T781, OC(O)OT782, OC(O)NHT783, OC(O)NT784T785, OP(O)(OT786)(OT787), OSi(T788)(T789)(T790), OS(O2)T791, NHC(O)T792, NT793C(O)T794, NHC(O)OT795, NHC(O)NHT796, NHC(O)NT797T798, NT799C(O)OT800, NT801C(O)NHT802, NT803C(O)NT804T805, NHS(O2)T806, NT807S(O2)T808, ST809, S(O)T810, S(O2)T811, S(O2)NHT812, S(O2)NT813T814, S(O2)OT815, P(O)(OT816)(OT817), Si(T818)(T819)(T820)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT769, NT770T771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T772, C (O) OT773, C (O) NHT774, C (O) NT775T776, OT777, O (T778-O) f H (f = 1, 2, 3, 4, 5), O (T779-O) f T780 (f = 1, 2, 3, 4, 5), OC (O) T781, OC (O) OT782, OC (O) NHT783 , OC (O) NT784T785, OP (O) (OT786) (OT787), OSi (T788) (T789) (T790), OS (O 2 ) T791, NHC (O) T792, NT793C (O) T794, NHC ( O) OT795, NHC (O) NHT796, NHC (O) NT797T798, NT799C (O) OT800, NT801C (O) NHT802, NT803C (O) NT804T805, NHS (O2) T806, NT807S (O2) T808, ST809, S ( O) T810, S (O 2 ) T811, S (O 2 ) NHT812, S (O 2 ) NT813T814, S (O 2 ) OT815, P (O) (OT816) (OT817), Si (T818) (T819) (T820) "

여기서, T769, T770, T771, T772, T773, T774, T775, T776, T777, T778, T779, T780, T781,T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812, T813, T814, T815, T816, T817, T818, T819, T820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T775, T776 및/또는 T784, T785 및/또는 T797, T798 및/또는 T804, T805 및/또는 T813, T814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T769, T770, T771, T772, T773, T774, T775, T776, T777, T778, T779, T780, T781, T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812, T813, T814, T815, T816, T817, T818, T819, T820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T775, T776 and / or T784, T785 and / or T797, T798 and / or T804, T805 and / or T813, T814 are also in each case" heterocycle. " Reels ",

(2) "C(Y5)NZ33Y6Z34"(2) "C (Y5) NZ33Y6Z34"

여기서, Y5, Y6은 각각 독립적으로 "O, S, =NH, =NZ35"로 이루어진 그룹으로부터 선택되고,Wherein Y5 and Y6 are each independently selected from the group consisting of "O, S, = NH, = NZ35",

여기서, Z33, Z34, Z35는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z33, Z34, Z35 are each independently selected from the group consisting of:

(I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cyclo Alkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocycle Reel, S (O 2 ) heterocyclylalkyl "

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT821, NT822T823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T824, C(O)OT825, C(O)NHT826, C(O)NT827T828, OT829, O(T830-O)gH (g = 1, 2, 3, 4, 5), O(T831-O)gT832 (g = 1, 2, 3, 4, 5), OC(O)T833, OC(O)OT834, OC(O)NHT835, OC(O)NT836T837, OP(O)(OT838)(OT839), OSi(T840)(T814)(T842), OS(O2)T843, NHC(O)T844, NT845C(O)T846, NHC(O)OT847, NHC(O)NHT848, NHC(O)NT849T850, NT851C(O)OT852, NT853C(O)NHT854, NT855C(O)NT856T857, NHS(O2)T858, NT859S(O2)T860, ST861, S(O)T862, S(O2)T863, S(O2)NHT864, S(O2)NT865T866, S(O2)OT867, P(O)(OT868)(OT869), Si(T870)(T871)(T872)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT821, NT822T823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T824, C (O) OT825, C (O) NHT826, C (O) NT827T828, OT829, O (T830-O) g H (g = 1, 2, 3, 4, 5), O (T831-O) g T832 (g = 1, 2, 3, 4, 5), OC (O) T833, OC (O) OT834, OC (O) NHT835 , OC (O) NT836T837, OP (O) (OT838) (OT839), OSi (T840) (T814) (T842), OS (O 2 ) T843, NHC (O) T844, NT845C (O) T846, NHC ( O) OT847, NHC (O) NHT848, NHC (O) NT849T850, NT851C (O) OT852, NT853C (O) NHT854, NT855C (O) NT856T857, NHS (O2) T858, NT859S (O2) T860, ST861, S ( O) T862, S (O 2 ) T863, S (O 2 ) NHT864, S (O 2 ) NT865T866, S (O 2 ) OT867, P (O) (OT868) (OT869), Si (T870) (T871) (T872) "

여기서, T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845, T846, T847, T848, T849, T850,T851, T852, T853, T854, T855, T856, T857, T858, T859, T860, T861, T862, T863, T864, T865, T866, T867, T868, T869, T870, T871, T872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T827, T828 및/또는 T836, T837 및/또는 T849, T850 및/또는 T856, T857 및/또는 T865, T866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845, T846, T847, T848, T849, T850, T851, T852, T853, T854, T855, T856, T857, T858, T859, T860, T861, T862, T863, T864, T865, T866, T867, T868, T869, T870, T871, T872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T827, T828 and / or T836, T837 and / or T849, T850 and / or T856, T857 and / or T865, T866 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT873, NT874T875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T876, C(O)OT877, C(O)NHT878, C(O)NT879T880, OT881, O(T882-O)hH (h = 1, 2, 3, 4, 5), O(T883-O)hT884 (h = 1, 2, 3, 4, 5), OC(O)T885, OC(O)OT886, OC(O)NHT887, OC(O)NT888T889, OP(O)(OT890)(OT891), OSi(T892)(T893)(T894), OS(O2)T895, NHC(O)T896, NT897C(O)T898, NHC(O)OT899, NHC(O)NHT900, NHC(O)NT901T902, NT903C(O)OT904, NT905C(O)NHT906, NT907C(O)NT908T909, NHS(O2)T910, NT911S(O2)T912, ST913, S(O)T914, S(O2)T915, S(O2)NHT916, S(O2)NT917T918, S(O2)OT919, P(O)(OT920)(OT921), Si(T922)(T923)(T924)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT873, NT874T875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T876, C (O) OT877, C (O) NHT878, C (O) NT879T880, OT881, O (T882-O) h H (h = 1, 2, 3, 4, 5), O (T883-O) h T884 (h = 1, 2, 3, 4, 5), OC (O) T885, OC (O) OT886, OC (O) NHT887 , OC (O) NT888T889, OP (O) (OT890) (OT891), OSi (T892) (T893) (T894), OS (O 2 ) T895, NHC (O) T896, NT897C (O) T898, NHC ( O) OT899, NHC (O) NHT900, NHC (O) NT901T902, NT903C (O) OT904, NT905C (O) NHT906, NT907C (O) NT908T909, NHS (O2) T910, NT911S (O2) T912, ST913, S ( O) T914, S (O 2 ) T915, S (O 2 ) NHT916, S (O 2 ) NT917T918, S (O 2 ) OT919, P (O) (OT920) (OT921), Si (T922) (T923) (T924) "

여기서, T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897, T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916, T917, T918, T919, T920, T921, T922, T923, T924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T879, T880 및/또는 T888, T889 및/또는 T901, T902 및/또는 T908, T909 및/또는 T917, T918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897, T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916, T917, T918, T919, T920, T921, T922, T923, T924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T879, T880 and / or T888, T889 and / or T901, T902 and / or T908, T909 and / or T917, T918 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT925, NT926T927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T928, C(O)OT929, C(O)NHT930, C(O)NT931T932, OT933, O(T934-O)iH (i = 1, 2, 3, 4, 5), O(T935-O)iT936 (i = 1, 2, 3, 4, 5), OC(O)T937, OC(O)OT938, OC(O)NHT939, OC(O)NT940T941, OP(O)(OT942)(OT943), OSi(T944)(T945)(T946), OS(O2)T947, NHC(O)T948, NT949C(O)T950, NHC(O)OT951, NHC(O)NHT952, NHC(O)NT953T954, NT955C(O)OT956, NT957C(O)NHT958, NT959C(O)NT960T961, NHS(O2)T962, NT963S(O2)T964, ST965, S(O)T966, S(O2)T967, S(O2)NHT968, S(O2)NT969T970, S(O2)OT971, P(O)(OT972)(OT973), Si(T974)(T975)(T976)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT925, NT926T927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T928, C (O) OT929, C (O) NHT930, C (O) NT931T932, OT933, O (T934-O) i H (i = 1, 2, 3, 4, 5), O (T935-O) i T936 (i = 1, 2, 3, 4, 5), OC (O) T937, OC (O) OT938, OC (O) NHT939 , OC (O) NT940T941, OP (O) (OT942) (OT943), OSi (T944) (T945) (T946), OS (O 2 ) T947, NHC (O) T948, NT949C (O) T950, NHC ( O) OT951, NHC (O) NHT952, NHC (O) NT953T954, NT955C (O) OT956, NT957C (O) NHT958, NT959C (O) NT960T961, NHS (O2) T962, NT963S (O2) T964, ST965, S ( O) T966, S (O 2 ) T967, S (O 2 ) NHT968, S (O 2 ) NT969T970, S (O 2 ) OT971, P (O) (OT972) (OT973), Si (T974) (T975) (T976) "

여기서, T925, T926, T927, T928, T929, T930, T931, T932,T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968, T969, T970, T971, T972, T973, T974, T975, T976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T931, T932 및/또는 T940, T941 및/또는 T953, T954 및/또는 T960, T961 및/또는 T969, T970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T925, T926, T927, T928, T929, T930, T931, T932, T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968, T969, T970, T971, T972, T973, T974, T975, T976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T931, T932 and / or T940, T941 and / or T953, T954 and / or T960, T961 and / or T969, T970 are also in each case" heterocycle Reels ",

Z26, Z27 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z26, Z27 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z26, Z27 radicals is independently selected from the group consisting of, or neither of the Z26, Z27 radicals is independently selected from the group consisting of:

(2) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, C(Y7)NZ36Z37, C(=NZ38)Z39, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(2) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, C (Y7) NZ36Z37, C (= NZ38) Z39, S (O 2 ) alkyl, S (O 2 ) ( C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S ( O 2 ) heteroarylalkyl, S (O 2 ) heterocyclyl, S (O 2 ) heterocyclylalkyl "

여기서, Y7은 독립적으로 "O, S, =NH, =NZ40"으로 이루어진 그룹으로부터 선택되고,Wherein Y7 is independently selected from the group consisting of "O, S, = NH, = NZ40",

여기서, Z36, Z37, Z38, Z39, Z40 라디칼은 각각 독립적으로 다음으로 이루 어진 그룹으로부터 선택되고:Wherein the Z36, Z37, Z38, Z39, Z40 radicals are each independently selected from the group consisting of:

(I) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(I) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl, C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O ) Heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocyclyl, S (O 2 ) heterocyclylalkyl "

여기서, 임의로, 치환체 그룹(3) 및/또는 치환체 그룹(I)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (3) and / or substituent group (I) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT977, NT978T979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T980, C(O)OT981, C(O)NHT982, C(O)NT983T984, OT985, O(T986-O)jH (j = 1, 2, 3, 4, 5), O(T987-O)jT988 (j = 1, 2, 3, 4, 5), OC(O)T989, OC(O)OT990, OC(O)NHT991, OC(O)NT992T993, OP(O)(OT994)(OT995), OSi(T996)(T997)(T998), OS(O2)T999, NHC(O)T1000, NT1001C(O)T1002, NHC(O)OT1003, NHC(O)NHT1004, NHC(O)NT1005T1006, NT1007C(O)OT1008, NT1009C(O)NHT1010, NT1011C(O)NT1012T1013, NHS(O2)T1014, NT1015S(O2)T1016, ST1017, S(O)T1018, S(O2)T1019, S(O2)NHT1020, S(O2)NT1021T1022, S(O2)OT1023, P(O)(OT1024)(OT1025), Si(T1026)(T1027)(T1028)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT977, NT978T979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T980, C (O) OT981, C (O) NHT982, C (O) NT983T984, OT985, O (T986-O) j H (j = 1, 2, 3, 4, 5), O (T987-O) j T988 (j = 1, 2, 3, 4, 5), OC (O) T989, OC (O) OT990, OC (O) NHT991 , OC (O) NT992T993, OP (O) (OT994) (OT995), OSi (T996) (T997) (T998), OS (O 2 ) T999, NHC (O) T1000, NT1001C (O) T1002, NHC ( O) OT1003, NHC (O) NHT1004, NHC (O) NT1005T1006, NT1007C (O) OT1008, NT1009C (O) NHT1010, NT1011C (O) NT1012T1013, NHS (O2) T1014, NT1015S (O2) T1016, ST1017, S ( O) T1018, S (O 2 ) T1019, S (O 2 ) NHT1020, S (O 2 ) NT1021T1022, S (O 2 ) OT1023, P (O) (OT1024) (OT1025), Si (T1026) (T1027) (T1028) "

여기서, T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004, T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T983, T984 및/또는 T992, T993 및/또는 T1005, T1006 및/또는 T1012, T1013 및/또는 T1021, T1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004, T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025 T1026, T1027, T1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021, T1022 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1029, NT1030T1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1032, C(O)OT1033, C(O)NHT1034, C(O)NT1035T1036, OT1037, O(T1038-O)kH (k = 1, 2, 3, 4, 5), O(T1039-O)kT1040 (k = 1, 2, 3, 4, 5), OC(O)T1041, OC(O)OT1042, OC(O)NHT1043, OC(O)NT1044T1045, OP(O)(OT1046)(OT1047), OSi(T1048)(T1049)(T1050), OS(O2)T1051, NHC(O)T1052, NT1053C(O)T1054, NHC(O)OT1055, NHC(O)NHT1056, NHC(O)NT1057T1058, NT1059C(O)OT1060, NT1061C(O)NHT1062, NT1063C(O)NT1064T1065, NHS(O2)T1066, NT1067S(O2)T1068, ST1069, S(O)T1070, S(O2)T1071, S(O2)NHT1072, S(O2)NT1073T1074, S(O2)OT1075, P(O)(OT1076)(OT1077), Si(T1078)(T1079)(T1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1029, NT1030T1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1032, C (O) OT1033, C (O) NHT1034, C (O) NT1035T1036, OT1037, O (T1038-O) k H (k = 1, 2, 3, 4, 5), O (T1039-O) k T1040 (k = 1, 2, 3, 4, 5), OC (O) T1041, OC (O) OT1042, OC (O) NHT1043 , OC (O) NT1044T1045, OP (O) (OT1046) (OT1047), OSi (T1048) (T1049) (T1050), OS (O 2 ) T1051, NHC (O) T1052, NT1053C (O) T1054, NHC ( O) OT1055, NHC (O) NHT1056, NHC (O) NT1057T1058, NT1059C (O) OT1060, NT1061C (O) NHT1062, NT1063C (O) NT1064T1065, NHS (O2) T1066, NT1067S (O2) T1068, ST1069, S ( O) T1070, S (O 2 ) T1071, S (O 2 ) NHT1072, S (O 2 ) NT1073T1074, S (O 2 ) OT1075, P (O) (OT1076) (OT1077), Si (T1078) (T1079) (T1080) "

여기서, T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059, T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알 킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1035, T1036 및/또는 T1044, T1045 및/또는 T1057, T1058 및/또는 T1064, T1065 및/또는 T1073, T1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059, T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1077 T1078, T1079, T1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", where, alternatively, T1035, T1036 and / or T1044, T1045 and / or T1057, T1058 and / or T1064, T1065 and / or T1073, T1074 are also in each case" hetero " Cyclyl ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1081, NT1082T1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1084, C(O)OT1085, C(O)NHT1086, C(O)NT1087T1088, OT1089, O(T1090-O)lH (l = 1, 2, 3, 4, 5), O(T1091-O)lT1092 (l = 1, 2, 3, 4, 5), OC(O)T1093, OC(O)OT1094, OC(O)NHT1095, OC(O)NT1096T1097, OP(O)(OT1098)(OT1099), OSi(T1100)(T1101)(T1102), OS(O2)T1103, NHC(O)T1104, NT1105C(O)T1106, NHC(O)OT1107, NHC(O)NHT1108, NHC(O)NT1109T1110, NT1111C(O)OT1112, NT1113C(O)NHT1114, NT1115C(O)NT1116T1117, NHS(O2)T1118, NT1119S(O2)T1120, ST1121, S(O)T1122, S(O2)T1123, S(O2)NHT1124, S(O2)NT1125T1126, S(O2)OT1127, P(O)(OT1128)(OT1129), Si(T1130)(T1131)(T1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1081, NT1082T1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1084, C (O) OT1085, C (O) NHT1086, C (O) NT1087T1088, OT1089, O (T1090-O) l H (l = 1, 2, 3, 4, 5), O (T1091-O) l T1092 (l = 1, 2, 3, 4, 5), OC (O) T1093, OC (O) OT1094, OC (O) NHT1095 , OC (O) NT1096T1097, OP (O) (OT1098) (OT1099), OSi (T1100) (T1101) (T1102), OS (O 2 ) T1103, NHC (O) T1104, NT1105C (O) T1106, NHC ( O) OT1107, NHC (O) NHT1108, NHC (O) NT1109T1110, NT1111C (O) OT1112, NT1113C (O) NHT1114, NT1115C (O) NT1116T1117, NHS (O2) T1118, NT1119S (O2) T1120, ST1121, S ( O) T1122, S (O 2 ) T1123, S (O 2 ) NHT1124, S (O 2 ) NT1125T1126, S (O 2 ) OT1127, P (O) (OT1128) (OT1129), Si (T1130) (T1131) (T1132) "

여기서, T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095, T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103, T1104, T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122, T1123, T1124, T1125, T1126, T1127, T1128, T1129, T1130, T1131, T1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1087, T1088 및/또는 T1096, T1097 및/또는 T1109, T1110 및/또는 T1116, T1117 및/또는 T1125, T1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095, T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103, T1104 T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122, T1123, T1124, T1125, T1126, T1127, T1128, 29 T1130, T1131, T1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1087, T1088 and / or T1096, T1097 and / or T1109, T1110 and / or T1116, T1117 and / or T1125, T1126 are also in each case a" heterocycle Reels ",

Z1, Z2 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z1, Z2 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z1, Z2 radicals is independently selected from the group consisting of, or neither of the Z1, Z2 radicals is independently selected from the group consisting of:

(c) 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1133, NT1134T1135, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1136, C(O)OT1137, C(O)NHT1138, C(O)NT1139T1140, OT1141, O(T1142-O)mH (m = 1, 2, 3, 4, 5), O(T1143-O)mT1144 (m = 1, 2, 3, 4, 5), OC(O)T1145, OC(O)OT1146, OC(O)NHT1147, OC(O)NT1148T1149, OP(O)(OT1150)(OT1151), OSi(T1152)(T1153)(T1154), OS(O2)T1155, NHC(O)T1156, NT1157C(O)T1158, NHC(O)OT1159, NHC(O)NHT1160, NHC(O)NT1161T1162, NT1163C(O)OT1164, NT1165C(O)NHT1166, NT1167C(O)NT1168T1169, NHS(O2)T1170, NT1171S(O2)T1172, ST1173, S(O)T1174, S(O2)T1175, S(O2)NHT1176, S(O2)NT1177T1178, S(O2)OT1179, P(O)(OT1180)(OT1181), Si(T1182)(T1183)(T1184)"(c) hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , NHT1133, NT1134T1135, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1136, C (O) OT1137, C (O) NHT1138, C (O) NT1139T1140, OT1141, O (T1142-O) m H (m = 1, 2, 3, 4, 5), O (T1143-O) m T1144 (m = 1, 2, 3, 4, 5), OC (O) T1145, OC (O) OT1146, OC (O) NHT1147, OC (O) NT1148T1149, OP (O) (OT1150) (OT1151), OSi (T1152) (T1153) (T1154), OS (O 2 ) T1155, NHC (O) T1156, NT1157C (O) T1158, NHC (O) OT1159, NHC (O) NHT1160, NHC (O) NT1161T1162, NT1163C (O) OT1164, NT1165C (O) NHT1166, NT1167C (O) NT1168T1169, NHS (O2) T1170, NT1171S (O2) T1172, ST1173, S (O) T1174, S (O 2 ) T1175, S (O 2 ) NHT1176, S (O 2 ) NT1177T1178, S (O 2 ) OT1179, P (O) (OT1180) (OT1181), Si (T1182) (T1183 ) (T1184) "

여기서, T1133, T1134, T1135, T1136, T1137, T1138, T1139, T1140, T1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149, T1150, T1151, T1152, T1153, T1154, T1155, T1156, T1157, T1158, T1159, T1160, T1161, T1162, T1163, T1164, T1165, T1166, T1167, T1168, T1169, T1170, T1171, T1172, T1173, T1174, T1175, T1176, T1177, T1178, T1179, T1180, T1181, T1182, T1183, T1184는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1139, T1140 및/또는 T1148, T1149 및/또는 T1161, T1162 및/또는 T1168, T1169 및/또는 T1177, T1178은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1133, T1134, T1135, T1136, T1137, T1138, T1139, T1140, T1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149, T1150, T1151, T1152, T1153, T1154, T1155, T1156, T1156, T1157, T1158, T1159, T1160, T1161, T1162, T1163, T1164, T1165, T1166, T1167, T1168, T1169, T1170, T1171, T1172, T1173, T1174, T1175, T1176, T1177, T1178, T1179, T1180, T118 T1182, T1183, T1184 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1139, T1140 and / or T1148, T1149 and / or T1161, T1162 and / or T1168, T1169 and / or T1177, T1178 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 추가로 치환될 수 있고:Wherein optionally, the aforementioned substituents of substituent group (c) may each be further substituted by one or more substituents, each independently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1185, NT1186T1187, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1188, C(O)OT1189, C(O)NHT1190, C(O)NT1191T1192, OT1193, O(T1194-O)nH (n = 1, 2, 3, 4, 5), O(T1195-O)nT1196 (n = 1, 2, 3, 4, 5), OC(O)T1197, OC(O)OT1198, OC(O)NHT1199, OC(O)NT1200T1201, OP(O)(OT1202)(OT1203), OSi(T1204)(T1205)(T1206), OS(O2)T1207, NHC(O)T1208, NT1209C(O)T1210, NHC(O)OT1211, NHC(O)NHT1212, NHC(O)NT1213T1214, NT1215C(O)OT1216, NT1217C(O)NHT1218, NT1219C(O)NT1220T1221, NHS(O2)T1222, NT1223S(O2)T1224, ST1225, S(O)T1226, S(O2)T1227, S(O2)NHT1228, S(O2)NT1229T1230, S(O2)OT1231, P(O)(OT1232)(OT1233), Si(T1234)(T1235)(T1236)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1185, NT1186T1187, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1188, C (O) OT1189, C (O) NHT1190, C (O) NT1191T1192, OT1193, O (T1194-O) nH (n = 1 , 2, 3, 4, 5), O (T1195-O) nT1196 (n = 1, 2, 3, 4, 5), OC (O) T1197, OC (O) OT1198, OC (O) NHT1199, OC (O) NT1200T1201, OP (O) (OT1202) (OT1203), OSi (T1204) (T1205) (T1206), OS (O 2 ) T1207, NHC (O) T1208, NT1209C (O) T1210, NHC (O) OT1211, NHC (O) NHT1212, NHC (O) NT1213T1214, NT1215C (O) OT1216, NT1217C (O) NHT1218, NT1219C (O) NT1220T1221, NHS (O2) T1222, NT1223S (O2) T1224, ST1225, S (O) T1226, S (O 2 ) T1227, S (O 2 ) NHT1228, S (O 2 ) NT1229T1230, S (O 2 ) OT1231, P (O) (OT1232) (OT1233), Si (T1234) (T1235) (T1236 ) "

여기서, T1185, T1186, T1187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1233, T1234, T1235, T1236은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이 클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1191, T1192 및/또는 T1200, T1201 및/또는 T1213, T1214 및/또는 T1220, T1221 및/또는 T1229, T1230은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1185, T1186, T1187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1232, T1232, T1234, T1235, T1236 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1191, T1192 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 are also in each case" hetero Cyclyl ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1237, NT1238T1239, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1240, C(O)OT1241, C(O)NHT1242, C(O)NT1243T1244, OT1245, O(T1246-O)oH (o = 1, 2, 3, 4, 5), O(T1247-O)oT1248 (o = 1, 2, 3, 4, 5), OC(O)T1249, OC(O)OT1250, OC(O)NHT1251, OC(O)NT1252T1253, OP(O)(OT1254)(OT1255), OSi(T1256)(T1257)(T1258), OS(O2)T1259, NHC(O)T1260, NT1261C(O)T1262, NHC(O)OT1263, NHC(O)NHT1264, NHC(O)NT1265T1266, NT1267C(O)OT1268, NT1269C(O)NHT1270, NT1271C(O)NT1272T1273, NHS(O2)T1274, NT1275S(O2)T1276, ST1277, S(O)T1278, S(O2)T1279, S(O2)NHT1280, S(O2)NT1281T1282, S(O2)OT1283, P(O)(OT1284)(OT1285), Si(T1286)(T1287)(T1288)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1237, NT1238T1239, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1240, C (O) OT1241, C (O) NHT1242, C (O) NT1243T1244, OT1245, O (T1246-O) oH (o = 1 , 2, 3, 4, 5), O (T1247-O) oT1248 (o = 1, 2, 3, 4, 5), OC (O) T1249, OC (O) OT1250, OC (O) NHT1251, OC (O) NT1252T1253, OP (O) (OT1254) (OT1255), OSi (T1256) (T1257) (T1258), OS (O 2 ) T1259, NHC (O) T1260, NT1261C (O) T1262, NHC (O) OT1263, NHC (O) NHT1264, NHC (O) NT1265T1266, NT1267C (O) OT1268, NT1269C (O) NHT1270, NT1271C (O) NT1272T1273, NHS (O2) T1274, NT1275S (O2) T1276, ST1277, S (O) T1278, S (O 2 ) T1279, S (O 2 ) NHT1280, S (O 2 ) NT1281T1282, S (O 2 ) OT1283, P (O) (OT1284) (OT1285), Si (T1286) (T1287) (T1288 ) "

여기서, T1237, T1238, T1239, T1240, T1241, T1242,T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260, T1261, T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1243, T1244 및/또는 T1252, T1253 및/또는 T1265, T1266 및/또는 T1272, T1273 및/또는 T1281, T1282는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260 T1261, T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1284, T1284, T1284 T1286, T1287, T1288 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 are also in each case" heterocycle Reels ",

(d) NZ41Z42 여기서, Z41, Z42 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(d) NZ41Z42 wherein the Z41 and Z42 radicals are each independently selected from the group consisting of:

(1) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬"(1) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl, C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O Heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl "

여기서, 임의로, 치환체 그룹(1)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (1) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1289, NT1290T1291, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1292, C(O)OT1293, C(O)NHT1294, C(O)NT1295T1296, OT1297, O(T1298-O)rrH (rr = 1, 2, 3, 4, 5), O(T1299-O)rrT1300 (rr = 1, 2, 3, 4, 5), OC(O)T1301, OC(O)OT1302, OC(O)NHT1303, OC(O)NT1304T1305, OP(O)(OT1306)(OT1307), OSi(T1308)(T1309)(T1310), OS(O2)T1311, NHC(O)T1312, NT1313C(O)T1314, NHC(O)OT1315, NHC(O)NHT1316, NHC(O)NT1317T1318, NT1319C(O)OT1320, NT1321C(O)NHT1322, NT1323C(O)NT1324T1325, NHS(O2)T1326, NT1327S(O2)T1328, ST1329, S(O)T1330, S(O2)T1331, S(O2)NHT1332, S(O2)NT1333T1334, S(O2)OT1335, P(O)(OT1336)(OT1337), Si(T1338)(T1339)(T1340)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1289, NT1290T1291, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1292, C (O) OT1293, C (O) NHT1294, C (O) NT1295T1296, OT1297, O (T1298-O) rr H (rr = 1, 2, 3, 4, 5), O (T1299-O) rr T1300 (rr = 1, 2, 3, 4, 5), OC (O) T1301, OC (O) OT1302, OC (O) NHT1303 , OC (O) NT1304T1305, OP (O) (OT1306) (OT1307), OSi (T1308) (T1309) (T1310), OS (O 2 ) T1311, NHC (O) T1312, NT1313C (O) T1314, NHC ( O) OT1315, NHC (O) NHT1316, NHC (O) NT1317T1318, NT1319C (O) OT1320, NT1321C (O) NHT1322, NT1323C (O) NT1324T1325, NHS (O2) T1326, NT1327S (O2) T1328, ST1329, S ( O) T1330, S (O 2 ) T1331, S (O 2 ) NHT1332, S (O 2 ) NT1333T1334, S (O 2 ) OT1335, P (O) (OT1336) (OT1337), Si (T1338) (T1339) (T1340) "

여기서, T1289, T1290, T1291, T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1295, T1296 및/또는 T1304, T1305 및/또는 T1317, T1318 및/또는 T1324, T1325 및/또는 T1333, T1334는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1289, T1290, T1291, T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1311, T1311 T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1336, T1338, T1339, T1340 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and / or T1333, T1334 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1341, NT1342T1343, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1344, C(O)OT1345, C(O)NHT1346, C(O)NT1347T1348, OT1349, O(T1350-O)rsH (rs = 1, 2, 3, 4, 5), O(T1351-O)rsT1352 (rs = 1, 2, 3, 4, 5), OC(O)T1353, OC(O)OT1354, OC(O)NHT1355, OC(O)NT1356T1357, OP(O)(OT1358)(OT1359), OSi(T1360)(T1361)(T1362), OS(O2)T1363, NHC(O)T1364, NT1365C(O)T1366, NHC(O)OT1367, NHC(O)NHT1368, NHC(O)NT1369T1370, NT1371C(O)OT1372, NT1373C(O)NHT1374, NT1375C(O)NT1376T1377, NHS(O2)T1378, NT1379S(O2)T1380, ST1381, S(O)T1382, S(O2)T1383, S(O2)NHT1384, S(O2)NT1385T1386, S(O2)OT1387, P(O)(OT1388)(OT1389), Si(T1390)(T1391)(T1392)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1341, NT1342T1343, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1344, C (O) OT1345, C (O) NHT1346, C (O) NT1347T1348, OT1349, O (T1350-O) rs H (rs = 1, 2, 3, 4, 5), O (T1351-O) rs T1352 (rs = 1, 2, 3, 4, 5), OC (O) T1353, OC (O) OT1354, OC (O) NHT1355 , OC (O) NT1356T1357, OP (O) (OT1358) (OT1359), OSi (T1360) (T1361) (T1362), OS (O 2 ) T1363, NHC (O) T1364, NT1365C (O) T1366, NHC ( O) OT1367, NHC (O) NHT1368, NHC (O) NT1369T1370, NT1371C (O) OT1372, NT1373C (O) NHT1374, NT1375C (O) NT1376T1377, NHS (O2) T1378, NT1379S (O2) T1380, ST1381, S ( O) T1382, S (O 2 ) T1383, S (O 2 ) NHT1384, S (O 2 ) NT1385T1386, S (O 2 ) OT1387, P (O) (OT1388) (OT1389), Si (T1390) (T1391) (T1392) "

여기서, T1341, T1342, T1343, T1344, T1345, T1346, T1347, T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389, T1390, T1391, T1392는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1347, T1348 및/또는 T1356, T1357 및/또는 T1369, T1370 및/또는 T1376, T1377 및/또는 T1385, T1386은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1341, T1342, T1343, T1344, T1345, T1346, T1347, T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389 T1390, T1391, T1392 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1347, T1348 and / or T1356, T1357 and / or T1369, T1370 and / or T1376, T1377 and / or T1385, T1386 are also in each case a" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1393, NT1394T1395, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1396, C(O)OT1397, C(O)NHT1398, C(O)NT1399T1400, OT1401, O(T1402-O)rtH (rt = 1, 2, 3, 4, 5), O(T1403-O)rtT1404 (rt = 1, 2, 3, 4, 5), OC(O)T1405, OC(O)OT1406, OC(O)NHT1407, OC(O)NT1408T1409, OP(O)(OT1410)(OT1411), OSi(T1412)(T1413)(T1414), OS(O2)T1415, NHC(O)T1416, NT1417C(O)T1418, NHC(O)OT1419, NHC(O)NHT1420, NHC(O)NT1421T1422, NT1423C(O)OT1424, NT1425C(O)NHT1426, NT1427C(O)NT1428T1429, NHS(O2)T1430, NT1431S(O2)T1432, ST1433, S(O)T1434, S(O2)T1435, S(O2)NHT1436, S(O2)NT1437T1438, S(O2)OT1439, P(O)(OT1440)(OT1441), Si(T1442)(T1443)(T1444)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1393, NT1394T1395, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1396, C (O) OT1397, C (O) NHT1398, C (O) NT1399T1400, OT1401, O (T1402-O) rt H (rt = 1, 2, 3, 4, 5), O (T1403-O) rt T1404 (rt = 1, 2, 3, 4, 5), OC (O) T1405, OC (O) OT1406, OC (O) NHT1407 , OC (O) NT1408T1409, OP (O) (OT1410) (OT1411), OSi (T1412) (T1413) (T1414), OS (O 2 ) T1415, NHC (O) T1416, NT1417C (O) T1418, NHC ( O) OT1419, NHC (O) NHT1420, NHC (O) NT1421T1422, NT1423C (O) OT1424, NT1425C (O) NHT1426, NT1427C (O) NT1428T1429, NHS (O2) T1430, NT1431S (O2) T1432, ST1433, S ( O) T1434, S (O 2 ) T1435, S (O 2 ) NHT1436, S (O 2 ) NT1437T1438, S (O 2 ) OT1439, P (O) (OT1440) (OT1441), Si (T1442) (T1443) (T1444) "

여기서, T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431, T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1399, T1400 및/또는 T1408, T1409 및/또는 T1421, T1422 및/또는 T1428, T1429 및/또는 T1437, T1438은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1416, T1416 T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431, T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1440 T1442, T1443, T1444 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 are also in each case a" heterocycle. " Reels ",

(2) "C(O)C(O)T1445, S(O2)NT1446T1447"(2) "C (O) C (O) T1445, S (O 2 ) NT1446T1447"

여기서, T1445, T1446, T1447은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein T1445, T1446, T1447 are each independently selected from the group consisting of:

(I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1448, NT1449T1450, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1451, C(O)OT1452, C(O)NHT1453, C(O)NT1454T1455, OT1456, O(T1457-O)ruH (ru = 1, 2, 3, 4, 5), O(T1458-O)ruT1459 (ru = 1, 2, 3, 4, 5), OC(O)T1460, OC(O)OT1461, OC(O)NHT1462, OC(O)NT1463T1464, OP(O)(OT1465)(OT1466), OSi(T1467)(T1468)(T1469), OS(O2)T1470, NHC(O)T1471, NT1472C(O)T1473, NHC(O)OT1474, NHC(O)NHT1475, NHC(O)NT1476T1477, NT1478C(O)OT1479, NT1480C(O)NHT1481, NT1482C(O)NT1483T1484, NHS(O2)T1485, NT1486S(O2)T1487, ST1488, S(O)T1489, S(O2)T1490, S(O2)NHT1491, S(O2)NT1492T1493, S(O2)OT1494, P(O)(OT1495)(OT1496), Si(T1497)(T1498)(T1499)"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHT1448, NT1449T1450, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1451, C (O) OT1452, C (O) NHT1453, C (O) NT1454T1455, OT1456, O (T1457-O) ru H ( ru = 1, 2, 3, 4, 5), O (T1458-O) ru T1459 (ru = 1, 2, 3, 4, 5), OC (O) T1460, OC (O) OT1461, OC (O NHT1462, OC (O) NT1463T1464, OP (O) (OT1465) (OT1466), OSi (T1467) (T1468) (T1469), OS (O 2 ) T1470, NHC (O) T1471, NT1472C (O) T1473, NHC (O) OT1474, NHC (O) NHT1475, NHC (O) NT1476T1477, NT1478C (O) OT1479, NT1480C (O) NHT1481, NT1482C (O) NT1483T1484, NHS (O2) T1485, NT1486S (O2) T1487, ST1488, S (O) T1489, S (O 2 ) T1490, S (O 2 ) NHT1491, S (O 2 ) NT1492T1493, S (O 2 ) OT1494, P (O) (OT1495) (OT1496), Si (T1497) ( T1498) (T1499) "

여기서, T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1496, T1497, T1498, T1499는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1454, T1455 및/또는 T1463, T1464 및/또는 T1476, T1477 및/또는 T1483, T1484 및/또는 T1492, T1493은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1495, T1495, T1495 T1497, T1498, T1499 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1454, T1455 and / or T1463, T1464 and / or T1476, T1477 and / or T1483, T1484 and / or T1492, T1493 are also in each case a" heterocycle Reels ",

여기서, 임의로, 치환 그룹(I)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1500, NT1501T1502, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1503, C(O)OT1504, C(O)NHT1505, C(O)NT1506T1507, OT1508, O(T1509-O)rvH (rv = 1, 2, 3, 4, 5), O(T1510-O)rvT1511 (rv = 1, 2, 3, 4, 5), OC(O)T1512, OC(O)OT1513, OC(O)NHT1514, OC(O)NT1515T1516, OP(O)(OT1517)(OT1518), OSi(T1519)(T1520)(T1521), OS(O2)T1522, NHC(O)T1523, NT1524C(O)T1525, NHC(O)OT1526, NHC(O)NHT1527, NHC(O)NT1528T1529, NT1530C(O)OT1531, NT1532C(O)NHT1533, NT1534C(O)NT1535T1536, NHS(O2)T1537, NT1538S(O2)T1539, ST1540, S(O)T1541, S(O2)T1542, S(O2)NHT1543, S(O2)NT1544T1545, S(O2)OT1546, P(O)(OT1547)(OT1548), Si(T1549)(T1550)(T1551)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1500, NT1501T1502, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1503, C (O) OT1504, C (O) NHT1505, C (O) NT1506T1507, OT1508, O (T1509-O) rv H (rv = 1, 2, 3, 4, 5), O (T1510-O) rv T1511 (rv = 1, 2, 3, 4, 5), OC (O) T1512, OC (O) OT1513, OC (O) NHT1514 , OC (O) NT1515T1516, OP (O) (OT1517) (OT1518), OSi (T1519) (T1520) (T1521), OS (O 2 ) T1522, NHC (O) T1523, NT1524C (O) T1525, NHC ( O) OT1526, NHC (O) NHT1527, NHC (O) NT1528T1529, NT1530C (O) OT1531, NT1532C (O) NHT1533, NT1534C (O) NT1535T1536, NHS (O2) T1537, NT1538S (O2) T1539, ST1540, S ( O) T1541, S (O 2 ) T1542, S (O 2 ) NHT1543, S (O 2 ) NT1544T1545, S (O 2 ) OT1546, P (O) (OT1547) (OT1548), Si (T1549) (T1550) (T1551) "

여기서, T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522, T1523, T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, T1548, T1549, T1550, T1551은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1506, T1507 및/또는 T1515, T1516 및/또는 T1528, T1529 및/또는 T1535, T1536 및/또는 T1544, T1545는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where: T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522, T1523 T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, 1553 T1549, T1550, T1551 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1506, T1507 and / or T1515, T1516 and / or T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1552, NT1553T1554, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1555, C(O)OT1556, C(O)NHT1557, C(O)NT1558T1559, OT1560, O(T1561-O)rwH (rw = 1, 2, 3, 4, 5), O(T1562-O)rwT1563 (rw = 1, 2, 3, 4, 5), OC(O)T1564, OC(O)OT1565, OC(O)NHT1566, OC(O)NT1567T1568, OP(O)(OT1569)(OT1570), OSi(T1571)(T1572)(T1573), OS(O2)T1574, NHC(O)T1575, NT1576C(O)T1577, NHC(O)OT1578, NHC(O)NHT1579, NHC(O)NT1580T1581, NT1582C(O)OT1583, NT1584C(O)NHT1585, NT1586C(O)NT1587T1588, NHS(O2)T1589, NT1590S(O2)T1591, ST1592, S(O)T1593, S(O2)T1594, S(O2)NHT1595, S(O2)NT1596T1597, S(O2)OT1598, P(O)(OT1599)(OT1600), Si(T1601)(T1602)(T1603)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1552, NT1553T1554, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1555, C (O) OT1556, C (O) NHT1557, C (O) NT1558T1559, OT1560, O (T1561-O) rw H (rw = 1, 2, 3, 4, 5), O (T1562-O) rw T1563 (rw = 1, 2, 3, 4, 5), OC (O) T1564, OC (O) OT1565, OC (O) NHT1566 , OC (O) NT1567T1568, OP (O) (OT1569) (OT1570), OSi (T1571) (T1572) (T1573), OS (O 2 ) T1574, NHC (O) T1575, NT1576C (O) T1577, NHC ( O) OT1578, NHC (O) NHT1579, NHC (O) NT1580T1581, NT1582C (O) OT1583, NT1584C (O) NHT1585, NT1586C (O) NT1587T1588, NHS (O2) T1589, NT1590S (O2) T1591, ST1592, S ( O) T1593, S (O 2 ) T1594, S (O 2 ) NHT1595, S (O 2 ) NT1596T1597, S (O 2 ) OT1598, P (O) (OT1599) (OT1600), Si (T1601) (T1602) (T1603) "

여기서, T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575, T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1558, T1559 및/또는 T1567, T1568 및/또는 T1580, T1581 및/또는 T1587, T1588 및/또는 T1596, T1597은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575 T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1599, T1599 T1601, T1602, T1603 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1558, T1559 and / or T1567, T1568 and / or T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 are also in each case a" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1604, NT1605T1606, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1607, C(O)OT1608, C(O)NHT1609, C(O)NT1610T1611, OT1612, O(T1613-O)rxH (rx = 1, 2, 3, 4, 5), O(T1614-O)rxT1615 (rx = 1, 2, 3, 4, 5), OC(O)T1616, OC(O)OT1617, OC(O)NHT1618, OC(O)NT1619T1620, OP(O)(OT1621)(OT1622), OSi(T1623)(T1624)(T1625), OS(O2)T1626, NHC(O)T1627, NT1628C(O)T1629, NHC(O)OT1630, NHC(O)NHT1631, NHC(O)NT1632T1633, NT1634C(O)OT1635, NT1636C(O)NHT1637, NT1638C(O)NT1639T1640, NHS(O2)T1641, NT1642S(O2)T1643, ST1644, S(O)T1645, S(O2)T1646, S(O2)NHT1647, S(O2)NT1648T1649, S(O2)OT1650, P(O)(OT1651)(OT1652), Si(T1653)(T1654)(T1655)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1604, NT1605T1606, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1607, C (O) OT1608, C (O) NHT1609, C (O) NT1610T1611, OT1612, O (T1613-O) rx H (rx = 1, 2, 3, 4, 5), O (T1614-O) rx T1615 (rx = 1, 2, 3, 4, 5), OC (O) T1616, OC (O) OT1617, OC (O) NHT1618 , OC (O) NT1619T1620, OP (O) (OT1621) (OT1622), OSi (T1623) (T1624) (T1625), OS (O 2 ) T1626, NHC (O) T1627, NT1628C (O) T1629, NHC ( O) OT1630, NHC (O) NHT1631, NHC (O) NT1632T1633, NT1634C (O) OT1635, NT1636C (O) NHT1637, NT1638C (O) NT1639T1640, NHS (O2) T1641, NT1642S (O2) T1643, ST1644, S ( O) T1645, S (O 2 ) T1646, S (O 2 ) NHT1647, S (O 2 ) NT1648T1649, S (O 2 ) OT1650, P (O) (OT1651) (OT1652), Si (T1653) (T1654) (T1655) "

여기서, T1604, T1605, T1606, T1607, T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651, T1652, T1653, T1654, T1655는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1610, T1611 및/또는 T1619, T1620 및/또는 T1632, T1633 및/또는 T1639, T1640 및/또는 T1648, T1649는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고, 여기서, 대안적으로, T1446, T1447은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Where: T1604, T1605, T1606, T1607, T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627 T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651, 2165 T1653, T1654, T1655 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1610, T1611 and / or T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 are also in each case" heterocycle. " Reel ", where, alternatively, T1446, T1447 together may also form" heterocyclyl ",

(3) "C(Y8)NZ43Z44, C(=NZ45)Z46, C(Y9)NZ47Y10Z48"(3) "C (Y8) NZ43Z44, C (= NZ45) Z46, C (Y9) NZ47Y10Z48"

여기서, Y8, Y9, Y10은 각각 독립적으로 "O, S, =NH, =NZ49"로 이루어진 그룹으로부터 선택되고,Wherein Y8, Y9, Y10 are each independently selected from the group consisting of "O, S, = NH, = NZ49",

여기서, Z43, Z44, Z45, Z46, Z47, Z48, Z49 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein the Z43, Z44, Z45, Z46, Z47, Z48, Z49 radicals are each independently selected from the group consisting of:

(I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로 사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cyclo Alkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocycle Reel, S (O 2 ) heterocyclylalkyl "

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (i) may also be independently substituted by one or more substituents, each independently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1656, NT1657T1658, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1659, C(O)OT1660, C(O)NHT1661, C(O)NT1662T1663, OT1664, O(T1665-O)ryH (ry = 1, 2, 3, 4, 5), O(T1666-O)ryT1667 (ry = 1, 2, 3, 4, 5), OC(O)T1668, OC(O)OT1669, OC(O)NHT1670, OC(O)NT1671T1672, OP(O)(OT1673)(OT1674), OSi(T1675)(T1676)(T1677), OS(O2)T1678, NHC(O)T1679, NT1680C(O)T1681, NHC(O)OT1682, NHC(O)NHT1683, NHC(O)NT1684T1685, NT1686C(O)OT1687, NT1688C(O)NHT1689, NT1690C(O)NT1691T1692, NHS(O2)T1693, NT1694S(O2)T1695, ST1696, S(O)T1697, S(O2)T1698, S(O2)NHT1699, S(O2)NT1700T1701, S(O2)OT1702, P(O)(OT1703)(OT1704), Si(T1705)(T1706)(T1707)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT 1656, NT1657T1658, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1659, C (O) OT1660, C (O) NHT1661, C (O) NT1662T1663, OT1664, O (T1665-O) ry H (ry = 1, 2, 3, 4, 5), O (T1666-O) ry T1667 (ry = 1, 2, 3, 4, 5), OC (O) T1668, OC (O) OT1669, OC (O) NHT1670 , OC (O) NT1671T1672, OP (O) (OT1673) (OT1674), OSi (T1675) (T1676) (T1677), OS (O 2 ) T1678, NHC (O) T1679, NT1680C (O) T1681, NHC ( O) OT1682, NHC (O) NHT1683, NHC (O) NT1684T1685, NT1686C (O) OT1687, NT1688C (O) NHT1689, NT1690C (O) NT1691T1692, NHS (O2) T1693, NT1694S (O2) T1695, ST1696, S ( O) T1697, S (O 2 ) T1698, S (O 2 ) NHT1699, S (O 2 ) NT1700T1701, S (O 2 ) OT1702, P (O) (OT1703) (OT1704), Si (T1705) (T1706) (T1707) "

여기서, T1656, T1657, T1658, T1659, T1660, T1661, T1662, T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679, T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694, T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702, T1703, T1704, T1705, T1706, T1707은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1662, T1663 및/또는 T1671, T1672 및/또는 T1684, T1685 및/또는 T1691, T1692 및/또는 T1700, T1701은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, T1656, T1657, T1658, T1659, T1660, T1661, T1662, T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679 T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694, T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702, T1703, T1705, T1706, T1707 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1662, T1663 and / or T1671, T1672 and / or T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1708, NT1709T1710, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1711, C(O)OT1712, C(O)NHT1713, C(O)NT1714T1715, OT1716, O(T1717-O)rzH (rz = 1, 2, 3, 4, 5), O(T1718-O)rzT1719 (rz = 1, 2, 3, 4, 5), OC(O)T1720, OC(O)OT1721, OC(O)NHT1722, OC(O)NT1723T1724, OP(O)(OT1725)(OT1726), OSi(T1727)(T1728)(T1729), OS(O2)T1730, NHC(O)T1731, NT1732C(O)T1733, NHC(O)OT1734, NHC(O)NHT1735, NHC(O)NT1736T1737, NT1738C(O)OT1739, NT1740C(O)NHT1741, NT1742C(O)NT1743T1744, NHS(O2)T1745, NT1746S(O2)T1747, ST1748, S(O)T1749, S(O2)T1750, S(O2)NHT1751, S(O2)NT1752T1753, S(O2)OT1754, P(O)(OT1755)(OT1756), Si(T1757)(T1758)(T1759)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT 1708, NT1709T1710, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1711, C (O) OT1712, C (O) NHT1713, C (O) NT1714T1715, OT1716, O (T1717-O) rz H (rz = 1, 2, 3, 4, 5), O (T1718-O) rz T1719 (rz = 1, 2, 3, 4, 5), OC (O) T1720, OC (O) OT1721, OC (O) NHT1722 , OC (O) NT1723T1724, OP (O) (OT1725) (OT1726), OSi (T1727) (T1728) (T1729), OS (O 2 ) T1730, NHC (O) T1731, NT1732C (O) T1733, NHC ( O) OT1734, NHC (O) NHT1735, NHC (O) NT1736T1737, NT1738C (O) OT1739, NT1740C (O) NHT1741, NT1742C (O) NT1743T1744, NHS (O2) T1745, NT1746S (O2) T1747, ST1748, S ( O) T1749, S (O 2 ) T1750, S (O 2 ) NHT1751, S (O 2 ) NT1752T1753, S (O 2 ) OT1754, P (O) (OT1755) (OT1756), Si (T1757) (T1758) (T1759) "

여기서, T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725,T1726, T1727, T1728, T1729, T1730, T1731, T1732, T1733, T1734, T1735, T1736, T1737, T1738, T1739, T1740, T1741, T1742, T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1714, T1715 및/또는 T1723, T1724 및/또는 T1736, T1737 및/또는 T1743, T1744 및/또는 T1752, T1753은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where: T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731 T1732, T1733, T1734, T1735, T1736, T1737, T1738, T1739, T1740, T1741, T1742, T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1755, T1757, T1758, T1759 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1714, T1715 and / or T1723, T1724 and / or T1736, T1737 and / or T1743, T1744 and / or T1752, T1753 are also in each case a" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1760, NT1761T1762, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1763, C(O)OT1764, C(O)NHT1765, C(O)NT1766T1767, OT1768, O(T1769-O)raH (ra = 1, 2, 3, 4, 5), O(T1770-O)raT1771 (ra = 1, 2, 3, 4, 5), OC(O)T1772, OC(O)OT1773, OC(O)NHT1774, OC(O)NT1775T1776, OP(O)(OT1777)(OT1778), OSi(T1779)(T1780)(T1781), OS(O2)T1782, NHC(O)T1783, NT1784C(O)T1785, NHC(O)OT1786, NHC(O)NHT1787, NHC(O)NT1788T1789, NT1790C(O)OT1791, NT1792C(O)NHT1793, NT1794C(O)NT1795T1796, NHS(O2)T1797, NT1798S(O2)T1799, ST1800, S(O)T1801, S(O2)T1802, S(O2)NHT1803, S(O2)NT1804T1805, S(O2)OT1806, P(O)(OT1807)(OT1808), Si(T1809)(T1810)(T1811)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1760, NT1761T1762, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1763, C (O) OT1764, C (O) NHT1765, C (O) NT1766T1767, OT1768, O (T1769-O) ra H (ra = 1, 2, 3, 4, 5), O (T1770-O) ra T1771 (ra = 1, 2, 3, 4, 5), OC (O) T1772, OC (O) OT1773, OC (O) NHT1774 , OC (O) NT1775T1776, OP (O) (OT1777) (OT1778), OSi (T1779) (T1780) (T1781), OS (O 2 ) T1782, NHC (O) T1783, NT1784C (O) T1785, NHC ( O) OT1786, NHC (O) NHT1787, NHC (O) NT1788T1789, NT1790C (O) OT1791, NT1792C (O) NHT1793, NT1794C (O) NT1795T1796, NHS (O2) T1797, NT1798S (O2) T1799, ST1800, S ( O) T1801, S (O 2 ) T1802, S (O 2 ) NHT1803, S (O 2 ) NT1804T1805, S (O 2 ) OT1806, P (O) (OT1807) (OT1808), Si (T1809) (T1810) (T1811) "

여기서, T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783, T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1808, T1809, T1810, T1811은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1766, T1767 및/또는 T1775, T1776 및/또는 T1788, T1789 및/또는 T1795, T1796 및/또는 T1804, T1805는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where: T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783 T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1807, T1809, T1810, T1811 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1766, T1767 and / or T1775, T1776 and / or T1788, T1789 and / or T1795, T1796 and / or T1804, T1805 are also in each case" heterocycle Reels ",

And

Z3, Z4 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z3 and Z4 radicals are each independently selected from the group consisting of:

(e) 수소;(e) hydrogen;

(f) 할로겐, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;

(g) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB457, NB458B459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B460, C(O)OB461, C(O)NHB462, C(O)NB463B464, OB465, O(B466-O)xH (x = 1, 2, 3, 4, 5), O(B467-O)xB468 (x = 1, 2, 3, 4, 5), OC(O)B469, OC(O)OB470, OC(O)NHB471, OC(O)NB472B473, OP(O)(OB474)(OB475), OSi(B476)(B477)(B478), OS(O2)B479, NHC(O)B480, NB481C(O)B482, NHC(O)OB483, NHC(O)NHB484, NHC(O)NB485B486, NB487C(O)OB488, NB489C(O)NHB490, NB491C(O)NB492B493, NHS(O2)B494, NB495S(O2)B496, SB497, S(O)B498, S(O2)B499, S(O2)NHB500, S(O2)NB501B502, S(O2)OB503, P(O)(OB504)(OB505), Si(B506)(B507)(B508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB457, NB458B459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B460, C (O) OB461, C (O) NHB462, C (O) NB463B464, OB465, O (B466-O) x H (x = 1, 2, 3, 4, 5), O (B467-O) x B468 (x = 1, 2, 3, 4, 5), OC (O) B469, OC (O) OB470, OC (O) NHB471 , OC (O) NB472B473, OP (O) (OB474) (OB475), OSi (B476) (B477) (B478), OS (O 2 ) B479, NHC (O) B480, NB481C (O) B482, NHC ( O) OB483, NHC (O) NHB484, NHC (O) NB485B486, NB487C (O) OB488, NB489C (O) NHB490, NB491C (O) NB492B493, NHS (O2) B494, NB495S (O2) B496, SB497, S ( O) B498, S (O 2 ) B499, S (O 2 ) NHB500, S (O 2 ) NB501B502, S (O 2 ) OB503, P (O) (OB504) (OB505), Si (B506) (B507) (B508) "

여기서, B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B463, B464 및/또는 B472, B473 및/또는 B485, B486 및/또는 B492, B493 및/또는 B501, B502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B463, B464 and / or B472, B473 and / or B485, B486 and / or B492, B493 and / or B501, B502 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB509, NB510B511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B512, C(O)OB513, C(O)NHB514, C(O)NB515B516, OB517, O(B518-O)yH (y = 1, 2, 3, 4, 5), O(B519-O)yB520 (y = 1, 2, 3, 4, 5), OC(O)B521, OC(O)OB522, OC(O)NHB523, OC(O)NB524B525, OP(O)(OB526)(OB527), OSi(B528)(B529)(B530), OS(O2)B531, NHC(O)B532, NB533C(O)B534, NHC(O)OB535, NHC(O)NHB536, NHC(O)NB537B538, NB539C(O)OB540, NB541C(O)NHB542, NB543C(O)NB544B545, NHS(O2)B546, NB547S(O2)B548, SB549, S(O)B550, S(O2)B551, S(O2)NHB552, S(O2)NB553B554, S(O2)OB555, P(O)(OB556)(OB557), Si(B558)(B559)(B560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB509, NB510B511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B512, C (O) OB513, C (O) NHB514, C (O) NB515B516, OB517, O (B518-O) y H (y = 1, 2, 3, 4, 5), O (B519-O) y B520 (y = 1, 2, 3, 4, 5), OC (O) B521, OC (O) OB522, OC (O) NHB523 , OC (O) NB524B525, OP (O) (OB526) (OB527), OSi (B528) (B529) (B530), OS (O 2 ) B531, NHC (O) B532, NB533C (O) B534, NHC ( O) OB535, NHC (O) NHB536, NHC (O) NB537B538, NB539C (O) OB540, NB541C (O) NHB542, NB543C (O) NB544B545, NHS (O2) B546, NB547S (O2) B548, SB549, S ( O) B550, S (O 2 ) B551, S (O 2 ) NHB552, S (O 2 ) NB553B554, S (O 2 ) OB555, P (O) (OB556) (OB557), Si (B558) (B559) (B560) "

여기서, B509, B510, B511, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B515, B516 및/또는 B524, B525 및/또는 B537, B538 및/또는 B544, B545 및/또는 B553, B554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B509, B510, B511, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B515, B516 and / or B524, B525 and / or B537, B538 and / or B544, B545 and / or B553, B554 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB561, NB562B563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B564, C(O)OB565, C(O)NHB566, C(O)NB567B568, OB569, O(B570-O)zH (z = 1, 2, 3, 4, 5), O(B571-O)zB572 (z = 1, 2, 3, 4, 5), OC(O)B573, OC(O)OB574, OC(O)NHB575, OC(O)NB576B577, OP(O)(OB578)(OB579), OSi(B580)(B581)(B582), OS(O2)B583, NHC(O)B584, NB585C(O)B586, NHC(O)OB587, NHC(O)NHB588, NHC(O)NB589B590, NB591C(O)OB592, NB593C(O)NHB594, NB595C(O)NB596B597, NHS(O2)B598, NB599S(O2)B600, SB601, S(O)B602, S(O2)B603, S(O2)NHB604, S(O2)NB605B606, S(O2)OB607, P(O)(OB608)(OB609), Si(B610)(B611)(B612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB561, NB562B563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B564, C (O) OB565, C (O) NHB566, C (O) NB567B568, OB569, O (B570-O) z H (z = 1, 2, 3, 4, 5), O (B571-O) z B572 (z = 1, 2, 3, 4, 5), OC (O) B573, OC (O) OB574, OC (O) NHB575 , OC (O) NB576B577, OP (O) (OB578) (OB579), OSi (B580) (B581) (B582), OS (O 2 ) B583, NHC (O) B584, NB585C (O) B586, NHC ( O) OB587, NHC (O) NHB588, NHC (O) NB589B590, NB591C (O) OB592, NB593C (O) NHB594, NB595C (O) NB596B597, NHS (O2) B598, NB599S (O2) B600, SB601, S ( O) B602, S (O 2 ) B603, S (O 2 ) NHB604, S (O 2 ) NB605B606, S (O 2 ) OB607, P (O) (OB608) (OB609), Si (B610) (B611) (B612) "

여기서, B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B567, B568 및/또는 B576, B577 및/또는 B589, B590 및/또는 B596, B597 및/또는 B605, B606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B567, B568 and / or B576, B577 and / or B589, B590 and / or B596, B597 and / or B605, B606 are also in each case" heterocycle. " Reels ",

(h) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB613, NB614B615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B616, C(O)OB617, C(O)NHB618, C(O)NB619B620, OB621, O(B622-O)aH (a = 1, 2, 3, 4, 5), O(B623-O)aB624 (a = 1, 2, 3, 4, 5), OC(O)B625, OC(O)OB626, OC(O)NHB627, OC(O)NB628B629, OP(O)(OB630)(OB631), OSi(B632)(B633)(B634), OS(O2)B635, NHC(O)B636, NB637C(O)B638, NHC(O)OB639, NHC(O)NHB640, NHC(O)NB641B642, NB643C(O)OB644, NB645C(O)NHB646, NB647C(O)NB648B649, NHS(O2)B650, NB651S(O2)B652, SB653, S(O)B654, S(O2)B655, S(O2)NHB656, S(O2)NB657B658, S(O2)OB659, P(O)(OB660)(OB661), Si(B662)(B663)(B664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB613, NB614B615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B616, C (O) OB617, C (O) NHB618, C (O) NB619B620, OB621, O (B622-O) a H (a = 1, 2, 3, 4, 5), O (B623-O) a B624 (a = 1, 2, 3, 4, 5), OC (O) B625, OC (O) OB626, OC (O) NHB627 , OC (O) NB628B629, OP (O) (OB630) (OB631), OSi (B632) (B633) (B634), OS (O 2 ) B635, NHC (O) B636, NB637C (O) B638, NHC ( O) OB639, NHC (O) NHB640, NHC (O) NB641B642, NB643C (O) OB644, NB645C (O) NHB646, NB647C (O) NB648B649, NHS (O2) B650, NB651S (O2) B652, SB653, S ( O) B654, S (O 2 ) B655, S (O 2 ) NHB656, S (O 2 ) NB657B658, S (O 2 ) OB659, P (O) (OB660) (OB661), Si (B662) (B663) (B664) "

여기서, B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Where B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl "

여기서, 대안적으로, B619, B620 및/또는 B628, B629 및/또는 B641, B642 및/또는 B648, B649 및/또는 B657, B658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, alternatively, B619, B620 and / or B628, B629 and / or B641, B642 and / or B648, B649 and / or B657, B658 may also together form “heterocyclyl” in each case,

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB665, NB666B667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B668, C(O)OB669, C(O)NHB670, C(O)NB671B672, OB673, O(B674-O)bH (b = 1, 2, 3, 4, 5), O(B675-O)bB676 (b = 1, 2, 3, 4, 5), OC(O)B677, OC(O)OB678, OC(O)NHB679, OC(O)NB680B681, OP(O)(OB682)(OB683), OSi(B684)(B685)(B686), OS(O2)B687, NHC(O)B688, NB689C(O)B690, NHC(O)OB691, NHC(O)NHB692, NHC(O)NB693B694, NB695C(O)OB696, NB697C(O)NHB698, NB699C(O)NB700B701, NHS(O2)B702, NB703S(O2)B704, SB705, S(O)B706, S(O2)B707, S(O2)NHB708, S(O2)NB709B710, S(O2)OB711, P(O)(OB712)(OB713), Si(B714)(B715)(B716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB665, NB666B667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B668, C (O) OB669, C (O) NHB670, C (O) NB671B672, OB673, O (B674-O) b H (b = 1, 2, 3, 4, 5), O (B675-O) b B676 (b = 1, 2, 3, 4, 5), OC (O) B677, OC (O) OB678, OC (O) NHB679 , OC (O) NB680B681, OP (O) (OB682) (OB683), OSi (B684) (B685) (B686), OS (O 2 ) B687, NHC (O) B688, NB689C (O) B690, NHC ( O) OB691, NHC (O) NHB692, NHC (O) NB693B694, NB695C (O) OB696, NB697C (O) NHB698, NB699C (O) NB700B701, NHS (O2) B702, NB703S (O2) B704, SB705, S ( O) B706, S (O 2 ) B707, S (O 2 ) NHB708, S (O 2 ) NB709B710, S (O 2 ) OB711, P (O) (OB712) (OB713), Si (B714) (B715) (B716) "

여기서, B665, B666, B667, B668, B669, B670, B671, B672, B673, B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B711, B712, B713, B714, B715, B716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B671, B672 및/또는 B680, B681 및/또는 B693, B694 및/또는 B700, B701 및/또는 B709, B710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B665, B666, B667, B668, B669, B670, B671, B672, B673, B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B711, B712, B713, B714, B715, B716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B671, B672 and / or B680, B681 and / or B693, B694 and / or B700, B701 and / or B709, B710 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB717, NB718B719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B720, C(O)OB721, C(O)NHB722, C(O)NB723B724, OB725, O(B726-O)cH (c = 1, 2, 3, 4, 5), O(B727-O)cB728 (c = 1, 2, 3, 4, 5), OC(O)B729, OC(O)OB730, OC(O)NHB731, OC(O)NB732B733, OP(O)(OB734)(OB735), OSi(B736)(B737)(B738), OS(O2)B739, NHC(O)B740, NB741C(O)B742, NHC(O)OB743, NHC(O)NHB744, NHC(O)NB745B746, NB747C(O)OB748, NB749C(O)NHB750, NB751C(O)NB752B753, NHS(O2)B754, NB755S(O2)B756, SB757, S(O)B758, S(O2)B759, S(O2)NHB760, S(O2)NB761B762, S(O2)OB763, P(O)(OB764)(OB765), Si(B766)(B767)(B768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB717, NB718B719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B720, C (O) OB721, C (O) NHB722, C (O) NB723B724, OB725, O (B726-O) c H (c = 1, 2, 3, 4, 5), O (B727-O) c B728 (c = 1, 2, 3, 4, 5), OC (O) B729, OC (O) OB730, OC (O) NHB731 , OC (O) NB732B733, OP (O) (OB734) (OB735), OSi (B736) (B737) (B738), OS (O 2 ) B739, NHC (O) B740, NB741C (O) B742, NHC ( O) OB743, NHC (O) NHB744, NHC (O) NB745B746, NB747C (O) OB748, NB749C (O) NHB750, NB751C (O) NB752B753, NHS (O2) B754, NB755S (O2) B756, SB757, S ( O) B758, S (O 2 ) B759, S (O 2 ) NHB760, S (O 2 ) NB761B762, S (O 2 ) OB763, P (O) (OB764) (OB765), Si (B766) (B767) (B768) "

여기서, B717, B718, B719, B720, B721, B722,B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B723, B724 및/또는 B732, B733 및/또는 B745, B746 및/또는 B752, B753 및/또는 B761, B762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B723, B724 and / or B732, B733 and / or B745, B746 and / or B752, B753 and / or B761, B762 are also in each case" heterocycle. " Reels ",

(j) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB769, NB770B771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B772, C(O)OB773, C(O)NHB774, C(O)NB775B776, OB777, O(B778-O)dH (d = 1, 2, 3, 4, 5), O(B779-O)dB780 (d = 1, 2, 3, 4, 5), OC(O)B781, OC(O)OB782, OC(O)NHB783, OC(O)NB784B785, OP(O)(OB786)(OB787), OSi(B788)(B789)(B790), OS(O2)B791, NHC(O)B792, NB793C(O)B794, NHC(O)OB795, NHC(O)NHB796, NHC(O)NB797B798, NB799C(O)OB800, NB801C(O)NHB802, NB803C(O)NB804B805, NHS(O2)B806, NB807S(O2)B808, SB809, S(O)B810, S(O2)B811, S(O2)NHB812, S(O2)NB813B814, S(O2)OB815, P(O)(OB816)(OB817), Si(B818)(B819)(B820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB769, NB770B771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B772, C (O) OB773, C (O) NHB774, C (O) NB775B776, OB777, O (B778-O) d H (d = 1, 2, 3, 4, 5), O (B779-O) d B780 (d = 1, 2, 3, 4, 5), OC (O) B781, OC (O) OB782, OC (O) NHB783 , OC (O) NB784B785, OP (O) (OB786) (OB787), OSi (B788) (B789) (B790), OS (O 2 ) B791, NHC (O) B792, NB793C (O) B794, NHC ( O) OB795, NHC (O) NHB796, NHC (O) NB797B798, NB799C (O) OB800, NB801C (O) NHB802, NB803C (O) NB804B805, NHS (O2) B806, NB807S (O2) B808, SB809, S ( O) B810, S (O 2 ) B811, S (O 2 ) NHB812, S (O 2 ) NB813B814, S (O 2 ) OB815, P (O) (OB816) (OB817), Si (B818) (B819) (B820) "

여기서, B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B811, B812, B813, B814, B815, B816, B817, B818, B819, B820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B775, B776 및/또는 B784, B785 및/또는 B797, B798 및/또는 B804, B805 및/또는 B813, B814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B811, B812, B813, B814, B815, B816, B817, B818, B819, B820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B775, B776 and / or B784, B785 and / or B797, B798 and / or B804, B805 and / or B813, B814 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB821, NB822B823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B824, C(O)OB825, C(O)NHB826, C(O)NB827B828, OB829, O(B830-O)eH (e = 1, 2, 3, 4, 5), O(B831-O)eB832 (e = 1, 2, 3, 4, 5), OC(O)B833, OC(O)OB834, OC(O)NHB835, OC(O)NB836B837, OP(O)(OB838)(OB839), OSi(B840)(B841)(B842), OS(O2)B843, NHC(O)B844, NB845C(O)B846, NHC(O)OB847, NHC(O)NHB848, NHC(O)NB849B850, NB851C(O)OB852, NB853C(O)NHB854, NB855C(O)NB856B857, NHS(O2)B858, NB859S(O2)B860, SB861, S(O)B862, S(O2)B863, S(O2)NHB864, S(O2)NB865B866, S(O2)OB867, P(O)(OB868)(OB869), Si(B870)(B871)(B872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB821, NB822B823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B824, C (O) OB825, C (O) NHB826, C (O) NB827B828, OB829, O (B830-O) e H (e = 1, 2, 3, 4, 5), O (B831-O) e B832 (e = 1, 2, 3, 4, 5), OC (O) B833, OC (O) OB834, OC (O) NHB835 , OC (O) NB836B837, OP (O) (OB838) (OB839), OSi (B840) (B841) (B842), OS (O 2 ) B843, NHC (O) B844, NB845C (O) B846, NHC ( O) OB847, NHC (O) NHB848, NHC (O) NB849B850, NB851C (O) OB852, NB853C (O) NHB854, NB855C (O) NB856B857, NHS (O2) B858, NB859S (O2) B860, SB861, S ( O) B862, S (O 2 ) B863, S (O 2 ) NHB864, S (O 2 ) NB865B866, S (O 2 ) OB867, P (O) (OB868) (OB869), Si (B870) (B871) (B872) "

여기서, B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869, B870, B871, B872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B827, B828 및/또는 B836, B837 및/또는 B849, B850 및/또는 B856, B857 및/또는 B865, B866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869, B870, B871, B872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B827, B828 and / or B836, B837 and / or B849, B850 and / or B856, B857 and / or B865, B866 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB873, NB874B875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B876, C(O)OB877, C(O)NHB878, C(O)NB879B880, OB881, O(B882-O)fH (f = 1, 2, 3, 4, 5), O(B883-O)fB884 (f = 1, 2, 3, 4, 5), OC(O)B885, OC(O)OB886, OC(O)NHB887, OC(O)NB888B889, OP(O)(OB890)(OB891), OSi(B892)(B893)(B894), OS(O2)B895, NHC(O)B896, NB897C(O)B898, NHC(O)OB899, NHC(O)NHB900, NHC(O)NB901B902, NB903C(O)OB904, NB905C(O)NHB906, NB907C(O)NB908B909, NHS(O2)B910, NB911S(O2)B912, SB913, S(O)B914, S(O2)B915, S(O2)NHB916, S(O2)NB917B918, S(O2)OB919, P(O)(OB920)(OB921), Si(B922)(B923)(B924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB873, NB874B875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B876, C (O) OB877, C (O) NHB878, C (O) NB879B880, OB881, O (B882-O) f H (f = 1, 2, 3, 4, 5), O (B883-O) f B884 (f = 1, 2, 3, 4, 5), OC (O) B885, OC (O) OB886, OC (O) NHB887 , OC (O) NB888B889, OP (O) (OB890) (OB891), OSi (B892) (B893) (B894), OS (O 2 ) B895, NHC (O) B896, NB897C (O) B898, NHC ( O) OB899, NHC (O) NHB900, NHC (O) NB901B902, NB903C (O) OB904, NB905C (O) NHB906, NB907C (O) NB908B909, NHS (O2) B910, NB911S (O2) B912, SB913, S ( O) B914, S (O 2 ) B915, S (O 2 ) NHB916, S (O 2 ) NB917B918, S (O 2 ) OB919, P (O) (OB920) (OB921), Si (B922) (B923) (B924) "

여기서, B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B879, B880 및/또는 B888, B889 및/또는 B901, B902 및/또는 B908, B909 및/또는 B917, B918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B879, B880 and / or B888, B889 and / or B901, B902 and / or B908, B909 and / or B917, B918 are also in each case" heterocycle Reels ",

(k) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB925, NB926B927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B928, C(O)OB929, C(O)NHB930, C(O)NB931B932, OB933, O(B934-O)gH (g = 1, 2, 3, 4, 5), O(B935-O)gB936 (g = 1, 2, 3, 4, 5), OC(O)B937, OC(O)OB938, OC(O)NHB939, OC(O)NB940B941, OP(O)(OB942)(OB943), OSi(B944)(B945)(B946), OS(O2)B947, NHC(O)B948, NB949C(O)B950, NHC(O)OB951, NHC(O)NHB952, NHC(O)NB953B954, NB955C(O)OB956, NB957C(O)NHB958, NB959C(O)NB960B961, NHS(O2)B962, NB963S(O2)B964, SB965, S(O)B966, S(O2)B967, S(O2)NHB968, S(O2)NB969B970, S(O2)OB971, P(O)(OB972)(OB973), Si(B974)(B975)(B976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB925, NB926B927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B928, C (O) OB929, C (O) NHB930, C (O) NB931B932, OB933, O (B934-O) g H (g = 1, 2, 3, 4, 5), O (B935-O) g B936 (g = 1, 2, 3, 4, 5), OC (O) B937, OC (O) OB938, OC (O) NHB939 , OC (O) NB940B941, OP (O) (OB942) (OB943), OSi (B944) (B945) (B946), OS (O 2 ) B947, NHC (O) B948, NB949C (O) B950, NHC ( O) OB951, NHC (O) NHB952, NHC (O) NB953B954, NB955C (O) OB956, NB957C (O) NHB958, NB959C (O) NB960B961, NHS (O2) B962, NB963S (O2) B964, SB965, S ( O) B966, S (O 2 ) B967, S (O 2 ) NHB968, S (O 2 ) NB969B970, S (O 2 ) OB971, P (O) (OB972) (OB973), Si (B974) (B975) (B976) "

여기서, B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973, B974, B975, B976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B931, B932 및/또는 B940, B941 및/또는 B953, B954 및/또는 B960, B961 및/또는 B969, B970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973, B974, B975, B976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B931, B932 and / or B940, B941 and / or B953, B954 and / or B960, B961 and / or B969, B970 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB977, NB978B979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B980, C(O)OB981, C(O)NHB982, C(O)NB983B984, OB985, O(B986-O)hH (h = 1, 2, 3, 4, 5), O(B987-O)hB988 (h = 1, 2, 3, 4, 5), OC(O)B989, OC(O)OB990, OC(O)NHB991, OC(O)NB992B993, OP(O)(OB994)(OB995), OSi(B996)(B997)(B998), OS(O2)B999, NHC(O)B1000, NB1001C(O)B1002, NHC(O)OB1003, NHC(O)NHB1004, NHC(O)NB1005B1006, NB1007C(O)OB1008, NB1009C(O)NHB1010, NB1011C(O)NB1012B1013, NHS(O2)B1014, NB1015S(O2)B1016, SB1017, S(O)B1018, S(O2)B1019, S(O2)NHB1020, S(O2)NB1021B1022, S(O2)OB1023, P(O)(OB1024)(OB1025), Si(B1026)(B1027)(B1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB977, NB978B979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B980, C (O) OB981, C (O) NHB982, C (O) NB983B984, OB985, O (B986-O) h H (h = 1, 2, 3, 4, 5), O (B987-O) h B988 (h = 1, 2, 3, 4, 5), OC (O) B989, OC (O) OB990, OC (O) NHB991 , OC (O) NB992B993, OP (O) (OB994) (OB995), OSi (B996) (B997) (B998), OS (O 2 ) B999, NHC (O) B1000, NB1001C (O) B1002, NHC ( O) OB1003, NHC (O) NHB1004, NHC (O) NB1005B1006, NB1007C (O) OB1008, NB1009C (O) NHB1010, NB1011C (O) NB1012B1013, NHS (O2) B1014, NB1015S (O2) B1016, SB1017 O) B1018, S (O 2 ) B1019, S (O 2 ) NHB1020, S (O 2 ) NB1021B1022, S (O 2 ) OB1023, P (O) (OB1024) (OB1025), Si (B1026) (B1027) (B1028) "

여기서, B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001, B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B1011, B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021, B1022, B1023, B1024, B1025, B1026, B1027, B1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B983, B984 및/또는 B992, B993 및/또는 B1005, B1006 및/또는 B1012, B1013 및/또는 B1021, B1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001, B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B1011, B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021, B1022, B1023, B1024, B1024 B1026, B1027, B1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B983, B984 and / or B992, B993 and / or B1005, B1006 and / or B1012, B1013 and / or B1021, B1022 are also in each case" heterocycle Reels ",

(l) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1029, NB1030B1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1032, C(O)OB1033, C(O)NHB1034, C(O)NB1035B1036, OB1037, O(B1038-O)iH (i = 1, 2, 3, 4, 5), O(B1039-O)iB1040 (i = 1, 2, 3, 4, 5), OC(O)B1041, OC(O)OB1042, OC(O)NHB1043, OC(O)NB1044B1045, OP(O)(OB1046)(OB1047), OSi(B1048)(B1049)(B1050), OS(O2)B1051, NHC(O)B1052, NB1053C(O)B1054, NHC(O)OB1055, NHC(O)NHB1056, NHC(O)NB1057B1058, NB1059C(O)OB1060, NB1061C(O)NHB1062, NB1063C(O)NB1064B1065, NHS(O2)B1066, NB1067S(O2)B1068, SB1069, S(O)B1070, S(O2)B1071, S(O2)NHB1072, S(O2)NB1073B1074, S(O2)OB1075, P(O)(OB1076)(OB1077), Si(B1078)(B1079)(B1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1029, NB1030B1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1032, C (O) OB1033, C (O) NHB1034, C (O) NB1035B1036, OB1037, O (B1038-O) i H (i = 1, 2, 3, 4, 5), O (B1039-O) i B1040 (i = 1, 2, 3, 4, 5), OC (O) B1041, OC (O) OB1042, OC (O) NHB1043 , OC (O) NB1044B1045, OP (O) (OB1046) (OB1047), OSi (B1048) (B1049) (B1050), OS (O 2 ) B1051, NHC (O) B1052, NB1053C (O) B1054, NHC ( O) OB1055, NHC (O) NHB1056, NHC (O) NB1057B1058, NB1059C (O) OB1060, NB1061C (O) NHB1062, NB1063C (O) NB1064B1065, NHS (O2) B1066, NB1067S (O2) B1068, SB1069, SB1069 O) B1070, S (O 2 ) B1071, S (O 2 ) NHB1072, S (O 2 ) NB1073B1074, S (O 2 ) OB1075, P (O) (OB1076) (OB1077), Si (B1078) (B1079) (B1080) "

여기서, B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041, B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050,B1051, B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1078, B1079, B1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1035, B1036 및/또는 B1044, B1045 및/또는 B1057, B1058 및/또는 B1064, B1065 및/또는 B1073, B1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041, B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051, B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1077 B1078, B1079, B1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B1035, B1036 and / or B1044, B1045 and / or B1057, B1058 and / or B1064, B1065 and / or B1073, B1074 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1081, NB1082B1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1084, C(O)OB1085, C(O)NHB1086, C(O)NB1087B1088, OB1089, O(B1090-O)jH (j = 1, 2, 3, 4, 5), O(B1091-O)jB1092 (j = 1, 2, 3, 4, 5), OC(O)B1093, OC(O)OB1094, OC(O)NHB1095, OC(O)NB1096B1097, OP(O)(OB1098)(OB1099), OSi(B1100)(B1101)(B1102), OS(O2)B1103, NHC(O)B1104, NB1105C(O)B1106, NHC(O)OB1107, NHC(O)NHB1108, NHC(O)NB1109B1110, NB1111C(O)OB1112, NB1113C(O)NHB1114, NB1115C(O)NB1116B1117, NHS(O2)B1118, NB1119S(O2)B1120, SB1121, S(O)B1122, S(O2)B1123, S(O2)NHB1124, S(O2)NB1125B1126, S(O2)OB1127, P(O)(OB1128)(OB1129), Si(B1130)(B1131)(B1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1081, NB1082B1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1084, C (O) OB1085, C (O) NHB1086, C (O) NB1087B1088, OB1089, O (B1090-O) j H (j = 1, 2, 3, 4, 5), O (B1091-O) j B1092 (j = 1, 2, 3, 4, 5), OC (O) B1093, OC (O) OB1094, OC (O) NHB1095 , OC (O) NB1096B1097, OP (O) (OB1098) (OB1099), OSi (B1100) (B1101) (B1102), OS (O 2 ) B1103, NHC (O) B1104, NB1105C (O) B1106, NHC ( O) OB1107, NHC (O) NHB1108, NHC (O) NB1109B1110, NB1111C (O) OB1112, NB1113C (O) NHB1114, NB1115C (O) NB1116B1117, NHS (O2) B1118, NB1119S (O2) B1120, SB112 O) B1122, S (O 2 ) B1123, S (O 2 ) NHB1124, S (O 2 ) NB1125B1126, S (O 2 ) OB1127, P (O) (OB1128) (OB1129), Si (B1130) (B1131) (B1132) "

여기서, B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095,B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104, B1105, B1106, B1107, B1108, B1109, B1110, B1111, B1112, B1113, B1114, B1115, B1116, B1117, B1118, B1119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1129, B1130, B1131, B1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1087, B1088 및/또는 B1096, B1097 및/또는 B1109, B1110 및/또는 B1116, B1117 및/또는 B1125, B1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095, B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104 B1105, B1106, B1107, B1108, B1109, B1110, B1111, B1112, B1113, B1114, B1115, B1116, B1117, B1118, B1119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1128, B1128 B1130, B1131, B1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1087, B1088 and / or B1096, B1097 and / or B1109, B1110 and / or B1116, B1117 and / or B1125, B1126 are also in each case" heterocycle. " Reels ",

(m) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)B1133, C(O)OB1134, C(O)NB1135B1136, S(O2)B1137, S(O2)OB1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) B1133 , C (O) OB1134, C (O) NB1135B1136, S (O 2 ) B1137, S (O 2 ) OB1138 "

여기서, B1133, B1134, B1135, B1136, B1137, B1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1135, B1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein B1133, B1134, B1135, B1136, B1137, B1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, B1135, B1136 together may also form" heterocyclyl ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1139, NB1140B1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1142, C(O)OB1143, C(O)NHB1144, C(O)NB1145B1146, OB1147, O(B1148-O)kH (k = 1, 2, 3, 4, 5), O(B1149-O)kB1150 (k = 1, 2, 3, 4, 5), OC(O)B1151, OC(O)OB1152, OC(O)NHB1153, OC(O)NB1154B1155, OP(O)(OB1156)(OB1157), OSi(B1158)(B1159)(B1160), OS(O2)B1161, NHC(O)B1162, NB1163C(O)B1164, NHC(O)OB1165, NHC(O)NHB1166, NHC(O)NB1167B1168, NB1169C(O)OB1170, NB1171C(O)NHB1172, NB1173C(O)NB1174B1175, NHS(O2)B1176, NB1177S(O2)B1178, SB1179, S(O)B1180, S(O2)B1181, S(O2)NHB1182, S(O2)NB1183B1184, S(O2)OB1185, P(O)(OB1186)(OB1187), Si(B1188)(B1189)(B1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1139, NB1140B1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1142, C (O) OB1143, C (O) NHB1144, C (O) NB1145B1146, OB1147, O (B1148-O) k H (k = 1, 2, 3, 4, 5), O (B1149-O) k B1150 (k = 1, 2, 3, 4, 5), OC (O) B1151, OC (O) OB1152, OC (O) NHB1153 , OC (O) NB1154B1155, OP (O) (OB1156) (OB1157), OSi (B1158) (B1159) (B1160), OS (O 2 ) B1161, NHC (O) B1162, NB1163C (O) B1164, NHC ( O) OB1165, NHC (O) NHB1166, NHC (O) NB1167B1168, NB1169C (O) OB1170, NB1171C (O) NHB1172, NB1173C (O) NB1174B1175, NHS (O2) B1176, NB1177S (O2) B1178, SB1179 O) B1180, S (O 2 ) B1181, S (O 2 ) NHB1182, S (O 2 ) NB1183B1184, S (O 2 ) OB1185, P (O) (OB1186) (OB1187), Si (B1188) (B1189) (B1190) "

여기서, B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166,B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1187, B1188, B1189, B1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1145, B1146 및/또는 B1154, B1155 및/또는 B1167, B1168 및/또는 B1174, B1175 및/또는 B1183, B1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1186, B1186 B1188, B1189, B1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1145, B1146 and / or B1154, B1155 and / or B1167, B1168 and / or B1174, B1175 and / or B1183, B1184 are also in each case" heterocycle Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1191, NB1192B1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1194, C(O)OB1195, C(O)NHB1196, C(O)NB1197B1198, OB1199, O(B1200-O)lH (l = 1, 2, 3, 4, 5), O(B1201-O)lB1202 (l = 1, 2, 3, 4, 5), OC(O)B1203, OC(O)OB1204, OC(O)NHB1205, OC(O)NB1206B1207, OP(O)(OB1208)(OB1209), OSi(B1210)(B1211)(B1212), OS(O2)B1213, NHC(O)B1214, NB1215C(O)B1216, NHC(O)OB1217, NHC(O)NHB1218, NHC(O)NB1219B1220, NB1221C(O)OB1222, NB1223C(O)NHB1224, NB1225C(O)NB1226B1227, NHS(O2)B1228, NB1229S(O2)B1230, SB1231, S(O)B1232, S(O2)B1233, S(O2)NHB1234, S(O2)NB1235B1236, S(O2)OB1237, P(O)(OB1238)(OB1239), Si(B1240)(B1241)(B1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1191, NB1192B1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1194, C (O) OB1195, C (O) NHB1196, C (O) NB1197B1198, OB1199, O (B1200-O) l H (l = 1, 2, 3, 4, 5), O (B1201-O) l B1202 (l = 1, 2, 3, 4, 5), OC (O) B1203, OC (O) OB1204, OC (O) NHB1205 , OC (O) NB1206B1207, OP (O) (OB1208) (OB1209), OSi (B1210) (B1211) (B1212), OS (O 2 ) B1213, NHC (O) B1214, NB1215C (O) B1216, NHC ( O) OB1217, NHC (O) NHB1218, NHC (O) NB1219B1220, NB1221C (O) OB1222, NB1223C (O) NHB1224, NB1225C (O) NB1226B1227, NHS (O2) B1228, NB1229S (O2) B1230, SB1231 O) B1232, S (O 2 ) B1233, S (O 2 ) NHB1234, S (O 2 ) NB1235B1236, S (O 2 ) OB1237, P (O) (OB1238) (OB1239), Si (B1240) (B1241) (B1242) "

여기서, B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209, B1210, B1211,B1212, B1213, B1214, B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239, B1240, B1241, B1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1197, B1198 및/또는 B1206, B1207 및/또는 B1219, B1220 및/또는 B1226, B1227 및/또는 B1235, B1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213, B1214, B1214, B1214 B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239 B1240, B1241, B1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1197, B1198 and / or B1206, B1207 and / or B1219, B1220 and / or B1226, B1227 and / or B1235, B1236 are also in each case" heterocycle. " Reels ",

And

Z5 라디칼은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z5 radicals are independently selected from the group consisting of:

(i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHD1, ND2D3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)D4, C(O)OD5, C(O)NHD6, C(O)ND7D8, OD9, O(D10-O)rH (r = 1, 2, 3, 4, 5), O(D11-O)rD12 (r = 1, 2, 3, 4, 5), OC(O)D13, OC(O)OD14, OC(O)NHD15, OC(O)ND16D17, OP(O)(OD18)(OD19), OSi(D20)(D21)(D22), OS(O2)D23, NHC(O)D24, ND25C(O)D26, NHC(O)OD27, NHC(O)NHD28, NHC(O)ND29D30, ND31C(O)OD32, ND33C(O)NHD34, ND35C(O)ND36D37, NHS(O2)D38, ND39S(O2)D40, SD41, S(O)D42, S(O2)D43, S(O2)NHD44, S(O2)ND45D46, S(O2)OD47, P(O)(OD48)(OD49), Si(D50)(D51)(D52)"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHD1, ND2D3, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) D4, C (O) OD5, C (O) NHD6, C (O) ND7D8, OD9, O (D10-O) r H ( r = 1, 2, 3, 4, 5), O (D11-O) r D12 (r = 1, 2, 3, 4, 5), OC (O) D13, OC (O) OD14, OC (O ) NHD15, OC (O) ND16D17, OP (O) (OD18) (OD19), OSi (D20) (D21) (D22), OS (O 2 ) D23, NHC (O) D24, ND25C (O) D26, NHC (O) OD27, NHC (O) NHD28, NHC (O) ND29D30, ND31C (O) OD32, ND33C (O) NHD34, ND35C (O) ND36D37, NHS (O2) D38, ND39S (O2) D40, SD41, S (O) D42, S (O 2 ) D43, S (O 2 ) NHD44, S (O 2 ) ND45D46, S (O 2 ) OD47, P (O) (OD48) (OD49), Si (D50) ( D51) (D52) "

여기서, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, D7, D8 및/또는 D16, D17 및/또는 D29, D30 및/또는 D36, D37 및/또는 D45, D46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D7, D8 and / or D16, D17 and / or D29, D30 and / or D36, D37 and / or D45, D46 may also in each case be" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHD53, ND54D55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)D56, C(O)OD57, C(O)NHD58, C(O)ND59D60, OD61, O(D62-O)sH (s = 1, 2, 3, 4, 5), O(D63-O)tD64 (t = 1, 2, 3, 4, 5), OC(O)D65, OC(O)OD66, OC(O)NHD67, OC(O)ND68D69, OP(O)(OD70)(OD71), OSi(D72)(D73)(D74), OS(O2)D75, NHC(O)D76, ND77C(O)D78, NHC(O)OD79, NHC(O)NHD80, NHC(O)ND81D82, ND83C(O)OD84, ND85C(O)NHD86, ND87C(O)ND88D89, NHS(O2)D90, ND91S(O2)D92, SD93, S(O)D94, S(O2)D95, S(O2)NHD96, S(O2)ND97D98, S(O2)OD99, P(O)(OD100)(OD101), Si(D102)(D103)(D104)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHD53, ND54D55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) D56, C (O) OD57, C (O) NHD58, C (O) ND59D60, OD61, O (D62-O) s H (s = 1, 2, 3, 4, 5), O (D63-O) t D64 (t = 1, 2, 3, 4, 5), OC (O) D65, OC (O) OD66, OC (O) NHD67 , OC (O) ND68D69, OP (O) (OD70) (OD71), OSi (D72) (D73) (D74), OS (O 2 ) D75, NHC (O) D76, ND77C (O) D78, NHC ( O) OD79, NHC (O) NHD80, NHC (O) ND81D82, ND83C (O) OD84, ND85C (O) NHD86, ND87C (O) ND88D89, NHS (O2) D90, ND91S (O2) D92, SD93, S ( O) D94, S (O 2 ) D95, S (O 2 ) NHD96, S (O 2 ) ND97D98, S (O 2 ) OD99, P (O) (OD100) (OD101), Si (D102) (D103) (D104) "

여기서, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102, D103, D104는 각각 독립적으로 다음 으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, D59, D60 및/또는 D68, D69 및/또는 D81, D82 및/또는 D88, D89 및/또는 D97, D98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102, D103, D104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D59, D60 and / or D68, D69 and / or D81, D82 and / or D88, D89 and / or D97, D98 are also in each case" heterocycle. " Reels ",

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHD105, ND106D107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)D108, C(O)OD109, C(O)NHD110, C(O)ND111D112, OD113, O(D114-O)tH (t = 1, 2, 3, 4, 5), O(D115-O)tD116 (t = 1, 2, 3, 4, 5), OC(O)D117, OC(O)OD118, OC(O)NHD119, OC(O)ND120D121, OP(O)(OD122)(OD123), OSi(D124)(D125)(D126), OS(O2)D127, NHC(O)D128, ND129C(O)D130, NHC(O)OD131, NHC(O)NHD132, NHC(O)ND133D134, ND135C(O)OD136, ND137C(O)NHD138, ND139C(O)ND140D141, NHS(O2)D142, ND143S(O2)D144, SD145, S(O)D146, S(O2)D147, S(O2)NHD148, S(O2)ND149D150, S(O2)OD151, P(O)(OD152)(OD153), Si(D154)(D155)(D156)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHD105, ND106D107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) D108, C (O) OD109, C (O) NHD110, C (O) ND111D112, OD113, O (D114-O) t H (t = 1, 2, 3, 4, 5), O (D115-O) t D116 (t = 1, 2, 3, 4, 5), OC (O) D117, OC (O) OD118, OC (O) NHD119 , OC (O) ND120D121, OP (O) (OD122) (OD123), OSi (D124) (D125) (D126), OS (O 2 ) D127, NHC (O) D128, ND129C (O) D130, NHC ( O) OD131, NHC (O) NHD132, NHC (O) ND133D134, ND135C (O) OD136, ND137C (O) NHD138, ND139C (O) ND140D141, NHS (O2) D142, ND143S (O2) D144, SD145, S ( O) D146, S (O 2 ) D147, S (O 2 ) NHD148, S (O 2 ) ND149D150, S (O 2 ) OD151, P (O) (OD152) (OD153), Si (D154) (D155) (D156) "

여기서, D105, D106, D107, D108, D109, D110, D111, D112, D113, D114, D115, D116, D117, D118, D119, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143, D144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, D111, D112 및/또는 D120, D121 및/또는 D133, D134 및/또는 D140, D141 및/또는 D149, D150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있다.Where D105, D106, D107, D108, D109, D110, D111, D112, D113, D114, D115, D116, D117, D118, D119, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143, D144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D111, D112 and / or D120, D121 and / or D133, D134 and / or D140, D141 and / or D149, D150 are also in each case" heterocycle. " Reel ".

모호한 표현을 피하기 위해, 화학식 I에 대해 상기한 경우 (A) 내지 (E)를 하기에 설명한다:In order to avoid ambiguity, (A) to (E) are described below for the above formula (I):

경우 (A)에서, 신규한 피리도[2,3-b]피라진 유도체는 하나 이상의 이의 Z3, Z4 라디칼에서 "치환된 아릴"에 의해 치환될 수 있고, 신규성은 하위-경우 (a)에 의해 또는 하위-경우 (c)에 의해 일어난다. 단지 하나의 Z3, Z4 라디칼이 신규한 "치환된 아릴"인 경우, 다른 Z3, Z4 라디칼은 각각의 경우 기재된 최대 범위내에 치환을 가질 수 있다[(하위-경우 (d)에서 "및" 결합]. 임의로, Z3, Z4 라디칼 둘 다는 또한 추가의 치환을 가질 수 있다[하위-경우 (b) 또는 (d)]. Z1, Z2 및 Z5 라디칼은 기재된 최대 범위내에 치환을 가질 수 있다[(하위-경우 (A) 내지 (D)에서 " 및" 결합].In case (A), the novel pyrido [2,3-b] pyrazine derivatives can be substituted by "substituted aryl" in one or more of its Z3, Z4 radicals, with novelty by sub-case Or by sub-case (c). If only one Z3, Z4 radical is a novel "substituted aryl", the other Z3, Z4 radicals may in each case have a substitution within the maximum ranges described ("and" bonds in sub-case (d)). Optionally, both Z3 and Z4 radicals may also have additional substitutions (sub-case (b) or (d)). Z1, Z2 and Z5 radicals may have substitutions within the maximum ranges indicated ((sub- In the case (A) to (D) "and" bond].

경우 (B)에서, 신규한 피리도[2,3-b]피라진 유도체는 하나 이상의 이의 Z3, Z4 라디칼에서 "치환된 헤테로아릴"에 의해 치환될 수 있고, 신규성은 하위-경우 (a)에 의해 또는 하위-경우 (c)에 의해 일어난다. 단지 하나의 Z3, Z4 라디칼이 신규한 "치환된 헤테로아릴"인 경우, 다른 Z3, Z4 라디칼은 각각의 경우 기재된 최대 범위내에 치환을 가질 수 있다[(하위-경우 (d)에서 "및" 결합]. 임의로, Z3, Z4 라디칼 둘 다는 또한 추가의 치환을 가질 수 있다[하위-경우 (b) 또는 (d)]. Z1, Z2 및 Z5 라디칼은 기재된 최대 범위내에 치환을 가질 수 있다[(경우 (A) 내지 (D)에서 "및" 결합].In case (B), the novel pyrido [2,3-b] pyrazine derivative may be substituted by “substituted heteroaryl” in one or more of its Z 3, Z 4 radicals, with novelty in sub-case (a) Or by sub-case (c). If only one Z3, Z4 radical is a novel "substituted heteroaryl", the other Z3, Z4 radicals may in each case have a substitution within the maximum ranges indicated (in the "sub-case (d)" and "bonds). Optionally, both Z3 and Z4 radicals may also have additional substitutions (sub-case (b) or (d)). Z1, Z2 and Z5 radicals may have substitutions within the maximum ranges described "And" bond in (A) to (D)].

경우 (C)에서, 신규한 피리도[2,3-b]피라진 유도체는 하나 이상의 이의 Z3, Z4 라디칼에서 신규한 방법으로 "치환된 알킬" 또는 "(C9-C30)알킬"에 의해 치환될 수 있다. 단지 하나의 Z3, Z4 라디칼이 신규한 "치환된 알킬" 또는 "(C9-C30)알킬"인 경우, 다른 Z3, Z4 라디칼은 각각의 경우 기재된 최대 범위내에 바람직한 치환을 가질 수 있다[(하위-경우 에서 "및" 결합 "(C9-C30)알킬"]. Z1, Z2 및 Z5 라디칼은 기재된 최대 범위내에 치환을 갖는다[(경우 (A) 내지 (D)에서 "및" 결합].In case (C), the novel pyrido [2,3-b] pyrazine derivatives are prepared by "substituted alkyl" or "(C 9 -C 30 ) alkyl" in a novel way in one or more of their Z3, Z4 radicals. Can be substituted. When only one Z3, Z4 radical is a novel "substituted alkyl" or "(C 9 -C 30 ) alkyl", the other Z3, Z4 radicals may in each case have the desired substitution within the maximum ranges described [( "And" bonds "(C 9 -C 30 ) alkyl" in sub-cases.Z1, Z2 and Z5 radicals have substitutions within the maximum ranges indicated (("and" bonds in cases (A) to (D)]). .

경우 (D)에서, 신규한 피리도[2,3-b]피라진 유도체는 하나 이상의 이의 Z3, Z4 라디칼에서 "OZ12, SZ13"에 의해 치환될 수 있고, 신규성은 하위-경우 (a)에 의해 또는 하위-경우 (b)에 의해 일어난다. 단지 하나의 Z3, Z4 라디칼이 신규한 "NZ10Z11, OZ12, SZ13"인 경우, 다른 Z3, Z4 라디칼은 각각의 경우 기재된 최대 범 위내에 바람직한 치환을 가질 수 있다[(하위-경우 (b)에서 "및" 결합]. Z1, Z2 및 Z5 라디칼은 기재된 최대 범위내에 바람직한 치환을 가질 수 있다[(경우 (A) 내지 (D)에서 "및" 결합]. In case (D), the novel pyrido [2,3-b] pyrazine derivatives may be substituted by "OZ12, SZ13" in one or more of its Z3, Z4 radicals, the novelty being of sub-case (a) Or by sub-case (b). When only one Z3, Z4 radical is the novel "NZ10Z11, OZ12, SZ13", the other Z3, Z4 radicals may have the desired substitution within the maximum range described in each case [(in sub-case (b) " And "bond". The Z1, Z2 and Z5 radicals may have the desired substitution within the maximum range described ("and" bond in cases (A) to (D)).

경우 (E)에서, 신규한 피리도[2,3-b]피라진 유도체는 하나 이상의 이의 Z1, Z2 라디칼에서 "NZ24Z25, NZ26Z27"에 의해 치환될 수 있고, 신규성은 하위-경우 (a)(1)에 의해, 하위-경우 (b)(1)(I), 하위-경우 (b)(1)(II) 또는 하위-경우 (b)(2)에 의해 일어난다. 단지 하나의 Z1, Z2 라디칼이 신규한 "NZ24Z25, NZ26Z27"인 경우, 나머지 Z1, Z2 라디칼은 각각의 경우 기재된 최대 범위내에 치환을 가질 수 있다[하위-경우 (c), (d)][(하위-경우 (b)(2)에서 "및" 결합]. Z3, Z4 및 Z5 라디칼은 기재된 최대 범위내에 치환을 갖는다[(하위-경우 (d)에서 "및" 결합].In case (E), the novel pyrido [2,3-b] pyrazine derivative may be substituted by "NZ24Z25, NZ26Z27" in one or more of its Z1, Z2 radicals, the novelty being in sub-case (a) (1 By sub-case (b) (1) (I), by sub-case (b) (1) (II) or by sub-case (b) (2). If only one Z1, Z2 radical is the novel "NZ24Z25, NZ26Z27", then the remaining Z1, Z2 radicals may have substitutions within the maximum ranges described in each case [sub-case (c), (d)] [( "And" bonds in the sub-case (b) (2) .Z3, Z4 and Z5 radicals have substitutions within the maximum ranges described (("and" bonds in the sub-case (d))).

바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (A)에서,In a preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (A)

Z1 라디칼은 독립적으로 "NZ14Z15"이고, 여기서, Z14는 수소 또는 "아릴"이고, Z15는 "C(O)NH알킬"이고, 여기서, "C(O)NH알킬"은 추가적으로, 임의로, "OH"에 의해 치환될 수 있고;Z1 radicals are independently "NZ14Z15" where Z14 is hydrogen or "aryl" and Z15 is "C (O) NHalkyl" where "C (O) NHalkyl" is additionally, optionally, "OH" May be substituted by ";

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from the group consisting of:

(a) "알킬, OC(O)알킬, O알킬, NHC(O)알킬"(a) "alkyl, OC (O) alkyl, Oalkyl, NHC (O) alkyl"

단, 치환체 그룹(a)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "아릴, 헤테로사이클릴, O알킬O알킬, O아릴알킬"(i) "aryl, heterocyclyl, OalkylOalkyl, Oarylalkyl"

또는 Z3 라디칼은 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고: Or the Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from the group consisting of:

(c) "OC(O)O알킬,OC(O)O아릴, OC(O)N(알킬)2, OC(O)NH알킬, OC(O)(C9-C30)알킬, NHC(O)O알킬, NHC(O)NH알킬, NHC(O)N(알킬)2, Si(알킬)3"(c) "OC (O) Oalkyl, OC (O) Oaryl, OC (O) N (alkyl) 2 , OC (O) NHalkyl, OC (O) (C 9 -C 30 ) alkyl, NHC ( O) Oalkyl, NHC (O) NHalkyl, NHC (O) N (alkyl) 2 , Si (alkyl) 3 "

여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "O알킬, O아릴알킬"(i) "Oalkyl, Oarylalkyl"

여기서, 임의로, Z3 라디칼은 또한 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the Z 3 radicals may also be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(d) "할로겐, F, Cl, Br, I, O알킬"(d) "halogen, F, Cl, Br, I, Oalkyl"

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소 Z5 radicals independently hydrogen

바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공될 수 있고, (A)에서,In a preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) may be provided as follows, in (A)

Z1 라디칼은 독립적으로 "NHC(O)NH에틸, NHC(O)NH부틸OH"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl, NHC (O) NHbutylOH",

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "4-페닐 메틸 카보네이트, 3-페닐 2-메톡시에틸 카보네이트, 4-페닐 2-메톡시에틸 카보네이트, 4-페닐 페닐 카보네이트, 4-페닐 N-디에틸카바메이트, 4-페닐 3-페닐아크릴레이트, 4-페닐 노나데카노에이트, 4-페닐 이소부틸 카보네이트, 4-페닐 부트-2-이닐 카보네이트, 4-페닐 N-디메틸카바메이트, 4-페닐 N-에틸카바메이트, 3급-부틸 N-(4-페닐)카바메이트, 2-메톡시에틸 N-(4-페닐)카바메이트, 4-(3-에틸우레아)페닐, 4-(3,3-메틸우레아)페닐, 4-모르폴린-4-일메틸페닐, 4-[2-(2-메톡시에톡시)에톡시]페닐, N-(4-페닐)-2-(2-메톡시에톡시)아세트아미드, 4-(2-메톡시)페닐 2-메톡시에틸 카보네이트, 4-페닐 2-벤질옥시에틸 카보네이트, 4-(2-메톡시)페닐 2-벤질옥시에틸 카보네이트, N-(4-페닐)-2-벤질옥시아세트아미드, 3-트리메틸실라닐페닐, 4-(2-메톡시)페닐 N-디에틸카바메이트, 4-(2-클로로-6-메톡시)페닐 N-디에틸카바메이트, 4-(2-메톡시)페닐 2-[2-(2-메톡시에톡시)에톡시]에틸 카보네이트"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently "4-phenyl methyl carbonate, 3-phenyl 2-methoxyethyl carbonate, 4-phenyl 2-methoxyethyl carbonate, 4-phenyl phenyl carbonate, 4-phenyl N-diethylcarbamate, 4- Phenyl 3-phenylacrylate, 4-phenyl nonadecanoate, 4-phenyl isobutyl carbonate, 4-phenyl but-2-ynyl carbonate, 4-phenyl N-dimethylcarbamate, 4-phenyl N-ethylcarbamate, Tert-butyl N- (4-phenyl) carbamate, 2-methoxyethyl N- (4-phenyl) carbamate, 4- (3-ethylurea) phenyl, 4- (3,3-methylurea) phenyl 4-morpholin-4-ylmethylphenyl, 4- [2- (2-methoxyethoxy) ethoxy] phenyl, N- (4-phenyl) -2- (2-methoxyethoxy) acetamide, 4- (2-methoxy) phenyl 2-methoxyethyl carbonate, 4-phenyl 2-benzyloxyethyl carbonate, 4- (2-methoxy) phenyl 2-benzyloxyethyl carbonate, N- (4-phenyl)- 2-benzyloxyacetamide, 3-trimethylsilanylphenyl, 4- (2-methoxy) phenyl N- Ethylcarbamate, 4- (2-chloro-6-methoxy) phenyl N-diethylcarbamate, 4- (2-methoxy) phenyl 2- [2- (2-methoxyethoxy) ethoxy] ethyl Carbonate ", and

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다. Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체 는 다음과 같이 제공되고, (B)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (B),

Z1 라디칼은 독립적으로 "NZ14Z15"이고, 여기서, Z14는 수소이고, Z15는 "C(O)NH알킬"이고;The Z1 radicals are independently "NZ14Z15", wherein Z14 is hydrogen and Z15 is "C (O) NHalkyl";

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "치환된 헤테로아릴", 여기서, "치환된 헤테로아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:Z 3 radicals are independently “substituted heteroaryl” wherein “substituted heteroaryl” is substituted by one or more substituents, identically or differently selected from the group consisting of:

(a) "NHC(O)NH알킬"(a) "NHC (O) NHalkyl"

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다. Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (B)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (B),

Z1 라디칼은 독립적으로 "NHC(O)NH에틸"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl",

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "6-(3-에틸우레아)피리딘-3-일"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently selected from the group consisting of "6- (3-ethylurea) pyridin-3-yl",

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다.Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서,화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (C)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula I are provided as follows, in (C),

Z1 라디칼은 독립적으로 "NZ14Z15"이고, 여기서, Z14는 수소이고, Z15는 "C(O)NH알킬"이고;The Z1 radicals are independently "NZ14Z15", wherein Z14 is hydrogen and Z15 is "C (O) NHalkyl";

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "치환된 알킬"이고, 여기서, "치환된 알킬"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:Z 3 radicals are independently “substituted alkyl” wherein “substituted alkyl” is substituted by one or more substituents identically or differently selected from the group consisting of:

(a) "아릴, 헤테로아릴, 사이클로알킬, N(알킬)2, O알킬"(a) "aryl, heteroaryl, cycloalkyl, N (alkyl) 2 , Oalkyl"

여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (a) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "할로겐, F, Cl, Br, I"(i) "halogen, F, Cl, Br, I"

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다.Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (C)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (C)

Z1 라디칼은 독립적으로 "NHC(O)NH에틸"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl",

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "페닐에티닐, 티오펜-3-일에티닐, 사이클로프로필에티닐, N-디메틸아미노프로프-1-이닐, 2-사이클로헥실비닐, 3-메톡시프로페닐, 벤질, 2-(4-플루오로페닐)에틸, 2-(4-플루오로페닐)비닐"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently "phenylethynyl, thiophen-3-ylethynyl, cyclopropylethynyl, N-dimethylaminoprop-1-ynyl, 2-cyclohexylvinyl, 3-methoxypropenyl, benzyl, 2- (4-fluorophenyl) ethyl, 2- (4-fluorophenyl) vinyl ", and

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다.Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (D)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (D)

Z1 라디칼은 독립적으로 "NZ14Z15"이고; 여기서, Z14는 수소이고, Z15는 "C(O)NH알킬"이고;The Z1 radicals are independently "NZ14Z15"; Wherein Z 14 is hydrogen and Z 15 is “C (O) NH alkyl”;

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z3 radicals are independently selected from the group consisting of:

(1) "NZ10Z11"(1) "NZ10Z11"

여기서, Z10, Z11 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein the Z10 and Z11 radicals are each independently selected from the group consisting of:

(a) "수소, 아릴"(a) "hydrogen, aryl"

단, 치환체 그룹(a)의 상기한 치환체는, 이들이 수소가 아닌 경우, 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents of substituent group (a) are further substituted by one or more substituents, each of which is independently the same or differently selected from the group consisting of:

(i) "사이클로알킬, 헤테로아릴, 헤테로사이클릴알킬, S(O)2알킬, NHS(O)2알킬, C(O)NH알킬, NHC(O)알킬, C(O)O알킬"(i) "cycloalkyl, heteroaryl, heterocyclylalkyl, S (O) 2 alkyl, NHS (O) 2 alkyl, C (O) NHalkyl, NHC (O) alkyl, C (O) Oalkyl"

(b) "C(O)아릴"(b) "C (O) aryl"

여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 및/또는 치환체 그룹(b) 은 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (a) and / or substituent group (b) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "알킬"(i) "alkyl"

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다.Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (D)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (D)

Z1 라디칼은 독립적으로 "NHC(O)NH에틸"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl",

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "4-메틸벤즈아미드, 4-사이클로헥실페닐아미노, 4-메탄설포닐페닐아미노, 3-(N-메탄설폰아미드)-4-메틸페닐아미노, 3-N-메틸벤즈아미드아미노, 4-피페리딘-1-일메틸페닐아미노, 4-티오펜-3-일페닐아미노, 4-N-아세트아미도페닐아미노, 3-(에틸 벤조에이트)아미노"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently "4-methylbenzamide, 4-cyclohexylphenylamino, 4-methanesulfonylphenylamino, 3- (N-methanesulfonamide) -4-methylphenylamino, 3-N-methylbenzamideamino , 4-piperidin-1-ylmethylphenylamino, 4-thiophen-3-ylphenylamino, 4-N-acetamidophenylamino, 3- (ethyl benzoate) amino ",

Z4 라디칼은 독립적으로 수소이고; Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다. Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (E)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (E),

Z1 라디칼 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z 1 radical is independently selected from the group consisting of:

(a) "NZ24Z25", 여기서, Z24는 수소이고, Z25는 "C(O)C(O)O알킬" 또는 "C(O)C(O)NH알킬" 또는 "C(O)NHO알킬"이고,(a) "NZ24Z25" wherein Z24 is hydrogen and Z25 is "C (O) C (O) Oalkyl" or "C (O) C (O) NHalkyl" or "C (O) NHOalkyl" ego,

여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents in substituent group (a) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "OSi(알킬)3, OC(O)NH알킬, OC(O)O알킬, P(O)(O알킬)2, P(O)(OH)2, O알킬"(i) "OSi (alkyl) 3 , OC (O) NHalkyl, OC (O) Oalkyl, P (O) (Oalkyl) 2 , P (O) (OH) 2 , Oalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(ii) "헤테로사이클릴, OH, N(알킬)2, OC(O)알킬"(ii) “heterocyclyl, OH, N (alkyl) 2 , OC (O) alkyl”

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (ii) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(iii) "알킬"(iii) "alkyl"

(b) "NZ26Z27", 여기서, Z26은 수소이고, Z27은 is "C(O)NH알킬"(b) "NZ26Z27" wherein Z26 is hydrogen and Z27 is "C (O) NHalkyl"

단, 치환체 그룹(b)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents of substituent group (b) are each independently further substituted by one or more substituents selected the same or differently from the group consisting of:

(i) "OSi(알킬)3, OC(O)NH알킬, OC(O)O알킬, P(O)(O알킬)2, P(O)(OH)2, O알 킬"(i) "OSi (alkyl) 3 , OC (O) NHalkyl, OC (O) Oalkyl, P (O) (Oalkyl) 2 , P (O) (OH) 2 , Oalalkyl"

여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(ii) "헤테로사이클릴, OH, N(알킬)2, OC(O)알킬"(ii) “heterocyclyl, OH, N (alkyl) 2 , OC (O) alkyl”

여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (ii) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(iii) "알킬"(iii) "alkyl"

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z3 radicals are independently selected from the group consisting of:

(a) "아릴"(a) "aryl"

여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents in substituent group (a) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "O알킬, OH"(i) "Oalkyl, OH"

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다.Z 5 radicals are independently hydrogen.

추가의 바람직한 양태에서, 화학식 I의 신규한 피리도[2,3-b]피라진 유도체는 다음과 같이 제공되고, (E)에서,In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (E),

Z1 라디칼은 독립적으로 "3-메톡시-1-일우레아, 3-(프로프-1-인-3-일)-1-일우레아, 3-[4-(3급-부틸디메틸실라닐옥시)부틸]-1-일우레아, 4-(N-에틸 카바메이트)부틸-1-일우레아, 4-(메틸 카보네이트)부틸-1-일우레아, 4-(2,3-디하이드록시프로필 카보네이트)부틸-1-일우레아, 4-(2,2-디메틸-[1,3]디옥솔란-4-일메틸 카보네이트)부틸-1-일우레아, 4-(디에틸 포스페이트)부틸-1-일우레아, 4-(부틸 포스페이트)-1-일우레아, N-옥살산 모노아미드 에틸 에스테르, N-에틸-N'-옥살아미드, 2-(디에틸 포스페이트)에틸-1-일우레아, 2-(에틸 포스페이트)-1-일우레아, 3-(2-디에틸아미노-에톡시)프로필-1-일우레아, 4-[(2,2-디메틸프로피오닐옥시메톡시)포스피노일옥시메틸 2,2-디메틸프로파노에이트]부틸-1-일우레아, 4-[1-(1-아세톡시에톡시)에톡시아세테이트]부틸-1-일우레아"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently "3-methoxy-1-ylurea, 3- (prop-1-yn-3-yl) -1-ylurea, 3- [4- (tert-butyldimethylsilanyloxy ) Butyl] -1-ylurea, 4- (N-ethyl carbamate) butyl-1-ylurea, 4- (methyl carbonate) butyl-1-ylurea, 4- (2,3-dihydroxypropyl carbonate ) Butyl-1-ylurea, 4- (2,2-dimethyl- [1,3] dioxolan-4-ylmethyl carbonate) butyl-1-ylurea, 4- (diethyl phosphate) butyl-1-yl Urea, 4- (butyl phosphate) -1-ylurea, N-oxalic acid monoamide ethyl ester, N-ethyl-N'-oxalamide, 2- (diethyl phosphate) ethyl-1-ylurea, 2- ( Ethyl phosphate) -1-ylurea, 3- (2-diethylamino-ethoxy) propyl-1-ylurea, 4-[(2,2-dimethylpropionyloxymethoxy) phosphinoyloxymethyl 2, 2-dimethylpropanoate] butyl-1-ylurea, 4- [1- (1-acetoxyethoxy) ethoxyacetate] butyl-1-ylurea " Is selected,

Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen;

Z3 라디칼은 독립적으로 "페닐, 4-하이드록시-3-메톡시페닐"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently selected from the group consisting of "phenyl, 4-hydroxy-3-methoxyphenyl",

Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen;

Z5 라디칼은 독립적으로 수소이다.Z 5 radicals are independently hydrogen.

본 발명의 추가의 양태는 화학식 II의 피리도[2,3-b]피라진의 그룹으로부터의 신규한 화합물에 관한 것이다. A further aspect of the invention relates to novel compounds from the group of pyrido [2,3-b] pyrazine of formula (II).

Figure 112008041801646-PCT00002
Figure 112008041801646-PCT00002

상기 화학식 II에서, In Chemical Formula II,

여기서, 치환체 R1-R4는 각각 다음에 정의된 바와 같다:Wherein the substituents R 1 -R 4 are each as defined below:

R1 및 R2는 각각 독립적으로 수소 또는 NR5R6일 수 있고, 단, R1 = NR5R6인 경우, R2 = H이고, R2 = NR5R6인 경우, R1 = H이고,R1 and R2 may each independently be hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H,

여기서, R5는 수소, 알킬, R38, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2 ,CHO, C(O)OH, C(O)OR12, C(O)NH2, C(O)NHR12, C(O)NR12R13, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R12 및 R13 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있거나, R12 및 R13은 함께 헤테로사이클릴 환일 수 있고,Wherein R 5 may be hydrogen, alkyl, R 38, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, Aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents are themselves each of F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (Alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) OR12, C (O) NH 2 , C (O) NHR12, C (O) NR12R13, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl , Mono- or polysubstituted identically or differently by heteroaryl, p may be a value of 0, 1, 2, 3, 4 or 5, and R12 and R13 radicals are each poison May be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R12 and R13 together may be a heterocyclyl ring,

R6은:R6 is:

-C(Y)NR7R8일 수 있고, 여기서, Y는 독립적으로 O 또는 S일 수 있고, R7 및 R8은 각각 독립적으로 다음과 같을 수 있다:-C (Y) NR7R8, wherein Y can be independently O or S, and R7 and R8 can each independently be:

수소, Hydrogen,

치환되지 않거나 치환된 알킬, 여기서, 알킬 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-사이클로알킬, S-헤테로사이클릴, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2,C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, Unsubstituted or substituted alkyl, wherein the alkyl radical is F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-hetero Aryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O ) -Heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylheteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O)- Interrogating heterocyclyl, OC (O) - aryl, OC (O) - heteroaryl, OC (O) - alkyl aryl, OC (O) - alkyl-heteroaryl, OSO 3 H, OSO 2 - alkyl, OSO 2 - cycloalkyl, , OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkylaryl, OSO 2 -alkylheteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C ( O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl Cycloalkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O ) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O ) N (heteroaryl) 2, SO- alkyl, SO- aryl, SO 2 - alkyl, SO 2 - aryl, SO 2 NH 2, SO 2 NH- alkyl, SO 2 NH- aryl, S O 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, cycloalkyl, heterocyclyl, aryl or hetero Mono- or polysubstituted identically or differently by aryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5,

치환되지 않거나 치환된 사이클로알킬, 여기서, 사이클로알킬 라디칼은 F, Cl, Br, I, NH2, NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, OH, O(-알킬O)p-알킬, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, CO2H, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, 알킬, 또는 아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, Unsubstituted or substituted cycloalkyl, wherein the cycloalkyl radical is F, Cl, Br, I, NH 2, NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH- Alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -Heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylheteroaryl, OH, O (-alkylO) p-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O)- Alkylaryl, OC (O) -alkylheteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -hete Loa reel, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, CO 2 H, CO 2 - alkyl, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 - alkyl-heteroaryl, C (O) -NH 2, C (O) NH- Alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C ( O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C Mono- or polysubstituted identically or differently by (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , alkyl, or aryl, wherein p is 0, 1, 2, 3 Can be a value of 4 or 5,

치환되지 않거나 치환된 헤테로사이클릴, 여기서, 헤테로사이클릴 라디칼은 OH, O-알킬, O-아릴, NH2, NH-알킬, NH-아릴, 알킬, 알킬아릴 또는 아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, Unsubstituted or substituted heterocyclyl, wherein the heterocyclyl radical is the same or differently selected by OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkylaryl or aryl Substituted or polysubstituted,

치환되지 않거나 치환된 아릴, 여기서, 아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬 아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-사이클로알킬, S-헤테로사이클릴, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, O-알킬OH, O-(CH2)n-O, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알 킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, n은 1, 2 또는 3의 값이고,Unsubstituted or substituted aryl, wherein the aryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl , NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O ) -Alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl aryl , NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylhetero Aryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylhetero Aryl, O- alkyl, OH, O- (CH 2) n -O, OC (O) - alkyl, OC (O) -R38, OC (O) - cycloalkyl, OC (O) - heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocycle Reel, OSO 2 - aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, C (O) - alkyl, C (O) - aryl, C (O) - heteroaryl, CO 2 H, CO 2 - alkyl, CO 2 -R38, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl, cycloalkyl Alkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O ) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkyl Heterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N ( Aryl) 2 , C ( O) N (heteroaryl) 2, SO- alkyl, SO- aryl, SO 2 - alkyl, SO 2 - aryl, SO 2 NH 2, SO 2 NH- alkyl, NH- SO 2 aryl, SO 2 NH- heteroaryl By, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl Same or differently mono- or polysubstituted, where p can be a value of 0, 1, 2, 3, 4 or 5, n is a value of 1, 2 or 3,

치환되지 않거나 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사 이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고,Unsubstituted or substituted heteroaryl, wherein the heteroaryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH -Aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O)- Alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2- Alkylheteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocycle Reel, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -R 38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl , OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkylaryl, OSO 2 -alkylheteroaryl, OP (O ) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -Heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl cycloalkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O ) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, hetero Mono- or polysubstituted identically or differently by cyclyl, aryl or heteroaryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5,

C(O)-R39, 여기서, R39는 알킬, 아릴 또는 헤테로아릴일 수 있고, 알킬, 아릴 및 헤테로아릴 치환체는 자체로 서로 치환될 수 있고,C (O) -R39, wherein R39 may be alkyl, aryl or heteroaryl, the alkyl, aryl and heteroaryl substituents may themselves be substituted for one another,

또는 R7 및 R8은 함께 헤테로사이클릴 환을 형성할 수 있고,Or R7 and R8 may together form a heterocyclyl ring,

R3 및 R4는 각각 독립적으로: R3 and R4 are each independently:

수소, 여기서, R3 및 R4는 동시에 수소, 치환된 알킬이 아니고, 여기서, 알킬 라디칼은 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OH, C(O)OR14, C(O)NH2, C(O)NHR14, C(O)NR14R15, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R14 및 R15 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R14 및 R15는 함께 헤테로사이클릴 환을 형성할 수 있고,Hydrogen, where R3 and R4 are not simultaneously hydrogen, substituted alkyl, wherein the alkyl radical is F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) OH, C (O) OR14, C (O) NH 2 , C (O) NHR14, C (O) NR14R15, SO 3 H, SO 2 Alkyl, SO Identically or differently by 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl Substituted or polysubstituted, wherein p can be a value of 0, 1, 2, 3, 4 or 5, wherein the R14 and R15 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, Alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R14 and R15 together may form a heterocyclyl ring,

치환된 아릴, 여기서, 아릴 라디칼은 NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, S-알킬, S-아릴, S-헤테로아릴, O-알킬, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 O(-알킬O)p-알킬, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OR16, C(O)NH2, C(O)NHR16, C(O)NR16R17, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환되고, 여기서, p는 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고, R16 및 R17 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있거나, R16 및 R17은 함께 헤테로사이클릴 환을 형성할 수 있고, Substituted aryl, wherein the aryl radical is NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl , NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2-alkyl aryl, NHSO 2-alkyl-heteroaryl, S- alkyl, S- aryl, S- heteroaryl, O- alkyl, O- cycloalkyl, O- heterocyclyl, O- aryl, O -Heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocycle Reel, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO2-alkyl, OSO2 -Cycloalkyl, OSO2-heterocyclyl, OSO2-aryl, OSO2-heteroaryl, OSO2-alkylaryl, OSO2-alkylheteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -hetero aryl, CO2- alkyl, CO2- cycloalkyl, CO2- heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 -alkylheteroaryl, C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO2-alkyl, SO2-aryl, SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl , To a group of heterocyclyl, aryl, heteroaryl and alkyl Disubstituted or polysubstituted, identically or differently, by a selected substituent, the cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves O (-) AlkylO) p-alkyl, OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) OR16, C (O) NH2, C (O) NHR16, C (O) NR16R17 , SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl or alkyl Substituted by aryl, wherein p is wherein p is a value of 0, 1, 2, 3, 4 or 5, and the R16 and R17 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, Heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R16 and R17 can together form a heterocyclyl ring,

단, R3 또는 R4가 알킬헤테로사이클릴-치환된 아릴인 경우, R4 또는 R3은 상응하는 아릴이고, Provided that when R 3 or R 4 is alkylheterocyclyl-substituted aryl, then R 4 or R 3 is the corresponding aryl,

여기서, 아릴 라디칼은 NR20-알킬, NH-R38, NHC(O)-R38, NR19C(O)-알킬, NR19C(O)-사이클로알킬, NR19C(O)-헤테로사이클릴, NR19C(O)-아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NR19C(O)-알킬아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, O-R38, OC(O)-R38, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴, OC(O)O-R19, OC(O)NR18R18, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)O-R38, C(O)NH-R38, C(O)NR20-알킬, C(O)NR19-알킬R21, C(O)NR18-O-R18, C(O)NR18NR18R18 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R22 및 R23 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R22 및 R23은 함께 헤테로사이클릴 환을 형성할 수 있고, Wherein the aryl radical is NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O) -aryl , NR19C (O) -heteroaryl, NR18C (O) -alkylcycloalkyl, NR18C (O) -alkylheterocyclyl, NR19C (O) -alkylaryl, NR19C (O) -alkylheteroaryl, NR18C (O) O -R19, NR18C (O) NR18R18, O-R38, OC (O) -R38, OC (O) -alkylcycloalkyl, OC (O) -alkylheterocyclyl, OC (O) O-R19, OC (O ) NR18R18, OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) O-R38, C (O) NH-R38, C (O) NR20-alkyl, C (O ) NR 19 -alkylR 21, C (O) NR 18 -O-R 18, C (O) NR 18 NR 18 R 18 and the same or differently substituted or substituted by a substituent selected from the group of alkyl, cycloalkyl, heterocyclyl, aryl, hetero The aryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO , C (O) OH, C (O) OR22, C (O) NH2, C (O) NHR22, C (O) NR22R23, SO3H, SO2 -alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, wherein p is 0, 1, Can have a value of 2, 3, 4 or 5, and the R22 and R23 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroarylyl Or R22 and R23 together may form a heterocyclyl ring,

치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, S-알킬, S-아릴, S-헤테로아릴, O-알킬, O-사이클로알킬, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO2-O-알킬, SO2-O-아릴, SO2-O- 알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 O(-알킬O)p-알킬, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OR16, C(O)NH2, C(O)NHR16, C(O)NR16R17, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환되고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고, R16 및 R17 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있거나, R16 및 R17은 함께 헤테로사이클릴 환을 형성할 수 있고,Substituted heteroaryl, wherein the heteroaryl radical is NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH- Alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O)- Aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 - heteroaryl, NHSO 2 - alkyl aryl, NHSO 2 - heteroaryl-alkyl, S- alkyl, S- aryl, heteroaryl, S-, O- alkyl, O- cycloalkyl, O- aryl, O- heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO2-alkyl, OSO2-between Chloalkyl, OSO2-heterocyclyl, OSO2-aryl, OSO2-heteroaryl, OSO2-alkylaryl, OSO2-alkylheteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl , CO2- alkyl, CO2- cycloalkyl, CO2- heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 -Alkylheteroaryl, C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, Substituents selected from the group of SO 2 NH-alkylaryl, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and alkyl Same by Differently disubstituted or polysubstituted, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves O (-alkylO) p-alkyl, OP (O) (O-alkyl) 2, OP (O) ( O aryl) 2, C (O) OR16 , C (O) NH2, C (O) NHR16, C (O) NR16R17, SO2 -alkyl, SO 2 aryl , P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, wherein , p can be a value of 0, 1, 2, 3, 4 or 5, and R16 and R17 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl , Alkylaryl or alkylheteroaryl, or R16 and R17 may together form a heterocyclyl ring,

여기서, 헤테로아릴 라디칼은 NR20-알킬, NH-R38, NHC(O)-R38, NR19C(O)-알킬, NR19C(O)-사이클로알킬, NR19C(O)-헤테로사이클릴, NR19C(O)-아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NR19C(O)-알킬아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-알킬헤테로사이클릴, O-R38, O-헤테로사이클릴, OC(O)-R38, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴, OC(O)O-R19, OC(O)NR18R18, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)O-R38, C(O)NH-R38, C(O)NR20-알킬, C(O)NR19-알킬R21, C(O)NR18-O-R18, C(O)NR18NR18R18, 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이 하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R22 및 R23 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R22 및 R23은 함께 헤테로사이클릴 환을 형성할 수 있고, Wherein the heteroaryl radical is NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O)- Aryl, NR 19 C (O) -heteroaryl, NR 18 C (O) -alkylcycloalkyl, NR 18 C (O) -alkylheterocyclyl, NR 19 C (O) -alkylaryl, NR 19 C (O) -alkylheteroaryl, NR 18 C (O) O-R19, NR18C (O) NR18R18, NHSO2-alkylheterocyclyl, O-R38, O-heterocyclyl, OC (O) -R38, OC (O) -alkylcycloalkyl, OC (O) -alkylhetero Cyclyl, OC (O) O-R19, OC (O) NR18R18, OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) O-R38, C (O) NH Disubstituted the same or differently by a substituent selected from the group of —R 38, C (O) NR 20 -alkyl, C (O) NR 19 -alkylR 21, C (O) NR 18 -O-R 18, C (O) NR 18 NR 18 R 18, and alkyl Or polysubstituted, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves each other F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) OR22, C (O) NH2, C ( O) NHR 22, C (O) NR 22 R 23, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, May be substituted by cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p may be a value of 0, 1, 2, 3, 4 or 5, and the R22 and R23 radicals are each independently alkyl , Cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R22 and R23 can together form a heterocyclyl ring,

NR24R25, 여기서, R24는 -C(O)-R26, SO2R26, C(O)OR26 또는 C(O)-NR27R28일 수 있고, 여기서, R25는 수소, 알킬, 사이클로알킬, 아릴 또는 헤테로아릴일 수 있고, 여기서, R26은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, R27 및 R28은 각각 독립적으로 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, 또는 R27 및 R28은 함께 헤테로사이클릴 환을 형성할 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클 릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,NR24R25, wherein R24 can be -C (O) -R26, SO2R26, C (O) OR26 or C (O) -NR27R28, wherein R25 can be hydrogen, alkyl, cycloalkyl, aryl or heteroaryl , Wherein R 26 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, and R27 and R28 are each independently hydrogen, alkyl, cyclo Alkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, or R27 and R28 together may form a heterocyclyl ring, alkyl, cycloalkyl , Heterocyclyl, aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for each other,

R18은 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R18 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,

R19는 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R 19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,

R20은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R20 may be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,

R21은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴일 수 있고,R21 may be cycloalkyl, heterocyclyl, aryl, heteroaryl,

R38은 알킬일 수 있고, 여기서, 알킬 라디칼은 9 내지 30개의 탄소원자를 갖는 포화되거나 불포화된, 직쇄 또는 측쇄일 수 있고, C9-30-알칸일, C9-30-알케닐 및 C9-30-알키닐이다. 알케닐은 하나 이상의 C-C 이중결합을 갖고, 알키닐은 하나 이상의 C-C 삼중결합을 갖고, 여기서, 알케닐은 (E)- 또는 (Z)-배치로 존재할 수 있다. 알킬 라디칼은 노닐, 데실, 도데실, 헥사데실, 옥타데실, 에이코실, 헤니코실, 도코실, 테트라코실, 노나코실, 옥타데세닐, 도코세닐, 테트라코세닐 및 옥타데시닐을 포함하는 그룹으로부터 선택된다. R 38 may be alkyl, wherein the alkyl radical may be saturated or unsaturated, straight or branched chain having 9 to 30 carbon atoms, C 9-30 -alkanyl , C 9-30 -alkenyl and C 9- 30 -alkynyl. Alkenyl has one or more CC double bonds and alkynyl has one or more CC triple bonds, where alkenyl may be present in (E)-or (Z) -configuration. Alkyl radicals include groups including nonyl, decyl, dodecyl, hexadecyl, octadecyl, eicosyl, henicosyl, docosyl, tetracosyl, nonacosyl, octadecenyl, docosenyl, tetracosenyl and octadecynyl Is selected from.

추가의 양태에서, 본 발명은 화학식 II의 피리도[2,3-b]피라진의 그룹으로부터의 신규한 화합물을 기술한다. In a further aspect, the present invention describes novel compounds from the group of pyrido [2,3-b] pyrazine of formula (II).

화학식 IIFormula II

Figure 112008041801646-PCT00003
Figure 112008041801646-PCT00003

상기 화학식 II에서, In Chemical Formula II,

여기서, 치환체 R1-R4는 각각 다음에 정의된 바와 같다:Wherein the substituents R 1 -R 4 are each as defined below:

R1 및 R2는 각각 독립적으로 수소 또는 NR5R6일 수 있고, 단, R1 = NR5R6인 경우, R2 = H이고, R2 = NR5R6인 경우, R1 = H이고,R1 and R2 may each independently be hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H,

여기서, R5는 수소, 알킬, R38, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)NH2, C(O)OR12, C(O)NHR12, C(O)NR12R13, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R12 및 R13 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있거나, R12 및 R13은 함께 헤 테로사이클릴 환일 수 있고,Wherein R 5 may be hydrogen, alkyl, R 38, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, Aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents are themselves each of F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (Alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) NH 2 , C (O) OR12, C (O) NHR12, C (O) NR12R13, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl , Mono- or polysubstituted identically or differently by heteroaryl, p may be a value of 0, 1, 2, 3, 4 or 5, and R12 and R13 radicals are each Neutral by alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, may be a alkyl aryl or alkyl-heteroaryl, R12 and R13 may together H. Tero heterocyclyl sun dog,

R6은:R6 is:

-C(O)NR9-Y-R10일 수 있고, 여기서, Y는 독립적으로 O 또는 NR11일 수 있고, -C (O) NR9-Y-R10, wherein Y can be independently O or NR11,

R9는 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 치환될 수 있고,R9 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl , Alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may be substituted by themselves,

R10 및 R11은 각각 독립적으로 다음과 같을 수 있고;R10 and R11 may each independently be as follows;

수소, Hydrogen,

치환되지 않거나 치환된 알킬, Unsubstituted or substituted alkyl,

치환되지 않거나 치환된 사이클로알킬, Unsubstituted or substituted cycloalkyl,

치환되지 않거나 치환된 헤테로사이클릴, 여기서, 헤테로사이클릴 라디칼은 OH, O-알킬, O-아릴, NH2, NH-알킬, NH-아릴, 알킬, 알킬아릴 또는 아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, Unsubstituted or substituted heterocyclyl, wherein the heterocyclyl radical is the same or differently selected by OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkylaryl or aryl Substituted or polysubstituted,

치환되지 않거나 치환된 아릴, 여기서, 아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬 아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-사이클로알킬, S-헤테로사이클릴, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, O-알킬OH, O-(CH2)n-O, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알 킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, n은 1, 2 또는 3의 값이고,Unsubstituted or substituted aryl, wherein the aryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl , NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O ) -Alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl aryl , NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylhetero Aryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylhetero Aryl, O- alkyl, OH, O- (CH 2) n -O, OC (O) - alkyl, OC (O) -R38, OC (O) - cycloalkyl, OC (O) - heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocycle Reel, OSO 2 - aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, C (O) - alkyl, C (O) - aryl, C (O) - heteroaryl, CO 2 H, CO 2 - alkyl, CO 2 -R38, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl, cycloalkyl Alkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O ) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkyl Heterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N ( Aryl) 2 , C ( O) N (heteroaryl) 2, SO- alkyl, SO- aryl, SO 2 - alkyl, SO 2 - aryl, SO 2 NH 2, SO 2 NH- alkyl, NH- SO 2 aryl, SO 2 NH- heteroaryl By, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl Same or differently mono- or polysubstituted, where p can be a value of 0, 1, 2, 3, 4 or 5, n is a value of 1, 2 or 3,

치환되지 않거나 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬,NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사 이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고,Unsubstituted or substituted heteroaryl, wherein the heteroaryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH -Aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O)- Alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2- Alkylheteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocycle Reel, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -R3 8, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl , OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkylaryl, OSO 2 -alkylheteroaryl, OP (O ) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -Heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl cycloalkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O ) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, hetero Mono- or polysubstituted identically or differently by cyclyl, aryl or heteroaryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5,

또는 R10 및 R11은 함께 헤테로사이클릴 환을 형성할 수 있고,Or R10 and R11 may together form a heterocyclyl ring,

R3 및 R4는 각각 독립적으로 다음과 같을 수 있다:R3 and R4 may each independently be as follows:

수소Hydrogen

하이드록실Hydroxyl

할로겐, 예를 들면, 불소, 염소, 브롬, 요오드Halogen, for example fluorine, chlorine, bromine, iodine

치환되지 않거나 치환된 알킬, 여기서, 알킬 라디칼은 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OH, C(O)OR14, C(O)NH2, C(O)NHR14, C(O)NR14R15, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동 일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R14 및 R15 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R14 및 R15는 함께 헤테로사이클릴 환을 형성할 수 있고,Unsubstituted or substituted alkyl, wherein the alkyl radical is selected from F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) OH, C (O) OR14, C (O) NH 2 , C (O) NHR14, C (O) NR14R15, SO 3 H, SO 2 Alkyl, SO 2 Aryl, P (O) (OH) Mono- or polysubstituted identically or differently by 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein , p can be a value of 0, 1, 2, 3, 4 or 5, and R14 and R15 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, Alkylaryl or alkylheteroaryl, or R 14 and R 15 together may form a heterocyclyl ring,

치환되지 않거나 치환된 아릴, 여기서, 아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬,NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NR20-알킬, NHC(O)-알킬, NHC(O)-R38, NR19(O)-알킬, NHC(O)-사이클로알킬, NR19C(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NR19C(O)-헤테로사이클릴, NHC(O)-아릴, NR19C(O)-아릴, NHC(O)-헤테로아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NHC(O)-알킬아릴, NR19C(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬헤테로사이클릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, O-(CH2)n-O, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤 테로아릴, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴 OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OC(O)O-R19, OC(O)NR18R18, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)-알킬, C(O)-아릴,C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, C(O)NR20-알킬, C(O)NR19-알킬R21, -C(O)NR18-O-R18, -C(O)NR18NR18R18, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, n은 1, 2 또는 3의 값으로 추정될 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,Unsubstituted or substituted aryl, wherein the aryl radical is selected from F, Cl, Br, I, CF 3, CN, NH 2, NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH -Heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NR 20 -alkyl, NHC (O) -alkyl , NHC (O) -R38, NR19 (O) -alkyl, NHC (O) -cycloalkyl, NR19C (O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -heterocyclyl, NHC (O) -aryl, NR 19 C (O) -aryl, NHC (O) -heteroaryl, NR 19 C (O) -heteroaryl, NR 18 C (O) -alkylcycloalkyl, NR 18 C (O) -alkylheterocyclyl, NHC ( O) -alkylaryl, NR19C (O) -alkylaryl, NHC (O) -alkylheteroaryl, NR19C (O) -alkylheteroaryl, NR18C (O) O-R19, NR18C (O) NR18R18, NHSO 2 -alkyl , NHSO 2 - cycloalkyl, NHSO 2 - heterocyclyl, NHSO 2 - aryl, NHSO 2 - heteroaryl, NHSO 2 - alkyl-heterocyclyl, NHSO 2 - alkyl aryl, NHSO 2 - heterocyclic alkyl ah , NO 2, SH, S- alkyl, S- aryl, S- heteroaryl, OH, OCF 3, O- alkyl, O-R38, O- cycloalkyl, O- heterocyclyl, O- aryl, O- heteroaryl Aryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylcycloalkyl, OC (O) -alkylheterocycle Reyl OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OC (O) O-R19, OC (O) NR18R18, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2- heterocyclyl, OSO 2 - aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, OP (O) (O -alkyl) 2, OP (O ) (Oaryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2-heterocyclyl, CO 2 aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 -Alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH- Heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl , C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl ) 2 , C (O) NR 20 -alkyl, C (O) NR 19 -alkylR 21, -C (O) NR 18 -O-R 18, -C (O) NR 18 NR 18 R 18, SO-alkyl, SO-aryl, SO 2 -alkyl , SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 Identical or different mono-substituted by -O-aryl, SO 2 -O-alkylaryl, alkyl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl Or polysubstituted, n can be estimated to be 1, 2 or 3, alkyl, cycloal , Heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl aryl and alkyl-heteroaryl substituents may be substituted with one another per se,

치환되지 않거나 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NR20-알킬, NHC(O)-알킬, NHC(O)-R38, NR19C(O)-알킬, NHC(O)-사이클로알킬, NR19C(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NR19C(O)-헤테로사이클릴, NHC(O)-아릴, NR19C(O)-아릴, NHC(O)-헤테로아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NHC(O)-알킬아릴, NR19C(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬헤테로사이클릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴 OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OC(O)O-R19, OC(O)NR18R18, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)-알킬, C(O)- 아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, C(O)NR20-알킬, C(O)NR19-알킬R21, -C(O)NR18-O-R18, -C(O)NR18NR18R18, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,Unsubstituted or substituted heteroaryl, wherein the heteroaryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH -Aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NR 20 -alkyl, NHC ( O) -alkyl, NHC (O) -R38, NR19C (O) -alkyl, NHC (O) -cycloalkyl, NR19C (O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -hetero Cyclyl, NHC (O) -aryl, NR19C (O) -aryl, NHC (O) -heteroaryl, NR19C (O) -heteroaryl, NR18C (O) -alkylcycloalkyl, NR18C (O) -alkylheterocycle Reel, NHC (O) -alkylaryl, NR19C (O) -alkylaryl, NHC (O) -alkylheteroaryl, NR19C (O) -alkylheteroaryl, NR18C (O) O-R19, NR18C (O) NR18R18, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylheterocyclyl, NHSO 2 -alkylaryl, NHSO 2 -alkylheteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O- Aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -R38, OC (O)- Cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylcycloalkyl, OC (O) -alkylheterocyclyl OC (O)- alkylaryl, OC (O) - alkyl-heteroaryl, OC (O) O-R19 , OC (O) NR18R18, OSO 3 H, OSO 2 - alkyl, OSO 2 - cycloalkyl, OSO 2 - heterocyclyl, OSO 2 -aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, OP (O) (O -alkyl) 2, OP (O) ( O aryl) 2 , C (O) - alkyl, C (O) - aryl, C (O) - heteroaryl, CO 2 H, CO 2 - alkyl, CO 2 -R38, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl heterocyclic , CO 2 - alkyl, aryl, CO 2 - alkyl-heteroaryl, C (O) -NH 2, C (O) NH- alkyl, C (O) NH-R38, C (O) NH- cycloalkyl, C (O ) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH -Alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (Heteroaryl) 2 , C (O) NR 20 -alkyl, C (O) NR 19 -alkyl R 21, -C (O) NR 18 -O-R 18, -C (O) NR 18 NR 18 R 18, SO 2 NH 2 , SO 2 NH— Alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, It may be the same or different mono- or polysubstituted by alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, alkyl, cycloalkyl, heterocyclyl , Aryl, heteroaryl, alkylcycloalkyl, alkylheterosa Cyclyl, alkylaryl and alkylheteroaryl substituents may themselves be substituted for one another,

OR29, 여기서, R29는 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,OR29, wherein R29 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl, Heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for one another,

SR30, 여기서, R30은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,SR30, wherein R30 can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl and Heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for one another,

NR31R32, 여기서, R31 및 R32는 각각 독립적으로 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴, -C(O)-R33, SO2R33, C(O)OR33 및 C(O)-NR34R35일 수 있고, 여기서, R33은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴,알킬헤테로아릴일 수 있고, R34 및 R35는 각각 독립적으로 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, 또는 R34 및 R35는 함께 헤테로사이클릴 환을 형성할 수 있고, NR31R32, wherein R31 and R32 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, -C (O) -R33 , SO2R33, C (O) OR33 and C (O) -NR34R35, wherein R33 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkyl Heteroaryl, R34 and R35 may each independently be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, or R34 And R 35 may together form a heterocyclyl ring,

또는 R31 및 R32는 함께 헤테로사이클릴 환을 형성할 수 있고, Or R31 and R32 may together form a heterocyclyl ring,

알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,Alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for one another,

R18은 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R18 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,

R19는 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클 로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,

R20은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R20 may be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,

R21은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴일 수 있고,R21 may be cycloalkyl, heterocyclyl, aryl, heteroaryl,

R38은 알킬일 수 있고, 여기서, 알킬 라디칼은 9 내지 30개의 탄소원자를 갖는 포화되거나 불포화된, 직쇄 또는 측쇄일 수 있고, C9-30-알칸일, C9-30-알케닐 및 C9-30-알키닐이다. 알케닐은 하나 이상의 C-C 이중결합을 갖고, 알키닐은 하나 이상의 C-C 삼중결합을 갖고, 여기서, 알케닐은 (E)- 또는 (Z)-배치로 존재할 수 있다. 알킬 라디칼은 노닐, 데실, 도데실, 헥사데실, 옥타데실, 에이코실, 헤니코실, 도코실, 테트라코실, 노나코실, 옥타데세닐, 도코세닐, 테트라코세닐 및 옥타데시닐을 포함하는 그룹으로부터 선택된다. R 38 may be alkyl, wherein the alkyl radical may be saturated or unsaturated, straight or branched chain having 9 to 30 carbon atoms, C 9-30 -alkanyl , C 9-30 -alkenyl and C 9- 30 -alkynyl. Alkenyl has one or more CC double bonds and alkynyl has one or more CC triple bonds, where alkenyl may be present in (E)-or (Z) -configuration. Alkyl radicals include groups including nonyl, decyl, dodecyl, hexadecyl, octadecyl, eicosyl, henicosyl, docosyl, tetracosyl, nonacosyl, octadecenyl, docosenyl, tetracosenyl and octadecynyl Is selected from.

R2 = H인 화학식 II의 피리도[2,3-b]피라진 유도체를 제공하는 것이 특히 바람직하다. It is particularly preferred to provide pyrido [2,3-b] pyrazine derivatives of formula II wherein R 2 = H.

R2 및 R4 = H인 화학식 II의 피리도[2,3-b]피라진 유도체를 제공하는 것이 추가로 특히 바람직하다. It is further particularly preferred to provide pyrido [2,3-b] pyrazine derivatives of formula II wherein R2 and R4 = H.

이의 유리 염기 또는 그외에 생리학적으로 허용되는 산의 약제학적으로 허용되는 염 형태로 존재할 수 있는 화학식 I 및 II의 다음의 피리도[2,3-b]피라진 유도체를 제공하는 것이 바람직하다:Preference is given to the following pyrido [2,3-b] pyrazine derivatives of the formulas (I) and (II) which may exist in their free base or else in the form of a pharmaceutically acceptable salt of a physiologically acceptable acid:

화합물 1 1-에틸-3-(3-페닐에티닐피리도[2,3-b]피라진-6-일)우레아Compound 1 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea

Figure 112008041801646-PCT00004
Figure 112008041801646-PCT00004

화합물 2 1-에틸-3-(3-티오펜-3-일에티닐피리도[2,3-b]피라진-6-일)우레아Compound 2 1-ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazin-6-yl) urea

Figure 112008041801646-PCT00005
Figure 112008041801646-PCT00005

화합물 3 1-(3-사이클로프로필에티닐피리도[2,3-b]피라진-6-일)-3-에틸우레아Compound 3 1- (3-cyclopropylethynylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea

Figure 112008041801646-PCT00006
Figure 112008041801646-PCT00006

화합물 4 1-[3-(3-디메틸아미노프로프-1-이닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 4 1- [3- (3-dimethylaminoprop-1-ynyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Figure 112008041801646-PCT00007
Figure 112008041801646-PCT00007

화합물 5 1-[3-((E)-2-사이클로헥실비닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 5 1- [3-((E) -2-cyclohexylvinyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Figure 112008041801646-PCT00008
Figure 112008041801646-PCT00008

화합물 6 1-에틸-3-[3-((E)-3-메톡시프로페닐)피리도[2,3-b]피라진-6-일]우 레아Compound 6 1-ethyl-3- [3-((E) -3-methoxypropenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00009
Figure 112008041801646-PCT00009

화합물 7Compound 7

Figure 112008041801646-PCT00010
Figure 112008041801646-PCT00010

화합물 8Compound 8

Figure 112008041801646-PCT00011
Figure 112008041801646-PCT00011

화합물 9 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 메틸 카보네이트Compound 9 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate

Figure 112008041801646-PCT00012
Figure 112008041801646-PCT00012

화합물 10 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트Compound 10 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate

Figure 112008041801646-PCT00013
Figure 112008041801646-PCT00013

화합물 11 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 페닐 카보네이트Compound 11 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl phenyl carbonate

Figure 112008041801646-PCT00014
Figure 112008041801646-PCT00014

화합물 12 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 디에틸카바메이트Compound 12 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl diethylcarbamate

Figure 112008041801646-PCT00015
Figure 112008041801646-PCT00015

화합물 13 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 (E)-3-페닐아크릴레이트Compound 13 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate

Figure 112008041801646-PCT00016
Figure 112008041801646-PCT00016

화합물 14 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 노나데카노에이트Compound 14 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate

Figure 112008041801646-PCT00017
Figure 112008041801646-PCT00017

화합물 15 1-(3-벤질피리도[2,3-b]피라진-6-일)-3-에틸우레아Compound 15 1- (3-benzylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea

Figure 112008041801646-PCT00018
Figure 112008041801646-PCT00018

화합물 16 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트Compound 16 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate

Figure 112008041801646-PCT00019
Figure 112008041801646-PCT00019

화합물 17 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 이소부틸 카보네이트Compound 17 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl isobutyl carbonate

Figure 112008041801646-PCT00020
Figure 112008041801646-PCT00020

화합물 18 부트-2-이닐 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트Compound 18 But-2-ynyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate

Figure 112008041801646-PCT00021
Figure 112008041801646-PCT00021

화합물 19 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 디메틸카바메이트Compound 19 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl dimethylcarbamate

Figure 112008041801646-PCT00022
Figure 112008041801646-PCT00022

화합물 20 4-[6-(3-에틸-1-페닐우레아)피리도[2,3-b]피라진-3-일]페닐 에틸카바메이트Compound 20 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl ethylcarbamate

Figure 112008041801646-PCT00023
Figure 112008041801646-PCT00023

화합물 21 3급-부틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-카바메이트 Compound 21 tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate

Figure 112008041801646-PCT00024
Figure 112008041801646-PCT00024

화합물 22 2-메톡시에틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-카바메이트Compound 22 2-methoxyethyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate

Figure 112008041801646-PCT00025
Figure 112008041801646-PCT00025

화합물 23 1-에틸-3-{3-[4-(3-에틸우레아)페닐]피리도[2,3-b]피라진-6-일}우레아Compound 23 1-ethyl-3- {3- [4- (3-ethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} urea

Figure 112008041801646-PCT00026
Figure 112008041801646-PCT00026

화합물 24 1-{3-[4-(3,3-디메틸우레아)페닐]피리도[2,3-b]피라진-6-일}-3-에틸우레아Compound 24 1- {3- [4- (3,3-dimethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea

Figure 112008041801646-PCT00027
Figure 112008041801646-PCT00027

화합물 25 1-에틸-3-{3-[6-(3-에틸우레아)피리딘-3-일]피리도[2,3-b]피라진-6-일}우레아Compound 25 1-ethyl-3- {3- [6- (3-ethylurea) pyridin-3-yl] pyrido [2,3-b] pyrazin-6-yl} urea

Figure 112008041801646-PCT00028
Figure 112008041801646-PCT00028

화합물 26 1-에틸-3-{3-[2-(4-플루오로페닐)에틸]피리도[2,3-b]피라진-6-일}우레아Compound 26 1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea

Figure 112008041801646-PCT00029
Figure 112008041801646-PCT00029

화합물 27 1-에틸-3-{3-[(E)-2-(4-플루오로페닐)비닐]피리도[2,3-b]피라진-6-일}-우레아Compound 27 1-ethyl-3- {3-[(E) -2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-yl} -urea

Figure 112008041801646-PCT00030
Figure 112008041801646-PCT00030

화합물 28 1-에틸-3-[3-(4-모르폴린-4-일메틸페닐)피리도[2,3-b]피라진-6-일]우레아Compound 28 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00031
Figure 112008041801646-PCT00031

화합물 29 1-에틸-3-(3-{4-[2-(2-메톡시에톡시)에톡시]페닐}피리도[2,3-b]피라진-6-일)우레아Compound 29 1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea

Figure 112008041801646-PCT00032
Figure 112008041801646-PCT00032

화합물 30 N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-2-(2-메톡시에톡시)아세트아미드Compound 30 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -2- (2-methoxyethoxy) acetamide

Figure 112008041801646-PCT00033
Figure 112008041801646-PCT00033

화합물 31 N-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-4-메틸벤즈아미드Compound 31 N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide

Figure 112008041801646-PCT00034
Figure 112008041801646-PCT00034

화합물 32 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 2-메톡시에틸 카보네이트Compound 32 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2-methoxyethyl carbonate

Figure 112008041801646-PCT00035
Figure 112008041801646-PCT00035

화합물 33 2-벤질옥시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트Compound 33 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate

Figure 112008041801646-PCT00036
Figure 112008041801646-PCT00036

화합물 34 2-벤질옥시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 카보네이트Compound 34 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl carbonate

Figure 112008041801646-PCT00037
Figure 112008041801646-PCT00037

화합물 35 2-벤질옥시-N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-아세트아미드Compound 35 2-benzyloxy-N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -acetamide

Figure 112008041801646-PCT00038
Figure 112008041801646-PCT00038

화합물 36 1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-(3-페닐피리도[2,3-b]-피라진-6-일)우레아Compound 36 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3-b] -pyrazin-6-yl) urea

Figure 112008041801646-PCT00039
Figure 112008041801646-PCT00039

화합물 37 1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아Compound 37 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine-6- Urea

Figure 112008041801646-PCT00040
Figure 112008041801646-PCT00040

화합물 38 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 에틸카바메이트Compound 38 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate

Figure 112008041801646-PCT00041
Figure 112008041801646-PCT00041

화합물 39 메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네 이트Compound 39 Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

Figure 112008041801646-PCT00042
Figure 112008041801646-PCT00042

화합물 40 2,2-디메틸[1,3]디옥솔란-4-일메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트Compound 40 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

Figure 112008041801646-PCT00043
Figure 112008041801646-PCT00043

화합물 41 2,3-디하이드록시프로필 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]-부틸 카보네이트Compound 41 2,3-dihydroxypropyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] -butyl carbonate

Figure 112008041801646-PCT00044
Figure 112008041801646-PCT00044

화합물 42 디에틸 {4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}-포스페이트 Compound 42 diethyl {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} -phosphate

Figure 112008041801646-PCT00045
Figure 112008041801646-PCT00045

화합물 43 {4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}인산Compound 43 {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphate

Figure 112008041801646-PCT00046
Figure 112008041801646-PCT00046

화합물 44 디에틸 (4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라 진-6-일]우레아}부틸)포스페이트 Compound 44 diethyl (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate

Figure 112008041801646-PCT00047
Figure 112008041801646-PCT00047

화합물 45 (4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)인산Compound 45 (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate

Figure 112008041801646-PCT00048
Figure 112008041801646-PCT00048

화합물 46 1-에틸-3-[3-(3-트리메틸실라닐페닐)피리도[2,3-b]피라진-6-일]우레아Compound 46 1-ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00049
Figure 112008041801646-PCT00049

화합물 47 1-[3-(4-사이클로헥실페닐아미노)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 47 1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Figure 112008041801646-PCT00050
Figure 112008041801646-PCT00050

화합물 48 1-에틸-3-[3-(4-메탄설포닐페닐아미노)피리도[2,3-b]-피라진-6-일]우레아Compound 48 1-ethyl-3- [3- (4-methanesulfonylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea

Figure 112008041801646-PCT00051
Figure 112008041801646-PCT00051

화합물 49 N-{5-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]-2-메틸-페닐}메탄설폰아미드Compound 49 N- {5- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -2-methyl-phenyl} methanesulfonamide

Figure 112008041801646-PCT00052
Figure 112008041801646-PCT00052

화합물 50 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]-N-메틸-벤즈아미드Compound 50 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -N-methyl-benzamide

Figure 112008041801646-PCT00053
Figure 112008041801646-PCT00053

화합물 51 1-에틸-3-[3-(4-피페리딘-1-일메틸페닐아미노)피리도[2,3-b]-피라진-6-일]우레아Compound 51 1-ethyl-3- [3- (4-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea

Figure 112008041801646-PCT00054
Figure 112008041801646-PCT00054

화합물 52 1-에틸-3-[3-(4-티오펜-3-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 52 1-ethyl-3- [3- (4-thiophen-3-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00055
Figure 112008041801646-PCT00055

화합물 53 N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]페닐}-아세트아미드Compound 53 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] phenyl} -acetamide

Figure 112008041801646-PCT00056
Figure 112008041801646-PCT00056

화합물 54 에틸 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]벤조에이트 Compound 54 ethyl 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] benzoate

Figure 112008041801646-PCT00057
Figure 112008041801646-PCT00057

화합물 55 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트 하이드로클로라이드Compound 55 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride

Figure 112008041801646-PCT00058
Figure 112008041801646-PCT00058

화합물 56 2-메톡시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트 p-톨루엔설포네이트Compound 56 2-methoxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate p-toluenesulfonate

Figure 112008041801646-PCT00059
Figure 112008041801646-PCT00059

화합물 57 4-{6-[3-(4-하이드록시부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트Compound 57 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate

Figure 112008041801646-PCT00060
Figure 112008041801646-PCT00060

화합물 58 4-{6-[3-(4-하이드록시부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트 하이드로클로라이드Compound 58 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride

Figure 112008041801646-PCT00061
Figure 112008041801646-PCT00061

화합물 59 N-(3-페닐피리도[2,3-b]피라진-6-일)옥살산 모노아미드 에틸 에스테르Compound 59 N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalic acid monoamide ethyl ester

Figure 112008041801646-PCT00062
Figure 112008041801646-PCT00062

화합물 60 N-에틸-N'-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미드Compound 60 N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide

Figure 112008041801646-PCT00063
Figure 112008041801646-PCT00063

화합물 61Compound 61

Figure 112008041801646-PCT00064
Figure 112008041801646-PCT00064

화합물 62 디에틸 {2-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]에틸}-포스페이트 Compound 62 Diethyl {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} -phosphate

Figure 112008041801646-PCT00065
Figure 112008041801646-PCT00065

화합물 63 {2-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]에틸}인산Compound 63 {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} phosphate

Figure 112008041801646-PCT00066
Figure 112008041801646-PCT00066

화합물 64 1-[3-(2-디에틸아미노에톡시)프로필]-3-[3-(4-하이드록시-3-메톡시-페닐)피리도[2,3-b]피라진-6-일]우레아Compound 64 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea

Figure 112008041801646-PCT00067
Figure 112008041801646-PCT00067

화합물 65 (2,2-디메틸프로피오닐옥시메톡시)-(4-{3-[3-(4-하이드록시-3-메톡시-페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스피노일옥시메틸 2,2-디메틸-프로파노에이트Compound 65 (2,2-dimethylpropionyloxymethoxy)-(4- {3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea} butyl) phosphinoyloxymethyl 2,2-dimethyl-propanoate

Figure 112008041801646-PCT00068
Figure 112008041801646-PCT00068

화합물 66 1-[(1-아세톡시에톡시)-(4-{3-[3-(4-하이드록시-3-메톡시페닐)-피리도[2,3-b]피라진-6-일]우레아}부틸)포스피노일옥시]에틸 아세테이트Compound 66 1-[(1-acetoxyethoxy)-(4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazin-6-yl ] Urea} butyl) phosphinoyloxy] ethyl acetate

Figure 112008041801646-PCT00069
Figure 112008041801646-PCT00069

화합물 67 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]2-메톡시페닐 디에틸카바메이트Compound 67 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] 2-methoxyphenyl diethylcarbamate

Figure 112008041801646-PCT00070
Figure 112008041801646-PCT00070

화합물 68 2-클로로-4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-6-메톡시-페닐 디에틸카바메이트Compound 68 2-chloro-4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl diethylcarbamate

Figure 112008041801646-PCT00071
Figure 112008041801646-PCT00071

화합물 69 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 2-[2-(2-메톡시에톡시)에톡시]에틸 카보네이트Compound 69 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2- [2- (2-methoxyethoxy) ethoxy] Ethyl carbonate

Figure 112008041801646-PCT00072
Figure 112008041801646-PCT00072

화합물 70 1-에틸-3-[4-(모르폴린-4-설포닐)페닐아미노]피리도[2,3- b]피라진-6-일우레아Compound 70 1-ethyl-3- [4- (morpholin-4-sulfonyl) phenylamino] pyrido [2,3-b] pyrazin-6-ylurea

Figure 112008041801646-PCT00073
Figure 112008041801646-PCT00073

화합물 71 에틸 5-[6-(3-에틸우레이도)피리도[2,3-b]피라진-3-일아미노]-2-하이드록시-벤조에이트Compound 71 Ethyl 5- [6- (3-ethylureido) pyrido [2,3-b] pyrazin-3-ylamino] -2-hydroxy-benzoate

Figure 112008041801646-PCT00074
Figure 112008041801646-PCT00074

화합물 72 1-[3-(3-디에틸아미노메틸-4-하이드록시페닐아미노)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 72 1- [3- (3-diethylaminomethyl-4-hydroxyphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Figure 112008041801646-PCT00075
Figure 112008041801646-PCT00075

화합물 73 1-에틸-3-[3-(6-모르폴린-4-일피리딘-3-일아미노)피리도[2,3-b]피라진-6-일]우레아Compound 73 1-ethyl-3- [3- (6-morpholin-4-ylpyridin-3-ylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00076
Figure 112008041801646-PCT00076

화합물 74 1-에틸-3-{3-[3-(1H-테트라졸-5-일)페닐아미노]피리도[2,3-b]피라진-6-일}우레아Compound 74 1-ethyl-3- {3- [3- (1H-tetrazol-5-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea

Figure 112008041801646-PCT00077
Figure 112008041801646-PCT00077

화합물 75 1-에틸-3-[3-(3-모르폴린-4-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 75 1-ethyl-3- [3- (3-morpholin-4-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00078
Figure 112008041801646-PCT00078

화합물 76 1-에틸-3-[3-(4-이미다졸-1-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 76 1-ethyl-3- [3- (4-imidazol-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00079
Figure 112008041801646-PCT00079

화합물 77 1-에틸-3-[3-(4-피롤리딘-1-일페닐아미노)피리도[2,3-b]피라진-6- 일]우레아Compound 77 1-ethyl-3- [3- (4-pyrrolidin-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00080
Figure 112008041801646-PCT00080

화합물 78 1-에틸-3-{3-[4-(4-메틸피페라진-1-일)페닐아미노]피리도[2,3-b]피라진-6-일}우레아Compound 78 1-ethyl-3- {3- [4- (4-methylpiperazin-1-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea

Figure 112008041801646-PCT00081
Figure 112008041801646-PCT00081

화합물 79 1-에틸-3-[3-(3-피페리딘-1-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 79 1-ethyl-3- [3- (3-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00082
Figure 112008041801646-PCT00082

화합물 80 1-에틸-3-[3-(4-모르폴린-4-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 80 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00083
Figure 112008041801646-PCT00083

화합물 81 1-{3-[3-(2-사이클로헥실에톡시)페닐아미노]피리도[2,3-b]피라진-6-일}-3-에틸우레아Compound 81 1- {3- [3- (2-cyclohexylethoxy) phenylamino] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea

Figure 112008041801646-PCT00084
Figure 112008041801646-PCT00084

화합물 82 1-에틸-3-[3-(3-[1,2,4]트리아졸-1-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 82 1-ethyl-3- [3- (3- [1,2,4] triazol-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Figure 112008041801646-PCT00085
Figure 112008041801646-PCT00085

화합물 83 2,2-디메틸[1,3]디옥솔란-4-일메틸 4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레이도}부틸 카보네이트Compound 83 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine- 6-yl] ureido} butyl carbonate

Figure 112008041801646-PCT00086
Figure 112008041801646-PCT00086

화합물 84 2,3-디하이드록시프로필 4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레이도}부틸 카보네이트Compound 84 2,3-dihydroxypropyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] ureido} butyl carbonate

Figure 112008041801646-PCT00087
Figure 112008041801646-PCT00087

화합물 85 1-[3-(2-디에틸아미노에톡시)프로필]-3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아Compound 85 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl Urea

Figure 112008041801646-PCT00088
Figure 112008041801646-PCT00088

모호한 표현을 피하기 위해: 상기한 명백한 화합물의 화학 구조 및 화학명이 잘못되어 서로 매치되지 않는 경우, 화학 구조는 명백하게 구체적인 명백한 화합물을 정의한다. In order to avoid ambiguity: If the chemical structure and chemical name of the above-mentioned clear compound are incorrect and do not match each other, the chemical structure clearly defines the specific clear compound.

상기한 화학식 I 및 II의 화합물, 바람직한 양태 및 명백히 언급된 화합물 1 내지 85의 피리도피라진은 "본 발명의 화합물"로서 하기에 집합적으로 언급된다.The aforementioned compounds of the formulas (I) and (II), preferred embodiments and the explicitly mentioned pyridopyrazines of the compounds 1 to 85 are collectively referred to below as “compounds of the invention”.

본 발명의 화합물을 설명하기 위해 명시된 표현 및 용어는, 명세서 및 청구의 범위에 달리 나타내지 않는 한, 원리적으로 다음과 같이 각각 정의된다:The expressions and terms specified to describe the compounds of the present invention are, in principle, defined as follows, unless otherwise indicated in the specification and claims:

본 발명에서, 표현 "알킬"은 측쇄 또는 직쇄일 수 있고 1 내지 8개 탄소원자를 갖는 아사이클릭 포화되거나 불포화된 탄화수소 라디칼이고, 즉, C1-8-알칸일, C2-8-알케닐 및 C2-8-알키닐을 포함한다. 알케닐은 하나 이상의 C-C 이중결합을 갖고, 알키닐은 하나 이상의 C-C 삼중결합을 갖는다. 알키닐은 추가적으로 또한 하나 이상의 C-C 이중결합을 가질 수 있다. 바람직한 알킬 라디칼은 메틸, 에틸, n-프로필, 2-프로필, n-부틸, 2급-부틸, 3급-부틸, n-펜틸, 이소-펜틸, 네오-펜틸, n-헥실, 2-헥실, n-헵틸, n-옥틸, n-노닐, n-데실, n-운데실, n-도데실, 에틸레닐 (비닐), 에티닐, 프로페닐 (-CH2CH=CH2 -CH=CH-CH3, -C(=CH2)-CH3), 프로피닐 (-CH2-C≡CH, -C≡C-CH3), 부테닐, 부티닐, 펜테닐, 펜티닐, 헥세닐, 헥시닐, 헵테닐, 헵티닐, 옥테닐, 옥타디에닐 및 옥티닐이다.In the present invention, the expression “alkyl” may be branched or straight chain and is an acyclic saturated or unsaturated hydrocarbon radical having 1 to 8 carbon atoms, ie C 1-8 -alkanyl, C 2-8 -alkenyl and C 2-8 -alkynyl. Alkenyl has one or more CC double bonds, and alkynyl has one or more CC triple bonds. Alkynyl may additionally also have one or more CC double bonds. Preferred alkyl radicals are methyl, ethyl, n -propyl, 2-propyl, n -butyl, secondary -butyl, tert-butyl, n -pentyl, iso-pentyl, neo-pentyl, n -hexyl, 2-hexyl, n-heptyl, n -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, ethylenyl (vinyl), ethynyl, propenyl (-CH 2 CH = CH 2 -CH = CH- CH 3 , -C (= CH 2 ) -CH 3 ), propynyl (-CH 2 -C≡CH, -C≡C-CH 3 ), butenyl, butynyl, pentenyl, pentynyl, hexenyl, Hexynyl, heptenyl, heptynyl, octenyl, octadienyl and octinyl.

본 발명에서, 표현 "(C9-C30)알킬"은 측쇄 또는 직쇄일 수 있고, 9 내지 30개의 탄소원자를 갖는 아사이클릭 포화되거나 불포화된 탄화수소 라디칼이고, 즉, C9-30-알칸일, C9-30-알케닐 및 C9-30-알키닐이다. C9-30-알케닐은 하나 이상의 C-C 이중결합을 갖고, C9-30-알키닐은 하나 이상의 C-C 삼중결합을 갖는다. C9-30-알키닐은 추 가적으로 또한 하나 이상의 C-C 이중결합을 가질 수 있다. 바람직한 (C9-C30)알킬 라디칼은 테트라데실, 헥사데실, 옥타데실, 에이코사닐, 시스-13-도코세닐(에루실), 트랜스-13-도코세닐(브라시딜), 시스-15-테트라코세닐(네르보닐) 및 트랜스-15-테트라코세닐이다. In the present invention, the expression “(C 9 -C 30 ) alkyl” may be branched or straight chain and is an acyclic saturated or unsaturated hydrocarbon radical having 9 to 30 carbon atoms, ie C 9-30 -alkanyl , C 9-30 -alkenyl and C 9-30 -alkynyl. C 9-30 -alkenyl has one or more CC double bonds, and C 9-30 -alkynyl has one or more CC triple bonds. C 9-30 -alkynyl may additionally also have one or more CC double bonds. Preferred (C 9 -C 30 ) alkyl radicals are tetradecyl, hexadecyl, octadecyl, eicosanyl, cis-13-docosenyl (erucyl), trans-13-docosenyl (brasidyl), cis-15-tetra Cosenyl (nerbonyl) and trans-15-tetracosenyl.

본 발명의 목적을 위해, 표현 "사이클로알킬"은 3 내지 20, 바람직하게는 3 내지 12개의 원자를 갖고 1 내지 3개의 환을 갖는 사이클릭 비방향족 탄화수소이고, 이들은 포화되거나 불포화될 수 있고, 보다 바람직하게는 (C3-C8)사이클로알킬이다. 사이클로알킬 라디칼은 또한 바이- 또는 폴리사이클릭 시스템의 부분일 수 있고, 여기서, 예를 들면, 사이클로알킬 라디칼은 임의의 가능한 및 목적하는 환 원(들)에 의해 본원에 정의된 아릴, 헤테로아릴 또는 헤테로사이클릴 라디칼에 융합된다. 화학식 I 및 II의 화합물로의 결합은 사이클로알킬 라디칼의 임의의 가능한 환 원를 통해 유효할 수 있다. 바람직한 사이클로알킬 라디칼은 사이클로프로필, 사이클로부틸, 사이클로펜틸, 사이클로헥실, 사이클로헵틸, 사이클로옥틸, 사이클로데실, 사이클로헥세닐, 사이클로펜테닐 및 사이클로옥타디에닐이다. For the purposes of the present invention, the expression "cycloalkyl" is a cyclic nonaromatic hydrocarbon having 3 to 20, preferably 3 to 12 atoms and having 1 to 3 rings, which may be saturated or unsaturated, and more Preferably (C 3 -C 8 ) cycloalkyl. Cycloalkyl radicals may also be part of a bi- or polycyclic system, where, for example, cycloalkyl radicals are aryl, heteroaryl or as defined herein by any possible and desired reduction (s). Fused to a heterocyclyl radical. The linkage to the compounds of formulas (I) and (II) may be effective through any possible reduction of the cycloalkyl radical. Preferred cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl and cyclooctadienyl.

표현 "헤테로사이클릴"은 3- 내지 14-원, 바람직하게는 3-, 4-, 5, 6-, 7- 또는 8-원, 사이클릭 유기 라디칼이고, 1개 이상의 헤테로원자, 임의로 2, 3, 4 또는 5개 헤테로원자이고, 이는 특히 질소, 산소 및/또는 황이고, 헤테로원자는 동일하거나 상이하고, 사이클릭 라디칼은 포화되거나 불포화되지만 방향족은 아니다. 헤테로사이클릴 라디칼은 또한 바이- 또는 폴리사이클릭 시스템의 부분일 수 있고, 여기서, 예를 들면, 헤테로사이클릴 라디칼은 본원에 정의된 아릴, 헤테로아릴 또는 사이클로알킬 라디칼에 임의의 가능한 및 목적하는 환 원(들)에 의해 융합된다. 화학식 I 및 II의 화합물로의 결합은 헤테로사이클릴 라디칼의 임의의 가능한 환 원을 통해 유효할 수 있다. 바람직한 헤테로사이클릴 라디칼은 테트라하이드로푸릴, 피롤리디닐, 이미다졸리디닐, 티아졸리디닐, 테트라하이드로피라닐, 피페리디닐, 피페라지닐, 모르폴리닐, 티아피롤리디닐, 옥사피페라지닐, 옥사피페리디닐 및 옥사디아졸릴이다.The expression "heterocyclyl" is a 3- to 14-membered, preferably 3-, 4-, 5, 6-, 7- or 8-membered, cyclic organic radical, and at least one heteroatom, optionally 2, 3, 4 or 5 heteroatoms, which in particular are nitrogen, oxygen and / or sulfur, heteroatoms are the same or different, and the cyclic radicals are saturated or unsaturated but not aromatic. The heterocyclyl radical may also be part of a bi- or polycyclic system, where, for example, the heterocyclyl radical is any possible and desired ring for the aryl, heteroaryl or cycloalkyl radicals defined herein. Fused by circle (s). The bond to the compounds of formulas (I) and (II) may be effective through any possible reduction of the heterocyclyl radical. Preferred heterocyclyl radicals are tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiapyrrolidinyl, oxapirazinyl, Oxapiperidinyl and oxadiazolyl.

본 발명에서, 표현 "아릴"은 3 내지 14개의 탄소원자, 바람직하게는 5 내지 14개의 탄소원자, 보다 바람직하게는 6 내지 14개의 탄소원자를 갖는 방향족 탄화수소이다. 아릴 라디칼은 또한 바이- 또는 폴리사이클릭 시스템의 부분일 수 있고, 여기서, 예를 들면, 아릴 라디칼은 본원에 정의된 헤테로사이클릴, 헤테로아릴 또는 사이클로알킬 라디칼에 임의의 가능한 및 목적하는 환 원(들)에 의해 융합되고, 예를 들면, 테트라하이드로푸란, 테트라하이드로티오펜, 피롤리딘, 이미다졸리딘, 티아졸리딘, 테트라하이드로피란, 디하이드로피란, 피페리딘, 푸란, 티오펜, 이미다졸, 티아졸, 옥사졸, 이속사졸이다. 화학식 I 및 II의 화합물로의 결합은 아릴 라디칼의 임의의 가능한 환 원을 통해 유효할 수 있다. 바람직한 아릴 라디칼은 페닐, 비페닐, 나프틸 및 안트라세닐이지만, 또한 인다닐, 인데닐 또는 1,2,3,4-테트라하이드로나프틸이다.In the present invention, the expression "aryl" is an aromatic hydrocarbon having 3 to 14 carbon atoms, preferably 5 to 14 carbon atoms, more preferably 6 to 14 carbon atoms. The aryl radicals may also be part of a bi- or polycyclic system, where, for example, the aryl radicals may be selected from any possible and desired reduction in the heterocyclyl, heteroaryl or cycloalkyl radicals defined herein. S), for example, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, thiazolidine, tetrahydropyran, dihydropyran, piperidine, furan, thiophene, Imidazole, thiazole, oxazole, isoxazole. Binding to compounds of formulas (I) and (II) may be effective through any possible reduction of the aryl radical. Preferred aryl radicals are phenyl, biphenyl, naphthyl and anthracenyl, but are also indanyl, indenyl or 1,2,3,4-tetrahydronaphthyl.

표현 "헤테로아릴"은 5-, 6- 또는 7-원 사이클릭 방향족 라디칼이고, 이는 1개 이상의 헤테로원자, 적합한 경우 또한 2, 3, 4 또는 5개의 헤테로원자를 포함하 고, 이는 특히 질소, 산소 및/또는 황이고, 헤테로원자는 동일하거나 상이하다. 질소 원자의 수는 바람직하게는 0 내지 3이고, 산소 및 황 원자의 수는 바람직하게는 0 또는 1이다. 헤테로아릴 라디칼은 또한 바이- 또는 폴리사이클릭 시스템의 부분이고, 여기서, 예를 들면, 헤테로아릴 라디칼은 본워에 정의된 헤테로사이클릴, 아릴 또는 사이클로알킬 라디칼에 임의의 가능한 및 목적하는 환 원(들)에 의해 융합된다. 화학식 I 및 II의 화합물로의 결합은 헤테로아릴 라디칼의 임의의 가능한 환 원을 통해 유효할 수 있다. 바람직한 헤테로아릴 라디칼은 피롤릴, 푸릴, 티에닐, 티아졸릴, 이소티아졸릴, 옥사졸릴, 옥사디아졸릴, 이속사졸릴, 피라졸릴, 이미다졸릴, 트리아졸, 테트라졸, 피리디닐, 피리미디닐, 피리다지닐, 피라지닐, 트리아진, 프탈라지닐, 인돌릴, 인다졸릴, 인돌리지닐, 퀴놀리닐, 이소퀴놀리닐, 퀴녹살리닐, 퀴나졸리닐, 프테리디닐, 카바졸릴, 페나지닐, 페녹사지닐, 페노티아지닐, 및 아크리디닐이다. The expression "heteroaryl" is a 5-, 6- or 7-membered cyclic aromatic radical, which comprises at least one heteroatom, if appropriate also 2, 3, 4 or 5 heteroatoms, in particular nitrogen, Oxygen and / or sulfur and heteroatoms are the same or different. The number of nitrogen atoms is preferably 0 to 3, and the number of oxygen and sulfur atoms is preferably 0 or 1. Heteroaryl radicals are also part of a bi- or polycyclic system, where, for example, the heteroaryl radical is any possible and desired reduction (s) to the heterocyclyl, aryl or cycloalkyl radicals defined herein. Fused by). The bond to the compounds of formulas (I) and (II) may be effective through any possible reduction of the heteroaryl radical. Preferred heteroaryl radicals are pyrrolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, oxdiazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazole, tetrazole, pyridinyl, pyrimidinyl , Pyridazinyl, pyrazinyl, triazine, phthalazinyl, indolyl, indazolyl, indolinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pterridinyl, carbazolyl, phena Genyl, phenoxazinyl, phenothiazinyl, and acridinyl.

본 발명의 목적을 위해, 표현 "알킬-사이클로알킬", "사이클로알킬알킬", "알킬-헤테로사이클릴", "헤테로사이클릴알킬", "알킬-아릴", "아릴알킬", "알킬-헤테로아릴" 및 "헤테로아릴알킬"은 알킬, 사이클로알킬, 헤테로사이클, 아릴 및 헤테로아릴이 각각 상기 정의한 바와 같고, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴 라디칼이 화학식 I 및 II의 화합물에 알킬 라디칼, 바람직하게는 C1-C8-알킬 라디칼, 보다 바람직하게는 C1-C4-알킬 라디칼을 통해 결합됨을 의미한다.For the purposes of the present invention, the expressions "alkyl-cycloalkyl", "cycloalkylalkyl", "alkyl-heterocyclyl", "heterocyclylalkyl", "alkyl-aryl", "arylalkyl", "alkyl- Heteroaryl "and" heteroarylalkyl "are as defined above for alkyl, cycloalkyl, heterocycle, aryl and heteroaryl, respectively, and the cycloalkyl, heterocyclyl, aryl and heteroaryl radicals are alkyl to the compounds of formulas I and II. By radicals, preferably C 1 -C 8 -alkyl radicals, more preferably C 1 -C 4 -alkyl radicals.

"알킬", "사이클로알킬", "헤테로사이클릴", "아릴", "헤테로아릴", "알킬- 사이클로알킬", "알킬-헤테로사이클릴", "알킬-아릴" 및 "알킬-헤테로아릴"과 연관되어, 본 발명에서 용어 "치환된"은, 명세서 또는 청구의 범위에서 명백하게 나타내지 않는 한, 하나 이상의 수소 라디칼의 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬-O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)OR36, C(O)NH2, C(O)NHR36, C(O)NR36R37, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴로의 치환을 의미하는 것으로 이해되고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고, 여기서, R36 및 R37 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬-사이클로알킬, 알킬-헤테로사이클릴, 알킬-아릴 또는 알킬-헤테로아릴일 수 있고, R36 및 R37은 함께 헤테로사이클릴 환을 형성할 수 있다. 치환체는 동일하거나 상이할 수 있고, 치환은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴 라디칼의 목적하고 가능한 위치에서 일어날 수 있다."Alkyl", "cycloalkyl", "heterocyclyl", "aryl", "heteroaryl", "alkyl-cycloalkyl", "alkyl-heterocyclyl", "alkyl-aryl" and "alkyl-heteroaryl In connection with "in the present invention," the term "substituted", unless expressly indicated in the specification or claims, F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl of one or more hydrogen radicals , NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH ) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) OR36, C (O) NH 2 , C (O) NHR36, C (O) NR 36 R 37, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cyclo Understood to mean a substitution with alkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can be a value of 0, 1, 2, 3, 4 or 5, where R36 and R37 radicals Are each independently alkyl, cycloalkyl, Interrogating heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl- may be a heteroaryl group, R36 and R37 may together form a heterocyclyl ring. Substituents may be the same or different and the substitution may occur at the desired and possible positions of the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl radicals.

본 발명에서, 표현 "할로겐"은 할로겐 원자, 불소, 염소, 브롬 및 요오드를 포함한다.In the present invention, the expression "halogen" includes halogen atoms, fluorine, chlorine, bromine and iodine.

다치환된 라디칼은 상이한 원자 또는 동일한 원자에서 다치환된, 예를 들면, 이- 또는 삼치환된 라디칼을 의미하고, 예를 들면, CF3, -CH2CF3의 경우는 동일한 탄소원자에 삼치환되고, 또는 CH(OH)-CH=CH-CHCl2의 경우는 상이한 위치에서 삼치환된다. 다치환은 동일한 치환체 또는 상이한 치환체에 의해 유효할 수 있다.Polysubstituted radicals mean, for example, di- or trisubstituted radicals which are polysubstituted at different atoms or at the same atom, for example in the case of CF 3 , -CH 2 CF 3 Or trisubstituted at different positions in the case of CH (OH) —CH═CH—CHCl 2 . Multisubstitution may be effective with the same substituent or with different substituents.

본 발명의 화합물이 하나 이상의 비대칭 중심을 갖는 경우, 이들은 이의 라세미체 형태, 순수한 에난티오머 및/또는 부분입체이성체 형태, 또는 이들 에난티오머 및/또는 부분입체이성체의 혼합물 형태 및 물질 형태로 또는 이들 화합물의 약제학적으로 허용되는 염으로서 존재할 수 있다. 혼합물은 입체이성체의 바람직한 혼합비로 존재할 수 있다. If the compounds of the invention have one or more asymmetric centers, they are in racemic form, pure enantiomer and / or diastereomeric form, or in the form and mixtures of these enantiomers and / or diastereomers. Or as pharmaceutically acceptable salts of these compounds. The mixture may be present in the preferred mixing ratio of stereoisomers.

예를 들면, 하나 이상의 키랄 중심을 갖고 라세미체로서 생성되는 본 발명의 화합물은 이의 광학 이성체, 즉, 에난티오머 또는 부분입체이성체로 자체 공지된 방법으로 분리될 수 있다. 분리는 키랄 상 칼럼 분리에 의해 또는 광학 활성 용매로부터 재결정화에 의해, 또는 광학 활성 산 또는 염기를 사용하여, 또는 광학 활성 시약, 예를 들면, 광학 활성 알콜을 사용한 유도에 의해, 라디칼을 후속적으로 분리하여 가능할 수 있다. For example, the compounds of the present invention having one or more chiral centers and produced as racemates can be separated by methods known per se as their optical isomers, ie enantiomers or diastereomers. Separation is followed by radical separation by chiral phase column separation or by recrystallization from an optically active solvent, or by using an optically active acid or base, or by induction with an optically active reagent such as an optically active alcohol. It may be possible to separate.

본 발명의 화합물은 "순수한" E 또는 Z 이성체와 같은 이의 이중결합 이성체 형태 또는 이들 이중결합 이성체의 혼합물 형태로 존재할 수 있다. The compounds of the present invention may exist in the form of their double bond isomers, such as "pure" E or Z isomers or in the form of mixtures of these double bond isomers.

가능한 경우, 본 발명의 화합물은 호변체 형태로 존재할 수 있다. Where possible, compounds of the invention may exist in tautomeric forms.

본 발명의 화합물은, 이들이 충분한 염기성 그룹, 예를 들면, 1급, 2급, 또는 3급 아민을 갖는 경우, 생리학적으로 허용되는 이의 염으로 무기 및 유기산을 사용하여 변화될 수 있다. 본 발명의 화합물의 약제학적으로 허용되는 염은 바람직하게는 염산, 브롬화수소산, 황산, 인산, 메탄설폰산, p-톨루엔설폰산, 카본산, 포름산, 아세트산, 트리플루오로아세트산, 설포아세트산, 옥살산, 말론산, 말레산, 석신산, 타르타르산, 피루브산, 말산, 엠본산, 만델산, 푸마르산, 락트산, 시트르산, 글루탐산 또는 아스파르트산과 함께 형성된다. 형성되는 염은 하이드로클로라이드, 하이드로브로마이드, 설페이트, 수소설페이트, 포스페이트, 메탄설포네이트, 토실레이트, 카보네이트, 수소카보네이트, 포르메이트, 아세테이트, 트리플레이트, 설포아세테이트, 옥살레이트, 말로네이트, 말레에이트, 석시네이트, 타르트레이트, 말레에이트, 엠보네이트, 만델레이트, 푸마레이트, 락테이트, 시트레이트, 글루타메이트 및 아스파르테이트를 포함한다. 형성되는 본 발명의 화합물의 염의 입체화학은 하나의 전체 또는 부분 집합일 수 있다.The compounds of the present invention can be changed using inorganic and organic acids as their physiologically acceptable salts if they have sufficient basic groups, for example primary, secondary, or tertiary amines. Pharmaceutically acceptable salts of the compounds of the invention are preferably hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, trifluoroacetic acid, sulfoacetic acid, oxalic acid , Malonic acid, maleic acid, succinic acid, tartaric acid, pyruvic acid, malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid. The salts formed are hydrochloride, hydrobromide, sulfate, hydrogensulfate, phosphate, methanesulfonate, tosylate, carbonate, hydrogencarbonate, formate, acetate, triflate, sulfoacetate, oxalate, malonate, maleate, succinate Nates, tartrates, maleates, emcarbonates, mandelate, fumarate, lactates, citrate, glutamate and aspartate. The stereochemistry of the salts of the compounds of the present invention formed may be one whole or a subset.

본 발명의 화합물은, 이들이 충분한 산성 그룹, 예를 들면, 카복실 그룹 또는 인산 그룹을 갖는 경우, 이의 생리학적으로 허용되는 염으로 무기 및 유기 염기를 사용하여 변환될 수 있다. 유용한 무기 염기의 예는 수산화나트륨, 수산화칼륨, 수산화칼슘을 포함하고; 유용한 유기 염기의 예는 에탄올아민, 디에탄올아민, 트리에탄올아민, 사이클로헥실아민, 디벤질에틸렌디아민 및 라이신을 포함한다. 형성되는 본 발명의 화합물의 염의 화학양론 하나의 전체 또는 부분 집합일 수 있다.The compounds of the present invention can be converted using inorganic and organic bases into their physiologically acceptable salts if they have sufficient acidic groups, such as carboxyl groups or phosphoric acid groups. Examples of useful inorganic bases include sodium hydroxide, potassium hydroxide, calcium hydroxide; Examples of useful organic bases include ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dibenzylethylenediamine and lysine. It may be one whole or a subset of the stoichiometry of the salts of the compounds of the invention formed.

예를 들면, 용매 또는 수성 용액으로부터 결정화하여 수득될 수 있는 본 발명의 화합물의 용매화물 및 특히 수화물을 제공하는 것이 바람직하다. 1, 2, 3 또는 가능한 많은 용매화물 또는 물 분자는 본 발명의 화합물에 결합되어 용매화물 및 수화물을 형성할 수 있다.Preference is given to providing solvates and in particular hydrates of the compounds of the invention which can be obtained, for example, by crystallization from solvents or aqueous solutions. One, two, three or as many solvates or water molecules as possible can be bound to a compound of the invention to form solvates and hydrates.

화학 물질은 다양한 순서 상태로 존재하는 고체를 형성하고, 이는 다형태 또는 변형으로 언급되는 것으로 공지되어 있다. 다형태 물질의 상이한 변형의 물리적 특성은 매우 상이할 수 있다. Chemicals form solids that exist in various order states, which are known to be referred to as polymorphs or modifications. The physical properties of the different modifications of the polymorphic material can be very different.

본 발명의 화합물은 다양한 다형태로 존재할 수 있고; 특정한 변형이 대사안정성 일 수 있다.Compounds of the invention can exist in a variety of polymorphs; Certain modifications may be metastable.

또한, 본 발명의 화합물이 임의의 프로드러그, 예를 들면, 에스테르, 카보네이트, 카바메이트, 우레아, 아미드 또는 포스페이트 형태로 존재할 수 있고, 여기서, 실제 생물학적 활성 형태는 단지 대사에 의해 방출된다.In addition, the compounds of the present invention may exist in any prodrug, eg, ester, carbonate, carbamate, urea, amide or phosphate form, where the actual biologically active form is only released by metabolism.

화학 물질은 체내에서 대사산물로 변환되고, 이는 몇몇의 경우 또한 특정한 환경하에서 보다 현저한 형태로 목적하는 생물학적 효과를 야기할 수 있는 것으로 공지되어 있다. It is known that chemicals are converted into metabolites in the body, which in some cases can also cause desired biological effects in more pronounced forms under certain circumstances.

본 발명의 화합물의 상응하는 프로드러그 및 대사산물는 본 발명의 일부로서 고려되어야 한다. Corresponding prodrugs and metabolites of the compounds of the invention should be considered as part of the invention.

본 발명의 화합물은 또한 2개 이상의 신호전달경로 또는 이러한 경로의 효소 상에서 작용하는, 즉, 조절 또는 억제 효과를 가질 수 있는 놀랍게도 유리한 방법으로 밝혀졌다. 본 발명의 화합물은 높은 선택도를 갖고 작용하는, 즉, 조절 또는 억제 효과를 가질 수 있는 것으로 밝혀졌다. The compounds of the present invention have also been found to be surprisingly advantageous methods that act on two or more signaling pathways or enzymes of these pathways, i.e. may have a modulating or inhibitory effect. It has been found that the compounds of the present invention can act with high selectivity, ie, have a modulating or inhibitory effect.

2개 이상의 신호전달경로, 예를 들면, ras-Raf-Mek-Erk 신호경로, PI3K-Akt 신호경로 및/또는 SAPK 신호경로, 보다 특히 Erk1/Erk2 및/또는 PI3K 및/또는 Jnk 및/또는 p38의 동시, 예를 들면, 이중, 조절 또는 억제는 하나의 신호전달경로의 유일한 단일 조절 또는 억제를 넘어 유리한데, 이는 상승적 치료학적 효과로, 예를 들면, 개선된 아폽토시스 및 보다 신속하고 효율적인 종양 회귀를 야기할 수 있기 때문이다. Two or more signaling pathways, for example ras-Raf-Mek-Erk signaling, PI3K-Akt signaling and / or SAPK signaling, more particularly Erk1 / Erk2 and / or PI3K and / or Jnk and / or p38 Simultaneous, eg, dual, modulation or inhibition, is advantageous over only a single regulation or inhibition of one signaling pathway, which is a synergistic therapeutic effect, eg, improved apoptosis and more rapid and efficient tumor regression. Because it can cause.

본 발명의 화합물의 놀라운 유리한 효과로 여러가지 치료학적 접근이 치료 또는 조절에 민감하거나 2개 이상의 신호전달경로에 의해 매개되는 생리학적 및/또는 병태생리학적 상태 또는 상태에 추구될 수 있다. With the surprising beneficial effects of the compounds of the present invention, various therapeutic approaches can be pursued in physiological and / or pathophysiological conditions or conditions that are sensitive to treatment or control or mediated by two or more signaling pathways.

본 발명의 화합물은 또한 ras-Raf-Mek-Erk 신호전달경로 또는 이의 효소 상에서 높은 선택도로 작용하는, 즉, 작용을 조절 또는 억제 효과를 가질 수 있고, 여러가지 작용 기작 및 상기한 치료학적 접근은 또한 이러한 신호 경로 또는 효소가 갖는 용도를 발견할 수 있다는 것이 놀랍게도 유리한 방법으로 밝혀졌다. The compounds of the present invention may also act with high selectivity on the ras-Raf-Mek-Erk signaling pathway or enzymes thereof, ie, have a modulating or inhibiting effect, and the various mechanisms of action and therapeutic approaches described above It has surprisingly been found to be an advantageous method to discover the use of such signal pathways or enzymes.

본 발명의 화합물은 또한 PI3K-Akt 신호전달경로 또는 이의 효소 상에서 높은 선택도로 작용하는, 즉, 작용을 조절 또는 억제 효과를 가질 수 있고, 여러가지 작용 기작 및 상기한 치료학적 접근은 또한 이러한 신호 경로 또는 효소가 갖는 용도를 발견할 수 있다는 것이 놀랍게도 유리한 방법으로 밝혀졌다. The compounds of the present invention may also act with high selectivity on the PI3K-Akt signaling pathway or enzymes thereof, ie, have a modulating or inhibiting effect, and the various mechanisms of action and therapeutic approaches described above may also provide such signaling pathways or It has been surprisingly found that the use of enzymes can be found.

본 발명의 화합물은 또한 SAPK 신호전달경로 또는 이의 효소 상에서 높은 선택도로 작용하는, 즉, 작용을 조절 또는 억제 효과를 가질 수 있고, 여러가지 작용 기작 및 상기한 치료학적 접근은 또한 이러한 신호 경로 또는 효소가 갖는 용도를 발견할 수 있다는 것이 놀랍게도 유리한 방법으로 밝혀졌다. The compounds of the present invention may also act with high selectivity on the SAPK signaling pathway or enzymes thereof, ie, have a modulating or inhibiting effect, and various mechanisms of action and therapeutic approaches described above may also be useful for It has been found that surprisingly advantageous methods can be found for use.

추가적으로, 본 발명의 화합물은 또한 효소, 예를 들면, ATM, ATR, mTOR, DNA-PK 및/또는 hSMG-1 상에서 높은 선택도로 작용하는, 즉, 작용을 조절 또는 억 제 효과를 가질 수 있고, 여러가지 작용 기작 및 상기한 치료학적 접근은 또한 이러한 효소가 갖는 용도를 발견할 수 있다는 것이 놀랍게도 유리한 방법으로 밝혀졌다. In addition, the compounds of the invention may also act with high selectivity on enzymes such as ATM, ATR, mTOR, DNA-PK and / or hSMG-1, ie, have a modulating or inhibitory effect, It has been surprisingly found that various mechanisms of action and the therapeutic approaches described above can also find use with such enzymes.

본 발명에 따라서, 용어 "조절"은 다음을 의미하는 것으로 이해된다: "활성화, 부분적 활성화, 억제, 부분적 억제". 평균적인 당해 기술분야의 숙련가의 기술 지식 내에서 이러한 활성화, 부분적 활성화, 억제 또는 부분적 억제는 통상적인 측정 및 결정 방법을 통해 측정하고 결정한다. 예를 들면, 부분적 활성화는 완전한 활성화와 관련되어 측정하고 결정할 수 있고; 또한 부분적 억제는 완전한 억제와 관련되어 측정하고 결정할 수 있다. According to the invention, the term "modulation" is understood to mean: "activation, partial activation, inhibition, partial inhibition". Within the average technical knowledge of those skilled in the art, such activation, partial activation, inhibition or partial inhibition is measured and determined through conventional measurement and determination methods. For example, partial activation can be measured and determined in connection with complete activation; Partial inhibition can also be measured and determined in relation to complete inhibition.

본 발명에 따라서, 용어 "억제"는 다음을 의미하는 것으로 이해된다: "부분적 또는 완전한 억제". 평균적인 당해 기술분야의 숙련가의 기술 지식 내에서 이러한 부분적 또는 완전한 억제는 통상적인 측정 및 결정 방법을 통해 측정하고 결정한다. 예를 들면, 부분적 억제는 완전한 억제와 관련되어 측정하고 결정할 수 있다. According to the invention, the term "inhibition" is understood to mean: "partial or complete inhibition". Within the technical knowledge of the average skilled person, such partial or complete inhibition is measured and determined through conventional measurement and determination methods. For example, partial inhibition can be measured and determined in connection with complete inhibition.

용어 "조절" 및 "억제"는 본 발명에서 "효소" 및/또는 "키나제"와 관련하여 특정한 효소 및/또는 키나제의 불활성 형태(효소적으로 불활성) 및/또는 활성 형태(효소적으로 활성) 둘 다에 관한 것이다. 본 발명에서 이는 본 발명의 화합물이 불활성 형태, 활성 형태 또는 효소 및/또는 키나제의 둘 다의 형태에서 이의 조절 작용을 나타낼 수 있다는 것을 의미한다. The terms "modulation" and "inhibition" are used herein to refer to an "enzyme" and / or "kinase" in an inactive form (enzymatically inactive) and / or active form (enzymatically active) of a particular enzyme and / or kinase. It's about both. In the present invention, this means that a compound of the present invention may exhibit its regulatory action in an inactive form, in an active form or in both an enzyme and / or a kinase.

추가의 양태에서, 본 발명의 목적은 놀랍게도 하나 이상의 본 발명의 화합물 을 포함하는 약제를 제공하여 성취할 수 있다.In a further aspect, the object of the invention may surprisingly be achieved by providing a medicament comprising at least one compound of the invention.

추가의 양태에서, 본 발명의 목적은 놀랍게도 하나 이상의 본 발명의 화합물을 하나 이상의 추가의 활성 약제학적 성분 및/또는 약제학적으로 허용되는 담체 및/또는 부형제를 포함하는 약제를 제공하여 성취할 수 있다.In a further aspect, the object of the present invention may surprisingly be achieved by providing one or more compounds of the invention with a medicament comprising one or more additional active pharmaceutical ingredients and / or pharmaceutically acceptable carriers and / or excipients. .

추가의 양태에서, 본 발명의 목적은 놀랍게도 약제학적으로 허용되는 담체 및/또는 부형제와 함게 하나 이상의 본 발명의 화합물을 가공하는, 즉, 치료학적으로 유용한 형태를 야기하여 약제학적 제형을 제공하는 것을 특징으로 하는, 약제의 제조방법을 제공하여 성취할 수 있다.In a further aspect, the object of the present invention is to surprisingly provide a pharmaceutical formulation by processing one or more compounds of the invention together with a pharmaceutically acceptable carrier and / or excipient, ie causing a therapeutically useful form. It can be achieved by providing a method for producing a medicament.

추가의 양태에서, 본 발명의 목적은 놀랍게도 잘못 지시된 세포 신호전달 프로세스를 조절하기 위해, 특히 활성 및 불활성 수용체 티로신 키나제, 및 또한 세포질 티로신, 세린/트레오닌 및 지질 키나제, 예를 들면, c-Raf, B-Raf, Mek, MAPKs, PDGFR베타, Flt-3, IGF1R, PI3K, PKB/Akt1, c-Kit, c-Abl, FGFR1 및 KDR의 작용에 영향을 주기 위한 약제에서 활성 성분으로서 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있다.In a further aspect, it is an object of the present invention to surprisingly misregulate cellular signaling processes, in particular active and inactive receptor tyrosine kinases, and also cytoplasmic tyrosine, serine / threonine and lipid kinases such as c-Raf. Can be used as active ingredients in pharmaceuticals to influence the action of B-Raf, Mek, MAPKs, PDGFRbeta, Flt-3, IGF1R, PI3K, PKB / Akt1, c-Kit, c-Abl, FGFR1 and KDR It can be achieved by providing a compound of the present invention.

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있고, 치료 또는 예방은 "ras-Raf-Mek-Erk 신호전달경로, PI3K-Akt 신호전달경로 및/또는 SAPK 신호전달경로"로 이루어진 그룹으로부터 선택되는 신호전달경로(들)의 조절에 의해 야기된다. In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by the regulation of a signaling pathway (s) selected from the group consisting of "ras-Raf-Mek-Erk signaling pathway, PI3K-Akt signaling pathway and / or SAPK signaling pathway."

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 효소에 의해 매개되는 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있다. In a further aspect, the object of the present invention is surprisingly in a mammal a physiological and / or pathophysiological condition mediated by an enzyme selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1". It can be accomplished by providing a compound of the present invention that can be used to prepare a therapeutic or prophylactic agent.

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있고, 치료 또는 예방은 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소를 변형시켜 야기된다. In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by modifying one or more enzymes selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1".

바람직한 양태에서, 본 발명의 화합물은 포유 동물에서 ras-Raf-Mek-Erk 신호전달경로 및/또는 PI3K-Akt 신호전달경로에 의해 매개된 생리학적 및/또는 병태생리학적 상태의 치료 및/또는 예방용 약제의 제조를 위한, 및/또는 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제의 제조를 위한 용도를 제공하고, 치료 또는 예방은 ras-Raf-Mek-Erk 신호전달경로 및 PI3K-Akt 신호전달경로의 조절에 의해 야기된다.In a preferred embodiment, the compounds of the invention treat and / or prevent the physiological and / or pathophysiological conditions mediated by the ras-Raf-Mek-Erk signaling pathway and / or the PI3K-Akt signaling pathway in mammals. For the manufacture of a medicament and / or for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, wherein the treatment or prophylaxis is provided by ras-Raf-Mek-Erk signaling. Caused by regulation of the pathway and PI3K-Akt signaling pathway.

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 ras-Raf-Mek-Erk 신호전달경로에 의해 매개되는 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있다.In a further aspect, the object of the present invention is surprisingly applicable to the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions mediated by ras-Raf-Mek-Erk signaling pathways in mammals. It can be achieved by providing a compound of the present invention.

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 PI3K-Akt 신호전달경로에 의해 매개된 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있다.In a further aspect, an object of the invention is surprisingly a compound of the invention which can be used to prepare a medicament for the treatment or prevention of a physiological and / or pathophysiological condition mediated by the PI3K-Akt signaling pathway in a mammal. Can be achieved by providing

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있고, 치료 또는 예방은 PI3K-Akt 신호전달경로의 조절에 의해 야기된다. In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by the regulation of the PI3K-Akt signaling pathway.

바람직한 양태에서, 본 발명의 화합물은 포유 동물에서 SAPK 신호전달경로 및/또는 PI3K-Akt 신호전달경로에 의해 매개되는 생리학적 및/또는 병태생리학적 상태의 치료 및/또는 예방용 약제의 제조를 위한, 및/또는 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제의 제조를 위하 용도를 제공하고, 치료 또는 예방은 SAPK 신호전달경로 및 PI3K-Akt 신호전달경로의 조절에 의해 야기된다. In a preferred embodiment, the compounds of the invention are for the manufacture of a medicament for the treatment and / or prophylaxis of physiological and / or pathophysiological conditions mediated by SAPK signaling pathway and / or PI3K-Akt signaling pathway in mammals. , And / or for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, wherein the treatment or prophylaxis is by regulation of the SAPK signaling pathway and the PI3K-Akt signaling pathway. Is caused.

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 SAPK 신호전달경로에 의해 매개된 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있다. In a further aspect, the object of the present invention surprisingly provides a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions mediated by SAPK signaling pathways in a mammal. Can be achieved.

추가의 양태에서, 본 발명의 목적은 놀랍게도 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있고, 치료 또는 예방은 SAPK 신호전달경로의 조절에 의해 야기된다. In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by the regulation of SAPK signaling pathways.

바람직한 양태에서, 본 발명의 화합물은 ras-Raf-Mek-Erk 신호전달경로의 조 절이 "티로신 키나제, 세린/트레오닌 키나제, 수용체 티로신 키나제, 세포질 티로신 키나제, 세포질 세린/트레오닌 키나제"로 이루어진 그룹으로부터 선택되는, 바람직하게는 "Erk, Erk1, Erk2"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 상기한 기재된 용도를 제공한다. In a preferred embodiment, the compounds of the invention are selected from the group wherein the regulation of the ras-Raf-Mek-Erk signaling pathway consists of "tyrosine kinase, serine / threonine kinase, receptor tyrosine kinase, cytoplasmic tyrosine kinase, cytoplasmic serine / threonine kinase" It provides a use as described above, preferably caused by the regulation of one or more enzymes selected from the group consisting of "Erk, Erk1, Erk2".

추가의 바람직한 양태에서, 본 발명의 화합물은 PI3K-Akt 신호전달경로의 조절이 "지질 키나제"로 이루어진 그룹으로부터 선택되는, 바람직하게는 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 상기한 기재된 용도를 제공한다.In a further preferred embodiment, the compounds of the invention are selected from the group consisting of "lipid kinase", wherein the regulation of the PI3K-Akt signaling pathway is preferably "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K -C2 alpha, PI3K-C2beta, PI3K-Vps34p "provide the use as described above caused by the regulation of one or more enzymes selected from the group consisting of.

추가의 바람직한 양태에서, 본 발명의 화합물은 SAPK 신호전달경로의 조절이 "티로신 키나제, 세린/트레오닌 키나제, 수용체 티로신 키나제, 세포질 티로신 키나제, 세포질 세린/트레오닌 키나제"로 이루어진 그룹으로부터 선택되는, 바람직하게는 "Jnk, Jnk1, Jnk2, Jnk3, p38, p38알파, p38베타, p38감마, p38델타"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 상기한 기재된 용도를 제공한다.In a further preferred embodiment, the compounds of the invention are preferably wherein the regulation of the SAPK signaling pathway is selected from the group consisting of "tyrosine kinase, serine / threonine kinase, receptor tyrosine kinase, cytosolic tyrosine kinase, cytoplasmic serine / threonine kinase" Provides the uses as described above, caused by the modulation of one or more enzymes selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta".

추가의 양태에서, 본 발명의 목적은 놀랍게도 상기한 양태, 바람직한 양태 및 용도에 따라 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위해 사용될 수 있는 본 발명의 화합물을 제공하여 성취될 수 있고, 치료 또는 예방은 2개 이상의 효소의 조절에 의해 야기된다. In a further aspect, the object of the present invention is surprisingly the compounds of the present invention which can be used for the preparation of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal according to the above embodiments, preferred embodiments and uses. Can be achieved, treatment or prevention is caused by the regulation of two or more enzymes.

보다 바람직한 양태에서, 본 발명의 화합물은 "Erk, Erk1, Erk2"로 이루어진 그룹으로부터 선택되는 2개 이상의 효소 및 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 치료 또는 예방에서 하나 이상의 효소의 상기한 용도를 제공한다.In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of "Erk, Erk1, Erk2" and "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K- The above uses of one or more enzymes in the treatment or prophylaxis caused by the modulation of one or more enzymes selected from the group consisting of C2beta, PI3K-Vps34p ".

보다 바람직한 양태에서, 본 발명의 화합물은 "Jnk, Jnk1, Jnk2, Jnk3, p38, p38알파, p38베타, p38감마, p38델타"로 이루어진 그룹으로부터 선택되는 2개 이상의 효소 및 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 치료 또는 예방에서 하나 이상의 효소의 상기한 용도를 제공한다. In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" and "PI3K, PI3Kalpha, The above uses of one or more enzymes in the treatment or prophylaxis caused by the modulation of one or more enzymes selected from the group consisting of PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p ". to provide.

보다 바람직한 양태에서, 본 발명의 화합물은 "Erk, Erk1, Erk2"로 이루어진 그룹으로부터 선택되는 2개 이상의 효소 및 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 치료 또는 예방에서 하나 이상의 효소의 상기한 용도를 제공한다.In a more preferred embodiment, the compound of the present invention is at least two enzymes selected from the group consisting of "Erk, Erk1, Erk2" and one selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1" The above uses of one or more enzymes in the treatment or prophylaxis caused by the regulation of the above enzymes are provided.

보다 바람직한 양태에서, 본 발명의 화합물은 "Jnk, Jnk1, Jnk2, Jnk3, p38, p38알파, p38베타, p38감마, p38델타"로 이루어진 그룹으로부터 선택되는 2개 이상의 효소 및 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 치료 또는 예방에서 하나 이상의 효소의 상기한 용도를 제공한다. In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" and "ATM, ATR, mTOR" The above uses of one or more enzymes in the treatment or prophylaxis caused by the modulation of one or more enzymes selected from the group consisting of DNA-PK, hSMG-1 ″.

보다 바람직한 양태에서, 본 발명의 화합물은 'PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되는 2개 이상의 효소 및 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소에 의해 야기되는 치료 또는 예방에서 하나 이상의 효소의 상기한 용도를 제공한다. In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of 'PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p "and The above uses of one or more enzymes in the treatment or prevention caused by one or more enzymes selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1".

또다른 바람직한 양태에서, 본 발명의 화합물은 조절이 억제인 상기한 용도를 제공한다. In another preferred embodiment, the compounds of the present invention provide the above uses, wherein the control is inhibition.

본 발명에서, 본 발명의 화합물은 치료 및/또는 예방을 위해 모든 공지된 포유동물, 특히 사람에게 투여될 수 있다. In the present invention, the compounds of the present invention can be administered to all known mammals, in particular humans, for treatment and / or prophylaxis.

또다른 바람직한 양태에서, 본 발명의 화합물은 포유동물이 "사람, 유용한 동물, 가축, 가정용 애완동물, 육우, 소, 양, 돼지, 염소, 말, 조랑말, 당나귀, 버새, 노새, 산토끼, 토끼, 고양이, 개, 기니아피그, 햄스터, 래트, 마우스"로 이루어진 그룹으로부터 선택되고, 바람직하게는 사람인 상기한 바와 같은 용도를 제공한다. In another preferred embodiment, the compounds of the present invention comprise a mammal as a “human, useful animal, livestock, domestic pet, beef cattle, cow, sheep, pig, goat, horse, pony, donkey, burrow, mule, hare, rabbit, Cats, dogs, guinea pigs, hamsters, rats, mice ", and preferably human.

본 발명에서, 본 발명의 화합물은 모든 공지된 생리학적 및/또는 병태생리학적 상태의 치료 및/또는 예방을 위해 사용될 수 있다. In the present invention, the compounds of the present invention can be used for the treatment and / or prevention of all known physiological and / or pathophysiological conditions.

바람직한 양태에서, 본 발명의 화합물은 다음으로 이루어진 그룹으로부터 선택된 생리학적 및/또는 병태생리학적 상태의 상기한 용도를 제공한다: "악성 종양, 양성 종양, 염증성 장애, 염증, 통증, 류마티스 장애, 관절염 장애, HIV 감염, 신경계 또는 신경변성 장애, 류마티스, 관절염, AIDS, ARC (AIDS 관련 콤플렉스), 카포시 육종, 뇌 및/또는 신경계 및/또는 뇌척수막으로부터 퍼지는 종양, 치매, 알츠 하이머질환, 과다증식성 장애, 건선, 자궁내막증, 흉터 형성, 전립샘비대 (BPH), 면역계 장애, 자가면역 장애, 면역결핍 장애, 결장 종양, 위 종양, 장 종양, 폐 종양, 췌장 종양, 난소 종양, 전립샘 종양, 백혈병, 흑색종, 간 종양, 신장 종양, 두부 종양, 인후 종양, 신경아교종, 유방 종양, 자궁 암, 자궁내막 암, 자궁경부 암, 뇌 종양, 선극세포종, 방광 암, 위 종양, 결장 종양, 식도 암, 부인과 종양, 난소 종양, 갑상샘 암, 림프종, 만성 백혈병, 급성 백혈병, 재협착, 당뇨병 당뇨병성 신병증, 섬유성 장애, 낭성섬유증, 악성 신장경화증, 혈전미세혈관병증 증후군, 기관이식거부, 사구체병증, 대사 장애, 고형 종양, 류마티스관절염, 당뇨병성 망막병증, 천식, 알레르기, 알레르기 장애, 만성 폐색성폐질환, 염증성 장질환, 섬유증, 아테롬성 동맥경화증, 심장 장애, 심혈관 장애, 심장근육의 장애, 혈관 장애, 혈관신생 장애, 신장 장애, 비염, 그레이브 질환, 국소 허혈, 심부전증, 허혈, 심장 비대, 신장 부전, 심장 근세포 기능장애, 고혈압, 혈관 협착, 뇌졸중, 과민성 쇼크, 혈소판 응집, 골격근 위축, 비만, 과체중, 글루코스 항상성, 울혈심부전증, 협심증, 심장 발작, 심근경색증, 과혈당, 저혈당, 고혈압". In a preferred embodiment, the compounds of the invention provide the above uses of physiological and / or pathophysiological conditions selected from the group consisting of: "malignant tumors, benign tumors, inflammatory disorders, inflammation, pain, rheumatic disorders, arthritis Disorders, HIV infection, nervous system or neurodegenerative disorders, rheumatism, arthritis, AIDS, ARC (AIDS related complexes), Kaposi's sarcoma, tumors spreading from the brain and / or nervous system and / or meninges, dementia, Alzheimer's disease, hyperproliferative disorders, Psoriasis, endometriosis, scar formation, prostatic hypertrophy (BPH), immune system disorders, autoimmune disorders, immunodeficiency disorders, colon tumors, gastric tumors, intestinal tumors, lung tumors, pancreatic tumors, ovarian tumors, prostate tumors, leukemias, melanoma , Liver tumor, kidney tumor, head tumor, throat tumor, glioma, breast tumor, uterine cancer, endometrial cancer, cervical cancer, brain tumor, acute cell tumor, bladder cancer, stomach tumor, Colon Tumor, Esophageal Cancer, Gynecologic Tumor, Ovarian Tumor, Thyroid Cancer, Lymphoma, Chronic Leukemia, Acute Leukemia, Restenosis, Diabetic Diabetic Nephropathy, Fibrotic Disorder, Cystic Fibrosis, Malignant Renal Sclerosis, Thrombomicroangiopathy Syndrome, Organs Transplant rejection, glomerulopathy, metabolic disorders, solid tumors, rheumatoid arthritis, diabetic retinopathy, asthma, allergies, allergic disorders, chronic obstructive pulmonary disease, inflammatory bowel disease, fibrosis, atherosclerosis, heart disorders, cardiovascular disorders, heart muscle Disorders, vascular disorders, angiogenesis disorders, kidney disorders, rhinitis, Grave disease, focal ischemia, heart failure, ischemia, cardiac hypertrophy, kidney failure, cardiomyocyte dysfunction, hypertension, vascular narrowing, stroke, irritable shock, platelet aggregation, skeletal muscle Atrophy, obesity, overweight, glucose homeostasis, congestive heart failure, angina pectoris, heart attack, myocardial infarction, hyperglycemia, hypoglycemia, hypertension ".

본 발명의 추가의 양태에서, 본 발명의 목적은 놀랍게도 상기한 양태, 바람직한 양태 및 용도에 따라서 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제의 제조를 위한 용도를 위해 본 발명의 화합물을 제공하여 성취될 수 있고, 약제는 하나 이상의 추가의 약리학적 활성 물질을 포함한다.In a further aspect of the invention, the object of the present invention is surprisingly contemplated for use for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal in accordance with the foregoing aspects, preferred embodiments and uses. It can be accomplished by providing a compound of the invention, wherein the medicament comprises one or more additional pharmacologically active substances.

본 발명의 추가의 양태에서, 본 발명의 목적은 놀랍게도 상기한 양태, 바람직한 양태 및 용도에 따라서 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제의 제조를 위한 용도를 위해 본 발명의 화합물을 제공하여 성취될 수 있고, 약제는 치료 전 및/또는 치료 동안 및/또는 치료 후 하나 이상의 추가의 약리학적 활성 물질과 함께 투여된다.In a further aspect of the invention, the object of the present invention is surprisingly contemplated for use for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal in accordance with the foregoing aspects, preferred embodiments and uses. It can be accomplished by providing a compound of the invention, wherein the medicament is administered with one or more additional pharmacologically active substances before and / or during and / or after treatment.

본 발명의 추가의 양태에서, 본 발명의 목적은 놀랍게도 상기한 양태, 바람직한 양태 및 용도에 따라서 포유 동물에서 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제의 제조를 위한 용도를 위해 본 발명의 화합물을 제공하여 성취될 수 있고, 약제는 방사선요법 및/또는 수술을 사용하는 치료 전 및/또는 치료 동안 및/또는 치료 후 함께 투여된다. In a further aspect of the invention, the object of the present invention is surprisingly contemplated for use for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal in accordance with the foregoing aspects, preferred embodiments and uses. It may be accomplished by providing a compound of the invention, wherein the medicaments are administered together before and / or during and / or after treatment using radiotherapy and / or surgery.

본 발명에서, 본 발명의 화합물은 상세된 병용요법에서 모든 공지된 약리학적 활성 물질과 함께 투여될 수 있다. In the present invention, the compounds of the present invention can be administered with all known pharmacologically active substances in the detailed combination therapy.

바람직한 양태에서, 본 발명의 화합물은 추가의 약리학적 활성 물질이 "DNA 국소이성화효소 I 및/또는 II 억제제, DNA 삽입제(intercalator), 알킬화제, 미세관 탈안정화제, 호르몬 및/또는 성장 인자 수용체 작용제 및/또는 길항제, 성장 인자 및 이의 수용체에 대한 항체, 키나제 억제제, 항대사물질"로 이루어진 그룹으로부터 선택되는 상기한 용도를 제공한다. In a preferred embodiment, the compounds of the invention further comprise pharmacologically active substances such as "DNA isomerase I and / or II inhibitors, DNA intercalators, alkylating agents, microtubule destabilizing agents, hormones and / or growth factor receptors. Agonists and / or antagonists, growth factors and antibodies to their receptors, kinase inhibitors, anti-metabolites.

바람직한 양태에서, 본 발명의 화합물은 추가의 약리학적 활성 물질이 다음으로 이루어진 그룹으로부터 선택되는 상기한 용도를 제공한다: "아스파라기나제, 블레오마이신, 카보플라틴, 카르무스틴, 클로르암부실, 시스플라틴, 콜라스파제, 사이클로포스파미드, 시타라빈, 다카바진, 다크티노마이신, 다우노루비신, 독소루비신 (아드리아마이신), 에피루비신, 에토포사이드, 5-플루오로우라실, 헥사메틸멜 라민, 하이드록시우레아, 이포스파미드, 이리노테칸, 류코보린, 로무스틴 메클로르에타민, 6-머캅토푸린, 메스나, 메토트렉세이트, 미토마이신 C,미톡산트론, 프레드니솔론, 프레드니손, 프로카바진, 랄록시펜, 스트렙토조신, 타목시펜, 티오구아닌, 토포테칸, 빈블라스틴, 빈크리스틴, 빈데신, 아미노글루테티미드, L-아스파라기나제, 아자티오프린, 5-아자시티딘 클라드리빈, 부설판, 디에틸스틸베스트롤, 2',2'-디플루오로데옥시시티딘, 독세탁셀, 에리트로하이드록시노닐아데닌, 에티닐에스트라디올, 5-플루오로데옥시우리딘, 5-플루오로데옥시우리딘 모노포스페이트, 플루다라빈 포스페이트, 플루옥시메스테론, 플루타미드, 하이드록시프로게스테론 카프로에이트, 이다루비신, 인터페론, 메드록시프로게스테론 아세테이트, 메게스트롤 아세테이트, 메팔란, 미토탄, 파클리탁셀, 옥살리플라틴, 펜토스타틴, N-포스포노아세틸-L-아스파르테이트 (PALA), 플리카마이신, 세무스틴, 테니포사이드, 테스토스테론 프로피오네이트, 티오테파, 트리메틸멜라민, 우리딘, 비노렐빈, 에포틸론, 겜시타빈, 탁소테레, BCNU, CCNU, DTIC, 5-플루오로우라실, 헤르셉틴, 아바스틴, 에르비툭스, 소라페니브, 글리벡, 이레사, 타르세바, 라파마이신, 아크티노마이신 D".In a preferred embodiment, the compounds of the present invention provide the above uses wherein the additional pharmacologically active substance is selected from the group consisting of: "asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, Cisplatin, Colaspase, Cyclophosphamide, Cytarabine, Dcarbazine, Darktinomycin, Daunorubicin, Doxorubicin (Adriamycin), Epirubicin, Etoposide, 5-Fluorouracil, Hexamethylmelamine, Hyde Loxyurea, Iphosphamide, Irinotecan, Leucovorin, Lomustine Mechlorethamine, 6-mercaptopurine, Mesna, Methotrexate, Mitomycin C, Mitoxantrone, Prednisolone, Prednisone, Procarbazine, Raloxifene, Streptozosin , Tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutetimide, L-asparaginase, azathioprine, 5- Azacytidine cladribine, busulfan, diethylstilbestrol, 2 ', 2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethynylestradiol, 5-fluorode Oxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, hydroxyprogesterone acetate, megestrol acetate , Mephalan, mitotan, paclitaxel, oxaliplatin, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, Uridine, vinorelbine, epothilones, gemcitabine, taxotere, BCNU, CCNU, DTIC, 5-fluorouracil, herceptin, avastin, erbitux, sorafenib, gleevec, iresa, tar Bar, rapamycin, arc actinomycin D ".

경구 투여는 예를 들면, 정제, 캡슐, 겔 캡슐, 피복된 정제, 과립 또는 분말과 같은 고체 형태 뿐만 아니라, 마실수 있는 용액 형태인 것이 효과적일 수 있다. 경구 투여를 위한, 상기한 본 발명의 신규한 화합물은 공지되고 통상적으로 사용되는 생리학적으로 허용되는 담체 및 부형제, 예를 들면, 아라비아 검, 탈크, 전분, 당, 예를 들면, 만니톨, 메틸셀룰로스, 락토즈, 젤라틴, 계면활성제, 마그네슘 스 테아레이트, 사이클로덱스트린, 수성 또는 비수성 담체, 희석제, 붕해제, 유화제, 보존제, 및 향미제(예를 들면, 에센셜 오일)와 배합될 수 있다. 본 발명의 화합물은 또한 마이크로미립자, 예를 들면, 나노미립자 조성물에 분산될 수 있다.Oral administration may be effective, for example, in the form of solids such as tablets, capsules, gel capsules, coated tablets, granules or powders, as well as in drinkable solution forms. For oral administration, the novel compounds of the invention described above are known and commonly used physiologically acceptable carriers and excipients such as gum arabic, talc, starch, sugars such as mannitol, methylcellulose , Lactose, gelatin, surfactants, magnesium stearate, cyclodextrins, aqueous or non-aqueous carriers, diluents, disintegrants, emulsifiers, preservatives, and flavoring agents (eg, essential oils). The compounds of the present invention may also be dispersed in microparticulates, such as nanoparticulate compositions.

비경구 투여는 예를 들면, 멸균 수성 또는 유성 용액, 현탁액 또는 에멀젼의 정맥내, 피하 또는 근육내 주사를 통해, 이식을 통해 또는 연고, 크림 또는 좌제를 통해 효과적일 수 있다. 적합한 경우, 투여는 또한 지속된 방출형이 효과적일 수 있다. 이식은 불활성 물질, 예를 들면, 생분해성 중합체 또는 합성 실리콘, 예를 들면, 실리콘 고무를 포함할 수 있다. 질내 투여는 예를 들면, 질 링으로 효과적일 수 있다. 자궁내 투여는 예를 들면, 가로막 또는 다른 적합한 자궁내 장치로 효과적일 수 있다. 추가적으로 경피 투여는 특히 이에 적합한 제형 및/또는 적합한 수단, 예를 들면, 고약으로 고려된다. Parenteral administration can be effective, for example, via intravenous, subcutaneous or intramuscular injection of sterile aqueous or oily solutions, suspensions or emulsions, through implantation or via ointments, creams or suppositories. If appropriate, administration may also be effective with sustained release. Implants may include inert materials such as biodegradable polymers or synthetic silicones such as silicone rubber. Intravaginal administration can be effective, for example, with a vaginal ring. Intrauterine administration can be effective, for example, with a diaphragm or other suitable intrauterine device. In addition, transdermal administration is in particular contemplated as a suitable formulation and / or suitable means, for example as a plaster.

본 발명의 약제는 적합한 투여형으로 피부로, 피내(epicutaneously)로, 용액, 현탁액, 에멀젼, 발포체, 연고, 페이스트 또는 고약으로서; 경구, 및 혀 점막, 구강, 혀 또는 설하로, 정제, 향정, 피복된 정제, 물약 또는 가글로서; 위 및 장 점막, 장관으로, 정제, 피복된 정제, 캡슐, 용액, 현탁액 또는 에멀젼으로; 직장 점막, 직장으로, 좌제, 직장 캡슐 또는 연고로서; 코 점막을 통해, 비내로, 점적액, 연고 또는 분무제로서; 기관지 및 폐포 상피, 폐 또는 흡입으로, 에어로졸 또는 흡입제로서; 결막, 결막으로, 점안약, 안용 연고, 안용 정제, 라멜라 또는 안약으로서; 생식기 점막, 질내로, 질 좌제, 연고 및 관주(douche)로서, 자궁내로, 자궁 페서리로서; 요로, 요도내로, 세척(irrigation), 연고 또는 부지(bougie)로서; 동맥, 동맥내로, 주사로서; 정맥으로, 정맥내, 주사 또는 주입으로; 피부로, 피내로, 주사 또는 임플란트로서; 피부 아래, 피하, 주사 또는 임플란트로서; 근육으로, 근육내, 주사 또는 임플란트로서; 복강, 복강내로, 주사 또는 주입으로 투여될 수 있다.The medicaments of the present invention may be administered in suitable dosage forms, into the skin, epicutaneously, as a solution, suspension, emulsion, foam, ointment, paste or plaster; Oral and tongue mucosa, mouth, tongue or sublingual, as tablets, pastilles, coated tablets, potions or gargles; Gastric and intestinal mucosa, intestinal, tablets, coated tablets, capsules, solutions, suspensions or emulsions; Rectal mucosa, rectally, as suppositories, rectal capsules or ointments; Through the nasal mucosa, intranasally, as drops, ointments or sprays; Bronchial and alveolar epithelium, lung or inhalation, as aerosols or inhalants; Conjunctiva, into the conjunctiva, as eye drops, ophthalmic ointments, ophthalmic tablets, lamellar or eye drops; Genital mucosa, intravaginally, as vaginal suppository, ointment and douche, intrauterine, as uterine pessary; As urinary tract, into the urethra, as an irrigation, ointment or bougie; Arteries, into arteries, as injections; Intravenously, intravenously, by injection or infusion; As skin, intradermal, by injection or implant; Under the skin, subcutaneously, by injection or as an implant; Intramuscularly, intramuscularly, as injections or implants; It may be administered intraperitoneally, intraperitoneally, by injection or infusion.

실제 치료학적 요구조건에 따라서, 본 발명의 화합물의 약제 작용은 적합한 방법으로 연장될 수 있다. 이러한 목적은 화학적 및/또는 약제학적 경로에 의해 성취될 수 있다. 연장된 작용의 성취의 예는 이식 및 리포솜의 용도, 약한 가용성 염 및 복합체의 형성, 또는 결정성 현탁액의 용도이다. Depending on the actual therapeutic requirements, the pharmaceutical action of the compounds of the present invention may be extended in a suitable manner. This object can be achieved by chemical and / or pharmaceutical routes. Examples of achieving prolonged action are the use of grafts and liposomes, the formation of weakly soluble salts and complexes, or the use of crystalline suspensions.

상기 설명한 바와 같이, 본 발명의 신규한 화합물은 또한 추가의 약제학적 활성 성분과 배합될 수 있다. 병용요법에서, 개별적인 활성 성분은 동일한 경로(예를 들면, 경구) 또는 개별적인 경로(예를 들면, 경구 및 주사로서)에 의해 동시에 또는 개별적으로 투여할 수 있다. 이들은 동일한 양 또는 상이한 양으로 단위 용량으로 존재하거나 투여될 수 있다. 또한, 적합한 특정 투여방식을 사용할 수 있다. 이러한 방법으로, 또한, 다수의 본 발명의 신규한 화합물을 다른 것과 배합할 수 있다. As described above, the novel compounds of the present invention may also be combined with additional pharmaceutically active ingredients. In combination therapy, the individual active ingredients can be administered simultaneously or separately by the same route (eg oral) or by separate routes (eg oral and injection). They may be present or administered in unit doses in the same or different amounts. In addition, certain suitable modes of administration may be employed. In this way, many of the novel compounds of the invention can also be combined with others.

용량은 지시 형태, 장애의 중증도, 투여 형태, 및 치료될 피험자의 연령, 성별, 체중 및 민감성에 좌우되어 광범위한 범위 내일 수 있다. 당해 기술분야의 숙련가의 능력 내에서 배합된 약제학적 조성물의 "약리학적 활성 양"이 결정된다. 투여는 단일 용량 또는 다수의 개별적인 용량으로 효과적일 수 있다. The dosage can be within a wide range depending on the indication form, the severity of the disorder, the dosage form, and the age, sex, weight, and sensitivity of the subject to be treated. The "pharmacologically active amount" of a pharmaceutical composition formulated within the capabilities of those skilled in the art is determined. Administration can be effective in a single dose or in multiple individual doses.

적합한 단위 용량은, 환자의 체중 1kg당, 예를 들면, 0.001mg 내지 100mg의 활성 성분, 즉, 하나 이상의 본 발명의 화합물 및 임의의 추가의 활성 약제학적 성분이다. Suitable unit doses are, for example, from 0.001 mg to 100 mg of active ingredient, ie one or more compounds of the present invention and any further active pharmaceutical ingredient, per kg of body weight of the patient.

본 발명의 추가의 양태에서, 본 발명은 이에 따라 또한 약리학적 활성 양의 하나 이상의 본 발명의 화합물, 바람직하게는 화합물 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 및/또는 화합물 85, 및 또한 임의로 약제학적으로 허용되는 담체 및/또는 부형제를 포함하는 약제학적 조성물을 포함한다. In a further aspect of the invention, the invention accordingly also relates to a pharmacologically active amount of at least one compound of the invention, preferably compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 and / or Compound 85, and also optionally a pharmaceutical composition comprising a pharmaceutically acceptable carrier and / or excipient.

바람직한 및 특히 바람직한 본 발명의 조성물은 하나 이상의 상기한 바람직한 본 발명의 화합물을 포함하는 것이다. 본 발명에 따른 약제학적 조성물에서, 상기한 하나 이상의 화합물 뿐만 아니라 상기한 하나 이상의 추가의 약제학적 활성 성분도 존재할 수 있다. Preferred and particularly preferred compositions of the invention comprise one or more of the aforementioned preferred compounds of the invention. In the pharmaceutical compositions according to the invention, not only one or more compounds described above, but also one or more additional pharmaceutically active ingredients mentioned above may be present.

본 발명의 약제학적 조성물에서, 상기한 하나 이상의 본 발명의 신규한 화합물은 약리학적 활성 양, 바람직하게는 단위 용량, 예를 들면, 상기한 단위 용량으로, 바람직하게는 경구 투여 가능한 투여형으로 존재한다. In the pharmaceutical compositions of the present invention, one or more of the novel compounds of the present invention described above are present in pharmacologically active amounts, preferably in unit doses, for example in the above unit doses, preferably in oral administrable dosage forms. do.

본 발명의 화합물을 포함하는 약제학적 조성물에 대해, 및 본 발명의 화합물의 약제로서의 용도에 대해서는, 가능한 용도 및 투여 방법에 관한 본 발명의 신규한 화합물 자체의 용도와 연관되어 이미 기술된 것을 참조한다. For pharmaceutical compositions comprising the compounds of the invention, and for the use of the compounds of the invention as medicaments, reference is made to those already described in connection with the use of the novel compounds of the invention pertaining to possible uses and methods of administration. .

본 발명의 추가의 양태에서, 본 발명의 목적은 놀랍게도 약리학적 활성 양의 하나 이상의 바람직한 상기한 본 발명의 화합물 및 상기한 약리학적 활성 양의 하나 이상의 추가의 약리학적 활성 성분을 포함하는 키트를 제공하여 성취될 수 있다.In a further aspect of the invention, it is an object of the present invention to surprisingly provide a kit comprising at least one preferred pharmacologically active amount of a compound of the invention as described above and at least one additional pharmacologically active ingredient of said pharmacologically active amount. Can be achieved.

본 발명의 화합물의 일반적인 합성 방법General Synthetic Methods of Compounds of the Invention

본 발명의 치환된 피리도[2,3-b]피라진의 제조방법은 하기에 예시된다. The preparation of the substituted pyrido [2,3-b] pyrazine of the invention is illustrated below.

본 발명의 화합물은 다음 반응식(반응식 1 - 9) 및 상응하는 당해 기술분야의 숙련가들에게 공지된 방법에 따라 수득할 수 있다:Compounds of the present invention can be obtained according to the following schemes (Scheme 1-9) and corresponding methods known to those skilled in the art:

다음 반응식에 나타난 R1 내지 R36 라디칼의 정의는 화학식 I 및 II, 예를 들면, Z 라디칼, R 라디칼, X 라디칼, T 라디칼 등에 관련된 상기한 치환체에 상응한다. 개별적인 연구는 당해 기술분야의 숙련가들에 의해 이들의 평균적인 기술 지식을 기초로 하여 간단한 방법으로 수행될 수 있다. The definitions of the R1 to R36 radicals shown in the following schemes correspond to the above-mentioned substituents relating to formulas I and II, for example Z radicals, R radicals, X radicals, T radicals and the like. Individual studies can be carried out in a simple manner by those skilled in the art based on their average technical knowledge.

반응식 1Scheme 1

Figure 112008041801646-PCT00089
Figure 112008041801646-PCT00089

치환체 R2 및 R4가 수소에 의해 치환된 본 발명의 피리도[2,3-b]피라진의 선택된 예를 위한 전구체는 예를 들면, 반응식 2의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득된다. Precursors for selected examples of the pyrido [2,3-b] pyrazines of the invention wherein substituents R2 and R4 are substituted by hydrogen are described, for example, in the methods of Scheme 2 or the corresponding known to those skilled in the art. Obtained by the method.

반응식 2Scheme 2

Figure 112008041801646-PCT00090
Figure 112008041801646-PCT00090

치환체 R3 및/또는 R4가 OR31, SR32, NR33R34 라디칼인 본 발명의 피리도[2,3-b]피라진의 선택된 예를 위한 전구체는 예를 들면, 반응식 3의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득된다. Precursors for selected examples of the pyrido [2,3-b] pyrazine of the invention wherein the substituents R3 and / or R4 are OR31, SR32, NR33R34 radicals are described, for example, to the methods of Scheme 3 or those skilled in the art. Obtained by known corresponding methods.

반응식 3Scheme 3

Figure 112008041801646-PCT00091
Figure 112008041801646-PCT00091

상기한 전구체 11을 위해, 반응식 6으로부터의 중간체 22 또는 반응식 5로부터의 그밖의 중간체 20, 21, 21a 및 21b가 사용될 수 있다. For precursor 11 described above, intermediates 22 from Scheme 6 or other intermediates 20, 21, 21a and 21b from Scheme 5 can be used.

치환체 R9가 H가 아닌 본 발명의 피리도[2,3-b]피라진의 선택된 예를 위한 전구체는 예를 들면, 반응식 4의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득된다.Precursors for selected examples of the pyrido [2,3-b] pyrazine of the invention wherein substituent R9 is not H are obtained, for example, by the method of Scheme 4 or by a corresponding method known to those skilled in the art. .

반응식 4Scheme 4

Figure 112008041801646-PCT00092
Figure 112008041801646-PCT00092

반응식 1-4로부터의 전구체 4, 7, 9 및 15는 본 발명의 치환된 피리도[2,3-b]피라진으로, 예를 들면, 반응식 5의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 변환될 수 있다. Precursors 4, 7, 9 and 15 from Schemes 1-4 are substituted pyrido [2,3-b] pyrazine of the present invention, for example, the methods of Scheme 5 or those known to those skilled in the art. Can be converted in a corresponding manner.

반응식 5Scheme 5

Figure 112008041801646-PCT00093
Figure 112008041801646-PCT00093

Figure 112008041801646-PCT00094
Figure 112008041801646-PCT00094

치환체 R3 및/또는 R4가 치환된 아릴, 헤테로아릴, 알킬, 알케닐 또는 알키닐 라디칼로부터 선택될 수 있는 본 발명의 피리도[2,3-b]피라진의 선택된 예는 예를 들면, 반응식 6의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득될 수 있다. Selected examples of pyrido [2,3-b] pyrazines of the invention, which may be selected from aryl, heteroaryl, alkyl, alkenyl or alkynyl radicals substituted with substituents R3 and / or R4, are described, for example, in Scheme 6 Or by a corresponding method known to those skilled in the art.

반응식 6Scheme 6

Figure 112008041801646-PCT00095
Figure 112008041801646-PCT00095

치환체 R3 및/또는 R4가 N-C(O)-, -N-SO2-, -N-C(O)-O- 및 N-C(O)-N-인 본 발명의 피리도[2,3-b]피라진의 선택된 예는 예를 들면, 반응식 7의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득될 수 있다. Of the pyrido [2,3-b] pyrazine of the invention wherein the substituents R3 and / or R4 are NC (O)-, -N-SO2-, -NC (O) -O- and NC (O) -N- Selected examples can be obtained, for example, by the method of Scheme 7 or corresponding methods known to those skilled in the art.

반응식 7Scheme 7

Figure 112008041801646-PCT00096
Figure 112008041801646-PCT00096

치환체 R3 및/또는 R4가 우레아-, 카바메이트- 또는 카보네이트-치환된 라디칼인 본 발명의 피리도[2,3-b]피라진의 선택된 예는 예를 들면, 반응식 8의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득될 수 있다. Selected examples of pyrido [2,3-b] pyrazine of the invention wherein substituents R3 and / or R4 are urea-, carbamate- or carbonate-substituted radicals are described, for example, in the methods of Scheme 8 or in the art. It can be obtained by the corresponding method known to the skilled person.

반응식 8Scheme 8

Figure 112008041801646-PCT00097
Figure 112008041801646-PCT00097

치환체 R3 및/또는 R4가 O-, S-, N-치환된 라디칼로부터 선택될 수 있는 본 발명의 피리도[2,3-b]피라진의 선택된 예는 예를 들면, 반응식 9의 방법 또는 당해 기술분야의 숙련가들에게 공지된 상응하는 방법으로 수득될 수 있다. Selected examples of pyrido [2,3-b] pyrazine of the invention wherein the substituents R3 and / or R4 can be selected from O-, S-, N-substituted radicals are described, for example, in the method of Scheme 9 or It can be obtained by corresponding methods known to those skilled in the art.

반응식 9Scheme 9

Figure 112008041801646-PCT00098
Figure 112008041801646-PCT00098

출발 화합물 및 중간체는 시판되거나, 당해 기술분야의 숙련가에게 자체 공 지된 방법으로 제조할 수 있다. 반응물 4, 7, 9-15, 22, 26, 31, 34 및 37은 본 발명의 피리도피라진의 제조를 위한 중요한 중간체이다. Starting compounds and intermediates are either commercially available or can be prepared by methods known per se to those skilled in the art. Reactants 4, 7, 9-15, 22, 26, 31, 34 and 37 are important intermediates for the preparation of pyridopyrazines of the invention.

출발 화합물, 중간체 및 본 발명의 피리도피라진을 제조하기 위해, 모 출원 WO2004/104002 및 WO2004/104003을 참조하고, 또한 예를 들면, 본원에 참조로서 인용된 다음 기본 문헌을 참조한다. To prepare the starting compounds, intermediates and pyridopyrazines of the invention, reference is made to the parent applications WO2004 / 104002 and WO2004 / 104003, and also to the following basic documents, for example, incorporated herein by reference.

본 발명의 화합물의 제조방법을 위한 일반적인 방법:General Methods for the Preparation of Compounds of the Invention:

Figure 112008041801646-PCT00099
Figure 112008041801646-PCT00099

Figure 112008041801646-PCT00100
Figure 112008041801646-PCT00100

본 발명의 화합물 제조를 위한 일반적 방법General Method for Making Compounds of the Invention

반응식 1: 제1 단계Scheme 1: first step

2,6-디아미노-3-니트로피리딘 또는 2-아미노-3,5-디니트로피리딘을 적합한 불활성 용매, 예를 들면, 메탄올, 에탄올, 디메틸포름아미드 또는 디옥산에 용해시켰다. 촉매, 예를 들면, 라네이 니켈, 탄소상 팔라듐 또는 이산화백금(IV)을 첨가한 후, 반응 혼합물을 수소 분위기하에 위치시키고, 1 내지 5bar의 압력을 성취하였다. 반응 혼합물을 수시간 동안, 예를 들면, 1-16시간 동안, 20℃ 내지 60℃ 범위의 온도에서 반응시켰다. 반응을 종결시킨 다음, 불용성 잔사를 여과제거하고, 이를 위해, 필터 매질은 실리카 겔, 셀라이트 또는 시판되는 유리 섬유 필터로 이루어질 수 있고, 이들을 적합한 용매로 세척하였다. 용액에 존재하는 조 생성물을 다음 반응을 위해 추가의 정제 없이 사용한다.2,6-Diamino-3-nitropyridine or 2-amino-3,5-dinitropyridine was dissolved in a suitable inert solvent such as methanol, ethanol, dimethylformamide or dioxane. After addition of a catalyst such as laney nickel, palladium on carbon or platinum (IV), the reaction mixture was placed under hydrogen atmosphere and a pressure of 1 to 5 bar was achieved. The reaction mixture was reacted for several hours, for example 1-16 hours, at a temperature ranging from 20 ° C. to 60 ° C. After completion of the reaction, the insoluble residue was filtered off, for which the filter medium could consist of silica gel, celite or commercially available glass fiber filters, which were washed with a suitable solvent. The crude product present in solution is used without further purification for the next reaction.

제2 단계2nd step

1,2-디온 유도체를 초기에 적합한 불활성 용매, 예를 들면, 메탄올, 에탄올, 디옥산, 톨루엔 또는 디메틸포름아미드에 채웠다. 2,3,6-트리아미노피리딘 또는 2,3,5-트리아미노피리딘을, 환원 후 직접적으로, 상기한 용매의 하나 중 조 생성물의 용액으로서, 초기에 채운 1,2-디온에 첨가하고, 임의로 산, 예를 들면, 아세트산 또는 염기, 예를 들면, 수산화칼륨을 첨가하여 채웠다. 반응 혼합물을 20℃ 내지 80℃ 범위의 온도에서 특정한 시간 동안, 예를 들면, 20분 내지 40시간 동안 반응시켰다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 디메틸포름아미드가 사용되는 경우, 반응 혼합물을 다량의 물로 교반하고, 침전된 고체를 여과제거하거나, 수성상을 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출하고, 유기상을 감압하에 농축시켰다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.1,2-dione derivatives were initially charged in a suitable inert solvent such as methanol, ethanol, dioxane, toluene or dimethylformamide. 2,3,6-triaminopyridine or 2,3,5-triaminopyridine is added directly after reduction to the initially filled 1,2-dione as a solution of the crude product in one of the solvents described above, Optionally filled with the addition of an acid such as acetic acid or a base such as potassium hydroxide. The reaction mixture was reacted at a temperature in the range of 20 ° C. to 80 ° C. for a certain time, for example 20 minutes to 40 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. If dimethylformamide is used, the reaction mixture is stirred with a large amount of water and the precipitated solid is filtered off or the aqueous phase is extracted with a suitable organic solvent such as dichloromethane or ethyl acetate and the organic phase is concentrated under reduced pressure. I was. The remaining crude product was recrystallized from a suitable solvent such as dioxane or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 2: 제1 단계Scheme 2: first step

피리도피라지논 유도체 8을 초기에 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 디옥산 또는 톨루엔에, 또는 용매없이 채웠다. 염소화제, 예를 들면, 포스포릴 클로라이드 또는 티오닐 클로라이드를 실온에서 첨가하고, 반응 혼합물을 20℃ 내지 10℃ 범위의 온도에서 특정한 시간 동안, 예를 들면, 1 시간 내지 24시간 동안 반응시키도록 한다. 반응을 종결시킨 다음, 반응 혼합물을 물에 붓고, 적합한 수성 염기, 예를 들면, 수산화나트륨 용액으로 중성화하였다. 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 잔사를 감압하에 건조시키거나, 수성상을 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출하고, 유기상을 감압하에 농축시켰다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Pyridopyrazinone derivative 8 was initially charged in a suitable inert solvent such as dimethylformamide, dioxane or toluene, or without solvent. A chlorinating agent such as phosphoryl chloride or thionyl chloride is added at room temperature and the reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 10 ° C. for a certain time, for example 1 hour to 24 hours. . After the reaction was terminated, the reaction mixture was poured into water and neutralized with a suitable aqueous base such as sodium hydroxide solution. The precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining residues are dried under reduced pressure or the aqueous phase is fitted with a suitable organic solvent, for example, Extract with dichloromethane or ethyl acetate and concentrate the organic phase under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane or toluene or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 3: 제1 단계Scheme 3: first step

2,3,6-트리아미노피리딘 또는 2,3,5-트리아미노피리딘을, 환원 후 직접적으로, 조 생성물의 용액으롯, 초기에 상기한 용매의 하나에 채웠다. 옥살산 유도체, 예를 들면, 디에틸 옥살레이트 또는 옥살릴 클로라이드를 첨가한 후, 반응 혼합물을, 임의로 산, 예를 들면, 염산, 황산 또는 빙초산을 첨가하여, 20℃ 내지 150℃ 범위의 온도에서 특정한 시간 동안, 예를 들면, 10분 내지 24 동안 반응시키도록 한다. 반응을 종결시킨 후, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 염기, 예를 들면, 수산화나트륨 용액으로 중성화하고, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다. 2,3,6-triaminopyridine or 2,3,5-triaminopyridine was initially charged after reduction directly with one of the solvents described above, as a solution of the crude product. After addition of an oxalic acid derivative, for example diethyl oxalate or oxalyl chloride, the reaction mixture is specified at a temperature ranging from 20 ° C. to 150 ° C., optionally with the addition of an acid such as hydrochloric acid, sulfuric acid or glacial acetic acid. The reaction is carried out for a time, for example, for 10 minutes to 24 minutes. After completion of the reaction, the precipitated solids are filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solids are dried under reduced pressure or the reaction mixture under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off, or the aqueous phase may be neutralized with a suitable aqueous base such as sodium hydroxide solution, and a suitable organic solvent such as For example, it can be extracted with dichloromethane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane or toluene or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

제2 단계2nd step

디온 유도체 10을 초기에 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 디옥산 또는 톨루엔에, 또는 용매없이 채웠다. 염소화제, 예를 들면, 포스포릴 클로라이드 또는 티오닐 클로라이드를 실온에서 첨가하고, 반응 혼합물을 20℃ 내지 10℃ 범위의 온도에서 특정한 시간 동안, 예를 들면, 1시간 내지 24시간 동안 반응시키도록 한다. 반응을 종결시킨 다음, 반응 혼합물을 물에 붓고, 적합한 수성 염기, 예를 들면, 수산화나트륨 용액로 중성화시키고. 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척 하고, 잔류하는 잔사를 감압하에 건조시키거나, 수성상을 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출하고, 유기상을 감압하에 농축시켰다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Dione derivative 10 was initially charged in a suitable inert solvent such as dimethylformamide, dioxane or toluene, or without solvent. A chlorinating agent such as phosphoryl chloride or thionyl chloride is added at room temperature and the reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 10 ° C. for a certain time, for example 1 hour to 24 hours. . After completion of the reaction, the reaction mixture is poured into water and neutralized with a suitable aqueous base such as sodium hydroxide solution. The precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining residues are dried under reduced pressure or the aqueous phase is fitted with a suitable organic solvent, for example, Extract with dichloromethane or ethyl acetate and concentrate the organic phase under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane or toluene or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

제3 단계3rd step

중간체 11을 적합한 알콜, 티올 또는 아민 및 임의로 적합한 염기, 바람직하게는 메탄올 중 수소화나트륨, 피리딘, 트리에틸아민, 탄산칼륨 또는 나트륨 메톡사이드와, 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 디메틸 설폭사이드, 메탄올, 톨루엔에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민에서, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 30분 내지 2일 동안, 20℃ 내지 140℃ 범위의 온도에서 반응시키도록 한다. 대안적으로, 중간체 11을 적합한 아민 및 적합한 촉매, 예를 들면, 트리스(디벤질리덴아세톤)디팔라듐(0) 또는 테트라키스(트리페닐포스핀)팔라듐(0), 및 적합한 리간드, 예를 들면, 2-(디사이클로헥실포스파닐)비페닐, 및 적합한 염기, 예를 들면, 나트륨 3급-부톡사이드와, 적합한 용매, 예를 들면, 톨루엔 또는 디메틸포름아미드에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 2시간 내지 30시간 동안, 60℃ 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 후, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산, 에틸 아세테이트 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Intermediate 11 is selected from a suitable alcohol, thiol or amine and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol, and a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide The reaction can be carried out in the side, methanol, toluene, or as a solvent, in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 140 ° C. for a specific time, for example, from 30 minutes to 2 days. Alternatively, intermediate 11 may be prepared by using a suitable amine and a suitable catalyst such as tris (dibenzylideneacetone) dipalladium (0) or tetrakis (triphenylphosphine) palladium (0), and suitable ligands such as , 2- (dicyclohexylphosphanyl) biphenyl, and a suitable base such as sodium tert-butoxide may be reacted in a suitable solvent such as toluene or dimethylformamide. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. to 120 ° C. for a specific time, for example 2 to 30 hours. After completion of the reaction, the precipitated solids are filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solids are dried under reduced pressure or the reaction mixture under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane, ethyl acetate or toluene, or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 4: 제1 단계Scheme 4: first step

중간체 4 및 7을 적합한 클로라이드, 브로마이드 또는 토실레이트 및 임의로 적합한 염기, 예를 들면, 메탄올 중 수소화나트륨, 피리딘, 트리에틸아민, 탄산칼륨 또는 나트륨 메톡사이드와 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 디메틸 설폭사이드, 메탄올에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 24시간 동안, 20℃ 내지 150℃ 범위의 온도에서 반응시키도록 한다. 대안적으로, 중간체 4 및 7을 적합한 아릴 브로마이드 또는 요오다이드 및 적합한 촉매, 예를 들면, 팔라듐 아세테이트 또는 Pd2(dba)3, 및 적합 한 리간드, 예를 들면, BINAP, 및 적합한 염기, 예를 들면, 탄산칼륨 또는 나트륨 3급-부톡사이드와, 적합한 용매, 예를 들면, 톨루엔 또는 디옥산에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 10시간 내지 30시간 동안, 60℃ 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 모든 촉매 잔사를 여과제거하고, 적합한 용매로 세척하고, 용매를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Intermediates 4 and 7 are suitable chlorides, bromide or tosylate and optionally suitable bases such as sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol and a suitable inert solvent such as dimethylformamide , In dimethyl sulfoxide, methanol, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 150 ° C. for a specific time, for example 1 hour to 24 hours. Alternatively, intermediates 4 and 7 may be substituted with suitable aryl bromide or iodide and suitable catalysts such as palladium acetate or Pd 2 (dba) 3 , and suitable ligands such as BINAP, and suitable bases such as For example, potassium carbonate or sodium tert-butoxide can be reacted in a suitable solvent such as toluene or dioxane. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. to 120 ° C. for a specific time, for example 10 to 30 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent, the remaining solid is dried under reduced pressure, or all catalyst residues are filtered off. Remove and wash with a suitable solvent and either dry the solvent under reduced pressure or remove the solvent under reduced pressure. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or toluene, or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 5: 제1 단계Scheme 5: first step

기본적인 프로세스 후, 기본적인 프로세스로 형성된 생성물을 전환 반응으로 본 발명의 전환 생성물로 당해 기술분야의 숙련가들에게 공지된 방법으로 전환시킬 수 있다.After the basic process, the product formed in the basic process can be converted to the conversion product of the present invention by a conversion reaction by a method known to those skilled in the art.

예를 들면, 생성물이 반응식 5에 따른 화합물 16의 유도체인 경우, 반응 생 성물 4, 7, 9 또는 15는 적합한 이소시아네이트 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 칼륨 헥사메틸디실라자이드, 피리딘, 트리에틸아민 또는 탄산칼륨과, 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 디메틸 설폭사이드, 아세토니트릴, 디클로로메탄, 1,2-디클로르에탄 또는 디옥산에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민에서, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 수시간 동안, 예를 들면, 1 내지 24시간 동안, 0 내지 80℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 16 according to Scheme 5, reaction products 4, 7, 9 or 15 are suitable isocyanates and optionally suitable bases, preferably sodium hydride, potassium hexamethyldisilazide, pyridine, In triethylamine or potassium carbonate and a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, dichloromethane, 1,2-dichlorethane or dioxane, or as a solvent, for example a base such as The reaction can be carried out in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 to 80 ° C. for several hours, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

또는, 대안적으로, 생성물이 반응식 5에 따른 화합물 17의 유도체인 경우, 반응 생성물 4, 7, 9 또는 15는 포스겐 또는 카보닐디이미다졸 및 적합한 아민과 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 테트라하이드로푸란, 톨루엔, 디클로로메탄 또는 아세토니트릴에서 반응시킬 수 있다. 적합한 경우, 적합한 염 기, 바람직하게는 피리딘, 나트륨 수소카보네이트, 트리에틸아민, N-메틸모르폴린 또는 나트륨 아세테이트가 사용된다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 15분 내지 24시간 동안 0 내지 60℃ 범위의 온도에서 반응시키도록 한다. 대안적으로, 반응 생성물 4, 7, 9 또는 15는 적합한 아민-페닐-카바메이트 시약 및 임의로 적합한 염기, 바람직하게는 피리딘, 탄산나트륨, 트리에틸아민 또는 수소화나트륨과, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 디옥산, 디클로로메탄, 디메틸포름아미드 또는 아세토니트릴에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 18시간 동안, 0℃ 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Alternatively, if the product is a derivative of compound 17 according to Scheme 5, reaction products 4, 7, 9 or 15 may be phosgene or carbonyldiimidazole and a suitable amine and a suitable inert solvent such as dimethylformamide. , Tetrahydrofuran, toluene, dichloromethane or acetonitrile. Where appropriate, suitable bases are used, preferably pyridine, sodium hydrogencarbonate, triethylamine, N-methylmorpholine or sodium acetate. The reaction mixture is allowed to react at a temperature in the range of 0 to 60 ° C. for a specific time, for example 15 minutes to 24 hours. Alternatively, reaction products 4, 7, 9 or 15 may be prepared with a suitable amine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium hydride, and a suitable inert solvent such as The reaction may be carried out in tetrahydrofuran, dioxane, dichloromethane, dimethylformamide or acetonitrile, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 ° C. to 120 ° C. for a specific time, for example 1 hour to 18 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 5에 따른 화합물 18의 유도체인 경우, 반응 생 성물 4, 7, 9 또는 15는 적합한 이소티오시아네이트 및 적합하게는 적합한 염기, 바람직하게는 수소화나트륨, 트리에틸아민, 탄산칼륨 또는 피리딘과, 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 테트라하이드로푸란, 아세톤 또는 톨루엔에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 30분 내지 90시간 동안, 0 내지 115도 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 18 according to Scheme 5, reaction products 4, 7, 9 or 15 are suitable isothiocyanates and suitably suitable bases, preferably sodium hydride, triethylamine, Potassium carbonate or pyridine can be reacted in a suitable inert solvent such as dimethylformamide, tetrahydrofuran, acetone or toluene, or as a solvent in a base such as pyridine or triethylamine, or without solvent. . The reaction mixture is allowed to react at 0-115 degrees for a certain time, for example, 30 minutes to 90 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

또는, 대안적으로, 생성물이 반응식 5에 따른 화합물 19의 유도체인 경우, 반응 생성물 4, 7, 9 또는 15는 티오포스겐 또는 티오카보닐디이미다졸 및 적합한 아민과 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 테트라하이드로푸란, 톨루엔, 디클로로메탄, 에탄올 또는 아세토니트릴에서 반응시킬 수 있다. 임의로, 적합한 염기, 바람직하게는 피리딘, 나트륨 수소카보네이트, 탄산칼륨, 트리에틸아 민 또는 이미다졸이 사용된다. 반응 혼합물을 수시간 동안, 예를 들면, 1 내지 24시간 동안, -10 내지 80℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Alternatively, when the product is a derivative of compound 19 according to Scheme 5, reaction products 4, 7, 9 or 15 may be thiophosphene or thiocarbonyldiimidazole and a suitable amine and a suitable inert solvent such as dimethyl It may be reacted in formamide, tetrahydrofuran, toluene, dichloromethane, ethanol or acetonitrile. Optionally, suitable bases are used, preferably pyridine, sodium hydrogencarbonate, potassium carbonate, triethylamine or imidazole. The reaction mixture is allowed to react at a temperature in the range of −10 to 80 ° C. for several hours, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the residual solid is dried under reduced pressure, or the reaction mixture is dried under reduced pressure. Was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 5에 따른 화합물 20의 유도체인 경우, 반응 생성물 4, 7, 9 또는 15를 포스겐 또는 카보닐디이미다졸 및 적합한 하이드록실아민과 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 테트라하이드로푸란, 디옥산, 디클로로메탄 또는 톨루엔에서 반응시킬 수 있다. 임의로, 적합한 염기, 바람직하게는 피리딘, 탄산나트륨, 트리에틸아민 또는 나트륨 아세테이트가 사용된다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 24시간 동안, 0 내지 100℃의 온도 범위에서 반응시키도록 한다. 대안적으로, 반응 생성물 4, 7, 9 또는 15를 적합한 하이드록실아민-페닐-카바메이트 시약 및 임의로 적합한 염기, 바람직하게는 피리딘, 탄산나트륨, 트리에틸아민 또는 나트륨 아세테이트와, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 디옥산, 디클로로메탄, 디메틸포름아미드 또는 톨루엔 중에, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 18시간 동안, 실온 내지 100℃의 온도 범위에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, if the product is a derivative of compound 20 according to Scheme 5, reaction products 4, 7, 9 or 15 may be reacted with phosgene or carbonyldiimidazole and a suitable hydroxylamine and a suitable inert solvent such as dimethylformamide. , Tetrahydrofuran, dioxane, dichloromethane or toluene. Optionally, suitable bases are used, preferably pyridine, sodium carbonate, triethylamine or sodium acetate. The reaction mixture is allowed to react in a temperature range of 0 to 100 ° C. for a specific time, for example 1 hour to 24 hours. Alternatively, reaction products 4, 7, 9 or 15 may be reacted with a suitable hydroxylamine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate, and a suitable inert solvent, for example For example, it may be reacted in tetrahydrofuran, dioxane, dichloromethane, dimethylformamide or toluene, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react in a temperature range of room temperature to 100 ° C. for a specific time, for example 1 hour to 18 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 5에 따른 화합물 21의 유도체인 경우, 반응 생성물 4, 7, 9 또는 15를 포스겐 또는 카보닐디이미다졸 및 적합한 하이드라진과 적합한 불활성 용매, 예를 들면, 디옥산, 클로로포름, 톨루엔 또는 에탄올에서 반응시킬 수 있다. 임의로, 적합한 염기, 바람직하게는 피리딘, 탄산나트륨, 디이소프로필에틸아민 또는 나트륨 아세테이트가 사용된다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 24시간 동안, 0 내지 100℃의 온도 범위에서 반응시키 도록 한다. 대안적으로, 반응 생성물 4, 7, 9 또는 15를 적합한 하이드라진-페닐-카바메이트 시약 및 임의로 적합한 염기, 바람직하게는 피리딘, 탄산나트륨, 트리에틸아민 또는 나트륨 아세테이트와, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 디옥산, 디클로로메탄, 디메틸포름아미드 또는 톨루엔 중에, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 15시간 동안, 0℃ 내지 10℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 21 according to Scheme 5, reaction products 4, 7, 9 or 15 may be reacted with phosgene or carbonyldiimidazole and a suitable hydrazine with a suitable inert solvent such as dioxane, chloroform, It may be reacted in toluene or ethanol. Optionally, suitable bases are used, preferably pyridine, sodium carbonate, diisopropylethylamine or sodium acetate. The reaction mixture is allowed to react in a temperature range of 0 to 100 ° C. for a specific time, for example 1 hour to 24 hours. Alternatively, reaction products 4, 7, 9 or 15 may be reacted with a suitable hydrazine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate, and a suitable inert solvent such as It can be reacted in tetrahydrofuran, dioxane, dichloromethane, dimethylformamide or toluene, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 ° C. to 10 ° C. for a specific time, for example 1 hour to 15 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

또는, 대안적으로, 생성물이 반응식 5에 따른 화합물 21a의 유도체인 경우, 반응 생성물 4, 7, 9 또는 15를 옥살릴 클로라이드 및 적합한 알콜, 임의로 적합한 염기, 바람직하게는 피리딘, 수산화나트륨, 트리에틸아민과, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 톨루엔, 디클로로메탄, 에탄올에서, 또는 용매로 서 염기, 예를 들면, 피리딘 또는 트리에틸아민에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 15분 내지 24시간 동안, -10 내지 60℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Alternatively, when the product is a derivative of compound 21a according to Scheme 5, reaction products 4, 7, 9 or 15 can be converted to oxalyl chloride and a suitable alcohol, optionally a suitable base, preferably pyridine, sodium hydroxide, triethyl The amine can be reacted in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol or as a solvent in a base such as pyridine or triethylamine. The reaction mixture is allowed to react at a temperature in the range of −10 to 60 ° C. for a specific time, for example 15 minutes to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

또는, 대안적으로, 생성물이 반응식 5에 따른 화합물 21b의 유도체인 경우, 반응 생성물 4, 7, 9 또는 15를 옥살릴 클로라이드 또는 에틸옥살릴 클로라이드 및 적합한 아민, 임의로 적합한 염기, 바람직하게는 피리딘, 수산화나트륨, 트리에틸아민과, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 톨루엔, 디클로로메탄, 에탄올에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 15분 내지 24시간 동안, -10 내지 60℃ 범위의 온도에서 반응시키도록 한다. 대안적으로, 중간체 21a를 적합한 아민, 임의로 적합한 염기, 바람직하게는 피리딘, 수소화나트륨 또는 트리에틸아민과, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 톨루엔, 디클로로메탄, 에탄올에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1시간 내지 50시간 동안, 10 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거할 수 있거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.Alternatively, when the product is a derivative of compound 21b according to Scheme 5, reaction products 4, 7, 9 or 15 can be converted to oxalyl chloride or ethyloxalyl chloride and a suitable amine, optionally a suitable base, preferably pyridine, Sodium hydroxide, triethylamine can be reacted in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol, or as a solvent in a base such as pyridine or triethylamine. The reaction mixture is allowed to react at a temperature in the range of −10 to 60 ° C. for a specific time, for example 15 minutes to 24 hours. Alternatively, intermediate 21a may be used in a suitable amine, optionally a suitable base, preferably pyridine, sodium hydride or triethylamine, with a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol, or as a solvent. The reaction may be carried out in a base such as pyridine or triethylamine. The reaction mixture is allowed to react at a temperature in the range of 10 to 120 ° C. for a specific time, for example 1 to 50 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 6: 제1 단계 Scheme 6: first step

기본적인 프로세스 후, 기본적인 프로세스로 형성된 생성물을 본 발명의 전환 생성물로 전환 반응으로 당해 기술분야의 숙련가들에게 공지된 방법으로 전환시킬 수 있다. After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

예를 들면, 생성물이 반응식 6에 따른 화합물 23의 유도체인 경우, 반응식 6에 따라, 반응 생성물 22를 적합한 아릴/헤테로아릴보론산 유도체 또는 아릴/헤테 로아릴오르가노틴 화합물 및 적합한 촉매, 예를 들면, Pd(PPh3)4, [1,1'-비스(디페닐포스피노)페로센]-디클로로팔라듐(II) 또는 Pd2(dba)3, 및 적합한 염기, 예를 들면, 탄산나트륨, 탄산세슘 또는 트리에틸아민과, 적합한 용매, 예를 들면, 디메틸포름아미드, 디메틸포름아미드/물, 톨루엔, 아세토니트릴, 디메톡시에탄 또는 디옥산에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 6시간 내지 수일 동안, 60℃ 및 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류 고체를 감압하에 건조시키거나, 존재하는 모든 촉매 잔사를 여과제거하고, 적합한 용매로 세척하고, 용매를 감압하에 제거하거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, if the product is a derivative of compound 23 according to Scheme 6, according to Scheme 6, the reaction product 22 may be replaced with a suitable aryl / heteroarylboronic acid derivative or aryl / heteroarylorganotin compound and a suitable catalyst, for example For example, Pd (PPh 3 ) 4 , [1,1′-bis (diphenylphosphino) ferrocene] -dichloropalladium (II) or Pd 2 (dba) 3 , and suitable bases such as sodium carbonate, cesium carbonate Or triethylamine with a suitable solvent such as dimethylformamide, dimethylformamide / water, toluene, acetonitrile, dimethoxyethane or dioxane. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. and 120 ° C. for a specific time, for example, from 6 hours to several days. After completion of the reaction, the precipitated solids are filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent, the residual solids are dried under reduced pressure, or any catalyst residues present Filter off, wash with a suitable solvent and remove the solvent under reduced pressure, or remove the solvent under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 6에 따른 화합물 23a의 유도체인 경우, 반응 생성물 22를 적합한 알킬아연 할라이드 및 적합한 촉매, 예를 들면, Pd(PPh3)4, [1,1'-비스(디페닐포스피노)페로센]-디클로로팔라듐(II) 또는 PdCl2(PPh3)2와 적합한 용매, 예를 들면, 디메틸포름아미드, 테트라하이드로푸란, 톨루엔, 디메톡시에탄 또는 디옥산에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 30분 내지 48시간 동안, 실온 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 존재하는 모든 촉매 잔사를 여과제거하고, 적합한 용매로 세척하고, 용매를 감압하에 제거하거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성상을, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 23a according to Scheme 6, the reaction product 22 is converted into a suitable alkylzinc halide and a suitable catalyst such as Pd (PPh 3 ) 4 , [1,1'-bis (diphenyl). Phosphino) ferrocene] -dichloropalladium (II) or PdCl 2 (PPh 3 ) 2 can be reacted in a suitable solvent such as dimethylformamide, tetrahydrofuran, toluene, dimethoxyethane or dioxane. The reaction mixture is allowed to react at a temperature ranging from room temperature to 120 ° C. for a specific time, for example, from 30 minutes to 48 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst residue present Was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture can be stirred with a large amount of water, the precipitated solid can be filtered off, or the aqueous phase can be extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and the organic phase under reduced pressure. Concentrated. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 6에 따른 화합물 24의 유도체인 경우, 반응 생성물 22를 적합한 비닐보론산 유도체, 비닐오르가노틴 화합물 또는 알켄 유도체 및 적합한 촉매, 예를 들면, Pd(PPh3)4, [1,1'-비스(디페닐포스피노)페로센]디클로로팔라듐(II) 또는 Pd(OAc)2, 및 적합한 리간드, 예를 들면, 트리페닐포스핀 또는 트리-o-톨릴포스핀, 및 적합한 염기, 예를 들면, 탄산칼륨, 탄산나트륨, 트리에틸아민 또는 나트륨 아세테이트와, 적합한 용매, 예를 들면, 톨루엔, 디메틸포름아미드, 디메틸포름아미드/물, 아세토니트릴, 디메톡시에탄 또는 디메틸아세트아미드에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 3시간 내지 24시간 동안, 60℃ 및 140℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 존재하는 모든 촉매 잔사를 여과제거하고, 적합한 용매로 세척하고, 용매를 감압하에 제거하거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 24 according to Scheme 6, the reaction product 22 may be converted into a suitable vinylboronic acid derivative, vinylorganotin compound or alkene derivative and a suitable catalyst such as Pd (PPh 3 ) 4 , [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) or Pd (OAc) 2 , and suitable ligands such as triphenylphosphine or tri-o-tolylphosphine, and suitable Reaction with a base such as potassium carbonate, sodium carbonate, triethylamine or sodium acetate in a suitable solvent such as toluene, dimethylformamide, dimethylformamide / water, acetonitrile, dimethoxyethane or dimethylacetamide You can. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. and 140 ° C. for a specific time, for example, from 3 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst residue present Was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or toluene, or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 6에 따른 화합물의 유도체 25인 경우, 반응 생성물 22를 적합한 알킨 유도체 및 적합한 촉매, 예를 들면, Pd(PPh3)4, PdCl2(PPh3)2 또는 Pd2(dba)3, 및 적합한 첨가제, 예를 들면, 구리(I) 요오다이드, 및 적합한 염기, 예를 들면, 탄산칼륨, 트리에틸아민 또는 칼륨 아세테이트,와 적합한 용매, 예 를 들면, 디메틸포름아미드, 테트라하이드로푸란, 테트라하이드로푸란/물, 톨루엔 또는 디메틸아세트아미드에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 시간 내지 수일 동안, 실온 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 후, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 존재하는 모든 촉매 잔사를 여과제거하고, 적합한 용매로 세척하고, 용매를 감압하에 제거하거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is derivative 25 of a compound according to Scheme 6, the reaction product 22 is a suitable alkyne derivative and a suitable catalyst, such as Pd (PPh 3 ) 4 , PdCl 2 (PPh 3 ) 2 or Pd 2 ( dba) 3 , and suitable additives such as copper (I) iodide, and suitable bases such as potassium carbonate, triethylamine or potassium acetate, and suitable solvents such as dimethylformamide, It may be reacted in tetrahydrofuran, tetrahydrofuran / water, toluene or dimethylacetamide. The reaction mixture is allowed to react at a temperature in the range of room temperature to 120 ° C. for a certain time, for example, from 1 hour to several days. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst residue present Was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or toluene, or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 7: 제1 단계Scheme 7: first step

기본적인 프로세스 후, 기본적인 프로세스로 형성된 생성물을 본 발명의 전환 생성물로 전환 반응으로 당해 기술분야의 숙련가들에게 공지된 방법으로 전환시킬 수 있다.After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

중간체 22를 적합한 아민 및 임의로 적합한 염기, 바람직하게는 메탄올 중 수소화나트륨, 피리딘, 트리에틸아민, 탄산칼륨 또는 나트륨 메톡사이드와, 적합한 불활성 용매, 예를 들면, 디메틸포름아미드, 디메틸 설폭사이드, 메탄올, 톨루엔에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1시간 내지 수일 동안, 20℃ 내지 140℃ 범위의 온도에서 반응시키도록 한다. 대안적으로, 중간체 22를 적합한 아민 및 적합한 촉매, 예를 들면, 팔라듐 아세테이트 또는 Pd2(dba)3, 및 적합한 리간드, 예를 들면, BINAP, 및 적합한 염기, 예를 들면, 탄산칼륨 또는 나트륨 3급-부톡사이드와, 적합한 용매, 예를 들면, 톨루엔 또는 디옥산에서 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 10시간 내지 30시간 동안, 60℃ 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 후, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 존재하는 임의의 촉매 잔사를 여과제거하고, 적합한 용매로 세척하고, 용매를 감압하에 제거하거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산, 에틸 아세테이트 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로 로메탄의 혼합물이다.Intermediate 22 may be selected from a suitable amine and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol and a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, methanol, It may be reacted in toluene or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 140 ° C. for a certain time, for example, from 1 hour to several days. Alternatively, intermediate 22 may be substituted with a suitable amine and a suitable catalyst such as palladium acetate or Pd 2 (dba) 3 , and a suitable ligand such as BINAP, and a suitable base such as potassium carbonate or sodium 3 The quat-butoxide may be reacted with a suitable solvent such as toluene or dioxane. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. to 120 ° C. for a specific time, for example 10 to 30 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst present The residue was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane, ethyl acetate or toluene, or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

제2 단계2nd step

예를 들면, 생성물이 반응식 7에 따른 화합물 27의 유도체인 경우, 반응 생성물 26을 적합한 카보닐 클로라이드 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 수산화칼륨, 피리딘, 트리에틸아민 또는 탄산칼륨, 및 임의의 촉매, 예를 들면, 디메틸아미노피리딘과, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 톨루엔, 아세토니트릴, 디클로로메탄, 아세톤 또는 디옥산에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 30분 내지 24시간 동안 0 내지 110℃ 범위의 온도에서 반응시킬 수 있다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다. For example, when the product is a derivative of compound 27 according to Scheme 7, reaction product 26 is selected from suitable carbonyl chlorides and optionally suitable bases, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and optionally In a catalyst such as dimethylaminopyridine and a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone or dioxane, or as a solvent, a base such as pyridine or tri The reaction can be carried out in ethylamine or without solvent. The reaction mixture can be reacted at a temperature in the range of 0 to 110 ° C. for a specific time, for example, 30 minutes to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 7에 따른 화합물 28의 유도체인 경우, 반응 생 성물 26을 적합한 설포닐 클로라이드 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 수산화칼륨, 피리딘, 트리에틸아민 또는 탄산칼륨, 및 임의의 촉매, 예를 들면, 디메틸아미노피리딘과, 적합한 불활성 용매, 예를 들면, 테트라하이드로푸란, 톨루엔, 아세토니트릴, 디클로로메탄, 아세톤, 디메틸포름아미드 또는 디옥산에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 30분 내지 16시간 동안, 0 내지 120℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다. For example, when the product is a derivative of compound 28 according to Scheme 7, reaction product 26 is prepared with a suitable sulfonyl chloride and optionally a suitable base, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and Base in any catalyst, such as dimethylaminopyridine and a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone, dimethylformamide or dioxane, or as a solvent, for example For example, it can be reacted in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 to 120 ° C. for a specific time, for example 30 minutes to 16 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 7에 따른 화합물 29의 유도체인 경우, 반응 생성물 26을 적합한 클로로카본산 에스테르 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 수산화나트륨, 피리딘, 트리에틸아민 또는 탄산칼륨, 및 임의의 촉매, 예를 들면, 디메틸아미노피리딘과, 적합한 불활성 용매, 예를 들면, 디옥산, 테트 라하이드로푸란, 디클로로메탄, 아세톤, 디메틸포름아미드 또는 디클로로에탄에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 내지 24시간 동안 -10℃ 내지 100℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다. For example, when the product is a derivative of compound 29 according to Scheme 7, reaction product 26 is prepared with a suitable chlorocarboxylic acid ester and optionally with a suitable base, preferably sodium hydride, sodium hydroxide, pyridine, triethylamine or potassium carbonate, and In any catalyst such as dimethylaminopyridine and a suitable inert solvent such as dioxane, tetrahydrofuran, dichloromethane, acetone, dimethylformamide or dichloroethane, or as a base, for example The reaction can be carried out in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of −10 ° C. to 100 ° C. for a specific time, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 7에 따른 화합물 30의 유도체인 경우, 반응 생성물 26을 적합한 이소시아네이트 또는 카바모일 클로라이드 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 피리딘, 트리에틸아민, 피페리딘 또는 탄산칼륨, 및 임의로 촉매, 예를 들면, 디메틸아미노피리딘과, 적합한 불활성 용매, 예를 들면, 디옥산, 테트라하이드로푸란, 디메틸포름아미드, 톨루엔 또는 아세토니트릴에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 2시간 내지 40시간 동안, 실온 내지 100℃의 온도 범위에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 30 according to Scheme 7, the reaction product 26 is selected from suitable isocyanates or carbamoyl chlorides and optionally of suitable bases, preferably sodium hydride, pyridine, triethylamine, piperidine or potassium carbonate. And, optionally in a catalyst such as dimethylaminopyridine and a suitable inert solvent such as dioxane, tetrahydrofuran, dimethylformamide, toluene or acetonitrile, or as a solvent, a base such as pyridine or The reaction can be carried out in triethylamine or without solvent. The reaction mixture is allowed to react in a temperature range of room temperature to 100 ° C. for a specific time, for example 2 to 40 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 8: 제1 단계Scheme 8: first step

기본적인 프로세스 후, 기본적인 프로세스로 형성된 생성물을 본 발명의 전환 생성물로 전환 반응으로 당해 기술분야의 숙련가들에게 공지된 방법으로 전환시킬 수 있다. After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

예를 들면, 생성물이 반응식 8에 따른 화합물 32 또는 35의 유도체인 경우, 반응 생성물 31 또는 34는 적합한 클로로카본산 에스테르 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 수산화나트륨, 피리딘, 트리에틸아민 또는 탄산칼륨, 및 임의의 촉매, 예를 들면, 디메틸아미노피리딘와, 적합한 불활성 용매, 예를 들면, 디옥산, 테트라하이드로푸란, 디클로로메탄, 아세톤, 디메틸포름아미드 또는 디클로로에탄에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 1 내지 24시간 동안, -10℃ 내지 100℃ 범위의 온도에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 32 or 35 according to Scheme 8, reaction product 31 or 34 is a suitable chlorocarboxylic acid ester and optionally a suitable base, preferably sodium hydride, sodium hydroxide, pyridine, triethylamine or Potassium carbonate, and any catalyst such as dimethylaminopyridine and a suitable inert solvent such as dioxane, tetrahydrofuran, dichloromethane, acetone, dimethylformamide or dichloroethane, or as a solvent, such as a base For example, it can be reacted in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of −10 ° C. to 100 ° C. for a specific time, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

예를 들면, 생성물이 반응식 8에 따른 화합물 33 또는 36의 유도체인 경우, 반응 생성물 31 또는 34는 적합한 이소시아네이트 또는 카바모일 클로라이드 및 임의로 적합한 염기, 바람직하게는 수소화나트륨, 피리딘, 트리에틸아민, 피페리딘 또는 탄산칼륨, 및 임의로 촉매, 예를 들면, 디메틸아미노피리딘과, 적합한 불활성 용매, 예를 들면, 디옥산, 테트라하이드로푸란, 디메틸포름아미드, 톨루엔 또는 아세토니트릴 중에, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들 면, 2시간 내지 40시간 동안, 실온 내지 100℃의 온도 범위에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 에탄올 또는 에틸 아세테이트로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, if the product is a derivative of compound 33 or 36 according to Scheme 8, reaction product 31 Or 34 is a suitable isocyanate or carbamoyl chloride and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, piperidine or potassium carbonate, and optionally a catalyst such as dimethylaminopyridine and a suitable inert solvent, For example, it can be reacted in dioxane, tetrahydrofuran, dimethylformamide, toluene or acetonitrile, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react for a specific time period, for example from 2 to 40 hours, in the temperature range from room temperature to 100 ° C. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the residual solid is dried under reduced pressure, or the reaction mixture is dried under reduced pressure. Was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

반응식 9: 제1 단계Scheme 9: first step

기본적인 프로세스 후, 기본적인 프로세스로 형성된 생성물을 본 발명의 전환 생성물로 전환 반응으로 당해 기술분야의 숙련가들에게 공지된 방법으로 전환시킬 수 있다.After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

예를 들면, 생성물이 반응식 9에 따른 화합물 38의 유도체인 경우, 반응 생성물 37은 예를 들면, 적합한 클로라이드, 브로마이드 또는 요오다이드와 임의로 적합한 염기, 바람직하게는 메탄올 중 수소화나트륨, 피리딘, 트리에틸아민, 탄산칼륨 또는 나트륨메톡사이드에서, 적합한 불활성 용매, 예를 들면, 디메틸포름아미 드, 디메틸 설폭사이드, 메탄올, 디옥산, 테트라하이드로푸란, 톨루엔에서, 또는 용매로서 염기, 예를 들면, 피리딘 또는 트리에틸아민 중에, 또는 용매없이 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 30분 내지 2일 동안, 0 내지 14℃의 온도 범위에서 반응시키도록 한다. 대안적으로, 아미노-치환된 중간체 37은 예를 들면, 적합한 클로라이드, 브로마이드 또는 요오다이드 및 적합한 촉매, 예를 들면, 트리스(디벤질리덴아세톤)디팔라듐(0) 또는 테트라키스(트리페닐포스핀)팔라듐(0), 및 적합한 리간드, 예를 들면, 2-(디사이클로헥실포스파닐)비페닐, 및 적합한 염기, 예를 들면, 나트륨 3급-부톡사이드와, 적합한 용매, 예를 들면, 톨루엔 또는 디메틸포름아미드 중에 반응시킬 수 있다. 반응 혼합물을 특정한 시간 동안, 예를 들면, 2시간 내지 30시간 동안, 6 내지 12℃의 온도 범위에서 반응시키도록 한다. 반응을 종결시킨 다음, 침전된 고체를 여과제거하고, 이를 위해 여과 매질은, 예를 들면, 여과지로 구성되고, 적합한 용매로 세척하고, 잔류하는 고체를 감압하에 건조시키거나, 반응 혼합물을 감압하에 용매를 제거하였다. 대안적으로, 반응 혼합물을 다량의 물로 교반할 수 있고, 침전된 고체를 여과제거하거나, 수성 상을, 적합한 수성 산, 예를 들면, 염산으로 중화시킨 후, 적합한 유기 용매, 예를 들면, 디클로로메탄 또는 에틸 아세테이트로 추출할 수 있고, 유기상을 감압하에 농축하였다. 잔류하는 조 생성물을 적합한 용매, 예를 들면, 디옥산, 에틸 아세테이트 또는 톨루엔으로부터 재결정화하거나, 실리카 겔 또는 알루미나 상 칼럼 또는 섬광 크로마토그래피로 정제하였다. 사용되는 용리액은, 예를 들면, 메탄올 및 디클로로메탄의 혼합물이다.For example, when the product is a derivative of compound 38 according to Scheme 9, reaction product 37 is, for example, a suitable chloride, bromide or iodide and optionally a suitable base, preferably sodium hydride, pyridine, triethyl in methanol In amines, potassium carbonate or sodium methoxide, in a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, methanol, dioxane, tetrahydrofuran, toluene, or as a solvent, a base such as pyridine or The reaction can be carried out in triethylamine or without solvent. The reaction mixture is allowed to react in a temperature range of 0 to 14 ° C. for a specific time, for example, from 30 minutes to 2 days. Alternatively, the amino-substituted intermediate 37 may be, for example, a suitable chloride, bromide or iodide and a suitable catalyst such as tris (dibenzylideneacetone) dipalladium (0) or tetrakis (triphenylphosph) Pin) palladium (0), and suitable ligands such as 2- (dicyclohexylphosphanyl) biphenyl, and suitable bases such as sodium tert-butoxide, and suitable solvents such as The reaction can be carried out in toluene or dimethylformamide. The reaction mixture is allowed to react in a temperature range of 6 to 12 ° C. for a specific time, for example 2 to 30 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane, ethyl acetate or toluene, or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

명시된 반응 조건 하에서, OH, SH 및 NH2 그룹은 목적하지 않은 부반응으로 도입될 수 있다. 따라서, 이들을 보호 그룹으로 보호하거나, NH2의 경우, NO2로 대체시킨 다음, 보호 그룹을 제거하거나, NO2 그룹을 환원시키는 것이 바람직하다. 예를 들면, 상기한 방법의 변형에서 출발 화합물에서 하나 이상의 OH 그룹은 예를 들면, 벤질옥시 그룹에 의해 치환될 수 있고, 및/또는 하나 이상의 SH 그룹은 예를 들면, S-벤질 그룹에 의해 치환될 수 있고 및/또는 하나 이상의 NH2 그룹은 예를 들면, NH-벤질 그룹 또는 NO2그룹에 의해 치환될 수 있다. 후속적으로, 하나 이상의 - 바람직하게는 모든 - 벤질옥시 그룹(들) 또는 NH-벤질 그룹(들)은 예를 들면, 수소 및 탄소상 팔라듐으로 제거될 수 있고, 및/또는 하나 이상의 바람직하게는 모든 - S-벤질 그룹(들)은 예를 들면, 암모니아 중 나트륨으로 제거될 수 있고, 및/또는 하나 이상의 - 바람직하게는 모든 - NO2그룹(들)은 예를 들면, 수소 및 라네이 니켈로 NH2으로 환원될 수 있다.Under the specified reaction conditions, the OH, SH and NH 2 groups can be introduced as undesired side reactions. Therefore, it is preferable to protect them with protecting groups or, in the case of NH 2 , replace them with NO 2 and then remove the protecting groups or reduce the NO 2 groups. For example, in variations of the process described above one or more OH groups in the starting compound may be substituted, for example by benzyloxy groups, and / or one or more SH groups may be replaced by, for example, S-benzyl groups And / or one or more NH 2 groups may be substituted, for example, by NH-benzyl groups or NO 2 groups. Subsequently, one or more-preferably all-benzyloxy group (s) or NH-benzyl group (s) can be removed with, for example, hydrogen and palladium on carbon, and / or one or more preferably All —S-benzyl group (s) may be removed, for example, with sodium in ammonia, and / or one or more—preferably all—NO 2 group (s) are, for example, hydrogen and ranei nickel. May be reduced to NH 2 .

상기한 반응 조건하에서, OH, NH2 및 COOH 그룹은 목적하지 않은 부반응으로 도입될 수 있다. 따라서, 하나 이상의 OH 그룹 및/또는 하나 이상의 NH2 그룹 및/또는 하나 이상의 COOH 그룹을 포함하는 출발 화합물 및 중간체를 상응하는 카복실산 에스테르 및 카복스아미드 유도체로 전환하는 것이 바람직하다. 상기한 방법의 변형에서 하나 이상의 OH 그룹를 갖고, 및/또는 하나 이상의 NH2 그룹을 갖는 출발 화합물 및 중간체는 카복실산 에스테르 또는 카복스아미드 유도체로 활성화된 카복실산 그룹, 예를 들면, 카보닐 클로라이드 그룹과 반응시켜 전환될 수 있다. 상기한 방법의 변형에서 하나 이상의 COOH를 포함하는 출발 화합물 및 중간체는 카복실산 에스테르 또는 카복스아미드 유도체로 활성화제, 예를 들면, 티오닐 클로라이드 또는 카보닐디이미다졸와의 반응, 및 적합한 알콜 또는 아민과의 후속적인 반응으로 전환될 수 있다. 후속적으로, 출발 화합물 및 중간체 중 하나 이상의 - 바람직하게는 모든 - 카복실산 에스테르 또는 카복스아미드 그룹(들)은 예를 들면, 희석딘 수성 산 또는 염기로 분리시켜 하나의 - 바람직하게는 모든 - OH 그룹(들) 및/또는 NH2 그룹(들) 및/또는 COOH 그룹(들)을 제거할 수 있다. Under the above reaction conditions, the OH, NH 2 and COOH groups can be introduced as undesired side reactions. It is therefore preferred to convert starting compounds and intermediates comprising at least one OH group and / or at least one NH 2 group and / or at least one COOH group to the corresponding carboxylic acid esters and carboxamide derivatives. In a variant of the process described above, starting compounds and intermediates having at least one OH group and / or having at least one NH 2 group are reacted with a carboxylic acid group activated with a carboxylic ester or carboxamide derivative, for example a carbonyl chloride group. Can be switched. Starting compounds and intermediates comprising at least one COOH in a variant of the above process are reacted with an activating agent such as thionyl chloride or carbonyldiimidazole with a carboxylic acid ester or carboxamide derivative, and with a suitable alcohol or amine Can be converted to a subsequent reaction. Subsequently, at least one of the starting compounds and intermediates—preferably all—carboxylic acid esters or carboxamide group (s) can be separated, for example, by dilution with an aqueous acid or base, and then one, preferably all, OH. The group (s) and / or NH 2 group (s) and / or COOH group (s) can be removed.

본 발명의 화합물 및 특히 화합물 1 내지 85는 AutoNom 2000 소프트웨어(ISIS / Draw 2.5; MDL)로 명명되었다. Compounds of the invention and in particular compounds 1 to 85 were named AutoNom 2000 software (ISIS / Draw 2.5; MDL).

본 발명은 다음 실시예를 참조하여 상세히 설명될 수 있고, 이들 실시예로 제한하려는 것이 아니다.The present invention may be described in detail with reference to the following examples, which are not intended to be limiting.

I) 본 발명의 화합물의 제조 I) Preparation of Compounds of the Invention

합성 반응식 1 내지 9를 기초로하는 일반적인 합성 방법을 다음 본 발명의 화합물을 합성하기 위해 사용하였다. 또한, 이들의 NMR 분광 데이타 및 질량 분광 데이타 및 융점이 포함된다.Synthetic general methods based on Schemes 1-9 were then used to synthesize the compounds of the present invention. Also included are their NMR spectroscopic data and mass spectroscopic data and melting points.

본 발명의 화합물의 제조에 사용되는 전구체는 - 달리 나타내지 않는 한 - 당해 기술분야의 숙련가들에게 공지된 방법으로 합성될 수 있다.Precursors used in the preparation of the compounds of the present invention-unless otherwise indicated-can be synthesized by methods known to those skilled in the art.

사용된 화학물질 및 용매는 통상적인 공급업자(Acros, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, 등)로부터 시판되는 것을 입수할 수 있거나, 합성할 수 있다. The chemicals and solvents used may be available commercially from conventional suppliers (Acros, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.) or may be synthesized.

실시예 1:Example 1:

1-에틸-3-(3-페닐에티닐피리도[2,3-b]피라진-6-일)우레아 (화합물 1)1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 1)

1-(3-클로로피리도[2,3-b]피라진-6-일)-3-에틸우레아의 제조(반응식 5에 따른 반응)Preparation of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (reaction according to Scheme 5)

100mg의 3-클로로피리도[2,3-b]피라진-6-일아민(0.55mmol)을 초기에 5ml의 피리딘에 채우고, 44㎕의 에틸 이소시아네이트(0.55mmol)를 실온에서 첨가하였다. 혼합물을 75℃에서 3시간 동안 교반한 다음, 또다른 132㎕의 총량 에틸 이소시아네이트(1.65mmol)를 반응 혼합물에 소분획으로 18시간 동안 첨가하였다. 이어서, 용매를 감압하에 제거하였다. 수득한 고체를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)을 통해 정제하였다. 이로서 밝은 황색 고체를 수득하였다. 100 mg of 3-chloropyrido [2,3-b] pyrazin-6-ylamine (0.55 mmol) was initially charged in 5 ml of pyridine and 44 μl of ethyl isocyanate (0.55 mmol) was added at room temperature. The mixture was stirred at 75 ° C. for 3 hours and then another 132 μl total ethyl isocyanate (1.65 mmol) was added to the reaction mixture in small portions for 18 hours. Then the solvent was removed under reduced pressure. The obtained solid was purified via column chromatography on silica gel (dichloromethane / methanol eluent). This gave a light yellow solid.

1-에틸-3-(3-페닐에티닐피리도[2,3-b]피라진-6-일)우레아의 제조(반응식 6에 따른 반응)Preparation of 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea (reaction according to Scheme 6)

98.1mg의 1-(3-클로로피리도[2,3-b]피라진-6-일)-3-에틸우레아(0.39mmol), 10.1mg 구리(I) 요오다이드(0.05mmol) 및 193㎕의 트리에틸아민(1.38mmol)을 초기 에 2ml의 무수 디메틸포름아미드에 보호 기체로서 질소하에서 채웠다. 후속적으로, 29.1mg의 디클로로비스(트리페닐포스핀)팔라듐(II)(0.04mmol) 및 54㎕의 페닐아세틸렌(0.49mmol)을 첨가하고, 혼합물을 실온에서 16시간 동안 교반하였다. 후처리를 위해 혼합물을 디클로로메탄으로 희석시키고, 희석된 염산에 첨가하였다. 침전된 고체를 흡입하에 여과제거하고, 유기 상을 희석된 염산 및 증류수로 세척하였다. 상 분리후, 유기 용매를 감압하에 제거하였다. 추가의 정제를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 실시하였다. 이로서 황색 고체를 수득하였다. 98.1 mg 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.39 mmol), 10.1 mg copper (I) iodide (0.05 mmol) and 193 μl Triethylamine (1.38 mmol) was initially charged in 2 ml of anhydrous dimethylformamide under nitrogen as protective gas. Subsequently, 29.1 mg of dichlorobis (triphenylphosphine) palladium (II) (0.04 mmol) and 54 μl of phenylacetylene (0.49 mmol) were added and the mixture was stirred at rt for 16 h. The mixture was diluted with dichloromethane for workup and added to diluted hydrochloric acid. The precipitated solid was filtered off with suction and the organic phase was washed with dilute hydrochloric acid and distilled water. After phase separation, the organic solvent was removed under reduced pressure. Further purification was carried out by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

융점: 236-238℃(분해)Melting Point: 236-238 ° C (Decomposition)

ESI-MS: 실측치 m/z = 318.0 (M + H+); 계산치 317 amuESI-MS: found m / z = 318.0 (M + H + ); Calc 317 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.35 - 3.45 (m, 2H), 7.51 - 7.59 (m, 3H), 7.68 (d, 1H), 7.75 (d, 2H), 8.37 (d, 1H), 9.01 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.35-3.45 (m, 2H), 7.51-7.59 (m, 3H), 7.68 (d, 1H), 7.75 (d, 2H) , 8.37 (d, 1H), 9.01 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm.

다음 실시예를 실시예 1 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 1 and general synthetic methods:

실시예 2:Example 2:

1-에틸-3-(3-티오펜-3-일에티닐피리도[2,3-b]피라진-6-일)우레아(화합물 2)1-ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 2)

m.p.: 239-242℃(분해)m.p .: 239-242 ° C. (decomposition)

ESI-MS: 실측치 m/z = 324.2 (M + H+); 계산치 323 amuESI-MS: found m / z = 324.2 (M + H + ); Calculated 323 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.35 (m, 2H), 7.43 (d, 1H), 7.66 (d, 1H), 7.76 (dd, 1H), 8.21 (d, 1H), 8.36 (d, 1H), 8.97 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.35 (m, 2H), 7.43 (d, 1H), 7.66 (d, 1H), 7.76 (dd, 1H), 8.21 (d, 1H), 8.36 (d, 1H), 8.97 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm.

실시예 3:Example 3:

1-(3-사이클로프로필에티닐피리도[2,3-b]피라진-6-일)-3-에틸우레아(화합물 3)1- (3-cyclopropylethynylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (Compound 3)

m.p.: 227-228℃(분해)m.p .: 227-228 ° C. (decomposition)

ESI-MS: 실측치 m/z = 282.3 (M + H+); 계산치 281 amuESI-MS: found m / z = 282.3 (M + H + ); Calculation 281 amu

1H NMR (d6-DMSO): δ = 1.00 - 1.10 (m, 2H), 1.19 (t, 3H), 1.69 - 1.79 (m, 1H), 3.25 - 3.35 (m, 2H), 7.63 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.11 (s, 1H), 10.18 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.00-1.10 (m, 2H), 1.19 (t, 3H), 1.69-1.79 (m, 1H), 3.25-3.35 (m, 2H), 7.63 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.11 (s, 1H), 10.18 (s, 1H) ppm.

실시예 4:Example 4:

1-[3-(3-디메틸아미노프로프-1-이닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아(화합물 4)1- [3- (3-dimethylaminoprop-1-ynyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Compound 4)

ESI-MS: 실측치 m/z = 299.2 (M + H+); 계산치 298 amuESI-MS: found m / z = 299.2 (M + H + ); Calc 298 amu

1H NMR (d6-DMSO): δ = 1.19 (t, 3H), 2.33 (s, 6H), 3.27 - 3.35 (m, 2H), 3.67 (s, 2H), 7.67 (d, 1H), 8.34 (d, 1H), 8.85 (s, 1H), 9.05 (s, 1H), 10.19 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.19 (t, 3H), 2.33 (s, 6H), 3.27-3.35 (m, 2H), 3.67 (s, 2H), 7.67 (d, 1H), 8.34 (d, 1 H), 8.85 (s, 1 H), 9.05 (s, 1 H), 10.19 (s, 1 H) ppm.

실시예 5:Example 5:

1-[3-((E)-2-사이클로헥실비닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아(화합물 5)1- [3-((E) -2-cyclohexylvinyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Compound 5)

1-[3-((E)-2-사이클로헥실비닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아의 제조(반응식 6에 따른 반응)Preparation of 1- [3-((E) -2-cyclohexylvinyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (reaction according to Scheme 6)

99.6mg의 1-(3-클로로피리도[2,3-b]피라진-6-일)-3-에틸우레아(0.40mmol), 73.6mg의 사이클로헥실비닐보론산(0.48mmol), 84.4mg의 탄산나트륨(0.80mmol) 및 33.4mg의 [1,1'-비스(디페닐포스피노)페로센]디클로로팔라듐(II)(0.04mmol)을 초기에 6ml의 디메틸포름아미드/물(1:1)에 질소하에서 채웠다. 이어서, 혼합물을 90℃로 6.5시간 동안 가열하였다. 이어서, 증류수를 반응 혼합물에 첨가하고, 수득한 침전을 흡입하여 여과제거하였다. 추가의 정제를 실리카 겔 상 칼럼 크로마토그래피(에틸 아세테이트/헵탄 용리액 혼합물)로 실시하였다. 밝은 갈색 고체를 수득하였다.99.6 mg 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.40 mmol), 73.6 mg cyclohexylvinylboronic acid (0.48 mmol), 84.4 mg Sodium carbonate (0.80 mmol) and 33.4 mg of [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (0.04 mmol) were initially charged in 6 ml of dimethylformamide / water (1: 1). Filled under. The mixture was then heated to 90 ° C. for 6.5 hours. Distilled water was then added to the reaction mixture, and the precipitate obtained was suctioned off and filtered off. Further purification was carried out by column chromatography on silica gel (ethyl acetate / heptane eluent mixture). A light brown solid was obtained.

m.p.: 202-204℃(분해)m.p .: 202-204 ° C. (decomposition)

ESI-MS: 실측치 m/z = 326.0 (M + H+); 계산치 325 amuESI-MS: found m / z = 326.0 (M + H + ); 325 amu

1H NMR (d6-DMSO): δ = 1.10 - 1.40 (m, 8H), 1.65 - 1.90 (m, 5H), 2.28 - 2.38 (m, 1H), 3.25 - 3.35 (m, 2H), 6.69 (d, 1H), 7.15 (dd, 1H), 7.58 (d, 1H), 8.28 (d, 1H), 8.98 (s, 1H), 9.15 (s, 1H), 10.05 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.10-1.40 (m, 8H), 1.65-1.90 (m, 5H), 2.28-2.38 (m, 1H), 3.25-3.35 (m, 2H), 6.69 ( d, 1H), 7.15 (dd, 1H), 7.58 (d, 1H), 8.28 (d, 1H), 8.98 (s, 1H), 9.15 (s, 1H), 10.05 (s, 1H) ppm.

다음 실시예를 실시예 5 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 5 and general synthetic methods:

실시예 6:Example 6:

1-에틸-3-[3-((E)-3-메톡시프로페닐)피리도[2,3-b]피라진-6-일]우레아(화합물 6)1-ethyl-3- [3-((E) -3-methoxypropenyl) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 6)

ESI-MS: 실측치 m/z = 288.3 (M + H+); 계산치 287 amuESI-MS: found m / z = 288.3 (M + H + ); Calculation 287 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.35 (m, 2H), 3.39 (s, 3H), 4.25 (d, 2H), 6.92 (d, 1H), 7.15 - 7.25 (m, 1H), 7.62 (d, 1H), 8.30 (d, 1H), 9.02 (s, 1H), 9.15 (s, 1H), 10.10 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.35 (m, 2H), 3.39 (s, 3H), 4.25 (d, 2H), 6.92 (d, 1H), 7.15 7.25 (m, 1H), 7.62 (d, 1H), 8.30 (d, 1H), 9.02 (s, 1H), 9.15 (s, 1H), 10.10 (s, 1H) ppm.

실시예 7:Example 7:

1-에틸-3-3-[(E)-2-(4-플루오로페닐)비닐]피리도[2,3-b]피라진-6-일우레아(화합물 27)1-ethyl-3-3-[(E) -2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-ylurea (Compound 27)

m.p.: 217-219℃m.p .: 217-219 ° C

ESI-MS: 실측치 m/z = 338.2 (M + H+); 계산치 337 amuESI-MS: found m / z = 338.2 (M + H + ); Calc 337 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.38 (m, 2H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.54 (d, 1H), 7.61 (d, 1H), 7.87 (t, 2H), 8.02 (d, 1H), 8.31 (d, 1H), 9.09 (s, 1H), 9.17 (bs, 1H), 10.09 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.38 (m, 2H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.54 (d, 1H), 7.61 (d, 1H), 7.87 (t, 2H), 8.02 (d, 1H), 8.31 (d, 1H), 9.09 (s, 1H), 9.17 (bs, 1H), 10.09 (s, 1H) ppm.

실시예 8Example 8

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 메틸 카보네이트(화합물 9)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate (Compound 9)

1-에틸-3-[3-(4-하이드록시페닐)피리도[2,3-b]피라진-6-일]우레아의 제조(반응식 5에 따른 반응)Preparation of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (reaction according to Scheme 5)

0.50g의 4-(6-아미노피리도[2,3-b]피라진-3-일)페놀(2.10mmol)을 초기에 5.0ml의 피리딘에 채웠다. 183㎕의 에틸 이소시아네이트(2.31mmol)를 실온에서 적가하고, 혼합물을 70 내지 80℃로 2시간 동안 가열하였다. 이후에, 또다른 183㎕의 에틸 이소시아네이트를 첨가하고, 혼합물을 70 내지 80℃로 추가로 2시간 동안 가열하였다. 반응을 종결시킨 후, 반응 혼합물을 빙수에 첨가하고, 1N 염산으로 중성화시켰다. 침전된 생성물을 흡입하에 여과제거하고, 건조시켰다. 여과된 생성물을 에탄올에 부분적으로 용해시키고, 52mg의 수산화칼륨(0.93mmol)과 혼합하고, 물에 용해시켰다. 혼합물을 40℃로 약 1시간 동안 가열하였다. 이후에, 반응 용액을 1N 염산으로 중성화시키고, 용매를 감압하에 제거하였다. 수득한 고체를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 황색 고체를 수득하였다. 0.50 g of 4- (6-aminopyrido [2,3-b] pyrazin-3-yl) phenol (2.10 mmol) was initially charged in 5.0 ml of pyridine. 183 μl ethyl isocyanate (2.31 mmol) was added dropwise at room temperature and the mixture was heated to 70-80 ° C. for 2 hours. Thereafter, another 183 μl of ethyl isocyanate was added and the mixture was heated to 70-80 ° C. for an additional 2 hours. After the reaction was terminated, the reaction mixture was added to ice water and neutralized with 1N hydrochloric acid. The precipitated product was filtered off under suction and dried. The filtered product was partially dissolved in ethanol, mixed with 52 mg potassium hydroxide (0.93 mmol) and dissolved in water. The mixture was heated to 40 ° C. for about 1 hour. Thereafter, the reaction solution was neutralized with 1N hydrochloric acid, and the solvent was removed under reduced pressure. The obtained solid was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 메틸 카보네이트의 제조(반응식 8에 따른 반응)Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate (reaction according to scheme 8)

100mg의 1-에틸-3-[3-(4-하이드록시페닐)피리도[2,3-b]피라진-6-일]우레 아(0.32mmol), 30㎕의 메틸 클로로포르메이트(0.39mmol) 및 45㎕의 트리에틸아민(0.32mmol)을 초기에 10ml의 무수 디옥산에 채우고, 10℃로 1시간 동안 가열하였다. 냉각 후, 침전된 고체를 흡입하에 여과제거하고, 건조시켰다. 에탄올으로부터 재결정화하여 엷은 황색 고체를 수득하였다. 100 mg of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (0.32 mmol), 30 μl of methyl chloroformate (0.39 mmol) ) And 45 μl of triethylamine (0.32 mmol) were initially charged in 10 ml of anhydrous dioxane and heated to 10 ° C. for 1 hour. After cooling, the precipitated solid was filtered off with suction and dried. Recrystallization from ethanol gave a pale yellow solid.

m.p.: 243-245℃m.p .: 243-245 ° C

ESI-MS: 실측치 m/z = 368.2 (M + H+); 계산치 367 amuESI-MS: found m / z = 368.2 (M + H + ); Calc 367 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.30 - 3.39 (m, 2H), 3.90 (s, 3H), 7.49 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.42 (d, 2H), 9.03 (s, 1H), 9.47 (s, 1H), 10.09 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.30-3.39 (m, 2H), 3.90 (s, 3H), 7.49 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.42 (d, 2H), 9.03 (s, 1H), 9.47 (s, 1H), 10.09 (s, 1H) ppm.

다음 실시예를 실시예 8 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 8 and general synthetic methods:

실시예 9:Example 9:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 (2-메톡시에틸) 카보네이트(화합물 10)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (2-methoxyethyl) carbonate (Compound 10)

m.p.: 230-232℃m.p .: 230-232 ℃

ESI-MS: 실측치 m/z = 412.2 (M + H+); 계산치 411 amuESI-MS: found m / z = 412.2 (M + H + ); Calculated 411 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.30 - 3.39 (m, 5H), 3.68 (t, 2H), 4.40 (t, 2H), 7.50 (d, 2H), 7.70 (d, 1H),8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.50 (s, 1H), 10.15 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.30-3.39 (m, 5H), 3.68 (t, 2H), 4.40 (t, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.50 (s, 1H), 10.15 (s, 1H) ppm.

실시예 10:Example 10:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 페닐 카보네이트(화합물 11)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl phenyl carbonate (Compound 11)

ESI-MS: 실측치 m/z = 430.2 (M + H+); 계산치 429 amuESI-MS: found m / z = 430.2 (M + H + ); Calculation 429 amu

1H NMR (d6-DMSO): δ = 1.21 (t, 3H), 3.30 - 3.33 (m, 2H), 7.33 7.38 (m, 1H), 7.43 (d, 2H), 7.51 (t, 2H), 7.65 (d, 2H), 8.39 (d, 1H), 8.45 (d, 2H), 9.11 (s, 1H), 9.50 (s, 1H), 10.19 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.21 (t, 3H), 3.30-3.33 (m, 2H), 7.33 7.38 (m, 1H), 7.43 (d, 2H), 7.51 (t, 2H), 7.65 (d, 2H), 8.39 (d, 1H), 8.45 (d, 2H), 9.11 (s, 1H), 9.50 (s, 1H), 10.19 (s, 1H) ppm.

실시예 11:Example 11:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 디에틸카바메이트(화합물 12)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl diethylcarbamate (Compound 12)

ESI-MS: 실측치 m/z = 409.4 (M + H+); 계산치 408 amuESI-MS: found m / z = 409.4 (M + H + ); Calc 408 amu

1H NMR (d6-DMSO): δ = 1.15 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.30 - 3.39 (m, 4H), 3.45 (q, 2H), 7.37 (d, 2H), 7.69 (d, 1H), 8.34 - 8.39 (m, 3H), 9.11 (s, 1H), 9.48 (s, 1H), 10.15 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.15 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.30-3.39 (m, 4H), 3.45 (q, 2H), 7.37 (d, 2H), 7.69 (d, 1H), 8.34-8.39 (m, 3H), 9.11 (s, 1H), 9.48 (s, 1H), 10.15 (s, 1H) ppm.

실시예 12:Example 12:

3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트(화합물 16)3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate (Compound 16)

ESI-MS: 실측치 m/z = 412.2 (M + H+); 계산치 411 amuESI-MS: found m / z = 412.2 (M + H + ); Calculated 411 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.33 - 3.38 (m, 5H), 3.63-3.66 (m, 2H), 4.37-4.39 (m, 2H), 7.48 (d, 2H), 7.68 (t, 1H), 7.72 (d, 1H), 8.22 (s, 1H), 8.29 (d, 1H), 8.39 (d, 1H), 9.06 (s, 1H), 9.48 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.33-3.38 (m, 5H), 3.63-3.66 (m, 2H), 4.37-4.39 (m, 2H), 7.48 (d, 2H), 7.68 (t, 1H), 7.72 (d, 1H), 8.22 (s, 1H), 8.29 (d, 1H), 8.39 (d, 1H), 9.06 (s, 1H), 9.48 (s, 1H ), 10.14 (s, 1H) ppm.

실시예 13:Example 13:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 이소부틸 카보네이트(화합물 17)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl isobutyl carbonate (Compound 17)

ESI-MS: 실측치 m/z = 410.3 (M + H+); 계산치 409 amuESI-MS: found m / z = 410.3 (M + H + ); Calculation 409 amu

1H NMR (d6-DMSO): δ = 0.97 (d, 6H), 1.20 (t, 3H), 2.02 (sep, 1H), 3.25 3.38 (m, 2H), 4.06 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 0.97 (d, 6H), 1.20 (t, 3H), 2.02 (sep, 1H), 3.25 3.38 (m, 2H), 4.06 (d, 2H), 7.50 ( d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm.

실시예 14:Example 14:

부트-2-이닐 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트(화합물 18)But-2-ynyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate (Compound 18)

ESI-MS: 실측치 m/z = 406.1 (M + H+); 계산치 405 amuESI-MS: found m / z = 406.1 (M + H + ); Calc. 405 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 1.89 (t, 3H), 3.25 3.38 (m, 2H), 4.90 (q, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (s, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 1.89 (t, 3H), 3.25 3.38 (m, 2H), 4.90 (q, 2H), 7.50 (d, 2H), 7.70 ( d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (s, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm.

실시예 15:Example 15:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 디메틸카바메이트(화합물 19)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl dimethylcarbamate (Compound 19)

실시예 15를 염기로서 수소화나트륨을 사용하고 용매로서 디메틸포름아미드를 사용하여 제조하였다.Example 15 was prepared using sodium hydride as the base and dimethylformamide as the solvent.

m.p.: > 230℃(분해)m.p .:> 230 ° C. (decomposition)

ESI-MS: 실측치 m/z = 381.2 (M + H+); 계산치 380 amuESI-MS: found m / z = 381.2 (M + H + ); 380 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 2.95 (s, 3H), 3.09 (s, 3H), 3.25 - 3.38 (m, 2H), 7.37 (d, 2H), 7.68 (d, 1H), 8.35-8.38 (m, 3H), 9.11 (s, 1H), 9.46 (s, 1H), 10.12 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.95 (s, 3H), 3.09 (s, 3H), 3.25-3.38 (m, 2H), 7.37 (d, 2H), 7.68 (d, 1H), 8.35-8.38 (m, 3H), 9.11 (s, 1H), 9.46 (s, 1H), 10.12 (s, 1H) ppm.

실시예 16:Example 16:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 2-메톡시에틸 카보네이트(화합물 32)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2-methoxyethyl carbonate (Compound 32)

ESI-MS: 실측치 m/z = 442.3 (M + H+); 계산치 441 amuESI-MS: found m / z = 442.3 (M + H + ); Calc 441 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.25 - 3.38 (m, 5H), 3.62 (dd, 2H), 3.97 (s, 3H), 4.35 (dd, 2H), 7.45 (d, 1H), 7.74 (d, 1H), 7.97 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1H), 8.99 (bs, 1H), 9.52 (s, 1H), 10.15 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.38 (m, 5H), 3.62 (dd, 2H), 3.97 (s, 3H), 4.35 (dd, 2H), 7.45 (d, 1H), 7.74 (d, 1H), 7.97 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1H), 8.99 (bs, 1H), 9.52 (s, 1H), 10.15 ( s, 1H) ppm.

실시예 17:Example 17:

2-벤질옥시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트(화합물 33)2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate (Compound 33)

ESI-MS: 실측치 m/z = 488.2 (M + H+); 계산치 487 amuESI-MS: found m / z = 488.2 (M + H + ); Calculation 487 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 3.75 (t, 2H), 4.43 (t, 2H), 4.57 (s, 2H), 7.31 (t, 1H), 7.36-7.40 (m, 4H), 7.48 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.13 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.28-3.38 (m, 2H), 3.75 (t, 2H), 4.43 (t, 2H), 4.57 (s, 2H), 7.31 (t, 1H), 7.36-7.40 (m, 4H), 7.48 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1 H), 10.13 (s, 1 H) ppm.

실시예 18:Example 18:

2-벤질옥시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 카보네이트(화합물 34)2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl carbonate (Compound 34)

m.p.: 172-174℃m.p .: 172-174 ° C

ESI-MS: 실측치 m/z = 518.3 (M + H+); 계산치 517 amuESI-MS: found m / z = 518.3 (M + H + ); Calc 517 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 3.74 (dd, 2H), 3.96 (s, 3H), 4.41 (dd, 2H), 4.56 (s, 2H), 7.31 (t, 1H), 7.35-7.40 (m, 3H), 7.44 (d, 2H), 7.74 (d, 1H), 7.97 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1H), 8.99 (bs, 1H), 9.51 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.28-3.38 (m, 2H), 3.74 (dd, 2H), 3.96 (s, 3H), 4.41 (dd, 2H), 4.56 (s, 2H), 7.31 (t, 1H), 7.35-7.40 (m, 3H), 7.44 (d, 2H), 7.74 (d, 1H), 7.97 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1 H), 8.99 (bs, 1 H), 9.51 (s, 1 H), 10.14 (s, 1 H) ppm.

실시예 19:Example 19:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 디에틸카바메이트(화합물 67)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl diethylcarbamate (Compound 67)

m.p.: 220-222℃m.p .: 220-222 ° C

ESI-MS: 실측치 m/z = 439.3 (M + H+); 계산치 438 amuESI-MS: found m / z = 439.3 (M + H + ); Calculated 438 amu

1H NMR (d6-DMSO): δ =1.13 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.28 - 3.36 (m, 4H), 3.44 (q, 2H), 3.94 (s, 3H), 7.31 (d, 1H), 7.73 (d, 1H), 7.94 (d, 1H), 8.01 (s, 1H), 8.37 (d, 1H), 8.97 (bs, 1H), 9.50 (s, 1H), 10.11 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.28-3.36 (m, 4H), 3.44 (q, 2H), 3.94 (s, 3H), 7.31 (d, 1H), 7.73 (d, 1H), 7.94 (d, 1H), 8.01 (s, 1H), 8.37 (d, 1H), 8.97 (bs, 1H), 9.50 ( s, 1H), 10.11 (s, 1H) ppm.

실시예 20:Example 20:

2-클로로-4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-6-메톡시페닐 디에틸카바메이트(화합물 68)2-chloro-4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -6-methoxyphenyl diethylcarbamate (Compound 68)

m.p.: 237-239℃m.p .: 237-239 ° C

ESI-MS: 실측치 m/z = 473.4 (M + H+); 계산치 472 amuESI-MS: found m / z = 473.4 (M + H + ); Calc 472 amu

1H NMR (d6-DMSO): δ = 1.14 (t, 3H), 1.19 (t, 3H), 1.27 (t, 3H), 3.25-3.38 (m, 4H), 3.46 (q, 2H), 3.97 (s, 3H), 7.76 (d, 1H), 8.00 (s, 1H), 8.09 (s, 1H), 8.39 (d, 1H), 8.94 (bs, 1H), 9.55 (s, 1H), 10.13 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.14 (t, 3H), 1.19 (t, 3H), 1.27 (t, 3H), 3.25-3.38 (m, 4H), 3.46 (q, 2H), 3.97 (s, 3H), 7.76 (d, 1H), 8.00 (s, 1H), 8.09 (s, 1H), 8.39 (d, 1H), 8.94 (bs, 1H), 9.55 (s, 1H), 10.13 ( s, 1H) ppm.

실시예 21:Example 21:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 2-[2-(2-메톡시에톡시)-에톡시]에틸 카보네이트(화합물 69)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2- [2- (2-methoxyethoxy) -ethoxy] ethyl Carbonate (Compound 69)

m.p.: 166-167℃m.p .: 166-167 ° C

ESI-MS: 실측치 m/z = 530.2 (M + H+); 계산치 529 amuESI-MS: found m / z = 530.2 (M + H + ); Calc 529 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.25 (s, 3H), 3.28-3.35 (m, 2H), 3.45 (t, 2H), 3.53-3.60 (m, 6H), 3.71 (t, 2H), 3.98 (s, 3H), 4.35 (t, 2H), 7.45 (d, 1H), 7.74 (d, 1H), 7.96 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1H), 8.96 (bs, 1H), 9.51 (s, 1H), 10.12 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25 (s, 3H), 3.28-3.35 (m, 2H), 3.45 (t, 2H), 3.53-3.60 (m, 6H) , 3.71 (t, 2H), 3.98 (s, 3H), 4.35 (t, 2H), 7.45 (d, 1H), 7.74 (d, 1H), 7.96 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1 H), 8.96 (bs, 1 H), 9.51 (s, 1 H), 10.12 (s, 1 H) ppm.

실시예 22:Example 22:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 (E)-3-페닐아크릴레이트(화합물 13)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate (Compound 13)

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 (E)-3-페닐아크릴레이트의 제조Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate

38.9mg의 1-에틸-3-[3-(4-하이드록시페닐)피리도[2,3-b]피라진-6-일]우레아(0.13mmol)를 초기에 3.0ml의 무수 피리딘에 채웠다. 17.5mg의 디메틸아미노피리딘(0.14mmol) 및 22.9mg의 트랜스-신나밀 클로라이드(0.13mmol)를 실온에서 첨가하고, 반응 혼합물을 실온에서 교반하였다. 3시간 후, 추가의 22.9mg의 트랜스-신나밀 클로라이드(0.13mmol)를 첨가하고, 혼합물을 실온에서 추가로 3시간 동안 교반하였다. 후처리를 위해 반응 혼합물을 얼음물로 붓고, 1N 염산으로 중성화시켰 다. 침전된 고체를 흡입하에 여과제거하고, 감압하에 건조시켰다. 추가의 정제 없이, 수득한 생성물을 황색 고체를 수득하였다. 38.9 mg of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (0.13 mmol) was initially charged in 3.0 ml of anhydrous pyridine. 17.5 mg of dimethylaminopyridine (0.14 mmol) and 22.9 mg of trans-cinnamil chloride (0.13 mmol) were added at room temperature and the reaction mixture was stirred at room temperature. After 3 hours, an additional 22.9 mg of trans-cinnamil chloride (0.13 mmol) was added and the mixture was stirred for an additional 3 hours at room temperature. The reaction mixture was poured into iced water for workup and neutralized with 1N hydrochloric acid. The precipitated solid was filtered off under suction and dried under reduced pressure. Without further purification, the obtained product gave a yellow solid.

m.p.: 236-238℃m.p .: 236-238 ° C

ESI-MS: 실측치 m/z = 440.3 (M + H+); 계산치 439 amuESI-MS: found m / z = 440.3 (M + H + ); Calc 439 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.40 (m, 2H), 6.95 (d, 1H), 7.46 - 7.51 (m, 5H), 7.70 (d, 1H), 7.83 - 7.87 (m, 2H), 7.94 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.12 (s, 1H), 9.49 (s, 1H), 10.19 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.40 (m, 2H), 6.95 (d, 1H), 7.46-7.51 (m, 5H), 7.70 (d, 1H) , 7.83-7.87 (m, 2H), 7.94 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.12 (s, 1H), 9.49 (s, 1H), 10.19 (s, 1H ) ppm.

실시예 23:Example 23:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 노나데카노에이트(화합물 14)4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate (Compound 14)

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 노나데카노에이트의 제조Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate

50.0mg의 1-에틸-3-[3-(4-하이드록시페닐)피리도[2,3-b]피라진-6-일]우레아(0.16mmol)를 초기에 5.0ml의 무수 피리딘에 채웠다. 19.7mg의 디메틸아미노피리딘(0.16mmol) 및 51.2mg의 노나데카노일 클로라이드(0.16mmol)를 실온에서 첨가하고, 반응 혼합물을 실온에서 4시간 동안 교반하였다. 후처리를 위해 반응 혼합물을 약 200ml의 증류수로 첨가하였다. 침전된 고체를 흡입하에 여과제거하고, 물로 세척하였다. 조 생성물의 실리카 겔 상 칼럼 크로마토그래피 정제(디클로로메탄/메탄올 용리액)로 백색 고체를 수득하였다.50.0 mg of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (0.16 mmol) was initially charged in 5.0 ml of anhydrous pyridine. 19.7 mg of dimethylaminopyridine (0.16 mmol) and 51.2 mg of nonadecanoyl chloride (0.16 mmol) were added at room temperature and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was added to about 200 ml of distilled water for workup. The precipitated solid was filtered off with suction and washed with water. Column chromatography on silica gel of the crude product (dichloromethane / methanol eluent) gave a white solid.

m.p.: 147.2℃m.p .: 147.2 ° C

1H NMR (d6-DMSO): δ = 0.90 (t, 3H), 1.20 1.50 (m, 33H), 1.75 - 1.85 (m, 2H), 2.60 - 2.68 (m, 2H), 3.50 - 3.60 (m, 2H), 7.26 - 7.36 (m, 3H), 8.25 - 8.31 (m, 3H), 8.71 (s, 1H), 9.22 (s, 1H), 9.75 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 0.90 (t, 3H), 1.20 1.50 (m, 33H), 1.75-1.85 (m, 2H), 2.60-2.68 (m, 2H), 3.50-3.60 (m , 2H), 7.26-7.36 (m, 3H), 8.25-8.31 (m, 3H), 8.71 (s, 1H), 9.22 (s, 1H), 9.75 (s, 1H) ppm.

실시예 24:Example 24:

1-(3-벤질피리도[2,3-b]피라진-6-일]-3-에틸우레아(화합물 15)1- (3-benzylpyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Compound 15)

1-(3-벤질피리도[2,3-b]피라진-6-일]-3-에틸우레아의 제조(반응식 6에 따른 반응)Preparation of 1- (3-benzylpyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (reaction according to Scheme 6)

THF 중 2.4ml의 0.5M 용액의 벤질아연 브로마이드(1.20mmol) 및 24.7mg의 테트라키스(트리페닐포스핀)팔라듐(0)(0.02mmol)을 초기에 1ml의 디옥산 질소하에서 채웠다. 후속적으로, 102.4mg의 1-(3-클로로피리도[2,3-b]피라진-6-일)-3-에틸우레아(0.41mmol) 및 1ml의 디옥산을 분획으로 첨가하였다. 이어서, 혼합물을 100℃로 가열하였다. 7시간 후, 반응 혼합물을 냉각시키고, 이어서, 포화된 염화암모늄 용액을 첨가하였다. 수성 상을 디클로로메탄으로 반복적으로 추출하고, 수집된 유기 상을 포화된 염화나트륨 용액으로 세척하고, 황상나트륨 상에서 건조시키고, 용매를 감압하에 제거하였다. 실리카 겔 상 칼럼 크로마토그래피 정제(디클로로메탄/메탄올 용리액)로 황색 고체를 수득하였다. 2.4 ml of 0.5M solution of benzylzinc bromide (1.20 mmol) and 24.7 mg of tetrakis (triphenylphosphine) palladium (0) (0.02 mmol) in THF were initially charged under 1 ml of dioxane nitrogen. Subsequently, 102.4 mg of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.41 mmol) and 1 ml dioxane were added in fractions. The mixture was then heated to 100 ° C. After 7 hours, the reaction mixture was cooled and then saturated ammonium chloride solution was added. The aqueous phase was extracted repeatedly with dichloromethane and the collected organic phases were washed with saturated sodium chloride solution, dried over sodium sulphate and the solvent was removed under reduced pressure. Column chromatography on silica gel purification (dichloromethane / methanol eluent) gave a yellow solid.

ESI-MS: 실측치 m/z = 308.3 (M + H+); 계산치 307 amuESI-MS: found m / z = 308.3 (M + H + ); Calc. 307 amu

1H NMR (d6-DMSO): δ = 1.19 (t, 3H), 3.25 - 3.35 (m, 2H), 4.35 (s, 2H), 7.25 (t, 1H), 7.30 - 7.39 (m, 4H), 7.64 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.05 (s, 1H), 10.08 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.19 (t, 3H), 3.25-3.35 (m, 2H), 4.35 (s, 2H), 7.25 (t, 1H), 7.30-7.39 (m, 4H) , 7.64 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.05 (s, 1H), 10.08 (s, 1H) ppm.

실시예 25:Example 25:

1-메톡시-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아(화합물 7)1-methoxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 7)

3-페닐피리도[2,3-b]피라진-6-일아민의 제조(반응식 6에 따른 반응)Preparation of 3-phenylpyrido [2,3-b] pyrazin-6-ylamine (reaction according to Scheme 6)

1.00g의 3-클로로피리도[2,3-b]피라진-6-일아민(5.54mmol), 743mg의 페닐보론산(6.09mmol), 640mg의 테트라키스(트리페닐포스핀)팔라듐(0)(0.55mmol) 및 1.76의 탄산나트륨(16.6mmol)을 초기에 100ml의 디메틸포름아미드/물(1:1)에 보호 기체로서 질소하에서 채우고, 80℃에서 2시간 동안 교반하였다. 반응을 종결시킨 후, 혼합물을 흡입하에 여과제거하고, 여액을 800ml의 증류수로 부었다. 수성 상을 에틸 아세테이트로 반복적으로 추출하였다. 유기 상을 용매를 감압하에 제거하였다. 수득한 고체를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 황색 고체를 수득하였다. 1.00 g of 3-chloropyrido [2,3-b] pyrazin-6-ylamine (5.54 mmol), 743 mg of phenylboronic acid (6.09 mmol), 640 mg of tetrakis (triphenylphosphine) palladium (0) (0.55 mmol) and 1.76 sodium carbonate (16.6 mmol) were initially charged in 100 ml of dimethylformamide / water (1: 1) under nitrogen as protective gas and stirred at 80 ° C. for 2 hours. After completion of the reaction, the mixture was filtered off with suction and the filtrate was poured into 800 ml of distilled water. The aqueous phase was extracted repeatedly with ethyl acetate. The organic phase was removed under reduced pressure. The obtained solid was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

1-메톡시-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아의 제조(반응식 5에 따른 반응)Preparation of 1-methoxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (reaction according to Scheme 5)

100mg의 3-페닐피리도[2,3-b]피라진-6-일아민(0.45mmol)을 피리딘에 용해시키고, 191mg의 p-니트로페닐 N-메톡시카바메이트(0.90mmol)와 혼합하였다. 혼합물을 환류하에 4시간 동안 가열하였다. 후처리를 위해 피리딘을 감압하에 제거하고, 잔사를 에틸 아세테이트 및 증류수에 분배하였다. 상을 분리시키고, 수성 상을 에틸 아세테이트로 2회 추출하였다. 합한 유기 상을 MgSO4 상에서 건조시키고, 용매를 감압하에 제거하였다. 잔사를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 밝은 베이지색 고체를 분리하였다. 100 mg of 3-phenylpyrido [2,3-b] pyrazin-6-ylamine (0.45 mmol) was dissolved in pyridine and mixed with 191 mg of p -nitrophenyl N-methoxycarbamate (0.90 mmol). The mixture was heated at reflux for 4 h. Pyridine was removed under reduced pressure for workup and the residue was partitioned between ethyl acetate and distilled water. The phases were separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over MgSO 4 and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (dichloromethane / methanol eluent). A light beige solid was separated.

ESI-MS: 실측치 m/z = 296.2 (M + H+); 계산치 295 amuESI-MS: found m / z = 296.2 (M + H + ); Calculated 295 amu

1H NMR (d6-DMSO): δ = 3.75 (s, 3H), 7.58 - 7.65 (m, 3H), 8.03 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.16 (s, 1H), 11.01 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 3.75 (s, 3H), 7.58-7.65 (m, 3H), 8.03 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.16 (s, 1H), 11.01 (s, 1H) ppm.

다음 실시예를 실시예 25 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 25 and general synthetic methods:

실시예 26:Example 26:

1-알릴옥시-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아(화합물 8)1-allyloxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 8)

ESI-MS: 실측치 m/z = 322.2 (M + H+); 계산치 321 amuESI-MS: found m / z = 322.2 (M + H + ); Calculated 321 amu

1H NMR (d6-DMSO): δ = 4.44 (d, 2H), 5.33 (d, 1H), 5.41 (d, 1H), 6.02 - 6.10 (m, 1H), 7.58 - 7.65 (m, 3H), 8.00 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.13 (s, 1H), 11.07 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 4.44 (d, 2H), 5.33 (d, 1H), 5.41 (d, 1H), 6.02-6.10 (m, 1H), 7.58-7.65 (m, 3H) , 8.00 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.13 (s, 1H), 11.07 (s, 1H) ppm.

실시예 27:Example 27:

1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아(화합물 36)1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 36)

ESI-MS: 실측치 m/z = 452.6 (M + H+); 계산치 451 amuESI-MS: found m / z = 452.6 (M + H + ); Calculated 451 amu

1H NMR (DMSO-d6) δ = 0.02 (s, 6H), 0.84 (s, 9H), 1.62-1.65 (m, 4H), 3.30-3.33 (m, 2H), 3.66-3.69 (m,2H), 7.59-7.62 (m, 3H), 7.64 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.37 (s, 1H), 9.47 (s, 1H), 10.15 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 0.02 (s, 6H), 0.84 (s, 9H), 1.62-1.65 (m, 4H), 3.30-3.33 (m, 2H), 3.66-3.69 (m, 2H ), 7.59-7.62 (m, 3H), 7.64 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.37 (s, 1H), 9.47 (s, 1H), 10.15 (s, 1H) ppm.

실시예 28:Example 28:

1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아(화합물 37)1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] Urea (Compound 37)

ESI-MS: 실측치 m/z = 498.5 (M + H+); 계산치 497 amuESI-MS: found m / z = 498.5 (M + H + ); Calculation 497 amu

1H NMR (DMSO-d6) = 0.01 (s, 6H), 0.83 (s, 9H), 1.61-1.66 (m, 4H), 3.30-3.33 (m, 2H), 3.65-3.68 (m, 2H), 3.93 (s, 3H), 6.96 (d, 1H), 7.59 (d, 1H), 7.86 (dd, 1H), 7.92 (d, 1H), 8.32 (d, 1H), 9.29 (s, 1H), 9.42 (s, 1H), 9.73 (s, 1H), 10.08 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) = 0.01 (s, 6H), 0.83 (s, 9H), 1.61-1.66 (m, 4H), 3.30-3.33 (m, 2H), 3.65-3.68 (m, 2H) , 3.93 (s, 3H), 6.96 (d, 1H), 7.59 (d, 1H), 7.86 (dd, 1H), 7.92 (d, 1H), 8.32 (d, 1H), 9.29 (s, 1H), 9.42 (s, 1 H), 9.73 (s, 1 H), 10.08 (s, 1 H) ppm.

실시예 29:Example 29:

디에틸 {4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}포스포네이트(화합물 42)Diethyl {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphonate (Compound 42)

ESI-MS: 실측치 m/z = 458.2 (M + H+); 계산치 457 amuESI-MS: found m / z = 458.2 (M + H + ); Calculated 457 amu

1H NMR (DMSO-d6) δ = 1.16 (t, 6H), 1.59-1.69 (m, 4H), 1.77-1.84 (m, 2H), 3.33-3.36 (m, 2H), 3.90-3.99 (m, 4H), 7.58-7.63 (m, 3H), 7.68 (d, 1H), 8.36 (d, 2H), 8.38 (d, 1H), 9.22 (s, 1H), 9.47 (s, 1H), 10.16 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.16 (t, 6H), 1.59-1.69 (m, 4H), 1.77-1.84 (m, 2H), 3.33-3.36 (m, 2H), 3.90-3.99 (m , 4H), 7.58-7.63 (m, 3H), 7.68 (d, 1H), 8.36 (d, 2H), 8.38 (d, 1H), 9.22 (s, 1H), 9.47 (s, 1H), 10.16 ( s, 1H) ppm.

실시예 30:Example 30:

디에틸 (4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스포네이트 (화합물 44)Diethyl (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphonate (Compound 44)

ESI-MS: 실측치 m/z = 504.5 (M + H+); 계산치 503 amuESI-MS: found m / z = 504.5 (M + H + ); Calc. 503 amu

1H NMR (DMSO-d6) δ = 1.15 (t, 6 H), 1.58-1.69 (m, 4H), 1.76-1.82 (m, 2H), 3.30-3.33 (m, 2H), 3.89-3.97 (m, 7H), 6.97 (d, 1H), 7.63 (d, 1H), 7.86 (dd, 1H), 7.91 (d, 1H), 8.32 (d, 1H), 9.13 (s, 1H), 9.41 (s, 1H), 9.71 (s, 1H), 10.07 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.15 (t, 6 H), 1.58-1.69 (m, 4H), 1.76-1.82 (m, 2H), 3.30-3.33 (m, 2H), 3.89-3.97 ( m, 7H), 6.97 (d, 1H), 7.63 (d, 1H), 7.86 (dd, 1H), 7.91 (d, 1H), 8.32 (d, 1H), 9.13 (s, 1H), 9.41 (s , 1H), 9.71 (s, 1H), 10.07 (s, 1H) ppm.

실시예 31:Example 31:

1-메톡시-3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아(화합물 61)1-methoxy-3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 61)

ESI-MS: 실측치 m/z = 342.3 (M + H+); 계산치 341 amuESI-MS: found m / z = 342.3 (M + H + ); Calc 341 amu

1H NMR (d6-DMSO): δ = 3.74 (s, 3H), 3.93 (s, 3H), 6.98 (d, 1H), 7.87 (dd, 1H), 7.91 (d, 1H), 8.02 (d, 1H), 8.39 (d, 1H), 9.46 (s, 1H), 9.74 (s, 1H), 10.03 (s, 1H), 10.84 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 3.74 (s, 3H), 3.93 (s, 3H), 6.98 (d, 1H), 7.87 (dd, 1H), 7.91 (d, 1H), 8.02 (d , 1H), 8.39 (d, 1H), 9.46 (s, 1H), 9.74 (s, 1H), 10.03 (s, 1H), 10.84 (s, 1H) ppm.

실시예 32:Example 32:

디에틸 {2-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]에틸}포스포네이트 (화합물 62)Diethyl {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} phosphonate (Compound 62)

ESI-MS: 실측치 m/z = 430.1 (M + H+); 계산치 429 amuESI-MS: found m / z = 430.1 (M + H + ); Calculation 429 amu

1H NMR (d6-DMSO): δ = 1.21 (t, 6H), 2.08-2.14 (m, 2H), 3.48-3.55 (m, 2H), 3.98-4.08 (m, 4H), 7.58-7.63 (m, 3H), 7.72 (d, 1H), 8.35 (d, 2H), 8.39 (d, 1H), 9.14 (s, 1H), 9.47 (s, 1H), 10.22 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.21 (t, 6H), 2.08-2.14 (m, 2H), 3.48-3.55 (m, 2H), 3.98-4.08 (m, 4H), 7.58-7.63 ( m, 3H), 7.72 (d, 1H), 8.35 (d, 2H), 8.39 (d, 1H), 9.14 (s, 1H), 9.47 (s, 1H), 10.22 (s, 1H) ppm.

실시예 33:Example 33:

4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 에틸카바메이트(화합물 38)4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate (compound 38)

1-(4-하이드록시부틸)-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아의 제조Preparation of 1- (4-hydroxybutyl) -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea

360mg(0.22mmol)의 1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아를 20ml의 디클로로메탄에 용해시키고, 5ml의 2mol 이소프로판올 HCl 용액과 혼합하였다. 실온에서 12시간 동안 교반한 후, 반응 혼합물을 물로 세척하고, 건조시켰다(Na2SO4). 용매를 감압하에 제거하여 밝은 황색 고체를 수득하였다.360 ml (0.22 mmol) of 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea was dissolved in 20 ml of dichloro It was dissolved in methane and mixed with 5 ml of 2 mol isopropanol HCl solution. After stirring for 12 hours at room temperature, the reaction mixture was washed with water and dried (Na 2 SO 4 ). The solvent was removed under reduced pressure to give a light yellow solid.

ESI-MS: 실측치 m/z = 338.3 (M + H+); 계산치 337 amuESI-MS: found m / z = 338.3 (M + H + ); Calc 337 amu

1H NMR (DMSO-d6) δ = 1.58-1.64 (m, 4H), 3.30-3.34 (m, 2H), 3.48-3.53 (m, 2H), 4.48 (t, 1H), 7.57-7.63 (m, 3H), 7.66 (d, 1H), 8.35-8.38 (m, 2H), 9.30 (s, 1H), 9.46 (s, 1H), 10.13 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.58-1.64 (m, 4H), 3.30-3.34 (m, 2H), 3.48-3.53 (m, 2H), 4.48 (t, 1H), 7.57-7.63 (m , 3H), 7.66 (d, 1H), 8.35-8.38 (m, 2H), 9.30 (s, 1H), 9.46 (s, 1H), 10.13 (s, 1H) ppm.

4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 에틸카바메이트의 제조Preparation of 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate

30mg(0.08mmol)의 1-(4-하이드록시부틸)-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아를 5ml의 피리딘에 용해시키고, 7.6㎕(0.10mmol)의 에틸 이소시아네이트와 혼합하고, 10℃에서 6시간 동안 교반하였다. 반응 혼합물을 200ml의 물에 붓고, 15분 동안 교반하였다. 침전된 고체를 여과제거하고, 건조시켰다. 이로서 백색 고체를 수득하였다. 30 mg (0.08 mmol) of 1- (4-hydroxybutyl) -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea are dissolved in 5 ml of pyridine and 7.6 μL (0.10) mmol) ethyl isocyanate and stirred at 10 ° C. for 6 h. The reaction mixture was poured into 200 ml of water and stirred for 15 minutes. The precipitated solid was filtered off and dried. This gave a white solid.

ESI-MS: 실측치 m/z = 409.4 (M + H+); 계산치 408 amuESI-MS: found m / z = 409.4 (M + H + ); Calc 408 amu

1H NMR (DMSO-d6) = 0.97 (t, 3H), 1.60-1.77 (m, 4H), 2.96-3.00 (m, 2H), 3.33-3.35 (m, 2H), 4.01-4.04 (m, 2H), 7.07 (t, 1H), 7.58-7.64 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.32 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) = 0.97 (t, 3H), 1.60-1.77 (m, 4H), 2.96-3.00 (m, 2H), 3.33-3.35 (m, 2H), 4.01-4.04 (m, 2H), 7.07 (t, 1H), 7.58-7.64 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.32 (s, 1H), 9.47 (s , 1H), 10.17 (s, 1H) ppm.

실시예 34:Example 34:

메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트(화합물 39)Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate (Compound 39)

메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트의 제조Preparation of Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

30mg(0.08mmol)의 1-(4-하이드록시부틸)-3-(3-페닐피리도[2,3-b]피라진-6-일)우레아를 2ml의 디클로로메탄에 현탁시키고, 9.3㎕(0.12mmol)의 메틸 클로로포르메이트, 23㎕(0.16mmol)의 트리에틸아민 및 1mg(0.01mmol)의 디메틸아미노피리딘과 혼합하였다. 용액을 실온에서 4시간 동안 교반하였다. 반응 혼합물을 50ml의 디클로로메탄으로 희석시키고, 물로 세척하고, 건조시켰다(Na2SO4). 용매를 감압하에 제거하고, 잔사를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 백색 고체를 분리하였다.30 mg (0.08 mmol) of 1- (4-hydroxybutyl) -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea are suspended in 2 ml of dichloromethane and 9.3 μl ( 0.12 mmol) of methyl chloroformate, 23 μl (0.16 mmol) of triethylamine and 1 mg (0.01 mmol) of dimethylaminopyridine. The solution was stirred at rt for 4 h. The reaction mixture was diluted with 50 ml of dichloromethane, washed with water and dried (Na 2 SO 4 ). The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (dichloromethane / methanol eluent). The white solid was separated.

ESI-MS: 실측치 m/z = 396.3 (M + H+); 계산치 395 amuESI-MS: found m / z = 396.3 (M + H + ); Calc 395 amu

1H NMR (DMSO-d6) = 1.61-1.66 (m, 2H), 1.76-1.78 (m, 2H), 3.34-3.36 (m, 2H), 3.67 (s, 1H), 4.17-4.19 (m, 2H), 7.59-7.63 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) = 1.61-1.66 (m, 2H), 1.76-1.78 (m, 2H), 3.34-3.36 (m, 2H), 3.67 (s, 1H), 4.17-4.19 (m, 2H), 7.59-7.63 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s , 1H) ppm.

다음 실시예를 실시예 34 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 34 and general synthetic methods:

실시예 35:Example 35:

2,2-디메틸[1,3]디옥솔란-4-일메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트(화합물 40)2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate (Compound 40)

ESI-MS: 실측치 m/z = 496.0 (M + H+); 계산치 495 amuESI-MS: found m / z = 496.0 (M + H + ); Calculated 495 amu

1H NMR (DMSO-d6) = 1.24 (s, 3H), 1.29 (s, 3H), 1.61-1.67 (m, 2H), 1.77-1.82 (m, 2H), 3.34-3.37 (m, 2H), 3.65 (dd, 1H), 3.98 (dd, 1H), 4.03 (dd, 1H), 4.15 (dd, 1H), 4.17-4.28 (m, 3H), 7.58-7.63 (m, 3H), 7.67 (d, 1H), 8.36 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) = 1.24 (s, 3H), 1.29 (s, 3H), 1.61-1.67 (m, 2H), 1.77-1.82 (m, 2H), 3.34-3.37 (m, 2H) , 3.65 (dd, 1H), 3.98 (dd, 1H), 4.03 (dd, 1H), 4.15 (dd, 1H), 4.17-4.28 (m, 3H), 7.58-7.63 (m, 3H), 7.67 (d , 1H), 8.36 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.

실시예 36:Example 36:

2,3-디하이드록시프로필 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트(화합물 41)2,3-dihydroxypropyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate (Compound 41)

2,3-디하이드록시프로필 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트의 제조Preparation of 2,3-dihydroxypropyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

50mg(0.10mmol)의 2,2-디메틸[1,3]디옥솔란-4-일메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트를 20ml의 디클로로메탄에 용해시키고, 17㎕(0.13mmol)의 보론 트리플루오라이드 에틸 에테레이트와 혼합하고, 실온에서 4시간 동안 교반하였다. 용매를 감압하에 제거하고, 잔사를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 백색 고체를 분리하였다.50 mg (0.10 mmol) of 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl The carbonate was dissolved in 20 ml of dichloromethane, mixed with 17 μl (0.13 mmol) of boron trifluoride ethyl etherate and stirred at room temperature for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (dichloromethane / methanol eluent). The white solid was separated.

ESI-MS: 실측치 m/z = 456.4 (M + H+); 계산치 455 amuESI-MS: found m / z = 456.4 (M + H + ); 455 amu

1H NMR (DMSO-d6) =1.62-1.67 (m, 2H), 1.76-1.82 (m, 2H), 3.28-3.52 (m, 4H), 3.62-3.66 (m, 1H), 3.96 (dd, 1H), 4.11 (dd, 1H), 4.16-4.20 (m, 2H), 4.66 (t, 1H), 4.96 (d, 1H), 7.58-7.65 (m, 3H), 7.67 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.31 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) = 1.62-1.67 (m, 2H), 1.76-1.82 (m, 2H), 3.28-3.52 (m, 4H), 3.62-3.66 (m, 1H), 3.96 (dd, 1H), 4.11 (dd, 1H), 4.16-4.20 (m, 2H), 4.66 (t, 1H), 4.96 (d, 1H), 7.58-7.65 (m, 3H), 7.67 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.31 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.

실시예 37:Example 37:

{4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}포스폰산(화합물 43){4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphonic acid (Compound 43)

{4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}포스폰산의 제조Preparation of {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphonic acid

60mg(0.13mmol)의 디에틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸을 각 5ml의 디클로로메탄 및 헥사메틸디실라잔에 용해시키고, 100mg(0.66mmol)의 브로모트리메틸실란과 혼합하였다. 실온에서 6시간 동안 교반한 후, 반응 혼합물을 감압하에 농축하고, 잔사를 물과 2시간 동안 교반하였다. 이로서 황색 고체를 수득하였다. 60 mg (0.13 mmol) of diethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl were dissolved in 5 ml of each dichloromethane and hexamethyldisilazane. And 100 mg (0.66 mmol) of bromotrimethylsilane. After stirring for 6 hours at room temperature, the reaction mixture was concentrated under reduced pressure and the residue was stirred with water for 2 hours. This gave a yellow solid.

ESI-MS: 실측치 m/z = 402.3 (M + H+); 계산치 401 amuESI-MS: found m / z = 402.3 (M + H + ); 401 amu

1H NMR (DMSO-d6) δ = 1.51-1.68 (m, 6H), 3.33-3.36 (m, 2H), 7.58-7.63 (m, 3H), 7.73 (d, 1H), 8.33-8.37 (m, 3H), 9.06 (s, 1H), 9.44 (s, 1H), 10.12 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.51-1.68 (m, 6H), 3.33-3.36 (m, 2H), 7.58-7.63 (m, 3H), 7.73 (d, 1H), 8.33-8.37 (m , 3H), 9.06 (s, 1H), 9.44 (s, 1H), 10.12 (s, 1H) ppm.

다음 실시예를 실시예 37 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 37 and general synthetic methods:

실시예 38:Example 38:

(4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스폰산(화합물 45)(4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphonic acid (Compound 45)

ESI-MS: 실측치 m/z = 448.3 (M + H+); 계산치 447 amuESI-MS: found m / z = 448.3 (M + H + ); 447 amu

1H NMR (DMSO-d6) δ = 1.48-1.67 (m, 6H), 3.24-3.28 (m, 2H), 3.92 (s, 3H), 6.98 (d, 1H), 7.70 (d, 1H), 7.85 (dd, 1H), 7.89 (d, 1H), 8.28 (d, 1H), 8.95 (s, 1H), 9.38 (s, 1H), 10.02 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.48-1.67 (m, 6H), 3.24-3.28 (m, 2H), 3.92 (s, 3H), 6.98 (d, 1H), 7.70 (d, 1H), 7.85 (dd, 1H), 7.89 (d, 1H), 8.28 (d, 1H), 8.95 (s, 1H), 9.38 (s, 1H), 10.02 (s, 1H) ppm.

실시예 39:Example 39:

{2-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]에틸}포스폰산(화합물 63){2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} phosphonic acid (Compound 63)

ESI-MS: 실측치 m/z = 374.2 (M + H+); 계산치 373 amuESI-MS: found m / z = 374.2 (M + H + ); Calc 373 amu

1H NMR (d6-DMSO): δ = 1.86-1.93 (m, 2H), 3.45-3.52 (m, 2H), 7.57-7.63 (m, 3H), 7.76 (d, 1H), 8.35 (d, 2H), 8.37 (d, 1H), 8.96 (s, 1H), 9.45 (s, 1H), 10.17 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.86-1.93 (m, 2H), 3.45-3.52 (m, 2H), 7.57-7.63 (m, 3H), 7.76 (d, 1H), 8.35 (d, 2H), 8.37 (d, 1H), 8.96 (s, 1H), 9.45 (s, 1H), 10.17 (s, 1H) ppm.

실시예 40:Example 40:

에틸 N-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미데이트(화합물 59)Ethyl N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamidate (Compound 59)

에틸 N-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미데이트의 제조(반응식 5에 따른 반응)Preparation of ethyl N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamidate (reaction according to scheme 5)

200mg(0.90mmol)의 3-페닐피리도[2,3-b]피라진-6-일아민을 20ml의 피리딘에 용해시키고, 0.11ml(0.99mmol)의 에틸옥살릴 클로라이드와 혼합하였다. 실온에서 2시간 동안 교반한 후, 용액을 빙수에 부었다. 침전된 고체를 여과제거하고, 물로 완전히 세척하였다. 이로서 밝은 황색 고체를 수득하였다.200 mg (0.90 mmol) of 3-phenylpyrido [2,3-b] pyrazin-6-ylamine were dissolved in 20 ml of pyridine and mixed with 0.11 ml (0.99 mmol) of ethyl oxalyl chloride. After stirring for 2 hours at room temperature, the solution was poured into ice water. The solid precipitated was filtered off and washed thoroughly with water. This gave a light yellow solid.

ESI-MS: 실측치 m/z = 323.2 (M + H+); 계산치 322 amuESI-MS: found m / z = 323.2 (M + H + ); Calc 322 amu

1H NMR (DMSO-d6) δ = 1.37 (t, 3H), 4.35-4.41 (m, 2H), 7.60-7.66 (m, 3H), 8.38 (d, 2H), 8.43 (bs, 1H), 8.61 (d, 1H), 9.63 (s, 1H), 11.67 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.37 (t, 3H), 4.35-4.41 (m, 2H), 7.60-7.66 (m, 3H), 8.38 (d, 2H), 8.43 (bs, 1H), 8.61 (d, 1 H), 9.63 (s, 1 H), 11.67 (s, 1 H) ppm.

실시예 41:Example 41:

N-에틸-N'-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미드(화합물 60)N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide (Compound 60)

N-에틸-N'-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미드의 제조(반응식 5에 따른 반응)Preparation of N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide (reaction according to Scheme 5)

23mg(0.07mmol)의 에틸 N-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미데이트를 5ml의 무수 THF에 용해시키고, THF 중 0-15ml(0.38mmol)의 2.0M 에틸아민 용액과 혼합하였다. 23 mg (0.07 mmol) of ethyl N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamidate is dissolved in 5 ml of dry THF and 0-15 ml (0.38 mmol) in THF Mixed with 2.0M ethylamine solution.

실온에서 48시간 동안 교반한 후, 반응 혼합물을 중성화시켰다. 침전된 고체를 여과제거하고, 여액을 농축하여 감압하에 건조시켰다. 수득한 고체를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 밝은 황색 고체를 수득하였다.After stirring for 48 hours at room temperature, the reaction mixture was neutralized. The precipitated solid was filtered off and the filtrate was concentrated to dryness under reduced pressure. The obtained solid was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a light yellow solid.

ESI-MS: 실측치 m/z = 322.3 (M + H+); 계산치 321 amuESI-MS: found m / z = 322.3 (M + H + ); Calculated 321 amu

1H NMR (DMSO-d6) δ = 1.13 (t, 3H), 3.27 (q, 2H), 7.60-7.66 (m, 3H), 8.39 (d, 2H), 8.54 (d, 1H), 8.65 (d, 1H), 9.24 (t, 1H), 9.64 (s, 1H), 10.31 (s, 1H) ppm. 1 H NMR (DMSO-d 6 ) δ = 1.13 (t, 3H), 3.27 (q, 2H), 7.60-7.66 (m, 3H), 8.39 (d, 2H), 8.54 (d, 1H), 8.65 ( d, 1H), 9.24 (t, 1H), 9.64 (s, 1H), 10.31 (s, 1H) ppm.

실시예 42:Example 42:

에틸 4-[6-(3-에틸-1-페닐우레아)피리도[2,3-b]피라진-3-일]페닐카바메이트(화합물 20)Ethyl 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenylcarbamate (compound 20)

에틸 4-[6-(3-에틸-1-페닐우레아)피리도[2,3-b]피라진-3-일]페닐카바메이트의 제조(반응식 5에 따른 반응)Preparation of ethyl 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenylcarbamate (reaction according to Scheme 5)

100mg의 4-(6-페닐아미노피리도[2,3-b]피라진-3-일)페놀 하이드로클로라이드(0.28mmol)를 초기에 3ml의 피리딘에 채우고, 65.3mg의 에틸 이소시아네이트(0.90mmol)를 실온에서 첨가하였다. 혼합물을 80℃에서 5시간 동안 교반하고, 이어서 또다른 32.0mg의 에틸 이소시아네이트(0.45mmol)를 첨가하고, 혼합물을 80℃에서 추가로 4시간 동안 교반하였다. 이어서, 용매를 감압하에 제거하였다. 수득한 고체를 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 및 n-헵탄/아세톤 용리액)로 2회 정제하였다. 이로서 밝은 황색 고체를 수득하였다. 100 mg of 4- (6-phenylaminopyrido [2,3-b] pyrazin-3-yl) phenol hydrochloride (0.28 mmol) were initially charged in 3 ml of pyridine and 65.3 mg of ethyl isocyanate (0.90 mmol) was added. Add at room temperature. The mixture was stirred at 80 ° C. for 5 hours, then another 32.0 mg of ethyl isocyanate (0.45 mmol) was added and the mixture was stirred at 80 ° C. for an additional 4 hours. Then the solvent was removed under reduced pressure. The obtained solid was purified twice by column chromatography on silica gel (dichloromethane / methanol and n-heptane / acetone eluent). This gave a light yellow solid.

m.p.: 147-151℃m.p .: 147-151 ° C

ESI-MS: 실측치 m/z = 457.3 (M + H+); 계산치 456 amuESI-MS: found m / z = 457.3 (M + H + ); 456 amu

1H NMR (CDCl3): δ =1.28 (t, 3H), 1.40 (t, 3H), 3.39 (quint, 2H), 3.57 (quint, 2H), 5.09 (t, 1H), 6.80 (d, 1H), 7.37 (d, 2H), 7.40 (d, 2H), 7.50 (t, 1H), 7.57 (t, 2H), 8.10 (d, 1H), 8.30 (d, 2H), 9.25 (s, 1H), 10.76 (t, 1H) ppm. 1 H NMR (CDCl 3 ): δ = 1.28 (t, 3H), 1.40 (t, 3H), 3.39 (quint, 2H), 3.57 (quint, 2H), 5.09 (t, 1H), 6.80 (d, 1H ), 7.37 (d, 2H), 7.40 (d, 2H), 7.50 (t, 1H), 7.57 (t, 2H), 8.10 (d, 1H), 8.30 (d, 2H), 9.25 (s, 1H) , 10.76 (t, 1 H) ppm.

4-(6-페닐아미노피리도[2,3-b]피라진-3-일)페놀 하이드로클로라이드를 제조하기 위해, WO 99/17759를 참조하였다.To prepare 4- (6-phenylaminopyrido [2,3-b] pyrazin-3-yl) phenol hydrochloride, reference was made to WO 99/17759.

실시예 43:Example 43:

3급-부틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}카바메이트(화합물 21)Tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} carbamate (Compound 21)

3급-부틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}카바메이트의 제조(반응식 6에 따른 반응)Preparation of tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} carbamate (reaction according to Scheme 6)

83mg의 1-(3-클로로피리도[2,3-b]피라진-6-일)-3-에틸우레아(0.33mmol), 120mg의 3급-부틸 [4-(4,4,5,5-테트라메틸[1,3,2]디옥사보롤란-2-일)페닐]카바메이트(0.36mmol), 106mg의 탄산나트륨(1.00mmol) 및 19mg의 테트라키스-(트리페닐포스핀)(0.02mmol)을 초기에 7ml의 탈기된 디메틸포름아미드/물 혼합물에 채웠다. 혼합물을 10℃로 4시간 동안 가열하였다. 냉각된 혼합물을 물과 혼합하였다. 침전된 고체를 여과제거하고, 물 및 디클로로메탄으로 세척하였다. 이로서 베이지색 고체를 수득하였다. 83 mg of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.33 mmol), 120 mg of tert-butyl [4- (4,4,5,5 Tetramethyl [1,3,2] dioxaborolan-2-yl) phenyl] carbamate (0.36 mmol), 106 mg sodium carbonate (1.00 mmol) and 19 mg tetrakis- (triphenylphosphine) (0.02 mmol) ) Was initially charged to 7 ml of degassed dimethylformamide / water mixture. The mixture was heated to 10 ° C for 4 h. The cooled mixture was mixed with water. The precipitated solid was filtered off and washed with water and dichloromethane. This gave a beige solid.

m.p.: 281-283℃m.p .: 281-283 ° C

ESI-MS: 실측치 m/z = 409.4 (M + H+); 계산치 408 amuESI-MS: found m / z = 409.4 (M + H + ); Calc 408 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 1.52 (s, 9H), 3.25 - 3.38 (m, 2H), 7.65 (d, 1H), 7.69 (d, 2H), 8.29 (d, 2H), 8.33 (d, 1H), 9.09 (bs, 1H), 9.41 (s, 1H), 9.72 (s, 1H), 10.09 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 1.52 (s, 9H), 3.25-3.38 (m, 2H), 7.65 (d, 1H), 7.69 (d, 2H), 8.29 (d, 2H), 8.33 (d, 1H), 9.09 (bs, 1H), 9.41 (s, 1H), 9.72 (s, 1H), 10.09 (s, 1H) ppm.

다음 실시예를 실시예 43 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 43 and general synthetic methods:

실시예 44:Example 44:

2-메톡시에틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}카바메이트(화합물 22)2-methoxyethyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} carbamate (Compound 22)

m.p.: 249-251℃m.p .: 249-251 ° C

ESI-MS: 실측치 m/z = 411.3 (M + H+); 계산치 410 amuESI-MS: found m / z = 411.3 (M + H + ); Calculated 410 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.31 (s, 3H), 3.45 - 3.38 (m, 2H), 3.58 - 3.64 (m, 2H), 4.24 - 4.27 (m, 2H), 7.65 (d, 1H), 7.70 (d, 2H), 8.31 (d, 2H), 8.37 (d, 1H), 9.08 (bs, 1H), 9.41 (s, 1H), 10.09 (s, 1H), 10.11 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.31 (s, 3H), 3.45-3.38 (m, 2H), 3.58-3.64 (m, 2H), 4.24-4.27 (m, 2H), 7.65 (d, 1H), 7.70 (d, 2H), 8.31 (d, 2H), 8.37 (d, 1H), 9.08 (bs, 1H), 9.41 (s, 1H), 10.09 (s, 1H ), 10.11 (s, 1H) ppm.

실시예 45:Example 45:

1-에틸-3-{3-[4-(3-에틸우레아)페닐]피리도[2,3-b]피라진-6-일}우레아(화합물 23)1-ethyl-3- {3- [4- (3-ethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} urea (Compound 23)

m.p.: > 350℃(분해)m.p .:> 350 ° C (decomposition)

ESI-MS: 실측치 m/z = 380.2 (M + H+); 계산치 379 amuESI-MS: found m / z = 380.2 (M + H + ); Calc 379 amu

1H NMR (d6-DMSO): δ =1.08 (t, 3H), 1.20 (t, 3H), 3.14 (quint, 2H), 3.32 - 3.38 (m, 2H), 6.33 (t, 1H), 7.60-7.64 (m, 3H), 8.25 (d, 2H), 8.32 (d, 1H), 8.88 (s, 1H), 9.12 (bs, 1H), 9.39 (s, 1H), 10.06 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.08 (t, 3H), 1.20 (t, 3H), 3.14 (quint, 2H), 3.32-3.38 (m, 2H), 6.33 (t, 1H), 7.60 -7.64 (m, 3H), 8.25 (d, 2H), 8.32 (d, 1H), 8.88 (s, 1H), 9.12 (bs, 1H), 9.39 (s, 1H), 10.06 (s, 1H) ppm .

실시예 46:Example 46:

1-{3-[4-(3,3-디메틸우레아)페닐]피리도[2,3-b]피라진-6-일}-3-에틸우레아(화합물 24)1- {3- [4- (3,3-dimethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea (Compound 24)

m.p.: > 350℃m.p .:> 350 ° C

ESI-MS: 실측치 m/z = 380.3 (M + H+); 계산치 379 amuESI-MS: found m / z = 380.3 (M + H + ); Calc 379 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 2.98 (s, 6H), 3.25 - 3.38 (m, 2H), 7.63 (d, 1H), 7.74 (d, 2H), 8.26 (d, 2H), 8.33 (d, 1H), 8.63 (s, 1H), 9.12 (bs, 1H), 9.41 (s, 1H), 10.07 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.98 (s, 6H), 3.25-3.38 (m, 2H), 7.63 (d, 1H), 7.74 (d, 2H), 8.26 (d, 2H), 8.33 (d, 1H), 8.63 (s, 1H), 9.12 (bs, 1H), 9.41 (s, 1H), 10.07 (s, 1H) ppm.

실시예 47:Example 47:

1-에틸-3-{3-[6-(3-에틸우레아)피리딘-3-일]피리도[2,3-b]피라진-6-일}우레아(화합물 25)1-ethyl-3- {3- [6- (3-ethylurea) pyridin-3-yl] pyrido [2,3-b] pyrazin-6-yl} urea (Compound 25)

ESI-MS: 실측치 m/z = 381.2 (M + H+); 계산치 380 amuESI-MS: found m / z = 381.2 (M + H + ); 380 amu

1H NMR (d6-DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 3.23 (quint, 2H), 3.25 3.38 (m, 2H), 7.63 (d, 1H), 7.67 (d, 1H), 8.25 (d, 1H), 8.00 (bs, 1H), 8.35 (d, 1H), 8.61 (d, 1H), 9.08 (bs, 1H), 9.17 (s, 1H), 9.44 (s, 1H), 9.55 (s, 1H), 10.12 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 3.23 (quint, 2H), 3.25 3.38 (m, 2H), 7.63 (d, 1H), 7.67 ( d, 1H), 8.25 (d, 1H), 8.00 (bs, 1H), 8.35 (d, 1H), 8.61 (d, 1H), 9.08 (bs, 1H), 9.17 (s, 1H), 9.44 (s , 1H), 9.55 (s, 1H), 10.12 (s, 1H) ppm.

실시예 48:Example 48:

1-에틸-3-[3-(4-모르폴린-4-일메틸페닐)피리도[2,3-b]피라진-6-일]우레아(화합물 28)1-ethyl-3- [3- (4-morpholin-4-ylmethylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 28)

ESI-MS: 실측치 m/z = 393.4 (M + H+); 계산치 392 amuESI-MS: found m / z = 393.4 (M + H + ); Calc 392 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 2.41 (bs, 4H), 3.33 - 3.38 (m, 2H), 3.58 (s, 2H), 3.61 (t, 4H), 7.55 (d, 2H), 7.69 (t, 1H), 8.30 (d, 2H), 8.37 (d, 1H), 9.10 (bs, 1H), 9.44 (s, 1H), 10.13 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.41 (bs, 4H), 3.33-3.38 (m, 2H), 3.58 (s, 2H), 3.61 (t, 4H), 7.55 (d, 2H), 7.69 (t, 1H), 8.30 (d, 2H), 8.37 (d, 1H), 9.10 (bs, 1H), 9.44 (s, 1H), 10.13 (s, 1H) ppm.

실시예 49:Example 49:

N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-2-(2-메톡시에톡시)아세트아미드(화합물 30) N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -2- (2-methoxyethoxy) acetamide (Compound 30)

m.p.: 212-215℃m.p .: 212-215 ° C

ESI-MS: 실측치 m/z = 425.2 (M + H+); 계산치 424 amuESI-MS: found m / z = 425.2 (M + H + ); Calculated 424 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.32 (s, 3H), 3.34 - 3.38 (m, 2H), 3.56 (dd, 2H), 3.71 (dd, 2H), 4.15 (s, 2H), 7.66 (d, 1H), 7.89 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.43 (s, 1H), 9.97 (s, 1H), 10.11 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.32 (s, 3H), 3.34-3.38 (m, 2H), 3.56 (dd, 2H), 3.71 (dd, 2H), 4.15 (s, 2H), 7.66 (d, 1H), 7.89 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.43 (s, 1H), 9.97 (s, 1H), 10.11 (s, 1 H) ppm.

실시예 50:Example 50:

2-벤질옥시-N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}아세트아미드(화합물 35)2-benzyloxy-N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} acetamide (Compound 35)

m.p.: 254-256℃m.p .: 254-256 ° C.

ESI-MS: 실측치 m/z = 457.3 (M + H+); 계산치 456 amuESI-MS: found m / z = 457.3 (M + H + ); 456 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 4.16 (s, 2H), 4.66 (s, 2H), 7.31 (t, 1H), 7.33 (t, 1H), 7.40 (t, 2H), 7.44 (d, 1H), 7.66 (d, 1H), 7.91 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.44 (s, 1H), 10.10 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.28-3.38 (m, 2H), 4.16 (s, 2H), 4.66 (s, 2H), 7.31 (t, 1H), 7.33 (t, 1H), 7.40 (t, 2H), 7.44 (d, 1H), 7.66 (d, 1H), 7.91 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.44 (s, 1 H), 10.10 (s, 1 H), 10.14 (s, 1 H) ppm.

실시예 51:Example 51:

1-에틸-3-[3-(3-트리메틸실라닐페닐)피리도[2,3-b]피라진-6-일]우레아(화합물 46)1-ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 46)

m.p.: 224-228℃m.p .: 224-228 ° C

ESI-MS: 실측치 m/z = 366.4 (M + H+); 계산치 365 amuESI-MS: found m / z = 366.4 (M + H + ); Calculated 365 amu

1H NMR (d6-DMSO): δ =0.35 (s, 9H), 1.21 (t, 3H), 3.28 - 3.38 (m, 2H), 7.60 (t, 1H), 7.73 (t, 2H), 8.32 (d, 1H), 8.37 (d, 1H), 8.46 (s, 1H), 9.04 (bs, 1H), 9.48 (s, 1H), 10.12 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 0.35 (s, 9H), 1.21 (t, 3H), 3.28-3.38 (m, 2H), 7.60 (t, 1H), 7.73 (t, 2H), 8.32 (d, 1H), 8.37 (d, 1H), 8.46 (s, 1H), 9.04 (bs, 1H), 9.48 (s, 1H), 10.12 (s, 1H) ppm.

실시예 51에서, 디옥산/물은 용매로서 디메틸포름아미드/물 대신 사용된다.In Example 51, dioxane / water is used instead of dimethylformamide / water as the solvent.

시판되지 않는 보론산 유도체는 다음 방법 또는 당해 기술분야의 숙련가들에게 공지된 방법으로 제조된다:Commercially available boronic acid derivatives are prepared by the following methods or by methods known to those skilled in the art:

2-메톡시에틸 [4-(4,4,5,5-테트라메틸[1,3,2]디옥사보롤란-2-일)페닐]의 제 조Preparation of 2-methoxyethyl [4- (4,4,5,5-tetramethyl [1,3,2] dioxaborolan-2-yl) phenyl]

107mg의 4-(4,4,5,5-테트라메틸[1,3,2]디옥사보롤란-2-일)페닐아민(0.48mmol)을 테트라하이드로푸란에 용해시켰다. 96mg의 2-메톡시에틸 클로로포르메이트 (0.68mmol) 및 79mg의 N-메틸모르폴린(0.78mmol)을 실온에서 첨가하였다. 혼합물을 실온에서 1일 동안 교반하고, 침전된 고체를 여과제거하고, 용매를 감압하에 제거하였다. 이로서 황색 오일을 수득하고, 이를 추가의 정제 없이 다음 반응에 사용하였다.107 mg of 4- (4,4,5,5-tetramethyl [1,3,2] dioxaborolan-2-yl) phenylamine (0.48 mmol) was dissolved in tetrahydrofuran. 96 mg 2-methoxyethyl chloroformate (0.68 mmol) and 79 mg N-methylmorpholine (0.78 mmol) were added at room temperature. The mixture was stirred at rt for 1 day, the precipitated solid was filtered off and the solvent was removed under reduced pressure. This gave a yellow oil which was used for the next reaction without further purification.

다음 보론산 유도체를 상기한 방법 또는 당해 기술분야의 숙련가들에게 공지된 방법으로 제조하였다:The following boronic acid derivatives were prepared by the methods described above or by methods known to those skilled in the art:

1-에틸-3-[4-(4,4,5,5-테트라메틸-[1,3,2]디옥사보롤란-2-일)페닐]우레아1-ethyl-3- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] urea

1,1-디메틸-3-[4-(4,4,5,5-테트라메틸-[1,3,2]디옥사보롤란-2-일)페닐]우레아1,1-dimethyl-3- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] urea

1-에틸-3-[5-(4,4,5,5-테트라메틸-[1,3,2]디옥사보롤란-2-일)피리딘-2-일]우레아1-ethyl-3- [5- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) pyridin-2-yl] urea

2-(2-메톡시에톡시)-N-[4-(4,4,5,5-테트라메틸-[1,3,2]디옥사보롤란-2-일)페닐]아세트아미드2- (2-methoxyethoxy) -N- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] acetamide

2-벤질옥시-N-[4-(4,4,5,5-테트라메틸-[1,3,2]디옥사보롤란-2-일)페닐]아세트아미드2-benzyloxy-N- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] acetamide

실시예 52:Example 52:

1-에틸-3-{3-[2-(4-플루오로페닐)에틸]피리도[2,3-b]피라진-6-일}우레아(화합물 26)1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea (Compound 26)

1-에틸-3-{3-[2-(4-플루오로페닐)에틸]피리도[2,3-b]피라진-6-일}우레아의 제조Preparation of 1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea

108mg의 1-에틸-3-3-[2-(4-플루오로페닐)비닐]피리도[2,3-b]피라진-6-일우레아(0.32mmol)(실시예 27)를 가열된 에탄올에 용해시켰다. 112mg의 암모늄 포메이트(1.78mmol) 및 110mg의 탄소상 팔라듐(10%)을 첨가하고, 반응 혼합물을 환류하에 7.5시간 동안 가열하였다. 촉매를 냉각된 반응 혼합물로부터 여과제거하고, 모액을 용매로부터 제거하였다. 조 생성물을 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 황색 고체를 수득하였다. 108 mg of 1-ethyl-3-3- [2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-ylurea (0.32 mmol) (Example 27) was heated to ethanol Dissolved in. 112 mg ammonium formate (1.78 mmol) and 110 mg palladium on carbon (10%) were added and the reaction mixture was heated to reflux for 7.5 h. The catalyst was filtered off from the cooled reaction mixture and the mother liquor was removed from the solvent. The crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

m.p.: 207-209℃m.p .: 207-209 ° C

ESI-MS: 실측치 m/z = 340.2 (M + H+); 계산치 339 amuESI-MS: found m / z = 340.2 (M + H + ); Calc 339 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.12 (t, 2H), 3.25 - 3.38 (m, 4H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.63 (d, 1H), 8.31 (d, 1H), 8.71 (s, 1H), 9.09 (bs, 1H), 10.06 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.12 (t, 2H), 3.25-3.38 (m, 4H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.63 (d, 1H), 8.31 (d, 1H), 8.71 (s, 1H), 9.09 (bs, 1H), 10.06 (s, 1H) ppm.

실시예 53:Example 53:

1-에틸-3-(3-{4-[2-(2-메톡시에톡시)에톡시]페닐}피리도[2,3-b]피라진-6-일)우레아(화합물 29)1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea (Compound 29)

1-에틸-3-(3-{4-[2-(2-메톡시에톡시)에톡시]페닐}피리도[2,3-b]피라진-6-일) 우레아의 제조(반응식 9에 따른 반응)Preparation of 1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea (Scheme 9) According to

29mg의 수소화나트륨(0.71mmol)(광유 중 60% 현탁액)을 초기에 4ml의 무수 디메틸포름아미드에 채웠다. 0℃에서, 70mg의 1-에틸-3-[3-(4-하이드록시-페닐)피리도[2,3-b]피라진-6-일]우레아(0.23mmol)를 첨가하고 2.5ml의 디메틸포름아미드에 용해시켰다. 혼합물을 실온에서 1시간 동안 교반하였다. 후속적으로, 68mg의 1-브로모-2-(2-에톡시메톡시)에탄(0.34mmol)을 0℃에서 첨가하고, 반응 혼합물을 실온에서 17시간 동안 교반하였다. 이후에, 또다른 22mg의 1-브로모-2-(2-에톡시메톡시)에탄(0.12mmol)을 첨가하고, 반응 혼합물을 80℃에서 2시간 동안 교반하였다. 물을 냉각된 반응 혼합물에 첨가하고, 수성 상을 디클로로메탄으로 추출하였다. 유기 상을 황산나트륨 상에서 건조시킨 후, 용매를 제거하고, 조 생성물을 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 황색 고체를 수득하였다.29 mg of sodium hydride (0.71 mmol) (60% suspension in mineral oil) was initially charged in 4 ml of anhydrous dimethylformamide. At 0 ° C., 70 mg of 1-ethyl-3- [3- (4-hydroxy-phenyl) pyrido [2,3-b] pyrazin-6-yl] urea (0.23 mmol) is added and 2.5 ml of dimethyl Dissolved in formamide. The mixture was stirred at rt for 1 h. Subsequently, 68 mg of 1-bromo-2- (2-ethoxymethoxy) ethane (0.34 mmol) was added at 0 ° C. and the reaction mixture was stirred at rt for 17 h. Thereafter, another 22 mg of 1-bromo-2- (2-ethoxymethoxy) ethane (0.12 mmol) was added and the reaction mixture was stirred at 80 ° C. for 2 hours. Water was added to the cooled reaction mixture and the aqueous phase was extracted with dichloromethane. After drying the organic phase over sodium sulfate, the solvent is removed and the crude product is purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

ESI-MS: 실측치 m/z = 412.3 (M + H+); 계산치 411 amuESI-MS: found m / z = 412.3 (M + H + ); Calculated 411 amu

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.26 (s, 3H), 3.29 - 3.38 (m, 2H), 3.48 (dd, 2H), 3.62 (dd, 2H), 3.80 (dd, 2H), 4.22 (dd, 2H), 7.17 (d, 2H), 7.64 (t, 1H), 8.31-8.35 (m, 3H), 9.14 (bs, 1H), 9.42 (s, 1H), 10.09 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.26 (s, 3H), 3.29-3.38 (m, 2H), 3.48 (dd, 2H), 3.62 (dd, 2H), 3.80 (dd, 2H), 4.22 (dd, 2H), 7.17 (d, 2H), 7.64 (t, 1H), 8.31-8.35 (m, 3H), 9.14 (bs, 1H), 9.42 (s, 1H), 10.09 (s, 1H) ppm.

실시예 54:Example 54:

N-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-4-메틸벤즈아미드(화합물 31) N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide (Compound 31)

N-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-4-메틸벤즈아미드의 제조(반응식 7에 따른 반응)Preparation of N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide (reaction according to Scheme 7)

100mg의 1-(3-아미노피리도[2,3-b]피라진-6-일)-3-에틸우레아(0.43mmol)를 초기에 5ml의 무수 피리딘에 채우고, 57㎕의 p-톨릴 클로라이드(0.43mmol)를 적가하였다. 혼합물을 60℃에서 2시간 동안 교반하였다. 이후에, 또다른 29㎕의 p톨릴 클로라이드(0.22mmol)를 적가하고, 반응 혼합물을 60℃에서 추가로 2시간 동안 교반하였다. 냉각된 반응 혼합물을 빙수에 첨가하고, 1N HCl로 중성화시키고, 고체를 흡입하여 여과제거하였다. 조 생성물을 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 황색 고체를 수득하였다. 100 mg of 1- (3-aminopyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.43 mmol) was initially charged in 5 ml of anhydrous pyridine and 57 μl of p-tolyl chloride ( 0.43 mmol) was added dropwise. The mixture was stirred at 60 ° C. for 2 hours. Thereafter, another 29 μl of ptolyl chloride (0.22 mmol) was added dropwise and the reaction mixture was stirred at 60 ° C. for an additional 2 hours. The cooled reaction mixture was added to ice water, neutralized with 1N HCl, and the solids were aspirated off. The crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

ESI-MS: 실측치 m/z = 351.1 (M + H+); 계산치 350 amuESI-MS: found m / z = 351.1 (M + H + ); Calculated 350 amu

1H NMR (d6-DMSO): δ = 1.18 (t, 3H), 2.42 (s, 3H), 3.31 (quint, 2H), 7.37 (d, 2H), 7.55 (d, 1H), 8.04 (d, 2H), 8.31 (d, 1H), 9.10 (bs, 1H), 9.56 (s, 1H), 9.96 (s, 1H), 11.39 (bs, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.18 (t, 3H), 2.42 (s, 3H), 3.31 (quint, 2H), 7.37 (d, 2H), 7.55 (d, 1H), 8.04 (d , 2H), 8.31 (d, 1H), 9.10 (bs, 1H), 9.56 (s, 1H), 9.96 (s, 1H), 11.39 (bs, 1H) ppm.

실시예 55:Example 55:

1-[3-(4-사이클로헥실페닐아미노)피리도[2,3-b]피라진-6-일]-3-에틸우레아(화합물 47)1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Compound 47)

1-[3-(4-사이클로헥실페닐아미노)피리도[2,3-b]피라진-6-일]-3-에틸우레아의 제조(반응식 3에 따른 반응)Preparation of 1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (reaction according to Scheme 3)

83mg의 1-(3-클로로피리도[2,3-b]피라진-6-일)-3-에틸우레아(0.33mmol), 99mg의 4-사이클로헥실아닐린(0.55mmol), 30mg의 나트륨 3급-부톡사이드(0.30mmol), 29mg의 트리스(디벤질리덴아세톤)디팔라듐(0)(0.03mmol) 및 68mg의 2(디사이클로헥실포스파닐)비페닐(0.19mmol)을 초기에 1.5ml의 무수 톨루엔에 충전시켰다. 반응 혼합물을 10℃에 질소하에서 마이크로파(100watt)에서 30분 동안 가열하였다. 용매를 감압하에 제거하고, 조 생성물을 실리카 겔 상 칼럼 크로마토그래피(디클로로메탄/메탄올 용리액)로 정제하였다. 이로서 황색 고체를 수득하였다.83 mg 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.33 mmol), 99 mg 4-cyclohexylaniline (0.55 mmol), 30 mg sodium tertiary Initially 1.5 ml of anhydrous butoxide (0.30 mmol), 29 mg tris (dibenzylideneacetone) dipalladium (0) (0.03 mmol) and 68 mg 2 (dicyclohexylphosphanyl) biphenyl (0.19 mmol) Toluene was charged. The reaction mixture was heated at 10 ° C. under nitrogen in microwave (100 watts) for 30 minutes. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

m.p.: 246-248℃m.p .: 246-248 ° C

ESI-MS: 실측치 m/z = 391.3 (M + H+); 계산치 390 amuESI-MS: found m / z = 391.3 (M + H + ); Calculated 390 amu

1H NMR (d6-DMSO): δ =1.18 (t, 3H), 1.22-1.26 (m, 1H), 1.33-1.44 (m, 4H), 1.71 (d, 1H), 1.80 (d, 4H), 2.45-2.51 (m, 1H), 3.25 - 3.30 (m, 2H), 7.22 (d, 2H), 7.40 (d, 1H), 7.89 (d, 2H), 8.08 (d, 1H), 8.37 (s, 1H), 8.73 (bs, 1H), 9.87 (s, 1H), 10.06 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.18 (t, 3H), 1.22-1.26 (m, 1H), 1.33-1.44 (m, 4H), 1.71 (d, 1H), 1.80 (d, 4H) , 2.45-2.51 (m, 1H), 3.25-3.30 (m, 2H), 7.22 (d, 2H), 7.40 (d, 1H), 7.89 (d, 2H), 8.08 (d, 1H), 8.37 (s , 1H), 8.73 (bs, 1H), 9.87 (s, 1H), 10.06 (s, 1H) ppm.

다음 실시예를 실시예 55 및 일반적인 합성 방법에 따라 합성하였다:The following examples were synthesized according to Example 55 and general synthetic methods:

실시예 56:Example 56:

1-에틸-3-[3-(4-메탄설포닐페닐아미노)피리도[2,3-b]피라진-6-일]우레아(화합물 48)1-ethyl-3- [3- (4-methanesulfonylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 48)

m.p.: 275-280℃m.p .: 275-280 ° C

ESI-MS: 실측치 m/z = 387.3 (M + H+); 계산치 386 amuESI-MS: found m / z = 387.3 (M + H + ); Calc. 386 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 3.19 (s, 3H), 3.25 - 3.38 (m, 2H), 7.54 (d, 1H), 7.92 (d, 2H), 8.16 (d, 1H), 8.24 (d, 2H), 8.49 (s, 1H), 8.62 (bs, 1H), 9.93 (s, 1H), 10.56 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.19 (s, 3H), 3.25-3.38 (m, 2H), 7.54 (d, 1H), 7.92 (d, 2H), 8.16 (d, 1H), 8.24 (d, 2H), 8.49 (s, 1H), 8.62 (bs, 1H), 9.93 (s, 1H), 10.56 (s, 1H) ppm.

실시예 57:Example 57:

N-5-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]-2-메틸페닐(화합물 49)N-5- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -2-methylphenyl (Compound 49)

m.p.: 247-250℃m.p .: 247-250 ° C

ESI-MS: 실측치 m/z = 416.2 (M + H+); 계산치 415 amuESI-MS: found m / z = 416.2 (M + H + ); Calc 415 amu

1H NMR (d6-DMSO): δ =1.17(t, 3H), 2.28 (s, 3H), 3.03 (s, 3H), 3.25 - 3.38 (m, 2H), 7.23 (d, 1H), 7.33 (d, 1H), 7.75 (d, 1H), 8.06-8.09 (m, 2H), 8.37 (s, 1H), 8.92 (bs, 1H), 9.09 (s, 1H), 9.77 (s, 1H), 10.09 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.17 (t, 3H), 2.28 (s, 3H), 3.03 (s, 3H), 3.25-3.38 (m, 2H), 7.23 (d, 1H), 7.33 (d, 1H), 7.75 (d, 1H), 8.06-8.09 (m, 2H), 8.37 (s, 1H), 8.92 (bs, 1H), 9.09 (s, 1H), 9.77 (s, 1H), 10.09 (s, 1H) ppm.

실시예 58:Example 58:

3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]-N-메틸벤즈아미드(화합물 50)3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -N-methylbenzamide (Compound 50)

m.p.: 228-234℃m.p .: 228-234 ° C

ESI-MS: 실측치 m/z = 366.4 (M + H+); 계산치 365 amuESI-MS: found m / z = 366.4 (M + H + ); Calculated 365 amu

1H NMR (d6-DMSO): δ = 1.19 (t, 3H), 2.80 (d, 3H), 3.25 - 3.38 (m, 2H), 7.39-7.48 (m, 3H), 8.09 - 8.11 (m, 2H), 8.41 (s, 2H), 8.46 (s, 1H), 8.83 (bs, 1H), 9.86 (s, 1H), 10.22 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.19 (t, 3H), 2.80 (d, 3H), 3.25-3.38 (m, 2H), 7.39-7.48 (m, 3H), 8.09-8.11 (m, 2H), 8.41 (s, 2H), 8.46 (s, 1H), 8.83 (bs, 1H), 9.86 (s, 1H), 10.22 (s, 1H) ppm.

실시예 59:Example 59:

1-에틸-3-[3-(4-피페리딘-1-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아(화합물 51)1-ethyl-3- [3- (4-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 51)

m.p.: 221-224℃ m.p .: 221-224 ° C

ESI-MS: 실측치 m/z = 406.4 (M + H+); 계산치 405 amuESI-MS: found m / z = 406.4 (M + H + ); Calc. 405 amu

1H NMR (d6-DMSO): δ =1.19 (t, 3H), 1.39 (bs, 2H), 1.49 (quint, 4H), 2.32 (bs, 4H), 3.25 3.35 (m, 2H), 3.39 (s, 2H), 7.27 (d, 2H), 7.39 (d, 1H), 7.92 (d, 2H), 8.08 (d, 1H), 8.38 (s, 1H), 8.78 (bs, 1H), 9.82 (s, 1H), 10.05 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.19 (t, 3H), 1.39 (bs, 2H), 1.49 (quint, 4H), 2.32 (bs, 4H), 3.25 3.35 (m, 2H), 3.39 ( s, 2H), 7.27 (d, 2H), 7.39 (d, 1H), 7.92 (d, 2H), 8.08 (d, 1H), 8.38 (s, 1H), 8.78 (bs, 1H), 9.82 (s , 1H), 10.05 (s, 1H) ppm.

실시예 60:Example 60:

1-에틸-3-[3-(4-티오펜-3-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아(화합물 52) 1-ethyl-3- [3- (4-thiophen-3-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 52)

m.p.: 264-267℃m.p .: 264-267 ℃

ESI-MS: 실측치 m/z = 391.4 (M + H+); 계산치 390 amuESI-MS: found m / z = 391.4 (M + H + ); Calculated 390 amu

1H NMR (d6-DMSO): δ =1.21 (t, 3H), 3.25 - 3.35 (m, 2H), 7.47 (d, 1H), 7.58 (d, 1H), 7.65 (dd, 1H), 7.74 (d, 2H), 7.82 (d, 1H), 8.05 (d, 2H), 8.11 (d, 1H), 8.42 (s, 1H), 8.62 (bs, 1H), 9.86 (s, 1H), 10.18 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.21 (t, 3H), 3.25-3.35 (m, 2H), 7.47 (d, 1H), 7.58 (d, 1H), 7.65 (dd, 1H), 7.74 (d, 2H), 7.82 (d, 1H), 8.05 (d, 2H), 8.11 (d, 1H), 8.42 (s, 1H), 8.62 (bs, 1H), 9.86 (s, 1H), 10.18 ( s, 1H) ppm.

실시예 61:Example 61:

N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]페닐}아세트아미드(화합물 53) N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] phenyl} acetamide (Compound 53)

ESI-MS: 실측치 m/z = 366.2 (M + H+); 계산치 365 amuESI-MS: found m / z = 366.2 (M + H + ); Calculated 365 amu

1H NMR (d6-DMSO): δ =1.20 (t, 3H), 2.03 (s, 3H), 3.25 - 3.35 (m, 2H), 7.27 (d, 1H), 7.34 (d, 2H), 7.57 (d, 2H), 7.90 (d, 1H), 8.07 (d, 1H), 8.94 (bs, 1H), 9.79 (s, 1H), 9.89 (s, 1H), 10.03 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.03 (s, 3H), 3.25-3.35 (m, 2H), 7.27 (d, 1H), 7.34 (d, 2H), 7.57 (d, 2H), 7.90 (d, 1H), 8.07 (d, 1H), 8.94 (bs, 1H), 9.79 (s, 1H), 9.89 (s, 1H), 10.03 (s, 1H) ppm.

실시예 62:Example 62:

에틸 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]벤조에이트(화합물 54) Ethyl 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] benzoate (compound 54)

m.p.: 252-255℃m.p .: 252-255 ° C

ESI-MS: 실측치 m/z = 381.3 (M + H+); 계산치 380 amuESI-MS: found m / z = 381.3 (M + H + ); 380 amu

1H NMR (d6-DMSO): δ =1.19 (t, 3H), 1.35 (t, 3H), 3.25 - 3.35 (m, 2H), 4.35 (q, 2H), 7.40 (d, 1H), 7.52 (t, 1H), 7.64 (d, 1H), 8.12 (d, 1H), 8.29 (d, 1H), 8.41 (s, 1H), 8.62 (s, 1H), 8.90 (bs, 1H), 9.86 (s, 1H), 10.31 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.19 (t, 3H), 1.35 (t, 3H), 3.25-3.35 (m, 2H), 4.35 (q, 2H), 7.40 (d, 1H), 7.52 (t, 1H), 7.64 (d, 1H), 8.12 (d, 1H), 8.29 (d, 1H), 8.41 (s, 1H), 8.62 (s, 1H), 8.90 (bs, 1H), 9.86 ( s, 1 H), 10.31 (s, 1 H) ppm.

실시예 63:Example 63:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트 하이드로클로라이드(화합물 55) 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride (Compound 55)

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트 하이드로클로라이드의 제조Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride

21mg의 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트(0.05mmol)(실시예 10)를 2.5ml의 디클로로메탄/메탄올(2:1)에 용해시켰다. 2-프로판올 중 0.02ml의 5-6N HCl 용액을 첨가하고, 혼합물을 실온에서 1일 동안 교반하였다. 이어서, 용매를 제거하였다. 이로서 황색 고체를 수득하였다.21 mg of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate (0.05 mmol) (Example 10) in 2.5 ml of dichloromethane Dissolved in methanol (2: 1). 0.02 ml of 5-6N HCl solution in 2-propanol was added and the mixture was stirred at room temperature for 1 day. The solvent was then removed. This gave a yellow solid.

m.p.: 190-193℃m.p .: 190-193 ° C

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.31 3.35 (m, 5H), 3.63-3.66 (m, 2H), 4.37 (dd, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.31 3.35 (m, 5H), 3.63-3.66 (m, 2H), 4.37 (dd, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm.

실시예 64:Example 64:

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트 p-톨루엔설포네이트(화합물 56) 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate p-toluenesulfonate (Compound 56)

4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이 트 p-톨루엔설포네이트의 제조Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate p-toluenesulfonate

48mg의 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트(0.12mmol)를 초기에 4ml의 디클로로메탄 및 0.7ml의 메탄올에 채웠다. 23mg의 p-톨루엔설폰산 일수화물(0.12mmol)을 실온에서 첨가하고, 2ml의 디클로로메탄 및 0.5ml의 메탄올에 용해시켰다. 반응 혼합물을 0℃에서 1시간 동안 교반하고, 실온에서 1일 동안 교반하였다. 용매를 제거하고, 잔사 디클로로메탄/n-헵탄으로부터 재결정화하였다. 침전된 생성물을 흡입하에 여과제거하고, n-헵탄으로 세척하였다. 이로서 황색 고체를 수득하였다.48 mg of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate (0.12 mmol) were initially added with 4 ml of dichloromethane and 0.7 ml Filled with methanol. 23 mg of p-toluenesulfonic acid monohydrate (0.12 mmol) was added at room temperature and dissolved in 2 ml of dichloromethane and 0.5 ml of methanol. The reaction mixture was stirred at 0 ° C. for 1 hour and at room temperature for 1 day. Solvent was removed and recrystallized from residue dichloromethane / n-heptane. The precipitated product was filtered off under suction and washed with n-heptane. This gave a yellow solid.

m.p.: 145-147℃m.p .: 145-147 ° C

1H NMR (d6-DMSO): δ = 1.20 (t, 3H), 2.29 (s, 3H), 3.30 3.36 (m, 5H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.11 (d, 2H), 7.47 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.29 (s, 3H), 3.30 3.36 (m, 5H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.11 ( d, 2H), 7.47 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s , 1H), 10.14 (s, 1H) ppm.

실시예 65:Example 65:

4-{6-[3-(4-하이드록시부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트 하이드로클로라이드(화합물 58) 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride (Compound 58)

4-{6-[3-(4-하이드록시부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트 하이드로클로라이드의 제조Preparation of 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride

117mg의 4-6-[3-(4-(3급-부틸디메틸실라닐옥시)부틸)우레아]피리도[2,3-b]피 라진-3-일-페닐 2-메톡시에틸 카보네이트(0.21mmol)를 40ml의 미리건조된 디클로로메탄에 용해시켰다. 2-프로판올 중 0.5ml의 5-6N HCl 용액을 첨가하고, 반응 혼합물을 실온에서 15분 동안 교반하였다. 유기 상을 물로 세척하고, 황산나트륨 상에서 건조시키고 농축시켰다. 이로서 황색 고체를 수득하였다. 117 mg of 4-6- [3- (4- (tert-butyldimethylsilanyloxy) butyl) urea] pyrido [2,3-b] pyrazin-3-yl-phenyl 2-methoxyethyl carbonate ( 0.21 mmol) was dissolved in 40 ml of pre-dried dichloromethane. 0.5 ml of 5-6N HCl solution in 2-propanol was added and the reaction mixture was stirred at room temperature for 15 minutes. The organic phase was washed with water, dried over sodium sulphate and concentrated. This gave a yellow solid.

m.p.: 165-168℃m.p .: 165-168 ° C.

ESI-MS: 실측치 m/z = 456.2 (M + H+); 계산치 455 amuESI-MS: found m / z = 456.2 (M + H + ); 455 amu

1H NMR (d6-DMSO): δ =1.61 (quint, 4H), 2.29 (s, 3H), 3.30 - 3.36 (m, 2H), 3.49 (t, 2H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.49 (d, 2H), 7.66 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.33 (bs, 1H), 9.48 (s, 1H), 10.17 (s, 1H)ppm. 1 H NMR (d 6 -DMSO): δ = 1.61 (quint, 4H), 2.29 (s, 3H), 3.30-3.36 (m, 2H), 3.49 (t, 2H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.49 (d, 2H), 7.66 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.33 (bs, 1H), 9.48 (s, 1H), 10.17 ( s, 1 H) ppm.

4-{6-[3-(4-(3급-부틸디메틸실라닐옥시)부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트의 제조를 위해, 반응식 5, 6 및 8, 일반적인 합성 방법 및 당해 기술분야의 숙련가들에게 공지된 방법을 참조하였다.Preparation of 4- {6- [3- (4- (tert-butyldimethylsilanyloxy) butyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate For reference, see Schemes 5, 6 and 8, general synthetic methods and methods known to those skilled in the art.

실시예 66:Example 66:

2,2-디메틸프로피오닐옥시메톡시-(4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스피노일옥시메틸 2,2-디메틸프로피오네이트(화합물 65)2,2-dimethylpropionyloxymethoxy- (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl Phosinoyloxymethyl 2,2-dimethylpropionate (Compound 65)

2,2-디메틸프로피오닐옥시메톡시-(4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스피노일옥시메틸 2,2-디메틸프로피오네이트의 제조2,2-dimethylpropionyloxymethoxy- (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl Preparation of phosphinoyloxymethyl 2,2-dimethylpropionate

94mg의 4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스포산(0.20mmol)을 15ml의 DMF에 용해시키고, 360㎕의 클로로메틸 피발레이트(2.40mmol) 및 30㎕의 트리에틸아민(0.21mmol)과 혼합하고, 60℃에서 10시간 동안 교반하였다. 혼합물을 50ml의 물에 붓고, 에틸 아세테이트로 3회 추출하였다. 합한 유기 상을 MgSO4 상에서 건조시키고, 용매를 감압하에 제거하였다. 잔사를 후속적으로 칼럼 크로마토그래피(용리액: 디클로로메탄/메탄올)로 정제하였다. 베이지색 고체를 분리하였다. 15 ml of 94 mg 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphonic acid (0.20 mmol) It was dissolved in DMF, mixed with 360 μl of chloromethyl pivalate (2.40 mmol) and 30 μl triethylamine (0.21 mmol) and stirred at 60 ° C. for 10 hours. The mixture was poured into 50 ml of water and extracted three times with ethyl acetate. The combined organic phases were dried over MgSO 4 and the solvent was removed under reduced pressure. The residue was subsequently purified by column chromatography (eluent: dichloromethane / methanol). Beige solid was separated.

ESI-MS: 실측치 m/z = 676.4 (M + H+); 계산치 675 amuESI-MS: found m / z = 676.4 (M + H + ); Calculated 675 amu

1H NMR (d6-DMSO): δ =1.12 (s, 18H), 1.57-1.68 (m, 4H), 1.90-1.97 (m, 2H), 3.28-3.31 (m, 3.93 (s, 3H), 5.54-5.59 (m, 4H), 6.97 (d, 1H), 7.64 (d, 1H), 7.86 (dd, 1H), 7.91 (d, 1H), 8.32 (d, 1H), 9.08 (s, 1H), 9.41 (s, 1H), 9.70 (s, 1H), 10.06 (s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.12 (s, 18H), 1.57-1.68 (m, 4H), 1.90-1.97 (m, 2H), 3.28-3.31 (m, 3.93 (s, 3H), 5.54-5.59 (m, 4H), 6.97 (d, 1H), 7.64 (d, 1H), 7.86 (dd, 1H), 7.91 (d, 1H), 8.32 (d, 1H), 9.08 (s, 1H) , 9.41 (s, 1 H), 9.70 (s, 1 H), 10.06 (s, 1 H) ppm.

II) 본 발명의 화합물의 생물학적 효과 II) Biological Effects of Compounds of the Invention

II.1) 세포-비함유 키나제 검정(ALPHA 기술을 사용)II.1) Cell-Free Kinase Assay (Using ALPHA Technology)

본 발명의 화합물의 억제 효과를 다양한 사람 세린/트레오닌 키나제, 티로신 키나제 및 지질 키나제에서 효소적 검정으로 시험하였다. 재조합 사람 키나제, 예를 들면, Erk2, PI3K알파, -베타, -감마, -델타, p38알파, p38감마, Jnk1, Jnk2 및 다른 것들을 몇몇의 경우 완전한-길이 키나제로서, 몇몇의 경우 결절된 단변으로서 사용하지만, 이는 적어도 작용성 키나제 도메인으로 이루어진다. 시판되는 키나제 단백질(Proqinase, Upstate)을 GST(글루타티온 S-트랜스퍼라제) 태그 또는 His 태그를 갖는 재조합 융합 단백질로서 사용하였다. 기질 형태에 의존하여, 상이한 키나제 반응은 적합한 ALPHATM 비드(PerkinElmer)를 통해 정량화된다. Inhibitory effects of the compounds of the invention were tested in enzymatic assays in various human serine / threonine kinases, tyrosine kinases and lipid kinases. Recombinant human kinases, such as Erk2, PI3Kalpha, -beta, -gamma, -delta, p38alpha, p38gamma, Jnk1, Jnk2 and others in some cases as full-length kinases, in some cases as nodular short sides Although used, it consists of at least a functional kinase domain. Commercial kinase proteins (Proqinase, Upstate) were used as recombinant fusion proteins with a GST (glutathione S-transferase) tag or His tag. Depending on the substrate morphology, different kinase reactions are quantified through suitable ALPHA beads (PerkinElmer).

시험exam

Erk 검정에서 기질 시험은 하기에 상세하게 기재된다. Erk2, PI3K알파 검정의 선택된 시험 결과는 하기에 인용된다. IC50 값을 측정하기 위해, 잠재적 억제제 물질을 10 하프-대수적 등급화 농도 3.16nM-100nM에서 연구된다.Substrate testing in the Erk assay is described in detail below. Selected test results of the Erk2, PI3Kalpha assay are cited below. To determine IC 50 values, potential inhibitor substances are studied at 10 half-logarithm grading concentrations of 3.16 nM-100 nM.

a) Erk2-ALPHA: 시험 물질, 0.625ng의 Erk2(#14-173, Upstate), 10μM ATP 및 15nM 바이오티닐화 MBP(마이엘린 염기성 단백질) 기질을 384-웰 옵티플레이트(Perkin Elmer)에서 15㎕의 용적으로 1시간 동안 25mM Tris, 10mM MgCl2, 0.1% Tween-20, 100μM NaVO4, 2mM DTT에서 pH 7.5에서 항온처리하였다. 이어서, 키나제 반응을 10㎕의 ALPHA 비드 믹스(10g/ml, #6760617/ PerkinElmer)를 가하여 정지시키고, 항-포스포 MBP 항체(320#05-429/ Upstate)로, 25mM Tris, 200mM NaCl, 100mM EDTA 및 0.3% BSA에서 예비-항온처리하고, 밤새 정치시켰다.a) Erk2-ALPHA: 15 μl of test substance, 0.625 ng of Erk2 (# 14-173, Upstate), 10 μM ATP and 15 nM biotinylated MBP (myelin basic protein) substrate in 384-well Optiplate (Perkin Elmer) Was incubated at pH 7.5 in 25 mM Tris, 10 mM MgCl 2 , 0.1% Tween-20, 100 μM NaVO 4 , 2 mM DTT for 1 h. The kinase reaction was then stopped by addition of 10 μl of ALPHA Bead Mix (10 g / ml, # 6760617 / PerkinElmer) and, with anti-phospho MBP antibody (320 # 05-429 / Upstate), 25 mM Tris, 200 mM NaCl, 100 mM Pre-incubated in EDTA and 0.3% BSA and left overnight.

b) PI3K-ALPHA(예를 들면, PI3K알파): 시험 물질, 1ng의 PI3K알파(#14-602, Upstate), 100μM ATP 및 20μM PIP2 기질(#P4508, Echelon)을 384-웰 옵티플레이트(Perkin Elmer)에서 1시간 동안 50mM Hepes, 50mM NaCl, 5mM MgCl2, 0.05% Chaps, 5mM DTT에서 pH 7.4에서 항온처리하였다. 후속적으로, 키나제 반응을 ALPHA 비드 믹스(10 g/ml, #6760603/ PerkinElmer를 가하여 정지시키고, 1nM GST:Grp1 융합 단백질(Upstate) 및 15nM 바이오티닐화 PIP3(#C-39B6/ Echelon)으로 50mM Hepes, 50mM NaCl, 50mM EDTA 및 0.1% BSA에서 예비-항온처리하고, 밤새 정치시켰다.b) PI3K-ALPHA (e.g., PI3Kalpha): test material, 1 ng of PI3Kalpha (# 14-602, Upstate), 100μM ATP and 20μM PIP 2 substrate (# P4508, Echelon) using a 384-well optiplate ( Perkin Elmer) was incubated for 1 hour at pH 7.4 in 50 mM Hepes, 50 mM NaCl, 5 mM MgCl 2 , 0.05% Chaps, 5 mM DTT. Subsequently, the kinase reaction was stopped by addition of ALPHA bead mix (10 g / ml, # 6760603 / PerkinElmer) and 50 mM with 1 nM GST: Grp1 fusion protein (Upstate) and 15 nM biotinylated PIP3 (# C-39B6 / Echelon). Pre-incubated in Hepes, 50 mM NaCl, 50 mM EDTA and 0.1% BSA and left overnight.

형광성은 FusionTM ALPHA 장치(Perkin Elmer)로 다음날 아침 측정한다.Fluorescence is measured in the morning Fusion TM ALPHA apparatus (Perkin Elmer).

평가evaluation

물질 농도당 억제율(%) 값의 계산은 FusionTM ALPHA에서 측정한 원래 데이타 값으로부터 다음 공식으로 수행된다:The calculation of% inhibition values per substance concentration is carried out in the following formula from the original data values measured in Fusion TM ALPHA:

Figure 112008041801646-PCT00101
Figure 112008041801646-PCT00101

대조군을 8회로 각각 측정하고, 물질 샘플을 각각 2회 측정된다. 0% 대조군은 ATP 또는 기질을 함유하지 않고; 100% 대조군은 시험 물질을 함유하지 않는다. IC50 값은 GraphPadPrism으로 측정한다.Controls are measured 8 times each and material samples are measured 2 times each. 0% control does not contain ATP or substrate; 100% control does not contain test substance. IC 50 values are measured with GraphPadPrism.

본 발명의 화합물은 88nM 이하의 IC50 값으로 Erk, PI3K, p38알파 및 Jnk1 + Jnk2의 효과적인 억제를 나타냈다(참조 표 1).Compounds of the present invention showed effective inhibition of Erk, PI3K, p38alpha and Jnk1 + Jnk2 with IC 50 values of 88 nM or less (see Table 1).

Figure 112008041801646-PCT00102
Figure 112008041801646-PCT00102

II.2) 세포 검정: 항증식성 작용에 대한 검정(XTT 검정)II.2) Cell Assay: Assay for Antiproliferative Action (XTT Assay)

당해 시험의 원리는 사립체 데하이드로게나제에 의한 테트라졸리움 염료 XTT(나트륨 3'-1-(페닐아미노카보닐)-3,4-테트라졸리움비스(4-메톡시-6-니트로)벤젠설폰산, Sigma)의 포르마잔 염료로의 세포내 감소를 기초로 한다. 염료는 단지 대사적으로 활성 세포에 의해 형성되고; 이의 광도측정가능한 강도는 살아있는 세포의 존재를 나타내는 정량적인 표시자이다. 물질을 사용한 세포의 항온처리 결과로서 염료 형성에서 감소는 항증식성 작용에 대한 파라미터로서 역할을 한다. The principle of this test is that tetrazolium dye XTT (sodium 3'-1- (phenylaminocarbonyl) -3,4-tetrazolium bis (4-methoxy-6-nitro) benzenesulfonic acid by particulate dehydrogenase , Sigma) is based on intracellular reduction to formazan dye. Dyes are only formed metabolically by active cells; Its photometric intensity is a quantitative indicator of the presence of living cells. The reduction in dye formation as a result of incubation of cells with the substance serves as a parameter for antiproliferative action.

시험exam

종양 세포주(ATCC)를 96-웰 마이크로티터 플레이트에 한정된 세포 계수로 시딩하고(5000개 세포/웰, BxPC3 및 Hct116의 경우; 10000 세포/웰, MDA MB468의 경우), 이어서, 밤새 인큐베이터에서 37℃, 5% CO2 및 95% 공기 습도에서 항온처리하였다. 시험 물질은 DMSO 중 원료 용액(10 mM)으로 이루어진다. EC50 값을 측정하기 위해, 잠재적 억제제 물질을 세포에 4회(quater)-대수적 등급 희석으로 첨가하여 최종 농도 0.28μM-50μM으로 한다. 이어서, 세포 플레이트를 45시간 동안 인큐베이터에서 37℃, 5% CO2 및 95% 공기 습도에서 항온처리하였다. Tumor cell lines (ATCC) are seeded with defined cell counts in 96-well microtiter plates (5000 cells / well, for BxPC3 and Hct116; 10000 cells / well, for MDA MB468) and then 37 ° C. in an incubator overnight. Incubated at 5% CO 2 and 95% air humidity. The test substance consists of a raw material solution (10 mM) in DMSO. To determine EC50 values, potential inhibitor substances are added to the cells in quad- logarithmic grade dilutions to a final concentration of 0.28 μM-50 μM. Cell plates were then incubated at 37 ° C., 5% CO 2 and 95% air humidity in incubator for 45 hours.

검출 반응을 위해, XTT 기질을 PMS(N-메틸디벤조피라진 메틸설페이트, Sigma)와 혼합하고, 세포로 첨가하고, 최종 농도 325μg의 XTT/ml 및 2.5μg PMS/ml를 야기한다. 이어서, 혼합물을 3시간 동안 37℃에서, 95% 공기 습도에서 항온처리하였다. 후속적으로 세포 데하이드로게나제에 의해 형성된 포르마잔 염을 490nm 흡광도에서 정량화하였다. For the detection reaction, the XTT substrate is mixed with PMS (N-methyldibenzopyrazine methylsulfate, Sigma) and added into the cells, resulting in XTT / ml and 2.5 μg PMS / ml at a final concentration of 325 μg. The mixture was then incubated for 3 hours at 37 ° C., 95% air humidity. Subsequently the formazan salt formed by cellular dehydrogenase was quantified at 490 nm absorbance.

평가evaluation

억제율(%) 값의 평가는 각각의 경우 490nm에서 측정한 광학 밀도의 값으로부터 다음 공식으로 수행된다:Evaluation of% inhibition values is in each case carried out by the following formula from the value of optical density measured at 490 nm:

Figure 112008041801646-PCT00103
Figure 112008041801646-PCT00103

대조군을 8회로 각각 측정하고, 물질 샘플을 각각 2회 측정된다. 0% 대조군은 세포를 함유하지 않고; 100% 대조군은 시험 물질을 함유하지 않는다. EC50 값은 GraphPadPrism으로 측정한다.Controls are measured 8 times each and material samples are measured 2 times each. 0% control does not contain cells; 100% control does not contain test substance. EC50 values are measured with GraphPadPrism.

본 발명의 화합물은 2.2μM 이하의 EC50 값으로 세포 증식의 효과적인 억제를 나타냈다(참조 표 2).Compounds of the present invention showed effective inhibition of cell proliferation with EC50 values of 2.2 μM or less (see Table 2).

Figure 112008041801646-PCT00104
Figure 112008041801646-PCT00104

II.3) 세포 검정: 기질 억제에 대한 시험(웨스턴 블롯팅)II.3) Cell Assay: Test for Substrate Inhibition (Western Blotting)

당해 방법으로 연구되는 키나제 조절제가 세포 배경에서 또한 목적하는 효과를 성취하는지 설명할 수 있고, 즉, 이러한 경우, 표적 키나제의 기질 단백질 다운스트림을 이의 포스포릴화 상태를 위해 시험하였다. 마지막에, 물질로 항온처리된 세포를 용해시키고, 전체 단백질을 감소된 폴리아크릴아미드 겔에서 분리된다. 후속적으로, 단백질을 웨스턴 블롯팅으로 PVDF 막으로 이동시키고, 모색된 기질 밴드를 특이 항체 및 적합한 검출 방법으로 가시화하였다. 표적 키나제의 기질 단백질 다운스트림은 항-포스포 항체로 동시에 검출되고, 이는 각각의 경우 특이적이고, 동시에 기질 전체 단백질을 인지하는 전체 항체이다. ODYSSEY 영상(LiCOR)의 이중 기술은 이러한 동시 측정을 가능하게 한다. 전체 기질 밴드의 강도는 포스포릴화 억제 또는 활성화를 정규화하고 정량화하는데 사용된다. It can be explained whether the kinase modulators studied by this method also achieve the desired effect in the cell background, ie in this case, the substrate protein downstream of the target kinase was tested for its phosphorylation state. Finally, the cells incubated with the material are lysed and the whole protein is separated on the reduced polyacrylamide gel. Subsequently, the proteins were transferred to PVDF membrane by western blotting and the sought substrate bands were visualized with specific antibodies and suitable detection methods. Substrate protein downstream of the target kinase is detected simultaneously with an anti-phospho antibody, which is the specific antibody in each case and at the same time a total antibody that recognizes the substrate whole protein. The dual technique of ODYSSEY imaging (LiCOR) makes this simultaneous measurement possible. The intensity of the entire substrate band is used to normalize and quantify phosphorylation inhibition or activation.

시험exam

적합한 종양 세포주(예를 들면, BxPC3, Hct116 또는 MDA MB468)를 6마이크로티터 플레이트로 한정된 세포 계수(예를 들면, 350 000세포/웰, BxPC3 및 Hct116에 대해)로 특정한 표준 완성된 배치에서 시딩하고, 이어서, 밤새 인큐베이터에서 37℃, 5% CO2 및 95% 공기 습도에서 항온처리하였다. 이어서, 세포를 추가로 24시간 동안 감소된 혈청 조건에서 항온처리하였고, 즉, 특정한 배지에서 단지 0.25% 혈청인 것을 예외로 한다. 시험 물질은 DMSO 중 원료 용액(10mM)으로 이루어지고, 세포로 최종 농도 5, 15.8 및 50μM에서 5시간 동안 항온처리하였다. 이어서, 25mM Tris, 150mM NaCl, 10mM 나트륨 피로포스페이트, 2mM EGTA, 25mM 베타-글리세로포스페이트, 25mM NaF, 10% 글리세롤, 0.75% NP-40, 100μM NaVO4 완충액에 세포를 용해시켰다. BCA(비신콘산 단백질 검정 키트, Sigma) 검정을 통해 단백질을 정량화 한 후, 트랙 하나당 약 20g의 단백질의 양을 램밀리 폴리아크릴아미드 겔에서 분리하고, 이어서, PVDF 막(Millipore)으로 반건조 웨스턴 블롯팅으로 0.8mA/㎤에서 21시간 동안 이동시켰다. 이를 1시간 동안 I-블록 시약(Applied Biosystems)으로 막을 예비부합화하고, 특이 항체로 밤새 항온처리하였다. Erk 및 PI3K 억제를 측정하기 위해, 다음 기질 Rsk1 다운스트림을 전체 항체(Rsk #sc-231g C-21, Santa Cruz), 포스포 항체(Phospho-p90RSK (S380) #9341, NEB Cell Signalling) 및 전체 항체를 갖는 Akt(Akt1 #sc-1618 C-20, Santa Cruz) 및 포스포 항체(Phospho-Akt (Ser 473) #9271, NEB Cell Signaling)로 검출하였다. 막을 세정한 후, 제2 항체를 포스포 항체에 대해서 항-토끼 IR 염료 800(#611-732-127, Rockland)와 전체 단백질 항체에 대해 항-염소 Alexa Fluor 680(#A-21081, Molecular samples)과 함께 항온처리하였다. 30분 동안 실온에서 암실에서 항온처리 후, 검출 항체의 부합화를 막에서 ODYSSEY 영상(LiCOR)에서 스캐닝하여 검출하였다.Suitable tumor cell lines (e.g. BxPC3, Hct116 or MDA MB468) are seeded in specific standard finished batches with cell counts (e.g. for 350 000 cells / well, BxPC3 and Hct116) defined as 6 microtiter plates. Then, it was incubated overnight at 37 ° C., 5% CO 2 and 95% air humidity in an incubator. Cells were then incubated for an additional 24 hours in reduced serum conditions, ie only 0.25% serum in certain media. The test material consisted of a stock solution in DMSO (10 mM) and the cells were incubated for 5 hours at final concentrations of 5, 15.8 and 50 μM. Cells were then lysed in 25 mM Tris, 150 mM NaCl, 10 mM sodium pyrophosphate, 2 mM EGTA, 25 mM beta-glycerophosphate, 25 mM NaF, 10% glycerol, 0.75% NP-40, 100 μM NaVO 4 buffer. After quantifying the protein via a BCA (Bincinconic Acid Protein Assay Kit, Sigma) assay, an amount of about 20 g of protein per track is separated from the rammyli polyacrylamide gel and then semi-dried Western blot with PVDF membrane (Millipore). The loting was run at 0.8 mA / cm 3 for 21 hours. This was pre-compounded with I-block reagent (Applied Biosystems) for 1 hour and incubated overnight with specific antibody. To determine Erk and PI3K inhibition, the following substrate Rsk1 downstream was analyzed with whole antibody (Rsk # sc-231g C-21, Santa Cruz), phospho antibody (Phospho-p90RSK (S380) # 9341, NEB Cell Signaling) and whole. The antibody was detected with Akt (Akt1 # sc-1618 C-20, Santa Cruz) and phospho antibody (Phospho-Akt (Ser 473) # 9271, NEB Cell Signaling). After washing the membrane, the second antibody was anti-rabbit IR dye 800 (# 611-732-127, Rockland) for the phospho antibody and anti-chlorine Alexa Fluor 680 (# A-21081, Molecular samples for the whole protein antibody). Incubated with). After incubation in the dark at room temperature for 30 minutes, the matching of the detection antibodies was detected by scanning on ODYSSEY images (LiCOR) in the membrane.

평가evaluation

5-50μM의 농도에서, 본 발명의 화합물은 Erk(MAPK1/2) 및 PI3K(표 3)의 이중 억제를 나타내고, 이는 2개의 상응하는 포스포-기질 단백질 Rsk1 및 Akt의 밴드 강도의 억제에 의해 나타난다. At concentrations of 5-50 μM, the compounds of the present invention exhibit double inhibition of Erk (MAPK1 / 2) and PI3K (Table 3), which is by inhibition of the band intensities of two corresponding phospho-substrate proteins Rsk1 and Akt appear.

Figure 112008041801646-PCT00105
Figure 112008041801646-PCT00105

약어 Abbreviation

Akt from: 쥐 Akt8 레트로바이러스 또는 단백질 키나제 B (PKB)Akt from: murine Akt8 retrovirus or protein kinase B (PKB)

Ask1 아폽토시스 신호-조절 키나제Ask1 Apoptosis Signal-regulating Kinase

ATR 모세혈관확장성조화운동불능 및 Rad3-관련ATR capillary dysregulation and Rad3-related

ATM 모세혈관확장성조화운동불능 돌연변이 ATM capillary dysregulation mutation

Bag1 Bcl-2 관련 아타노겐(athanogene)-1Bag1 Bcl-2 related atanogen-1

Bcl-2 B-세포 백혈병/림프종-2 유전자Bcl-2 B-cell leukemia / lymphoma-2 gene

DNA-PK DNA-의존 단백질 키나제DNA-PK DNA-dependent Protein Kinase

Erk 세포외 신호-조절 키나제Erk Extracellular Signal-regulated Kinase

Flt-3 fms 유사 티로신 키나제 3Flt-3 fms pseudotyrosine kinase 3

GSK-3 글리코겐 신타제 키나제-3GSK-3 glycogen synthase kinase-3

hSMG-1 7개 선충류 유전자-1의 산물의 사람 오르토로그 Human ortholog of the product of hSMG-1 seven nematode gene-1

JAK-3 Janus 키나제 3JAK-3 Janus Kinase 3

JNK c-jun N-말단 키나제JNK c-jun N-terminal kinase

MAPK 미토겐 활성화된 단백질 키나제MAPK Mitogen Activated Protein Kinase

Mek MAP 또는 Erk 키나제Mek MAP or Erk Kinase

mTOR 라파마이신의 포유동물 표적 Mammalian Target of mTOR Rapamycin

PDGFR 혈소판 유도된 성장 인자 수용체PDGFR Platelet-Induced Growth Factor Receptor

PI3K 포스포이니시톨 3-키나제PI3K Phosphoinisitol 3-kinase

PIKK 포스포이니시톨 3-키나제 관련 키나제PIKK Phosphoiniditol 3-kinase Related Kinases

PIP2 포스파티딜이니시톨 비포스페이트PIP2 Phosphatidyl Inisitol Biphosphate

PIP3 포스파티딜이니시톨 트리포스페이트PIP3 Phosphatidyl Innisitol Triphosphate

PtdIns 포스파티딜이니시톨 PtdIns Phosphatidyl Inisitol

Raf 신속한 가속화된 섬유육종Raf Rapid Accelerated Fibrosarcoma

Ras 래트 육종Ras Rat Sarcoma

RTK 수용체 티로신 키나제RTK Receptor Tyrosine Kinase

SAPK 스트레스-활성화된 단백질 키나제SAPK Stress-activated Protein Kinase

Ser 세린Ser Serine

Syk 비장 티로신 키나제Syk Spleen Tyrosine Kinase

Thr 트레오닌Thr threonine

Tyr 티로신Tyr tyrosine

VEGFR 혈관내피 성장인자 수용체VEGFR Vascular Endothelial Growth Factor Receptor

Claims (60)

화학식 I의 신규한 피리도[2,3-b]피라진 유도체.Novel pyrido [2,3-b] pyrazine derivatives of formula (I). 화학식 IFormula I
Figure 112008041801646-PCT00106
Figure 112008041801646-PCT00106
상기 화학식 I에서, In Formula I, (A) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:(A) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted aryl" wherein "substituted aryl" is substituted by one or more substituents identically or differently selected from the group consisting of: : (a) "알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, NHX1, N(알킬)2, NHC(O)알킬, NHC(O)사이클로알킬, NHC(O)헤테로사이클릴, NHC(O)아릴, NHC(O)헤테로아릴, NHC(O)아릴알킬, NHC(O)헤테로아릴알킬, NHS(O2)알킬, NHS(O2)사이클로알킬, NHS(O2)헤테로사이클릴, NHS(O2)아릴, NHS(O2)헤테로아릴, NHS(O2)아릴알킬, NHS(O2)헤테로아릴알킬, S알킬, S아릴, S헤테로아릴, OX2, OC(O)알킬, OC(O)사이클로알킬, OC(O)헤테로사이클릴, OC(O)아릴, OC(O)헤테로아릴, OC(O)아릴알킬, OC(O)헤테로아릴알킬, OS(O2)알킬, OS(O2)사이클로알킬, OS(O2)헤테로사이클릴, OS(O2)아릴, OS(O2)헤테로아릴, OS(O2)아릴알킬, OS(O2)헤테로아릴알킬, C(O)알킬, C(O)아 릴, C(O)헤테로아릴, C(O)OX3, C(O)NHX4, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, S(O)알킬, S(O)아릴, S(O2)알킬, S(O2)아릴, S(O2)NH알킬, S(O2)NH아릴, S(O2)NH헤테로아릴, S(O2)NH아릴알킬, S(O2)O알킬, S(O2)O아릴, S(O2)O아릴알킬"(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, NHX1, N (alkyl) 2 , NHC (O) alkyl, NHC (O) cycloalkyl, NHC (O) heterocyclyl, NHC (O ) Aryl, NHC (O) heteroaryl, NHC (O) arylalkyl, NHC (O) heteroarylalkyl, NHS (O 2 ) alkyl, NHS (O 2 ) cycloalkyl, NHS (O 2 ) heterocyclyl, NHS (O 2 ) aryl, NHS (O 2 ) heteroaryl, NHS (O 2 ) arylalkyl, NHS (O 2 ) heteroarylalkyl, Salkyl, Saryl, Sheteroaryl, OX 2, OC (O) alkyl, OC (O) cycloalkyl, OC (O) heterocyclyl, OC (O) aryl, OC (O) heteroaryl, OC (O) arylalkyl, OC (O) heteroarylalkyl, OS (O 2 ) alkyl, OS (O 2 ) cycloalkyl, OS (O 2 ) heterocyclyl, OS (O 2 ) aryl, OS (O 2 ) heteroaryl, OS (O 2 ) arylalkyl, OS (O 2 ) heteroarylalkyl, C ( O) alkyl, C (O) aryl, C (O) heteroaryl, C (O) OX3, C (O) NHX4, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , S (O) alkyl, S (O) aryl, S (O 2 ) alkyl, S (O 2 ) aryl , S (O 2 ) NHalkyl, S (O 2 ) NHaryl, S (O 2 ) NH heteroaryl, S (O 2 ) NHarylalkyl, S (O 2 ) Oalkyl, S (O 2 ) Oaryl , S (O 2 ) Oarylalkyl " 여기서, X1, X2, X3, X4는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Wherein X 1, X 2, X 3, X 4 are each independently selected from the group consisting of: “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl Alkyl " 단, 치환체 그룹(a)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of: (i) "(C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, N3, NH사이클로알킬, NH사이클로알킬알킬, NH헤테로아릴, NH헤테로아릴알킬, NH아릴알킬, NH헤테로사이클릴, NH헤테로사이클릴알킬, NX5X6, S사이클로알킬, S사이클로알킬알킬, S아릴, S아릴알킬, S헤테로아릴, S헤테로아릴알킬, S헤테로사이클릴, S헤테로사이클릴알킬, O사이클로알킬, O사이클로알킬알킬, O아릴알킬, O헤테로아릴, O헤테로아릴알킬, O헤테로사이클릴, O헤테로사이클릴알킬, O(X7-O)pX8 (p = 1, 2, 3, 4, 5), OP(O)(OX9)(OX10), C(O)OX11, C(O)NH2, C(O)NHX12, C(O)NX13X14, S(O2)X15, P(O)(OH)2, P(O)(OX16)(OX17), Si(X18)(X19)(X20), OSi(X21)(X22)(X23), OC(O)OX24, OC(O)NHX25, OC(O)NX26X27, NHC(O)OX28, NHC(O)NHX29, NHC(O)NX30X31, NX32C(O)OX33, NX34C(O)NHX35, NX36C(O)NX37X38, OS(O2)X39, NHC(O)X40, NX41C(O)X42, C(O)X43, OC(O)X44, S(O)X45, S(O2)NHX46, S(O2)NX47X48, S(O2)OX49, O(X50-O)p-H (p = 1, 2, 3, 4, 5)"(i) "(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , NHcycloalkyl, NHcyclo Alkylalkyl, NH heteroaryl, NH heteroarylalkyl, NH arylalkyl, NH heterocyclyl, NH heterocyclylalkyl, NX5X6, Scycloalkyl, Scycloalkylalkyl, Saryl, Sarylalkyl, S heteroaryl, S Heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, Ocycloalkyl, Ocycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O ( X7-O) p X8 (p = 1, 2, 3, 4, 5), OP (O) (OX9) (OX10), C (O) OX11, C (O) NH 2 , C (O) NHX12, C (O) NX13X14, S (O 2 ) X15, P (O) (OH) 2 , P (O) (OX16) (OX17), Si (X18) (X19) (X20), OSi (X21) (X22 (X23), OC (O) OX24, OC (O) NHX25, OC (O) NX26X27, NHC (O) OX28, NHC (O) NHX29, NHC (O) NX30X31, NX32C (O) OX33, NX34C (O ) NHX35, NX36C (O) NX37X38, OS (O 2 ) X39, NHC (O) X40, NX41C (O) X42, C (O) X43, OC (O) X44, S (O) X45, S (O 2 ) NHX46, S (O 2 ) NX47X48, S (O 2 ) OX49, O (X50-O) p -H (p = 1, 2, 3, 4, 5) " 추가로 단, "N(알킬)2"는 다음 치환체 그룹(b)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further provided that "N (alkyl) 2 " is further substituted by one or more substituents selected from the following substituent groups (b); 여기서, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X13, X14 및/또는 X26, X27 및/또는 X30, X31 및/또는 X37, X38 및/또는 X47, X48은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50 are each independently composed of Selected from the group: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein the alternative As such, X13, X14 and / or X26, X27 and / or X30, X31 and / or X37, X38 and / or X47, X48 together may also form “heterocyclyl”, 추가로 단, Z3 또는 Z4 라디칼 중 하나가 "헤테로사이클릴알킬"에 의해 치환된 "치환된 아릴"인 경우, 나머지 Z3 또는 Z4 라디칼은 각각의 경우 "치환되거나 치환되지 않은 아릴"이 아니고,Further provided that if one of the Z3 or Z4 radicals is "substituted aryl" substituted by "heterocyclylalkyl", then the remaining Z3 or Z4 radicals are in each case not "substituted or unsubstituted aryl", 여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (b) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX51, NX52X53, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X54, C(O)OX55, C(O)NHX56, C(O)NX57X58, OX59, O(X60-O)rH (r = 1, 2, 3, 4, 5), O(X61-O)rX62 (r = 1, 2, 3, 4, 5), OC(O)X63, OC(O)OX64, OC(O)NHX65, OC(O)NX66X67, OP(O)(OX68)(OX69), OSi(X70)(X71)(X72), OS(O2)X73, NHC(O)X74, NX75C(O)X76, NHC(O)OX77, NHC(O)NHX78, NHC(O)NX79X80, NX81C(O)OX82, NX83C(O)NHX84, NX85C(O)NX86X87, NHS(O2)X88, NX89S(O2)X90, SX91, S(O)X92, S(O2)X93, S(O2)NHX94, S(O2)NX95X96, S(O2)OX97, P(O)(OX98)(OX99), Si(X100)(X101)(X102)"(b) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX51, NX52X53, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X54, C (O) OX55, C (O) NHX56, C (O) NX57X58, OX59, O (X60-O) r H (r = 1, 2, 3, 4, 5), O (X61-O) r X62 (r = 1, 2, 3, 4, 5), OC (O) X63, OC (O) OX64, OC (O) NHX65 , OC (O) NX66X67, OP (O) (OX68) (OX69), OSi (X70) (X71) (X72), OS (O 2 ) X73, NHC (O) X74, NX75C (O) X76, NHC ( O) OX77, NHC (O) NHX78, NHC (O) NX79X80, NX81C (O) OX82, NX83C (O) NHX84, NX85C (O) NX86X87, NHS (O 2 ) X88, NX89S (O 2 ) X90, SX91, S (O) X92, S (O 2 ) X93, S (O 2 ) NHX94, S (O 2 ) NX95X96, S (O 2 ) OX97, P (O) (OX98) (OX99), Si (X100) ( X101) (X102) " 여기서, X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클 로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X57, X58 및/또는 X66, X67 및/또는 X79, X80 및/또는 X86, X87 및/또는 X95, X96은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Where X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102 are each independently selected from the group consisting of: "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero Aryl, heteroarylalkyl ", wherein, alternatively, X57, X58 and / or X66, X67 and / or X79, X80 and / or X86, X87 and / or X95, X96 together also form" heterocyclyl " Can do it, 여기서, 임의로, 치환체 그룹(b)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX103, NX104X105, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X106, C(O)OX107, C(O)NHX108, C(O)NX109X110, OX111, O(X112-O)sH (s = 1, 2, 3, 4, 5), O(X113-O)sX114 (s = 1, 2, 3, 4, 5), OC(O)X115, OC(O)OX116, OC(O)NHX117, OC(O)NX118X119, OP(O)(OX120)(OX121), OSi(X122)(X123)(X124), OS(O2)X125, NHC(O)X126, NX127C(O)X128, NHC(O)OX129, NHC(O)NHX130, NHC(O)NX131X132, NX133C(O)OX134, NX135C(O)NHX136, NX137C(O)NX138X139, NHS(O2)X140, NX141S(O2)X142, SX143, S(O)X144, S(O2)X145, S(O2)NHX146, S(O2)NX147X148, S(O2)OX149, P(O)(OX150)(OX151), Si(X152)(X153)(X154)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX 103, NX104X105, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X106, C (O) OX107, C (O) NHX108, C (O) NX109X110, OX111, O (X112-O) s H (s = 1, 2, 3, 4, 5), O (X113-O) s X114 (s = 1, 2, 3, 4, 5), OC (O) X115, OC (O) OX116, OC (O) NHX117 , OC (O) NX118X119, OP (O) (OX120) (OX121), OSi (X122) (X123) (X124), OS (O 2 ) X125, NHC (O) X126, NX127C (O) X128, NHC ( O) OX129, NHC (O) NHX130, NHC (O) NX131X132, NX133C (O) OX134, NX135C (O) NHX136, NX137C (O) NX138X139, NHS (O 2 ) X140, NX141S (O 2 ) X142, SX143, S (O) X144, S (O 2 ) X145, S (O 2 ) NHX146, S (O 2 ) NX147X148, S (O 2 ) OX149, P (O) (OX150) (OX151), Si (X152) ( X153) (X154) " 여기서, X103, X104, X105, X106, X107, X108, X109, X110, X111, X112, X113, X114, X115, X116, X117, X118, X119, X120, X121, X122, X123, X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, X149, X150, X151, X152, X153, X154는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X109, X110 및/또는 X118, X119 및/또는 X131, X132 및/또는 X138, X139 및/또는 X147, X148은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where X103, X104, X105, X106, X107, X108, X109, X110, X111, X112, X113, X114, X115, X116, X117, X118, X119, X120, X121, X122, X123, X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, X149, X150, X151, X152, X153, X154 are each independently selected from the group consisting of: "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl , Heteroarylalkyl ", where, alternatively, X109, X110 and / or X118, X119 and / or X131, X132 and / or X138, X139 and / or X147, X148 together may also form" heterocyclyl " Can, 여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX155, NX156X157, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X158, C(O)OX159, C(O)NHX160, C(O)NX161X162, OX163, O(X164-O)tH (t = 1, 2, 3, 4, 5), O(X165-O)tX166 (t = 1, 2, 3, 4, 5), OC(O)X167, OC(O)OX168, OC(O)NHX169, OC(O)NX170X171, OP(O)(OX172)(OX173), OSi(X174)(X175)(X176), OS(O2)X177, NHC(O)X178, NX179C(O)X180, NHC(O)OX181, NHC(O)NHX182, NHC(O)NX183X184, NX185C(O)OX186, NX187C(O)NHX188, NX189C(O)NX190X191, NHS(O2)X192, NX193S(O2)X194, SX195, S(O)X196, S(O2)X197, S(O2)NHX198, S(O2)NX199X200, S(O2)OX201, P(O)(OX202)(OX203), Si(X204)(X205)(X206)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX155, NX156X157, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X158, C (O) OX159, C (O) NHX160, C (O) NX161X162, OX163, O (X164-O) t H (t = 1, 2, 3, 4, 5), O (X165-O) t X166 (t = 1, 2, 3, 4, 5), OC (O) X167, OC (O) OX168, OC (O) NHX169 , OC (O) NX170X171, OP (O) (OX172) (OX173), OSi (X174) (X175) (X176), OS (O 2 ) X177, NHC (O) X178, NX179C (O) X180, NHC ( O) OX181, NHC (O) NHX182, NHC (O) NX183X184, NX185C (O) OX186, NX187C (O) NHX188, NX189C (O) NX190X191, NHS (O 2 ) X192, NX193S (O 2 ) X194, SX195, S (O) X196, S (O 2 ) X197, S (O 2 ) NHX198, S (O 2 ) NX199X200, S (O 2 ) OX201, P (O) (OX202) (OX203), Si (X204) ( X205) (X206) " 여기서, X155, X156, X157, X158, X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X175, X176, X177, X178, X179, X180, X181, X182, X183, X184, X185, X186, X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X161, X162 및/또는 X170, X171 및/또는 X183, X184 및/또는 X190, X191 및/또는 X199, X200은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where X155, X156, X157, X158, X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X175, X176, X177, X178, X179, X180, X181, X182, X183, X184, X185, X186, X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X161, X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 together may also refer to" heterocyclyl " Can form, 또는 Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고: Or one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted aryl" wherein "substituted aryl" is substituted by one or more substituents identically or differently selected from the group consisting of: (c) "(C9-C30)알킬, NX207X208, NH(C9-C30)알킬, NHC(O)사이클로알킬알킬, NHC(O)헤테로사이클릴알킬, NHC(O)(C9-C30)알킬, NX209C(O)X210, NX211C(O)(C9-C30)알킬, NHC(O)OX212, NX213C(O)OX214, NHC(O)NHX215, NHC(O)NX216X217, NX218C(O)NHX219, NX220C(O)NX221X222, NHS(O2)사이클로알킬알킬, NHS(O2)헤테로사이클릴알킬, NX223S(O2)X224, O(C9-C30)알킬, S사이클로알킬, S헤테로사이클릴, S아릴알킬, S헤테로아릴알킬, S사이클로알킬알킬, S헤테로사이클릴알킬, S(C9-C30)알킬, OC(O)사이클로알킬알킬, OC(O)헤테로사이클릴알킬, OC(O)(C9-C30)알킬, OS(O2)사이클로알킬알킬, OS(O2)헤테로사이클릴알킬, OS(O2)(C9-C30)알킬, OC(O)OX225, OC(O)NHX226, OC(O)NX227X228, OP(O)(OX229)(OX230), C(O)사이클로알킬, C(O)헤테로사이클릴, C(O)아릴알킬, C(O)헤테로아릴알킬, C(O)사이클로알킬알킬, C(O)헤테로사이클릴알킬, C(O)(C9-C30)알킬, C(O)O(C9-C30)알킬, C(O)NH(C9-C30)알킬, C(O)NX231X232, C(O)NHOX233, C(O)NX234-OX235, C(O)NHNX236X237, C(O)NX238NX239X240, S(O)사이클로알킬, S(O)헤테로사이클릴, S(O)헤테로아릴, S(O)아릴알킬, S(O)헤테로아릴알킬, S(O)사이클로알킬알킬, S(O)헤테로사이클릴알킬, S(O)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)헤테로사이클릴, S(O2)헤테로아릴, S(O2)아릴알킬, S(O2)헤테로아릴알킬, S(O2)사이클로알킬알킬, S(O2)헤테로사이클릴알킬, S(O2)(C9-C30)알킬, S(O2)NH사이클로알킬, S(O2)NH헤테로사이클릴, S(O2)NH헤테로아릴알킬, S(O2)NH사이클로알킬알킬, S(O2)NH헤테로사이클릴알킬, S(O2)NH(C9-C30) 알킬, S(O2)O사이클로알킬, S(O2)O헤테로사이클릴, S(O2)O헤테로아릴, S(O2)O헤테로아릴알킬, S(O2)O사이클로알킬알킬, S(O2)O헤테로사이클릴알킬, S(O2)O(C9-C30)알킬, P(O)(OH)2, P(O)(OX241)(OX242), Si(X243)(X244)(X245), OSi(X246)(X247)(X248)"(c) "(C 9 -C 30 ) alkyl, NX207X208, NH (C 9 -C 30 ) alkyl, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NHC (O) (C 9- C 30 ) alkyl, NX209C (O) X210, NX211C (O) (C 9 -C 30 ) alkyl, NHC (O) OX212, NX213C (O) OX214, NHC (O) NHX215, NHC (O) NX216X217, NX218C ( O) NHX219, NX220C (O) NX221X222, NHS (O 2 ) cycloalkylalkyl, NHS (O 2 ) heterocyclylalkyl, NX223S (O 2 ) X224, O (C 9 -C 30 ) alkyl, Scycloalkyl, S heterocyclyl, Sarylalkyl, S heteroarylalkyl, Scycloalkylalkyl, S heterocyclylalkyl, S (C 9 -C 30 ) alkyl, OC (O) cycloalkylalkyl, OC (O) heterocyclyl Alkyl, OC (O) (C 9 -C 30 ) alkyl, OS (O 2 ) cycloalkylalkyl, OS (O 2 ) heterocyclylalkyl, OS (O 2 ) (C 9 -C 30 ) alkyl, OC ( O) OX225, OC (O) NHX226, OC (O) NX227X228, OP (O) (OX229) (OX230), C (O) cycloalkyl, C (O) heterocyclyl, C (O) arylalkyl, C (O) heteroarylalkyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O) (C 9 -C 30 ) alkyl, C (O) O (C 9 -C 30 ) alkyl, C (O) NH (C 9 -C 30 ) alkyl, C (O) NX231X232, C (O) NHOX233, C (O) NX234-OX235, C ( O) NHNX236X237, C (O) NX238NX239X240, S (O) cycloalkyl, S (O) heterocyclyl, S (O) heteroaryl, S (O) arylalkyl, S (O) heteroarylalkyl, S (O ) Cycloalkylalkyl, S (O) heterocyclylalkyl, S (O) (C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) heterocyclyl, S (O 2 ) hetero Aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroarylalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) heterocyclylalkyl, S (O 2 ) (C 9 -C 30 ) Alkyl, S (O 2 ) NH cycloalkyl, S (O 2 ) NH heterocyclyl, S (O 2 ) NH heteroarylalkyl, S (O 2 ) NH cycloalkylalkyl, S (O 2 ) NH heterocyclyl Alkyl, S (O 2 ) NH (C 9 -C 30 ) Alkyl, S (O 2 ) Ocycloalkyl, S (O 2 ) O Heterocyclyl, S (O 2 ) O Heteroaryl, S (O 2 ) O heteroarylalkyl, S (O 2 ) Ocycloalkylalkyl, S (O 2 ) Oheterocyclylalkyl, S (O 2 ) O (C 9 -C 30 ) alkyl, P (O) (OH) 2 , P (O) (OX241) ( OX242), Si (X243) (X244) (X245), OSi (X246) (X247) (X248) " 여기서, X207, X208, X209, X210, X211, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X216, X217 및/또는 X221, X222 및/또는 X227, X228 및/또는 X231, X232 및/또는 X236, X237 및/또는 X239, X240은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X207, X208, X209, X210, X211, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, X216, X217 and / or X221, X222 and / or X227, X228 and / or X231, X232 and / or X236, X237 and / or X239, X240 may also together form "heterocyclyl" in each case, 단, 치환체 "N(알킬)2", "C(O)N(알킬)2", "C(O)N(사이클로알킬)2", "C(O)N(아릴)2", "C(O)N(헤테로아릴)2"는 다음 치환체 그룹(i)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Provided that the substituents "N (alkyl) 2 ", "C (O) N (alkyl) 2 ", "C (O) N (cycloalkyl) 2 ", "C (O) N (aryl) 2 ", "C (O) N (heteroaryl) 2 ″ is further substituted by one or more substituents selected from the following substituent groups (i); 추가로 단, Z3 또는 Z4 라디칼 중 하나가 "헤테로사이클릴알킬"에 의해 치환된 "치환된 아릴"인 경우, 나머지 Z3 또는 Z4 라디칼은 각각의 경우 "치환되지 않거나 치환된 아릴"이 아니고,Further provided that if one of the Z3 or Z4 radicals is "substituted aryl" substituted by "heterocyclylalkyl", then the remaining Z3 or Z4 radicals in each case are not "unsubstituted or substituted aryl", 여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX249, NX250X251, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X252, C(O)OX253, C(O)NHX254, C(O)NX255X256, OX257, O(X258-O)uH (u = 1, 2, 3, 4, 5), O(X259-O)uX260 (u = 1, 2, 3, 4, 5), OC(O)X261, OC(O)OX262, OC(O)NHX263, OC(O)NX264X265, OP(O)(OX266)(OX267), OSi(X268)(X269)(X270), OS(O2)X271, NHC(O)X272, NX273C(O)X274, NHC(O)OX275, NHC(O)NHX276, NHC(O)NX277X278, NX279C(O)OX280, NX281C(O)NHX282, NX283C(O)NX284X285, NHS(O2)X286, NX287S(O2)X288, SX289, S(O)X290, S(O2)X291, S(O2)NHX292, S(O2)NX293X294, S(O2)OX295, P(O)(OX296)(OX297), Si(X298)(X299)(X300)"(i) "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN , CF 3 , N 3 , NH 2 , NHX249, NX250X251, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X252, C (O) OX253, C (O) NHX254, C (O) NX255X256, OX257, O (X258-O) u H (u = 1, 2, 3, 4, 5), O (X259-O) u X260 (u = 1, 2, 3, 4, 5), OC (O) X261, OC (O) OX262, OC (O) NHX263, OC (O) NX264X265, OP (O) (OX266) (OX267), OSi (X268) (X269) (X270), OS (O 2 ) X271, NHC (O) X272, NX273C (O) X274, NHC (O) OX275, NHC (O) NHX276, NHC (O) NX277X278, NX279C (O) OX280, NX281C (O) NHX282, NX283C (O) NX284X285, NHS (O 2 ) X286, NX287S (O 2 ) X288, SX289, S ( O) X290, S (O 2 ) X291, S (O 2 ) NHX292, S (O 2 ) NX293X294, S (O 2 ) OX295, P (O) (OX296) (OX297), Si (X298) (X299) (X300) " 여기서, X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X296, X297, X298, X299, X300은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X255, X256 및/또는 X264, X265 및/또는 X277, X278 및/또는 X284, X285 및/또는 X293, X294는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X296, X297, X298, X299, X300 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X255, X256 and / or X264, X265 and / or X277, X278 and / or X284, X285 and / or X293, X294 are also in each case" heterocycle Reels ", 여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (d) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX301, NX302X303, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X304, C(O)OX305, C(O)NHX306, C(O)NX307X308, OX309, O(X310-O)uuH (uu = 1, 2, 3, 4, 5), O(X311-O)uuX312 (uu = 1, 2, 3, 4, 5), OC(O)X313, OC(O)OX314, OC(O)NHX315, OC(O)NX316X317, OP(O)(OX318)(OX319), OSi(X320)(X321)(X322), OS(O2)X323, NHC(O)X324, NX325C(O)X326, NHC(O)OX327, NHC(O)NHX328, NHC(O)NX329X330, NX331C(O)OX332, NX333C(O)NHX334, NX335C(O)NX336X337, NHS(O2)X338, NX339S(O2)X340, SX341, S(O)X342, S(O2)X343, S(O2)NHX344, S(O2)NX345X346, S(O2)OX347, P(O)(OX348)(OX349), Si(X350)(X351)(X352)"(d) "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN , CF 3 , N 3 , NH 2 , NHX301, NX302X303, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X304, C (O) OX305, C (O) NHX306, C (O) NX307X308, OX309, O (X310-O) uu H (uu = 1, 2, 3, 4, 5), O (X311-O) uu X312 (uu = 1, 2, 3, 4, 5), OC (O) X313, OC (O) OX314, OC (O) NHX315, OC (O) NX316X317, OP (O) (OX318) (OX319), OSi (X320) (X321) (X322), OS (O 2 ) X323, NHC (O) X324, NX325C (O) X326, NHC (O) OX327, NHC (O) NHX328, NHC (O) NX329X330, NX331C (O) OX332, NX333C (O) NHX334, NX335C (O) NX336X337, NHS (O 2 ) X338, NX339S (O 2 ) X340, SX341, S ( O) X342, S (O 2 ) X343, S (O 2 ) NHX344, S (O 2 ) NX345X346, S (O 2 ) OX347, P (O) (OX348) (OX349), Si (X350) (X351) (X352) " 여기서, X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312, X313, X314, X315, X316, X317, X318, X319, X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X332, X333, X334, X335, X336, X337, X338, X339, X340, X341, X342, X343, X344, X345, X346, X347, X348, X349, X350, X351, X352는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X307, X308 및/또는 X316, X317 및/또는 X329, X330 및/또는 X336, X337 및/또는 X345, X346은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312, X313, X314, X315, X316, X317, X318, X319, X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X332, X333, X334, X335, X336, X337, X338, X339, X340, X341, X342, X343, X344, X345, X346, X347, X348, X349, X350, X351, X352 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X307, X308 and / or X316, X317 and / or X329, X330 and / or X336, X337 and / or X345, X346 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(d)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (d) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX353, NX354X355, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X356, C(O)OX357, C(O)NHX358, C(O)NX359X360, OX361, O(X362-O)vH (v = 1, 2, 3, 4, 5), O(X363- O)vX364 (v = 1, 2, 3, 4, 5), OC(O)X365, OC(O)OX366, OC(O)NHX367, OC(O)NX368X369, OP(O)(OX370)(OX371), OSi(X372)(X373)(X374), OS(O2)X375, NHC(O)X376, NX377C(O)X378, NHC(O)OX379, NHC(O)NHX380, NHC(O)NX381X382, NX383C(O)OX384, NX385C(O)NHX386, NX387C(O)NX388X389, NHS(O2)X390, NX391S(O2)X392, SX393, S(O)X394, S(O2)X395, S(O2)NHX396, S(O2)NX397X398, S(O2)OX399, P(O)(OX400)(OX401), Si(X402)(X403)(X404)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX353, NX354X355, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X356, C (O) OX357, C (O) NHX358, C (O) NX359X360, OX361, O (X362-O) v H (v = 1, 2, 3, 4, 5), O (X363- O) v X364 (v = 1, 2, 3, 4, 5), OC (O) X365, OC (O) OX366, OC (O) NHX367 , OC (O) NX368X369, OP (O) (OX370) (OX371), OSi (X372) (X373) (X374), OS (O 2 ) X375, NHC (O) X376, NX377C (O) X378, NHC ( O) OX379, NHC (O) NHX380, NHC (O) NX381X382, NX383C (O) OX384, NX385C (O) NHX386, NX387C (O) NX388X389, NHS (O 2 ) X390, NX391S (O 2 ) X392, SX393 S (O) X394, S (O 2 ) X395, S (O 2 ) NHX396, S (O 2 ) NX397X398, S (O 2 ) OX399, P (O) (OX400) (OX401), Si (X402) ( X403) (X404) " 여기서, X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X375, X376, X377, X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X400, X401, X402, X403, X404는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X359, X360 및/또는 X368, X369 및/또는 X381, X382 및/또는 X388, X389 및/또는 X397, X398은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X375, X376, X377, X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X400, X401, X401 X402, X403, X404 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X359, X360 and / or X368, X369 and / or X381, X382 and / or X388, X389 and / or X397, X398 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX405, NX406X407, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X408, C(O)OX409, C(O)NHX410, C(O)NX411X412, OX413, O(X414-O)wH (w = 1, 2, 3, 4, 5), O(X415-O)wX416 (w = 1, 2, 3, 4, 5), OC(O)X417, OC(O)OX418, OC(O)NHX419, OC(O)NX420X421, OP(O)(OX422)(OX423), OSi(X424)(X425)(X426), OS(O2)X427, NHC(O)X428, NX429C(O)X430, NHC(O)OX431, NHC(O)NHX432, NHC(O)NX433X434, NX435C(O)OX436, NX437C(O)NHX438, NX439C(O)NX440X441, NHS(O2)X442, NX443S(O2)X444, SX445, S(O)X446, S(O2)X447, S(O2)NHX448, S(O2)NX449X450, S(O2)OX451, P(O)(OX452)(OX453), Si(X454)(X455)(X456)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX405, NX406X407, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X408, C (O) OX409, C (O) NHX410, C (O) NX411X412, OX413, O (X414-O) w H (w = 1, 2, 3, 4, 5), O (X415-O) w X416 (w = 1, 2, 3, 4, 5), OC (O) X417, OC (O) OX418, OC (O) NHX419 , OC (O) NX420X421, OP (O) (OX422) (OX423), OSi (X424) (X425) (X426), OS (O 2 ) X427, NHC (O) X428, NX429C (O) X430, NHC ( O) OX431, NHC (O) NHX432, NHC (O) NX433X434, NX435C (O) OX436, NX437C (O) NHX438, NX439C (O) NX440X441, NHS (O 2 ) X442, NX443S (O 2 ) X444, SX445, S (O) X446, S (O 2 ) X447, S (O 2 ) NHX448, S (O 2 ) NX449X450, S (O 2 ) OX451, P (O) (OX452) (OX453), Si (X454) ( X455) (X456) " 여기서, X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X411, X412 및/또는 X420, X421 및/또는 X433, X434 및/또는 X440, X441 및/또는 X449, X450은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X411, X412 and / or X420, X421 and / or X433, X434 and / or X440, X441 and / or X449, X450 are also in each case" heterocycle Reels "; Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of: (e) 수소;(e) hydrogen; (f) 할로겐, F, Cl, Br, I;(f) halogen, F, Cl, Br, I; (g) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX457, NX458X459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X460, C(O)OX461, C(O)NHX462, C(O)NX463X464, OX465, O(X466-O)xH (x = 1, 2, 3, 4, 5), O(X467-O)xX468 (x = 1, 2, 3, 4, 5), OC(O)X469, OC(O)OX470, OC(O)NHX471, OC(O)NX472X473, OP(O)(OX474)(OX475), OSi(X476)(X477)(X478), OS(O2)X479, NHC(O)X480, NX481C(O)X482, NHC(O)OX483, NHC(O)NHX484, NHC(O)NX485X486, NX487C(O)OX488, NX489C(O)NHX490, NX491C(O)NX492X493, NHS(O2)X494, NX495S(O2)X496, SX497, S(O)X498, S(O2)X499, S(O2)NHX500, S(O2)NX501X502, S(O2)OX503, P(O)(OX504)(OX505), Si(X506)(X507)(X508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX457, NX458X459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X460, C (O) OX461, C (O) NHX462, C (O) NX463X464, OX465, O (X466-O) x H (x = 1, 2, 3, 4, 5), O (X467-O) x X468 (x = 1, 2, 3, 4, 5), OC (O) X469, OC (O) OX470, OC (O) NHX471 , OC (O) NX472X473, OP (O) (OX474) (OX475), OSi (X476) (X477) (X478), OS (O 2 ) X479, NHC (O) X480, NX481C (O) X482, NHC ( O) OX483, NHC (O) NHX484, NHC (O) NX485X486, NX487C (O) OX488, NX489C (O) NHX490, NX491C (O) NX492X493, NHS (O 2 ) X494, NX495S (O 2 ) X496, SX497, S (O) X498, S (O 2 ) X499, S (O 2 ) NHX500, S (O 2 ) NX501X502, S (O 2 ) OX503, P (O) (OX504) (OX505), Si (X506) ( X507) (X508) " 여기서, X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X463, X464 및/또는 X472, X473 및/또는 X485, X486 및/또는 X492, X493 및/또는 X501, X502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X463, X464 and / or X472, X473 and / or X485, X486 and / or X492, X493 and / or X501, X502 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX509, NX510X511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X512, C(O)OX513, C(O)NHX514, C(O)NX515X516, OX517, O(X518-O)yH (y = 1, 2, 3, 4, 5), O(X519-O)yX520 (y = 1, 2, 3, 4, 5), OC(O)X521, OC(O)OX522, OC(O)NHX523, OC(O)NX524X525, OP(O)(OX526)(OX527), OSi(X528)(X529)(X530), OS(O2)X531, NHC(O)X532, NX533C(O)X534, NHC(O)OX535, NHC(O)NHX536, NHC(O)NX537X538, NX539C(O)OX540, NX541C(O)NHX542, NX543C(O)NX544X545, NHS(O2)X546, NX547S(O2)X548, SX549, S(O)X550, S(O2)X551, S(O2)NHX552, S(O2)NX553X554, S(O2)OX555, P(O)(OX556)(OX557), Si(X558)(X559)(X560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX509, NX510X511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X512, C (O) OX513, C (O) NHX514, C (O) NX515X516, OX517, O (X518-O) y H (y = 1, 2, 3, 4, 5), O (X519-O) y X520 (y = 1, 2, 3, 4, 5), OC (O) X521, OC (O) OX522, OC (O) NHX523 , OC (O) NX524X525, OP (O) (OX526) (OX527), OSi (X528) (X529) (X530), OS (O 2 ) X531, NHC (O) X532, NX533C (O) X534, NHC ( O) OX535, NHC (O) NHX536, NHC (O) NX537X538, NX539C (O) OX540, NX541C (O) NHX542, NX543C (O) NX544X545, NHS (O 2 ) X546, NX547S (O 2 ) X548, SX549, S (O) X550, S (O 2 ) X551, S (O 2 ) NHX552, S (O 2 ) NX553X554, S (O 2 ) OX555, P (O) (OX556) (OX557), Si (X558) ( X559) (X560) " 여기서, X509, X510, X511, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527, X528, X529, X530, X531, X532, X533, X534, X535, X536, X537, X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X515, X516 및/또는 X524, X525 및/또는 X537, X538 및/또는 X544, X545 및/또는 X553, X554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X509, X510, X511, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527, X528, X529, X530, X531, X532, X533, X534, X535, X536, X537, X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X515, X516 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX561, NX562X563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X564, C(O)OX565, C(O)NHX566, C(O)NX567X568, OX569, O(X570-O)zH (z = 1, 2, 3, 4, 5), O(X571-O)zX572 (z = 1, 2, 3, 4, 5), OC(O)X573, OC(O)OX574, OC(O)NHX575, OC(O)NX576X577, OP(O)(OX578)(OX579), OSi(X580)(X581)(X582), OS(O2)X583, NHC(O)X584, NX585C(O)X586, NHC(O)OX587, NHC(O)NHX588, NHC(O)NX589X590, NX591C(O)OX592, NX593C(O)NHX594, NX595C(O)NX596X597, NHS(O2)X598, NX599S(O2)X600, SX601, S(O)X602, S(O2)X603, S(O2)NHX604, S(O2)NX605X606, S(O2)OX607, P(O)(OX608)(OX609), Si(X610)(X611)(X612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX561, NX562X563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X564, C (O) OX565, C (O) NHX566, C (O) NX567X568, OX569, O (X570-O) z H (z = 1, 2, 3, 4, 5), O (X571-O) z X572 (z = 1, 2, 3, 4, 5), OC (O) X573, OC (O) OX574, OC (O) NHX575 , OC (O) NX576X577, OP (O) (OX578) (OX579), OSi (X580) (X581) (X582), OS (O 2 ) X583, NHC (O) X584, NX585C (O) X586, NHC ( O) OX587, NHC (O) NHX588, NHC (O) NX589X590, NX591C (O) OX592, NX593C (O) NHX594, NX595C (O) NX596X597, NHS (O 2 ) X598, NX599S (O 2 ) X600, SX601, S (O) X602, S (O 2 ) X603, S (O 2 ) NHX604, S (O 2 ) NX605X606, S (O 2 ) OX607, P (O) (OX608) (OX609), Si (X610) ( X611) (X612) " 여기서, X561, X562, X563, X564, X565, X566, X567, X568, X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X611, X612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X567, X568 및/또는 X576, X577 및/또는 X589, X590 및/또는 X596, X597 및/또는 X605, X606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X561, X562, X563, X564, X565, X566, X567, X568, X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X611, X612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X567, X568 and / or X576, X577 and / or X589, X590 and / or X596, X597 and / or X605, X606 are also in each case" heterocycle. " Reels ", (h) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX613, NX614X615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X616, C(O)OX617, C(O)NHX618, C(O)NX619X620, OX621, O(X622-O)aH (a = 1, 2, 3, 4, 5), O(X623-O)aX624 (a = 1, 2, 3, 4, 5), OC(O)X625, OC(O)OX626, OC(O)NHX627, OC(O)NX628X629, OP(O)(OX630)(OX631), OSi(X632)(X633)(X634), OS(O2)X635, NHC(O)X636, NX637C(O)X638, NHC(O)OX639, NHC(O)NHX640, NHC(O)NX641X642, NX643C(O)OX644, NX645C(O)NHX646, NX647C(O)NX648X649, NHS(O2)X650, NX651S(O2)X652, SX653, S(O)X654, S(O2)X655, S(O2)NHX656, S(O2)NX657X658, S(O2)OX659, P(O)(OX660)(OX661), Si(X662)(X663)(X664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX613, NX614X615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X616, C (O) OX617, C (O) NHX618, C (O) NX619X620, OX621, O (X622-O) a H (a = 1, 2, 3, 4, 5), O (X623-O) a X624 (a = 1, 2, 3, 4, 5), OC (O) X625, OC (O) OX626, OC (O) NHX627 , OC (O) NX628X629, OP (O) (OX630) (OX631), OSi (X632) (X633) (X634), OS (O 2 ) X635, NHC (O) X636, NX637C (O) X638, NHC ( O) OX639, NHC (O) NHX640, NHC (O) NX641X642, NX643C (O) OX644, NX645C (O) NHX646, NX647C (O) NX648X649, NHS (O 2 ) X650, NX651S (O 2 ) X652, SX653, S (O) X654, S (O 2 ) X655, S (O 2 ) NHX656, S (O 2 ) NX657X658, S (O 2 ) OX659, P (O) (OX660) (OX661), Si (X662) ( X663) (X664) " 여기서, X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631, X632, X633, X634, X635, X636, X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651, X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, X663, X664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X619, X620 및/또는 X628, X629 및/또는 X641, X642 및/또는 X648, X649 및/또는 X657, X658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631, X632, X633, X634, X635, X636, X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651, X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, X663, X664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X619, X620 and / or X628, X629 and / or X641, X642 and / or X648, X649 and / or X657, X658 are also in each case a" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX665, NX666X667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X668, C(O)OX669, C(O)NHX670, C(O)NX671X672, OX673, O(X674-O)bH (b = 1, 2, 3, 4, 5), O(X675-O)bX676 (b = 1, 2, 3, 4, 5), OC(O)X677, OC(O)OX678, OC(O)NHX679, OC(O)NX680X681, OP(O)(OX682)(OX683), OSi(X684)(X685)(X686), OS(O2)X687, NHC(O)X688, NX689C(O)X690, NHC(O)OX691, NHC(O)NHX692, NHC(O)NX693X694, NX695C(O)OX696, NX697C(O)NHX698, NX699C(O)NX700X701, NHS(O2)X702, NX703S(O2)X704, SX705, S(O)X706, S(O2)X707, S(O2)NHX708, S(O2)NX709X710, S(O2)OX711, P(O)(OX712)(OX713), Si(X714)(X715)(X716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX665, NX666X667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X668, C (O) OX669, C (O) NHX670, C (O) NX671X672, OX673, O (X674-O) b H (b = 1, 2, 3, 4, 5), O (X675-O) b X676 (b = 1, 2, 3, 4, 5), OC (O) X677, OC (O) OX678, OC (O) NHX679 , OC (O) NX680X681, OP (O) (OX682) (OX683), OSi (X684) (X685) (X686), OS (O 2 ) X687, NHC (O) X688, NX689C (O) X690, NHC ( O) OX691, NHC (O) NHX692, NHC (O) NX693X694, NX695C (O) OX696, NX697C (O) NHX698, NX699C (O) NX700X701, NHS (O 2 ) X702, NX703S (O 2 ) X704, SX705, S (O) X706, S (O 2 ) X707, S (O 2 ) NHX708, S (O 2 ) NX709X710, S (O 2 ) OX711, P (O) (OX712) (OX713), Si (X714) ( X715) (X716) " 여기서, X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X687, X688, X689, X690, X691, X692, X693, X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X671, X672 및/또는 X680, X681 및/또는 X693, X694 및/또는 X700, X701 및/또는 X709, X710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X687, X688, X689, X690, X691, X692, X693, X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X671, X672 and / or X680, X681 and / or X693, X694 and / or X700, X701 and / or X709, X710 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX717, NX718X719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X720, C(O)OX721, C(O)NHX722, C(O)NX723X724, OX725, O(X726-O)cH (c = 1, 2, 3, 4, 5), O(X727-O)cX728 (c = 1, 2, 3, 4, 5), OC(O)X729, OC(O)OX730, OC(O)NHX731, OC(O)NX732X733, OP(O)(OX734)(OX735), OSi(X736)(X737)(X738), OS(O2)X739, NHC(O)X740, NX741C(O)X742, NHC(O)OX743, NHC(O)NHX744, NHC(O)NX745X746, NX747C(O)OX748, NX749C(O)NHX750, NX751C(O)NX752X753, NHS(O2)X754, NX755S(O2)X756, SX757, S(O)X758, S(O2)X759, S(O2)NHX760, S(O2)NX761X762, S(O2)OX763, P(O)(OX764)(OX765), Si(X766)(X767)(X768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX717, NX718X719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X720, C (O) OX721, C (O) NHX722, C (O) NX723X724, OX725, O (X726-O) c H (c = 1, 2, 3, 4, 5), O (X727-O) c X728 (c = 1, 2, 3, 4, 5), OC (O) X729, OC (O) OX730, OC (O) NHX731 , OC (O) NX732X733, OP (O) (OX734) (OX735), OSi (X736) (X737) (X738), OS (O 2 ) X739, NHC (O) X740, NX741C (O) X742, NHC ( O) OX743, NHC (O) NHX744, NHC (O) NX745X746, NX747C (O) OX748, NX749C (O) NHX750, NX751C (O) NX752X753, NHS (O 2 ) X754, NX755S (O 2 ) X756, SX757, S (O) X758, S (O 2 ) X759, S (O 2 ) NHX760, S (O 2 ) NX761X762, S (O 2 ) OX763, P (O) (OX764) (OX765), Si (X766) ( X767) (X768) " 여기서, X717, X718, X719, X720, X721, X722, X723, X724, X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X723, X724 및/또는 X732, X733 및/또는 X745, X746 및/또는 X752, X753 및/또는 X761, X762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X717, X718, X719, X720, X721, X722, X723, X724, X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X723, X724 and / or X732, X733 and / or X745, X746 and / or X752, X753 and / or X761, X762 are also in each case" heterocycle. " Reels ", (j) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX769, NX770X771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X772, C(O)OX773, C(O)NHX774, C(O)NX775X776, OX777, O(X778-O)dH (d = 1, 2, 3, 4, 5), O(X779-O)dX780 (d = 1, 2, 3, 4, 5), OC(O)X781, OC(O)OX782, OC(O)NHX783, OC(O)NX784X785, OP(O)(OX786)(OX787), OSi(X788)(X789)(X790), OS(O2)X791, NHC(O)X792, NX793C(O)X794, NHC(O)OX795, NHC(O)NHX796, NHC(O)NX797X798, NX799C(O)OX800, NX801C(O)NHX802, NX803C(O)NX804X805, NHS(O2)X806, NX807S(O2)X808, SX809, S(O)X810, S(O2)X811, S(O2)NHX812, S(O2)NX813X814, S(O2)OX815, P(O)(OX816)(OX817), Si(X818)(X819)(X820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX769, NX770X771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X772, C (O) OX773, C (O) NHX774, C (O) NX775X776, OX777, O (X778-O) d H (d = 1, 2, 3, 4, 5), O (X779-O) d X780 (d = 1, 2, 3, 4, 5), OC (O) X781, OC (O) OX782, OC (O) NHX783 , OC (O) NX784X785, OP (O) (OX786) (OX787), OSi (X788) (X789) (X790), OS (O 2 ) X791, NHC (O) X792, NX793C (O) X794, NHC ( O) OX795, NHC (O) NHX796, NHC (O) NX797X798, NX799C (O) OX800, NX801C (O) NHX802, NX803C (O) NX804X805, NHS (O 2 ) X806, NX807S (O 2 ) X808, SX809, S (O) X810, S (O 2 ) X811, S (O 2 ) NHX812, S (O 2 ) NX813X814, S (O 2 ) OX815, P (O) (OX816) (OX817), Si (X818) ( X819) (X820) " 여기서, X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779, X780, X781, X782, X783, X784, X785, X786, X787, X788, X789, X790, X791, X792, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807, X808, X809, X810, X811, X812, X813, X814, X815, X816, X817, X818, X819, X820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X775, X776 및/또는 X784, X785 및/또는 X797, X798 및/또는 X804, X805 및/또는 X813, X814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779, X780, X781, X782, X783, X784, X785, X786, X787, X788, X789, X790, X791, X792, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807, X808, X809, X810, X811, X812, X813, X814, X815, X816, X817, X818, X819, X820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X775, X776 and / or X784, X785 and / or X797, X798 and / or X804, X805 and / or X813, X814 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX821, NX822X823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X824, C(O)OX825, C(O)NHX826, C(O)NX827X828, OX829, O(X830-O)eH (e = 1, 2, 3, 4, 5), O(X831-O)eX832 (e = 1, 2, 3, 4, 5), OC(O)X833, OC(O)OX834, OC(O)NHX835, OC(O)NX836X837, OP(O)(OX838)(OX839), OSi(X840)(X841)(X842), OS(O2)X843, NHC(O)X844, NX845C(O)X846, NHC(O)OX847, NHC(O)NHX848, NHC(O)NX849X850, NX851C(O)OX852, NX853C(O)NHX854, NX855C(O)NX856X857, NHS(O2)X858, NX859S(O2)X860, SX861, S(O)X862, S(O2)X863, S(O2)NHX864, S(O2)NX865X866, S(O2)OX867, P(O)(OX868)(OX869), Si(X870)(X871)(X872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX821, NX822X823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X824, C (O) OX825, C (O) NHX826, C (O) NX827X828, OX829, O (X830-O) e H (e = 1, 2, 3, 4, 5), O (X831-O) e X832 (e = 1, 2, 3, 4, 5), OC (O) X833, OC (O) OX834, OC (O) NHX835 , OC (O) NX836X837, OP (O) (OX838) (OX839), OSi (X840) (X841) (X842), OS (O 2 ) X843, NHC (O) X844, NX845C (O) X846, NHC ( O) OX847, NHC (O) NHX848, NHC (O) NX849X850, NX851C (O) OX852, NX853C (O) NHX854, NX855C (O) NX856X857, NHS (O 2 ) X858, NX859S (O 2 ) X860, SX861, S (O) X862, S (O 2 ) X863, S (O 2 ) NHX864, S (O 2 ) NX865X866, S (O 2 ) OX867, P (O) (OX868) (OX869), Si (X870) ( X871) (X872) " 여기서, X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839, X840, X841, X842, X843, X844, X845, X846, X847, X848, X849, X850, X851, X852, X853, X854, X855, X856,X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X827, X828 및/또는 X836, X837 및/또는 X849, X850 및/또는 X856, X857 및/또는 X865, X866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839, X840, X841, X842, X843, X844, X845, X846, X847, X848, X849, X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X827, X828 and / or X836, X837 and / or X849, X850 and / or X856, X857 and / or X865, X866 are also in each case a" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX873, NX874X875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X876, C(O)OX877, C(O)NHX878, C(O)NX879X880, OX881, O(X882-O)fH (f = 1, 2, 3, 4, 5), O(X883-O)fX884 (f = 1, 2, 3, 4, 5), OC(O)X885, OC(O)OX886, OC(O)NHX887, OC(O)NX888X889, OP(O)(OX890)(OX891), OSi(X892)(X893)(X894), OS(O2)X895, NHC(O)X896, NX897C(O)X898, NHC(O)OX899, NHC(O)NHX900, NHC(O)NX901X902, NX903C(O)OX904, NX905C(O)NHX906, NX907C(O)NX908X909, NHS(O2)X910, NX911S(O2)X912, SX913, S(O)X914, S(O2)X915, S(O2)NHX916, S(O2)NX917X918, S(O2)OX919, P(O)(OX920)(OX921), Si(X922)(X923)(X924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX873, NX874X875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X876, C (O) OX877, C (O) NHX878, C (O) NX879X880, OX881, O (X882-O) f H (f = 1, 2, 3, 4, 5), O (X883-O) f X884 (f = 1, 2, 3, 4, 5), OC (O) X885, OC (O) OX886, OC (O) NHX887 , OC (O) NX888X889, OP (O) (OX890) (OX891), OSi (X892) (X893) (X894), OS (O 2 ) X895, NHC (O) X896, NX897C (O) X898, NHC ( O) OX899, NHC (O) NHX900, NHC (O) NX901X902, NX903C (O) OX904, NX905C (O) NHX906, NX907C (O) NX908X909, NHS (O 2 ) X910, NX911S (O 2 ) X912, SX913, S (O) X914, S (O 2 ) X915, S (O 2 ) NHX916, S (O 2 ) NX917X918, S (O 2 ) OX919, P (O) (OX920) (OX921), Si (X922) ( X923) (X924) " 여기서, X873, X874, X875, X876, X877, X878, X879, X880, X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X879, X880 및/또는 X888, X889 및/또는 X901, X902 및/또는 X908, X909 및/또는 X917, X918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X873, X874, X875, X876, X877, X878, X879, X880, X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, X879, X880 and / or X888, X889 and / or X901, X902 and / or X908, X909 and / or X917, X918 are also in each case" heterocycle Reels ", (k) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) OZ6, wherein Z6 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX925, NX926X927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X928, C(O)OX929, C(O)NHX930, C(O)NX931X932, OX933, O(X934-O)gH (g = 1, 2, 3, 4, 5), O(X935-O)gX936 (g = 1, 2, 3, 4, 5), OC(O)X937, OC(O)OX938, OC(O)NHX939, OC(O)NX940X941, OP(O)(OX942)(OX943), OSi(X944)(X945)(X946), OS(O2)X947, NHC(O)X948, NX949C(O)X950, NHC(O)OX951, NHC(O)NHX952, NHC(O)NX953X954, NX955C(O)OX956, NX957C(O)NHX958, NX959C(O)NX960X961, NHS(O2)X962, NX963S(O2)X964, SX965, S(O)X966, S(O2)X967, S(O2)NHX968, S(O2)NX969X970, S(O2)OX971, P(O)(OX972)(OX973), Si(X974)(X975)(X976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX925, NX926X927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X928, C (O) OX929, C (O) NHX930, C (O) NX931X932, OX933, O (X934-O) g H (g = 1, 2, 3, 4, 5), O (X935-O) g X936 (g = 1, 2, 3, 4, 5), OC (O) X937, OC (O) OX938, OC (O) NHX939 , OC (O) NX940X941, OP (O) (OX942) (OX943), OSi (X944) (X945) (X946), OS (O 2 ) X947, NHC (O) X948, NX949C (O) X950, NHC ( O) OX951, NHC (O) NHX952, NHC (O) NX953X954, NX955C (O) OX956, NX957C (O) NHX958, NX959C (O) NX960X961, NHS (O 2 ) X962, NX963S (O 2 ) X964, SX965, S (O) X966, S (O 2 ) X967, S (O 2 ) NHX968, S (O 2 ) NX969X970, S (O 2 ) OX971, P (O) (OX972) (OX973), Si (X974) ( X975) (X976) " 여기서, X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943, X944, X945, X946,X947, X948, X949, X950, X951, X952, X953, X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X931, X932 및/또는 X940, X941 및/또는 X953, X954 및/또는 X960, X961 및/또는 X969, X970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943, X944, X945, X946, X947, X948, X949, X950, X951, X952, X953, X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X931, X932 and / or X940, X941 and / or X953, X954 and / or X960, X961 and / or X969, X970 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX977, NX978X979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X980, C(O)OX981, C(O)NHX982, C(O)NX983X984, OX985, O(X986-O)hH (h = 1, 2, 3, 4, 5), O(X987-O)hX988 (h = 1, 2, 3, 4, 5), OC(O)X989, OC(O)OX990, OC(O)NHX991, OC(O)NX992X993, OP(O)(OX994)(OX995), OSi(X996)(X997)(X998), OS(O2)X999, NHC(O)X1000, NX1001C(O)X1002, NHC(O)OX1003, NHC(O)NHX1004, NHC(O)NX1005X1006, NX1007C(O)OX1008, NX1009C(O)NHX1010, NX1011C(O)NX1012X1013, NHS(O2)X1014, NX1015S(O2)X1016, SX1017, S(O)X1018, S(O2)X1019, S(O2)NHX1020, S(O2)NX1021X1022, S(O2)OX1023, P(O)(OX1024)(OX1025), Si(X1026)(X1027)(X1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX977, NX978X979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X980, C (O) OX981, C (O) NHX982, C (O) NX983X984, OX985, O (X986-O) h H (h = 1, 2, 3, 4, 5), O (X987-O) h X988 (h = 1, 2, 3, 4, 5), OC (O) X989, OC (O) OX990, OC (O) NHX991 , OC (O) NX992X993, OP (O) (OX994) (OX995), OSi (X996) (X997) (X998), OS (O 2 ) X999, NHC (O) X1000, NX1001C (O) X1002, NHC ( O) OX1003, NHC (O) NHX1004, NHC (O) NX1005X1006, NX1007C (O) OX1008, NX1009C (O) NHX1010, NX1011C (O) NX1012X1013, NHS (O 2 ) X1014, NX1015S (O 2 ) X1016, SX1016 S (O) X1018, S (O 2 ) X1019, S (O 2 ) NHX1020, S (O 2 ) NX1021X1022, S (O 2 ) OX1023, P (O) (OX1024) (OX1025), Si (X1026) ( X1027) (X1028) " 여기서, X977, X978, X979, X980, X981, X982, X983, X984, X985, X986, X987, X988, X989, X990, X991, X992, X993, X994, X995, X996, X997, X998, X999, X1000, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X1011, X1012, X1013, X1014, X1015, X1016, X1017, X1018, X1019, X1020, X1021, X1022, X1023, X1024, X1025, X1026, X1027, X1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X983, X984 및/또는 X992, X993 및/또는 X1005, X1006 및/또는 X1012, X1013 및/또는 X1021, X1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X977, X978, X979, X980, X981, X982, X983, X984, X985, X986, X987, X988, X989, X990, X991, X992, X993, X994, X995, X996, X997, X998, X999, X1000, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X1011, X1012, X1013, X1014, X1015, X1016, X1017, X1018, X1019, X1020, X1021, X1022, X1023, X1024, X1024 X1026, X1027, X1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X983, X984 and / or X992, X993 and / or X1005, X1006 and / or X1012, X1013 and / or X1021, X1022 are also in each case" heterocycle Reels ", (l) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) SZ7, wherein Z7 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1029, NX1030X1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1032, C(O)OX1033, C(O)NHX1034, C(O)NX1035X1036, OX1037, O(X1038-O)iH (i = 1, 2, 3, 4, 5), O(X1039-O)iX1040 (i = 1, 2, 3, 4, 5), OC(O)X1041, OC(O)OX1042, OC(O)NHX1043, OC(O)NX1044X1045, OP(O)(OX1046)(OX1047), OSi(X1048)(X1049)(X1050), OS(O2)X1051, NHC(O)X1052, NX1053C(O)X1054, NHC(O)OX1055, NHC(O)NHX1056, NHC(O)NX1057X1058, NX1059C(O)OX1060, NX1061C(O)NHX1062, NX1063C(O)NX1064X1065, NHS(O2)X1066, NX1067S(O2)X1068, SX1069, S(O)X1070, S(O2)X1071, S(O2)NHX1072, S(O2)NX1073X1074, S(O2)OX1075, P(O)(OX1076)(OX1077), Si(X1078)(X1079)(X1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1029, NX1030X1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1032, C (O) OX1033, C (O) NHX1034, C (O) NX1035X1036, OX1037, O (X1038-O) i H (i = 1, 2, 3, 4, 5), O (X1039-O) i X1040 (i = 1, 2, 3, 4, 5), OC (O) X1041, OC (O) OX1042, OC (O) NHX1043 , OC (O) NX1044X1045, OP (O) (OX1046) (OX1047), OSi (X1048) (X1049) (X1050), OS (O 2 ) X1051, NHC (O) X1052, NX1053C (O) X1054, NHC ( O) OX1055, NHC (O) NHX1056, NHC (O) NX1057X1058, NX1059C (O) OX1060, NX1061C (O) NHX1062, NX1063C (O) NX1064X1065, NHS (O 2 ) X1066, NX1067S (O 2 ) X1068, SX1069 S (O) X1070, S (O 2 ) X1071, S (O 2 ) NHX1072, S (O 2 ) NX1073X1074, S (O 2 ) OX1075, P (O) (OX1076) (OX1077), Si (X1078) ( X1079) (X1080) " 여기서, X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051, X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, X1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1035, X1036 및/또는 X1044, X1045 및/또는 X1057, X1058 및/또는 X1064, X1065 및/또는 X1073, X1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051, X1052 X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077 X1078, X1079, X1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1035, X1036 and / or X1044, X1045 and / or X1057, X1058 and / or X1064, X1065 and / or X1073, X1074 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1081, NX1082X1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1084, C(O)OX1085, C(O)NHX1086, C(O)NX1087X1088, OX1089, O(X1090-O)jH (j = 1, 2, 3, 4, 5), O(X1091-O)jX1092 (j = 1, 2, 3, 4, 5), OC(O)X1093, OC(O)OX1094, OC(O)NHX1095, OC(O)NX1096X1097, OP(O)(OX1098)(OX1099), OSi(X1100)(X1101)(X1102), OS(O2)X1103, NHC(O)X1104, NX1105C(O)X1106, NHC(O)OX1107, NHC(O)NHX1108, NHC(O)NX1109X1110, NX1111C(O)OX1112, NX1113C(O)NHX1114, NX1115C(O)NX1116X1117, NHS(O2)X1118, NX1119S(O2)X1120, SX1121, S(O)X1122, S(O2)X1123, S(O2)NHX1124, S(O2)NX1125X1126, S(O2)OX1127, P(O)(OX1128)(OX1129), Si(X1130)(X1131)(X1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1081, NX1082X1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1084, C (O) OX1085, C (O) NHX1086, C (O) NX1087X1088, OX1089, O (X1090-O) j H (j = 1, 2, 3, 4, 5), O (X1091-O) j X1092 (j = 1, 2, 3, 4, 5), OC (O) X1093, OC (O) OX1094, OC (O) NHX1095 , OC (O) NX1096X1097, OP (O) (OX1098) (OX1099), OSi (X1100) (X1101) (X1102), OS (O 2 ) X1103, NHC (O) X1104, NX1105C (O) X1106, NHC ( O) OX1107, NHC (O) NHX1108, NHC (O) NX1109X1110, NX1111C (O) OX1112, NX1113C (O) NHX1114, NX1115C (O) NX1116X1117, NHS (O 2 ) X1118, NX1119S (O 2 ) X1120, SX112 S (O) X1122, S (O 2 ) X1123, S (O 2 ) NHX1124, S (O 2 ) NX1125X1126, S (O 2 ) OX1127, P (O) (OX1128) (OX1129), Si (X1130) ( X1131) (X1132) " 여기서, X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1104, X1105, X1106, X1107, X1108, X1109, X1110, X1111, X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131, X1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1087, X1088 및/또는 X1096, X1097 및/또는 X1109, X1110 및/또는 X1116, X1117 및/또는 X1125, X1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1104 X1105, X1106, X1107, X1108, X1109, X1110, X1111, X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1128, X1128 X1130, X1131, X1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1087, X1088 and / or X1096, X1097 and / or X1109, X1110 and / or X1116, X1117 and / or X1125, X1126 are also in each case" heterocycle Reels ", (m) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)X1133, C(O)OX1134, C(O)NX1135X1136, S(O2)X1137, S(O2)OX1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) X1133 , C (O) OX1134, C (O) NX1135X1136, S (O 2 ) X1137, S (O 2 ) OX1138 " 여기서, X1133, X1134, X1135, X1136, X1137, X1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1135, X1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein X1133, X1134, X1135, X1136, X1137, X1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl Alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, X1135, X1136 together may also form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1139, NX1140X1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1142, C(O)OX1143, C(O)NHX1144, C(O)NX1145X1146, OX1147, O(X1148-O)kH (k = 1, 2, 3, 4, 5), O(X1149-O)kX1150 (k = 1, 2, 3, 4, 5), OC(O)X1151, OC(O)OX1152, OC(O)NHX1153, OC(O)NX1154X1155, OP(O)(OX1156)(OX1157), OSi(X1158)(X1159)(X1160), OS(O2)X1161, NHC(O)X1162, NX1163C(O)X1164, NHC(O)OX1165, NHC(O)NHX1166, NHC(O)NX1167X1168, NX1169C(O)OX1170, NX1171C(O)NHX1172, NX1173C(O)NX1174X1175, NHS(O2)X1176, NX1177S(O2)X1178, SX1179, S(O)X1180, S(O2)X1181, S(O2)NHX1182, S(O2)NX1183X1184, S(O2)OX1185, P(O)(OX1186)(OX1187), Si(X1188)(X1189)(X1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1139, NX1140X1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1142, C (O) OX1143, C (O) NHX1144, C (O) NX1145X1146, OX1147, O (X1148-O) k H (k = 1, 2, 3, 4, 5), O (X1149-O) k X1150 (k = 1, 2, 3, 4, 5), OC (O) X1151, OC (O) OX1152, OC (O) NHX1153 , OC (O) NX1154X1155, OP (O) (OX1156) (OX1157), OSi (X1158) (X1159) (X1160), OS (O 2 ) X1161, NHC (O) X1162, NX1163C (O) X1164, NHC ( O) OX1165, NHC (O) NHX1166, NHC (O) NX1167X1168, NX1169C (O) OX1170, NX1171C (O) NHX1172, NX1173C (O) NX1174X1175, NHS (O 2 ) X1176, NX1177S (O 2 ) X1178, SX1178 S (O) X1180, S (O 2 ) X1181, S (O 2 ) NHX1182, S (O 2 ) NX1183X1184, S (O 2 ) OX1185, P (O) (OX1186) (OX1187), Si (X1188) ( X1189) (X1190) " 여기서, X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181, X1182, X1183, X1184, X1185, X1186, X1187, X1188, X1189, X1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1145, X1146 및/또는 X1154, X1155 및/또는 X1167, X1168 및/또는 X1174, X1175 및/또는 X1183, X1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1162 X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181, X1182, X1183, X1184, X1185, X1186, X1186, X1186 X1188, X1189, X1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1145, X1146 and / or X1154, X1155 and / or X1167, X1168 and / or X1174, X1175 and / or X1183, X1184 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHX1191, NX1192X1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)X1194, C(O)OX1195, C(O)NHX1196, C(O)NX1197X1198, OX1199, O(X1200-O)lH (l = 1, 2, 3, 4, 5), O(X1201-O)lX1202 (l = 1, 2, 3, 4, 5), OC(O)X1203, OC(O)OX1204, OC(O)NHX1205, OC(O)NX1206X1207, OP(O)(OX1208)(OX1209), OSi(X1210)(X1211)(X1212), OS(O2)X1213, NHC(O)X1214, NX1215C(O)X1216, NHC(O)OX1217, NHC(O)NHX1218, NHC(O)NX1219X1220, NX1221C(O)OX1222, NX1223C(O)NHX1224, NX1225C(O)NX1226X1227, NHS(O2)X1228, NX1229S(O2)X1230, SX1231, S(O)X1232, S(O2)X1233, S(O2)NHX1234, S(O2)NX1235X1236, S(O2)OX1237, P(O)(OX1238)(OX1239), Si(X1240)(X1241)(X1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHX1191, NX1192X1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) X1194, C (O) OX1195, C (O) NHX1196, C (O) NX1197X1198, OX1199, O (X1200-O) l H (l = 1, 2, 3, 4, 5), O (X1201-O) l X1202 (l = 1, 2, 3, 4, 5), OC (O) X1203, OC (O) OX1204, OC (O) NHX1205 , OC (O) NX1206X1207, OP (O) (OX1208) (OX1209), OSi (X1210) (X1211) (X1212), OS (O 2 ) X1213, NHC (O) X1214, NX1215C (O) X1216, NHC ( O) OX1217, NHC (O) NHX1218, NHC (O) NX1219X1220, NX1221C (O) OX1222, NX1223C (O) NHX1224, NX1225C (O) NX1226X1227, NHS (O 2 ) X1228, NX1229S (O 2 ) X1230, SX123 S (O) X1232, S (O 2 ) X1233, S (O 2 ) NHX1234, S (O 2 ) NX1235X1236, S (O 2 ) OX1237, P (O) (OX1238) (OX1239), Si (X1240) ( X1241) (X1242) " 여기서, X1191, X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237, X1238, X1239, X1240, X1241, X1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, X1197, X1198 및/또는 X1206, X1207 및/또는 X1219, X1220 및/또는 X1226, X1227 및/또는 X1235, X1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where X1191, X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1214 X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237, X1238, X1239, X1240, X1241, X1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, X1197, X1198 and / or X1206, X1207 and / or X1219, X1220 and / or X1226, X1227 and / or X1235, X1236 are also in each case" heterocycle Reels ", 또는or (B) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "치환 된 헤테로아릴"이고, 여기서, "치환된 헤테로아릴"은 다음으로 이루어진 그룹으로부터 선택된 하나 이상의 치환체에 의해 치환되고:(B) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted heteroaryl" wherein "substituted heteroaryl" is substituted by one or more substituents selected from the group consisting of: (a) "알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, NHV1, N(알킬)2, NHC(O)알킬, NHC(O)사이클로알킬, NHC(O)헤테로사이클릴, NHC(O)아릴, NHC(O)헤테로아릴, NHC(O)아릴알킬, NHC(O)헤테로아릴알킬, NHS(O2)알킬, NHS(O2)사이클로알킬, NHS(O2)헤테로사이클릴, NHS(O2)아릴, NHS(O2)헤테로아릴, NHS(O2)아릴알킬, NHS(O2)헤테로아릴알킬, S알킬, S아릴, S헤테로아릴, O알킬, O사이클로알킬, O사이클로알킬알킬, O아릴, O아릴알킬, O헤테로아릴, O-헤테로아릴알킬, O헤테로사이클릴알킬, OC(O)알킬, OC(O)사이클로알킬, OC(O)헤테로사이클릴, OC(O)아릴, OC(O)헤테로아릴, OC(O)아릴알킬, OC(O)헤테로아릴알킬, OS(O2)알킬, OS(O2)사이클로알킬, OS(O2)헤테로사이클릴, OS(O2)아릴, OS(O2)헤테로아릴, OS(O2)아릴알킬, OS(O2)헤테로아릴알킬, C(O)알킬, C(O)아릴, C(O)헤테로아릴, C(O)OV2, C(O)NHV3, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, S(O2)NH알킬, S(O2)NH아릴, S(O2)NH헤테로아릴, S(O2)NH아릴알킬, S(O2)O알킬, S(O2)O아릴, S(O2)O아릴알킬"(a) “alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, NHV 1, N (alkyl) 2 , NHC (O) alkyl, NHC (O) cycloalkyl, NHC (O) heterocyclyl, NHC (O ) Aryl, NHC (O) heteroaryl, NHC (O) arylalkyl, NHC (O) heteroarylalkyl, NHS (O 2 ) alkyl, NHS (O 2 ) cycloalkyl, NHS (O 2 ) heterocyclyl, NHS (O 2 ) aryl, NHS (O 2 ) heteroaryl, NHS (O 2 ) arylalkyl, NHS (O 2 ) heteroarylalkyl, Salkyl, Saryl, Sheteroaryl, Oalkyl, Ocycloalkyl, Ocyclo Alkylalkyl, Oaryl, Oarylalkyl, Oheteroaryl, O-heteroarylalkyl, Oheterocyclylalkyl, OC (O) alkyl, OC (O) cycloalkyl, OC (O) heterocyclyl, OC (O ) Aryl, OC (O) heteroaryl, OC (O) arylalkyl, OC (O) heteroarylalkyl, OS (O 2 ) alkyl, OS (O 2 ) cycloalkyl, OS (O 2 ) heterocyclyl, OS (O 2 ) aryl, OS (O 2 ) heteroaryl, OS (O 2 ) arylalkyl, OS (O 2 ) heteroarylalkyl, C (O) alkyl, C (O) aryl, C (O) heteroaryl, C (O) OV2, C (O) NHV 3, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , S (O 2 ) NH Alkyl, S (O 2 ) NH aryl, S (O 2 ) NH heteroaryl, S (O 2 ) NH arylalkyl, S (O 2 ) O alkyl, S (O 2 ) O aryl, S (O 2 ) O Arylalkyl " 여기서, V1, V2, V3은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Wherein V 1, V 2, V 3 are each independently selected from the group consisting of: “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” 단, 치환체 그룹(a)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of: (i) "(C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, N3, NH사이클로알킬, NH사이클로알킬알킬, NH헤테로아릴, NH헤테로아릴알킬, NH아릴알킬, NH헤테로사이클릴, NH헤테로사이클릴알킬, NV4V5, S사이클로알킬, S사이클로알킬알킬, S아릴, S아릴알킬, S헤테로아릴, S헤테로아릴알킬, S헤테로사이클릴, S헤테로사이클릴알킬, O사이클로알킬, O사이클로알킬알킬, O아릴알킬, O헤테로아릴, O헤테로아릴알킬, O헤테로사이클릴, O헤테로사이클릴알킬, O(V6-O)pH (p = 1, 2, 3, 4, 5), O(V7-O)pV8 (p = 1, 2, 3, 4, 5), OP(O)(OV9)(OV10), C(O)OV11, C(O)NH2, C(O)NHV12, C(O)NV13V14, S(O2)V15, P(O)(OH)2, P(O)(OV16)(OV17), Si(V18)(V19)(V20), OSi(V21)(V22)(V23), OC(O)OV24, OC(O)NHV25, OC(O)NV26V27, NHC(O)OV28, NHC(O)NHV29, NHC(O)NV30V31, NV32C(O)OV33, NV34C(O)NHV35, NV36C(O)NV37V38, NV39S(O2)V40, NHS(O2)V41, OS(O2)V42, NHC(O)V43, NV44C(O)V45, C(O)V46, OC(O)V47, S(O)V48, S(O2)NHV49, S(O2)NV50V51, S(O2)OV52" (i) "(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , NHcycloalkyl, NHcyclo Alkylalkyl, NH heteroaryl, NH heteroarylalkyl, NH arylalkyl, NH heterocyclyl, NH heterocyclylalkyl, NV4V5, Scycloalkyl, Scycloalkylalkyl, Saryl, Sarylalkyl, S heteroaryl, S Heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, Ocycloalkyl, Ocycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O ( V6-O) p H (p = 1, 2, 3, 4, 5), O (V7-O) p V8 (p = 1, 2, 3, 4, 5), OP (O) (OV9) ( OV10), C (O) OV11, C (O) NH2, C (O) NHV12, C (O) NV13V14, S (O 2 ) V15, P (O) (OH) 2 , P (O) (OV16) (OV17), Si (V18) (V19) (V20), OSi (V21) (V22) (V23), OC (O) OV24, OC (O) NHV25, OC (O) NV26V27, NHC (O) OV28, NHC (O) NHV29, NHC (O) NV30V31, NV32C (O) OV33, NV34C (O) NHV35, NV36C (O) NV37V38, NV39S (O 2 ) V40, NHS (O 2 ) V41, OS (O 2 ) V42, NHC (O) V43, NV44C (O) V45, C (O) V46, OC (O ) V47, S (O) V48, S (O 2 ) NHV49, S (O 2 ) NV50V51, S (O 2 ) OV52 " 추가로 단, "N(알킬)2"는 다음 치환체 그룹(b)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further provided that "N (alkyl) 2 " is further substituted by one or more substituents selected from the following substituent groups (b); 여기서, V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V26, V27, V28, V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43, V44, V45, V46, V47, V48, V49, V50, V51, V52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V13, V14 및/또는 V26, V27 및/또는 V30, V31 및/또는 V37, V38 및/또는 V50, V51 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V26, V27, V28, V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43, V44, V45, V46, V47, V48, V49, V50, V51, V52 Each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", Where, alternatively, V13, V14 and / or V26, V27 and / or V30, V31 and / or V37, V38 and / or V50, V51 may also together form" heterocyclyl ", 여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (b) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV53, NV54V55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V56, C(O)OV57, C(O)NHV58, C(O)NV59V60, OV61, O(V62-O)rH (r = 1, 2, 3, 4, 5), O(V63-O)rV64 (r = 1, 2, 3, 4, 5), OC(O)V65, OC(O)OV66, OC(O)NHV67, OC(O)NV68V69, OP(O)(OV70)(OV71), OSi(V72)(V73)(V74), OS(O2)V75, NHC(O)V76, NV77C(O)V78, NHC(O)OV79, NHC(O)NHV80, NHC(O)NV81V82, NV83C(O)OV84, NV85C(O)NHV86, NV87C(O)NV88V89, NHS(O2)V90, NV91S(O2)V92, SV93, S(O)V94, S(O2)V95, S(O2)NHV96, S(O2)NV97V98, S(O2)OV99, P(O)(OV100)(OV101), Si(V102)(V103)(V104)"(b) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV53, NV54V55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V56, C (O) OV57, C (O) NHV58, C (O) NV59V60, OV61, O (V62-O) r H (r = 1, 2, 3, 4, 5), O (V63-O) r V64 (r = 1, 2, 3, 4, 5), OC (O) V65, OC (O) OV66, OC (O) NHV67 , OC (O) NV68V69, OP (O) (OV70) (OV71), OSi (V72) (V73) (V74), OS (O 2 ) V75, NHC (O) V76, NV77C (O) V78, NHC ( O) OV79, NHC (O) NHV80, NHC (O) NV81V82, NV83C (O) OV84, NV85C (O) NHV86, NV87C (O) NV88V89, NHS (O 2 ) V90, NV91S (O 2 ) V92, SV93, S (O) V94, S (O 2 ) V95, S (O 2 ) NHV96, S (O 2 ) NV97V98, S (O 2 ) OV99, P (O) (OV100) (OV101), Si (V102) ( V103) (V104) " 여기서, V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65, V66, V67, V68, V69, V70, V71, V72,V73, V74, V75, V76, V77, V78, V79, V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V59, V60 및/또는 V68, V69 및/또는 V81, V82 및/또는 V88, V89 및/또는 V97, V98은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65, V66, V67, V68, V69, V70, V71, V72, V73, V74, V75, V76, V77, V78, V79, V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V59, V60 and / or V68, V69 and / or V81, V82 and / or V88, V89 and / or V97, V98 together may also refer to" heterocyclyl " Can form, 여기서, 임의로, 치환체 그룹(b)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV105, NV106V107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V108, C(O)OV109, C(O)NHV110, C(O)NV111V112, OV113, O(V114-O)sH (s = 1, 2, 3, 4, 5), O(V115-O)sV116 (s = 1, 2, 3, 4, 5), OC(O)V117, OC(O)OV118, OC(O)NHV119, OC(O)NV120V121, OP(O)(OV122)(OV123), OSi(V124)(V125)(V126), OS(O2)V127, NHC(O)V128, NV129C(O)V130, NHC(O)OV131, NHC(O)NHV132, NHC(O)NV133V134, NV135C(O)OV136, NV137C(O)NHV138, NV139C(O)NV140V141, NHS(O2)V142, NV143S(O2)V144, SV145, S(O)V146, S(O2)V147, S(O2)NHV148, S(O2)NV149V150, S(O2)OV151, P(O)(OV152)(OV153), Si(V154)(V155)(V156)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV105, NV106V107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V108, C (O) OV109, C (O) NHV110, C (O) NV111V112, OV113, O (V114-O) s H (s = 1, 2, 3, 4, 5), O (V115-O) s V116 (s = 1, 2, 3, 4, 5), OC (O) V117, OC (O) OV118, OC (O) NHV119 , OC (O) NV120V121, OP (O) (OV122) (OV123), OSi (V124) (V125) (V126), OS (O 2 ) V127, NHC (O) V128, NV129C (O) V130, NHC ( O) OV131, NHC (O) NHV132, NHC (O) NV133V134, NV135C (O) OV136, NV137C (O) NHV138, NV139C (O) NV140V141, NHS (O 2 ) V142, NV143S (O 2 ) V144, SV145, S (O) V146, S (O 2 ) V147, S (O 2 ) NHV148, S (O 2 ) NV149V150, S (O 2 ) OV151, P (O) (OV152) (OV153), Si (V154) ( V155) (V156) " 여기서, V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141, V142, V143, V144, V145, V146, V147, V148, V149, V150, V151, V152, V153, V154, V155, V156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V111, V112 및/또는 V120, V121 및/또는 V133, V134 및/또는 V140, V141 및/또는 V149, V150은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141, V142, V143, V144, V145, V146, V147, V148, V149, V150, V151, V152, V153, V154, V155, V156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V111, V112 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 may also together refer to" heterocyclyl " Can form, 여기서, 임의로, Where, optionally 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Said substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV157, NV158V159, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V160, C(O)OV161, C(O)NHV162, C(O)NV163V164, OV165, O(V166-O)tH (t = 1, 2, 3, 4, 5), O(V167-O)tV168 (t = 1, 2, 3, 4, 5), OC(O)V169, OC(O)OV170, OC(O)NHV171, OC(O)NV172V173, OP(O)(OV174)(OV175), OSi(V176)(V177)(V178), OS(O2)V179, NHC(O)V180, NV181C(O)V182, NHC(O)OV183, NHC(O)NHV184, NHC(O)NV185V186, NV187C(O)OV188, NV189C(O)NHV190, NV191C(O)NV192V193, NHS(O2)V194, NV195S(O2)V196, SV197, S(O)V198, S(O2)V199, S(O2)NHV200, S(O2)NV201V202, S(O2)OV203, P(O)(OV204)(OV205), Si(V206)(V207)(V208)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV157, NV158V159, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V160, C (O) OV161, C (O) NHV162, C (O) NV163V164, OV165, O (V166-O) t H (t = 1, 2, 3, 4, 5), O (V167-O) t V168 (t = 1, 2, 3, 4, 5), OC (O) V169, OC (O) OV170, OC (O) NHV171 , OC (O) NV172V173, OP (O) (OV174) (OV175), OSi (V176) (V177) (V178), OS (O 2 ) V179, NHC (O) V180, NV181C (O) V182, NHC ( O) OV183, NHC (O) NHV184, NHC (O) NV185V186, NV187C (O) OV188, NV189C (O) NHV190, NV191C (O) NV192V193, NHS (O 2 ) V194, NV195S (O 2 ) V196, SV197, S (O) V198, S (O 2 ) V199, S (O 2 ) NHV200, S (O 2 ) NV201V202, S (O 2 ) OV203, P (O) (OV204) (OV205), Si (V206) ( V207) (V208) " 여기서, V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194, V195, V196, V197, V198, V199, V200, V201, V202, V203, V204, V205, V206, V207, V208은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬" 여기서, 대안적으로, V163, V164 및/또는 V172, V173 및/또는 V185, V186 및/또는 V192, V193 및/또는 V201, V202는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194, V195, V196, V197, V198, V199, V200, V201, V202, V203, V204, V205, V206, V207, V208 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl "wherein, alternatively, V163, V164 and / or V172, V173 and / or V185, V186 and / or V192, V193 and / or V201, V202 together also form" heterocyclyl " Can do it, 또는 Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "치환된 헤테로아릴"이고, 여기서, "치환된 헤테로아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고: Or one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted heteroaryl" wherein "substituted heteroaryl" is substituted by one or more substituents identically or differently selected from the group consisting of: Being: (c) "(C9-C30)알킬, NV209V210, NH(C9-C30)알킬, NHC(O)사이클로알킬알킬, NHC(O)헤테로사이클릴알킬, NHC(O)(C9-C30)알킬, NV211C(O)V212, NV213C(O)(C9-C30)알킬, NHC(O)OV214, NV215C(O)OV216, NHC(O)NHV217, NHC(O)NV218V219, NV220C(O)NHV221, NV222C(O)NV223V224, NHS(O2)사이클로알킬알킬, NHS(O2)헤테로사이클릴알킬, NV225S(O2)V226, O헤테로사이클릴, O(C9-C30)알킬, S사이클로알킬, S헤테로사이클릴, S아릴알킬, S헤테로아릴알킬, S사이클로알킬알킬, S헤테로사이클릴알킬, S(C9-C30)알킬, OC(O)사이클로알킬알킬, OC(O)헤테로사이클릴알킬, OC(O)(C9-C30)알킬, OC(O)OV227, OC(O)NHV228, OC(O)NV229V230, OP(O)(OV231)(OV232), OS(O2)사이클로알킬알킬, OS(O2)헤테로사이클릴알킬, OS(O2)(C9-C30)알킬, C(O)사이클로알킬, C(O)헤테로사이클릴, C(O)아릴알킬, C(O)헤테로아릴알킬, C(O)사이클로알킬알 킬, C(O)헤테로사이클릴알킬, C(O)(C9-C30)알킬, C(O)O(C9-C30)알킬, C(O)NH(C9-C30)알킬, C(O)NV233V234, C(O)NHOV235, C(O)NV236-OV237, C(O)NHNV238V239, C(O)NV240NV241V242, S(O)V243, S(O2)V244, S(O2)NH사이클로알킬, S(O2)NH헤테로사이클릴, S(O2)NH헤테로아릴알킬, S(O2)NH사이클로알킬알킬, S(O2)NH헤테로사이클릴알킬, S(O2)NH(C9-C30)알킬, S(O2)O사이클로알킬, S(O2)O헤테로사이클릴, S(O2)O헤테로아릴, S(O2)O헤테로아릴알킬, S(O2)O사이클로알킬알킬, S(O2)O헤테로사이클릴알킬, S(O2)O(C9-C30)알킬, P(O)(OH)2, P(O)(OV245)(OV246), Si(V247)(V248)(V249), OSi(V250)(V251)(V252)"(c) "(C 9 -C 30 ) alkyl, NV209V210, NH (C 9 -C 30 ) alkyl, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NHC (O) (C 9- C 30 ) alkyl, NV211C (O) V212, NV213C (O) (C 9 -C 30 ) alkyl, NHC (O) OV214, NV215C (O) OV216, NHC (O) NHV217, NHC (O) NV218V219, NV220C ( O) NHV221, NV222C (O) NV223V224, NHS (O 2 ) cycloalkylalkyl, NHS (O 2 ) heterocyclylalkyl, NV225S (O 2 ) V226, O heterocyclyl, O (C 9 -C 30 ) alkyl , Scycloalkyl, Sheterocyclyl, Sarylalkyl, Sheteroarylalkyl, Scycloalkylalkyl, Sheterocyclylalkyl, S (C 9 -C 30 ) alkyl, OC (O) cycloalkylalkyl, OC ( O) Heterocyclylalkyl, OC (O) (C 9 -C 30 ) alkyl, OC (O) OV227, OC (O) NHV228, OC (O) NV229V230, OP (O) (OV231) (OV232), OS (O 2 ) cycloalkylalkyl, OS (O 2) heterocyclylalkyl, OS (O 2 ) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) heterocyclyl, C (O) Arylalkyl, C (O) heteroarylalkyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O) (C 9 -C 30 ) alkyl, C (O) O (C 9 -C 30 ) alkyl, C (O) NH (C 9 -C 30 ) alkyl, C (O) NV233V234, C (O) NHOV235, C (O) NV236-OV237, C (O) NHNV238V239, C (O) NV240NV241V242, S (O) V243, S (O2) V244, S (O 2 ) NH cycloalkyl, S (O 2 ) NH hetero Cyclyl, S (O 2 ) NH heteroarylalkyl, S (O 2 ) NH cycloalkylalkyl, S (O 2 ) NH heterocyclylalkyl, S (O 2 ) NH (C 9 -C 30 ) alkyl, S (O 2 ) Ocycloalkyl, S (O 2 ) O heterocyclyl, S (O 2 ) O heteroaryl, S (O 2 ) O heteroarylalkyl, S (O 2 ) Ocycloalkylalkyl, S (O 2 ) O heterocyclylalkyl, S (O 2 ) O (C 9 -C 30 ) alkyl, P (O) (OH) 2, P (O) (OV245) (OV246), Si (V247) (V248) (V249), OSi (V250) (V251) (V252) " 여기서, V209, V210, V211, V212, V213, V214, V215, V216, V217, V218, V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229, V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V218, V219 및/또는 V223, V224 및/또는 V229, V230 및/또는 V233, V234 및/또는 V238, V239 및/또는 V241, V242는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V209, V210, V211, V212, V213, V214, V215, V216, V217, V218, V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229, V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are each independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein, alternatively, V218, V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 together may also form “heterocyclyl”, 단, 치환체 "N(알킬)2", "C(O)N(알킬)2", "C(O)N(사이클로알킬)2", "C(O)N(아 릴)2", "C(O)N(헤테로아릴)2"는 다음 치환체 그룹(i)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Provided that the substituents "N (alkyl) 2 ", "C (O) N (alkyl) 2 ", "C (O) N (cycloalkyl) 2 ", "C (O) N (aryl) 2 ", " C (O) N (heteroaryl) 2 ″ is further substituted by one or more substituents selected from the following substituent groups (i); 여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV253, NV254V255, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V256, C(O)OV257, C(O)NHV258, C(O)NV259V260, OV261, O(V262-O)uH (u = 1, 2, 3, 4, 5), O(V263-O)uV264 (u = 1, 2, 3, 4, 5), OC(O)V265, OC(O)OV266, OC(O)NHV267, OC(O)NV268V269, OP(O)(OV270)(OV271), OSi(V272)(V273)(V274), OS(O2)V275, NHC(O)V276, NV277C(O)V278, NHC(O)OV279, NHC(O)NHV280, NHC(O)NV281V282, NV283C(O)OV284, NV285C(O)NHV286, NV287C(O)NV288V289, NHS(O2)V290, NV291S(O2)V292, SV293, S(O)V294, S(O2)V295, S(O2)NHV296, S(O2)NV297V298, S(O2)OV299, P(O)(OV300)(OV301), Si(V302)(V303)(V304)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV253, NV254V255, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V256, C (O) OV257, C (O) NHV258, C (O) NV259V260, OV261, O (V262-O) u H (u = 1, 2, 3, 4, 5), O (V263-O) u V264 (u = 1, 2, 3, 4, 5), OC (O) V265, OC (O) OV266, OC (O) NHV267 , OC (O) NV268V269, OP (O) (OV270) (OV271), OSi (V272) (V273) (V274), OS (O 2 ) V275, NHC (O) V276, NV277C (O) V278, NHC ( O) OV279, NHC (O) NHV280, NHC (O) NV281V282, NV283C (O) OV284, NV285C (O) NHV286, NV287C (O) NV288V289, NHS (O2) V290, NV291S (O2) V292, SV293, S ( O) V294, S (O 2 ) V295, S (O 2 ) NHV296, S (O 2 ) NV297V298, S (O 2 ) OV299, P (O) (OV300) (OV301), Si (V302) (V303) (V304) " 여기서, V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274, V275, V276, V277, V278, V279, V280, V281, V282, V283, V284, V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V259, V260 및/또는 V268, V269 및/또는 V281, V282 및/또는 V288, V289 및/또는 V297, V298은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274, V275, V276, V277, V278, V279, V280, V281, V282, V283, V284, V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V259, V260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 together may also refer to" heterocyclyl " Can form, 여기서, 임의로, 추가적으로 Z3, Z4 라디칼 중 하나 또는 추가적으로 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (d) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV305, NV306V307, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V308, C(O)OV309, C(O)NHV310, C(O)NV311V312, OV313, O(V314-O)vH (v = 1, 2, 3, 4, 5), O(V315-O)vV316 (v = 1, 2, 3, 4, 5), OC(O)V317, OC(O)OV318, OC(O)NHV319, OC(O)NV320V321, OP(O)(OV322)(OV323), OSi(V324)(V325)(V326), OS(O2)V327, NHC(O)V328, NV329C(O)V330, NHC(O)OV331, NHC(O)NHV332, NHC(O)NV333V334, NV335C(O)OV336, NV337C(O)NHV338, NV339C(O)NV340V341, NHS(O2)V342, NV343S(O2)V344, SV345, S(O)V346, S(O2)V347, S(O2)NHV348, S(O2)NV349V350, S(O2)OV351, P(O)(OV352)(OV353), Si(V354)(V355)(V356)"(d) "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN , CF 3 , N 3 , NH 2 , NHV305, NV306V307, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V308, C (O) OV309, C (O) NHV310, C (O) NV311V312, OV313, O (V314-O) v H (v = 1, 2, 3, 4, 5), O (V315-O) v V316 (v = 1, 2, 3, 4, 5), OC (O) V317, OC (O) OV318, OC (O) NHV319, OC (O) NV320V321, OP (O) (OV322) (OV323), OSi (V324) (V325) (V326), OS (O 2 ) V327, NHC (O) V328, NV329C (O) V330, NHC (O) OV331, NHC (O) NHV332, NHC (O) NV333V334, NV335C (O) OV336, NV337C (O) NHV338, NV339C (O) NV340V341, NHS (O2) V342, NV343S (O2) V344, SV345, S (O) V346, S (O 2 ) V347, S (O 2 ) NHV348, S (O 2 ) NV349V350, S (O 2 ) OV351, P (O) (OV352) (OV353), Si (V354) (V355) (V356 ) " 여기서, V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331, V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V311, V312 및/또는 V320, V321 및/또는 V333, V334 및/또는 V340, V341 및/또는 V349, V350은 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331, V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V311, V312 and / or V320, V321 and / or V333, V334 and / or V340, V341 and / or V349, V350 may also be referred to as" heterocyclyl " Can form, 여기서, 임의로, 치환체 그룹(d)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (d) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV357, NV358V359, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V360, C(O)OV361, C(O)NHV362, C(O)NV363V364, OV365, O(V366-O)wH (w = 1, 2, 3, 4, 5), O(V367-O)wV368 (w = 1, 2, 3, 4, 5), OC(O)V369, OC(O)OV370, OC(O)NHV371, OC(O)NV372V373, OP(O)(OV374)(OV375), OSi(V376)(V377)(V378), OS(O2)V379, NHC(O)V380, NV381C(O)V382, NHC(O)OV383, NHC(O)NHV384, NHC(O)NV385V386, NV387C(O)OV388, NV389C(O)NHV390, NV391C(O)NV392V393, NHS(O2)V394, NV395S(O2)V396, SV397, S(O)V398, S(O2)V399, S(O2)NHV400, S(O2)NV401V402, S(O2)OV403, P(O)(OV404)(OV405), Si(V406)(V407)(V408)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV357, NV358V359, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V360, C (O) OV361, C (O) NHV362, C (O) NV363V364, OV365, O (V366-O) w H (w = 1, 2, 3, 4, 5), O (V367-O) w V368 (w = 1, 2, 3, 4, 5), OC (O) V369, OC (O) OV370, OC (O) NHV371 , OC (O) NV372V373, OP (O) (OV374) (OV375), OSi (V376) (V377) (V378), OS (O 2 ) V379, NHC (O) V380, NV381C (O) V382, NHC ( O) OV383, NHC (O) NHV384, NHC (O) NV385V386, NV387C (O) OV388, NV389C (O) NHV390, NV391C (O) NV392V393, NHS (O2) V394, NV395S (O2) V396, SV397, S ( O) V398, S (O 2 ) V399, S (O 2 ) NHV400, S (O 2 ) NV401V402, S (O 2 ) OV403, P (O) (OV404) (OV405), Si (V406) (V407) (V408) " 여기서, V357, V358, V359, V360, V361, V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V363, V364 및/또는 V372, V373 및/또는 V385, V386 및/또는 V392, V393 및/또는 V401, V402는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V357, V358, V359, V360, V361, V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V363, V364 and / or V372, V373 and / or V385, V386 and / or V392, V393 and / or V401, V402 together also represent" heterocyclyl " Can form, 여기서, 임의로, 치환체 그룹(i) 및/또는 치환체 그룹(ii)의 상기한 치환체 는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV409, NV410V411, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V412, C(O)OV413, C(O)NHV414, C(O)NV415V416, OV417, O(V418-O)xH (x = 1, 2, 3, 4, 5), O(V419-O)xV420 (x = 1, 2, 3, 4, 5), OC(O)V421, OC(O)OV422, OC(O)NHV423, OC(O)NV424V425, OP(O)(OV426)(OV427), OSi(V428)(V429)(V430), OS(O2)V431, NHC(O)V432, NV433C(O)V434, NHC(O)OV435, NHC(O)NHV436, NHC(O)NV437V438, NV439C(O)OV440, NV441C(O)NHV442, NV443C(O)NV444V445, NHS(O2)V446, NV447S(O2)V448, SV449, S(O)V450, S(O2)V451, S(O2)NHV452, S(O2)NV453V454, S(O2)OV455, P(O)(OV456a)(OV456b), Si(V456c)(V456d)(V456e)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV 409, NV410V411, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V412, C (O) OV413, C (O) NHV414, C (O) NV415V416, OV417, O (V418-O) x H (x = 1, 2, 3, 4, 5), O (V419-O) x V420 (x = 1, 2, 3, 4, 5), OC (O) V421, OC (O) OV422, OC (O) NHV423 , OC (O) NV424V425, OP (O) (OV426) (OV427), OSi (V428) (V429) (V430), OS (O 2 ) V431, NHC (O) V432, NV433C (O) V434, NHC ( O) OV435, NHC (O) NHV436, NHC (O) NV437V438, NV439C (O) OV440, NV441C (O) NHV442, NV443C (O) NV444V445, NHS (O 2 ) V446, NV447S (O2) V448, SV449, S (O) V450, S (O 2 ) V451, S (O 2 ) NHV452, S (O 2 ) NV453V454, S (O 2 ) OV455, P (O) (OV456a) (OV456b), Si (V456c) (V456d ) (V456e) " 여기서, V409, V410, V411, V412, V413, V414, V415, V416, V417, V418, V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429, V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V415, V416 및/또는 V424, V425 및/또는 V437, V438 및/또는 V444, V445 및/또는 V453, V454는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where V409, V410, V411, V412, V413, V414, V415, V416, V417, V418, V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429, V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V415, V416 and / or V424, V425 and / or V437, V438 and / or V444, V445 and / or V453, V454 together also refer to" heterocyclyl " Can form, Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of: (e) 수소;(e) hydrogen; (f) 할로겐, F, Cl, Br, I;(f) halogen, F, Cl, Br, I; (g) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV457, NV458V459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V460, C(O)OV461, C(O)NHV462, C(O)NV463V464, OV465, O(V466-O)yH (y = 1, 2, 3, 4, 5), O(V467-O)yV468 (y = 1, 2, 3, 4, 5), OC(O)V469, OC(O)OV470, OC(O)NHV471, OC(O)NV472V473, OP(O)(OV474)(OV475), OSi(V476)(V477)(V478), OS(O2)V479, NHC(O)V480, NV481C(O)V482, NHC(O)OV483, NHC(O)NHV484, NHC(O)NV485V486, NV487C(O)OV488, NV489C(O)NHV490, NV491C(O)NV492V493, NHS(O2)V494, NV495S(O2)V496, SV497, S(O)V498, S(O2)V499, S(O2)NHV500, S(O2)NV501V502, S(O2)OV503, P(O)(OV504)(OV505), Si(V506)(V507)(V508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV457, NV458V459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V460, C (O) OV461, C (O) NHV462, C (O) NV463V464, OV465, O (V466-O) y H (y = 1, 2, 3, 4, 5), O (V467-O) y V468 (y = 1, 2, 3, 4, 5), OC (O) V469, OC (O) OV470, OC (O) NHV471 , OC (O) NV472V473, OP (O) (OV474) (OV475), OSi (V476) (V477) (V478), OS (O 2 ) V479, NHC (O) V480, NV481C (O) V482, NHC ( O) OV483, NHC (O) NHV484, NHC (O) NV485V486, NV487C (O) OV488, NV489C (O) NHV490, NV491C (O) NV492V493, NHS (O2) V494, NV495S (O2) V496, SV497, S ( O) V498, S (O 2 ) V499, S (O 2 ) NHV500, S (O 2 ) NV501V502, S (O 2 ) OV503, P (O) (OV504) (OV505), Si (V506) (V507) (V508) " 여기서, V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495, V496, V497, V498, V499, V500, V501, V502, V503, V504, V505, V506, V507, V508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V463, V464 및/또는 V472, V473 및/또는 V485, V486 및/또는 V492, V493 및/또는 V501, V502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495, V496, V497, V498, V499, V500, V501, V502, V503, V504, V505, V506, V507, V508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V463, V464 and / or V472, V473 and / or V485, V486 and / or V492, V493 and / or V501, V502 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV509, NV510V511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V512, C(O)OV513, C(O)NHV514, C(O)NV515V516, OV517, O(V518-O)zH (z = 1, 2, 3, 4, 5), O(V519-O)zV520 (z = 1, 2, 3, 4, 5), OC(O)V521, OC(O)OV522, OC(O)NHV523, OC(O)NV524V525, OP(O)(OV526)(OV527), OSi(V528)(V529)(V530), OS(O2)V531, NHC(O)V532, NV533C(O)V534, NHC(O)OV535, NHC(O)NHV536, NHC(O)NV537V538, NV539C(O)OV540, NV541C(O)NHV542, NV543C(O)NV544V545, NHS(O2)V546, NV547S(O2)V548, SV549, S(O)V550, S(O2)V551, S(O2)NHV552, S(O2)NV553V554, S(O2)OV555, P(O)(OV556)(OV557), Si(V558)(V559)(V560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV509, NV510V511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V512, C (O) OV513, C (O) NHV514, C (O) NV515V516, OV517, O (V518-O) z H (z = 1, 2, 3, 4, 5), O (V519-O) z V520 (z = 1, 2, 3, 4, 5), OC (O) V521, OC (O) OV522, OC (O) NHV523 , OC (O) NV524V525, OP (O) (OV526) (OV527), OSi (V528) (V529) (V530), OS (O 2 ) V531, NHC (O) V532, NV533C (O) V534, NHC ( O) OV535, NHC (O) NHV536, NHC (O) NV537V538, NV539C (O) OV540, NV541C (O) NHV542, NV543C (O) NV544V545, NHS (O 2 ) V546, NV547S (O 2 ) V548, SV549, S (O) V550, S (O 2 ) V551, S (O 2 ) NHV552, S (O 2 ) NV553V554, S (O 2 ) OV555, P (O) (OV556) (OV557), Si (V558) ( V559) (V560) " 여기서, V509, V510, V511, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527, V528, V529, V530, V531, V532, V533, V534, V535, V536, V537, V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V515, V516 및/또는 V524, V525 및/또는 V537, V538 및/또는 V544, V545 및/또는 V553, V554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, V509, V510, V511, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527, V528, V529, V530, V531, V532, V533, V534, V535, V536, V537, V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V515, V516 and / or V524, V525 and / or V537, V538 and / or V544, V545 and / or V553, V554 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV561, NV562V563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V564, C(O)OV565, C(O)NHV566, C(O)NV567V568, OV569, O(V570-O)aH (a = 1, 2, 3, 4, 5), O(V571-O)aV572 (a = 1, 2, 3, 4, 5), OC(O)V573, OC(O)OV574, OC(O)NHV575, OC(O)NV576V577, OP(O)(OV578)(OV579), OSi(V580)(V581)(V582), OS(O2)V583, NHC(O)V584, NV585C(O)V586, NHC(O)OV587, NHC(O)NHV588, NHC(O)NV589V590, NV591C(O)OV592, NV593C(O)NHV594, NV595C(O)NV596V597, NHS(O2)V598, NV599S(O2)V600, SV601, S(O)V602, S(O2)V603, S(O2)NHV604, S(O2)NV605V606, S(O2)OV607, P(O)(OV608)(OV609), Si(V610)(V611)(V612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV561, NV562V563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V564, C (O) OV565, C (O) NHV566, C (O) NV567V568, OV569, O (V570-O) a H (a = 1, 2, 3, 4, 5), O (V571-O) a V572 (a = 1, 2, 3, 4, 5), OC (O) V573, OC (O) OV574, OC (O) NHV575 , OC (O) NV576V577, OP (O) (OV578) (OV579), OSi (V580) (V581) (V582), OS (O 2 ) V583, NHC (O) V584, NV585C (O) V586, NHC ( O) OV587, NHC (O) NHV588, NHC (O) NV589V590, NV591C (O) OV592, NV593C (O) NHV594, NV595C (O) NV596V597, NHS (O 2 ) V598, NV599S (O 2 ) V600, SV601, S (O) V602, S (O 2 ) V603, S (O 2 ) NHV604, S (O 2 ) NV605V606, S (O 2 ) OV607, P (O) (OV608) (OV609), Si (V610) ( V611) (V612) " 여기서, V561, V562, V563, V564, V565, V566, V567, V568, V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V567, V568 및/또는 V576, V577 및/또는 V589, V590 및/또는 V596, V597 및/또는 V605, V606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V561, V562, V563, V564, V565, V566, V567, V568, V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V567, V568 and / or V576, V577 and / or V589, V590 and / or V596, V597 and / or V605, V606 are also in each case" heterocycle. " Reels ", (h) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV613, NV614V615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V616, C(O)OV617, C(O)NHV618, C(O)NV619V620, OV621, O(V622-O)bH (b = 1, 2, 3, 4, 5), O(V623-O)bV624 (b = 1, 2, 3, 4, 5), OC(O)V625, OC(O)OV626, OC(O)NHV627, OC(O)NV628V629, OP(O)(OV630)(OV631), OSi(V632)(V633)(V634), OS(O2)V635, NHC(O)V636, NV637C(O)V638, NHC(O)OV639, NHC(O)NHV640, NHC(O)NV641V642, NV643C(O)OV644, NV645C(O)NHV646, NV647C(O)NV648V649, NHS(O2)V650, NV651S(O2)V652, SV653, S(O)V654, S(O2)V655, S(O2)NHV656, S(O2)NV657V658, S(O2)OV659, P(O)(OV660)(OV661), Si(V662)(V663)(V664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV613, NV614V615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V616, C (O) OV617, C (O) NHV618, C (O) NV619V620, OV621, O (V622-O) b H (b = 1, 2, 3, 4, 5), O (V623-O) b V624 (b = 1, 2, 3, 4, 5), OC (O) V625, OC (O) OV626, OC (O) NHV627 , OC (O) NV628V629, OP (O) (OV630) (OV631), OSi (V632) (V633) (V634), OS (O 2 ) V635, NHC (O) V636, NV637C (O) V638, NHC ( O) OV639, NHC (O) NHV640, NHC (O) NV641V642, NV643C (O) OV644, NV645C (O) NHV646, NV647C (O) NV648V649, NHS (O 2 ) V650, NV651S (O 2 ) V652, SV653, S (O) V654, S (O 2 ) V655, S (O 2 ) NHV656, S (O 2 ) NV657V658, S (O 2 ) OV659, P (O) (OV660) (OV661), Si (V662) ( V663) (V664) " 여기서, V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631, V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651, V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V619, V620 및/또는 V628, V629 및/또는 V641, V642 및/또는 V648, V649 및/또는 V657, V658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631, V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651, V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V619, V620 and / or V628, V629 and / or V641, V642 and / or V648, V649 and / or V657, V658 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV665, NV666V667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V668, C(O)OV669, C(O)NHV670, C(O)NV671V672, OV673, O(V674-O)cH (c = 1, 2, 3, 4, 5), O(V675- O)cV676 (c = 1, 2, 3, 4, 5), OC(O)V677, OC(O)OV678, OC(O)NHV679, OC(O)NV680V681, OP(O)(OV682)(OV683), OSi(V684)(V685)(V686), OS(O2)V687, NHC(O)V688, NV689C(O)V690, NHC(O)OV691, NHC(O)NHV692, NHC(O)NV693V694, NV695C(O)OV696, NV697C(O)NHV698, NV699C(O)NV700V701, NHS(O2)V702, NV703S(O2)V704, SV705, S(O)V706, S(O2)V707, S(O2)NHV708, S(O2)NV709V710, S(O2)OV711, P(O)(OV712)(OV713), Si(V714)(V715)(V716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV665, NV666V667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V668, C (O) OV669, C (O) NHV670, C (O) NV671V672, OV673, O (V674-O) c H (c = 1, 2, 3, 4, 5), O (V675-O) c V676 (c = 1, 2, 3, 4, 5), OC (O) V677, OC (O) OV678, OC (O) NHV679 , OC (O) NV680V681, OP (O) (OV682) (OV683), OSi (V684) (V685) (V686), OS (O 2 ) V687, NHC (O) V688, NV689C (O) V690, NHC ( O) OV691, NHC (O) NHV692, NHC (O) NV693V694, NV695C (O) OV696, NV697C (O) NHV698, NV699C (O) NV700V701, NHS (O 2 ) V702, NV703S (O2) V704, SV705, S (O) V706, S (O 2 ) V707, S (O 2 ) NHV708, S (O 2 ) NV709V710, S (O 2 ) OV711, P (O) (OV712) (OV713), Si (V714) (V715 ) (V716) " 여기서, V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V687, V688, V689, V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V712, V713, V714, V715, V716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V671, V672 및/또는 V680, V681 및/또는 V693, V694 및/또는 V700, V701 및/또는 V709, V710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V687, V688, V689, V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V712, V713, V714, V715, V716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V671, V672 and / or V680, V681 and / or V693, V694 and / or V700, V701 and / or V709, V710 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV717, NV718V719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V720, C(O)OV721, C(O)NHV722, C(O)NV723V724, OV725, O(V726-O)dH (d = 1, 2, 3, 4, 5), O(V727-O)dV728 (d = 1, 2, 3, 4, 5), OC(O)V729, OC(O)OV730, OC(O)NHV731, OC(O)NV732V733, OP(O)(OV734)(OV735), OSi(V736)(V737)(V738), OS(O2)V739, NHC(O)V740, NV741C(O)V742, NHC(O)OV743, NHC(O)NHV744, NHC(O)NV745V746, NV747C(O)OV748, NV749C(O)NHV750, NV751C(O)NV752V753, NHS(O2)V754, NV755S(O2)V756, SV757, S(O)V758, S(O2)V759, S(O2)NHV760, S(O2)NV761V762, S(O2)OV763, P(O)(OV764)(OV765), Si(V766)(V767)(V768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV717, NV718V719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V720, C (O) OV721, C (O) NHV722, C (O) NV723V724, OV725, O (V726-O) d H (d = 1, 2, 3, 4, 5), O (V727-O) d V728 (d = 1, 2, 3, 4, 5), OC (O) V729, OC (O) OV730, OC (O) NHV731 , OC (O) NV732V733, OP (O) (OV734) (OV735), OSi (V736) (V737) (V738), OS (O 2 ) V739, NHC (O) V740, NV741C (O) V742, NHC ( O) OV743, NHC (O) NHV744, NHC (O) NV745V746, NV747C (O) OV748, NV749C (O) NHV750, NV751C (O) NV752V753, NHS (O2) V754, NV755S (O2) V756, SV757, S ( O) V758, S (O 2 ) V759, S (O 2 ) NHV760, S (O 2 ) NV761V762, S (O 2 ) OV763, P (O) (OV764) (OV765), Si (V766) (V767) (V768) " 여기서, V717, V718, V719, V720, V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V723, V724 및/또는 V732, V733 및/또는 V745, V746 및/또는 V752, V753 및/또는 V761, V762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V717, V718, V719, V720, V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V723, V724 and / or V732, V733 and / or V745, V746 and / or V752, V753 and / or V761, V762 are also in each case" heterocycle. " Reels ", (j) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV769, NV770V771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V772, C(O)OV773, C(O)NHV774, C(O)NV775V776, OV777, O(V778-O)eH (e = 1, 2, 3, 4, 5), O(V779-O)eV780 (e = 1, 2, 3, 4, 5), OC(O)V781, OC(O)OV782, OC(O)NHV783, OC(O)NV784V785, OP(O)(OV786)(OV787), OSi(V788)(V789)(V790), OS(O2)V791, NHC(O)V792, NV793C(O)V794, NHC(O)OV795, NHC(O)NHV796, NHC(O)NV797V798, NV799C(O)OV800, NV801C(O)NHV802, NV803C(O)NV804V805, NHS(O2)V806, NV807S(O2)V808, SV809, S(O)V810, S(O2)V811, S(O2)NHV812, S(O2)NV813V814, S(O2)OV815, P(O)(OV816)(OV817), Si(V818)(V819)(V820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV769, NV770V771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V772, C (O) OV773, C (O) NHV774, C (O) NV775V776, OV777, O (V778-O) e H (e = 1, 2, 3, 4, 5), O (V779-O) e V780 (e = 1, 2, 3, 4, 5), OC (O) V781, OC (O) OV782, OC (O) NHV783 , OC (O) NV784V785, OP (O) (OV786) (OV787), OSi (V788) (V789) (V790), OS (O 2 ) V791, NHC (O) V792, NV793C (O) V794, NHC ( O) OV795, NHC (O) NHV796, NHC (O) NV797V798, NV799C (O) OV800, NV801C (O) NHV802, NV803C (O) NV804V805, NHS (O 2 ) V806, NV807S (O 2 ) V808, SV809, S (O) V810, S (O 2 ) V811, S (O 2 ) NHV812, S (O 2 ) NV813V814, S (O 2 ) OV815, P (O) (OV816) (OV817), Si (V818) ( V819) (V820) " 여기서, V769, V770, V771, V772, V773, V774, V775, V776, V777, V778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V791, V792, V793, V794, V795, V796, V797, V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V775, V776 및/또는 V784, V785 및/또는 V797, V798 및/또는 V804, V805 및/또는 V813, V814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V769, V770, V771, V772, V773, V774, V775, V776, V777, V778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V791, V792, V793, V794, V795, V796, V797, V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V775, V776 and / or V784, V785 and / or V797, V798 and / or V804, V805 and / or V813, V814 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV821, NV822V823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V824, C(O)OV825, C(O)NHV826, C(O)NV827V828, OV829, O(V830-O)fH (f = 1, 2, 3, 4, 5), O(V831-O)fV832 (f = 1, 2, 3, 4, 5), OC(O)V833, OC(O)OV834, OC(O)NHV835, OC(O)NV836V837, OP(O)(OV838)(OV839), OSi(V840)(V841)(V842), OS(O2)V843, NHC(O)V844, NV845C(O)V846, NHC(O)OV847, NHC(O)NHV848, NHC(O)NV849V850, NV851C(O)OV852, NV853C(O)NHV854, NV855C(O)NV856V857, NHS(O2)V858, NV859S(O2)V860, SV861, S(O)V862, S(O2)V863, S(O2)NHV864, S(O2)NV865V866, S(O2)OV867, P(O)(OV868)(OV869), Si(V870)(V871)(V872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV821, NV822V823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V824, C (O) OV825, C (O) NHV826, C (O) NV827V828, OV829, O (V830-O) f H (f = 1, 2, 3, 4, 5), O (V831-O) f V832 (f = 1, 2, 3, 4, 5), OC (O) V833, OC (O) OV834, OC (O) NHV835 , OC (O) NV836V837, OP (O) (OV838) (OV839), OSi (V840) (V841) (V842), OS (O 2 ) V843, NHC (O) V844, NV845C (O) V846, NHC ( O) OV847, NHC (O) NHV848, NHC (O) NV849V850, NV851C (O) OV852, NV853C (O) NHV854, NV855C (O) NV856V857, NHS (O 2 ) V858, NV859S (O 2 ) V860, SV861, S (O) V862, S (O 2 ) V863, S (O 2 ) NHV864, S (O 2 ) NV865V866, S (O 2 ) OV867, P (O) (OV868) (OV869), Si (V870) ( V871) (V872) " 여기서, V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856,V857, V858, V859, V860, V861, V862, V863, V864, V865, V866, V867, V868, V869, V870, V871, V872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V827, V828 및/또는 V836, V837 및/또는 V849, V850 및/또는 V856, V857 및/또는 V865, V866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859, V860, V861, V862, V863, V864, V865, V866, V867, V868, V869, V870, V871, V872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V827, V828 and / or V836, V837 and / or V849, V850 and / or V856, V857 and / or V865, V866 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV873, NV874V875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V876, C(O)OV877, C(O)NHV878, C(O)NV879V880, OV881, O(V882-O)gH (g = 1, 2, 3, 4, 5), O(V883-O)gV884 (g = 1, 2, 3, 4, 5), OC(O)V885, OC(O)OV886, OC(O)NHV887, OC(O)NV888V889, OP(O)(OV890)(OV891), OSi(V892)(V893)(V894), OS(O2)V895, NHC(O)V896, NV897C(O)V898, NHC(O)OV899, NHC(O)NHV900, NHC(O)NV901V902, NV903C(O)OV904, NV905C(O)NHV906, NV907C(O)NV908V909, NHS(O2)V910, NV911S(O2)V912, SV913, S(O)V914, S(O2)V915, S(O2)NHV916, S(O2)NV917V918, S(O2)OV919, P(O)(OV920)(OV921), Si(V922)(V923)(V924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV873, NV874V875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V876, C (O) OV877, C (O) NHV878, C (O) NV879V880, OV881, O (V882-O) g H (g = 1, 2, 3, 4, 5), O (V883-O) g V884 (g = 1, 2, 3, 4, 5), OC (O) V885, OC (O) OV886, OC (O) NHV887 , OC (O) NV888V889, OP (O) (OV890) (OV891), OSi (V892) (V893) (V894), OS (O 2 ) V895, NHC (O) V896, NV897C (O) V898, NHC ( O) OV899, NHC (O) NHV900, NHC (O) NV901V902, NV903C (O) OV904, NV905C (O) NHV906, NV907C (O) NV908V909, NHS (O 2 ) V910, NV911S (O 2 ) V912, SV913, S (O) V914, S (O 2 ) V915, S (O 2 ) NHV916, S (O 2 ) NV917V918, S (O 2 ) OV919, P (O) (OV920) (OV921), Si (V922) ( V923) (V924) " 여기서, V873, V874, V875, V876, V877, V878, V879, V880, V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V879, V880 및/또는 V888, V889 및/또는 V901, V902 및/또는 V908, V909 및/또는 V917, V918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V873, V874, V875, V876, V877, V878, V879, V880, V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V879, V880 and / or V888, V889 and / or V901, V902 and / or V908, V909 and / or V917, V918 are also in each case" heterocycle Reels ", (k) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) OZ6, wherein Z6 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV925, NV926V927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V928, C(O)OV929, C(O)NHV930, C(O)NV931V932, OV933, O(V934-O)hH (h = 1, 2, 3, 4, 5), O(V935-O)hV936 (h = 1, 2, 3, 4, 5), OC(O)V937, OC(O)OV938, OC(O)NHV939, OC(O)NV940V941, OP(O)(OV942)(OV943), OSi(V944)(V945)(V946), OS(O2)V947, NHC(O)V948, NV949C(O)V950, NHC(O)OV951, NHC(O)NHV952, NHC(O)NV953V954, NV955C(O)OV956, NV957C(O)NHV958, NV959C(O)NV960V961, NHS(O2)V962, NV963S(O2)V964, SV965, S(O)V966, S(O2)V967, S(O2)NHV968, S(O2)NV969V970, S(O2)OV971, P(O)(OV972)(OV973), Si(V974)(V975)(V976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV925, NV926V927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V928, C (O) OV929, C (O) NHV930, C (O) NV931V932, OV933, O (V934-O) h H (h = 1, 2, 3, 4, 5), O (V935-O) h V936 (h = 1, 2, 3, 4, 5), OC (O) V937, OC (O) OV938, OC (O) NHV939 , OC (O) NV940V941, OP (O) (OV942) (OV943), OSi (V944) (V945) (V946), OS (O 2 ) V947, NHC (O) V948, NV949C (O) V950, NHC ( O) OV951, NHC (O) NHV952, NHC (O) NV953V954, NV955C (O) OV956, NV957C (O) NHV958, NV959C (O) NV960V961, NHS (O 2 ) V962, NV963S (O 2 ) V964, SV965, S (O) V966, S (O 2 ) V967, S (O 2 ) NHV968, S (O 2 ) NV969V970, S (O 2 ) OV971, P (O) (OV972) (OV973), Si (V974) ( V975) (V976) " 여기서, V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946,V947, V948, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963, V964, V965, V966, V967, V968, V969, V970, V971, V972, V973, V974, V975, V976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V931, V932 및/또는 V940, V941 및/또는 V953, V954 및/또는 V960, V961 및/또는 V969, V970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963, V964, V965, V966, V967, V968, V969, V970, V971, V972, V973, V974, V975, V976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V931, V932 and / or V940, V941 and / or V953, V954 and / or V960, V961 and / or V969, V970 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV977, NV978V979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V980, C(O)OV981, C(O)NHV982, C(O)NV983V984, OV985, O(V986-O)iH (i = 1, 2, 3, 4, 5), O(V987- O)iV988 (i = 1, 2, 3, 4, 5), OC(O)V989, OC(O)OV990, OC(O)NHV991, OC(O)NV992V993, OP(O)(OV994)(OV995), OSi(V996)(V997)(V998), OS(O2)V999, NHC(O)V1000, NV1001C(O)V1002, NHC(O)OV1003, NHC(O)NHV1004, NHC(O)NV1005V1006, NV1007C(O)OV1008, NV1009C(O)NHV1010, NV1011C(O)NV1012V1013, NHS(O2)V1014, NV1015S(O2)V1016, SV1017, S(O)V1018, S(O2)V1019, S(O2)NHV1020, S(O2)NV1021V1022, S(O2)OV1023, P(O)(OV1024)(OV1025), Si(V1026)(V1027)(V1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV977, NV978V979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V980, C (O) OV981, C (O) NHV982, C (O) NV983V984, OV985, O (V986-O) i H (i = 1, 2, 3, 4, 5), O (V987-O) i V988 (i = 1, 2, 3, 4, 5), OC (O) V989, OC (O) OV990, OC (O) NHV991 , OC (O) NV992V993, OP (O) (OV994) (OV995), OSi (V996) (V997) (V998), OS (O 2 ) V999, NHC (O) V1000, NV1001C (O) V1002, NHC ( O) OV1003, NHC (O) NHV1004, NHC (O) NV1005V1006, NV1007C (O) OV1008, NV1009C (O) NHV1010, NV1011C (O) NV1012V1013, NHS (O2) V1014, NV1015S (O2) V1016, SV1017, S (10) O) V1018, S (O 2 ) V1019, S (O 2 ) NHV1020, S (O 2 ) NV1021V1022, S (O 2 ) OV1023, P (O) (OV1024) (OV1025), Si (V1026) (V1027) (V1028) " 여기서, V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1025, V1026, V1027, V1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V983, V984 및/또는 V992, V993 및/또는 V1005, V1006 및/또는 V1012, V1013 및/또는 V1021, V1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1024 V1026, V1027, V1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V983, V984 and / or V992, V993 and / or V1005, V1006 and / or V1012, V1013 and / or V1021, V1022 are also in each case" heterocycle Reels ", (l) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) SZ7, wherein Z7 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1029, NV1030V1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1032, C(O)OV1033, C(O)NHV1034, C(O)NV1035V1036, OV1037, O(V1038-O)jH (j = 1, 2, 3, 4, 5), O(V1039-O)jV1040 (j = 1, 2, 3, 4, 5), OC(O)V1041, OC(O)OV1042, OC(O)NHV1043, OC(O)NV1044V1045, OP(O)(OV1046)(OV1047), OSi(V1048)(V1049)(V1050), OS(O2)V1051, NHC(O)V1052, NV1053C(O)V1054, NHC(O)OV1055, NHC(O)NHV1056, NHC(O)NV1057V1058, NV1059C(O)OV1060, NV1061C(O)NHV1062, NV1063C(O)NV1064V1065, NHS(O2)V1066, NV1067S(O2)V1068, SV1069, S(O)V1070, S(O2)V1071, S(O2)NHV1072, S(O2)NV1073V1074, S(O2)OV1075, P(O)(OV1076)(OV1077), Si(V1078)(V1079)(V1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1029, NV1030V1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1032, C (O) OV1033, C (O) NHV1034, C (O) NV1035V1036, OV1037, O (V1038-O) j H (j = 1, 2, 3, 4, 5), O (V1039-O) j V1040 (j = 1, 2, 3, 4, 5), OC (O) V1041, OC (O) OV1042, OC (O) NHV1043 , OC (O) NV1044V1045, OP (O) (OV1046) (OV1047), OSi (V1048) (V1049) (V1050), OS (O 2 ) V1051, NHC (O) V1052, NV1053C (O) V1054, NHC ( O) OV1055, NHC (O) NHV1056, NHC (O) NV1057V1058, NV1059C (O) OV1060, NV1061C (O) NHV1062, NV1063C (O) NV1064V1065, NHS (O2) V1066, NV1067S (O2) V1068, SV1069, S ( O) V1070, S (O 2 ) V1071, S (O 2 ) NHV1072, S (O 2 ) NV1073V1074, S (O 2 ) OV1075, P (O) (OV1076) (OV1077), Si (V1078) (V1079) (V1080) " 여기서, V1029, V1030, V1031, V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051, V1052, V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1077, V1078, V1079, V1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1035, V1036 및/또는 V1044, V1045 및/또는 V1057, V1058 및/또는 V1064, V1065 및/또는 V1073, V1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1029, V1030, V1031, V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051, V1052 V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1076, V1076 V1078, V1079, V1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V1035, V1036 and / or V1044, V1045 and / or V1057, V1058 and / or V1064, V1065 and / or V1073, V1074 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1081, NV1082V1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1084, C(O)OV1085, C(O)NHV1086, C(O)NV1087V1088, OV1089, O(V1090-O)kH (k = 1, 2, 3, 4, 5), O(V1091-O)kV1092 (k = 1, 2, 3, 4, 5), OC(O)V1093, OC(O)OV1094, OC(O)NHV1095, OC(O)NV1096V1097, OP(O)(OV1098)(OV1099), OSi(V1100)(V1101)(V1102), OS(O2)V1103, NHC(O)V1104, NV1105C(O)V1106, NHC(O)OV1107, NHC(O)NHV1108, NHC(O)NV1109V1110, NV1111C(O)OV1112, NV1113C(O)NHV1114, NV1115C(O)NV1116V1117, NHS(O2)V1118, NV1119S(O2)V1120, SV1121, S(O)V1122, S(O2)V1123, S(O2)NHV1124, S(O2)NV1125V1126, S(O2)OV1127, P(O)(OV1128)(OV1129), Si(V1130)(V1131)(V1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1081, NV1082V1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1084, C (O) OV1085, C (O) NHV1086, C (O) NV1087V1088, OV1089, O (V1090-O) k H (k = 1, 2, 3, 4, 5), O (V1091-O) k V1092 (k = 1, 2, 3, 4, 5), OC (O) V1093, OC (O) OV1094, OC (O) NHV1095 , OC (O) NV1096V1097, OP (O) (OV1098) (OV1099), OSi (V1100) (V1101) (V1102), OS (O 2 ) V1103, NHC (O) V1104, NV1105C (O) V1106, NHC ( O) OV1107, NHC (O) NHV1108, NHC (O) NV1109V1110, NV1111C (O) OV1112, NV1113C (O) NHV1114, NV1115C (O) NV1116V1117, NHS (O2) V1118, NV1119S (O2) V1120, SV1121, S112 (S) O) V1122, S (O 2 ) V1123, S (O 2 ) NHV1124, S (O 2 ) NV1125V1126, S (O 2 ) OV1127, P (O) (OV1128) (OV1129), Si (V1130) (V1131) (V1132) " 여기서, V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105, V1106, V1107, V1108, V1109, V1110, V1111, V1112, V1113, V1114, V1115, V1116, V1117, V1118, V1119, V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1129, V1130, V1131, V1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1087, V1088 및/또는 V1096, V1097 및/또는 V1109, V1110 및/또는 V1116, V1117 및/또는 V1125, V1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1104 V1105, V1106, V1107, V1108, V1109, V1110, V1111, V1112, V1113, V1114, V1115, V1116, V1117, V1118, V1119, V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1128, V1128, V1128 V1130, V1131, V1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V1087, V1088 and / or V1096, V1097 and / or V1109, V1110 and / or V1116, V1117 and / or V1125, V1126 are also in each case" heterocycle. " Reels ", (m) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사 이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)V1133, C(O)OV1134, C(O)NV1135V1136, S(O2)V1137, S(O2)OV1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) V1133, C (O) OV1134, C (O) NV1135V1136, S (O2) V1137, S (O2) OV1138 " 여기서, V1133, V1134, V1135, V1136, V1137, V1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1135, V1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein V1133, V1134, V1135, V1136, V1137, V1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl Alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, V1135, V1136 together may also form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1139, NV1140V1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1142, C(O)OV1143, C(O)NHV1144, C(O)NV1145V1146, OV1147, O(V1148-O)lH (l = 1, 2, 3, 4, 5), O(V1149-O)lV1150 (l = 1, 2, 3, 4, 5), OC(O)V1151, OC(O)OV1152, OC(O)NHV1153, OC(O)NV1154V1155, OP(O)(OV1156)(OV1157), OSi(V1158)(V1159)(V1160), OS(O2)V1161, NHC(O)V1162, NV1163C(O)V1164, NHC(O)OV1165, NHC(O)NHV1166, NHC(O)NV1167V1168, NV1169C(O)OV1170, NV1171C(O)NHV1172, NV1173C(O)NV1174V1175, NHS(O2)V1176, NV1177S(O2)V1178, SV1179, S(O)V1180, S(O2)V1181, S(O2)NHV1182, S(O2)NV1183V1184, S(O2)OV1185, P(O)(OV1186)(OV1187), Si(V1188)(V1189)(V1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1139, NV1140V1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1142, C (O) OV1143, C (O) NHV1144, C (O) NV1145V1146, OV1147, O (V1148-O) l H (l = 1, 2, 3, 4, 5), O (V1149-O) l V1150 (l = 1, 2, 3, 4, 5), OC (O) V1151, OC (O) OV1152, OC (O) NHV1153 , OC (O) NV1154V1155, OP (O) (OV1156) (OV1157), OSi (V1158) (V1159) (V1160), OS (O 2 ) V1161, NHC (O) V1162, NV1163C (O) V1164, NHC ( O) OV1165, NHC (O) NHV1166, NHC (O) NV1167V1168, NV1169C (O) OV1170, NV1171C (O) NHV1172, NV1173C (O) NV1174V1175, NHS (O2) V1176, NV1177S (O2) V1178, SV1179, S (11) O) V1180, S (O 2 ) V1181, S (O 2 ) NHV1182, S (O 2 ) NV1183V1184, S (O 2 ) OV1185, P (O) (OV1186) (OV1187), Si (V1188) (V1189) (V1190) " 여기서, V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1161, V1162, V1163, V1164, V1165, V1166, V1167, V1168, V1169, V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1186, V1187, V1188, V1189, V1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1145, V1146 및/또는 V1154, V1155 및/또는 V1167, V1168 및/또는 V1174, V1175 및/또는 V1183, V1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1161, V1162, V1162 V1163, V1164, V1165, V1166, V1167, V1168, V1169, V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1186, V1187 V1188, V1189, V1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, V1145, V1146 and / or V1154, V1155 and / or V1167, V1168 and / or V1174, V1175 and / or V1183, V1184 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHV1191, NV1192V1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)V1194, C(O)OV1195, C(O)NHV1196, C(O)NV1197V1198, OV1199, O(V1200-O)mH (m = 1, 2, 3, 4, 5), O(V1201-O)mV1202 (m = 1, 2, 3, 4, 5), OC(O)V1203, OC(O)OV1204, OC(O)NHV1205, OC(O)NV1206V1207, OP(O)(OV1208)(OV1209), OSi(V1210)(V1211)(V1212), OS(O2)V1213, NHC(O)V1214, NV1215C(O)V1216, NHC(O)OV1217, NHC(O)NHV1218, NHC(O)NV1219V1220, NV1221C(O)OV1222, NV1223C(O)NHV1224, NV1225C(O)NV1226V1227, NHS(O2)V1228, NV1229S(O2)V1230, SV1231, S(O)V1232, S(O2)V1233, S(O2)NHV1234, S(O2)NV1235V1236, S(O2)OV1237, P(O)(OV1238)(OV1239), Si(V1240)(V1241)(V1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHV1191, NV1192V1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) V1194, C (O) OV1195, C (O) NHV1196, C (O) NV1197V1198, OV1199, O (V1200-O) m H (m = 1, 2, 3, 4, 5), O (V1201-O) m V1202 (m = 1, 2, 3, 4, 5), OC (O) V1203, OC (O) OV1204, OC (O) NHV1205 , OC (O) NV1206V1207, OP (O) (OV1208) (OV1209), OSi (V1210) (V1211) (V1212), OS (O 2 ) V1213, NHC (O) V1214, NV1215C (O) V1216, NHC ( O) OV1217, NHC (O) NHV1218, NHC (O) NV1219V1220, NV1221C (O) OV1222, NV1223C (O) NHV1224, NV1225C (O) NV1226V1227, NHS (O2) V1228, NV1229S (O2) V1230, SV1231, S (123) O) V1232, S (O 2 ) V1233, S (O 2) NHV1234, S (O 2) NV1235V1236, S (O 2) OV1237, P (O) (OV1238) (OV1239), Si (V1240) (V1241) (V1242) " 여기서, V1191, V1192, V1193, V1194, V1195, V1196, V1197, V1198, V1199, V1200, V1201, V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V1211, V1212, V1213, V1214, V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1235, V1236, V1237, V1238, V1239, V1240, V1241, V1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, V1197, V1198 및/또는 V1206, V1207 및/또는 V1219, V1220 및/또는 V1226, V1227 및/또는 V1235, V1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where V1191, V1192, V1193, V1194, V1195, V1196, V1197, V1198, V1199, V1200, V1201, V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V1211, V1212, V1213, V1214, V1214 V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1235, V1236, V1237, V1238, V1239 V1240, V1241, V1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, V1197, V1198 and / or V1206, V1207 and / or V1219, V1220 and / or V1226, V1227 and / or V1235, V1236 are also in each case" heterocycle. " Reels ", 또는or (C) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "치환된 알킬", 여기서, "치환된 알킬"은 다음으로 이루어진 그룹으로부터 선택된 하나 이상의 치환체에 의해 치환되고:(C) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently substituted by "substituted alkyl" wherein "substituted alkyl" is substituted by one or more substituents selected from the group consisting of: (a) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1, NW2W3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W4, C(O)OW5, C(O)NHW6, C(O)NW7W8, OW9, O(W10-O)rH (r = 1, 2, 3, 4, 5), O(W11-O)rW12 (r = 1, 2, 3, 4, 5), OC(O)W13, OC(O)OW14, OC(O)NHW15, OC(O)NW16W17, OP(O)(OW18)(OW19), OSi(W20)(W21)(W22), OS(O2)W23, NHC(O)W24, NW25C(O)W26, NHC(O)OW27, NHC(O)NHW28, NHC(O)NW29W30, NW31C(O)OW32, NW33C(O)NHW34, NW35C(O)NW36W37, NHS(O2)W38, NW39S(O2)W40, SW41, S(O)W42, S(O2)W43, S(O2)NHW44, S(O2)NW45W46, S(O2)OW47, P(O)(OW48)(OW49), Si(W50)(W51)(W52)"(a) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW 1 , NW 2 W 3 , NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W4, C (O) OW5, C (O) NHW6, C (O) NW7W8, OW9, O (W10-O) r H (r = 1, 2, 3, 4, 5), O (W11-O) r W12 (r = 1, 2, 3, 4, 5), OC (O) W13, OC (O) OW14, OC (O) NHW15 , OC (O) NW16W17, OP (O) (OW18) (OW19), OSi (W20) (W21) (W22), OS (O 2 ) W23, NHC (O) W24, NW25C (O) W26, NHC ( O) OW27, NHC (O) NHW28, NHC (O) NW29W30, NW31C (O) OW32, NW33C (O) NHW34, NW35C (O) NW36W37, NHS (O 2 ) W38, NW39S (O 2 ) W40, SW41, S (O) W42, S (O 2 ) W43, S (O 2 ) NHW44, S (O 2 ) NW45W46, S (O 2 ) OW47, P (O) (OW48) (OW49), Si (W50) ( W51) (W52) " 여기서, W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W11, W12, W13, W14, W15, W16, W17, W18, W19, W20, W21, W22, W23, W24, W25, W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W7, W8 및/또는 W16, W17 및/또는 W29, W30 및/또는 W36, W37 및/또는 W45, W46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W11, W12, W13, W14, W15, W16, W17, W18, W19, W20, W21, W22, W23, W24, W25, W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W7, W8 and / or W16, W17 and / or W29, W30 and / or W36, W37 and / or W45, W46 are also in each case" heterocycle. " Reels ", 단, "C(O)NH아릴", "C(O)NH헤테로아릴", "C(O)NH사이클로알킬", "C(O)NH헤테로사이클릴"은 다음 치환 그룹(i)로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Provided that "C (O) NHaryl", "C (O) NH heteroaryl", "C (O) NH cycloalkyl", "C (O) NH heterocyclyl" are selected from the following substitution groups (i) Further substituted by one or more substituents; 여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (a) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW53, NW54W55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W56, C(O)OW57, C(O)NHW58, C(O)NW59W60, OW61, O(W62-O)sH (s = 1, 2, 3, 4, 5), O(W63-O)tW64 (t = 1, 2, 3, 4, 5), OC(O)W65, OC(O)OW66, OC(O)NHW67, OC(O)NW68W69, OP(O)(OW70)(OW71), OSi(W72)(W73)(W74), OS(O2)W75, NHC(O)W76, NW77C(O)W78, NHC(O)OW79, NHC(O)NHW80, NHC(O)NW81W82, NW83C(O)OW84, NW85C(O)NHW86, NW87C(O)NW88W89, NHS(O2)W90, NW91S(O2)W92, SW93, S(O)W94, S(O2)W95, S(O2)NHW96, S(O2)NW97W98, S(O2)OW99, P(O)(OW100)(OW101), Si(W102)(W103)(W104)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW53, NW54W55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W56, C (O) OW57, C (O) NHW58, C (O) NW59W60, OW61, O (W62-O) s H (s = 1, 2, 3, 4, 5), O (W63-O) t W64 (t = 1, 2, 3, 4, 5), OC (O) W65, OC (O) OW66, OC (O) NHW67 , OC (O) NW68W69, OP (O) (OW70) (OW71), OSi (W72) (W73) (W74), OS (O 2 ) W75, NHC (O) W76, NW77C (O) W78, NHC ( O) OW79, NHC (O) NHW80, NHC (O) NW81W82, NW83C (O) OW84, NW85C (O) NHW86, NW87C (O) NW88W89, NHS (O 2 ) W90, NW91S (O 2 ) W92, SW93, S (O) W94, S (O 2 ) W95, S (O 2 ) NHW96, S (O 2 ) NW97W98, S (O 2 ) OW99, P (O) (OW100) (OW101), Si (W102) ( W103) (W104) " 여기서, W53, W54, W55, W56, W57, W58, W59, W60, W61, W62, W63, W64, W65, W66, W67, W68, W69, W70, W71, W72, W73, W74, W75, W76, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88, W89, W90, W91, W92, W93, W94, W95, W96, W97, W98, W99, W100, W101, W102, W103, W104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W59, W60 및/또는 W68, W69 및/또는 W81, W82 및/또는 W88, W89 및/또는 W97, W98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W53, W54, W55, W56, W57, W58, W59, W60, W61, W62, W63, W64, W65, W66, W67, W68, W69, W70, W71, W72, W73, W74, W75, W76, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88, W89, W90, W91, W92, W93, W94, W95, W96, W97, W98, W99, W100, W101, W102, W103, W104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W59, W60 and / or W68, W69 and / or W81, W82 and / or W88, W89 and / or W97, W98 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW105, NW106W107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W108, C(O)OW109, C(O)NHW110, C(O)NW111W112, OW113, O(W114-O)tH (t = 1, 2, 3, 4, 5), O(W115-O)tW116 (t = 1, 2, 3, 4, 5), OC(O)W117, OC(O)OW118, OC(O)NHW119, OC(O)NW120W121, OP(O)(OW122)(OW123), OSi(W124)(W125)(W126), OS(O2)W127, NHC(O)W128, NW129C(O)W130, NHC(O)OW131, NHC(O)NHW132, NHC(O)NW133W134, NW135C(O)OW136, NW137C(O)NHW138, NW139C(O)NW140W141, NHS(O2)W142, NW143S(O2)W144, SW145, S(O)W146, S(O2)W147, S(O2)NHW148, S(O2)NW149W150, S(O2)OW151, P(O)(OW152)(OW153), Si(W154)(W155)(W156)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW105, NW106W107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W108, C (O) OW109, C (O) NHW110, C (O) NW111W112, OW113, O (W114-O) t H (t = 1, 2, 3, 4, 5), O (W115-O) t W116 (t = 1, 2, 3, 4, 5), OC (O) W117, OC (O) OW118, OC (O) NHW119 , OC (O) NW120W121, OP (O) (OW122) (OW123), OSi (W124) (W125) (W126), OS (O 2 ) W127, NHC (O) W128, NW129C (O) W130, NHC ( O) OW131, NHC (O) NHW132, NHC (O) NW133W134, NW135C (O) OW136, NW137C (O) NHW138, NW139C (O) NW140W141, NHS (O 2 ) W142, NW143S (O 2 ) W144, SW145, S (O) W146, S (O 2 ) W147, S (O 2 ) NHW148, S (O 2 ) NW149W150, S (O 2 ) OW151, P (O) (OW152) (OW153), Si (W154) ( W155) (W156) " 여기서, W105, W106, W107, W108, W109, W110, W111, W112, W113, W114, W115, W116, W117, W118, W119,W120, W121, W122, W123, W124, W125, W126, W127, W128, W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152, W153, W154, W155, W156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W111, W112 및/또는 W120, W121 및/또는 W133, W134 및/또는 W140, W141 및/또는 W149, W150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Here, W105, W106, W107, W108, W109, W110, W111, W112, W113, W114, W115, W116, W117, W118, W119, W120, W121, W122, W123, W124, W125, W126, W127, W128, W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152, W153, W154, W155, W156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W111, W112 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 are also in each case" heterocycle. " Reels "; 또는 Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는, 독립적으로 "(C9-C30)알킬"이고; Or one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "(C 9 -C 30 ) alkyl"; 여기서, "(C9-C30)알킬"은 독립적으로 임의로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein “(C 9 -C 30 ) alkyl” may be independently substituted by one or more substituents, optionally selected the same or different from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW157, NW158W159, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W160, C(O)OW161, C(O)NHW162, C(O)NW163W164, OW165, O(W166-O)uH (u = 1, 2, 3, 4, 5), O(W167-O)uW168 (u = 1, 2, 3, 4, 5), OC(O)W169, OC(O)OW170, OC(O)NHW171, OC(O)NW172W173, OP(O)(OW174)(OW175), OSi(W176)(W177)(W178), OS(O2)W179, NHC(O)W180, NW181C(O)W182, NHC(O)OW183, NHC(O)NHW184, NHC(O)NW185W186, NW187C(O)OW188, NW189C(O)NHW190, NW191C(O)NW192W193, NHS(O2)W194, NW195S(O2)W196, SW197, S(O)W198, S(O2)W199, S(O2)NHW200, S(O2)NW201W202, S(O2)OW203, P(O)(OW204)(OW205), Si(W206)(W207)(W208)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW157, NW158W159, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W160, C (O) OW161, C (O) NHW162, C (O) NW163W164, OW165, O (W166-O) u H (u = 1, 2, 3, 4, 5), O (W167-O) u W168 (u = 1, 2, 3, 4, 5), OC (O) W169, OC (O) OW170, OC (O) NHW171 , OC (O) NW172W173, OP (O) (OW174) (OW175), OSi (W176) (W177) (W178), OS (O 2 ) W179, NHC (O) W180, NW181C (O) W182, NHC ( O) OW183, NHC (O) NHW184, NHC (O) NW185W186, NW187C (O) OW188, NW189C (O) NHW190, NW191C (O) NW192W193, NHS (O 2 ) W194, NW195S (O 2 ) W196, SW197, S (O) W198, S (O 2 ) W199, S (O 2 ) NHW200, S (O 2 ) NW201W202, S (O 2 ) OW203, P (O) (OW204) (OW205), Si (W206) ( W207) (W208) " 여기서, W157, W158, W159, W160, W161, W162, W163, W164, W165, W166, W167, W168, W169, W170, W171, W172, W173, W174, W175, W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Here, W157, W158, W159, W160, W161, W162, W163, W164, W165, W166, W167, W168, W169, W170, W171, W172, W173, W174, W175, W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl " 여기서, 대안적으로, W163, W164 및/또는 W172, W173 및/또는 W185, W186 및/또는 W192, W193 및/또는 W201, W202는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, alternatively, W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 may also together form “heterocyclyl” in each case, 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW209, NW210W211, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W212, C(O)OW213, C(O)NHW214, C(O)NW215W216, OW217, O(W218-O)vH (v = 1, 2, 3, 4, 5), O(W219-O)vW220 (v = 1, 2, 3, 4, 5), OC(O)W221, OC(O)OW222, OC(O)NHW223, OC(O)NW224W225, OP(O)(OW226)(OW227), OSi(W228)(W229)(W230), OS(O2)W231, NHC(O)W232, NW233C(O)W234, NHC(O)OW235, NHC(O)NHW236, NHC(O)NW237W238, NW239C(O)OW240, NW241C(O)NHW242, NW243C(O)NW244W245, NHS(O2)W246, NW247S(O2)W248, SW249, S(O)W250, S(O2)W251, S(O2)NHW252, S(O2)NW253W254, S(O2)OW255, P(O)(OW256)(OW257), Si(W258)(W259)(W260)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW209, NW210W211, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W212, C (O) OW213, C (O) NHW214, C (O) NW215W216, OW217, O (W218-O) v H (v = 1, 2, 3, 4, 5), O (W219-O) v W220 (v = 1, 2, 3, 4, 5), OC (O) W221, OC (O) OW222, OC (O) NHW223 , OC (O) NW224W225, OP (O) (OW226) (OW227), OSi (W228) (W229) (W230), OS (O 2 ) W231, NHC (O) W232, NW233C (O) W234, NHC ( O) OW235, NHC (O) NHW236, NHC (O) NW237W238, NW239C (O) OW240, NW241C (O) NHW242, NW243C (O) NW244W245, NHS (O 2 ) W246, NW247S (O 2 ) W248, SW249, S (O) W250, S (O 2 ) W251, S (O 2 ) NHW252, S (O 2 ) NW253W254, S (O 2 ) OW255, P (O) (OW256) (OW257), Si (W258) ( W259) (W260) " 여기서, W209, W210, W211, W212, W213, W214, W215, W216, W217, W218, W219, W220, W221, W222, W223, W224, W225, W226, W227, W228, W229, W230, W231, W232, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W215, W216 및/또는 W224, W225 및/또는 W237, W238 및/또는 W244, W245 및/또는 W253, W254는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W209, W210, W211, W212, W213, W214, W215, W216, W217, W218, W219, W220, W221, W222, W223, W224, W225, W226, W227, W228, W229, W230, W231, W232, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 are also in each case" heterocycle. " Reels ", Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of: (b) 수소;(b) hydrogen; (c) 할로겐, F, Cl, Br, I;(c) halogen, F, Cl, Br, I; (d) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(d) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW457, NW458W459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W460, C(O)OW461, C(O)NHW462, C(O)NW463W464, OW465, O(W466-O)xH (x = 1, 2, 3, 4, 5), O(W467-O)xW468 (x = 1, 2, 3, 4, 5), OC(O)W469, OC(O)OW470, OC(O)NHW471, OC(O)NW472W473, OP(O)(OW474)(OW475), OSi(W476)(W477)(W478), OS(O2)W479, NHC(O)W480, NW481C(O)W482, NHC(O)OW483, NHC(O)NHW484, NHC(O)NW485W486, NW487C(O)OW488, NW489C(O)NHW490, NW491C(O)NW492W493, NHS(O2)W494, NW495S(O2)W496, SW497, S(O)W498, S(O2)W499, S(O2)NHW500, S(O2)NW501W502, S(O2)OW503, P(O)(OW504)(OW505), Si(W506)(W507)(W508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW457, NW458W459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W460, C (O) OW461, C (O) NHW462, C (O) NW463W464, OW465, O (W466-O) x H (x = 1, 2, 3, 4, 5), O (W467-O) x W468 (x = 1, 2, 3, 4, 5), OC (O) W469, OC (O) OW470, OC (O) NHW471 , OC (O) NW472W473, OP (O) (OW474) (OW475), OSi (W476) (W477) (W478), OS (O 2 ) W479, NHC (O) W480, NW481C (O) W482, NHC ( O) OW483, NHC (O) NHW484, NHC (O) NW485W486, NW487C (O) OW488, NW489C (O) NHW490, NW491C (O) NW492W493, NHS (O 2 ) W494, NW495S (O 2 ) W496, SW497, S (O) W498, S ( O 2) W499, S (O 2) NHW500, S (O 2) NW501W502, S (O 2) OW503, P (O) (OW504) (OW505), Si (W506) ( W507) (W508) " 여기서, W457, W458, W459, W460, W461, W462, W463, W464, W465, W466, W467, W468, W469, W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W480, W481, W482, W483, W484, W485, W486, W487, W488, W489, W490, W491, W492, W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W463, W464 및/또는 W472, W473 및/또는 W485, W486 및/또는 W492, W493 및/또는 W501, W502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W457, W458, W459, W460, W461, W462, W463, W464, W465, W466, W467, W468, W469, W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W480, W481, W482, W483, W484, W485, W486, W487, W488, W489, W490, W491, W492, W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W463, W464 and / or W472, W473 and / or W485, W486 and / or W492, W493 and / or W501, W502 are also in each case a" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW509, NW510W511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W512, C(O)OW513, C(O)NHW514, C(O)NW515W516, OW517, O(W518-O)yH (y = 1, 2, 3, 4, 5), O(W519-O)yW520 (y = 1, 2, 3, 4, 5), OC(O)W521, OC(O)OW522, OC(O)NHW523, OC(O)NW524W525, OP(O)(OW526)(OW527), OSi(W528)(W529)(W530), OS(O2)W531, NHC(O)W532, NW533C(O)W534, NHC(O)OW535, NHC(O)NHW536, NHC(O)NW537W538, NW539C(O)OW540, NW541C(O)NHW542, NW543C(O)NW544W545, NHS(O2)W546, NW547S(O2)W548, SW549, S(O)W550, S(O2)W551, S(O2)NHW552, S(O2)NW553W554, S(O2)OW555, P(O)(OW556)(OW557), Si(W558)(W559)(W560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW509, NW510W511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W512, C (O) OW513, C (O) NHW514, C (O) NW515W516, OW517, O (W518-O) y H (y = 1, 2, 3, 4, 5), O (W519-O) y W520 (y = 1, 2, 3, 4, 5), OC (O) W521, OC (O) OW522, OC (O) NHW523 , OC (O) NW524W525, OP (O) (OW526) (OW527), OSi (W528) (W529) (W530), OS (O 2 ) W531, NHC (O) W532, NW533C (O) W534, NHC ( O) OW535, NHC (O) NHW536, NHC (O) NW537W538, NW539C (O) OW540, NW541C (O) NHW542, NW543C (O) NW544W545, NHS (O 2 ) W546, NW547S (O 2 ) W548, SW549, S (O) W550, S (O 2 ) W551, S (O 2 ) NHW552, S (O 2 ) NW553W554, S (O 2 ) OW555, P (O) (OW556) (OW557), Si (W558) ( W559) (W560) " 여기서, W509, W510, W511, W512, W513, W514, W515, W516, W517, W518, W519, W520, W521, W522, W523, W524, W525, W526, W527, W528, W529, W530, W531, W532, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552, W553, W554, W555, W556, W557, W558, W559, W560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W515, W516 및/또는 W524, W525 및/또는 W537, W538 및/또는 W544, W545 및/또는 W553, W554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W509, W510, W511, W512, W513, W514, W515, W516, W517, W518, W519, W520, W521, W522, W523, W524, W525, W526, W527, W528, W529, W530, W531, W532, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552, W553, W554, W555, W556, W557, W558, W559, W560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W515, W516 and / or W524, W525 and / or W537, W538 and / or W544, W545 and / or W553, W554 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW561, NW562W563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W564, C(O)OW565, C(O)NHW566, C(O)NW567W568, OW569, O(W570-O)zH (z = 1, 2, 3, 4, 5), O(W571- O)zW572 (z = 1, 2, 3, 4, 5), OC(O)W573, OC(O)OW574, OC(O)NHW575, OC(O)NW576W577, OP(O)(OW578)(OW579), OSi(W580)(W581)(W582), OS(O2)W583, NHC(O)W584, NW585C(O)W586, NHC(O)OW587, NHC(O)NHW588, NHC(O)NW589W590, NW591C(O)OW592, NW593C(O)NHW594, NW595C(O)NW596W597, NHS(O2)W598, NW599S(O2)W600, SW601, S(O)W602, S(O2)W603, S(O2)NHW604, S(O2)NW605W606, S(O2)OW607, P(O)(OW608)(OW609), Si(W610)(W611)(W612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW561, NW562W563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W564, C (O) OW565, C (O) NHW566, C (O) NW567W568, OW569, O (W570-O) z H (z = 1, 2, 3, 4, 5), O (W571-O) z W572 (z = 1, 2, 3, 4, 5), OC (O) W573, OC (O) OW574, OC (O) NHW575 , OC (O) NW576W577, OP (O) (OW578) (OW579), OSi (W580) (W581) (W582), OS (O 2 ) W583, NHC (O) W584, NW585C (O) W586, NHC ( O) OW587, NHC (O) NHW588, NHC (O) NW589W590, NW591C (O) OW592, NW593C (O) NHW594, NW595C (O) NW596W597, NHS (O 2 ) W598, NW599S (O 2 ) W600, SW601, S (O) W602, S (O 2 ) W603, S (O 2 ) NHW604, S (O 2 ) NW605W606, S (O 2 ) OW607, P (O) (OW608) (OW609), Si (W610) ( W611) (W612) " 여기서, W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576, W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W611, W612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W567, W568 및/또는 W576, W577 및/또는 W589, W590 및/또는 W596, W597 및/또는 W605, W606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576, W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W611, W612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W567, W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 are also in each case" heterocycle Reels ", (e) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(e) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW613, NW614W615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W616, C(O)OW617, C(O)NHW618, C(O)NW619W620, OW621, O(W622-O)aH (a = 1, 2, 3, 4, 5), O(W623-O)aW624 (a = 1, 2, 3, 4, 5), OC(O)W625, OC(O)OW626, OC(O)NHW627, OC(O)NW628W629, OP(O)(OW630)(OW631), OSi(W632)(W633)(W634), OS(O2)W635, NHC(O)W636, NW637C(O)W638, NHC(O)OW639, NHC(O)NHW640, NHC(O)NW641W642, NW643C(O)OW644, NW645C(O)NHW646, NW647C(O)NW648W649, NHS(O2)W650, NW651S(O2)W652, SW653, S(O)W654, S(O2)W655, S(O2)NHW656, S(O2)NW657W658, S(O2)OW659, P(O)(OW660)(OW661), Si(W662)(W663)(W664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW613, NW614W615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W616, C (O) OW617, C (O) NHW618, C (O) NW619W620, OW621, O (W622-O) a H (a = 1, 2, 3, 4, 5), O (W623-O) a W624 (a = 1, 2, 3, 4, 5), OC (O) W625, OC (O) OW626, OC (O) NHW627 , OC (O) NW628W629, OP (O) (OW630) (OW631), OSi (W632) (W633) (W634), OS (O 2 ) W635, NHC (O) W636, NW637C (O) W638, NHC ( O) OW639, NHC (O) NHW640, NHC (O) NW641W642, NW643C (O) OW644, NW645C (O) NHW646, NW647C (O) NW648W649, NHS (O 2 ) W650, NW651S (O 2 ) W652, SW653, S (O) W654, S (O 2 ) W655, S (O 2 ) NHW656, S (O 2 ) NW657W658, S (O 2 ) OW659, P (O) (OW660) (OW661), Si (W662) ( W663) (W664) " 여기서, W613, W614, W615, W616, W617, W618,W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636, W637, W638, W639, W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W619, W620 및/또는 W628, W629 및/또는 W641, W642 및/또는 W648, W649 및/또는 W657, W658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W613, W614, W615, W616, W617, W618, W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636, W637, W638, W639, W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W619, W620 and / or W628, W629 and / or W641, W642 and / or W648, W649 and / or W657, W658 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW665, NW666W667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W668, C(O)OW669, C(O)NHW670, C(O)NW671W672, OW673, O(W674-O)bH (b = 1, 2, 3, 4, 5), O(W675-O)bW676 (b = 1, 2, 3, 4, 5), OC(O)W677, OC(O)OW678, OC(O)NHW679, OC(O)NW680W681, OP(O)(OW682)(OW683), OSi(W684)(W685)(W686), OS(O2)W687, NHC(O)W688, NW689C(O)W690, NHC(O)OW691, NHC(O)NHW692, NHC(O)NW693W694, NW695C(O)OW696, NW697C(O)NHW698, NW699C(O)NW700W701, NHS(O2)W702, NW703S(O2)W704, SW705, S(O)W706, S(O2)W707, S(O2)NHW708, S(O2)NW709W710, S(O2)OW711, P(O)(OW712)(OW713), Si(W714)(W715)(W716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW665, NW666W667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W668, C (O) OW669, C (O) NHW670, C (O) NW671W672, OW673, O (W674-O) b H (b = 1, 2, 3, 4, 5), O (W675-O) b W676 (b = 1, 2, 3, 4, 5), OC (O) W677, OC (O) OW678, OC (O) NHW679 , OC (O) NW680W681, OP (O) (OW682) (OW683), OSi (W684) (W685) (W686), OS (O 2 ) W687, NHC (O) W688, NW689C (O) W690, NHC ( O) OW691, NHC (O) NHW692, NHC (O) NW693W694, NW695C (O) OW696, NW697C (O) NHW698, NW699C (O) NW700W701, NHS (O 2 ) W702, NW703S (O 2 ) W704, SW705, S (O) W706, S (O 2 ) W707, S (O 2 ) NHW708, S (O 2 ) NW709W710, S (O 2 ) OW711, P (O) (OW712) (OW713), Si (W714) ( W715) (W716) " 여기서, W665, W666, W667, W668, W669, W670, W671, W672, W673, W674, W675, W676, W677, W678, W679, W680, W681, W682, W683, W684, W685, W686, W687, W688, W689, W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, W700, W701, W702, W703, W704, W705, W706, W707, W708, W709, W710, W711, W712, W713, W714, W715, W716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W671, W672 및/또는 W680, W681 및/또는 W693, W694 및/또는 W700, W701 및/또는 W709, W710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W665, W666, W667, W668, W669, W670, W671, W672, W673, W674, W675, W676, W677, W678, W679, W680, W681, W682, W683, W684, W685, W686, W687, W688, W689, W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, W700, W701, W702, W703, W704, W705, W706, W707, W708, W709, W710, W711, W712, W713, W714, W715, W716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W671, W672 and / or W680, W681 and / or W693, W694 and / or W700, W701 and / or W709, W710 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW717, NW718W719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W720, C(O)OW721, C(O)NHW722, C(O)NW723W724, OW725, O(W726-O)cH (c = 1, 2, 3, 4, 5), O(W727-O)cW728 (c = 1, 2, 3, 4, 5), OC(O)W729, OC(O)OW730, OC(O)NHW731, OC(O)NW732W733, OP(O)(OW734)(OW735), OSi(W736)(W737)(W738), OS(O2)W739, NHC(O)W740, NW741C(O)W742, NHC(O)OW743, NHC(O)NHW744, NHC(O)NW745W746, NW747C(O)OW748, NW749C(O)NHW750, NW751C(O)NW752W753, NHS(O2)W754, NW755S(O2)W756, SW757, S(O)W758, S(O2)W759, S(O2)NHW760, S(O2)NW761W762, S(O2)OW763, P(O)(OW764)(OW765), Si(W766)(W767)(W768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW717, NW718W719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W720, C (O) OW721, C (O) NHW722, C (O) NW723W724, OW725, O (W726-O) c H (c = 1, 2, 3, 4, 5), O (W727-O) c W728 (c = 1, 2, 3, 4, 5), OC (O) W729, OC (O) OW730, OC (O) NHW731 , OC (O) NW732W733, OP (O) (OW734) (OW735), OSi (W736) (W737) (W738), OS (O 2 ) W739, NHC (O) W740, NW741C (O) W742, NHC ( O) OW743, NHC (O) NHW744, NHC (O) NW745W746, NW747C (O) OW748, NW749C (O) NHW750, NW751C (O) NW752W753, NHS (O 2 ) W754, NW755S (O 2 ) W756, SW757, S (O) W758, S (O 2 ) W759, S (O 2 ) NHW760, S (O 2 ) NW761W762, S (O 2 ) OW763, P (O) (OW764) (OW765), Si (W766) ( W767) (W768) " 여기서, W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740, W741, W742, W743, W744,W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756, W757, W758, W759, W760, W761, W762, W763, W764, W765, W766, W767, W768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W723, W724 및/또는 W732, W733 및/또는 W745, W746 및/또는 W752, W753 및/또는 W761, W762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740, W741, W742, W743, W744, W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756, W757, W758, W759, W760, W761, W762, W763, W764, W765, W766, W767, W768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 are also in each case a" heterocycle. " Reels ", (f) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(f) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW769, NW770W771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W772, C(O)OW773, C(O)NHW774, C(O)NW775W776, OW777, O(W778-O)dH (d = 1, 2, 3, 4, 5), O(W779-O)dW780 (d = 1, 2, 3, 4, 5), OC(O)W781, OC(O)OW782, OC(O)NHW783, OC(O)NW784W785, OP(O)(OW786)(OW787), OSi(W788)(W789)(W790), OS(O2)W791, NHC(O)W792, NW793C(O)W794, NHC(O)OW795, NHC(O)NHW796, NHC(O)NW797W798, NW799C(O)OW800, NW801C(O)NHW802, NW803C(O)NW804W805, NHS(O2)W806, NW807S(O2)W808, SW809, S(O)W810, S(O2)W811, S(O2)NHW812, S(O2)NW813W814, S(O2)OW815, P(O)(OW816)(OW817), Si(W818)(W819)(W820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW769, NW770W771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W772, C (O) OW773, C (O) NHW774, C (O) NW775W776, OW777, O (W778-O) d H (d = 1, 2, 3, 4, 5), O (W779-O) d W780 (d = 1, 2, 3, 4, 5), OC (O) W781, OC (O) OW782, OC (O) NHW783 , OC (O) NW784W785, OP (O) (OW786) (OW787), OSi (W788) (W789) (W790), OS (O 2 ) W791, NHC (O) W792, NW793C (O) W794, NHC ( O) OW795, NHC (O) NHW796, NHC (O) NW797W798, NW799C (O) OW800, NW801C (O) NHW802, NW803C (O) NW804W805, NHS (O 2 ) W806, NW807S (O 2 ) W808, SW809, S (O) W810, S (O 2 ) W811, S (O 2 ) NHW812, S (O 2 ) NW813W814, S (O 2 ) OW815, P (O) (OW816) (OW817), Si (W818) ( W819) (W820) " 여기서, W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W791, W792, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W811, W812, W813, W814, W815, W816, W817, W818, W819, W820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W775, W776 및/또는 W784, W785 및/또는 W797, W798 및/또는 W804, W805 및/또는 W813, W814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W791, W792, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W811, W812, W813, W814, W815, W816, W817, W818, W819, W820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W775, W776 and / or W784, W785 and / or W797, W798 and / or W804, W805 and / or W813, W814 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW821, NW822W823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W824, C(O)OW825, C(O)NHW826, C(O)NW827W828, OW829, O(W830-O)eH (e = 1, 2, 3, 4, 5), O(W831-O)eW832 (e = 1, 2, 3, 4, 5), OC(O)W833, OC(O)OW834, OC(O)NHW835, OC(O)NW836W837, OP(O)(OW838)(OW839), OSi(W840)(W841)(W842), OS(O2)W843, NHC(O)W844, NW845C(O)W846, NHC(O)OW847, NHC(O)NHW848, NHC(O)NW849W850, NW851C(O)OW852, NW853C(O)NHW854, NW855C(O)NW856W857, NHS(O2)W858, NW859S(O2)W860, SW861, S(O)W862, S(O2)W863, S(O2)NHW864, S(O2)NW865W866, S(O2)OW867, P(O)(OW868)(OW869), Si(W870)(W871)(W872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW821, NW822W823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W824, C (O) OW825, C (O) NHW826, C (O) NW827W828, OW829, O (W830-O) e H (e = 1, 2, 3, 4, 5), O (W831-O) e W832 (e = 1, 2, 3, 4, 5), OC (O) W833, OC (O) OW834, OC (O) NHW835 , OC (O) NW836W837, OP (O) (OW838) (OW839), OSi (W840) (W841) (W842), OS (O 2 ) W843, NHC (O) W844, NW845C (O) W846, NHC ( O) OW847, NHC (O) NHW848, NHC (O) NW849W850, NW851C (O) OW852, NW853C (O) NHW854, NW855C (O) NW856W857, NHS (O 2 ) W858, NW859S (O 2 ) W860, SW861, S (O) W862, S (O 2 ) W863, S (O 2 ) NHW864, S (O 2 ) NW865W866, S (O 2 ) OW867, P (O) (OW868) (OW869), Si (W870) ( W871) (W872) " 여기서, W821, W822, W823, W824, W825, W826, W827, W828, W829, W830, W831, W832, W833, W834, W835, W836, W837, W838, W839, W840, W841, W842, W843, W844, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W827, W828 및/또는 W836, W837 및/또는 W849, W850 및/또는 W856, W857 및/또는 W865, W866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W821, W822, W823, W824, W825, W826, W827, W828, W829, W830, W831, W832, W833, W834, W835, W836, W837, W838, W839, W840, W841, W842, W843, W844, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W827, W828 and / or W836, W837 and / or W849, W850 and / or W856, W857 and / or W865, W866 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW873, NW874W875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W876, C(O)OW877, C(O)NHW878, C(O)NW879W880, OW881, O(W882-O)fH (f = 1, 2, 3, 4, 5), O(W883-O)fW884 (f = 1, 2, 3, 4, 5), OC(O)W885, OC(O)OW886, OC(O)NHW887, OC(O)NW888W889, OP(O)(OW890)(OW891), OSi(W892)(W893)(W894), OS(O2)W895, NHC(O)W896, NW897C(O)W898, NHC(O)OW899, NHC(O)NHW900, NHC(O)NW901W902, NW903C(O)OW904, NW905C(O)NHW906, NW907C(O)NW908W909, NHS(O2)W910, NW911S(O2)W912, SW913, S(O)W914, S(O2)W915, S(O2)NHW916, S(O2)NW917W918, S(O2)OW919, P(O)(OW920)(OW921), Si(W922)(W923)(W924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW873, NW874W875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W876, C (O) OW877, C (O) NHW878, C (O) NW879W880, OW881, O (W882-O) f H (f = 1, 2, 3, 4, 5), O (W883-O) f W884 (f = 1, 2, 3, 4, 5), OC (O) W885, OC (O) OW886, OC (O) NHW887 , OC (O) NW888W889, OP (O) (OW890) (OW891), OSi (W892) (W893) (W894), OS (O 2 ) W895, NHC (O) W896, NW897C (O) W898, NHC ( O) OW899, NHC (O) NHW900, NHC (O) NW901W902, NW903C (O) OW904, NW905C (O) NHW906, NW907C (O) NW908W909, NHS (O 2 ) W910, NW911S (O 2 ) W912, SW913, S (O) W914, S (O 2 ) W915, S (O 2 ) NHW916, S (O 2 ) NW917W918, S (O 2 ) OW919, P (O) (OW920) (OW921), Si (W922) ( W923) (W924) " 여기서, W873, W874, W875, W876, W877, W878, W879, W880, W881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W896, W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W911, W912, W913, W914, W915, W916, W917, W918, W919, W920, W921, W922, W923, W924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W879, W880 및/또는 W888, W889 및/또는 W901, W902 및/또는 W908, W909 및/또는 W917, W918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where W873, W874, W875, W876, W877, W878, W879, W880, W881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W896, W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W911, W912, W913, W914, W915, W916, W917, W918, W919, W920, W921, W922, W923, W924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W879, W880 and / or W888, W889 and / or W901, W902 and / or W908, W909 and / or W917, W918 are also in each case" heterocycle. " Reels "; (g) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(g) OZ6, wherein Z6 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW925, NW926W927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W928, C(O)OW929, C(O)NHW930, C(O)NW931W932, OW933, O(W934-O)gH (g = 1, 2, 3, 4, 5), O(W935-O)gW936 (g = 1, 2, 3, 4, 5), OC(O)W937, OC(O)OW938, OC(O)NHW939, OC(O)NW940W941, OP(O)(OW942)(OW943), OSi(W944)(W945)(W946), OS(O2)W947, NHC(O)W948, NW949C(O)W950, NHC(O)OW951, NHC(O)NHW952, NHC(O)NW953W954, NW955C(O)OW956, NW957C(O)NHW958, NW959C(O)NW960W961, NHS(O2)W962, NW963S(O2)W964, SW965, S(O)W966, S(O2)W967, S(O2)NHW968, S(O2)NW969W970, S(O2)OW971, P(O)(OW972)(OW973), Si(W974)(W975)(W976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW925, NW926W927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W928, C (O) OW929, C (O) NHW930, C (O) NW931W932, OW933, O (W934-O) g H (g = 1, 2, 3, 4, 5), O (W935-O) g W936 (g = 1, 2, 3, 4, 5), OC (O) W937, OC (O) OW938, OC (O) NHW939 , OC (O) NW940W941, OP (O) (OW942) (OW943), OSi (W944) (W945) (W946), OS (O 2 ) W947, NHC (O) W948, NW949C (O) W950, NHC ( O) OW951, NHC (O) NHW952, NHC (O) NW953W954, NW955C (O) OW956, NW957C (O) NHW958, NW959C (O) NW960W961, NHS (O 2 ) W962, NW963S (O 2 ) W964, SW965, S (O) W966, S (O 2 ) W967, S (O 2 ) NHW968, S (O 2 ) NW969W970, S (O 2 ) OW971, P (O) (OW972) (OW973), Si (W974) ( W975) (W976) " 여기서, W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941, W942, W943, W944, W945, W946, W947, W948, W949, W950, W951, W952, W953, W954, W955, W956, W957, W958, W959, W960, W961, W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W972, W973, W974, W975, W976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W931, W932 및/또는 W940, W941 및/또는 W953, W954 및/또는 W960, W961 및/또는 W969, W970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941, W942, W943, W944, W945, W946, W947, W948, W949, W950, W951, W952, W953, W954, W955, W956, W957, W958, W959, W960, W961, W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W972, W973, W974, W975, W976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W931, W932 and / or W940, W941 and / or W953, W954 and / or W960, W961 and / or W969, W970 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW977, NW978W979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W980, C(O)OW981, C(O)NHW982, C(O)NW983W984, OW985, O(W986-O)hH (h = 1, 2, 3, 4, 5), O(W987-O)hW988 (h = 1, 2, 3, 4, 5), OC(O)W989, OC(O)OW990, OC(O)NHW991, OC(O)NW992W993, OP(O)(OW994)(OW995), OSi(W996)(W997)(W998), OS(O2)W999, NHC(O)W1000, NW1001C(O)W1002, NHC(O)OW1003, NHC(O)NHW1004, NHC(O)NW1005W1006, NW1007C(O)OW1008, NW1009C(O)NHW1010, NW1011C(O)NW1012W1013, NHS(O2)W1014, NW1015S(O2)W1016, SW1017, S(O)W1018, S(O2)W1019, S(O2)NHW1020, S(O2)NW1021W1022, S(O2)OW1023, P(O)(OW1024)(OW1025), Si(W1026)(W1027)(W1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW977, NW978W979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W980, C (O) OW981, C (O) NHW982, C (O) NW983W984, OW985, O (W986-O) h H (h = 1, 2, 3, 4, 5), O (W987-O) h W988 (h = 1, 2, 3, 4, 5), OC (O) W989, OC (O) OW990, OC (O) NHW991 , OC (O) NW992W993, OP (O) (OW994) (OW995), OSi (W996) (W997) (W998), OS (O 2 ) W999, NHC (O) W1000, NW1001C (O) W1002, NHC ( O) OW1003, NHC (O) NHW1004, NHC (O) NW1005W1006, NW1007C (O) OW1008, NW1009C (O) NHW1010, NW1011C (O) NW1012W1013, NHS (O 2 ) W1014, NW1015S (O 2 ) W1016, SW1016 S (O) W1018, S (O 2 ) W1019, S (O 2 ) NHW1020, S (O 2 ) NW1021W1022, S (O 2 ) OW1023, P (O) (OW1024) (OW1025), Si (W1026) ( W1027) (W1028) " 여기서, W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988, W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001, W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W1011, W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, W1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W983, W984 및/또는 W992, W993 및/또는 W1005, W1006 및/또는 W1012, W1013 및/또는 W1021, W1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988, W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001, W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W1011, W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1024 W1026, W1027, W1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022 are also in each case" heterocycle Reels ", (h) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(h) SZ7, wherein Z7 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1029, NW1030W1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1032, C(O)OW1033, C(O)NHW1034, C(O)NW1035W1036, OW1037, O(W1038-O)iH (i = 1, 2, 3, 4, 5), O(W1039-O)iW1040 (i = 1, 2, 3, 4, 5), OC(O)W1041, OC(O)OW1042, OC(O)NHW1043, OC(O)NW1044W1045, OP(O)(OW1046)(OW1047), OSi(W1048)(W1049)(W1050), OS(O2)W1051, NHC(O)W1052, NW1053C(O)W1054, NHC(O)OW1055, NHC(O)NHW1056, NHC(O)NW1057W1058, NW1059C(O)OW1060, NW1061C(O)NHW1062, NW1063C(O)NW1064W1065, NHS(O2)W1066, NW1067S(O2)W1068, SW1069, S(O)W1070, S(O2)W1071, S(O2)NHW1072, S(O2)NW1073W1074, S(O2)OW1075, P(O)(OW1076)(OW1077), Si(W1078)(W1079)(W1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1029, NW1030W1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1032, C (O) OW1033, C (O) NHW1034, C (O) NW1035W1036, OW1037, O (W1038-O) i H (i = 1, 2, 3, 4, 5), O (W1039-O) i W1040 (i = 1, 2, 3, 4, 5), OC (O) W1041, OC (O) OW1042, OC (O) NHW1043 , OC (O) NW1044W1045, OP (O) (OW1046) (OW1047), OSi (W1048) (W1049) (W1050), OS (O 2 ) W1051, NHC (O) W1052, NW1053C (O) W1054, NHC ( O) OW1055, NHC (O) NHW1056, NHC (O) NW1057W1058, NW1059C (O) OW1060, NW1061C (O) NHW1062, NW1063C (O) NW1064W1065, NHS (O 2 ) W1066, NW1067S (O 2 ) W1068, SW1069 S (O) W1070, S (O 2 ) W1071, S (O 2 ) NHW1072, S (O 2 ) NW1073W1074, S (O 2 ) OW1075, P (O) (OW1076) (OW1077), Si (W1078) ( W1079) (W1080) " 여기서, W1029, W1030, W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051, W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1035, W1036 및/또는 W1044, W1045 및/또는 W1057, W1058 및/또는 W1064, W1065 및/또는 W1073, W1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W1029, W1030, W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051, W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1076 W1078, W1079, W1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W1035, W1036 and / or W1044, W1045 and / or W1057, W1058 and / or W1064, W1065 and / or W1073, W1074 are also in each case a" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1081, NW1082W1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1084, C(O)OW1085, C(O)NHW1086, C(O)NW1087W1088, OW1089, O(W1090-O)jH (j = 1, 2, 3, 4, 5), O(W1091-O)jW1092 (j = 1, 2, 3, 4, 5), OC(O)W1093, OC(O)OW1094, OC(O)NHW1095, OC(O)NW1096W1097, OP(O)(OW1098)(OW1099), OSi(W1100)(W1101)(W1102), OS(O2)W1103, NHC(O)W1104, NW1105C(O)W1106, NHC(O)OW1107, NHC(O)NHW1108, NHC(O)NW1109W1110, NW1111C(O)OW1112, NW1113C(O)NHW1114, NW1115C(O)NW1116W1117, NHS(O2)W1118, NW1119S(O2)W1120, SW1121, S(O)W1122, S(O2)W1123, S(O2)NHW1124, S(O2)NW1125W1126, S(O2)OW1127, P(O)(OW1128)(OW1129), Si(W1130)(W1131)(W1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1081, NW1082W1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1084, C (O) OW1085, C (O) NHW1086, C (O) NW1087W1088, OW1089, O (W1090-O) j H (j = 1, 2, 3, 4, 5), O (W1091-O) j W1092 (j = 1, 2, 3, 4, 5), OC (O) W1093, OC (O) OW1094, OC (O) NHW1095 , OC (O) NW1096W1097, OP (O) (OW1098) (OW1099), OSi (W1100) (W1101) (W1102), OS (O 2 ) W1103, NHC (O) W1104, NW1105C (O) W1106, NHC ( O) OW1107, NHC (O) NHW1108, NHC (O) NW1109W1110, NW1111C (O) OW1112, NW1113C (O) NHW1114, NW1115C (O) NW1116W1117, NHS (O 2 ) W1118, NW1119S (O 2 ) W1120, SW112 S (O) W1122, S (O 2 ) W1123, S (O 2 ) NHW1124, S (O 2 ) NW1125W1126, S (O 2 ) OW1127, P (O) (OW1128) (OW1129), Si (W1130) ( W1131) (W1132) " 여기서, W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092, W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1104, W1105, W1106, W1107, W1108, W1109, W1110, W1111, W1112, W1113, W1114, W1115, W1116, W1117, W1118, W1119, W1120, W1121, W1122, W1123, W1124, W1125, W1126, W1127, W1128, W1129, W1130, W1131, W1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1087, W1088 및/또는 W1096, W1097 및/또는 W1109, W1110 및/또는 W1116, W1117 및/또는 W1125, W1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092, W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1103 W1105, W1106, W1107, W1108, W1109, W1110, W1111, W1112, W1113, W1114, W1115, W1116, W1117, W1118, W1119, W1120, W1121, W1122, W1123, W1124, W1125, W1126, W1127, W1128, 29 W1130, W1131, W1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, W1087, W1088 and / or W1096, W1097 and / or W1109, W1110 and / or W1116, W1117 and / or W1125, W1126 are also in each case" heterocycle. " Reels ", (j) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(j) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)W1133, C(O)OW1134, C(O)NW1135W1136, S(O2)W1137, S(O2)OW1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) W1133 , C (O) OW1134, C (O) NW1135W1136, S (O 2 ) W1137, S (O2) OW1138 " 여기서, W1133, W1134, W1135, W1136, W1137, W1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1135, W1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein W1133, W1134, W1135, W1136, W1137, W1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl Alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, W1135, W1136 together may also form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1139, NW1140W1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1142, C(O)OW1143, C(O)NHW1144, C(O)NW1145W1146, OW1147, O(W1148-O)kH (k = 1, 2, 3, 4, 5), O(W1149-O)kW1150 (k = 1, 2, 3, 4, 5), OC(O)W1151, OC(O)OW1152, OC(O)NHW1153, OC(O)NW1154W1155, OP(O)(OW1156)(OW1157), OSi(W1158)(W1159)(W1160), OS(O2)W1161, NHC(O)W1162, NW1163C(O)W1164, NHC(O)OW1165, NHC(O)NHW1166, NHC(O)NW1167W1168, NW1169C(O)OW1170, NW1171C(O)NHW1172, NW1173C(O)NW1174W1175, NHS(O2)W1176, NW1177S(O2)W1178, SW1179, S(O)W1180, S(O2)W1181, S(O2)NHW1182, S(O2)NW1183W1184, S(O2)OW1185, P(O)(OW1186)(OW1187), Si(W1188)(W1189)(W1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1139, NW1140W1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1142, C (O) OW1143, C (O) NHW1144, C (O) NW1145W1146, OW1147, O (W1148-O) k H (k = 1, 2, 3, 4, 5), O (W1149-O) k W1150 (k = 1, 2, 3, 4, 5), OC (O) W1151, OC (O) OW1152, OC (O) NHW1153 , OC (O) NW1154W1155, OP (O) (OW1156) (OW1157), OSi (W1158) (W1159) (W1160), OS (O 2 ) W1161, NHC (O) W1162, NW1163C (O) W1164, NHC ( O) OW1165, NHC (O) NHW1166, NHC (O) NW1167W1168, NW1169C (O) OW1170, NW1171C (O) NHW1172, NW1173C (O) NW1174W1175, NHS (O 2 ) W1176, NW1177S (O 2 ) W1179, SW1179 S (O) W1180, S (O 2 ) W1181, S (O 2 ) NHW1182, S (O 2 ) NW1183W1184, S (O 2 ) OW1185, P (O) (OW1186) (OW1187), Si (W1188) ( W1189) (W1190) " 여기서, W1139, W1140, W1141, W1142, W1143, W1144, W1145, W1146, W1147, W1148, W1149, W1150, W1151, W1152, W1153, W1154, W1155, W1156, W1157, W1158, W1159, W1160, W1161, W1162, W1163, W1164, W1165, W1166, W1167, W1168, W1169, W1170, W1171, W1172, W1173, W1174, W1175, W1176, W1177, W1178, W1179, W1180, W1181, W1182, W1183, W1184, W1185, W1186, W1187, W1188, W1189, W1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알 킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1145, W1146 및/또는 W1154, W1155 및/또는 W1167, W1168 및/또는 W1174, W1175 및/또는 W1183, W1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, W1139, W1140, W1141, W1142, W1143, W1144, W1145, W1146, W1147, W1148, W1149, W1150, W1151, W1152, W1153, W1154, W1155, W1156, W1157, W1158, W1159, W1160, W1161, W1162, W1163, W1164, W1165, W1166, W1167, W1168, W1169, W1170, W1171, W1172, W1173, W1174, W1175, W1176, W1177, W1178, W1179, W1180, W1181, W1182, W1183, W1184, W1185, W1186, W1186, W1188, W1189, W1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, W1145, W1146 and / or W1154, W1155 and / or W1167, W1168 and / or W1174, W1175 and / or W1183, W1184 are also in each case" hetero " Cyclyl ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHW1191, NW1192W1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)W1194, C(O)OW1195, C(O)NHW1196, C(O)NW1197W1198, OW1199, O(W1200-O)lH (l = 1, 2, 3, 4, 5), O(W1201-O)lW1202 (l = 1, 2, 3, 4, 5), OC(O)W1203, OC(O)OW1204, OC(O)NHW1205, OC(O)NW1206W1207, OP(O)(OW1208)(OW1209), OSi(W1210)(W1211)(W1212), OS(O2)W1213, NHC(O)W1214, NW1215C(O)W1216, NHC(O)OW1217, NHC(O)NHW1218, NHC(O)NW1219W1220, NW1221C(O)OW1222, NW1223C(O)NHW1224, NW1225C(O)NW1226W1227, NHS(O2)W1228, NW1229S(O2)W1230, SW1231, S(O)W1232, S(O2)W1233, S(O2)NHW1234, S(O2)NW1235W1236, S(O2)OW1237, P(O)(OW1238)(OW1239), Si(W1240)(W1241)(W1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHW1191, NW1192W1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) W1194, C (O) OW1195, C (O) NHW1196, C (O) NW1197W1198, OW1199, O (W1200-O) l H (l = 1, 2, 3, 4, 5), O (W1201-O) l W1202 (l = 1, 2, 3, 4, 5), OC (O) W1203, OC (O) OW1204, OC (O) NHW1205 , OC (O) NW1206W1207, OP (O) (OW1208) (OW1209), OSi (W1210) (W1211) (W1212), OS (O 2 ) W1213, NHC (O) W1214, NW1215C (O) W1216, NHC ( O) OW1217, NHC (O) NHW1218, NHC (O) NW1219W1220, NW1221C (O) OW1222, NW1223C (O) NHW1224, NW1225C (O) NW1226W1227, NHS (O 2 ) W1228, NW1229S (O 2 ) W1230, SW123 S (O) W1232, S (O 2 ) W1233, S (O 2 ) NHW1234, S (O 2 ) NW1235W1236, S (O 2 ) OW1237, P (O) (OW1238) (OW1239), Si (W1240) ( W1241) (W1242) " 여기서, W1191, W1192, W1193, W1194, W1195, W1196, W1197, W1198, W1199, W1200, W1201, W1202, W1203, W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1238, W1239, W1240, W1241, W1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, W1197, W1198 및/또는 W1206, W1207 및/또는 W1219, W1220 및/또는 W1226, W1227 및/또는 W1235, W1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where W1191, W1192, W1193, W1194, W1195, W1196, W1197, W1198, W1199, W1200, W1201, W1202, W1203, W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1214 W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1238, W1240, W1241, W1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, W1197, W1198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 are also in each case a" heterocycle. " Reels ", 또는or (D) Z3, Z4 라디칼 중 하나 또는 Z3, Z4 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(D) one of the Z3, Z4 radicals or both Z3, Z4 radicals is each independently selected from the group consisting of: (1) "NZ10Z11, OZ12, SZ13"(1) "NZ10Z11, OZ12, SZ13" 여기서, Z10, Z11 라디칼 중 하나 또는 Z10, Z11 라디칼 및 Z12, Z13 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein one of Z10, Z11 radicals or both Z10, Z11 radicals and Z12, Z13 radicals are each independently selected from the group consisting of: (a) "수소, 알킬, 사이클로알킬, 사이클로알킬알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 헤테로사이클릴, 헤테로사이클릴알킬"(a) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl" 단, Z10, Z11 라디칼 둘 다는 동시에 수소가 아니고;Provided that both Z10 and Z11 radicals are not simultaneously hydrogen; 추가로 단, Z12 라디칼은 수소가 아니고;Further provided that the Z12 radical is not hydrogen; 추가로 단, 치환체 그룹(a)의 상기한 치환체는, 이들이 수소가 아닌 경우, 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Further provided that the aforementioned substituents of substituent group (a) are further substituted by one or more substituents, each of which is independently the same or differently selected from the group consisting of: (i) "(C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, N3, NH사이클로알킬, NH사이클로알킬알킬, NH헤테로아릴, NH헤테로아릴알킬, NH아릴알킬, NH헤테로사이클릴, NH헤테로사이클릴알킬, NQ1Q2, S사이클로알킬, S사이클로알킬알킬, S아릴, S아릴알킬, S헤테로아릴, S헤테로아릴알킬, S헤테로사이클릴, S헤테로사이클릴알킬, O사이클로알킬, O사이클로알킬알킬, O아릴알킬, O헤테로아릴, O헤테로아릴알킬, O헤테로사이클릴, O헤테로사이클릴알킬, O(Q3-O)pH (p = 1, 2, 3, 4, 5), O(Q4-O)pQ5 (p = 1, 2, 3, 4, 5), OP(O)(OQ6)(OQ7), C(O)OQ8, C(O)NH2, C(O)NHQ9, C(O)NQ10Q11, S(O2)Q12, P(O)(OH)2, P(O)(OQ13)(OQ14), Si(Q15)(Q16)(Q17), OSi(Q18)(Q19)(Q20), OC(O)OQ21, OC(O)NHQ22, OC(O)NQ23Q24, NHC(O)OQ25, NHC(O)NHQ26, NHC(O)NQ27Q28, NQ29C(O)OQ30, NQ31C(O)NHQ32, NQ33C(O)NQ34Q35, NQ36S(O2)Q37, NHS(O2)Q38, OS(O2)Q39, NHC(O)Q40, NQ41C(O)Q42, C(O)Q43, OC(O)Q44, S(O)Q45, S(O2)NHQ46, S(O2)NQ47Q48, S(O2)OQ49"(i) "(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, NHcycloalkyl, NHcycloalkyl Alkyl, NH heteroaryl, NH heteroarylalkyl, NH arylalkyl, NH heterocyclyl, NH heterocyclylalkyl, NQ1Q2, Scycloalkyl, Scycloalkylalkyl, Saryl, Sarylalkyl, S heteroaryl, S hetero Arylalkyl, S heterocyclyl, S heterocyclylalkyl, Ocycloalkyl, Ocycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O (Q3 -O) p H (p = 1, 2, 3, 4, 5), O (Q4-O) p Q5 (p = 1, 2, 3, 4, 5), OP (O) (OQ6) (OQ7 ), C (O) OQ8, C (O) NH2, C (O) NHQ9, C (O) NQ10Q11, S (O2) Q12, P (O) (OH) 2, P (O) (OQ13) (OQ14 ), Si (Q15) (Q16) (Q17), OSi (Q18) (Q19) (Q20), OC (O) OQ21, OC (O) NHQ22, OC (O) NQ23Q24, NHC (O) OQ25, NHC ( O) NHQ26, NHC (O) NQ27Q28, NQ29C (O) OQ30, NQ31C (O) NHQ32, NQ 33C (O) NQ34Q35, NQ36S (O2) Q37, NHS (O2) Q38, OS (O2) Q39, NHC (O) Q40, NQ41C (O) Q42, C (O) Q43, OC (O) Q44, S ( O) Q45, S (O 2 ) NHQ46, S (O 2 ) NQ47Q48, S (O 2 ) OQ49 " 추가로 단, "N(알킬)2"는 다음 치환체 그룹(ii)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further provided that "N (alkyl) 2 " is further substituted by one or more substituents selected from the following substituent groups (ii); 여기서, Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20,Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q10, Q11 및/또는 Q23, Q24 및/또는 Q27, Q28 및/또는 Q34, Q35 및/또는 Q47, Q48은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 Each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", Where, alternatively, Q10, Q11 and / or Q23, Q24 and / or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 may also together form" heterocyclyl "in each case There is, 여기서, 임의로, 치환체 그룹(a) 및/또는 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (a) and / or substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ50, NQ51Q52, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q53, C(O)OQ54, C(O)NHQ55, C(O)NQ56Q57, OQ58, O(Q59-O)rH (r = 1, 2, 3, 4, 5), O(Q60-O)rQ61 (r = 1, 2, 3, 4, 5), OC(O)Q62, OC(O)OQ63, OC(O)NHQ64, OC(O)NQ65Q66, OP(O)(OQ67)(OQ68), OSi(Q69)(Q70)(Q71), OS(O2)Q72, NHC(O)Q73, NQ74C(O)Q75, NHC(O)OQ76, NHC(O)NHQ77, NHC(O)NQ78Q79, NQ80C(O)OQ81, NQ82C(O)NHQ83, NQ84C(O)NQ85Q86, NHS(O2)Q87, NQ88S(O2)Q89, SQ90, S(O)Q91, S(O2)Q92, S(O2)NHQ93, S(O2)NQ94Q95, S(O2)OQ96, P(O)(OQ97)(OQ98), Si(Q99)(Q100)(Q101)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ50, NQ51Q52, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q53, C (O) OQ54, C (O) NHQ55, C (O) NQ56Q57, OQ58, O (Q59-O) r H (r = 1, 2, 3, 4, 5), O (Q60-O) r Q61 (r = 1, 2, 3, 4, 5), OC (O) Q62, OC (O) OQ63, OC (O) NHQ64 , OC (O) NQ65Q66, OP (O) (OQ67) (OQ68), OSi (Q69) (Q70) (Q71), OS (O 2 ) Q72, NHC (O) Q73, NQ74C (O) Q75, NHC ( O) OQ76, NHC (O) NHQ77, NHC (O) NQ78Q79, NQ80C (O) OQ81, NQ82C (O) NHQ83, NQ84C (O) NQ85Q86, NHS (O2) Q87, NQ88S (O2) Q89, SQ90, S ( O) Q91, S (O 2 ) Q92, S (O 2 ) NHQ93, S (O 2 ) NQ94Q95, S (O 2 ) OQ96, P (O) (OQ97) (OQ98), Si (Q99) (Q100) (Q101) " 여기서, Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71, Q72, Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q56, Q57 및/또는 Q65, Q66 및/또는 Q78, Q79 및/또는 Q85, Q86 및/또는 Q94, Q95는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71, Q72, Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or Q94, Q95 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ102, NQ103Q104, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q105, C(O)OQ106, C(O)NHQ107, C(O)NQ108Q109, OQ110, O(Q111-O)sH (s = 1, 2, 3, 4, 5), O(Q112-O)sQ113 (s = 1, 2, 3, 4, 5), OC(O)Q114, OC(O)OQ115, OC(O)NHQ116, OC(O)NQ117Q118, OP(O)(OQ119)(OQ120), OSi(Q121)(Q122)(Q123), OS(O2)Q124, NHC(O)Q125, NQ126C(O)Q127, NHC(O)OQ128, NHC(O)NHQ129, NHC(O)NQ130Q131, NQ132C(O)OQ133, NQ134C(O)NHQ135, NQ136C(O)NQ137Q138, NHS(O2)Q139, NQ140S(O2)Q141, SQ142, S(O)Q143, S(O2)Q144, S(O2)NHQ145, S(O2)NQ146Q147, S(O2)OQ148, P(O)(OQ149)(OQ150), Si(Q151)(Q152)(Q153)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ102, NQ103Q104, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q105, C (O) OQ106, C (O) NHQ107, C (O) NQ108Q109, OQ110, O (Q111-O) s H (s = 1, 2, 3, 4, 5), O (Q112-O) s Q113 (s = 1, 2, 3, 4, 5), OC (O) Q114, OC (O) OQ115, OC (O) NHQ116 , OC (O) NQ117Q118, OP (O) (OQ119) (OQ120), OSi (Q121) (Q122) (Q123), OS (O 2 ) Q124, NHC (O) Q125, NQ126C (O) Q127, NHC ( O) OQ128, NHC (O) NHQ129, NHC (O) NQ130Q131, NQ132C (O) OQ133, NQ134C (O) NHQ135, NQ136C (O) NQ137Q138, NHS (O2) Q139, NQ140S (O2) Q141, SQ142, S ( O) Q143, S (O 2 ) Q144, S (O 2 ) NHQ145, S (O 2 ) NQ146Q147, S (O 2 ) OQ148, P (O) (OQ149) (OQ150), Si (Q151) (Q152) (Q153) " 여기서, Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111, Q112, Q113, Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q108, Q109 및/또는 Q117, Q118 및/또는 Q130, Q131 및/또는 Q137, Q138 및/또는 Q146, Q147은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111, Q112, Q113, Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q108, Q109 and / or Q117, Q118 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 are also in each case" heterocycle Reels ", (b) "(C9-C30)알킬, C(O)Q154, C(O)OQ155, C(O)NQ156Q157, S(O2)Q158, S(O2)OQ159"(b) "(C 9 -C 30 ) alkyl, C (O) Q154, C (O) OQ155, C (O) NQ156Q157, S (O2) Q158, S (O 2 ) OQ159" 여기서, Q154, Q155, Q156, Q157, Q158, Q159는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q156, Q157은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein Q154, Q155, Q156, Q157, Q158, Q159 are each independently selected from the group consisting of: "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, Heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q156, Q157 together may also form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(b)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ160, NQ161Q162, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q163, C(O)OQ164, C(O)NHQ165, C(O)NQ166Q167, OQ168, O(Q169-O)tH (t = 1, 2, 3, 4, 5), O(Q170-O)tQ171 (t = 1, 2, 3, 4, 5), OC(O)Q172, OC(O)OQ173, OC(O)NHQ174, OC(O)NQ175Q176, OP(O)(OQ177)(OQ178), OSi(Q179)(Q180)(Q181), OS(O2)Q182, NHC(O)Q183, NQ184C(O)Q185, NHC(O)OQ186, NHC(O)NHQ187, NHC(O)NQ188Q189, NQ190C(O)OQ191, NQ192C(O)NHQ193, NQ194C(O)NQ195Q196, NHS(O2)Q197, NQ198S(O2)Q199, SQ200, S(O)Q201, S(O2)Q202, S(O2)NHQ203, S(O2)NQ204Q205, S(O2)OQ206, P(O)(OQ207)(OQ208), Si(Q209)(Q210)(Q211)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ160, NQ161Q162, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q163, C (O) OQ164, C (O) NHQ165, C (O) NQ166Q167, OQ168, O (Q169-O) t H (t = 1, 2, 3, 4, 5), O (Q170-O) t Q171 (t = 1, 2, 3, 4, 5), OC (O) Q172, OC (O) OQ173, OC (O) NHQ174 , OC (O) NQ175Q176, OP (O) (OQ177) (OQ178), OSi (Q179) (Q180) (Q181), OS (O 2 ) Q182, NHC (O) Q183, NQ184C (O) Q185, NHC ( O) OQ186, NHC (O) NHQ187, NHC (O) NQ188Q189, NQ190C (O) OQ191, NQ192C (O) NHQ193, NQ194C (O) NQ195Q196, NHS (O2) Q197, NQ198S (O2) Q199, SQ200, S ( O) Q201, S (O 2 ) Q202, S (O 2 ) NHQ203, S (O 2 ) NQ204Q205, S (O 2 ) OQ206, P (O) (OQ207) (OQ208), Si (Q209) (Q210) (Q211) " 여기서, Q160, Q161, Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208, Q209, Q210, Q211은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q166, Q167 및/또는 Q175, Q176 및/또는 Q188, Q189 및/또는 Q195, Q196 및/또는 Q204, Q205는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q160, Q161, Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208, Q209, Q210, Q211 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q166, Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204, Q205 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ212, NQ213Q214, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q215, C(O)OQ216, C(O)NHQ217, C(O)NQ218Q219, OQ220, O(Q221-O)uH (u = 1, 2, 3, 4, 5), O(Q222- O)uQ223 (u = 1, 2, 3, 4, 5), OC(O)Q224, OC(O)OQ225, OC(O)NHQ226, OC(O)NQ227Q228, OP(O)(OQ229)(OQ230), OSi(Q231)(Q232)(Q233), OS(O2)Q234, NHC(O)Q235, NQ236C(O)Q237, NHC(O)OQ238, NHC(O)NHQ239, NHC(O)NQ240Q241, NQ242C(O)OQ243, NQ244C(O)NHQ245, NQ246C(O)NQ247Q248, NHS(O2)Q249, NQ250S(O2)Q251, SQ252, S(O)Q253, S(O2)Q254, S(O2)NHQ255, S(O2)NQ256Q257, S(O2)OQ258, P(O)(OQ259)(OQ260), Si(Q261)(Q262)(Q263)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ212, NQ213Q214, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q215, C (O) OQ216, C (O) NHQ217, C (O) NQ218Q219, OQ220, O (Q221-O) u H (u = 1, 2, 3, 4, 5), O (Q222-O) u Q223 (u = 1, 2, 3, 4, 5), OC (O) Q224, OC (O) OQ225, OC (O) NHQ226 , OC (O) NQ227Q228, OP (O) (OQ229) (OQ230), OSi (Q231) (Q232) (Q233), OS (O 2 ) Q234, NHC (O) Q235, NQ236C (O) Q237, NHC ( O) OQ238, NHC (O) NHQ239, NHC (O) NQ240Q241, NQ242C (O) OQ243, NQ244C (O) NHQ245, NQ246C (O) NQ247Q248, NHS (O2) Q249, NQ250S (O2) Q251, SQ252, S ( O) Q253, S (O 2 ) Q254, S (O 2 ) NHQ255, S (O 2 ) NQ256Q257, S (O 2 ) OQ258, P (O) (OQ259) (OQ260), Si (Q261) (Q262) (Q263) " 여기서, Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229, Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q218, Q219 및/또는 Q227, Q228 및/또는 Q240, Q241 및/또는 Q247, Q248 및/또는 Q256, Q257은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229, Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q218, Q219 and / or Q227, Q228 and / or Q240, Q241 and / or Q247, Q248 and / or Q256, Q257 are also in each case" heterocycle. " Reels "; 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ264, NQ265Q266, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q267, C(O)OQ268, C(O)NHQ269, C(O)NQ270Q271, OQ272, O(Q273-O)vH (v = 1, 2, 3, 4, 5), O(Q274-O)vQ275 (v = 1, 2, 3, 4, 5), OC(O)Q276, OC(O)OQ277, OC(O)NHQ278, OC(O)NQ279Q280, OP(O)(OQ281)(OQ282), OSi(Q283)(Q284)(Q285), OS(O2)Q286, NHC(O)Q287, NQ288C(O)Q289, NHC(O)OQ290, NHC(O)NHQ291, NHC(O)NQ292Q293, NQ294C(O)OQ295, NQ296C(O)NHQ297, NQ298C(O)NQ299Q300, NHS(O2)Q301, NQ302S(O2)Q303, SQ304, S(O)Q305, S(O2)Q306, S(O2)NHQ307, S(O2)NQ308Q309, S(O2)OQ310, P(O)(OQ311)(OQ312), Si(Q313)(Q314)(Q315)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ264, NQ265Q266, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q267, C (O) OQ268, C (O) NHQ269, C (O) NQ270Q271, OQ272, O (Q273-O) v H (v = 1, 2, 3, 4, 5), O (Q274-O) v Q275 (v = 1, 2, 3, 4, 5), OC (O) Q276, OC (O) OQ277, OC (O) NHQ278 , OC (O) NQ279Q280, OP (O) (OQ281) (OQ282), OSi (Q283) (Q284) (Q285), OS (O 2 ) Q286, NHC (O) Q287, NQ288C (O) Q289, NHC ( O) OQ290, NHC (O) NHQ291, NHC (O) NQ292Q293, NQ294C (O) OQ295, NQ296C (O) NHQ297, NQ298C (O) NQ299Q300, NHS (O2) Q301, NQ302S (O2) Q303, SQ304, S (304) O) Q305, S (O 2 ) Q306, S (O 2 ) NHQ307, S (O 2 ) NQ308Q309, S (O 2 ) OQ310, P (O) (OQ311) (OQ312), Si (Q313) (Q314) (Q315) " 여기서, Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271, Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289, Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q311, Q312, Q313, Q314, Q315는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q270, Q271 및/또는 Q279, Q280 및/또는 Q292, Q293 및/또는 Q299, Q300 및/또는 Q308, Q309는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271, Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289, Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q311, Q312, Q313, Q314, Q315 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q270, Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Q309 are also in each case" heterocycle Reels ", 또는 Z10, Z11 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z10, Z11 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: Or one of the Z10, Z11 radicals is independently selected from the group consisting of, or neither of the Z10, Z11 radicals is independently selected from the group consisting of: (c) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 헤테로사이클릴, 헤테로사이클릴알킬, C(O)Q316, C(O)OQ317, C(O)NQ318Q319, S(O2)Q320, S(O2)OQ321"(c) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, C (O) Q316 , C (O) OQ317, C (O) NQ318Q319, S (O2) Q320, S (O 2 ) OQ321 " 여기서, Q316, Q317, Q318, Q319, Q320, Q321은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q318, Q319는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Wherein Q316, Q317, Q318, Q319, Q320, Q321 are each independently selected from the group consisting of: "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, Heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q318, Q319 can also together form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는, 이들이 수소가 아닌 경우, 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may be substituted by one or more substituents, each of which, independently of one another, is identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ322, NQ323Q324, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q325, C(O)OQ326, C(O)NHQ327, C(O)NQ328Q329, OQ330, O(Q331-O)wH (w = 1, 2, 3, 4, 5), O(Q332-O)wQ333 (w = 1, 2, 3, 4, 5), OC(O)Q334, OC(O)OQ335, OC(O)NHQ336, OC(O)NQ337Q338, OP(O)(OQ339)(OQ340), OSi(Q341)(Q342)(Q343), OS(O2)Q344, NHC(O)Q345, NQ346C(O)Q347, NHC(O)OQ348, NHC(O)NHQ349, NHC(O)NQ350Q351, NQ352C(O)OQ353, NQ354C(O)NHQ355, NQ356C(O)NQ357Q358, NHS(O2)Q359, NQ360S(O2)Q361, SQ362, S(O)Q363, S(O2)Q364, S(O2)NHQ365, S(O2)NQ366Q367, S(O2)OQ368, P(O)(OQ369)(OQ370), Si(Q371)(Q372)(Q373)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ322, NQ323Q324, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q325, C (O) OQ326, C (O) NHQ327, C (O) NQ328Q329, OQ330, O (Q331-O) w H (w = 1, 2, 3, 4, 5), O (Q332-O) w Q333 (w = 1, 2, 3, 4, 5), OC (O) Q334, OC (O) OQ335, OC (O) NHQ336 , OC (O) NQ337Q338, OP (O) (OQ339) (OQ340), OSi (Q341) (Q342) (Q343), OS (O 2 ) Q344, NHC (O) Q345, NQ346C (O) Q347, NHC ( O) OQ348, NHC (O) NHQ349, NHC (O) NQ350Q351, NQ352C (O) OQ353, NQ354C (O) NHQ355, NQ356C (O) NQ357Q358, NHS (O2) Q359, NQ360S (O2) Q361, SQ362, S ( O) Q363, S (O 2 ) Q364, S (O 2 ) NHQ365, S (O 2 ) NQ366Q367, S (O 2 ) OQ368, P (O) (OQ369) (OQ370), Si (Q371) (Q372) (Q373) " 여기서, Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341, Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350, Q351, Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360, Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q328, Q329 및/또는 Q337, Q338 및/또는 Q350, Q351 및/또는 Q357, Q358 및/또는 Q366, Q367은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341, Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350, Q351, Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360, Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q328, Q329 and / or Q337, Q338 and / or Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 may also in each case be" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 추가로 치환되고:Wherein, optionally, the aforementioned substituents of substituent group (i) are each further substituted by one or more substituents, independently of one another, selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ374, NQ375Q376, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q377, C(O)OQ378, C(O)NHQ379, C(O)NQ380Q381, OQ382, O(Q383-O)xH (x = 1, 2, 3, 4, 5), O(Q384-O)xQ385 (x = 1, 2, 3, 4, 5), OC(O)Q386, OC(O)OQ387, OC(O)NHQ388, OC(O)NQ389Q390, OP(O)(OQ391)(OQ392), OSi(Q393)(Q394)(Q395), OS(O2)Q396, NHC(O)Q397, NQ398C(O)Q399, NHC(O)OQ400, NHC(O)NHQ401, NHC(O)NQ402Q403, NQ404C(O)OQ405, NQ406C(O)NHQ407, NQ408C(O)NQ409Q410, NHS(O2)Q411, NQ412S(O2)Q413, SQ414, S(O)Q415, S(O2)Q416, S(O2)NHQ417, S(O2)NQ418Q419, S(O2)OQ420, P(O)(OQ421)(OQ422), Si(Q423)(Q424)(Q425)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ374, NQ375Q376, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q377, C (O) OQ378, C (O) NHQ379, C (O) NQ380Q381, OQ382, O (Q383-O) x H (x = 1, 2, 3, 4, 5), O (Q384-O) x Q385 (x = 1, 2, 3, 4, 5), OC (O) Q386, OC (O) OQ387, OC (O) NHQ388 , OC (O) NQ389Q390, OP (O) (OQ391) (OQ392), OSi (Q393) (Q394) (Q395), OS (O 2 ) Q396, NHC (O) Q397, NQ398C (O) Q399, NHC ( O) OQ400, NHC (O) NHQ401, NHC (O) NQ402Q403, NQ404C (O) OQ405, NQ406C (O) NHQ407, NQ408C (O) NQ409Q410, NHS (O2) Q411, NQ412S (O2) Q413, SQ414, S ( O) Q415, S (O 2 ) Q416, S (O 2 ) NHQ417, S (O 2 ) NQ418Q419, S (O 2 ) OQ420, P (O) (OQ421) (OQ422), Si (Q423) (Q424) (Q425) " 여기서, Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381, Q382, Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391, Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400, Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q380, Q381 및/또는 Q389, Q390 및/또는 Q402, Q403 및/또는 Q409, Q410 및/또는 Q418, Q419는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381, Q382, Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391, Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400, Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q380, Q381 and / or Q389, Q390 and / or Q402, Q403 and / or Q409, Q410 and / or Q418, Q419 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ426, NQ427Q428, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q429, C(O)OQ430, C(O)NHQ431, C(O)NQ432Q433, OQ434, O(Q435-O)yH (y = 1, 2, 3, 4, 5), O(Q436-O)yQ437 (y = 1, 2, 3, 4, 5), OC(O)Q438, OC(O)OQ439, OC(O)NHQ440, OC(O)NQ441Q442, OP(O)(OQ443)(OQ444), OSi(Q445)(Q446)(Q447), OS(O2)Q448, NHC(O)Q449, NQ450C(O)Q451, NHC(O)OQ452, NHC(O)NHQ453, NHC(O)NQ454Q455, NQ456aC(O)OQ456b, NQ456cC(O)NHQ456d, NQ456eC(O)NQ456fQ456g, NHS(O2)Q456h, NQ456iS(O2)Q456j, SQ456k, S(O)Q456l, S(O2)Q456m, S(O2)NHQ456n, S(O2)NQ456-OQ456p, S(O2)OQ456q, P(O)(OQ456r)(OQ456s), Si(Q456t)(Q456u)(Q456v)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ426, NQ427Q428, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q429, C (O) OQ430, C (O) NHQ431, C (O) NQ432Q433, OQ434, O (Q435-O) y H (y = 1, 2, 3, 4, 5), O (Q436-O) y Q437 (y = 1, 2, 3, 4, 5), OC (O) Q438, OC (O) OQ439, OC (O) NHQ440 , OC (O) NQ441Q442, OP (O) (OQ443) (OQ444), OSi (Q445) (Q446) (Q447), OS (O 2 ) Q448, NHC (O) Q449, NQ450C (O) Q451, NHC ( O) OQ452, NHC (O) NHQ453, NHC (O) NQ454Q455, NQ456aC (O) OQ456b, NQ456cC (O) NHQ456d, NQ456eC (O) NQ456fQ456g, NHS (O2) Q456h, NQ456iS (O2) Q456j, SQ456k, SQ456k O) Q456l, S (O 2 ) Q456m, S (O 2 ) NHQ456n, S (O 2 ) NQ456-OQ456p, S (O 2 ) OQ456q, P (O) (OQ456r) (OQ456s), Si (Q456t) ( Q456u) (Q456v) " 여기서, Q426, Q427, Q428, Q429, Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451, Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456j, Q456k, Q456l, Q456m, Q456n, Q456-O, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q432, Q433 및/또는 Q441, Q442 및/또는 Q454, Q455 및/또는 Q456f, Q456g 및/또는 Q456-O, Q456p, 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q426, Q427, Q428, Q429, Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451, Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456j, Q456k, Q456l, Q456m, Q456n, Q456-O, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aryl Alkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456-O, Q456p, and in each case Together can form a "heterocyclyl", Z3, Z4 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z3, Z4 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of: (d) 수소;(d) hydrogen; (e) 할로겐, F, Cl, Br, I;(e) halogen, F, Cl, Br, I; (f) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(f) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ457, NQ458Q459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q460, C(O)OQ461, C(O)NHQ462, C(O)NQ463Q464, OQ465, O(Q466-O)zH (z = 1, 2, 3, 4, 5), O(Q467-O)zQ468 (z = 1, 2, 3, 4, 5), OC(O)Q469, OC(O)OQ470, OC(O)NHQ471, OC(O)NQ472Q473, OP(O)(OQ474)(OQ475), OSi(Q476)(Q477)(Q478), OS(O2)Q479, NHC(O)Q480, NQ481C(O)Q482, NHC(O)OQ483, NHC(O)NHQ484, NHC(O)NQ485Q486, NQ487C(O)OQ488, NQ489C(O)NHQ490, NQ491C(O)NQ492Q493, NHS(O2)Q494, NQ495S(O2)Q496, SQ497, S(O)Q498, S(O2)Q499, S(O2)NHQ500, S(O2)NQ501Q502, S(O2)OQ503, P(O)(OQ504)(OQ505), Si(Q506)(Q507)(Q508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ457, NQ458Q459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q460, C (O) OQ461, C (O) NHQ462, C (O) NQ463Q464, OQ465, O (Q466-O) z H (z = 1, 2, 3, 4, 5), O (Q467-O) z Q468 (z = 1, 2, 3, 4, 5), OC (O) Q469, OC (O) OQ470, OC (O) NHQ471 , OC (O) NQ472Q473, OP (O) (OQ474) (OQ475), OSi (Q476) (Q477) (Q478), OS (O 2 ) Q479, NHC (O) Q480, NQ481C (O) Q482, NHC ( O) OQ483, NHC (O) NHQ484, NHC (O) NQ485Q486, NQ487C (O) OQ488, NQ489C (O) NHQ490, NQ491C (O) NQ492Q493, NHS (O2) Q494, NQ495S (O2) Q496, SQ497, SQ497 O) Q498, S (O 2 ) Q499, S (O 2 ) NHQ500, S (O 2 ) NQ501Q502, S (O 2 ) OQ503, P (O) (OQ504) (OQ505), Si (Q506) (Q507) (Q508) " 여기서, Q457, Q458, Q459, Q460, Q461, Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485, Q486, Q487, Q488, Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505, Q506, Q507, Q508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q463, Q464 및/또는 Q472, Q473 및/또는 Q485, Q486 및/또는 Q492, Q493 및/또는 Q501, Q502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q457, Q458, Q459, Q460, Q461, Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485, Q486, Q487, Q488, Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505, Q506, Q507, Q508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Q502 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ509, NQ510Q511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q512, C(O)OQ513, C(O)NHQ514, C(O)NQ515Q516, OQ517, O(Q518-O)aH (a = 1, 2, 3, 4, 5), O(Q519-O)aQ520 (a = 1, 2, 3, 4, 5), OC(O)Q521, OC(O)OQ522, OC(O)NHQ523, OC(O)NQ524Q525, OP(O)(OQ526)(OQ527), OSi(Q528)(Q529)(Q530), OS(O2)Q531, NHC(O)Q532, NQ533C(O)Q534, NHC(O)OQ535, NHC(O)NHQ536, NHC(O)NQ537Q538, NQ539C(O)OQ540, NQ541C(O)NHQ542, NQ543C(O)NQ544Q545, NHS(O2)Q546, NQ547S(O2)Q548, SQ549, S(O)Q550, S(O2)Q551, S(O2)NHQ552, S(O2)NQ553Q554, S(O2)OQ555, P(O)(OQ556)(OQ557), Si(Q558)(Q559)(Q560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ509, NQ510Q511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q512, C (O) OQ513, C (O) NHQ514, C (O) NQ515Q516, OQ517, O (Q518-O) a H (a = 1, 2, 3, 4, 5), O (Q519-O) a Q520 (a = 1, 2, 3, 4, 5), OC (O) Q521, OC (O) OQ522, OC (O) NHQ523 , OC (O) NQ524Q525, OP (O) (OQ526) (OQ527), OSi (Q528) (Q529) (Q530), OS (O 2 ) Q531, NHC (O) Q532, NQ533C (O) Q534, NHC ( O) OQ535, NHC (O) NHQ536, NHC (O) NQ537Q538, NQ539C (O) OQ540, NQ541C (O) NHQ542, NQ543C (O) NQ544Q545, NHS (O2) Q546, NQ547S (O2) Q548, SQ549, S ( O) Q550, S (O 2 ) Q551, S (O 2 ) NHQ552, S (O 2 ) NQ553Q554, S (O 2 ) OQ555, P (O) (OQ556) (OQ557), Si (Q558) (Q559) (Q560) " 여기서, Q509, Q510, Q511, Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519, Q520, Q521, Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q531, Q532, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q515, Q516 및/또는 Q524, Q525 및/또는 Q537, Q538 및/또는 Q544, Q545 및/또는 Q553, Q554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where Q509, Q510, Q511, Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519, Q520, Q521, Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q531, Q532, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 are each independently selected from the group consisting of: "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl , Heteroarylalkyl ", wherein, alternatively, Q515, Q516 and / or Q524, Q525 and / or Q537, Q538 and / or Q544, Q545 and / or Q553, Q554 are also in each case" heterocyclyl " Can form; 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ561, NQ562Q563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q564, C(O)OQ565, C(O)NHQ566, C(O)NQ567Q568, OQ569, O(Q570-O)bH (b = 1, 2, 3, 4, 5), O(Q571-O)bQ572 (b = 1, 2, 3, 4, 5), OC(O)Q573, OC(O)OQ574, OC(O)NHQ575, OC(O)NQ576Q577, OP(O)(OQ578)(OQ579), OSi(Q580)(Q581)(Q582), OS(O2)Q583, NHC(O)Q584, NQ585C(O)Q586, NHC(O)OQ587, NHC(O)NHQ588, NHC(O)NQ589Q590, NQ591C(O)OQ592, NQ593C(O)NHQ594, NQ595C(O)NQ596Q597, NHS(O2)Q598, NQ599S(O2)Q600, SQ601, S(O)Q602, S(O2)Q603, S(O2)NHQ604, S(O2)NQ605Q606, S(O2)OQ607, P(O)(OQ608)(OQ609), Si(Q610)(Q611)(Q612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ561, NQ562Q563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q564, C (O) OQ565, C (O) NHQ566, C (O) NQ567Q568, OQ569, O (Q570-O) b H (b = 1, 2, 3, 4, 5), O (Q571-O) b Q572 (b = 1, 2, 3, 4, 5), OC (O) Q573, OC (O) OQ574, OC (O) NHQ575 , OC (O) NQ576Q577, OP (O) (OQ578) (OQ579), OSi (Q580) (Q581) (Q582), OS (O 2 ) Q583, NHC (O) Q584, NQ585C (O) Q586, NHC ( O) OQ587, NHC (O) NHQ588, NHC (O) NQ589Q590, NQ591C (O) OQ592, NQ593C (O) NHQ594, NQ595C (O) NQ596Q597, NHS (O2) Q598, NQ599S (O2) Q600, SQ601, S (601) O) Q602, S (O 2 ) Q603, S (O 2 ) NHQ604, S (O 2 ) NQ605Q606, S (O 2 ) OQ607, P (O) (OQ608) (OQ609), Si (Q610) (Q611) (Q612) " 여기서, Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581, Q582, Q583, Q584, Q585, Q586, Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q609, Q610, Q611, Q612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬,헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q567, Q568 및/또는 Q576, Q577 및/또는 Q589, Q590 및/또는 Q596, Q597 및/또는 Q605, Q606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581, Q582, Q583, Q584, Q585, Q586, Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q609, Q610, Q611, Q612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 are also in each case" heterocycle. " Reels ", (g) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ613, NQ614Q615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q616, C(O)OQ617, C(O)NHQ618, C(O)NQ619Q620, OQ621, O(Q622-O)cH (c = 1, 2, 3, 4, 5), O(Q623-O)cQ624 (c = 1, 2, 3, 4, 5), OC(O)Q625, OC(O)OQ626, OC(O)NHQ627, OC(O)NQ628Q629, OP(O)(OQ630)(OQ631), OSi(Q632)(Q633)(Q634), OS(O2)Q635, NHC(O)Q636, NQ637C(O)Q638, NHC(O)OQ639, NHC(O)NHQ640, NHC(O)NQ641Q642, NQ643C(O)OQ644, NQ645C(O)NHQ646, NQ647C(O)NQ648Q649, NHS(O2)Q650, NQ651S(O2)Q652, SQ653, S(O)Q654, S(O2)Q655, S(O2)NHQ656, S(O2)NQ657Q658, S(O2)OQ659, P(O)(OQ660)(OQ661), Si(Q662)(Q663)(Q664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ613, NQ614Q615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q616, C (O) OQ617, C (O) NHQ618, C (O) NQ619Q620, OQ621, O (Q622-O) c H (c = 1, 2, 3, 4, 5), O (Q623-O) c Q624 (c = 1, 2, 3, 4, 5), OC (O) Q625, OC (O) OQ626, OC (O) NHQ627 , OC (O) NQ628Q629, OP (O) (OQ630) (OQ631), OSi (Q632) (Q633) (Q634), OS (O 2 ) Q635, NHC (O) Q636, NQ637C (O) Q638, NHC ( O) OQ639, NHC (O) NHQ640, NHC (O) NQ641Q642, NQ643C (O) OQ644, NQ645C (O) NHQ646, NQ647C (O) NQ648Q649, NHS (O2) Q650, NQ651S (O2) Q652, SQ653, S ( O) Q654, S (O 2 ) Q655, S (O 2 ) NHQ656, S (O 2 ) NQ657Q658, S (O 2 ) OQ659, P (O) (OQ660) (OQ661), Si (Q662) (Q663) (Q664) " 여기서, Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621, Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641, Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q619, Q620 및/또는 Q628, Q629 및/또는 Q641, Q642 및/또는 Q648, Q649 및/또는 Q657, Q658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621, Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641, Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q619, Q620 and / or Q628, Q629 and / or Q641, Q642 and / or Q648, Q649 and / or Q657, Q658 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ665, NQ666Q667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q668, C(O)OQ669, C(O)NHQ670, C(O)NQ671Q672, OQ673, O(Q674-O)dH (d = 1, 2, 3, 4, 5), O(Q675-O)dQ676 (d = 1, 2, 3, 4, 5), OC(O)Q677, OC(O)OQ678, OC(O)NHQ679, OC(O)NQ680Q681, OP(O)(OQ682)(OQ683), OSi(Q684)(Q685)(Q686), OS(O2)Q687, NHC(O)Q688, NQ689C(O)Q690, NHC(O)OQ691, NHC(O)NHQ692, NHC(O)NQ693Q694, NQ695C(O)OQ696, NQ697C(O)NHQ698, NQ699C(O)NQ700Q701, NHS(O2)Q702, NQ703S(O2)Q704, SQ705, S(O)Q706, S(O2)Q707, S(O2)NHQ708, S(O2)NQ709Q710, S(O2)OQ711, P(O)(OQ712)(OQ713), Si(Q714)(Q715)(Q716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ665, NQ666Q667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q668, C (O) OQ669, C (O) NHQ670, C (O) NQ671Q672, OQ673, O (Q674-O) d H (d = 1, 2, 3, 4, 5), O (Q675-O) d Q676 (d = 1, 2, 3, 4, 5), OC (O) Q677, OC (O) OQ678, OC (O) NHQ679 , OC (O) NQ680Q681, OP (O) (OQ682) (OQ683), OSi (Q684) (Q685) (Q686), OS (O 2 ) Q687, NHC (O) Q688, NQ689C (O) Q690, NHC ( O) OQ691, NHC (O) NHQ692, NHC (O) NQ693Q694, NQ695C (O) OQ696, NQ697C (O) NHQ698, NQ699C (O) NQ700Q701, NHS (O2) Q702, NQ703S (O2) Q704, SQ705, S ( O) Q706, S (O 2 ) Q707, S (O 2 ) NHQ708, S (O 2 ) NQ709Q710, S (O 2 ) OQ711, P (O) (OQ712) (OQ713), Si (Q714) (Q715) (Q716) " 여기서, Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711, Q712, Q713, Q714, Q715, Q716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q671, Q672 및/또는 Q680, Q681 및/또는 Q693, Q694 및/또는 Q700, Q701 및/또는 Q709, Q710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711, Q712, Q713, Q714, Q715, Q716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q671, Q672 and / or Q680, Q681 and / or Q693, Q694 and / or Q700, Q701 and / or Q709, Q710 are also in each case" heterocycle. " Reels "; 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ717, NQ718Q719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q720, C(O)OQ721, C(O)NHQ722, C(O)NQ723Q724, OQ725, O(Q726-O)eH (e = 1, 2, 3, 4, 5), O(Q727-O)eQ728 (e = 1, 2, 3, 4, 5), OC(O)Q729, OC(O)OQ730, OC(O)NHQ731, OC(O)NQ732Q733, OP(O)(OQ734)(OQ735), OSi(Q736)(Q737)(Q738), OS(O2)Q739, NHC(O)Q740, NQ741C(O)Q742, NHC(O)OQ743, NHC(O)NHQ744, NHC(O)NQ745Q746, NQ747C(O)OQ748, NQ749C(O)NHQ750, NQ751C(O)NQ752Q753, NHS(O2)Q754, NQ755S(O2)Q756, SQ757, S(O)Q758, S(O2)Q759, S(O2)NHQ760, S(O2)NQ761Q762, S(O2)OQ763, P(O)(OQ764)(OQ765), Si(Q766)(Q767)(Q768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ717, NQ718Q719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q720, C (O) OQ721, C (O) NHQ722, C (O) NQ723Q724, OQ725, O (Q726-O) e H (e = 1, 2, 3, 4, 5), O (Q727-O) e Q728 (e = 1, 2, 3, 4, 5), OC (O) Q729, OC (O) OQ730, OC (O) NHQ731 , OC (O) NQ732Q733, OP (O) (OQ734) (OQ735), OSi (Q736) (Q737) (Q738), OS (O 2 ) Q739, NHC (O) Q740, NQ741C (O) Q742, NHC ( O) OQ743, NHC (O) NHQ744, NHC (O) NQ745Q746, NQ747C (O) OQ748, NQ749C (O) NHQ750, NQ751C (O) NQ752Q753, NHS (O2) Q754, NQ755S (O2) Q756, SQ757, S ( O) Q758, S (O 2 ) Q759, S (O 2 ) NHQ760, S (O 2 ) NQ761Q762, S (O 2 ) OQ763, P (O) (OQ764) (OQ765), Si (Q766) (Q767) (Q768) " 여기서, Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q723, Q724 및/또는 Q732, Q733 및/또는 Q745, Q746 및/또는 Q752, Q753 및/또는 Q761, Q762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q723, Q724 and / or Q732, Q733 and / or Q745, Q746 and / or Q752, Q753 and / or Q761, Q762 are also in each case" heterocycle. " Reels ", (h) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ769, NQ770Q771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q772, C(O)OQ773, C(O)NHQ774, C(O)NQ775Q776, OQ777, O(Q778-O)fH (f = 1, 2, 3, 4, 5), O(Q779-O)fQ780 (f = 1, 2, 3, 4, 5), OC(O)Q781, OC(O)OQ782, OC(O)NHQ783, OC(O)NQ784Q785, OP(O)(OQ786)(OQ787), OSi(Q788)(Q789)(Q790), OS(O2)Q791, NHC(O)Q792, NQ793C(O)Q794, NHC(O)OQ795, NHC(O)NHQ796, NHC(O)NQ797Q798, NQ799C(O)OQ800, NQ801C(O)NHQ802, NQ803C(O)NQ804Q805, NHS(O2)Q806, NQ807S(O2)Q808, SQ809, S(O)Q810, S(O2)Q811, S(O2)NHQ812, S(O2)NQ813Q814, S(O2)OQ815, P(O)(OQ816)(OQ817), Si(Q818)(Q819)(Q820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ769, NQ770Q771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q772, C (O) OQ773, C (O) NHQ774, C (O) NQ775Q776, OQ777, O (Q778-O) f H (f = 1, 2, 3, 4, 5), O (Q779-O) f Q780 (f = 1, 2, 3, 4, 5), OC (O) Q781, OC (O) OQ782, OC (O) NHQ783 , OC (O) NQ784Q785, OP (O) (OQ786) (OQ787), OSi (Q788) (Q789) (Q790), OS (O 2 ) Q791, NHC (O) Q792, NQ793C (O) Q794, NHC ( O) OQ795, NHC (O) NHQ796, NHC (O) NQ797Q798, NQ799C (O) OQ800, NQ801C (O) NHQ802, NQ803C (O) NQ804Q805, NHS (O2) Q806, NQ807S (O2) Q808, SQ809, S ( O) Q810, S (O 2 ) Q811, S (O 2 ) NHQ812, S (O 2 ) NQ813Q814, S (O 2 ) OQ815, P (O) (OQ816) (OQ817), Si (Q818) (Q819) (Q820) " 여기서, Q769, Q770, Q771, Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q811, Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Where Q769, Q770, Q771, Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q811, Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl " 여기서, 대안적으로, Q775, Q776 및/또는 Q784, Q785 및/또는 Q797, Q798 및/또는 Q804, Q805 및/또는 Q813, Q814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, alternatively, Q775, Q776 and / or Q784, Q785 and / or Q797, Q798 and / or Q804, Q805 and / or Q813, Q814 may also together form "heterocyclyl" in each case, 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ821, NQ822Q823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q824, C(O)OQ825, C(O)NHQ826, C(O)NQ827Q828, OQ829, O(Q830-O)gH (g = 1, 2, 3, 4, 5), O(Q831-O)gQ832 (g = 1, 2, 3, 4, 5), OC(O)Q833, OC(O)OQ834, OC(O)NHQ835, OC(O)NQ836Q837, OP(O)(OQ838)(OQ839), OSi(Q840)(Q841)(Q842), OS(O2)Q843, NHC(O)Q844, NQ845C(O)Q846, NHC(O)OQ847, NHC(O)NHQ848, NHC(O)NQ849Q850, NQ851C(O)OQ852, NQ853C(O)NHQ854, NQ855C(O)NQ856Q857, NHS(O2)Q858, NQ859S(O2)Q860, SQ861, S(O)Q862, S(O2)Q863, S(O2)NHQ864, S(O2)NQ865Q866, S(O2)OQ867, P(O)(OQ868)(OQ869), Si(Q870)(Q871)(Q872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ821, NQ822Q823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q824, C (O) OQ825, C (O) NHQ826, C (O) NQ827Q828, OQ829, O (Q830-O) g H (g = 1, 2, 3, 4, 5), O (Q831-O) g Q832 (g = 1, 2, 3, 4, 5), OC (O) Q833, OC (O) OQ834, OC (O) NHQ835 , OC (O) NQ836Q837, OP (O) (OQ838) (OQ839), OSi (Q840) (Q841) (Q842), OS (O 2 ) Q843, NHC (O) Q844, NQ845C (O) Q846, NHC ( O) OQ847, NHC (O) NHQ848, NHC (O) NQ849Q850, NQ851C (O) OQ852, NQ853C (O) NHQ854, NQ855C (O) NQ856Q857, NHS (O2) Q858, NQ859S (O2) Q860, SQ861, S ( O) Q862, S (O 2 ) Q863, S (O 2 ) NHQ864, S (O 2 ) NQ865Q866, S (O 2 ) OQ867, P (O) (OQ868) (OQ869), Si (Q870) (Q871) (Q872) " 여기서, Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"Where Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl " 여기서, 대안적으로, Q827, Q828 및/또는 Q836, Q837 및/또는 Q849, Q850 및/또는 Q856, Q857 및/또는 Q865, Q866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, alternatively, Q827, Q828 and / or Q836, Q837 and / or Q849, Q850 and / or Q856, Q857 and / or Q865, Q866 may also together form “heterocyclyl” in each case, 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ873, NQ874Q875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q876, C(O)OQ877, C(O)NHQ878, C(O)NQ879Q880, OQ881, O(Q882-O)hH (h = 1, 2, 3, 4, 5), O(Q883-O)hQ884 (h = 1, 2, 3, 4, 5), OC(O)Q885, OC(O)OQ886, OC(O)NHQ887, OC(O)NQ888Q889, OP(O)(OQ890)(OQ891), OSi(Q892)(Q893)(Q894), OS(O2)Q895, NHC(O)Q896, NQ897C(O)Q898, NHC(O)OQ899, NHC(O)NHQ900, NHC(O)NQ901Q902, NQ903C(O)OQ904, NQ905C(O)NHQ906, NQ907C(O)NQ908Q909, NHS(O2)Q910, NQ911S(O2)Q912, SQ913, S(O)Q914, S(O2)Q915, S(O2)NHQ916, S(O2)NQ917Q918, S(O2)OQ919, P(O)(OQ920)(OQ921), Si(Q922)(Q923)(Q924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ873, NQ874Q875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q876, C (O) OQ877, C (O) NHQ878, C (O) NQ879Q880, OQ881, O (Q882-O) h H (h = 1, 2, 3, 4, 5), O (Q883-O) h Q884 (h = 1, 2, 3, 4, 5), OC (O) Q885, OC (O) OQ886, OC (O) NHQ887 , OC (O) NQ888Q889, OP (O) (OQ890) (OQ891), OSi (Q892) (Q893) (Q894), OS (O 2 ) Q895, NHC (O) Q896, NQ897C (O) Q898, NHC ( O) OQ899, NHC (O) NHQ900, NHC (O) NQ901Q902, NQ903C (O) OQ904, NQ905C (O) NHQ906, NQ907C (O) NQ908Q909, NHS (O2) Q910, NQ911S (O2) Q912, SQ913, S ( O) Q914, S (O 2 ) Q915, S (O 2 ) NHQ916, S (O 2 ) NQ917Q918, S (O 2 ) OQ919, P (O) (OQ920) (OQ921), Si (Q922) (Q923) (Q924) " 여기서, Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891, Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923, Q924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q879, Q880 및/또는 Q888, Q889 및/또는 Q901, Q902 및/또는 Q908, Q909 및/또는 Q917, Q918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891, Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923, Q924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q879, Q880 and / or Q888, Q889 and / or Q901, Q902 and / or Q908, Q909 and / or Q917, Q918 are also in each case" heterocycle. " Reels ", (j) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(j) OZ6, wherein Z6 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ925, NQ926Q927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q928, C(O)OQ929, C(O)NHQ930, C(O)NQ931Q932, OQ933, O(Q934-O)iH (i = 1, 2, 3, 4, 5), O(Q935-O)iQ936 (i = 1, 2, 3, 4, 5), OC(O)Q937, OC(O)OQ938, OC(O)NHQ939, OC(O)NQ940Q941, OP(O)(OQ942)(OQ943), OSi(Q944)(Q945)(Q946), OS(O2)Q947, NHC(O)Q948, NQ949C(O)Q950, NHC(O)OQ951, NHC(O)NHQ952, NHC(O)NQ953Q954, NQ955C(O)OQ956, NQ957C(O)NHQ958, NQ959C(O)NQ960Q961, NHS(O2)Q962, NQ963S(O2)Q964, SQ965, S(O)Q966, S(O2)Q967, S(O2)NHQ968, S(O2)NQ969Q970, S(O2)OQ971, P(O)(OQ972)(OQ973), Si(Q974)(Q975)(Q976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ925, NQ926Q927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q928, C (O) OQ929, C (O) NHQ930, C (O) NQ931Q932, OQ933, O (Q934-O) i H (i = 1, 2, 3, 4, 5), O (Q935-O) i Q936 (i = 1, 2, 3, 4, 5), OC (O) Q937, OC (O) OQ938, OC (O) NHQ939 , OC (O) NQ940Q941, OP (O) (OQ942) (OQ943), OSi (Q944) (Q945) (Q946), OS (O 2 ) Q947, NHC (O) Q948, NQ949C (O) Q950, NHC ( O) OQ951, NHC (O) NHQ952, NHC (O) NQ953Q954, NQ955C (O) OQ956, NQ957C (O) NHQ958, NQ959C (O) NQ960Q961, NHS (O2) Q962, NQ963S (O2) Q964, SQ965, S ( O) Q966, S (O 2 ) Q967, S (O 2 ) NHQ968, S (O 2 ) NQ969Q970, S (O 2 ) OQ971, P (O) (OQ972) (OQ973), Si (Q974) (Q975) (Q976) " 여기서, Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957,Q958, Q959, Q960, Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q931, Q932 및/또는 Q940, Q941 및/또는 Q953, Q954 및/또는 Q960, Q961 및/또는 Q969, Q970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960, Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ977, NQ978Q979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q980, C(O)OQ981, C(O)NHQ982, C(O)NQ983Q984, OQ985, O(Q986-O)jH (j = 1, 2, 3, 4, 5), O(Q987-O)jQ988 (j = 1, 2, 3, 4, 5), OC(O)Q989, OC(O)OQ990, OC(O)NHQ991, OC(O)NQ992Q993, OP(O)(OQ994)(OQ995), OSi(Q996)(Q997)(Q998), OS(O2)Q999, NHC(O)Q1000, NQ1001C(O)Q1002, NHC(O)OQ1003, NHC(O)NHQ1004, NHC(O)NQ1005Q1006, NQ1007C(O)OQ1008, NQ1009C(O)NHQ1010, NQ1011C(O)NQ1012Q1013, NHS(O2)Q1014, NQ1015S(O2)Q1016, SQ1017, S(O)Q1018, S(O2)Q1019, S(O2)NHQ1020, S(O2)NQ1021Q1022, S(O2)OQ1023, P(O)(OQ1024)(OQ1025), Si(Q1026)(Q1027)(Q1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ977, NQ978Q979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q980, C (O) OQ981, C (O) NHQ982, C (O) NQ983Q984, OQ985, O (Q986-O) j H (j = 1, 2, 3, 4, 5), O (Q987-O) j Q988 (j = 1, 2, 3, 4, 5), OC (O) Q989, OC (O) OQ990, OC (O) NHQ991 , OC (O) NQ992Q993, OP (O) (OQ994) (OQ995), OSi (Q996) (Q997) (Q998), OS (O 2 ) Q999, NHC (O) Q1000, NQ1001C (O) Q1002, NHC ( O) OQ1003, NHC (O) NHQ1004, NHC (O) NQ1005Q1006, NQ1007C (O) OQ1008, NQ1009C (O) NHQ1010, NQ1011C (O) NQ1012Q1013, NHS (O2) Q1014, NQ1015S (O2) Q1016, SQ1016, SQ1016 O) Q1018, S (O 2 ) Q1019, S (O 2 ) NHQ1020, S (O 2 ) NQ1021Q1022, S (O 2 ) OQ1023, P (O) (OQ1024) (OQ1025), Si (Q1026) (Q1027) (Q1028) " 여기서, Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001, Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q983, Q984 및/또는 Q992, Q993 및/또는 Q1005, Q1006 및/또는 Q1012, Q1013 및/또는 Q1021, Q1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001, Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1024, Q1024 Q1026, Q1027, Q1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 are also in each case" heterocycle Reels ", (k) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) SZ7, wherein Z7 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1029, NQ1030Q1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1032, C(O)OQ1033, C(O)NHQ1034, C(O)NQ1035Q1036, OQ1037, O(Q1038-O)kH (k = 1, 2, 3, 4, 5), O(Q1039-O)kQ1040 (k = 1, 2, 3, 4, 5), OC(O)Q1041, OC(O)OQ1042, OC(O)NHQ1043, OC(O)NQ1044Q1045, OP(O)(OQ1046)(OQ1047), OSi(Q1048)(Q1049)(Q1050), OS(O2)Q1051, NHC(O)Q1052, NQ1053C(O)Q1054, NHC(O)OQ1055, NHC(O)NHQ1056, NHC(O)NQ1057Q1058, NQ1059C(O)OQ1060, NQ1061C(O)NHQ1062, NQ1063C(O)NQ1064Q1065, NHS(O2)Q1066, NQ1067S(O2)Q1068, SQ1069, S(O)Q1070, S(O2)Q1071, S(O2)NHQ1072, S(O2)NQ1073Q1074, S(O2)OQ1075, P(O)(OQ1076)(OQ1077), Si(Q1078)(Q1079)(Q1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1029, NQ1030Q1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1032, C (O) OQ1033, C (O) NHQ1034, C (O) NQ1035Q1036, OQ1037, O (Q1038-O) k H (k = 1, 2, 3, 4, 5), O (Q1039-O) k Q1040 (k = 1, 2, 3, 4, 5), OC (O) Q1041, OC (O) OQ1042, OC (O) NHQ1043 , OC (O) NQ1044Q1045, OP (O) (OQ1046) (OQ1047), OSi (Q1048) (Q1049) (Q1050), OS (O 2 ) Q1051, NHC (O) Q1052, NQ1053C (O) Q1054, NHC ( O) OQ1055, NHC (O) NHQ1056, NHC (O) NQ1057Q1058, NQ1059C (O) OQ1060, NQ1061C (O) NHQ1062, NQ1063C (O) NQ1064Q1065, NHS (O2) Q1066, NQ1067S (O2) Q1068, SQ1069 O) Q1070, S (O 2 ) Q1071, S (O 2 ) NHQ1072, S (O 2 ) NQ1073Q1074, S (O 2 ) OQ1075, P (O) (OQ1076) (OQ1077), Si (Q1078) (Q1079) (Q1080) " 여기서, Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1076, Q1077, Q1078, Q1079, Q1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1035, Q1036 및/또는 Q1044, Q1045 및/또는 Q1057, Q1058 및/또는 Q1064, Q1065 및/또는 Q1073, Q1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1077, Q1077 Q1078, Q1079, Q1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1081, NQ1082Q1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1084, C(O)OQ1085, C(O)NHQ1086, C(O)NQ1087Q1088, OQ1089, O(Q1090-O)lH (l = 1, 2, 3, 4, 5), O(Q1091-O)lQ1092 (l = 1, 2, 3, 4, 5), OC(O)Q1093, OC(O)OQ1094, OC(O)NHQ1095, OC(O)NQ1096Q1097, OP(O)(OQ1098)(OQ1099), OSi(Q1100)(Q1101)(Q1102), OS(O2)Q1103, NHC(O)Q1104, NQ1105C(O)Q1106, NHC(O)OQ1107, NHC(O)NHQ1108, NHC(O)NQ1109Q1110, NQ1111C(O)OQ1112, NQ1113C(O)NHQ1114, NQ1115C(O)NQ1116Q1117, NHS(O2)Q1118, NQ1119S(O2)Q1120, SQ1121, S(O)Q1122, S(O2)Q1123, S(O2)NHQ1124, S(O2)NQ1125Q1126, S(O2)OQ1127, P(O)(OQ1128)(OQ1129), Si(Q1130)(Q1131)(Q1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1081, NQ1082Q1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1084, C (O) OQ1085, C (O) NHQ1086, C (O) NQ1087Q1088, OQ1089, O (Q1090-O) l H (l = 1, 2, 3, 4, 5), O (Q1091-O) l Q1092 (l = 1, 2, 3, 4, 5), OC (O) Q1093, OC (O) OQ1094, OC (O) NHQ1095 , OC (O) NQ1096Q1097, OP (O) (OQ1098) (OQ1099), OSi (Q1100) (Q1101) (Q1102), OS (O 2 ) Q1103, NHC (O) Q1104, NQ1105C (O) Q1106, NHC ( O) OQ1107, NHC (O) NHQ1108, NHC (O) NQ1109Q1110, NQ1111C (O) OQ1112, NQ1113C (O) NHQ1114, NQ1115C (O) NQ1116Q1117, NHS (O2) Q1118, NQ1119S (O2) Q1120, SQ112 O) Q1122, S (O 2 ) Q1123, S (O 2 ) NHQ1124, S (O 2 ) NQ1125Q1126, S (O 2 ) OQ1127, P (O) (OQ1128) (OQ1129), Si (Q1130) (Q1131) (Q1132) " 여기서, Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104, Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121, Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128, Q1129, Q1130, Q1131, Q1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1087, Q1088 및/또는 Q1096, Q1097 및/또는 Q1109, Q1110 및/또는 Q1116, Q1117 및/또는 Q1125, Q1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104 Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121, Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128,11 Q1130, Q1131, Q1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1087, Q1088 and / or Q1096, Q1097 and / or Q1109, Q1110 and / or Q1116, Q1117 and / or Q1125, Q1126 are also in each case" heterocycle. " Reels ", (l) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)Q1133, C(O)OQ1134, C(O)NQ1135Q1136, S(O2)Q1137, S(O2)OQ1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) Q1133 , C (O) OQ1134, C (O) NQ1135Q1136, S (O2) Q1137, S (O2) OQ1138 " 여기서, Q1133, Q1134, Q1135, Q1136, Q1137, Q1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1135, Q1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein Q1133, Q1134, Q1135, Q1136, Q1137, Q1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl Alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q1135, Q1136 together may also form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1139, NQ1140Q1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1142, C(O)OQ1143, C(O)NHQ1144, C(O)NQ1145Q1146, OQ1147, O(Q1148-O)mH (m = 1, 2, 3, 4, 5), O(Q1149-O)mQ1150 (m = 1, 2, 3, 4, 5), OC(O)Q1151, OC(O)OQ1152, OC(O)NHQ1153, OC(O)NQ1154Q1155, OP(O)(OQ1156)(OQ1157), OSi(Q1158)(Q1159)(Q1160), OS(O2)Q1161, NHC(O)Q1162, NQ1163C(O)Q1164, NHC(O)OQ1165, NHC(O)NHQ1166, NHC(O)NQ1167Q1168, NQ1169C(O)OQ1170, NQ1171C(O)NHQ1172, NQ1173C(O)NQ1174Q1175, NHS(O2)Q1176, NQ1177S(O2)Q1178, SQ1179, S(O)Q1180, S(O2)Q1181, S(O2)NHQ1182, S(O2)NQ1183Q1184, S(O2)OQ1185, P(O)(OQ1186)(OQ1187), Si(Q1188)(Q1189)(Q1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1139, NQ1140Q1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1142, C (O) OQ1143, C (O) NHQ1144, C (O) NQ1145Q1146, OQ1147, O (Q1148-O) m H (m = 1, 2, 3, 4, 5), O (Q1149-O) m Q1150 (m = 1, 2, 3, 4, 5), OC (O) Q1151, OC (O) OQ1152, OC (O) NHQ1153 , OC (O) NQ1154Q1155, OP (O) (OQ1156) (OQ1157), OSi (Q1158) (Q1159) (Q1160), OS (O 2 ) Q1161, NHC (O) Q1162, NQ1163C (O) Q1164, NHC ( O) OQ1165, NHC (O) NHQ1166, NHC (O) NQ1167Q1168, NQ1169C (O) OQ1170, NQ1171C (O) NHQ1172, NQ1173C (O) NQ1174Q1175, NHS (O2) Q1176, NQ1177S (O2) Q1178, SQ1178, SQ1178 O) Q1180, S (O 2 ) Q1181, S (O 2 ) NHQ1182, S (O 2 ) NQ1183Q1184, S (O 2 ) OQ1185, P (O) (OQ1186) (OQ1187), Si (Q1188) (Q1189) (Q1190) " 여기서, Q1139, Q1140, Q1141, Q1142, Q1143, Q1144, Q1145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153, Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185, Q1186, Q1187, Q1188, Q1189, Q1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1145, Q1146 및/또는 Q1154, Q1155 및/또는 Q1167, Q1168 및/또는 Q1174, Q1175 및/또는 Q1183, Q1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1139, Q1140, Q1141, Q1142, Q1143, Q1144, Q1145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153, Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1162 Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185, Q1186, Q1188, Q1189 and Q1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1145, Q1146 and / or Q1154, Q1155 and / or Q1167, Q1168 and / or Q1174, Q1175 and / or Q1183, Q1184 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHQ1191, NQ1192Q1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)Q1194, C(O)OQ1195, C(O)NHQ1196, C(O)NQ1197Q1198, OQ1199, O(Q1200-O)nH (n = 1, 2, 3, 4, 5), O(Q1201-O)nQ1202 (n = 1, 2, 3, 4, 5), OC(O)Q1203, OC(O)OQ1204, OC(O)NHQ1205, OC(O)NQ1206Q1207, OP(O)(OQ1208)(OQ1209), OSi(Q1210)(Q1211)(Q1212), OS(O2)Q1213, NHC(O)Q1214, NQ1215C(O)Q1216, NHC(O)OQ1217, NHC(O)NHQ1218, NHC(O)NQ1219Q1220, NQ1221C(O)OQ1222, NQ1223C(O)NHQ1224, NQ1225C(O)NQ1226Q1227, NHS(O2)Q1228, NQ1229S(O2)Q1230, SQ1231, S(O)Q1232, S(O2)Q1233, S(O2)NHQ1234, S(O2)NQ1235Q1236, S(O2)OQ1237, P(O)(OQ1238)(OQ1239), Si(Q1240)(Q1241)(Q1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHQ1191, NQ1192Q1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) Q1194, C (O) OQ1195, C (O) NHQ1196, C (O) NQ1197Q1198, OQ1199, O (Q1200-O) nH (n = 1 , 2, 3, 4, 5), O (Q1201-O) nQ1202 (n = 1, 2, 3, 4, 5), OC (O) Q1203, OC (O) OQ1204, OC (O) NHQ1205, OC (O) NQ1206Q1207, OP (O) (OQ1208) (OQ1209), OSi (Q1210) (Q1211) (Q1212), OS (O 2 ) Q1213, NHC (O) Q1214, NQ1215C (O) Q1216, NHC (O) OQ1217, NHC (O) NHQ1218, NHC (O) NQ1219Q1220, NQ1221C (O) OQ1222, NQ1223C (O) NHQ1224, NQ1225C (O) NQ1226Q1227, NHS (O2) Q1228, NQ1229S (O2) Q1230, SQ1231, SQ1231 Q1232, S (O 2 ) Q1233, S (O 2 ) NHQ1234, S (O 2 ) NQ1235Q1236, S (O 2 ) OQ1237, P (O) (OQ1238) (OQ1239), Si (Q1240) (Q1241) (Q1242 ) " 여기서, Q1191, Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211, Q1212, Q1213, Q1214, Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239, Q1240, Q1241, Q1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, Q1197, Q1198 및/또는 Q1206, Q1207 및/또는 Q1219, Q1220 및/또는 Q1226, Q1227 및/또는 Q1235, Q1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where Q1191, Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211, Q1212, Q1213, Q1214, Q1214 Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239 Q1240, Q1241, Q1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q1197, Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 are also in each case" heterocycle. " Reels ", And Z1, Z2 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "수소, NZ14Z15"Z1 and Z2 radicals are each independently selected from the group consisting of: "hydrogen, NZ14Z15" 단, Z1 = H인 경우, Z2 = NZ14Z15이고, Z1 = NZ14Z15인 경우, Z2 = H이고;Provided that when Z1 = H, Z2 = NZ14Z15, and when Z1 = NZ14Z15, Z2 = H; 여기서, Z14, Z15는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z14 and Z15 are each independently selected from the group consisting of: (a) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(Y1)NZ16Z17, C(=NZ18)Z19, C(Y2)NZ20Y3Z21"(a) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (Y1) NZ16Z17 , C (= NZ18) Z19, C (Y2) NZ20Y3Z21 " 단, Z14, Z15는 동시에 수소 또는 "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"이 아니고,Provided that Z14 and Z15 are not simultaneously hydrogen or "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 추가로 단, Z14, Z15 라디칼 중 하나가 수소 또는 "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"인 경우, 나머지 Z14, Z15 라디칼은 각각의 경우 "C(Y1)NZ16Z17", "C(=NZ18)Z19" 또는 "C(Y2)NZ20Y3Z21"이고,Further provided that one of the Z14, Z15 radicals is hydrogen or "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", The remaining Z14, Z15 radicals are in each case" C (Y1) NZ16Z17 "," C (= NZ18) Z19 "or" C (Y2) NZ20Y3Z21 ", 여기서, Y1, Y2, Y3은 각각 독립적으로 "O, S, =NH, =NZ22"로 이루어진 그룹으로부터 선택되고,Wherein Y1, Y2, Y3 are each independently selected from the group consisting of "O, S, = NH, = NZ22", 여기서, Z16, Z17, Z18, Z19, Z20, Z21, Z22는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z16, Z17, Z18, Z19, Z20, Z21, Z22 are each independently selected from the group consisting of: (1) 수소(1) hydrogen (2) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 헤테로사이클릴, 헤테로사이클릴알킬"(2) "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl" 여기서, 치환 그룹(a) 및/또는 치환 그룹(2)의 상기한 치환체는 임의로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein said substituents of substitution group (a) and / or substitution group (2) may be optionally substituted each independently by one or more substituents, identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU1, NU2U3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U4, C(O)OU5, C(O)NHU6, C(O)NU7U8, OU9, O(U10-O)rH (r = 1, 2, 3, 4, 5), O(U11-O)rU12 (r = 1, 2, 3, 4, 5), OC(O)U13, OC(O)OU14, OC(O)NHU15, OC(O)NU16U17, OP(O)(OU18)(OU19), OSi(U20)(U21)(U22), OS(O2)U23, NHC(O)U24, NU25C(O)U26, NHC(O)OU27, NHC(O)NHU28, NHC(O)NU29U30, NU31C(O)OU32, NU33C(O)NHU34, NU35C(O)NU36U37, NHS(O2)U38, NU39S(O2)U40, SU41, S(O)U42, S(O2)U43, S(O2)NHU44, S(O2)NU45U46, S(O2)OU47, P(O)(OU48)(OU49), Si(U50)(U51)(U52)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU 1, NU2U3, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U4, C (O) OU5, C (O) NHU6, C (O) NU7U8, OU9, O (U10-O) r H (r = 1, 2, 3, 4, 5), O (U11-O) r U12 (r = 1, 2, 3, 4, 5), OC (O) U13, OC (O) OU14, OC (O) NHU15 , OC (O) NU16U17, OP (O) (OU18) (OU19), OSi (U20) (U21) (U22), OS (O 2 ) U23, NHC (O) U24, NU25C (O) U26, NHC ( O) OU27, NHC (O) NHU28, NHC (O) NU29U30, NU31C (O) OU32, NU33C (O) NHU34, NU35C (O) NU36U37, NHS (O 2 ) U38, NU39S (O 2 ) U40, SU41, S (O) U42, S (O 2 ) U43, S (O 2 ) NHU44, S (O 2 ) NU45U46, S (O 2 ) OU47, P (O) (OU48) (OU49), Si (U50) ( U51) (U52) " 여기서, U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11, U12, U13, U14, U15, U16, U17, U18, U19, U20, U21, U22, U23, U24, U25, U26, U27, U28, U29, U30, U31, U32, U33, U34, U35, U36, U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U7, U8 및/또는 U16, U17 및/또는 U29, U30 및/또는 U36, U37 및/또는 U45, U46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11, U12, U13, U14, U15, U16, U17, U18, U19, U20, U21, U22, U23, U24, U25, U26, U27, U28, U29, U30, U31, U32, U33, U34, U35, U36, U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U7, U8 and / or U16, U17 and / or U29, U30 and / or U36, U37 and / or U45, U46 may also in each case be" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU53, NU54U55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U56, C(O)OU57, C(O)NHU58, C(O)NU59U60, OU61, O(U62-O)rH (r = 1, 2, 3, 4, 5), O(U63-O)rU64 (r = 1, 2, 3, 4, 5), OC(O)U65, OC(O)OU66, OC(O)NHU67, OC(O)NU68U69, OP(O)(OU70)(OU71), OSi(U72)(U73)(U74), OS(O2)U75, NHC(O)U76, NU77C(O)U78, NHC(O)OU79, NHC(O)NHU80, NHC(O)NU81U82, NU83C(O)OU84, NU85C(O)NHU86, NU87C(O)NU88U89, NHS(O2)U90, NU91S(O2)U92, SU93, S(O)U94, S(O2)U95, S(O2)NHU96, S(O2)NU97U98, S(O2)OU99, P(O)(OU100)(OU101), Si(U102)(U103)(U104)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU53, NU54U55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U56, C (O) OU57, C (O) NHU58, C (O) NU59U60, OU61, O (U62-O) r H (r = 1, 2, 3, 4, 5), O (U63-O) r U64 (r = 1, 2, 3, 4, 5), OC (O) U65, OC (O) OU66, OC (O) NHU67 , OC (O) NU68U69, OP (O) (OU70) (OU71), OSi (U72) (U73) (U74), OS (O 2 ) U75, NHC (O) U76, NU77C (O) U78, NHC ( O) OU79, NHC (O) NHU80, NHC (O) NU81U82, NU83C (O) OU84, NU85C (O) NHU86, NU87C (O) NU88U89, NHS (O2) U90, NU91S (O2) U92, SU93, S ( O) U94, S (O 2 ) U95, S (O 2 ) NHU96, S (O 2 ) NU97U98, S (O 2 ) OU99, P (O) (OU100) (OU101), Si (U102) (U103) (U104) " 여기서, U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63, U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77, U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99, U100, U101, U102, U103, U104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U59, U60 및/또는 U68, U69 및/또는 U81, U82 및/또는 U88, U89 및/또는 U97, U98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63, U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77, U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99, U100, U101, U102, U103, U104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U59, U60 and / or U68, U69 and / or U81, U82 and / or U88, U89 and / or U97, U98 may also in each case be" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU105, NU106U107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U108, C(O)OU109, C(O)NHU110, C(O)NU111U112, OU113, O(U114-O)sH (s = 1, 2, 3, 4, 5), O(U115-O)sU116 (s = 1, 2, 3, 4, 5), OC(O)U117, OC(O)OU118, OC(O)NHU119, OC(O)NU120U121, OP(O)(OU122)(OU123), OSi(U124)(U125)(U126), OS(O2)U127, NHC(O)U128, NU129C(O)U130, NHC(O)OU131, NHC(O)NHU132, NHC(O)NU133U134, NU135C(O)OU136, NU137C(O)NHU138, NU139C(O)NU140U141, NHS(O2)U142, NU143S(O2)U144, SU145, S(O)U146, S(O2)U147, S(O2)NHU148, S(O2)NU149U150, S(O2)OU151, P(O)(OU152)(OU153), Si(U154)(U155)(U156)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU105, NU106U107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U108, C (O) OU109, C (O) NHU110, C (O) NU111U112, OU113, O (U114-O) s H (s = 1, 2, 3, 4, 5), O (U115-O) s U116 (s = 1, 2, 3, 4, 5), OC (O) U117, OC (O) OU118, OC (O) NHU119 , OC (O) NU120U121, OP (O) (OU122) (OU123), OSi (U124) (U125) (U126), OS (O 2 ) U127, NHC (O) U128, NU129C (O) U130, NHC ( O) OU131, NHC (O) NHU132, NHC (O) NU133U134, NU135C (O) OU136, NU137C (O) NHU138, NU139C (O) NU140U141, NHS (O2) U142, NU143S (O2) U144, SU145, S ( O) U146, S (O 2 ) U147, S (O 2 ) NHU148, S (O 2 ) NU149U150, S (O 2 ) OU151, P (O) (OU152) (OU153), Si (U154) (U155) (U156) " 여기서, U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U111, U112 및/또는 U120, U121 및/또는 U133, U134 및/또는 U140, U141 및/또는 U149, U150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U111, U112 and / or U120, U121 and / or U133, U134 and / or U140, U141 and / or U149, U150 are also in each case" heterocycle. " Reels ", (3) C(O)Z23, 여기서, Z23은 독립적으로 다음으로 이루어진 그룹으로부터 선 택되고:(3) C (O) Z23, wherein Z23 is independently selected from the group consisting of: (a) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(a) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 치환 그룹(a)의 상기 치환체는 임의로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein said substituents in substitution group (a) may each be optionally substituted independently by one or more substituents selected the same or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU157, NU158U159, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U160, C(O)OU161, C(O)NHU162, C(O)NU163U164, OU165, O(U166-O)tH (t = 1, 2, 3, 4, 5), O(U167-O)tU168 (t = 1, 2, 3, 4, 5), OC(O)U169, OC(O)OU170, OC(O)NHU171, OC(O)NU172U173, OP(O)(OU174)(OU175), OSi(U176)(U177)(U178), OS(O2)U179, NHC(O)U180, NU181C(O)U182, NHC(O)OU183, NHC(O)NHU184, NHC(O)NU185U186, NU187C(O)OU188, NU189C(O)NHU190, NU191C(O)NU192U193, NHS(O2)U194, NU195S(O2)U196, SU197, S(O)U198, S(O2)U199, S(O2)NHU200, S(O2)NU201U202, S(O2)OU203, P(O)(OU204)(OU205), Si(U206)(U207)(U208)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU157, NU158U159, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U160, C (O) OU161, C (O) NHU162, C (O) NU163U164, OU165, O (U166-O) t H (t = 1, 2, 3, 4, 5), O (U167-O) t U168 (t = 1, 2, 3, 4, 5), OC (O) U169, OC (O) OU170, OC (O) NHU171 , OC (O) NU172U173, OP (O) (OU174) (OU175), OSi (U176) (U177) (U178), OS (O 2 ) U179, NHC (O) U180, NU181C (O) U182, NHC ( O) OU183, NHC (O) NHU184, NHC (O) NU185U186, NU187C (O) OU188, NU189C (O) NHU190, NU191C (O) NU192U193, NHS (O2) U194, NU195S (O2) U196, SU197, S ( O) U198, S (O 2 ) U199, S (O 2 ) NHU200, S (O 2 ) NU201U202, S (O 2 ) OU203, P (O) (OU204) (OU205), Si (U206) (U207) (U208) " 여기서, U157, U158, U159, U160, U161, U162, U163, U164, U165, U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181, U182, U183, U184,U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195, U196, U197, U198, U199, U200, U201, U202, U203, U204, U205, U206, U207, U208은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U163, U164 및/또는 U172, U173 및/또는 U185, U186 및/또는 U192, U193 및/또는 U201, U202는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U157, U158, U159, U160, U161, U162, U163, U164, U165, U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181, U182, U183, U184, U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195, U196, U197, U198, U199, U200, U201, U202, U203, U204, U205, U206, U207, U208 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U163, U164 and / or U172, U173 and / or U185, U186 and / or U192, U193 and / or U201, U202 are also in each case a" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU209, NU210U211, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U212, C(O)OU213, C(O)NHU214, C(O)NU215U216, OU217, O(U218-O)uH (u = 1, 2, 3, 4, 5), O(U219-O)uU220 (u = 1, 2, 3, 4, 5), OC(O)U221, OC(O)OU222, OC(O)NHU223, OC(O)NU224U225, OP(O)(OU226)(OU227), OSi(U228)(U229)(U230), OS(O2)U231, NHC(O)U232, NU233C(O)U234, NHC(O)OU235, NHC(O)NHU236, NHC(O)NU237U238, NU239C(O)OU240, NU241C(O)NHU242, NU243C(O)NU244U245, NHS(O2)U246, NU247S(O2)U248, SU249, S(O)U250, S(O2)U251, S(O2)NHU252, S(O2)NU253U254, S(O2)OU255, P(O)(OU256)(OU257), Si(U258)(U259)(U260)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU209, NU210U211, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U212, C (O) OU213, C (O) NHU214, C (O) NU215U216, OU217, O (U218-O) u H (u = 1, 2, 3, 4, 5), O (U219-O) u U220 (u = 1, 2, 3, 4, 5), OC (O) U221, OC (O) OU222, OC (O) NHU223 , OC (O) NU224U225, OP (O) (OU226) (OU227), OSi (U228) (U229) (U230), OS (O 2 ) U231, NHC (O) U232, NU233C (O) U234, NHC ( O) OU235, NHC (O) NHU236, NHC (O) NU237U238, NU239C (O) OU240, NU241C (O) NHU242, NU243C (O) NU244U245, NHS (O2) U246, NU247S (O2) U248, SU249, S ( O) U250, S (O 2 ) U251, S (O 2 ) NHU252, S (O 2 ) NU253U254, S (O 2 ) OU255, P (O) (OU256) (OU257), Si (U258) (U259) (U260) " 여기서, U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U215, U216 및/또는 U224, U225 및/또는 U237, U238 및/또는 U244, U245 및/또는 U253, U254는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU261, NU262U263, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U264, C(O)OU265, C(O)NHU266, C(O)NU267U268, OU269, O(U270-O)vH (v = 1, 2, 3, 4, 5), O(U271-O)vU272 (v = 1, 2, 3, 4, 5), OC(O)U273, OC(O)OU274, OC(O)NHU275, OC(O)NU276U277, OP(O)(OU278)(OU279), OSi(U280)(U281)(U282), OS(O2)U283, NHC(O)U284, NU285C(O)U286, NHC(O)OU287, NHC(O)NHU288, NHC(O)NU289U290, NU291C(O)OU292, NU293C(O)NHU294, NU295C(O)NU296U297, NHS(O2)U298, NU299S(O2)U300, SU301, S(O)U302, S(O2)U303, S(O2)NHU304, S(O2)NU305U306, S(O2)OU307, P(O)(OU308)(OU309), Si(U310)(U311)(U312)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU261, NU262U263, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U264, C (O) OU265, C (O) NHU266, C (O) NU267U268, OU269, O (U270-O) v H (v = 1, 2, 3, 4, 5), O (U271-O) v U272 (v = 1, 2, 3, 4, 5), OC (O) U273, OC (O) OU274, OC (O) NHU275 , OC (O) NU276U277, OP (O) (OU278) (OU279), OSi (U280) (U281) (U282), OS (O 2 ) U283, NHC (O) U284, NU285C (O) U286, NHC ( O) OU287, NHC (O) NHU288, NHC (O) NU289U290, NU291C (O) OU292, NU293C (O) NHU294, NU295C (O) NU296U297, NHS (O2) U298, NU299S (O2) U300, SU301, S ( O) U302, S (O 2 ) U303, S (O 2 ) NHU304, S (O 2 ) NU305U306, S (O 2 ) OU307, P (O) (OU308) (OU309), Si (U310) (U311) (U312) " 여기서, U261, U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301, U302, U303, U304, U305, U306, U307, U308, U309, U310, U311, U312는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U267, U268 및/또는 U276, U277 및/또는 U289, U290 및/또는 U296, U297 및/또는 U305, U306은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U261, U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301, U302, U303, U304, U305, U306, U307, U308, U309, U310, U311, U312 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U267, U268 and / or U276, U277 and / or U289, U290 and / or U296, U297 and / or U305, U306 are also in each case a" heterocycle Reels ", (4) Z16, Z17은 또한 독립적으로 임의로 함께 "헤테로사이클릴"을 형성할 수 있고;(4) Z16, Z17 can also independently optionally form "heterocyclyl"; (5) "C(O)C(O)U313, S(O2)NU314U315"(5) "C (O) C (O) U313, S (O 2 ) NU314U315" 여기서, U313, U314, U315는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein U313, U314 and U315 are each independently selected from the group consisting of: (I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU316, NU317U318, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U319, C(O)OU320, C(O)NHU321, C(O)NU322U323, OU324, O(U325-O)wH (w = 1, 2, 3, 4, 5), O(U326-O)wU327 (w = 1, 2, 3, 4, 5), OC(O)U328, OC(O)OU329, OC(O)NHU330, OC(O)NU331U332, OP(O)(OU333)(OU334), OSi(U335)(U336)(U337), OS(O2)U338, NHC(O)U339, NU340C(O)U341, NHC(O)OU342, NHC(O)NHU343, NHC(O)NU344U345, NU346C(O)OU347, NU348C(O)NHU349, NU350C(O)NU351U352, NHS(O2)U353, NU354S(O2)U355, SU356, S(O)U357, S(O2)U358, S(O2)NHU359, S(O2)NU360U361, S(O2)OU362, P(O)(OU363)(OU364), Si(U365)(U366)(U367)"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHU316, NU317U318, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U319, C (O) OU320, C (O) NHU321, C (O) NU322U323, OU324, O (U325-O) w H ( w = 1, 2, 3, 4, 5), O (U326-O) w U327 (w = 1, 2, 3, 4, 5), OC (O) U328, OC (O) OU329, OC (O NHU330, OC (O) NU331U332, OP (O) (OU333) (OU334), OSi (U335) (U336) (U337), OS (O 2 ) U338, NHC (O) U339, NU340C (O) U341, NHC (O) OU342, NHC (O) NHU343, NHC (O) NU344U345, NU346C (O) OU347, NU348C (O) NHU349, NU350C (O) NU351U352, NHS (O2) U353, NU354S (O2) U355, SU356, S (O) U357, S (O 2 ) U358, S (O 2 ) NHU359, S (O 2 ) NU360U361, S (O 2 ) OU362, P (O) (OU363) (OU364), Si (U365) ( U366) (U367) " 여기서, U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328, U329, U330, U331, U332, U333,U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344, U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U322, U323 및/또는 U331, U332 및/또는 U344, U345 및/또는 U351, U352 및/또는 U360, U361은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328, U329, U330, U331, U332, U333, U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344, U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U322, U323 and / or U331, U332 and / or U344, U345 and / or U351, U352 and / or U360, U361 may also in each case be" heterocycle. " Reels ", 여기서, 임의로, 치환 그룹(I)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU368, NU369U370, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U371, C(O)OU372, C(O)NHU373, C(O)NU374U375, OU376, O(U377-O)xH (x = 1, 2, 3, 4, 5), O(U378-O)xU379 (x = 1, 2, 3, 4, 5), OC(O)U380, OC(O)OU381, OC(O)NHU382, OC(O)NU383U384, OP(O)(OU385)(OU386), OSi(U387)(U388)(U389), OS(O2)U390, NHC(O)U391, NU392C(O)U393, NHC(O)OU394, NHC(O)NHU395, NHC(O)NU396U397, NU398C(O)OU399, NU400C(O)NHU401, NU402C(O)NU403U404, NHS(O2)U405, NU406S(O2)U407, SU408, S(O)U409, S(O2)U410, S(O2)NHU411, S(O2)NU412U413, S(O2)OU414, P(O)(OU415)(OU416), Si(U417)(U418)(U419)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU368, NU369U370, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U371, C (O) OU372, C (O) NHU373, C (O) NU374U375, OU376, O (U377-O) x H (x = 1, 2, 3, 4, 5), O (U378-O) x U379 (x = 1, 2, 3, 4, 5), OC (O) U380, OC (O) OU381, OC (O) NHU382 , OC (O) NU383U384, OP (O) (OU385) (OU386), OSi (U387) (U388) (U389), OS (O 2 ) U390, NHC (O) U391, NU392C (O) U393, NHC ( O) OU394, NHC (O) NHU395, NHC (O) NU396U397, NU398C (O) OU399, NU400C (O) NHU401, NU402C (O) NU403U404, NHS (O2) U405, NU406S (O2) U407, SU408, S ( O) U409, S (O 2 ) U410, S (O 2 ) NHU411, S (O 2 ) NU412U413, S (O 2 ) OU414, P (O) (OU415) (OU416), Si (U417) (U418) (U419) " 여기서, U368, U369, U370, U371, U372, U373, U374, U375, U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U374, U375 및/또는 U383, U384 및/또는 U396, U397 및/또는 U403, U404 및/또는 U412, U413은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U368, U369, U370, U371, U372, U373, U374, U375, U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U374, U375 and / or U383, U384 and / or U396, U397 and / or U403, U404 and / or U412, U413 are also in each case a" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU420, NU421U422, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U423, C(O)OU424, C(O)NHU425, C(O)NU426U427, OU428, O(U429-O)yH (y = 1, 2, 3, 4, 5), O(U430-O)yU431 (y = 1, 2, 3, 4, 5), OC(O)U432, OC(O)OU433, OC(O)NHU434, OC(O)NU435U436, OP(O)(OU437)(OU438), OSi(U439)(U440)(U441), OS(O2)U442, NHC(O)U443, NU444C(O)U445, NHC(O)OU446, NHC(O)NHU447, NHC(O)NU448U449, NU450C(O)OU451, NU452C(O)NHU453, NU454C(O)NU455U456, NHS(O2)U457, NU458S(O2)U459, SU460, S(O)U461, S(O2)U462, S(O2)NHU463, S(O2)NU464U465, S(O2)OU466, P(O)(OU467)(OU468), Si(U469)(U470)(U471)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU420, NU421U422, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U423, C (O) OU424, C (O) NHU425, C (O) NU426U427, OU428, O (U429-O) y H (y = 1, 2, 3, 4, 5), O (U430-O) y U431 (y = 1, 2, 3, 4, 5), OC (O) U432, OC (O) OU433, OC (O) NHU434 , OC (O) NU435U436, OP (O) (OU437) (OU438), OSi (U439) (U440) (U441), OS (O 2 ) U442, NHC (O) U443, NU444C (O) U445, NHC ( O) OU446, NHC (O) NHU447, NHC (O) NU448U449, NU450C (O) OU451, NU452C (O) NHU453, NU454C (O) NU455U456, NHS (O2) U457, NU458S (O2) U459, SU460, S ( O) U461, S (O 2 ) U462, S (O 2 ) NHU463, S (O 2 ) NU464U465, S (O 2 ) OU466, P (O) (OU467) (OU468), Si (U469) (U470) (U471) " 여기서, U420, U421, U422, U423, U424, U425, U426, U427, U428, U429, U430, U431, U432, U433, U434, U435, U436, U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U426, U427 및/또는 U435, U436 및/또는 U448, U449 및/또는 U455, U456 및/또는 U464, U465는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where U420, U421, U422, U423, U424, U425, U426, U427, U428, U429, U430, U431, U432, U433, U434, U435, U436, U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U426, U427 and / or U435, U436 and / or U448, U449 and / or U455, U456 and / or U464, U465 are also in each case together a" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHU472, NU473U474, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)U475, C(O)OU476, C(O)NHU477, C(O)NU478U479, OU480, O(U481-O)zH (z = 1, 2, 3, 4, 5), O(U482-O)zU483 (z = 1, 2, 3, 4, 5), OC(O)U484, OC(O)OU485, OC(O)NHU486, OC(O)NU487U488, OP(O)(OU489)(OU490), OSi(U491)(U492)(U493), OS(O2)U494, NHC(O)U495, NU496C(O)U497, NHC(O)OU498, NHC(O)NHU499, NHC(O)NU500U501, NU502C(O)OU503, NU504C(O)NHU505, NU506C(O)NU507U508, NHS(O2)U509, NU510S(O2)U511, SU512, S(O)U513, S(O2)U514, S(O2)NHU515, S(O2)NU516U517, S(O2)OU518, P(O)(OU519)(OU520), Si(U521)(U522)(U523)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHU472, NU473U474, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) U475, C (O) OU476, C (O) NHU477, C (O) NU478U479, OU480, O (U481-O) z H (z = 1, 2, 3, 4, 5), O (U482-O) z U483 (z = 1, 2, 3, 4, 5), OC (O) U484, OC (O) OU485, OC (O) NHU486 , OC (O) NU487U488, OP (O) (OU489) (OU490), OSi (U491) (U492) (U493), OS (O 2 ) U494, NHC (O) U495, NU496C (O) U497, NHC ( O) OU498, NHC (O) NHU499, NHC (O) NU500U501, NU502C (O) OU503, NU504C (O) NHU505, NU506C (O) NU507U508, NHS (O2) U509, NU510S (O2) U511, SU512, S ( O) U513, S (O 2 ) U514, S (O 2 ) NHU515, S (O 2 ) NU516U517, S (O 2 ) OU518, P (O) (OU519) (OU520), Si (U521) (U522) (U523) " 여기서, U472, U473, U474, U475, U476, U477, U478, U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, U478, U479 및/또는 U487, U488 및/또는 U500, U501 및/또는 U507, U508 및/또는 U516, U517은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고, 여기서, 대안적으로, U314, U315는 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where U472, U473, U474, U475, U476, U477, U478, U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U478, U479 and / or U487, U488 and / or U500, U501 and / or U507, U508 and / or U516, U517 are also in each case a" heterocycle. " Reel ", where, alternatively, U314, U315 may also together form" heterocyclyl ", And Z5 라디칼은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z5 radicals are independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHA1, NA2A3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)A4, C(O)OA5, C(O)NHA6, C(O)NA7A8, OA9, O(A10-O)rH (r = 1, 2, 3, 4, 5), O(A11-O)rA12 (r = 1, 2, 3, 4, 5), OC(O)A13, OC(O)OA14, OC(O)NHA15, OC(O)NA16A17, OP(O)(OA18)(OA19), OSi(A20)(A21)(A22), OS(O2)A23, NHC(O)A24, NA25C(O)A26, NHC(O)OA27, NHC(O)NHA28, NHC(O)NA29A30, NA31C(O)OA32, NA33C(O)NHA34, NA35C(O)NA36A37, NHS(O2)A38, NA39S(O2)A40, SA41, S(O)A42, S(O2)A43, S(O2)NHA44, S(O2)NA45A46, S(O2)OA47, P(O)(OA48)(OA49), Si(A50)(A51)(A52)"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHA1, NA2A3, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) A4, C (O) OA5, C (O) NHA6, C (O) NA7A8, OA9, O (A10-O) r H ( r = 1, 2, 3, 4, 5), O (A11-O) r A12 (r = 1, 2, 3, 4, 5), OC (O) A13, OC (O) OA14, OC (O NHA15, OC (O) NA16A17, OP (O) (OA18) (OA19), OSi (A20) (A21) (A22), OS (O 2 ) A23, NHC (O) A24, NA25C (O) A26, NHC (O) OA27, NHC (O) NHA28, NHC (O) NA29A30, NA31C (O) OA32, NA33C (O) NHA34, NA35C (O) NA36A37, NHS (O2) A38, NA39S (O2) A40, SA41, S (O) A42, S (O 2 ) A43, S (O 2 ) NHA44, S (O 2 ) NA45A46, S (O 2 ) OA47, P (O) (OA48) (OA49), Si (A50) ( A51) (A52) " 여기서, A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, A7, A8 및/또는 A16, A17 및/또는 A29, A30 및/또는 A36, A37 및/또는 A45, A46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, A7, A8 and / or A16, A17 and / or A29, A30 and / or A36, A37 and / or A45, A46 may also in each case be" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHA53, NA54A55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)A56, C(O)OA57, C(O)NHA58, C(O)NA59A60, OA61, O(A62-O)sH (s = 1, 2, 3, 4, 5), O(A63-O)tA64 (t = 1, 2, 3, 4, 5), OC(O)A65, OC(O)OA66, OC(O)NHA67, OC(O)NA68A69, OP(O)(OA70)(OA71), OSi(A72)(A73)(A74), OS(O2)A75, NHC(O)A76, NA77C(O)A78, NHC(O)OA79, NHC(O)NHA80, NHC(O)NA81A82, NA83C(O)OA84, NA85C(O)NHA86, NA87C(O)NA88A89, NHS(O2)A90, NA91S(O2)A92, SA93, S(O)A94, S(O2)A95, S(O2)NHA96, S(O2)NA97A98, S(O2)OA99, P(O)(OA100)(OA101), Si(A102)(A103)(A104)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHA53, NA54A55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) A56, C (O) OA57, C (O) NHA58, C (O) NA59A60, OA61, O (A62-O) s H (s = 1, 2, 3, 4, 5), O (A63-O) t A64 (t = 1, 2, 3, 4, 5), OC (O) A65, OC (O) OA66, OC (O) NHA67 , OC (O) NA68A69, OP (O) (OA70) (OA71), OSi (A72) (A73) (A74), OS (O 2 ) A75, NHC (O) A76, NA77C (O) A78, NHC ( O) OA79, NHC (O) NHA80, NHC (O) NA81A82, NA83C (O) OA84, NA85C (O) NHA86, NA87C (O) NA88A89, NHS (O 2 ) A90, NA91S (O 2 ) A92, SA93, S (O) A94, S (O 2 ) A95, S (O 2 ) NHA96, S (O 2 ) NA97A98, S (O 2 ) OA99, P (O) (OA100) (OA101), Si (A102) ( A103) (A104) " 여기서, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, A59, A60 및/또는 A68, A69 및/또는 A81, A82 및/또는 A88, A89 및/또는 A97, A98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHA105, NA106A107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)A108, C(O)OA109, C(O)NHA110, C(O)NA111A112, OA113, O(A114-O)tH (t = 1, 2, 3, 4, 5), O(A115- O)tA116 (t = 1, 2, 3, 4, 5), OC(O)A117, OC(O)OA118, OC(O)NHA119, OC(O)NA120A121, OP(O)(OA122)(OA123), OSi(A124)(A125)(A126), OS(O2)A127, NHC(O)A128, NA129C(O)A130, NHC(O)OA131, NHC(O)NHA132, NHC(O)NA133A134, NA135C(O)OA136, NA137C(O)NHA138, NA139C(O)NA140A141, NHS(O2)A142, NA143S(O2)A144, SA145, S(O)A146, S(O2)A147, S(O2)NHA148, S(O2)NA149A150, S(O2)OA151, P(O)(OA152)(OA153), Si(A154)(A155)(A156)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHA105, NA106A107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) A108, C (O) OA109, C (O) NHA110, C (O) NA111A112, OA113, O (A114-O) t H (t = 1, 2, 3, 4, 5), O (A115-O) t A116 (t = 1, 2, 3, 4, 5), OC (O) A117, OC (O) OA118, OC (O) NHA119 , OC (O) NA120A121, OP (O) (OA122) (OA123), OSi (A124) (A125) (A126), OS (O 2 ) A127, NHC (O) A128, NA129C (O) A130, NHC ( O) OA131, NHC (O) NHA132, NHC (O) NA133A134, NA135C (O) OA136, NA137C (O) NHA138, NA139C (O) NA140A141, NHS (O2) A142, NA143S (O2) A144, SA145, S ( O) A146, S (O2) A147, S (O 2 ) NHA148, S (O 2 ) NA149A150, S (O 2 ) OA151, P (O) (OA152) (OA153), Si (A154) (A155) ( A156) " 여기서, A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, A111, A112 및/또는 A120, A121 및/또는 A133, A134 및/또는 A140, A141 및/또는 A149, A150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, A111, A112 and / or A120, A121 and / or A133, A134 and / or A140, A141 and / or A149, A150 are also in each case" heterocycle Reels ", 또는or (E) Z1, Z2 라디칼 중 하나 또는 Z1, Z2 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(E) one of the Z1, Z2 radicals or both Z1, Z2 radicals is each independently selected from the group consisting of: (a) NZ24Z25;(a) NZ24Z25; 단, Z24, Z25 라디칼 중 하나 또는 Z24, Z25 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Provided that either one of the Z24, Z25 radicals or both Z24, Z25 radicals is each independently selected from the group consisting of: (1) "C(O)C(O)T1, S(O2)NT2T3"(1) "C (O) C (O) T1, S (O 2 ) NT2T3" 여기서, T1, T2, T3은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein T1, T2, T3 are each independently selected from the group consisting of: (I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT4, NT5T6, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T7, C(O)OT8, C(O)NHT9, C(O)NT10T11, OT12, O(T13-O)pH (p = 1, 2, 3, 4, 5), O(T14-O)pT15 (p = 1, 2, 3, 4, 5), OC(O)T16, OC(O)OT17, OC(O)NHT18, OC(O)NT19T20, OP(O)(OT21)(OT22), OSi(T23)(T24)(T25), OS(O2)T26, NHC(O)T27, NT28C(O)T29, NHC(O)OT30, NHC(O)NHT31, NHC(O)NT32T33, NT34C(O)OT35, NT36C(O)NHT37, NT38C(O)NT39T40, NHS(O2)T41, NT42S(O2)T43, ST44, S(O)T45, S(O2)T46, S(O2)NHT47, S(O2)NT48T49, S(O2)OT50, P(O)(OT51)(OT52), Si(T53)(T54)(T55)"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHT4, NT5T6, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T7, C (O) OT8, C (O) NHT9, C (O) NT10T11, OT12, O (T13-O) p H ( p = 1, 2, 3, 4, 5), O (T14-O) p T15 (p = 1, 2, 3, 4, 5), OC (O) T16, OC (O) OT17, OC (O NHT18, OC (O) NT19T20, OP (O) (OT21) (OT22), OSi (T23) (T24) (T25), OS (O 2 ) T26, NHC (O) T27, NT28C (O) T29, NHC (O) OT30, NHC (O) NHT31, NHC (O) NT32T33, NT34C (O) OT35, NT36C (O) NHT37, NT38C (O) NT39T40, NHS (O 2 ) T41, NT42S (O 2 ) T43, ST44, S (O) T45, S (O 2 ) T46, S (O 2 ) NHT47, S (O 2 ) NT48T49, S (O 2 ) OT50, P (O) (OT51) (OT52), Si (T53 ) (T54) (T55) " 여기서, T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48,T49, T50, T51, T52, T53, T54, T55는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T10, T11 및/또는 T19, T20 및/또는 T32, T33 및/또는 T39, T40 및/또는 T48, T49는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T10, T11 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환 그룹(I)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT56, NT57T58, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T59, C(O)OT60, C(O)NHT61, C(O)NT62T63, OT64, O(T65-O)rH (r = 1, 2, 3, 4, 5), O(T66-O)rT67 (r = 1, 2, 3, 4, 5), OC(O)T68, OC(O)OT69, OC(O)NHT70, OC(O)NT71T72, OP(O)(OT73)(OT74), OSi(T75)(T76)(T77), OS(O2)T78, NHC(O)T79, NT80C(O)T81, NHC(O)OT82, NHC(O)NHT83, NHC(O)NT84T85, NT86C(O)OT87, NT88C(O)NHT89, NT90C(O)NT91T92, NHS(O2)T93, NT94S(O2)T95, ST96, S(O)T97, S(O2)T98, S(O2)NHT99, S(O2)NT100T101, S(O2)OT102, P(O)(OT103)(OT104), Si(T105)(T106)(T107)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT56, NT57T58, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T59, C (O) OT60, C (O) NHT61, C (O) NT62T63, OT64, O (T65-O) r H (r = 1, 2, 3, 4, 5), O (T66-O) r T67 (r = 1, 2, 3, 4, 5), OC (O) T68, OC (O) OT69, OC (O) NHT70 , OC (O) NT71T72, OP (O) (OT73) (OT74), OSi (T75) (T76) (T77), OS (O 2 ) T78, NHC (O) T79, NT80C (O) T81, NHC ( O) OT82, NHC (O) NHT83, NHC (O) NT84T85, NT86C (O) OT87, NT88C (O) NHT89, NT90C (O) NT91T92, NHS (O 2 ) T93, NT94S (O 2 ) T95, ST96, S (O) T97, S (O 2 ) T98, S (O 2 ) NHT99, S (O 2 ) NT100T101, S (O 2 ) OT102, P (O) (OT103) (OT104), Si (T105) ( T106) (T107) " 여기서, T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102, T103, T104, T105, T106, T107은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T62, T63 및/또는 T71, T72 및/또는 T84, T85 및/또는 T91, T92 및/또는 T100, T101은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102, T103, T104, T105, T106, T107 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T62, T63 and / or T71, T72 and / or T84, T85 and / or T91, T92 and / or T100, T101 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT108, NT109T110, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T111, C(O)OT112, C(O)NHT113, C(O)NT114T115, OT116, O(T117-O)sH (s = 1, 2, 3, 4, 5), O(T118- O)sT119 (s = 1, 2, 3, 4, 5), OC(O)T120, OC(O)OT121, OC(O)NHT122, OC(O)NT123T124, OP(O)(OT125)(OT126), OSi(T127)(T128)(T129), OS(O2)T130, NHC(O)T131, NT132C(O)T133, NHC(O)OT134, NHC(O)NHT135, NHC(O)NT136T137, NT138C(O)OT139, NT140C(O)NHT141, NT142C(O)NT143T144, NHS(O2)T145, NT146S(O2)T147, ST148, S(O)T149, S(O2)T150, S(O2)NHT151, S(O2)NT152T153, S(O2)OT154, P(O)(OT155)(OT156), Si(T157)(T158)(T159)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT108, NT109T110, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T111, C (O) OT112, C (O) NHT113, C (O) NT114T115, OT116, O (T117-O) s H (s = 1, 2, 3, 4, 5), O (T118-O) s T119 (s = 1, 2, 3, 4, 5), OC (O) T120, OC (O) OT121, OC (O) NHT122 , OC (O) NT123T124, OP (O) (OT125) (OT126), OSi (T127) (T128) (T129), OS (O 2 ) T130, NHC (O) T131, NT132C (O) T133, NHC ( O) OT134, NHC (O) NHT135, NHC (O) NT136T137, NT138C (O) OT139, NT140C (O) NHT141, NT142C (O) NT143T144, NHS (O 2 ) T145, NT146S (O 2 ) T147, ST148, S (O) T149, S (O 2 ) T150, S (O 2 ) NHT151, S (O 2 ) NT152T153, S (O 2 ) OT154, P (O) (OT155) (OT156), Si (T157) ( T158) (T159) " 여기서, T108, T109, T110, T111, T112, T113, T114, T115, T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139, T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151, T152, T153, T154, T155, T156, T157, T158, T159는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T114, T115 및/또는 T123, T124 및/또는 T136, T137 및/또는 T143, T144 및/또는 T152, T153은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T108, T109, T110, T111, T112, T113, T114, T115, T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139, T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151, T152, T153, T154, T155, T156, T157, T158, T159 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T114, T115 and / or T123, T124 and / or T136, T137 and / or T143, T144 and / or T152, T153 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT160, NT161T162, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T163, C(O)OT164, C(O)NHT165, C(O)NT166T167, OT168, O(T169-O)tH (t = 1, 2, 3, 4, 5), O(T170-O)tT171 (t = 1, 2, 3, 4, 5), OC(O)T172, OC(O)OT173, OC(O)NHT174, OC(O)NT175T176, OP(O)(OT177)(OT178), OSi(T179)(T180)(T181), OS(O2)T182, NHC(O)T183, NT184C(O)T185, NHC(O)OT186, NHC(O)NHT187, NHC(O)NT188T189, NT190C(O)OT191, NT192C(O)NHT193, NT194C(O)NT195T196, NHS(O2)T197, NT198S(O2)T199, ST200, S(O)T201, S(O2)T202, S(O2)NHT203, S(O2)NT204T205, S(O2)OT206, P(O)(OT207)(OT208), Si(T209)(T210)(T211)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT160, NT161T162, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T163, C (O) OT164, C (O) NHT165, C (O) NT166T167, OT168, O (T169-O) t H (t = 1, 2, 3, 4, 5), O (T170-O) t T171 (t = 1, 2, 3, 4, 5), OC (O) T172, OC (O) OT173, OC (O) NHT174 , OC (O) NT175T176, OP (O) (OT177) (OT178), OSi (T179) (T180) (T181), OS (O 2 ) T182, NHC (O) T183, NT184C (O) T185, NHC ( O) OT186, NHC (O) NHT187, NHC (O) NT188T189, NT190C (O) OT191, NT192C (O) NHT193, NT194C (O) NT195T196, NHS (O 2 ) T197, NT198S (O 2 ) T199, ST200, S (O) T201, S (O 2 ) T202, S (O 2 ) NHT203, S (O 2 ) NT204T205, S (O 2 ) OT206, P (O) (OT207) (OT208), Si (T209) ( T210) (T211) " 여기서, T160, T161, T162, T163, T164, T165, T166, T167, T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T211은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T166, T167 및/또는 T175, T176 및/또는 T188, T189 및/또는 T195, T196 및/또는 T204, T205는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고, 여기서, 대안적으로, T2, T3 또한 함께 "헤테로사이클릴"을 형성할 수 있고,Where T160, T161, T162, T163, T164, T165, T166, T167, T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T211 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T166, T167 and / or T175, T176 and / or T188, T189 and / or T195, T196 and / or T204, T205 are also in each case" heterocycle. " Reel ", where, alternatively, T2, T3 together may also form" heterocyclyl ", Z24, Z25 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z24, Z25 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z24, Z25 radicals is independently selected from the group consisting of, or neither of the Z24, Z25 radicals is independently selected from the group consisting of: (2) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(2) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환 그룹(2)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of the substitution group (2) may each be further substituted by one or more substituents independently or identically selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT212, NT213T214, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T215, C(O)OT216, C(O)NHT217, C(O)NT218T219, OT220, O(T221-O)uH (u = 1, 2, 3, 4, 5), O(T222-O)uT223 (u = 1, 2, 3, 4, 5), OC(O)T224, OC(O)OT225, OC(O)NHT226, OC(O)NT227T228, OP(O)(OT229)(OT230), OSi(T231)(T232)(T233), OS(O2)T234, NHC(O)T235, NT236C(O)T237, NHC(O)OT238, NHC(O)NHT239, NHC(O)NT240T241, NT242C(O)OT243, NT244C(O)NHT245, NT246C(O)NT247T248, NHS(O2)T249, NT250S(O2)T251, ST252, S(O)T253, S(O2)T254, S(O2)NHT255, S(O2)NT256T257, S(O2)OT258, P(O)(OT259)(OT260), Si(T261)(T262)(T263)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT212, NT213T214, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T215, C (O) OT216, C (O) NHT217, C (O) NT218T219, OT220, O (T221-O) u H (u = 1, 2, 3, 4, 5), O (T222-O) u T223 (u = 1, 2, 3, 4, 5), OC (O) T224, OC (O) OT225, OC (O) NHT226 , OC (O) NT227T228, OP (O) (OT229) (OT230), OSi (T231) (T232) (T233), OS (O 2 ) T234, NHC (O) T235, NT236C (O) T237, NHC ( O) OT238, NHC (O) NHT239, NHC (O) NT240T241, NT242C (O) OT243, NT244C (O) NHT245, NT246C (O) NT247T248, NHS (O 2 ) T249, NT250S (O 2 ) T251, ST252, S (O) T253, S (O 2 ) T254, S (O 2 ) NHT255, S (O 2 ) NT256T257, S (O 2 ) OT258, P (O) (OT259) (OT260), Si (T261) ( T262) (T263) " 여기서, T212, T213, T214, T215, T216, T217, T218, T219, T220, T221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260, T261, T262, T263은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T218, T219 및/또는 T227, T228 및/또는 T240, T241 및/또는 T247, T248 및/또는 T256, T257은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T212, T213, T214, T215, T216, T217, T218, T219, T220, T221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260, T261, T262, T263 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T218, T219 and / or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT264, NT265T266, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T267, C(O)OT268, C(O)NHT269, C(O)NT270T271, OT272, O(T273-O)vH (v = 1, 2, 3, 4, 5), O(T274-O)vT275 (v = 1, 2, 3, 4, 5), OC(O)T276, OC(O)OT277, OC(O)NHT278, OC(O)NT279T280, OP(O)(OT281)(OT282), OSi(T283)(T284)(T285), OS(O2)T286, NHC(O)T287, NT288C(O)T289, NHC(O)OT290, NHC(O)NHT291, NHC(O)NT292T293, NT294C(O)OT295, NT296C(O)NHT297, NT298C(O)NT299T300, NHS(O2)T301, NT302S(O2)T303, ST304, S(O)T305, S(O2)T306, S(O2)NHT307, S(O2)NT308T309, S(O2)OT310, P(O)(OT311)(OT312), Si(T313)(T314)(T315)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT264, NT265T266, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T267, C (O) OT268, C (O) NHT269, C (O) NT270T271, OT272, O (T273-O) v H (v = 1, 2, 3, 4, 5), O (T274-O) v T275 (v = 1, 2, 3, 4, 5), OC (O) T276, OC (O) OT277, OC (O) NHT278 , OC (O) NT279T280, OP (O) (OT281) (OT282), OSi (T283) (T284) (T285), OS (O 2 ) T286, NHC (O) T287, NT288C (O) T289, NHC ( O) OT290, NHC (O) NHT291, NHC (O) NT292T293, NT294C (O) OT295, NT296C (O) NHT297, NT298C (O) NT299T300, NHS (O 2 ) T301, NT302S (O 2 ) T303, ST304, S (O) T305, S (O 2 ) T306, S (O 2 ) NHT307, S (O 2 ) NT308T309, S (O 2 ) OT310, P (O) (OT311) (OT312), Si (T313) ( T314) (T315) " 여기서, T264, T265, T266, T267, T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282, T283, T284, T285, T286, T287, T288, T289, T290, T291, T292, T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T270, T271 및/또는 T279, T280 및/또는 T292, T293 및/또는 T299, T300 및/또는 T308, T309는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T264, T265, T266, T267, T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282, T283, T284, T285, T286, T287, T288, T289, T290, T291, T292, T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T270, T271 and / or T279, T280 and / or T292, T293 and / or T299, T300 and / or T308, T309 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT316, NT317T318, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T319, C(O)OT320, C(O)NHT321, C(O)NT322T323, OT324, O(T325-O)wH (w = 1, 2, 3, 4, 5), O(T326-O)wT327 (w = 1, 2, 3, 4, 5), OC(O)T328, OC(O)OT329, OC(O)NHT330, OC(O)NT331T332, OP(O)(OT333)(OT334), OSi(T335)(T336)(T337), OS(O2)T338, NHC(O)T339, NT340C(O)T341, NHC(O)OT342, NHC(O)NHT343, NHC(O)NT344T345, NT346C(O)OT347, NT348C(O)NHT349, NT350C(O)NT351T352, NHS(O2)T353, NT354S(O2)T355, ST356, S(O)T357, S(O2)T358, S(O2)NHT359, S(O2)NT360T361, S(O2)OT362, P(O)(OT363)(OT364), Si(T365)(T366)(T367)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT316, NT317T318, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T319, C (O) OT320, C (O) NHT321, C (O) NT322T323, OT324, O (T325-O) w H (w = 1, 2, 3, 4, 5), O (T326-O) w T327 (w = 1, 2, 3, 4, 5), OC (O) T328, OC (O) OT329, OC (O) NHT330 , OC (O) NT331T332, OP (O) (OT333) (OT334), OSi (T335) (T336) (T337), OS (O 2 ) T338, NHC (O) T339, NT340C (O) T341, NHC ( O) OT342, NHC (O) NHT343, NHC (O) NT344T345, NT346C (O) OT347, NT348C (O) NHT349, NT350C (O) NT351T352, NHS (O 2 ) T353, NT354S (O 2 ) T355, ST356, S (O) T357, S (O 2 ) T358, S (O 2 ) NHT359, S (O 2 ) NT360T361, S (O 2 ) OT362, P (O) (OT363) (OT364), Si (T365) ( T366) (T367) " 여기서, T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334, T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350, T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T322, T323 및/또는 T331, T332 및/또는 T344, T345 및/또는 T351, T352 및/또는 T360, T361은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334, T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350, T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 may also in each case be" heterocycle. " Reels ", (b) NZ26Z27 여기서, Z26, Z27 라디칼 중 하나 또는 Z26, Z27 라디칼 둘 다는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(b) NZ26Z27 wherein one of the Z26, Z27 radicals or both Z26, Z27 radicals is each independently selected from the group consisting of: (1) "C(Y4)NZ28Z29, C(=NZ30)Z31"(1) "C (Y4) NZ28Z29, C (= NZ30) Z31" 여기서, Y4는 독립적으로 "O, S, =NH, =NZ32"로 이루어진 그룹으로부터 선택되고,Wherein Y4 is independently selected from the group consisting of "O, S, = NH, = NZ32", 단, Z28, Z29 라디칼 중 적어도 하나 및 Z30, Z31 라디칼 중 적어도 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Provided that at least one of the Z28, Z29 radicals and at least one of the Z30, Z31 radicals is independently selected from the group consisting of: (I) "알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, C(O)알킬, C(O)아릴, C(O)헤테로아릴"(I) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl, C (O) heteroaryl" 추가로 단, 치환체 그룹(I)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:And further provided that said substituents of substituent group (I) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of: (i) "(C9-C30)알킬, 사이클로알킬알킬, 헤테로사이클릴알킬, 아릴알킬, 헤테로아릴알킬, N3, NT368T369, NHC(O)사이클로알킬알킬, NHC(O)헤테로사이클릴알킬, NT370C(O)T371, NHC(O)OT372, NHC(O)NHT373, NHC(O)NT374T375, NT376C(O)OT377, NT378C(O)NHT379, NT380C(O)NT381T382, NHS(O2)사이클로알킬알킬, NHS(O2)헤테로사이클릴알킬, NT383S(O2)T384, OT385, O(T386-O)xT387 (x = 1, 2, 3, 4, 5), O(T388-O)xH (x = 1, 2, 3, 4, 5), OC(O)-사이클로알킬알킬, OC(O)-헤테로사이클릴알킬, OC(O)OT389, OC(O)NHT390, OC(O)NT391T392, OS(O2)사이클로알킬알킬, OS(O2)헤테로사이클릴알킬, -OP(O)(OT393)(OT394), OSi(T395)(T396)(T397), CHO, C(O)사이클로알킬, C(O)헤테로사이클릴, C(O)사이클로알킬알킬, C(O)헤테로사이클릴알킬, C(O)아릴알킬, C(O)헤테로아릴알킬, S 사이클로알킬알킬, S헤테로사이클릴알킬, S아릴알킬, S헤테로아릴알킬, S(O)사이클로알킬, S(O)헤테로사이클릴, S(O)헤테로아릴, S(O)사이클로알킬알킬, S(O)헤테로사이클릴알킬, S(O)아릴알킬, S(O)헤테로아릴알킬, S(O2)사이클로알킬, S(O2)헤테로사이클릴, S(O2)헤테로아릴, S(O2)사이클로알킬알킬, S(O2)헤테로사이클릴알킬, S(O2)아릴알킬, S(O2)헤테로아릴알킬, S(O2)NH사이클로알킬, S(O2)NH헤테로사이클릴, S(O2)NH사이클로알킬알킬, S(O2)NH헤테로사이클릴알킬, S(O2)NH헤테로아릴알킬, S(O2)NT398T399, S(O2)O사이클로알킬, S(O2)O헤테로사이클릴, S(O2)O헤테로아릴, S(O2)O사이클로알킬알킬, S(O2)O헤테로사이클릴알킬, S(O2)O헤테로아릴알킬, P(O)(OH)2, P(O)(OT400)(OT401), Si(T402)(T403)(T404)"(i) "(C 9 -C 30 ) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, N3, NT368T369, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NT370C (O) T371, NHC (O) OT372, NHC (O) NHT373, NHC (O) NT374T375, NT376C (O) OT377, NT378C (O) NHT379, NT380C (O) NT381T382, NHS (O 2 ) cycloalkylalkyl , NHS (O 2 ) heterocyclylalkyl, NT383S (O 2 ) T384, OT385, O (T386-O) x T387 (x = 1, 2, 3, 4, 5), O (T388-O) x H (x = 1, 2, 3, 4, 5), OC (O) -cycloalkylalkyl, OC (O) -heterocyclylalkyl, OC (O) OT389, OC (O) NHT390, OC (O) NT391T392 , OS (O 2 ) cycloalkylalkyl, OS (O2) heterocyclylalkyl, -OP (O) (OT393) (OT394), OSi (T395) (T396) (T397), CHO, C (O) cycloalkyl , C (O) heterocyclyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O) arylalkyl, C (O) heteroarylalkyl, S cycloalkylalkyl, S heterocyclyl Alkyl, Sarylalkyl, Sheteroarylalkyl, S (O) cycloalkyl, S (O) hete Heterocyclyl, S (O) heteroaryl, S (O) cycloalkyl-alkyl, S (O) heterocyclyl-alkyl, S (O) aryl, S (O) heteroaryl-alkyl, S (O 2) cycloalkyl, S (O2) heterocyclyl, S (O2) heteroaryl, S (O 2 ) cycloalkylalkyl, S (O2) heterocyclylalkyl, S (O2) arylalkyl, S (O2) heteroarylalkyl, S ( O 2 ) NH cycloalkyl, S (O 2 ) NH heterocyclyl, S (O 2 ) NH cycloalkylalkyl, S (O 2 ) NH heterocyclylalkyl, S (O 2 ) NH heteroarylalkyl, S (O 2 ) NT398T399, S (O 2) O -cycloalkyl, S (O 2) O-heterocyclyl, S (O 2) O-heteroaryl, S (O 2) O-cycloalkyl-alkyl, S (O2) O heterocyclylalkyl , S (O2) Oheteroarylalkyl, P (O) (OH) 2, P (O) (OT400) (OT401), Si (T402) (T403) (T404) " 추가로 단, "N(알킬)2", "C(O)N(알킬)2", "C(O)N(사이클로알킬)2", "C(O)N(아릴)2", "C(O)N(헤테로아릴)2"는 다음 치환체 그룹(ii)으로부터 선택된 하나 이상의 치환체에 의해 추가로 치환되고;Further, provided that "N (alkyl) 2 ", "C (O) N (alkyl) 2 ", "C (O) N (cycloalkyl) 2 ", "C (O) N (aryl) 2 ", " C (O) N (heteroaryl) 2 ″ is further substituted by one or more substituents selected from the following substituent group (ii); 여기서, T368, T369, T370, T371, T372, T373, T374, T375, T376, T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T374, T375 및/또는 T381, T382 및/또는 T391, T392 및/또는 T398, T399는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T368, T369, T370, T371, T372, T373, T374, T375, T376, T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cyclo Alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, T374, T375 and / or T381, T382 and / or T391, T392 and And / or T398, T399 may also in each case together form a “heterocyclyl”, 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT405, NT406T407, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T408, C(O)OT409, C(O)NHT410, C(O)NT411T412, OT413, O(T414-O)yH (y = 1, 2, 3, 4, 5), O(T415-O)yT416 (y = 1, 2, 3, 4, 5), OC(O)T417, OC(O)OT418, OC(O)NHT419, OC(O)NT420T421, OP(O)(OT422)(OT423), OSi(T424)(T425)(T426), OS(O2)T427, NHC(O)T428, NT429C(O)T430, NHC(O)OT431, NHC(O)NHT432, NHC(O)NT433T434, NT435C(O)OT436, NT437C(O)NHT438, NT439C(O)NT440T441, NHS(O2)T442, NT443S(O2)T444, ST445, S(O)T446, S(O2)T447, S(O2)NHT448, S(O2)NT449T450, S(O2)OT451, P(O)(OT452)(OT453), Si(T454)(T455)(T456)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT405, NT406T407, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T408, C (O) OT409, C (O) NHT410, C (O) NT411T412, OT413, O (T414-O) y H (y = 1, 2, 3, 4, 5), O (T415-O) y T416 (y = 1, 2, 3, 4, 5), OC (O) T417, OC (O) OT418, OC (O) NHT419 , OC (O) NT420T421, OP (O) (OT422) (OT423), OSi (T424) (T425) (T426), OS (O 2 ) T427, NHC (O) T428, NT429C (O) T430, NHC ( O) OT431, NHC (O) NHT432, NHC (O) NT433T434, NT435C (O) OT436, NT437C (O) NHT438, NT439C (O) NT440T441, NHS (O 2 ) T442, NT443S (O 2 ) T444, ST445, S (O) T446, S (O 2 ) T447, S (O 2 ) NHT448, S (O 2 ) NT449T450, S (O 2 ) OT451, P (O) (OT452) (OT453), Si (T454) ( T455) (T456) " 여기서, T405, T406, T407, T408, T409, T410, T411, T412, T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T411, T412 및/또는 T420, T421 및/또는 T433, T434 및/또는 T440, T441 및/또는 T449, T450은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T405, T406, T407, T408, T409, T410, T411, T412, T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T411, T412 and / or T420, T421 and / or T433, T434 and / or T440, T441 and / or T449, T450 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT457, NT458T459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T460, C(O)OT461, C(O)NHT462, C(O)NT463T464, OT465, O(T466-O)zH (z = 1, 2, 3, 4, 5), O(T467-O)zT468 (z = 1, 2, 3, 4, 5), OC(O)T469, OC(O)OT470, OC(O)NHT471, OC(O)NT472T473, OP(O)(OT474)(OT475), OSi(T476)(T477)(T478), OS(O2)T479, NHC(O)T480, NT481C(O)T482, NHC(O)OT483, NHC(O)NHT484, NHC(O)NT485T486, NT487C(O)OT488, NT489C(O)NHT490, NT491C(O)NT492T493, NHS(O2)T494, NT495S(O2)T496, ST497, S(O)T498, S(O2)T499, S(O2)NHT500, S(O2)NT501T502, S(O2)OT503, P(O)(OT504)(OT505), Si(T506)(T507)(T508)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT457, NT458T459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T460, C (O) OT461, C (O) NHT462, C (O) NT463T464, OT465, O (T466-O) z H (z = 1, 2, 3, 4, 5), O (T467-O) z T468 (z = 1, 2, 3, 4, 5), OC (O) T469, OC (O) OT470, OC (O) NHT471 , OC (O) NT472T473, OP (O) (OT474) (OT475), OSi (T476) (T477) (T478), OS (O 2 ) T479, NHC (O) T480, NT481C (O) T482, NHC ( O) OT483, NHC (O) NHT484, NHC (O) NT485T486, NT487C (O) OT488, NT489C (O) NHT490, NT491C (O) NT492T493, NHS (O 2 ) T494, NT495S (O 2 ) T496, ST497, S (O) T498, S (O 2 ) T499, S (O 2 ) NHT500, S (O 2 ) NT501T502, S (O 2 ) OT503, P (O) (OT504) (OT505), Si (T506) ( T507) (T508) " 여기서, T457, T458, T459, T460, T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T463, T464 및/또는 T472, T473 및/또는 T485, T486 및/또는 T492, T493 및/또는 T501, T502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T457, T458, T459, T460, T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T463, T464 and / or T472, T473 and / or T485, T486 and / or T492, T493 and / or T501, T502 are also in each case" heterocycle. " Reels ", 또는 단, Z28, Z29 라디칼 중 적어도 하나 및 Z30, Z31 라디칼 중 적어도 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: Or provided that at least one of the Z28, Z29 radicals and at least one of the Z30, Z31 radicals is independently selected from the group consisting of: (II) "(C9-C30)알킬, 사이클로알킬알킬, 헤테로사이클릴알킬, 아릴알킬, 헤테로아릴알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴알킬, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(II) "(C 9 -C 30 ) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) arylalkyl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocyclyl, S (O 2 ) heterocyclylalkyl " 여기서, 임의로, 치환 그룹(II)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (II) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT509, NT510T511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T512, C(O)OT513, C(O)NHT514, C(O)NT515T516, OT517, O(T518-O)aH (a = 1, 2, 3, 4, 5), O(T519-O)aT520 (a = 1, 2, 3, 4, 5), OC(O)T521, OC(O)OT522, OC(O)NHT523, OC(O)NT524T525, OP(O)(OT526)(OT527), OSi(T528)(T529)(T530), OS(O2)T531, NHC(O)T532, NT533C(O)T534, NHC(O)OT535, NHC(O)NHT536, NHC(O)NT537T538, NT539C(O)OT540, NT541C(O)NHT542, NT543C(O)NT544T545, NHS(O2)T546, NT547S(O2)T548, ST549, S(O)T550, S(O2)T551, S(O2)NHT552, S(O2)NT553T554, S(O2)OT555, P(O)(OT556)(OT557), Si(T558)(T559)(T560)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT509, NT510T511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T512, C (O) OT513, C (O) NHT514, C (O) NT515T516, OT517, O (T518-O) a H (a = 1, 2, 3, 4, 5), O (T519-O) a T520 (a = 1, 2, 3, 4, 5), OC (O) T521, OC (O) OT522, OC (O) NHT523 , OC (O) NT524T525, OP (O) (OT526) (OT527), OSi (T528) (T529) (T530), OS (O 2 ) T531, NHC (O) T532, NT533C (O) T534, NHC ( O) OT535, NHC (O) NHT536, NHC (O) NT537T538, NT539C (O) OT540, NT541C (O) NHT542, NT543C (O) NT544T545, NHS (O 2 ) T546, NT547S (O 2 ) T548, ST549, S (O) T550, S (O 2 ) T551, S (O 2 ) NHT552, S (O 2 ) NT553T554, S (O 2 ) OT555, P (O) (OT556) (OT557), Si (T558) ( T559) (T560) " 여기서, T509, T510, T511, T512, T513, T514, T515, T516, T517, T518, T519, T520, T521, T522, T523, T524, T525, T526, T527, T528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544, T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557, T558, T559, T560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T515, T516 및/또는 T524, T525 및/또는 T537, T538 및/또는 T544, T545 및/또는 T553, T554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T509, T510, T511, T512, T513, T514, T515, T516, T517, T518, T519, T520, T521, T522, T523, T524, T525, T526, T527, T528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544, T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557, T558, T559, T560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T515, T516 and / or T524, T525 and / or T537, T538 and / or T544, T545 and / or T553, T554 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT561, NT562T563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T564, C(O)OT565, C(O)NHT566, C(O)NT567T568, OT569, O(T570-O)bH (b = 1, 2, 3, 4, 5), O(T571-O)bT572 (b = 1, 2, 3, 4, 5), OC(O)T573, OC(O)OT574, OC(O)NHT575, OC(O)NT576T577, OP(O)(OT578)(OT579), OSi(T580)(T581)(T582), OS(O2)T583, NHC(O)T584, NT585C(O)T586, NHC(O)OT587, NHC(O)NHT588, NHC(O)NT589T590, NT591C(O)OT592, NT593C(O)NHT594, NT595C(O)NT596T597, NHS(O2)T598, NT599S(O2)T600, ST601, S(O)T602, S(O2)T603, S(O2)NHT604, S(O2)NT605T606, S(O2)OT607, P(O)(OT608)(OT609), Si(T610)(T611)(T612)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT561, NT562T563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T564, C (O) OT565, C (O) NHT566, C (O) NT567T568, OT569, O (T570-O) b H (b = 1, 2, 3, 4, 5), O (T571-O) b T572 (b = 1, 2, 3, 4, 5), OC (O) T573, OC (O) OT574, OC (O) NHT575 , OC (O) NT576T577, OP (O) (OT578) (OT579), OSi (T580) (T581) (T582), OS (O 2 ) T583, NHC (O) T584, NT585C (O) T586, NHC ( O) OT587, NHC (O) NHT588, NHC (O) NT589T590, NT591C (O) OT592, NT593C (O) NHT594, NT595C (O) NT596T597, NHS (O 2 ) T598, NT599S (O 2 ) T600, ST601, S (O) T602, S (O 2 ) T603, S (O 2 ) NHT604, S (O 2 ) NT605T606, S (O 2 ) OT607, P (O) (OT608) (OT609), Si (T610) ( T611) (T612) " 여기서, T561, T562, T563, T564, T565, T566, T567, T568, T569, T570, T571, T572, T573, T574, T575, T576, T577, T578, T579, T580, T581, T582, T583, T584, T585, T586, T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T567, T568 및/또는 T576, T577 및/또는 T589, T590 및/또는 T596, T597 및/또는 T605, T606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T561, T562, T563, T564, T565, T566, T567, T568, T569, T570, T571, T572, T573, T574, T575, T576, T577, T578, T579, T580, T581, T582, T583, T584, T585, T586, T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T567, T568 and / or T576, T577 and / or T589, T590 and / or T596, T597 and / or T605, T606 are also in each case a" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, said substituents in substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT613, NT614T615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T616, C(O)OT617, C(O)NHT618, C(O)NT619T620, OT621, O(T622-O)cH (c = 1, 2, 3, 4, 5), O(T623-O)cT624 (c = 1, 2, 3, 4, 5), OC(O)T625, OC(O)OT626, OC(O)NHT627, OC(O)NT628T629, OP(O)(OT630)(OT631), OSi(T632)(T633)(T634), OS(O2)T635, NHC(O)T636, NT637C(O)T638, NHC(O)OT639, NHC(O)NHT640, NHC(O)NT641T642, NT643C(O)OT644, NT645C(O)NHT646, NT647C(O)NT648T649, NHS(O2)T650, NT651S(O2)T652, ST653, S(O)T654, S(O2)T655, S(O2)NHT656, S(O2)NT657T658, S(O2)OT659, P(O)(OT660)(OT661), Si(T662)(T663)(T664)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT613, NT614T615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T616, C (O) OT617, C (O) NHT618, C (O) NT619T620, OT621, O (T622-O) c H (c = 1, 2, 3, 4, 5), O (T623-O) c T624 (c = 1, 2, 3, 4, 5), OC (O) T625, OC (O) OT626, OC (O) NHT627 , OC (O) NT628T629, OP (O) (OT630) (OT631), OSi (T632) (T633) (T634), OS (O 2 ) T635, NHC (O) T636, NT637C (O) T638, NHC ( O) OT639, NHC (O) NHT640, NHC (O) NT641T642, NT643C (O) OT644, NT645C (O) NHT646, NT647C (O) NT648T649, NHS (O 2 ) T650, NT651S (O 2 ) T652, ST653, S (O) T654, S (O 2 ) T655, S (O 2 ) NHT656, S (O 2 ) NT657T658, S (O 2 ) OT659, P (O) (OT660) (OT661), Si (T662) ( T663) (T664) " 여기서, T613, T614, T615, T616, T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638, T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T619, T620 및/또는 T628, T629 및/또는 T641, T642 및/또는 T648, T649 및/또는 T657, T658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where T613, T614, T615, T616, T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638, T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T619, T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 are also in each case" heterocycle. " Reels "; Z28, Z29 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z28, Z29 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고, Z30, Z31 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z30, Z31 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고, Z32 라디칼은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: And one of the Z28, Z29 radicals is independently selected from the group consisting of: or none of the Z28, Z29 radicals is independently selected from the group consisting of: and one of the Z30, Z31 radicals is independently from the group consisting of: Or none of the Z30, Z31 radicals is independently selected from the group consisting of: and the Z32 radicals are independently selected from the group consisting of: (III) "수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, C(O)알킬, C(O)아릴, C(O)헤테로아릴"(III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl, C (O) heteroaryl" 여기서, 임의로, 치환체 그룹(III)의 상기 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, said substituents of substituent group (III) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT665, NT666T667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T668, C(O)OT669, C(O)NHT670, C(O)NT671T672, OT673, O(T674-O)dH (d = 1, 2, 3, 4, 5), O(T675-O)dT676 (d = 1, 2, 3, 4, 5), OC(O)T677, OC(O)OT678, OC(O)NHT679, OC(O)NT680T681, OP(O)(OT682)(OT683), OSi(T684)(T685)(T686), OS(O2)T687, NHC(O)T688, NT689C(O)T690, NHC(O)OT691, NHC(O)NHT692, NHC(O)NT693T694, NT695C(O)OT696, NT697C(O)NHT698, NT699C(O)NT700T701, NHS(O2)T702, NT703S(O2)T704, ST705, S(O)T706, S(O2)T707, S(O2)NHT708, S(O2)NT709T710, S(O2)OT711, P(O)(OT712)(OT713), Si(T714)(T715)(T716)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT665, NT666T667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T668, C (O) OT669, C (O) NHT670, C (O) NT671T672, OT673, O (T674-O) d H (d = 1, 2, 3, 4, 5), O (T675-O) d T676 (d = 1, 2, 3, 4, 5), OC (O) T677, OC (O) OT678, OC (O) NHT679 , OC (O) NT680T681, OP (O) (OT682) (OT683), OSi (T684) (T685) (T686), OS (O 2 ) T687, NHC (O) T688, NT689C (O) T690, NHC ( O) OT691, NHC (O) NHT692, NHC (O) NT693T694, NT695C (O) OT696, NT697C (O) NHT698, NT699C (O) NT700T701, NHS (O 2 ) T702, NT703S (O 2 ) T704, ST705, S (O) T706, S (O 2 ) T707, S (O 2 ) NHT708, S (O 2 ) NT709T710, S (O 2 ) OT711, P (O) (OT712) (OT713), Si (T714) ( T715) (T716) " 여기서, T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676, T677, T678, T679, T680, T681, T682, T683, T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T711, T712, T713, T714, T715, T716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T671, T672 및/또는 T680, T681 및/또는 T693, T694 및/또는 T700, T701 및/또는 T709, T710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676, T677, T678, T679, T680, T681, T682, T683, T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T711, T712, T713, T714, T715, T716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T671, T672 and / or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT717, NT718T719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T720, C(O)OT721, C(O)NHT722, C(O)NT723T724, OT725, O(T726-O)eH (e = 1, 2, 3, 4, 5), O(T727-O)eT728 (e = 1, 2, 3, 4, 5), OC(O)T729, OC(O)OT730, OC(O)NHT731, OC(O)NT732T733, OP(O)(OT734)(OT735), OSi(T736)(T737)(T738), OS(O2)T739, NHC(O)T740, NT741C(O)T742, NHC(O)OT743, NHC(O)NHT744, NHC(O)NT745T746, NT747C(O)OT748, NT749C(O)NHT750, NT751C(O)NT752T753, NHS(O2)T754, NT755S(O2)T756, ST757, S(O)T758, S(O2)T759, S(O2)NHT760, S(O2)NT761T762, S(O2)OT763, P(O)(OT764)(OT765), Si(T766)(T767)(T768)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT717, NT718T719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T720, C (O) OT721, C (O) NHT722, C (O) NT723T724, OT725, O (T726-O) e H (e = 1, 2, 3, 4, 5), O (T727-O) e T728 (e = 1, 2, 3, 4, 5), OC (O) T729, OC (O) OT730, OC (O) NHT731 , OC (O) NT732T733, OP (O) (OT734) (OT735), OSi (T736) (T737) (T738), OS (O 2 ) T739, NHC (O) T740, NT741C (O) T742, NHC ( O) OT743, NHC (O) NHT744, NHC (O) NT745T746, NT747C (O) OT748, NT749C (O) NHT750, NT751C (O) NT752T753, NHS (O 2 ) T754, NT755S (O 2 ) T756, ST757, S (O) T758, S (O 2 ) T759, S (O 2 ) NHT760, S (O 2 ) NT761T762, S (O 2 ) OT763, P (O) (OT764) (OT765), Si (T766) ( T767) (T768) " 여기서, T717, T718, T719, T720, T721, T722, T723, T724, T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T723, T724 및/또는 T732, T733 및/또는 T745, T746 및/또는 T752, T753 및/또는 T761, T762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T717, T718, T719, T720, T721, T722, T723, T724, T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T723, T724 and / or T732, T733 and / or T745, T746 and / or T752, T753 and / or T761, T762 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT769, NT770T771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T772, C(O)OT773, C(O)NHT774, C(O)NT775T776, OT777, O(T778-O)fH (f = 1, 2, 3, 4, 5), O(T779- O)fT780 (f = 1, 2, 3, 4, 5), OC(O)T781, OC(O)OT782, OC(O)NHT783, OC(O)NT784T785, OP(O)(OT786)(OT787), OSi(T788)(T789)(T790), OS(O2)T791, NHC(O)T792, NT793C(O)T794, NHC(O)OT795, NHC(O)NHT796, NHC(O)NT797T798, NT799C(O)OT800, NT801C(O)NHT802, NT803C(O)NT804T805, NHS(O2)T806, NT807S(O2)T808, ST809, S(O)T810, S(O2)T811, S(O2)NHT812, S(O2)NT813T814, S(O2)OT815, P(O)(OT816)(OT817), Si(T818)(T819)(T820)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT769, NT770T771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T772, C (O) OT773, C (O) NHT774, C (O) NT775T776, OT777, O (T778-O) f H (f = 1, 2, 3, 4, 5), O (T779-O) f T780 (f = 1, 2, 3, 4, 5), OC (O) T781, OC (O) OT782, OC (O) NHT783 , OC (O) NT784T785, OP (O) (OT786) (OT787), OSi (T788) (T789) (T790), OS (O 2 ) T791, NHC (O) T792, NT793C (O) T794, NHC ( O) OT795, NHC (O) NHT796, NHC (O) NT797T798, NT799C (O) OT800, NT801C (O) NHT802, NT803C (O) NT804T805, NHS (O 2 ) T806, NT807S (O 2 ) T808, ST809, S (O) T810, S (O 2 ) T811, S (O 2 ) NHT812, S (O 2 ) NT813T814, S (O 2 ) OT815, P (O) (OT816) (OT817), Si (T818) ( T819) (T820) " 여기서, T769, T770, T771, T772, T773, T774, T775, T776, T777, T778, T779, T780, T781, T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812, T813, T814, T815, T816, T817, T818, T819, T820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T775, T776 및/또는 T784, T785 및/또는 T797, T798 및/또는 T804, T805 및/또는 T813, T814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T769, T770, T771, T772, T773, T774, T775, T776, T777, T778, T779, T780, T781, T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812, T813, T814, T815, T816, T817, T818, T819, T820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T775, T776 and / or T784, T785 and / or T797, T798 and / or T804, T805 and / or T813, T814 are also in each case" heterocycle. " Reels ", (2) "C(Y5)NZ33Y6Z34"(2) "C (Y5) NZ33Y6Z34" 여기서, Y5, Y6은 각각 독립적으로 "O, S, =NH, =NZ35"로 이루어진 그룹으로부터 선택되고,Wherein Y5 and Y6 are each independently selected from the group consisting of "O, S, = NH, = NZ35", 여기서, Z33, Z34, Z35는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein Z33, Z34, Z35 are each independently selected from the group consisting of: (I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cyclo Alkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocycle Reel, S (O 2 ) heterocyclylalkyl " 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT821, NT822T823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T824, C(O)OT825, C(O)NHT826, C(O)NT827T828, OT829, O(T830-O)gH (g = 1, 2, 3, 4, 5), O(T831-O)gT832 (g = 1, 2, 3, 4, 5), OC(O)T833, OC(O)OT834, OC(O)NHT835, OC(O)NT836T837, OP(O)(OT838)(OT839), OSi(T840)(T814)(T842), OS(O2)T843, NHC(O)T844, NT845C(O)T846, NHC(O)OT847, NHC(O)NHT848, NHC(O)NT849T850, NT851C(O)OT852, NT853C(O)NHT854, NT855C(O)NT856T857, NHS(O2)T858, NT859S(O2)T860, ST861, S(O)T862, S(O2)T863, S(O2)NHT864, S(O2)NT865T866, S(O2)OT867, P(O)(OT868)(OT869), Si(T870)(T871)(T872)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT821, NT822T823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T824, C (O) OT825, C (O) NHT826, C (O) NT827T828, OT829, O (T830-O) g H (g = 1, 2, 3, 4, 5), O (T831-O) g T832 (g = 1, 2, 3, 4, 5), OC (O) T833, OC (O) OT834, OC (O) NHT835 , OC (O) NT836T837, OP (O) (OT838) (OT839), OSi (T840) (T814) (T842), OS (O 2 ) T843, NHC (O) T844, NT845C (O) T846, NHC ( O) OT847, NHC (O) NHT848, NHC (O) NT849T850, NT851C (O) OT852, NT853C (O) NHT854, NT855C (O) NT856T857, NHS (O 2 ) T858, NT859S (O 2 ) T860, ST861, S (O) T862, S (O 2 ) T863, S (O 2 ) NHT864, S (O 2 ) NT865T866, S (O 2 ) OT867, P (O) (OT868) (OT869), Si (T870) ( T871) (T872) " 여기서, T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845, T846, T847, T848, T849, T850, T851, T852, T853, T854, T855, T856, T857, T858, T859, T860, T861, T862, T863, T864, T865, T866, T867, T868, T869, T870, T871, T872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T827, T828 및/또는 T836, T837 및/또는 T849, T850 및/또는 T856, T857 및/또는 T865, T866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845, T846, T847, T848, T849, T850, T851, T852, T853, T854, T855, T856, T857, T858, T859, T860, T861, T862, T863, T864, T865, T866, T867, T868, T869, T870, T871, T872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T827, T828 and / or T836, T837 and / or T849, T850 and / or T856, T857 and / or T865, T866 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT873, NT874T875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T876, C(O)OT877, C(O)NHT878, C(O)NT879T880, OT881, O(T882-O)hH (h = 1, 2, 3, 4, 5), O(T883-O)hT884 (h = 1, 2, 3, 4, 5), OC(O)T885, OC(O)OT886, OC(O)NHT887, OC(O)NT888T889, OP(O)(OT890)(OT891), OSi(T892)(T893)(T894), OS(O2)T895, NHC(O)T896, NT897C(O)T898, NHC(O)OT899, NHC(O)NHT900, NHC(O)NT901T902, NT903C(O)OT904, NT905C(O)NHT906, NT907C(O)NT908T909, NHS(O2)T910, NT911S(O2)T912, ST913, S(O)T914, S(O2)T915, S(O2)NHT916, S(O2)NT917T918, S(O2)OT919, P(O)(OT920)(OT921), Si(T922)(T923)(T924)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT873, NT874T875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T876, C (O) OT877, C (O) NHT878, C (O) NT879T880, OT881, O (T882-O) h H (h = 1, 2, 3, 4, 5), O (T883-O) h T884 (h = 1, 2, 3, 4, 5), OC (O) T885, OC (O) OT886, OC (O) NHT887 , OC (O) NT888T889, OP (O) (OT890) (OT891), OSi (T892) (T893) (T894), OS (O 2 ) T895, NHC (O) T896, NT897C (O) T898, NHC ( O) OT899, NHC (O) NHT900, NHC (O) NT901T902, NT903C (O) OT904, NT905C (O) NHT906, NT907C (O) NT908T909, NHS (O 2 ) T910, NT911S (O 2 ) T912, ST913, S (O) T914, S (O 2 ) T915, S (O 2 ) NHT916, S (O 2 ) NT917T918, S (O 2 ) OT919, P (O) (OT920) (OT921), Si (T922) ( T923) (T924) " 여기서, T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897, T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916, T917, T918, T919, T920, T921, T922, T923, T924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T879, T880 및/또는 T888, T889 및/또는 T901, T902 및/또는 T908, T909 및/또는 T917, T918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,;Where T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897, T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916, T917, T918, T919, T920, T921, T922, T923, T924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T879, T880 and / or T888, T889 and / or T901, T902 and / or T908, T909 and / or T917, T918 are also in each case" heterocycle Reels "; 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT925, NT926T927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T928, C(O)OT929, C(O)NHT930, C(O)NT931T932, OT933, O(T934-O)iH (i = 1, 2, 3, 4, 5), O(T935-O)iT936 (i = 1, 2, 3, 4, 5), OC(O)T937, OC(O)OT938, OC(O)NHT939, OC(O)NT940T941, OP(O)(OT942)(OT943), OSi(T944)(T945)(T946), OS(O2)T947, NHC(O)T948, NT949C(O)T950, NHC(O)OT951, NHC(O)NHT952, NHC(O)NT953T954, NT955C(O)OT956, NT957C(O)NHT958, NT959C(O)NT960T961, NHS(O2)T962, NT963S(O2)T964, ST965, S(O)T966, S(O2)T967, S(O2)NHT968, S(O2)NT969T970, S(O2)OT971, P(O)(OT972)(OT973), Si(T974)(T975)(T976)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT925, NT926T927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T928, C (O) OT929, C (O) NHT930, C (O) NT931T932, OT933, O (T934-O) i H (i = 1, 2, 3, 4, 5), O (T935-O) i T936 (i = 1, 2, 3, 4, 5), OC (O) T937, OC (O) OT938, OC (O) NHT939 , OC (O) NT940T941, OP (O) (OT942) (OT943), OSi (T944) (T945) (T946), OS (O 2 ) T947, NHC (O) T948, NT949C (O) T950, NHC ( O) OT951, NHC (O) NHT952, NHC (O) NT953T954, NT955C (O) OT956, NT957C (O) NHT958, NT959C (O) NT960T961, NHS (O 2 ) T962, NT963S (O 2 ) T964, ST965, S (O) T966, S (O 2 ) T967, S (O 2 ) NHT968, S (O 2 ) NT969T970, S (O 2 ) OT971, P (O) (OT972) (OT973), Si (T974) ( T975) (T976) " 여기서, T925, T926, T927, T928, T929, T930, T931, T932, T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968, T969, T970, T971, T972, T973, T974, T975, T976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T931, T932 및/또는 T940, T941 및/또는 T953, T954 및/또는 T960, T961 및/또는 T969, T970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T925, T926, T927, T928, T929, T930, T931, T932, T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968, T969, T970, T971, T972, T973, T974, T975, T976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T931, T932 and / or T940, T941 and / or T953, T954 and / or T960, T961 and / or T969, T970 are also in each case" heterocycle Reels ", Z26, Z27 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z26, Z27 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z26, Z27 radicals is independently selected from the group consisting of, or neither of the Z26, Z27 radicals is independently selected from the group consisting of: (2) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, C(Y7)NZ36Z37, C(=NZ38)Z39, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(2) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, C (Y7) NZ36Z37, C (= NZ38) Z39, S (O2) alkyl, S (O 2 ) (C 9- C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocyclyl, S (O 2 ) heterocyclylalkyl " 여기서, Y7은 독립적으로 "O, S, =NH, =NZ40"로 이루어진 그룹으로부터 선택되고,Wherein Y7 is independently selected from the group consisting of "O, S, = NH, = NZ40", 여기서, Z36, Z37, Z38, Z39, Z40 라디칼은 각각 독립적으로 다음으로 이루 어진 그룹으로부터 선택되고:Wherein the Z36, Z37, Z38, Z39, Z40 radicals are each independently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl, C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O ) Heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cycloalkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocyclyl, S (O 2 ) heterocyclylalkyl " 여기서, 임의로, 치환체 그룹(3) 및/또는 치환체 그룹(I)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (3) and / or substituent group (I) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT977, NT978T979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T980, C(O)OT981, C(O)NHT982, C(O)NT983T984, OT985, O(T986-O)jH (j = 1, 2, 3, 4, 5), O(T987-O)jT988 (j = 1, 2, 3, 4, 5), OC(O)T989, OC(O)OT990, OC(O)NHT991, OC(O)NT992T993, OP(O)(OT994)(OT995), OSi(T996)(T997)(T998), OS(O2)T999, NHC(O)T1000, NT1001C(O)T1002, NHC(O)OT1003, NHC(O)NHT1004, NHC(O)NT1005T1006, NT1007C(O)OT1008, NT1009C(O)NHT1010, NT1011C(O)NT1012T1013, NHS(O2)T1014, NT1015S(O2)T1016, ST1017, S(O)T1018, S(O2)T1019, S(O2)NHT1020, S(O2)NT1021T1022, S(O2)OT1023, P(O)(OT1024)(OT1025), Si(T1026)(T1027)(T1028)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT977, NT978T979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T980, C (O) OT981, C (O) NHT982, C (O) NT983T984, OT985, O (T986-O) j H (j = 1, 2, 3, 4, 5), O (T987-O) j T988 (j = 1, 2, 3, 4, 5), OC (O) T989, OC (O) OT990, OC (O) NHT991 , OC (O) NT992T993, OP (O) (OT994) (OT995), OSi (T996) (T997) (T998), OS (O 2 ) T999, NHC (O) T1000, NT1001C (O) T1002, NHC ( O) OT1003, NHC (O) NHT1004, NHC (O) NT1005T1006, NT1007C (O) OT1008, NT1009C (O) NHT1010, NT1011C (O) NT1012T1013, NHS (O 2 ) T1014, NT1015S (O 2 ) T1016, ST1017, S (O) T1018, S (O 2 ) T1019, S (O 2 ) NHT1020, S (O 2 ) NT1021T1022, S (O 2 ) OT1023, P (O) (OT1024) (OT1025), Si (T1026) ( T1027) (T1028) " 여기서, T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004, T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T983, T984 및/또는 T992, T993 및/또는 T1005, T1006 및/또는 T1012, T1013 및/또는 T1021, T1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004, T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025 T1026, T1027, T1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021, T1022 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1029, NT1030T1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1032, C(O)OT1033, C(O)NHT1034, C(O)NT1035T1036, OT1037, O(T1038-O)kH (k = 1, 2, 3, 4, 5), O(T1039-O)kT1040 (k = 1, 2, 3, 4, 5), OC(O)T1041, OC(O)OT1042, OC(O)NHT1043, OC(O)NT1044T1045, OP(O)(OT1046)(OT1047), OSi(T1048)(T1049)(T1050), OS(O2)T1051, NHC(O)T1052, NT1053C(O)T1054, NHC(O)OT1055, NHC(O)NHT1056, NHC(O)NT1057T1058, NT1059C(O)OT1060, NT1061C(O)NHT1062, NT1063C(O)NT1064T1065, NHS(O2)T1066, NT1067S(O2)T1068, ST1069, S(O)T1070, S(O2)T1071, S(O2)NHT1072, S(O2)NT1073T1074, S(O2)OT1075, P(O)(OT1076)(OT1077), Si(T1078)(T1079)(T1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1029, NT1030T1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1032, C (O) OT1033, C (O) NHT1034, C (O) NT1035T1036, OT1037, O (T1038-O) k H (k = 1, 2, 3, 4, 5), O (T1039-O) k T1040 (k = 1, 2, 3, 4, 5), OC (O) T1041, OC (O) OT1042, OC (O) NHT1043 , OC (O) NT1044T1045, OP (O) (OT1046) (OT1047), OSi (T1048) (T1049) (T1050), OS (O 2 ) T1051, NHC (O) T1052, NT1053C (O) T1054, NHC ( O) OT1055, NHC (O) NHT1056, NHC (O) NT1057T1058, NT1059C (O) OT1060, NT1061C (O) NHT1062, NT1063C (O) NT1064T1065, NHS (O 2 ) T1066, NT1067S (O 2 ) T1068, ST1069, S (O) T1070, S (O 2 ) T1071, S (O 2 ) NHT1072, S (O 2 ) NT1073T1074, S (O 2 ) OT1075, P (O) (OT1076) (OT1077), Si (T1078) ( T1079) (T1080) " 여기서, T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056,T1057, T1058, T1059, T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이 클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1035, T1036 및/또는 T1044, T1045 및/또는 T1057, T1058 및/또는 T1064, T1065 및/또는 T1073, T1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059, T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1077 T1078, T1079, T1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", where, alternatively, T1035, T1036 and / or T1044, T1045 and / or T1057, T1058 and / or T1064, T1065 and / or T1073, T1074 are also in each case" hetero " Cyclyl ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1081, NT1082T1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1084, C(O)OT1085, C(O)NHT1086, C(O)NT1087T1088, OT1089, O(T1090-O)lH (l = 1, 2, 3, 4, 5), O(T1091-O)lT1092 (l = 1, 2, 3, 4, 5), OC(O)T1093, OC(O)OT1094, OC(O)NHT1095, OC(O)NT1096T1097, OP(O)(OT1098)(OT1099), OSi(T1100)(T1101)(T1102), OS(O2)T1103, NHC(O)T1104, NT1105C(O)T1106, NHC(O)OT1107, NHC(O)NHT1108, NHC(O)NT1109T1110, NT1111C(O)OT1112, NT1113C(O)NHT1114, NT1115C(O)NT1116T1117, NHS(O2)T1118, NT1119S(O2)T1120, ST1121, S(O)T1122, S(O2)T1123, S(O2)NHT1124, S(O2)NT1125T1126, S(O2)OT1127, P(O)(OT1128)(OT1129), Si(T1130)(T1131)(T1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1081, NT1082T1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1084, C (O) OT1085, C (O) NHT1086, C (O) NT1087T1088, OT1089, O (T1090-O) l H (l = 1, 2, 3, 4, 5), O (T1091-O) l T1092 (l = 1, 2, 3, 4, 5), OC (O) T1093, OC (O) OT1094, OC (O) NHT1095 , OC (O) NT1096T1097, OP (O) (OT1098) (OT1099), OSi (T1100) (T1101) (T1102), OS (O 2 ) T1103, NHC (O) T1104, NT1105C (O) T1106, NHC ( O) OT1107, NHC (O) NHT1108, NHC (O) NT1109T1110, NT1111C (O) OT1112, NT1113C (O) NHT1114, NT1115C (O) NT1116T1117, NHS (O 2 ) T1118, NT1119S (O 2 ) T1120, ST1121, S (O) T1122, S (O 2 ) T1123, S (O 2 ) NHT1124, S (O 2 ) NT1125T1126, S (O 2 ) OT1127, P (O) (OT1128) (OT1129), Si (T1130) ( T1131) (T1132) " 여기서, T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095, T1096, T1097, T1098, T1099, T1100, T1101,T1102, T1103, T1104, T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122, T1123, T1124, T1125, T1126, T1127, T1128, T1129, T1130, T1131, T1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1087, T1088 및/또는 T1096, T1097 및/또는 T1109, T1110 및/또는 T1116, T1117 및/또는 T1125, T1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095, T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103, T1104 T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122, T1123, T1124, T1125, T1126, T1127, T1128, 29 T1130, T1131, T1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1087, T1088 and / or T1096, T1097 and / or T1109, T1110 and / or T1116, T1117 and / or T1125, T1126 are also in each case a" heterocycle Reels ", Z1, Z2 라디칼 중 하나는 독립적으로 다음으로 이루어진 그룹으로부터 선택되거나, Z1, Z2 라디칼 중 어느 하나도 독립적으로 다음으로 이루어진 그룹으로부터 선택되지 않고: And one of the Z1, Z2 radicals is independently selected from the group consisting of, or neither of the Z1, Z2 radicals is independently selected from the group consisting of: (c) 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1133, NT1134T1135, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1136, C(O)OT1137, C(O)NHT1138, C(O)NT1139T1140, OT1141, O(T1142-O)mH (m = 1, 2, 3, 4, 5), O(T1143-O)mT1144 (m = 1, 2, 3, 4, 5), OC(O)T1145, OC(O)OT1146, OC(O)NHT1147, OC(O)NT1148T1149, OP(O)(OT1150)(OT1151), OSi(T1152)(T1153)(T1154), OS(O2)T1155, NHC(O)T1156, NT1157C(O)T1158, NHC(O)OT1159, NHC(O)NHT1160, NHC(O)NT1161T1162, NT1163C(O)OT1164, NT1165C(O)NHT1166, NT1167C(O)NT1168T1169, NHS(O2)T1170, NT1171S(O2)T1172, ST1173, S(O)T1174, S(O2)T1175, S(O2)NHT1176, S(O2)NT1177T1178, S(O2)OT1179, P(O)(OT1180)(OT1181), Si(T1182)(T1183)(T1184)"(c) hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , NHT1133, NT1134T1135, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1136, C (O) OT1137, C (O) NHT1138, C (O) NT1139T1140, OT1141, O (T1142-O) m H (m = 1 , 2, 3, 4, 5), O (T1143-O) m T1144 (m = 1, 2, 3, 4, 5), OC (O) T1145, OC (O) OT1146, OC (O) NHT1147, OC (O) NT1148T1149, OP (O) (OT1150) (OT1151), OSi (T1152) (T1153) (T1154), OS (O 2 ) T1155, NHC (O) T1156, NT1157C (O) T1158, NHC (O ) OT1159, NHC (O) NHT1160, NHC (O) NT1161T1162, NT1163C (O) OT1164, NT1165C (O) NHT1166, NT1167C (O) NT1168T1169, NHS (O 2 ) T1170, NT1171S (O 2 ) T1172, ST1173, S (O) T1174, S (O 2 ) T1175, S (O 2 ) NHT1176, S (O 2 ) NT1177T1178, S (O 2 ) OT1179, P (O) (OT1180) (OT1181), Si (T1182) (T1183 ) (T1184) " 여기서, T1133, T1134, T1135, T1136, T1137, T1138, T1139, T1140, T1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149, T1150, T1151, T1152, T1153, T1154, T1155, T1156, T1157, T1158, T1159, T1160, T1161, T1162, T1163, T1164, T1165, T1166, T1167, T1168, T1169, T1170, T1171, T1172, T1173, T1174, T1175, T1176, T1177, T1178, T1179, T1180, T1181, T1182, T1183, T1184는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1139, T1140 및/또는 T1148, T1149 및/또는 T1161, T1162 및/또는 T1168, T1169 및/또는 T1177, T1178은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1133, T1134, T1135, T1136, T1137, T1138, T1139, T1140, T1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149, T1150, T1151, T1152, T1153, T1154, T1155, T1156, T1156, T1157, T1158, T1159, T1160, T1161, T1162, T1163, T1164, T1165, T1166, T1167, T1168, T1169, T1170, T1171, T1172, T1173, T1174, T1175, T1176, T1177, T1178, T1179, T1180, T118 T1182, T1183, T1184 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1139, T1140 and / or T1148, T1149 and / or T1161, T1162 and / or T1168, T1169 and / or T1177, T1178 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 추가로 치환될 수 있고:Wherein optionally, the aforementioned substituents of substituent group (c) may each be further substituted by one or more substituents, each independently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1185, NT1186T1187, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1188, C(O)OT1189, C(O)NHT1190, C(O)NT1191T1192, OT1193, O(T1194-O)nH (n = 1, 2, 3, 4, 5), O(T1195-O)nT1196 (n = 1, 2, 3, 4, 5), OC(O)T1197, OC(O)OT1198, OC(O)NHT1199, OC(O)NT1200T1201, OP(O)(OT1202)(OT1203), OSi(T1204)(T1205)(T1206), OS(O2)T1207, NHC(O)T1208, NT1209C(O)T1210, NHC(O)OT1211, NHC(O)NHT1212, NHC(O)NT1213T1214, NT1215C(O)OT1216, NT1217C(O)NHT1218, NT1219C(O)NT1220T1221, NHS(O2)T1222, NT1223S(O2)T1224, ST1225, S(O)T1226, S(O2)T1227, S(O2)NHT1228, S(O2)NT1229T1230, S(O2)OT1231, P(O)(OT1232)(OT1233), Si(T1234)(T1235)(T1236)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1185, NT1186T1187, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1188, C (O) OT1189, C (O) NHT1190, C (O) NT1191T1192, OT1193, O (T1194-O) nH (n = 1 , 2, 3, 4, 5), O (T1195-O) nT1196 (n = 1, 2, 3, 4, 5), OC (O) T1197, OC (O) OT1198, OC (O) NHT1199, OC (O) NT1200T1201, OP (O) (OT1202) (OT1203), OSi (T1204) (T1205) (T1206), OS (O 2 ) T1207, NHC (O) T1208, NT1209C (O) T1210, NHC (O) OT1211, NHC (O) NHT1212, NHC (O) NT1213T1214, NT1215C (O) OT1216, NT1217C (O) NHT1218, NT1219C (O) NT1220T1221, NHS (O 2 ) T1222, NT1223S (O 2 ) T1224, ST1225, S ( O) T1226, S (O 2 ) T1227, S (O 2 ) NHT1228, S (O 2 ) NT1229T1230, S (O 2 ) OT1231, P (O) (OT1232) (OT1233), Si (T1234) (T1235) (T1236) " 여기서, T1185, T1186, T1187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1233, T1234, T1235, T1236은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이 클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1191, T1192 및/또는 T1200, T1201 및/또는 T1213, T1214 및/또는 T1220, T1221 및/또는 T1229, T1230은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1185, T1186, T1187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1232, T1232, T1234, T1235, T1236 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1191, T1192 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 are also in each case" hetero Cyclyl ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1237, NT1238T1239, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1240, C(O)OT1241, C(O)NHT1242, C(O)NT1243T1244, OT1245, O(T1246-O)oH (o = 1, 2, 3, 4, 5), O(T1247-O)oT1248 (o = 1, 2, 3, 4, 5), OC(O)T1249, OC(O)OT1250, OC(O)NHT1251, OC(O)NT1252T1253, OP(O)(OT1254)(OT1255), OSi(T1256)(T1257)(T1258), OS(O2)T1259, NHC(O)T1260, NT1261C(O)T1262, NHC(O)OT1263, NHC(O)NHT1264, NHC(O)NT1265T1266, NT1267C(O)OT1268, NT1269C(O)NHT1270, NT1271C(O)NT1272T1273, NHS(O2)T1274, NT1275S(O2)T1276, ST1277, S(O)T1278, S(O2)T1279, S(O2)NHT1280, S(O2)NT1281T1282, S(O2)OT1283, P(O)(OT1284)(OT1285), Si(T1286)(T1287)(T1288)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1237, NT1238T1239, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1240, C (O) OT1241, C (O) NHT1242, C (O) NT1243T1244, OT1245, O (T1246-O) oH (o = 1 , 2, 3, 4, 5), O (T1247-O) oT1248 (o = 1, 2, 3, 4, 5), OC (O) T1249, OC (O) OT1250, OC (O) NHT1251, OC (O) NT1252T1253, OP (O) (OT1254) (OT1255), OSi (T1256) (T1257) (T1258), OS (O 2 ) T1259, NHC (O) T1260, NT1261C (O) T1262, NHC (O) OT1263, NHC (O) NHT1264, NHC (O) NT1265T1266, NT1267C (O) OT1268, NT1269C (O) NHT1270, NT1271C (O) NT1272T1273, NHS (O 2 ) T1274, NT1275S (O 2 ) T1276, ST1277, S ( O) T1278, S (O 2 ) T1279, S (O 2 ) NHT1280, S (O 2 ) NT1281T1282, S (O 2 ) OT1283, P (O) (OT1284) (OT1285), Si (T1286) (T1287) (T1288) " 여기서, T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260, T1261, T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1243, T1244 및/또는 T1252, T1253 및/또는 T1265, T1266 및/또는 T1272, T1273 및/또는 T1281, T1282는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260 T1261, T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1284, T1284, T1284 T1286, T1287, T1288 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 are also in each case" heterocycle Reels ", (d) NZ41Z42 여기서, Z41, Z42 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(d) NZ41Z42 wherein the Z41 and Z42 radicals are each independently selected from the group consisting of: (1) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O)아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬"(1) "alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl, C (O ) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) hetero Arylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl " 여기서, 임의로, 치환체 그룹(1)의 상기한 치환체는 각각 독립적으로 다음으 로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (1) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1289, NT1290T1291, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1292, C(O)OT1293, C(O)NHT1294, C(O)NT1295T1296, OT1297, O(T1298-O)rrH (rr = 1, 2, 3, 4, 5), O(T1299-O)rrT1300 (rr = 1, 2, 3, 4, 5), OC(O)T1301, OC(O)OT1302, OC(O)NHT1303, OC(O)NT1304T1305, OP(O)(OT1306)(OT1307), OSi(T1308)(T1309)(T1310), OS(O2)T1311, NHC(O)T1312, NT1313C(O)T1314, NHC(O)OT1315, NHC(O)NHT1316, NHC(O)NT1317T1318, NT1319C(O)OT1320, NT1321C(O)NHT1322, NT1323C(O)NT1324T1325, NHS(O2)T1326, NT1327S(O2)T1328, ST1329, S(O)T1330, S(O2)T1331, S(O2)NHT1332, S(O2)NT1333T1334, S(O2)OT1335, P(O)(OT1336)(OT1337), Si(T1338)(T1339)(T1340)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1289, NT1290T1291, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1292, C (O) OT1293, C (O) NHT1294, C (O) NT1295T1296, OT1297, O (T1298-O) rr H (rr = 1, 2, 3, 4, 5), O (T1299-O) rr T1300 (rr = 1, 2, 3, 4, 5), OC (O) T1301, OC (O) OT1302, OC (O) NHT1303 , OC (O) NT1304T1305, OP (O) (OT1306) (OT1307), OSi (T1308) (T1309) (T1310), OS (O 2 ) T1311, NHC (O) T1312, NT1313C (O) T1314, NHC ( O) OT1315, NHC (O) NHT1316, NHC (O) NT1317T1318, NT1319C (O) OT1320, NT1321C (O) NHT1322, NT1323C (O) NT1324T1325, NHS (O 2 ) T1326, NT1327S (O 2 ) T1328, ST1329, S (O) T1330, S (O 2 ) T1331, S (O 2 ) NHT1332, S (O 2 ) NT1333T1334, S (O 2 ) OT1335, P (O) (OT1336) (OT1337), Si (T1338) ( T1339) (T1340) " 여기서, T1289, T1290, T1291, T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304,T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1295, T1296 및/또는 T1304, T1305 및/또는 T1317, T1318 및/또는 T1324, T1325 및/또는 T1333, T1334는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1289, T1290, T1291, T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1311 T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1336, T1338, T1339, T1340 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and / or T1333, T1334 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1341, NT1342T1343, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1344, C(O)OT1345, C(O)NHT1346, C(O)NT1347T1348, OT1349, O(T1350-O)rsH (rs = 1, 2, 3, 4, 5), O(T1351-O)rsT1352 (rs = 1, 2, 3, 4, 5), OC(O)T1353, OC(O)OT1354, OC(O)NHT1355, OC(O)NT1356T1357, OP(O)(OT1358)(OT1359), OSi(T1360)(T1361)(T1362), OS(O2)T1363, NHC(O)T1364, NT1365C(O)T1366, NHC(O)OT1367, NHC(O)NHT1368, NHC(O)NT1369T1370, NT1371C(O)OT1372, NT1373C(O)NHT1374, NT1375C(O)NT1376T1377, NHS(O2)T1378, NT1379S(O2)T1380, ST1381, S(O)T1382, S(O2)T1383, S(O2)NHT1384, S(O2)NT1385T1386, S(O2)OT1387, P(O)(OT1388)(OT1389), Si(T1390)(T1391)(T1392)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1341, NT1342T1343, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1344, C (O) OT1345, C (O) NHT1346, C (O) NT1347T1348, OT1349, O (T1350-O) rs H (rs = 1, 2, 3, 4, 5), O (T1351-O) rs T1352 (rs = 1, 2, 3, 4, 5), OC (O) T1353, OC (O) OT1354, OC (O) NHT1355 , OC (O) NT1356T1357, OP (O) (OT1358) (OT1359), OSi (T1360) (T1361) (T1362), OS (O 2 ) T1363, NHC (O) T1364, NT1365C (O) T1366, NHC ( O) OT1367, NHC (O) NHT1368, NHC (O) NT1369T1370, NT1371C (O) OT1372, NT1373C (O) NHT1374, NT1375C (O) NT1376T1377, NHS (O 2 ) T1378, NT1379S (O 2 ) T1380, ST1381, S (O) T1382, S (O 2 ) T1383, S (O 2 ) NHT1384, S (O 2 ) NT1385T1386, S (O 2 ) OT1387, P (O) (OT1388) (OT1389), Si (T1390) ( T1391) (T1392) " 여기서, T1341, T1342, T1343, T1344, T1345, T1346, T1347, T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389, T1390, T1391, T1392는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1347, T1348 및/또는 T1356, T1357 및/또는 T1369, T1370 및/또는 T1376, T1377 및/또는 T1385, T1386은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1341, T1342, T1343, T1344, T1345, T1346, T1347, T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389 T1390, T1391, T1392 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1347, T1348 and / or T1356, T1357 and / or T1369, T1370 and / or T1376, T1377 and / or T1385, T1386 are also in each case a" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1393, NT1394T1395, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1396, C(O)OT1397, C(O)NHT1398, C(O)NT1399T1400, OT1401, O(T1402-O)rtH (rt = 1, 2, 3, 4, 5), O(T1403-O)rtT1404 (rt = 1, 2, 3, 4, 5), OC(O)T1405, OC(O)OT1406, OC(O)NHT1407, OC(O)NT1408T1409, OP(O)(OT1410)(OT1411), OSi(T1412)(T1413)(T1414), OS(O2)T1415, NHC(O)T1416, NT1417C(O)T1418, NHC(O)OT1419, NHC(O)NHT1420, NHC(O)NT1421T1422, NT1423C(O)OT1424, NT1425C(O)NHT1426, NT1427C(O)NT1428T1429, NHS(O2)T1430, NT1431S(O2)T1432, ST1433, S(O)T1434, S(O2)T1435, S(O2)NHT1436, S(O2)NT1437T1438, S(O2)OT1439, P(O)(OT1440)(OT1441), Si(T1442)(T1443)(T1444)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1393, NT1394T1395, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1396, C (O) OT1397, C (O) NHT1398, C (O) NT1399T1400, OT1401, O (T1402-O) rt H (rt = 1, 2, 3, 4, 5), O (T1403-O) rt T1404 (rt = 1, 2, 3, 4, 5), OC (O) T1405, OC (O) OT1406, OC (O) NHT1407 , OC (O) NT1408T1409, OP (O) (OT1410) (OT1411), OSi (T1412) (T1413) (T1414), OS (O 2 ) T1415, NHC (O) T1416, NT1417C (O) T1418, NHC ( O) OT1419, NHC (O) NHT1420, NHC (O) NT1421T1422, NT1423C (O) OT1424, NT1425C (O) NHT1426, NT1427C (O) NT1428T1429, NHS (O 2 ) T1430, NT1431S (O 2 ) T1432, ST1433, S (O) T1434, S (O 2 ) T1435, S (O 2 ) NHT1436, S (O 2 ) NT1437T1438, S (O 2 ) OT1439, P (O) (OT1440) (OT1441), Si (T1442) ( T1443) (T1444) " 여기서, T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431, T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1399, T1400 및/또는 T1408, T1409 및/또는 T1421, T1422 및/또는 T1428, T1429 및/또는 T1437, T1438은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1416, T1416 T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431, T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1440 T1442, T1443, T1444 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 are also in each case a" heterocycle. " Reels ", (2) "C(O)C(O)T1445, S(O2)NT1446T1447"(2) "C (O) C (O) T1445, S (O 2 ) NT1446T1447" 여기서, T1445, T1446, T1447은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein T1445, T1446, T1447 are each independently selected from the group consisting of: (I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1448, NT1449T1450, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1451, C(O)OT1452, C(O)NHT1453, C(O)NT1454T1455, OT1456, O(T1457-O)ruH (ru = 1, 2, 3, 4, 5), O(T1458-O)ruT1459 (ru = 1, 2, 3, 4, 5), OC(O)T1460, OC(O)OT1461, OC(O)NHT1462, OC(O)NT1463T1464, OP(O)(OT1465)(OT1466), OSi(T1467)(T1468)(T1469), OS(O2)T1470, NHC(O)T1471, NT1472C(O)T1473, NHC(O)OT1474, NHC(O)NHT1475, NHC(O)NT1476T1477, NT1478C(O)OT1479, NT1480C(O)NHT1481, NT1482C(O)NT1483T1484, NHS(O2)T1485, NT1486S(O2)T1487, ST1488, S(O)T1489, S(O2)T1490, S(O2)NHT1491, S(O2)NT1492T1493, S(O2)OT1494, P(O)(OT1495)(OT1496), Si(T1497)(T1498)(T1499)"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHT1448, NT1449T1450, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1451, C (O) OT1452, C (O) NHT1453, C (O) NT1454T1455, OT1456, O (T1457-O) ru H ( ru = 1, 2, 3, 4, 5), O (T1458-O) ru T1459 (ru = 1, 2, 3, 4, 5), OC (O) T1460, OC (O) OT1461, OC (O NHT1462, OC (O) NT1463T1464, OP (O) (OT1465) (OT1466), OSi (T1467) (T1468) (T1469), OS (O 2 ) T1470, NHC (O) T1471, NT1472C (O) T1473, NHC (O) OT1474, NHC (O) NHT1475, NHC (O) NT1476T1477, NT1478C (O) OT1479, NT1480C (O) NHT1481, NT1482C (O) NT1483T1484, NHS (O 2 ) T1485, NT1486S (O 2 ) T1487, ST1488, S (O) T1489, S (O 2 ) T1490, S (O 2 ) NHT1491, S (O 2 ) NT1492T1493, S (O 2 ) OT1494, P (O) (OT1495) (OT1496), Si (T1497 ) (T1498) (T1499) " 여기서, T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1496, T1497, T1498, T1499는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1454, T1455 및/또는 T1463, T1464 및/또는 T1476, T1477 및/또는 T1483, T1484 및/또는 T1492, T1493은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1495, T1495, T1495 T1497, T1498, T1499 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1454, T1455 and / or T1463, T1464 and / or T1476, T1477 and / or T1483, T1484 and / or T1492, T1493 are also in each case a" heterocycle Reels ", 여기서, 임의로, 치환 그룹(I)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1500, NT1501T1502, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1503, C(O)OT1504, C(O)NHT1505, C(O)NT1506T1507, OT1508, O(T1509-O)rvH(rv = 1, 2, 3, 4, 5), O(T1510-O)rvT1511 (rv = 1, 2, 3, 4, 5), OC(O)T1512, OC(O)OT1513, OC(O)NHT1514, OC(O)NT1515T1516, OP(O)(OT1517)(OT1518), OSi(T1519)(T1520)(T1521), OS(O2)T1522, NHC(O)T1523, NT1524C(O)T1525, NHC(O)OT1526, NHC(O)NHT1527, NHC(O)NT1528T1529, NT1530C(O)OT1531, NT1532C(O)NHT1533, NT1534C(O)NT1535T1536, NHS(O2)T1537, NT1538S(O2)T1539, ST1540, S(O)T1541, S(O2)T1542, S(O2)NHT1543, S(O2)NT1544T1545, S(O2)OT1546, P(O)(OT1547)(OT1548), Si(T1549)(T1550)(T1551)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1500, NT1501T1502, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1503, C (O) OT1504, C (O) NHT1505, C (O) NT1506T1507, OT1508, O (T1509-O) rv H (rv = 1, 2, 3, 4, 5), O (T1510-O) rv T1511 (rv = 1, 2, 3, 4, 5), OC (O) T1512, OC (O) OT1513, OC (O) NHT1514 , OC (O) NT1515T1516, OP (O) (OT1517) (OT1518), OSi (T1519) (T1520) (T1521), OS (O 2 ) T1522, NHC (O) T1523, NT1524C (O) T1525, NHC ( O) OT1526, NHC (O) NHT1527, NHC (O) NT1528T1529, NT1530C (O) OT1531, NT1532C (O) NHT1533, NT1534C (O) NT1535T1536, NHS (O 2 ) T1537, NT1538S (O 2 ) T1539, ST1540, S (O) T1541, S (O 2 ) T1542, S (O 2 ) NHT1543, S (O 2 ) NT1544T1545, S (O 2 ) OT1546, P (O) (OT1547) (OT1548), Si (T1549) ( T1550) (T1551) " 여기서, T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522, T1523, T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, T1548, T1549, T1550, T1551은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1506, T1507 및/또는 T1515, T1516 및/또는 T1528, T1529 및/또는 T1535, T1536 및/또는 T1544, T1545는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where: T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522, T1523 T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, 1553 T1549, T1550, T1551 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1506, T1507 and / or T1515, T1516 and / or T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클 릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1552, NT1553T1554, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1555, C(O)OT1556, C(O)NHT1557, C(O)NT1558T1559, OT1560, O(T1561-O)rwH (rw = 1, 2, 3, 4, 5), O(T1562-O)rwT1563 (rw = 1, 2, 3, 4, 5), OC(O)T1564, OC(O)OT1565, OC(O)NHT1566, OC(O)NT1567T1568, OP(O)(OT1569)(OT1570), OSi(T1571)(T1572)(T1573), OS(O2)T1574, NHC(O)T1575, NT1576C(O)T1577, NHC(O)OT1578, NHC(O)NHT1579, NHC(O)NT1580T1581, NT1582C(O)OT1583, NT1584C(O)NHT1585, NT1586C(O)NT1587T1588, NHS(O2)T1589, NT1590S(O2)T1591, ST1592, S(O)T1593, S(O2)T1594, S(O2)NHT1595, S(O2)NT1596T1597, S(O2)OT1598, P(O)(OT1599)(OT1600), Si(T1601)(T1602)(T1603)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1552, NT1553T1554, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1555, C (O) OT1556, C (O) NHT1557, C (O) NT1558T1559, OT1560, O (T1561-O) rw H (rw = 1, 2, 3, 4, 5), O (T1562-O) rw T1563 (rw = 1, 2, 3, 4, 5), OC (O) T1564, OC (O) OT1565, OC (O) NHT1566 , OC (O) NT1567T1568, OP (O) (OT1569) (OT1570), OSi (T1571) (T1572) (T1573), OS (O 2 ) T1574, NHC (O) T1575, NT1576C (O) T1577, NHC ( O) OT1578, NHC (O) NHT1579, NHC (O) NT1580T1581, NT1582C (O) OT1583, NT1584C (O) NHT1585, NT1586C (O) NT1587T1588, NHS (O 2 ) T1589, NT1590S (O 2 ) T1591, ST1592, S (O) T1593, S (O 2 ) T1594, S (O 2 ) NHT1595, S (O 2 ) NT1596T1597, S (O 2 ) OT1598, P (O) (OT1599) (OT1600), Si (T1601) ( T1602) (T1603) " 여기서, T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575, T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알 킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1558, T1559 및/또는 T1567, T1568 및/또는 T1580, T1581 및/또는 T1587, T1588 및/또는 T1596, T1597은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575 T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1599, T1599 T1601, T1602, T1603 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1558, T1559 and / or T1567, T1568 and / or T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 are also in each case" hetero " Cyclyl ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1604, NT1605T1606, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1607, C(O)OT1608, C(O)NHT1609, C(O)NT1610T1611, OT1612, O(T1613-O)rxH (rx = 1, 2, 3, 4, 5), O(T1614-O)rxT1615 (rx = 1, 2, 3, 4, 5), OC(O)T1616, OC(O)OT1617, OC(O)NHT1618, OC(O)NT1619T1620, OP(O)(OT1621)(OT1622), OSi(T1623)(T1624)(T1625), OS(O2)T1626, NHC(O)T1627, NT1628C(O)T1629, NHC(O)OT1630, NHC(O)NHT1631, NHC(O)NT1632T1633, NT1634C(O)OT1635, NT1636C(O)NHT1637, NT1638C(O)NT1639T1640, NHS(O2)T1641, NT1642S(O2)T1643, ST1644, S(O)T1645, S(O2)T1646, S(O2)NHT1647, S(O2)NT1648T1649, S(O2)OT1650, P(O)(OT1651)(OT1652), Si(T1653)(T1654)(T1655)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1604, NT1605T1606, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1607, C (O) OT1608, C (O) NHT1609, C (O) NT1610T1611, OT1612, O (T1613-O) rx H (rx = 1, 2, 3, 4, 5), O (T1614-O) rx T1615 (rx = 1, 2, 3, 4, 5), OC (O) T1616, OC (O) OT1617, OC (O) NHT1618 , OC (O) NT1619T1620, OP (O) (OT1621) (OT1622), OSi (T1623) (T1624) (T1625), OS (O 2 ) T1626, NHC (O) T1627, NT1628C (O) T1629, NHC ( O) OT1630, NHC (O) NHT1631, NHC (O) NT1632T1633, NT1634C (O) OT1635, NT1636C (O) NHT1637, NT1638C (O) NT1639T1640, NHS (O 2 ) T1641, NT1642S (O 2 ) T1643, ST1644, S (O) T1645, S (O 2 ) T1646, S (O 2 ) NHT1647, S (O 2 ) NT1648T1649, S (O 2 ) OT1650, P (O) (OT1651) (OT1652), Si (T1653) ( T1654) (T1655) " 여기서, T1604, T1605, T1606, T1607, T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651, T1652, T1653, T1654, T1655는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1610, T1611 및/또는 T1619, T1620 및/또는 T1632, T1633 및/또는 T1639, T1640 및/또는 T1648, T1649는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고, 여기서, 대안적으로, T1446, T1447은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Where: T1604, T1605, T1606, T1607, T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627 T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651, 2165 T1653, T1654, T1655 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1610, T1611 and / or T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 are also in each case" heterocycle. " Reel ", where, alternatively, T1446, T1447 together may also form" heterocyclyl ", (3) "C(Y8)NZ43Z44, C(=NZ45)Z46, C(Y9)NZ47Y10Z48"(3) "C (Y8) NZ43Z44, C (= NZ45) Z46, C (Y9) NZ47Y10Z48" 여기서, Y8, Y9, Y10은 각각 독립적으로 "O, S, =NH, =NZ49"로 이루어진 그룹으로부터 선택되고,Wherein Y8, Y9, Y10 are each independently selected from the group consisting of "O, S, = NH, = NZ49", 여기서, Z43, Z44, Z45, Z46, Z47, Z48, Z49 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein the Z43, Z44, Z45, Z46, Z47, Z48, Z49 radicals are each independently selected from the group consisting of: (I) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)알킬, C(O)(C9-C30)알킬, C(O)사이클로알킬, C(O)사이클로알킬알킬, C(O)아릴, C(O) 아릴알킬, C(O)헤테로아릴, C(O)헤테로아릴알킬, C(O)헤테로사이클릴, C(O)헤테로사이클릴알킬, S(O2)알킬, S(O2)(C9-C30)알킬, S(O2)사이클로알킬, S(O2)사이클로알킬알킬, S(O2)아릴, S(O2)아릴알킬, S(O2)헤테로아릴, S(O2)헤테로아릴알킬, S(O2)헤테로사이클릴, S(O2)헤테로사이클릴알킬"(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C 9 -C 30 ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O 2 ) (C 9 -C 30 ) alkyl, S (O 2 ) cyclo Alkyl, S (O 2 ) cycloalkylalkyl, S (O 2 ) aryl, S (O 2 ) arylalkyl, S (O 2 ) heteroaryl, S (O 2 ) heteroarylalkyl, S (O 2 ) heterocycle Reel, S (O 2 ) heterocyclylalkyl " 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (i) may also be independently substituted by one or more substituents, each independently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1656, NT1657T1658, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1659, C(O)OT1660, C(O)NHT1661, C(O)NT1662T1663, OT1664, O(T1665-O)ryH (ry = 1, 2, 3, 4, 5), O(T1666-O)ryT1667 (ry = 1, 2, 3, 4, 5), OC(O)T1668, OC(O)OT1669, OC(O)NHT1670, OC(O)NT1671T1672, OP(O)(OT1673)(OT1674), OSi(T1675)(T1676)(T1677), OS(O2)T1678, NHC(O)T1679, NT1680C(O)T1681, NHC(O)OT1682, NHC(O)NHT1683, NHC(O)NT1684T1685, NT1686C(O)OT1687, NT1688C(O)NHT1689, NT1690C(O)NT1691T1692, NHS(O2)T1693, NT1694S(O2)T1695, ST1696, S(O)T1697, S(O2)T1698, S(O2)NHT1699, S(O2)NT1700T1701, S(O2)OT1702, P(O)(OT1703)(OT1704), Si(T1705)(T1706)(T1707)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT 1656, NT1657T1658, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1659, C (O) OT1660, C (O) NHT1661, C (O) NT1662T1663, OT1664, O (T1665-O) ry H (ry = 1, 2, 3, 4, 5), O (T1666-O) ry T1667 (ry = 1, 2, 3, 4, 5), OC (O) T1668, OC (O) OT1669, OC (O) NHT1670 , OC (O) NT1671T1672, OP (O) (OT1673) (OT1674), OSi (T1675) (T1676) (T1677), OS (O 2 ) T1678, NHC (O) T1679, NT1680C (O) T1681, NHC ( O) OT1682, NHC (O) NHT1683, NHC (O) NT1684T1685, NT1686C (O) OT1687, NT1688C (O) NHT1689, NT1690C (O) NT1691T1692, NHS (O 2 ) T1693, NT1694S (O 2 ) T1695, ST1696, S (O) T1697, S (O 2 ) T1698, S (O 2 ) NHT1699, S (O 2 ) NT1700T1701, S (O 2 ) OT1702, P (O) (OT1703) (OT1704), Si (T1705) ( T1706) (T1707) " 여기서, T1656, T1657, T1658, T1659, T1660, T1661, T1662, T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679, T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694, T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702, T1703, T1704, T1705, T1706, T1707은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1662, T1663 및/또는 T1671, T1672 및/또는 T1684, T1685 및/또는 T1691, T1692 및/또는 T1700, T1701은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Here, T1656, T1657, T1658, T1659, T1660, T1661, T1662, T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679 T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694, T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702, T1703, T1705, T1706, T1707 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1662, T1663 and / or T1671, T1672 and / or T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1708, NT1709T1710, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1711, C(O)OT1712, C(O)NHT1713, C(O)NT1714T1715, OT1716, O(T1717-O)rzH (rz = 1, 2, 3, 4, 5), O(T1718-O)rzT1719 (rz = 1, 2, 3, 4, 5), OC(O)T1720, OC(O)OT1721, OC(O)NHT1722, OC(O)NT1723T1724, OP(O)(OT1725)(OT1726), OSi(T1727)(T1728)(T1729), OS(O2)T1730, NHC(O)T1731, NT1732C(O)T1733, NHC(O)OT1734, NHC(O)NHT1735, NHC(O)NT1736T1737, NT1738C(O)OT1739, NT1740C(O)NHT1741, NT1742C(O)NT1743T1744, NHS(O2)T1745, NT1746S(O2)T1747, ST1748, S(O)T1749, S(O2)T1750, S(O2)NHT1751, S(O2)NT1752T1753, S(O2)OT1754, P(O)(OT1755)(OT1756), Si(T1757)(T1758)(T1759)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT 1708, NT1709T1710, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1711, C (O) OT1712, C (O) NHT1713, C (O) NT1714T1715, OT1716, O (T1717-O) rz H (rz = 1, 2, 3, 4, 5), O (T1718-O) rz T1719 (rz = 1, 2, 3, 4, 5), OC (O) T1720, OC (O) OT1721, OC (O) NHT1722 , OC (O) NT1723T1724, OP (O) (OT1725) (OT1726), OSi (T1727) (T1728) (T1729), OS (O 2 ) T1730, NHC (O) T1731, NT1732C (O) T1733, NHC ( O) OT1734, NHC (O) NHT1735, NHC (O) NT1736T1737, NT1738C (O) OT1739, NT1740C (O) NHT1741, NT1742C (O) NT1743T1744, NHS (O 2 ) T1745, NT1746S (O 2 ) T1747, ST1748, S (O) T1749, S (O 2 ) T1750, S (O 2 ) NHT1751, S (O 2 ) NT1752T1753, S (O 2 ) OT1754, P (O) (OT1755) (OT1756), Si (T1757) ( T1758) (T1759) " 여기서, T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731, T1732, T1733, T1734, T1735, T1736, T1737, T1738, T1739, T1740, T1741, T1742, T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1714, T1715 및/또는 T1723, T1724 및/또는 T1736, T1737 및/또는 T1743, T1744 및/또는 T1752, T1753은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731 T1732, T1733, T1734, T1735, T1736, T1737, T1738, T1739, T1740, T1741, T1742, T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1755, T1757, T1758, T1759 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1714, T1715 and / or T1723, T1724 and / or T1736, T1737 and / or T1743, T1744 and / or T1752, T1753 are also in each case a" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHT1760, NT1761T1762, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)T1763, C(O)OT1764, C(O)NHT1765, C(O)NT1766T1767, OT1768, O(T1769-O)raH (ra = 1, 2, 3, 4, 5), O(T1770-O)raT1771 (ra = 1, 2, 3, 4, 5), OC(O)T1772, OC(O)OT1773, OC(O)NHT1774, OC(O)NT1775T1776, OP(O)(OT1777)(OT1778), OSi(T1779)(T1780)(T1781), OS(O2)T1782, NHC(O)T1783, NT1784C(O)T1785, NHC(O)OT1786, NHC(O)NHT1787, NHC(O)NT1788T1789, NT1790C(O)OT1791, NT1792C(O)NHT1793, NT1794C(O)NT1795T1796, NHS(O2)T1797, NT1798S(O2)T1799, ST1800, S(O)T1801, S(O2)T1802, S(O2)NHT1803, S(O2)NT1804T1805, S(O2)OT1806, P(O)(OT1807)(OT1808), Si(T1809)(T1810)(T1811)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHT1760, NT1761T1762, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) T1763, C (O) OT1764, C (O) NHT1765, C (O) NT1766T1767, OT1768, O (T1769-O) ra H (ra = 1, 2, 3, 4, 5), O (T1770-O) ra T1771 (ra = 1, 2, 3, 4, 5), OC (O) T1772, OC (O) OT1773, OC (O) NHT1774 , OC (O) NT1775T1776, OP (O) (OT1777) (OT1778), OSi (T1779) (T1780) (T1781), OS (O 2 ) T1782, NHC (O) T1783, NT1784C (O) T1785, NHC ( O) OT1786, NHC (O) NHT1787, NHC (O) NT1788T1789, NT1790C (O) OT1791, NT1792C (O) NHT1793, NT1794C (O) NT1795T1796, NHS (O 2 ) T1797, NT1798S (O 2 ) T1799, ST1800, S (O) T1801, S (O 2 ) T1802, S (O 2 ) NHT1803, S (O 2 ) NT1804T1805, S (O 2 ) OT1806, P (O) (OT1807) (OT1808), Si (T1809) ( T1810) (T1811) " 여기서, T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783, T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1808, T1809, T1810, T1811은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, T1766, T1767 및/또는 T1775, T1776 및/또는 T1788, T1789 및/또는 T1795, T1796 및/또는 T1804, T1805는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where: T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783 T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1807, T1809, T1810, T1811 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1766, T1767 and / or T1775, T1776 and / or T1788, T1789 and / or T1795, T1796 and / or T1804, T1805 are also in each case" heterocycle Reels ", And Z3, Z4 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z3 and Z4 radicals are each independently selected from the group consisting of: (e) 수소;(e) hydrogen; (f) 할로겐, F, Cl, Br, I;(f) halogen, F, Cl, Br, I; (g) 치환되지 않거나 치환된 알킬 또는 (C9-C30)알킬, 여기서, 임의로, 알킬 또는 (C9-C30)알킬 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (C 9 -C 30 ) alkyl radical is selected by one or more substituents identically or differently selected from the group consisting of Can be substituted: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB457, NB458B459, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B460, C(O)OB461, C(O)NHB462, C(O)NB463B464, OB465, O(B466-O)xH (x = 1, 2, 3, 4, 5), O(B467-O)xB468 (x = 1, 2, 3, 4, 5), OC(O)B469, OC(O)OB470, OC(O)NHB471, OC(O)NB472B473, OP(O)(OB474)(OB475), OSi(B476)(B477)(B478), OS(O2)B479, NHC(O)B480, NB481C(O)B482, NHC(O)OB483, NHC(O)NHB484, NHC(O)NB485B486, NB487C(O)OB488, NB489C(O)NHB490, NB491C(O)NB492B493, NHS(O2)B494, NB495S(O2)B496, SB497, S(O)B498, S(O2)B499, S(O2)NHB500, S(O2)NB501B502, S(O2)OB503, P(O)(OB504)(OB505), Si(B506)(B507)(B508)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB457, NB458B459, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B460, C (O) OB461, C (O) NHB462, C (O) NB463B464, OB465, O (B466-O) x H (x = 1, 2, 3, 4, 5), O (B467-O) x B468 (x = 1, 2, 3, 4, 5), OC (O) B469, OC (O) OB470, OC (O) NHB471 , OC (O) NB472B473, OP (O) (OB474) (OB475), OSi (B476) (B477) (B478), OS (O 2 ) B479, NHC (O) B480, NB481C (O) B482, NHC ( O) OB483, NHC (O) NHB484, NHC (O) NB485B486, NB487C (O) OB488, NB489C (O) NHB490, NB491C (O) NB492B493, NHS (O2) B494, NB495S (O2) B496, SB497, S ( O) B498, S (O2) B499, S (O 2 ) NHB500, S (O 2 ) NB501B502, S (O 2 ) OB503, P (O) (OB504) (OB505), Si (B506) (B507) ( B508) " 여기서, B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B463, B464 및/또는 B472, B473 및/또는 B485, B486 및/또는 B492, B493 및/또는 B501, B502는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B463, B464 and / or B472, B473 and / or B485, B486 and / or B492, B493 and / or B501, B502 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB509, NB510B511, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B512, C(O)OB513, C(O)NHB514, C(O)NB515B516, OB517, O(B518-O)yH (y = 1, 2, 3, 4, 5), O(B519-O)yB520 (y = 1, 2, 3, 4, 5), OC(O)B521, OC(O)OB522, OC(O)NHB523, OC(O)NB524B525, OP(O)(OB526)(OB527), OSi(B528)(B529)(B530), OS(O2)B531, NHC(O)B532, NB533C(O)B534, NHC(O)OB535, NHC(O)NHB536, NHC(O)NB537B538, NB539C(O)OB540, NB541C(O)NHB542, NB543C(O)NB544B545, NHS(O2)B546, NB547S(O2)B548, SB549, S(O)B550, S(O2)B551, S(O2)NHB552, S(O2)NB553B554, S(O2)OB555, P(O)(OB556)(OB557), Si(B558)(B559)(B560)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB509, NB510B511, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B512, C (O) OB513, C (O) NHB514, C (O) NB515B516, OB517, O (B518-O) y H (y = 1, 2, 3, 4, 5), O (B519-O) y B520 (y = 1, 2, 3, 4, 5), OC (O) B521, OC (O) OB522, OC (O) NHB523 , OC (O) NB524B525, OP (O) (OB526) (OB527), OSi (B528) (B529) (B530), OS (O 2 ) B531, NHC (O) B532, NB533C (O) B534, NHC ( O) OB535, NHC (O) NHB536, NHC (O) NB537B538, NB539C (O) OB540, NB541C (O) NHB542, NB543C (O) NB544B545, NHS (O2) B546, NB547S (O2) B548, SB549, S ( O) B550, S (O2) B551, S (O 2 ) NHB552, S (O 2 ) NB553B554, S (O 2 ) OB555, P (O) (OB556) (OB557), Si (B558) (B559) ( B560) " 여기서, B509, B510, B511, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이 클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B515, B516 및/또는 B524, B525 및/또는 B537, B538 및/또는 B544, B545 및/또는 B553, B554는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B509, B510, B511, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B515, B516 and / or B524, B525 and / or B537, B538 and / or B544, B545 and / or B553, B554 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB561, NB562B563, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B564, C(O)OB565, C(O)NHB566, C(O)NB567B568, OB569, O(B570-O)zH (z = 1, 2, 3, 4, 5), O(B571-O)zB572 (z = 1, 2, 3, 4, 5), OC(O)B573, OC(O)OB574, OC(O)NHB575, OC(O)NB576B577, OP(O)(OB578)(OB579), OSi(B580)(B581)(B582), OS(O2)B583, NHC(O)B584, NB585C(O)B586, NHC(O)OB587, NHC(O)NHB588, NHC(O)NB589B590, NB591C(O)OB592, NB593C(O)NHB594, NB595C(O)NB596B597, NHS(O2)B598, NB599S(O2)B600, SB601, S(O)B602, S(O2)B603, S(O2)NHB604, S(O2)NB605B606, S(O2)OB607, P(O)(OB608)(OB609), Si(B610)(B611)(B612)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB561, NB562B563, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B564, C (O) OB565, C (O) NHB566, C (O) NB567B568, OB569, O (B570-O) z H (z = 1, 2, 3, 4, 5), O (B571-O) z B572 (z = 1, 2, 3, 4, 5), OC (O) B573, OC (O) OB574, OC (O) NHB575 , OC (O) NB576B577, OP (O) (OB578) (OB579), OSi (B580) (B581) (B582), OS (O 2 ) B583, NHC (O) B584, NB585C (O) B586, NHC ( O) OB587, NHC (O) NHB588, NHC (O) NB589B590, NB591C (O) OB592, NB593C (O) NHB594, NB595C (O) NB596B597, NHS (O2) B598, NB599S (O2) B600, SB601, S ( O) B602, S (O2) B603, S (O 2 ) NHB604, S (O 2 ) NB605B606, S (O 2 ) OB607, P (O) (OB608) (OB609), Si (B610) (B611) ( B612) " 여기서, B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B567, B568 및/또는 B576, B577 및/또는 B589, B590 및/또는 B596, B597 및/또는 B605, B606은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B567, B568 and / or B576, B577 and / or B589, B590 and / or B596, B597 and / or B605, B606 are also in each case" heterocycle. " Reels ", (h) 치환되지 않거나 치환된 아릴, 여기서, 임의로, 아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB613, NB614B615, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B616, C(O)OB617, C(O)NHB618, C(O)NB619B620, OB621, O(B622-O)aH (a = 1, 2, 3, 4, 5), O(B623-O)aB624 (a = 1, 2, 3, 4, 5), OC(O)B625, OC(O)OB626, OC(O)NHB627, OC(O)NB628B629, OP(O)(OB630)(OB631), OSi(B632)(B633)(B634), OS(O2)B635, NHC(O)B636, NB637C(O)B638, NHC(O)OB639, NHC(O)NHB640, NHC(O)NB641B642, NB643C(O)OB644, NB645C(O)NHB646, NB647C(O)NB648B649, NHS(O2)B650, NB651S(O2)B652, SB653, S(O)B654, S(O2)B655, S(O2)NHB656, S(O2)NB657B658, S(O2)OB659, P(O)(OB660)(OB661), Si(B662)(B663)(B664)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB613, NB614B615, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B616, C (O) OB617, C (O) NHB618, C (O) NB619B620, OB621, O (B622-O) a H (a = 1, 2, 3, 4, 5), O (B623-O) a B624 (a = 1, 2, 3, 4, 5), OC (O) B625, OC (O) OB626, OC (O) NHB627 , OC (O) NB628B629, OP (O) (OB630) (OB631), OSi (B632) (B633) (B634), OS (O 2 ) B635, NHC (O) B636, NB637C (O) B638, NHC ( O) OB639, NHC (O) NHB640, NHC (O) NB641B642, NB643C (O) OB644, NB645C (O) NHB646, NB647C (O) NB648B649, NHS (O2) B650, NB651S (O2) B652, SB653, S ( O) B654, S (O2) B655, S (O 2 ) NHB656, S (O 2 ) NB657B658, S (O 2 ) OB659, P (O) (OB660) (OB661), Si (B662) (B663) ( B664) " 여기서, B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B619, B620 및/또는 B628, B629 및/또는 B641, B642 및/또는 B648, B649 및/또는 B657, B658은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B619, B620 and / or B628, B629 and / or B641, B642 and / or B648, B649 and / or B657, B658 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB665, NB666B667, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B668, C(O)OB669, C(O)NHB670, C(O)NB671B672, OB673, O(B674-O)bH (b = 1, 2, 3, 4, 5), O(B675-O)bB676 (b = 1, 2, 3, 4, 5), OC(O)B677, OC(O)OB678, OC(O)NHB679, OC(O)NB680B681, OP(O)(OB682)(OB683), OSi(B684)(B685)(B686), OS(O2)B687, NHC(O)B688, NB689C(O)B690, NHC(O)OB691, NHC(O)NHB692, NHC(O)NB693B694, NB695C(O)OB696, NB697C(O)NHB698, NB699C(O)NB700B701, NHS(O2)B702, NB703S(O2)B704, SB705, S(O)B706, S(O2)B707, S(O2)NHB708, S(O2)NB709B710, S(O2)OB711, P(O)(OB712)(OB713), Si(B714)(B715)(B716)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB665, NB666B667, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B668, C (O) OB669, C (O) NHB670, C (O) NB671B672, OB673, O (B674-O) b H (b = 1, 2, 3, 4, 5), O (B675-O) b B676 (b = 1, 2, 3, 4, 5), OC (O) B677, OC (O) OB678, OC (O) NHB679 , OC (O) NB680B681, OP (O) (OB682) (OB683), OSi (B684) (B685) (B686), OS (O 2 ) B687, NHC (O) B688, NB689C (O) B690, NHC ( O) OB691, NHC (O) NHB692, NHC (O) NB693B694, NB695C (O) OB696, NB697C (O) NHB698, NB699C (O) NB700B701, NHS (O2) B702, NB703S (O2) B704, SB705, S ( O) B706, S (O2) B707, S (O 2 ) NHB708, S (O 2 ) NB709B710, S (O 2 ) OB711, P (O) (OB712) (OB713), Si (B714) (B715) ( B716) " 여기서, B665, B666, B667, B668, B669, B670, B671, B672, B673, B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B711, B712, B713, B714, B715, B716은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B671, B672 및/또는 B680, B681 및/또는 B693, B694 및/또는 B700, B701 및/또는 B709, B710은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B665, B666, B667, B668, B669, B670, B671, B672, B673, B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B711, B712, B713, B714, B715, B716 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B671, B672 and / or B680, B681 and / or B693, B694 and / or B700, B701 and / or B709, B710 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB717, NB718B719, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B720, C(O)OB721, C(O)NHB722, C(O)NB723B724, OB725, O(B726-O)cH (c = 1, 2, 3, 4, 5), O(B727-O)cB728 (c = 1, 2, 3, 4, 5), OC(O)B729, OC(O)OB730, OC(O)NHB731, OC(O)NB732B733, OP(O)(OB734)(OB735), OSi(B736)(B737)(B738), OS(O2)B739, NHC(O)B740, NB741C(O)B742, NHC(O)OB743, NHC(O)NHB744, NHC(O)NB745B746, NB747C(O)OB748, NB749C(O)NHB750, NB751C(O)NB752B753, NHS(O2)B754, NB755S(O2)B756, SB757, S(O)B758, S(O2)B759, S(O2)NHB760, S(O2)NB761B762, S(O2)OB763, P(O)(OB764)(OB765), Si(B766)(B767)(B768)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB717, NB718B719, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B720, C (O) OB721, C (O) NHB722, C (O) NB723B724, OB725, O (B726-O) c H (c = 1, 2, 3, 4, 5), O (B727-O) c B728 (c = 1, 2, 3, 4, 5), OC (O) B729, OC (O) OB730, OC (O) NHB731 , OC (O) NB732B733, OP (O) (OB734) (OB735), OSi (B736) (B737) (B738), OS (O 2 ) B739, NHC (O) B740, NB741C (O) B742, NHC ( O) OB743, NHC (O) NHB744, NHC (O) NB745B746, NB747C (O) OB748, NB749C (O) NHB750, NB751C (O) NB752B753, NHS (O2) B754, NB755S (O2) B756, SB757, S ( O) B758, S (O2) B759, S (O 2 ) NHB760, S (O 2 ) NB761B762, S (O 2 ) OB763, P (O) (OB764) (OB765), Si (B766) (B767) ( B768) " 여기서, B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: " 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B723, B724 및/또는 B732, B733 및/또는 B745, B746 및/또는 B752, B753 및/또는 B761, B762는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B723, B724 and / or B732, B733 and / or B745, B746 and / or B752, B753 and / or B761, B762 are also in each case" heterocycle. " Reels ", (j) 치환되지 않거나 치환된 헤테로아릴 여기서, 임의로, 헤테로아릴 라디칼은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of: (i) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB769, NB770B771, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B772, C(O)OB773, C(O)NHB774, C(O)NB775B776, OB777, O(B778-O)dH (d = 1, 2, 3, 4, 5), O(B779-O)dB780 (d = 1, 2, 3, 4, 5), OC(O)B781, OC(O)OB782, OC(O)NHB783, OC(O)NB784B785, OP(O)(OB786)(OB787), OSi(B788)(B789)(B790), OS(O2)B791, NHC(O)B792, NB793C(O)B794, NHC(O)OB795, NHC(O)NHB796, NHC(O)NB797B798, NB799C(O)OB800, NB801C(O)NHB802, NB803C(O)NB804B805, NHS(O2)B806, NB807S(O2)B808, SB809, S(O)B810, S(O2)B811, S(O2)NHB812, S(O2)NB813B814, S(O2)OB815, P(O)(OB816)(OB817), Si(B818)(B819)(B820)"(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB769, NB770B771, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B772, C (O) OB773, C (O) NHB774, C (O) NB775B776, OB777, O (B778-O) d H (d = 1, 2, 3, 4, 5), O (B779-O) d B780 (d = 1, 2, 3, 4, 5), OC (O) B781, OC (O) OB782, OC (O) NHB783 , OC (O) NB784B785, OP (O) (OB786) (OB787), OSi (B788) (B789) (B790), OS (O 2 ) B791, NHC (O) B792, NB793C (O) B794, NHC ( O) OB795, NHC (O) NHB796, NHC (O) NB797B798, NB799C (O) OB800, NB801C (O) NHB802, NB803C (O) NB804B805, NHS (O2) B806, NB807S (O2) B808, SB809, S ( O) B810, S (O2) B811, S (O 2 ) NHB812, S (O 2 ) NB813B814, S (O 2 ) OB815, P (O) (OB816) (OB817), Si (B818) (B819) ( B820) " 여기서, B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B811, B812, B813, B814, B815, B816, B817, B818, B819, B820은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B775, B776 및/또는 B784, B785 및/또는 B797, B798 및/또는 B804, B805 및/또는 B813, B814는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B811, B812, B813, B814, B815, B816, B817, B818, B819, B820 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B775, B776 and / or B784, B785 and / or B797, B798 and / or B804, B805 and / or B813, B814 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB821, NB822B823, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B824, C(O)OB825, C(O)NHB826, C(O)NB827B828, OB829, O(B830-O)eH (e = 1, 2, 3, 4, 5), O(B831-O)eB832 (e = 1, 2, 3, 4, 5), OC(O)B833, OC(O)OB834, OC(O)NHB835, OC(O)NB836B837, OP(O)(OB838)(OB839), OSi(B840)(B841)(B842), OS(O2)B843, NHC(O)B844, NB845C(O)B846, NHC(O)OB847, NHC(O)NHB848, NHC(O)NB849B850, NB851C(O)OB852, NB853C(O)NHB854, NB855C(O)NB856B857, NHS(O2)B858, NB859S(O2)B860, SB861, S(O)B862, S(O2)B863, S(O2)NHB864, S(O2)NB865B866, S(O2)OB867, P(O)(OB868)(OB869), Si(B870)(B871)(B872)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB821, NB822B823, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B824, C (O) OB825, C (O) NHB826, C (O) NB827B828, OB829, O (B830-O) e H (e = 1, 2, 3, 4, 5), O (B831-O) e B832 (e = 1, 2, 3, 4, 5), OC (O) B833, OC (O) OB834, OC (O) NHB835 , OC (O) NB836B837, OP (O) (OB838) (OB839), OSi (B840) (B841) (B842), OS (O 2 ) B843, NHC (O) B844, NB845C (O) B846, NHC ( O) OB847, NHC (O) NHB848, NHC (O) NB849B850, NB851C (O) OB852, NB853C (O) NHB854, NB855C (O) NB856B857, NHS (O2) B858, NB859S (O2) B860, SB861, S ( O) B862, S (O2) B863, S (O 2 ) NHB864, S (O 2 ) NB865B866, S (O 2 ) OB867, P (O) (OB868) (OB869), Si (B870) (B871) ( B872) " 여기서, B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856,B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869, B870, B871, B872는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B827, B828 및/또는 B836, B837 및/또는 B849, B850 및/또는 B856, B857 및/또는 B865, B866은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869, B870, B871, B872 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B827, B828 and / or B836, B837 and / or B849, B850 and / or B856, B857 and / or B865, B866 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB873, NB874B875, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B876, C(O)OB877, C(O)NHB878, C(O)NB879B880, OB881, O(B882-O)fH (f = 1, 2, 3, 4, 5), O(B883-O)fB884 (f = 1, 2, 3, 4, 5), OC(O)B885, OC(O)OB886, OC(O)NHB887, OC(O)NB888B889, OP(O)(OB890)(OB891), OSi(B892)(B893)(B894), OS(O2)B895, NHC(O)B896, NB897C(O)B898, NHC(O)OB899, NHC(O)NHB900, NHC(O)NB901B902, NB903C(O)OB904, NB905C(O)NHB906, NB907C(O)NB908B909, NHS(O2)B910, NB911S(O2)B912, SB913, S(O)B914, S(O2)B915, S(O2)NHB916, S(O2)NB917B918, S(O2)OB919, P(O)(OB920)(OB921), Si(B922)(B923)(B924)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB873, NB874B875, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B876, C (O) OB877, C (O) NHB878, C (O) NB879B880, OB881, O (B882-O) f H (f = 1, 2, 3, 4, 5), O (B883-O) f B884 (f = 1, 2, 3, 4, 5), OC (O) B885, OC (O) OB886, OC (O) NHB887 , OC (O) NB888B889, OP (O) (OB890) (OB891), OSi (B892) (B893) (B894), OS (O 2 ) B895, NHC (O) B896, NB897C (O) B898, NHC ( O) OB899, NHC (O) NHB900, NHC (O) NB901B902, NB903C (O) OB904, NB905C (O) NHB906, NB907C (O) NB908B909, NHS (O2) B910, NB911S (O2) B912, SB913, S ( O) B914, S (O2) B915, S (O 2 ) NHB916, S (O 2 ) NB917B918, S (O 2 ) OB919, P (O) (OB920) (OB921), Si (B922) (B923) ( B924) " 여기서, B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B879, B880 및/또는 B888, B889 및/또는 B901, B902 및/또는 B908, B909 및/또는 B917, B918은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B879, B880 and / or B888, B889 and / or B901, B902 and / or B908, B909 and / or B917, B918 are also in each case" heterocycle Reels ", (k) OZ6, 여기서, Z6은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(k) OZ6, wherein Z6 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB925, NB926B927, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B928, C(O)OB929, C(O)NHB930, C(O)NB931B932, OB933, O(B934-O)gH (g = 1, 2, 3, 4, 5), O(B935-O)gB936 (g = 1, 2, 3, 4, 5), OC(O)B937, OC(O)OB938, OC(O)NHB939, OC(O)NB940B941, OP(O)(OB942)(OB943), OSi(B944)(B945)(B946), OS(O2)B947, NHC(O)B948, NB949C(O)B950, NHC(O)OB951, NHC(O)NHB952, NHC(O)NB953B954, NB955C(O)OB956, NB957C(O)NHB958, NB959C(O)NB960B961, NHS(O2)B962, NB963S(O2)B964, SB965, S(O)B966, S(O2)B967, S(O2)NHB968, S(O2)NB969B970, S(O2)OB971, P(O)(OB972)(OB973), Si(B974)(B975)(B976)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB925, NB926B927, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B928, C (O) OB929, C (O) NHB930, C (O) NB931B932, OB933, O (B934-O) g H (g = 1, 2, 3, 4, 5), O (B935-O) g B936 (g = 1, 2, 3, 4, 5), OC (O) B937, OC (O) OB938, OC (O) NHB939 , OC (O) NB940B941, OP (O) (OB942) (OB943), OSi (B944) (B945) (B946), OS (O 2 ) B947, NHC (O) B948, NB949C (O) B950, NHC ( O) OB951, NHC (O) NHB952, NHC (O) NB953B954, NB955C (O) OB956, NB957C (O) NHB958, NB959C (O) NB960B961, NHS (O2) B962, NB963S (O2) B964, SB965, S ( O) B966, S (O2) B967, S (O 2 ) NHB968, S (O 2 ) NB969B970, S (O 2 ) OB971, P (O) (OB972) (OB973), Si (B974) (B975) ( B976) " 여기서, B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946,B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973, B974, B975, B976은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B931, B932 및/또는 B940, B941 및/또는 B953, B954 및/또는 B960, B961 및/또는 B969, B970은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973, B974, B975, B976 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B931, B932 and / or B940, B941 and / or B953, B954 and / or B960, B961 and / or B969, B970 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB977, NB978B979, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B980, C(O)OB981, C(O)NHB982, C(O)NB983B984, OB985, O(B986-O)hH (h = 1, 2, 3, 4, 5), O(B987-O)hB988 (h = 1, 2, 3, 4, 5), OC(O)B989, OC(O)OB990, OC(O)NHB991, OC(O)NB992B993, OP(O)(OB994)(OB995), OSi(B996)(B997)(B998), OS(O2)B999, NHC(O)B1000, NB1001C(O)B1002, NHC(O)OB1003, NHC(O)NHB1004, NHC(O)NB1005B1006, NB1007C(O)OB1008, NB1009C(O)NHB1010, NB1011C(O)NB1012B1013, NHS(O2)B1014, NB1015S(O2)B1016, SB1017, S(O)B1018, S(O2)B1019, S(O2)NHB1020, S(O2)NB1021B1022, S(O2)OB1023, P(O)(OB1024)(OB1025), Si(B1026)(B1027)(B1028)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB977, NB978B979, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B980, C (O) OB981, C (O) NHB982, C (O) NB983B984, OB985, O (B986-O) h H (h = 1, 2, 3, 4, 5), O (B987-O) h B988 (h = 1, 2, 3, 4, 5), OC (O) B989, OC (O) OB990, OC (O) NHB991 , OC (O) NB992B993, OP (O) (OB994) (OB995), OSi (B996) (B997) (B998), OS (O 2 ) B999, NHC (O) B1000, NB1001C (O) B1002, NHC ( O) OB1003, NHC (O) NHB1004, NHC (O) NB1005B1006, NB1007C (O) OB1008, NB1009C (O) NHB1010, NB1011C (O) NB1012B1013, NHS (O2) B1014, NB1015S (O2) B1016, SB1017, SB1017 O) B1018, S (O2) B1019, S (O 2 ) NHB1020, S (O 2 ) NB1021B1022, S (O 2 ) OB1023, P (O) (OB1024) (OB1025), Si (B1026) (B1027) ( B1028) " 여기서, B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001, B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B1011, B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021, B1022, B1023, B1024, B1025, B1026, B1027, B1028은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B983, B984 및/또는 B992, B993 및/또는 B1005, B1006 및/또는 B1012, B1013 및/또는 B1021, B1022는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001, B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B1011, B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021, B1022, B1023, B1024, B1024 B1026, B1027, B1028 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B983, B984 and / or B992, B993 and / or B1005, B1006 and / or B1012, B1013 and / or B1021, B1022 are also in each case" heterocycle Reels ", (l) SZ7, 여기서, Z7은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(l) SZ7, wherein Z7 is independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1029, NB1030B1031, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1032, C(O)OB1033, C(O)NHB1034, C(O)NB1035B1036, OB1037, O(B1038-O)iH (i = 1, 2, 3, 4, 5), O(B1039-O)iB1040 (i = 1, 2, 3, 4, 5), OC(O)B1041, OC(O)OB1042, OC(O)NHB1043, OC(O)NB1044B1045, OP(O)(OB1046)(OB1047), OSi(B1048)(B1049)(B1050), OS(O2)B1051, NHC(O)B1052, NB1053C(O)B1054, NHC(O)OB1055, NHC(O)NHB1056, NHC(O)NB1057B1058, NB1059C(O)OB1060, NB1061C(O)NHB1062, NB1063C(O)NB1064B1065, NHS(O2)B1066, NB1067S(O2)B1068, SB1069, S(O)B1070, S(O2)B1071, S(O2)NHB1072, S(O2)NB1073B1074, S(O2)OB1075, P(O)(OB1076)(OB1077), Si(B1078)(B1079)(B1080)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1029, NB1030B1031, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1032, C (O) OB1033, C (O) NHB1034, C (O) NB1035B1036, OB1037, O (B1038-O) i H (i = 1, 2, 3, 4, 5), O (B1039-O) i B1040 (i = 1, 2, 3, 4, 5), OC (O) B1041, OC (O) OB1042, OC (O) NHB1043 , OC (O) NB1044B1045, OP (O) (OB1046) (OB1047), OSi (B1048) (B1049) (B1050), OS (O 2 ) B1051, NHC (O) B1052, NB1053C (O) B1054, NHC ( O) OB1055, NHC (O) NHB1056, NHC (O) NB1057B1058, NB1059C (O) OB1060, NB1061C (O) NHB1062, NB1063C (O) NB1064B1065, NHS (O2) B1066, NB1067S (O2) B1068, SB1069, SB1069 O) B1070, S (O2) B1071, S (O 2 ) NHB1072, S (O 2 ) NB1073B1074, S (O 2 ) OB1075, P (O) (OB1076) (OB1077), Si (B1078) (B1079) ( B1080) " 여기서, B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041, B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051, B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1078, B1079, B1080은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1035, B1036 및/또는 B1044, B1045 및/또는 B1057, B1058 및/또는 B1064, B1065 및/또는 B1073, B1074는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041, B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051, B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1077 B1078, B1079, B1080 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1035, B1036 and / or B1044, B1045 and / or B1057, B1058 and / or B1064, B1065 and / or B1073, B1074 are also in each case a" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1081, NB1082B1083, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1084, C(O)OB1085, C(O)NHB1086, C(O)NB1087B1088, OB1089, O(B1090-O)jH (j = 1, 2, 3, 4, 5), O(B1091-O)jB1092 (j = 1, 2, 3, 4, 5), OC(O)B1093, OC(O)OB1094, OC(O)NHB1095, OC(O)NB1096B1097, OP(O)(OB1098)(OB1099), OSi(B1100)(B1101)(B1102), OS(O2)B1103, NHC(O)B1104, NB1105C(O)B1106, NHC(O)OB1107, NHC(O)NHB1108, NHC(O)NB1109B1110, NB1111C(O)OB1112, NB1113C(O)NHB1114, NB1115C(O)NB1116B1117, NHS(O2)B1118, NB1119S(O2)B1120, SB1121, S(O)B1122, S(O2)B1123, S(O2)NHB1124, S(O2)NB1125B1126, S(O2)OB1127, P(O)(OB1128)(OB1129), Si(B1130)(B1131)(B1132)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1081, NB1082B1083, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1084, C (O) OB1085, C (O) NHB1086, C (O) NB1087B1088, OB1089, O (B1090-O) j H (j = 1, 2, 3, 4, 5), O (B1091-O) j B1092 (j = 1, 2, 3, 4, 5), OC (O) B1093, OC (O) OB1094, OC (O) NHB1095 , OC (O) NB1096B1097, OP (O) (OB1098) (OB1099), OSi (B1100) (B1101) (B1102), OS (O 2 ) B1103, NHC (O) B1104, NB1105C (O) B1106, NHC ( O) OB1107, NHC (O) NHB1108, NHC (O) NB1109B1110, NB1111C (O) OB1112, NB1113C (O) NHB1114, NB1115C (O) NB1116B1117, NHS (O2) B1118, NB1119S (O2) B1120, SB112 O) B1122, S (O2) B1123, S (O 2 ) NHB1124, S (O 2 ) NB1125B1126, S (O 2 ) OB1127, P (O) (OB1128) (OB1129), Si (B1130) (B1131) ( B1132) " 여기서, B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095, B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104, B1105, B1106, B1107, B1108, B1109, B1110, B1111, B1112, B1113, B1114, B1115, B1116, B1117, B1118, B1119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1129, B1130, B1131, B1132는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1087, B1088 및/또는 B1096, B1097 및/또는 B1109, B1110 및/또는 B1116, B1117 및/또는 B1125, B1126은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095, B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104 B1105, B1106, B1107, B1108, B1109, B1110, B1111, B1112, B1113, B1114, B1115, B1116, B1117, B1118, B1119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1128, B1128 B1130, B1131, B1132 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1087, B1088 and / or B1096, B1097 and / or B1109, B1110 and / or B1116, B1117 and / or B1125, B1126 are also in each case" heterocycle. " Reels ", (m) NZ8Z9, 여기서, Z8, Z9는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, C(O)B1133, C(O)OB1134, C(O)NB1135B1136, S(O2)B1137, S(O2)OB1138"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) B1133 , C (O) OB1134, C (O) NB1135B1136, S (O2) B1137, S (O 2 ) OB1138 " 여기서, B1133, B1134, B1135, B1136, B1137, B1138은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: 수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1135, B1136은 함께 또한 "헤테로사이클릴"을 형성할 수 있고,Wherein B1133, B1134, B1135, B1136, B1137, B1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C9-C30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl Alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, B1135, B1136 together may also form" heterocyclyl ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1139, NB1140B1141, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1142, C(O)OB1143, C(O)NHB1144, C(O)NB1145B1146, OB1147, O(B1148-O)kH (k = 1, 2, 3, 4, 5), O(B1149-O)kB1150 (k = 1, 2, 3, 4, 5), OC(O)B1151, OC(O)OB1152, OC(O)NHB1153, OC(O)NB1154B1155, OP(O)(OB1156)(OB1157), OSi(B1158)(B1159)(B1160), OS(O2)B1161, NHC(O)B1162, NB1163C(O)B1164, NHC(O)OB1165, NHC(O)NHB1166, NHC(O)NB1167B1168, NB1169C(O)OB1170, NB1171C(O)NHB1172, NB1173C(O)NB1174B1175, NHS(O2)B1176, NB1177S(O2)B1178, SB1179, S(O)B1180, S(O2)B1181, S(O2)NHB1182, S(O2)NB1183B1184, S(O2)OB1185, P(O)(OB1186)(OB1187), Si(B1188)(B1189)(B1190)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1139, NB1140B1141, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1142, C (O) OB1143, C (O) NHB1144, C (O) NB1145B1146, OB1147, O (B1148-O) k H (k = 1, 2, 3, 4, 5), O (B1149-O) k B1150 (k = 1, 2, 3, 4, 5), OC (O) B1151, OC (O) OB1152, OC (O) NHB1153 , OC (O) NB1154B1155, OP (O) (OB1156) (OB1157), OSi (B1158) (B1159) (B1160), OS (O 2 ) B1161, NHC (O) B1162, NB1163C (O) B1164, NHC ( O) OB1165, NHC (O) NHB1166, NHC (O) NB1167B1168, NB1169C (O) OB1170, NB1171C (O) NHB1172, NB1173C (O) NB1174B1175, NHS (O2) B1176, NB1177S (O2) B1178, SB1179 O) B1180, S (O2) B1181, S (O 2 ) NHB1182, S (O 2 ) NB1183B1184, S (O 2 ) OB1185, P (O) (OB1186) (OB1187), Si (B1188) (B1189) ( B1190) " 여기서, B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1187, B1188, B1189, B1190은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1145, B1146 및/또는 B1154, B1155 및/또는 B1167, B1168 및/또는 B1174, B1175 및/또는 B1183, B1184는 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1186, B1186, B1186 B1188, B1189, B1190 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1145, B1146 and / or B1154, B1155 and / or B1167, B1168 and / or B1174, B1175 and / or B1183, B1184 are also in each case" heterocycle Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHB1191, NB1192B1193, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)B1194, C(O)OB1195, C(O)NHB1196, C(O)NB1197B1198, OB1199, O(B1200-O)lH (l = 1, 2, 3, 4, 5), O(B1201-O)lB1202 (l = 1, 2, 3, 4, 5), OC(O)B1203, OC(O)OB1204, OC(O)NHB1205, OC(O)NB1206B1207, OP(O)(OB1208)(OB1209), OSi(B1210)(B1211)(B1212), OS(O2)B1213, NHC(O)B1214, NB1215C(O)B1216, NHC(O)OB1217, NHC(O)NHB1218, NHC(O)NB1219B1220, NB1221C(O)OB1222, NB1223C(O)NHB1224, NB1225C(O)NB1226B1227, NHS(O2)B1228, NB1229S(O2)B1230, SB1231, S(O)B1232, S(O2)B1233, S(O2)NHB1234, S(O2)NB1235B1236, S(O2)OB1237, P(O)(OB1238)(OB1239), Si(B1240)(B1241)(B1242)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHB1191, NB1192B1193, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) B1194, C (O) OB1195, C (O) NHB1196, C (O) NB1197B1198, OB1199, O (B1200-O) l H (l = 1, 2, 3, 4, 5), O (B1201-O) l B1202 (l = 1, 2, 3, 4, 5), OC (O) B1203, OC (O) OB1204, OC (O) NHB1205 , OC (O) NB1206B1207, OP (O) (OB1208) (OB1209), OSi (B1210) (B1211) (B1212), OS (O 2 ) B1213, NHC (O) B1214, NB1215C (O) B1216, NHC ( O) OB1217, NHC (O) NHB1218, NHC (O) NB1219B1220, NB1221C (O) OB1222, NB1223C (O) NHB1224, NB1225C (O) NB1226B1227, NHS (O2) B1228, NB1229S (O2) B1230, SB1231 O) B1232, S (O2) B1233, S (O 2 ) NHB1234, S (O 2 ) NB1235B1236, S (O 2 ) OB1237, P (O) (OB1238) (OB1239), Si (B1240) (B1241) ( B1242) " 여기서, B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213, B1214, B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239, B1240, B1241, B1242는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, B1197, B1198 및/또는 B1206, B1207 및/또는 B1219, B1220 및/또는 B1226, B1227 및/또는 B1235, B1236은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213, B1214, B1214, and B1214 B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239 B1240, B1241, B1242 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B1197, B1198 and / or B1206, B1207 and / or B1219, B1220 and / or B1226, B1227 and / or B1235, B1236 are also in each case" heterocycle. " Reels ", And Z5 라디칼은 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z5 radicals are independently selected from the group consisting of: (i) "수소, 알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHD1, ND2D3, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)D4, C(O)OD5, C(O)NHD6, C(O)ND7D8, OD9, O(D10-O)rH (r = 1, 2, 3, 4, 5), O(D11-O)rD12 (r = 1, 2, 3, 4, 5), OC(O)D13, OC(O)OD14, OC(O)NHD15, OC(O)ND16D17, OP(O)(OD18)(OD19), OSi(D20)(D21)(D22), OS(O2)D23, NHC(O)D24, ND25C(O)D26, NHC(O)OD27, NHC(O)NHD28, NHC(O)ND29D30, ND31C(O)OD32, ND33C(O)NHD34, ND35C(O)ND36D37, NHS(O2)D38, ND39S(O2)D40, SD41, S(O)D42, S(O2)D43, S(O2)NHD44, S(O2)ND45D46, S(O2)OD47, P(O)(OD48)(OD49), Si(D50)(D51)(D52)"(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF 3 , N 3 , NH 2 , NHD1, ND2D3, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) D4, C (O) OD5, C (O) NHD6, C (O) ND7D8, OD9, O (D10-O) r H ( r = 1, 2, 3, 4, 5), O (D11-O) r D12 (r = 1, 2, 3, 4, 5), OC (O) D13, OC (O) OD14, OC (O ) NHD15, OC (O) ND16D17, OP (O) (OD18) (OD19), OSi (D20) (D21) (D22), OS (O 2 ) D23, NHC (O) D24, ND25C (O) D26, NHC (O) OD27, NHC (O) NHD28, NHC (O) ND29D30, ND31C (O) OD32, ND33C (O) NHD34, ND35C (O) ND36D37, NHS (O2) D38, ND39S (O2) D40, SD41, S (O) D42, S (O2) D43, S (O 2 ) NHD44, S (O 2 ) ND45D46, S (O 2 ) OD47, P (O) (OD48) (OD49), Si (D50) (D51 ) (D52) " 여기서, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52는 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, D7, D8 및/또는 D16, D17 및/또는 D29, D30 및/또는 D36, D37 및/또는 D45, D46은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D7, D8 and / or D16, D17 and / or D29, D30 and / or D36, D37 and / or D45, D46 may also in each case be" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (ii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHD53, ND54D55, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)D56, C(O)OD57, C(O)NHD58, C(O)ND59D60, OD61, O(D62-O)sH (s = 1, 2, 3, 4, 5), O(D63-O)tD64 (t = 1, 2, 3, 4, 5), OC(O)D65, OC(O)OD66, OC(O)NHD67, OC(O)ND68D69, OP(O)(OD70)(OD71), OSi(D72)(D73)(D74), OS(O2)D75, NHC(O)D76, ND77C(O)D78, NHC(O)OD79, NHC(O)NHD80, NHC(O)ND81D82, ND83C(O)OD84, ND85C(O)NHD86, ND87C(O)ND88D89, NHS(O2)D90, ND91S(O2)D92, SD93, S(O)D94, S(O2)D95, S(O2)NHD96, S(O2)ND97D98, S(O2)OD99, P(O)(OD100)(OD101), Si(D102)(D103)(D104)"(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHD53, ND54D55, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) D56, C (O) OD57, C (O) NHD58, C (O) ND59D60, OD61, O (D62-O) s H (s = 1, 2, 3, 4, 5), O (D63-O) t D64 (t = 1, 2, 3, 4, 5), OC (O) D65, OC (O) OD66, OC (O) NHD67 , OC (O) ND68D69, OP (O) (OD70) (OD71), OSi (D72) (D73) (D74), OS (O 2 ) D75, NHC (O) D76, ND77C (O) D78, NHC ( O) OD79, NHC (O) NHD80, NHC (O) ND81D82, ND83C (O) OD84, ND85C (O) NHD86, ND87C (O) ND88D89, NHS (O2) D90, ND91S (O2) D92, SD93, S ( O) D94, S (O2) D95, S (O 2 ) NHD96, S (O 2 ) ND97D98, S (O 2 ) OD99, P (O) (OD100) (OD101), Si (D102) (D103) ( D104) " 여기서, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102, D103, D104는 각각 독립적으로 다음 으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, D59, D60 및/또는 D68, D69 및/또는 D81, D82 및/또는 D88, D89 및/또는 D97, D98은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있고,Where D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102, D103, D104 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D59, D60 and / or D68, D69 and / or D81, D82 and / or D88, D89 and / or D97, D98 are also in each case" heterocycle. " Reels ", 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (iii) "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, F, Cl, Br, I, CN, CF3, N3, NH2, NHD105, ND106D107, NO2, OH, OCF3, SH, OSO3H, OP(O)(OH)2, CHO, COOH, C(O)NH2, SO3H, P(O)(OH)2, C(O)D108, C(O)OD109, C(O)NHD110, C(O)ND111D112, OD113, O(D114-O)tH (t = 1, 2, 3, 4, 5), O(D115-O)tD116 (t = 1, 2, 3, 4, 5), OC(O)D117, OC(O)OD118, OC(O)NHD119, OC(O)ND120D121, OP(O)(OD122)(OD123), OSi(D124)(D125)(D126), OS(O2)D127, NHC(O)D128, ND129C(O)D130, NHC(O)OD131, NHC(O)NHD132, NHC(O)ND133D134, ND135C(O)OD136, ND137C(O)NHD138, ND139C(O)ND140D141, NHS(O2)D142, ND143S(O2)D144, SD145, S(O)D146, S(O2)D147, S(O2)NHD148, S(O2)ND149D150, S(O2)OD151, P(O)(OD152)(OD153), Si(D154)(D155)(D156)"(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF 3 , N 3 , NH 2 , NHD105, ND106D107, NO 2 , OH, OCF 3 , SH, OSO 3 H, OP (O) (OH) 2 , CHO, COOH, C (O) NH 2 , SO 3 H, P (O) (OH) 2 , C (O) D108, C (O) OD109, C (O) NHD110, C (O) ND111D112, OD113, O (D114-O) t H (t = 1, 2, 3, 4, 5), O (D115-O) t D116 (t = 1, 2, 3, 4, 5), OC (O) D117, OC (O) OD118, OC (O) NHD119 , OC (O) ND120D121, OP (O) (OD122) (OD123), OSi (D124) (D125) (D126), OS (O 2 ) D127, NHC (O) D128, ND129C (O) D130, NHC ( O) OD131, NHC (O) NHD132, NHC (O) ND133D134, ND135C (O) OD136, ND137C (O) NHD138, ND139C (O) ND140D141, NHS (O2) D142, ND143S (O2) D144, SD145, S ( O) D146, S (O2) D147, S (O 2 ) NHD148, S (O 2 ) ND149D150, S (O 2 ) OD151, P (O) (OD152) (OD153), Si (D154) (D155) ( D156) " 여기서, D105, D106, D107, D108, D109, D110, D111, D112, D113, D114, D115, D116, D117, D118, D119, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143, D144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고: "알킬, (C9-C30)알킬, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬", 여기서, 대안적으로, D111, D112 및/또는 D120, D121 및/또는 D133, D134 및/또는 D140, D141 및/또는 D149, D150은 또한 각각의 경우 함께 "헤테로사이클릴"을 형성할 수 있다.Where D105, D106, D107, D108, D109, D110, D111, D112, D113, D114, D115, D116, D117, D118, D119, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143, D144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156 are each independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D111, D112 and / or D120, D121 and / or D133, D134 and / or D140, D141 and / or D149, D150 are also in each case" heterocycle. " Reel ".
제1항에 있어서, The method of claim 1, (A)에서,In (A), Z1 라디칼은 독립적으로 "NZ14Z15"이고, 여기서, Z14는 수소 또는 "아릴"이고, Z15는 "C(O)NH알킬"이고, 여기서, "C(O)NH알킬"은 추가적으로, 임의로, "OH"에 의해 치환될 수 있고;Z1 radicals are independently "NZ14Z15" where Z14 is hydrogen or "aryl" and Z15 is "C (O) NHalkyl" where "C (O) NHalkyl" is additionally, optionally, "OH" May be substituted by "; Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의 해 치환되고:Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents, identically or differently, selected from the group consisting of: (a) "알킬, OC(O)알킬, O알킬, NHC(O)알킬"(a) "alkyl, OC (O) alkyl, Oalkyl, NHC (O) alkyl" 단, 치환체 그룹(a)의 상기 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of: (c) "아릴, 헤테로사이클릴, O알킬O알킬, O아릴알킬"(c) "aryl, heterocyclyl, OalkylOalkyl, Oarylalkyl" 또는 Z3 라디칼은 독립적으로 "치환된 아릴"이고, 여기서, "치환된 아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고: Or the Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from the group consisting of: a. "OC(O)O알킬,OC(O)O아릴, OC(O)N(알킬)2, OC(O)NH알킬, OC(O)(C9-C30)알킬, NHC(O)O알킬, NHC(O)NH알킬, NHC(O)N(알킬)2, Si(알킬)3"a. "OC (O) Oalkyl, OC (O) Oaryl, OC (O) N (alkyl) 2 , OC (O) NHalkyl, OC (O) (C 9 -C 30 ) alkyl, NHC (O) O Alkyl, NHC (O) NHalkyl, NHC (O) N (alkyl) 2 , Si (alkyl) 3 " 여기서, 임의로, 치환체 그룹(c)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "O알킬, O아릴알킬"(i) "Oalkyl, Oarylalkyl" 여기서, 임의로, Z3 라디칼은 또한 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the Z 3 radicals may also be independently substituted by one or more substituents selected identically or differently from the group consisting of: (i) "할로겐, F, Cl, Br, I, O알킬"(i) "halogen, F, Cl, Br, I, Oalkyl" Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 Z5 radicals are independently hydrogen 화학식 I의 신규한 피리도[2,3-b]피라진 유도체.Novel pyrido [2,3-b] pyrazine derivatives of formula (I). 제1항 또는 제2항에 있어서, The method according to claim 1 or 2, (A)에서,In (A), Z1 라디칼은 독립적으로 "NHC(O)NH에틸, NHC(O)NH부틸OH"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl, NHC (O) NHbutylOH", Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "4-페닐 메틸 카보네이트, 3-페닐 2-메톡시에틸 카보네이트, 4-페닐 2-메톡시에틸 카보네이트, 4-페닐 페닐 카보네이트, 4-페닐 N-디에틸카바메이트, 4-페닐 3-페닐아크릴레이트, 4-페닐 노나데카노에이트, 4-페닐 이소부틸 카보네이트, 4-페닐 부트-2-이닐 카보네이트, 4-페닐 N-디메틸카바메이트, 4-페닐 N-에틸카바메이트, 3급-부틸 N-(4-페닐)카바메이트, 2-메톡시에틸 N-(4-페닐)카바메이트, 4-(3-에틸우레아)페닐, 4-(3,3-메틸우레아)페닐, 4-모르폴린-4-일메틸페닐, 4-[2-(2-메톡시에톡시)에톡시]페닐, N-(4-페닐)-2-(2-메톡시에톡시)아세트아미드, 4-(2-메톡시)페닐 2-메톡시에틸 카보네이트, 4-페닐 2-벤질옥시에틸 카보네이트, 4-(2-메톡시)페닐 2-벤질옥시에틸 카보네이트, N-(4-페닐)-2-벤질옥시아세트아미드, 3-트리메틸실라닐페닐, 4-(2-메톡시)페닐 N-디에틸카바메이트, 4-(2-클로로-6-메톡시)페닐 N-디에틸카바메이트, 4-(2-메톡시)페닐 2-[2-(2-메톡시에톡시)에톡시]에틸 카보네이트"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently "4-phenyl methyl carbonate, 3-phenyl 2-methoxyethyl carbonate, 4-phenyl 2-methoxyethyl carbonate, 4-phenyl phenyl carbonate, 4-phenyl N-diethylcarbamate, 4- Phenyl 3-phenylacrylate, 4-phenyl nonadecanoate, 4-phenyl isobutyl carbonate, 4-phenyl but-2-ynyl carbonate, 4-phenyl N-dimethylcarbamate, 4-phenyl N-ethylcarbamate, Tert-butyl N- (4-phenyl) carbamate, 2-methoxyethyl N- (4-phenyl) carbamate, 4- (3-ethylurea) phenyl, 4- (3,3-methylurea) phenyl 4-morpholin-4-ylmethylphenyl, 4- [2- (2-methoxyethoxy) ethoxy] phenyl, N- (4-phenyl) -2- (2-methoxyethoxy) acetamide, 4- (2-methoxy) phenyl 2-methoxyethyl carbonate, 4-phenyl 2-benzyloxyethyl carbonate, 4- (2-methoxy) phenyl 2-benzyloxyethyl carbonate, N- (4-phenyl)- 2-benzyloxyacetamide, 3-trimethylsilanylphenyl, 4- (2-methoxy) phenyl N- Ethylcarbamate, 4- (2-chloro-6-methoxy) phenyl N-diethylcarbamate, 4- (2-methoxy) phenyl 2- [2- (2-methoxyethoxy) ethoxy] ethyl Carbonate ", and Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체. A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항에 있어서, The method of claim 1, (B)에서,In (B), Z1 라디칼은 독립적으로 "NZ14Z15"이고, 여기서, Z14는 수소이고, Z1 radicals are independently "NZ14Z15", wherein Z14 is hydrogen, Z15는 "C(O)NH알킬"이고;Z15 is "C (O) NHalkyl"; Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "치환된 헤테로아릴", 여기서, "치환된 헤테로아릴"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:Z 3 radicals are independently “substituted heteroaryl” wherein “substituted heteroaryl” is substituted by one or more substituents, identically or differently selected from the group consisting of: (a) "NHC(O)NH알킬"(a) "NHC (O) NHalkyl" Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체.A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항 또는 제4항에 있어서, The method according to claim 1 or 4, (B)에서,In (B), Z1 라디칼은 독립적으로 "NHC(O)NH에틸"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl", Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "6-(3-에틸우레아)피리딘-3-일"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently selected from the group consisting of "6- (3-ethylurea) pyridin-3-yl", Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체. A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항에 있어서, The method of claim 1, (C)에서,In (C), Z1 라디칼은 독립적으로 "NZ14Z15"이고; 여기서, Z14는 수소이고, Z15는 "C(O)NH알킬"이고;The Z1 radicals are independently "NZ14Z15"; Wherein Z 14 is hydrogen and Z 15 is “C (O) NH alkyl”; Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "치환된 알킬"이고, 여기서, "치환된 알킬"은 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환되고:Z 3 radicals are independently “substituted alkyl” wherein “substituted alkyl” is substituted by one or more substituents identically or differently selected from the group consisting of: (a) "아릴, 헤테로아릴, 사이클로알킬, N(알킬)2, O알킬"(a) "aryl, heteroaryl, cycloalkyl, N (alkyl) 2, Oalkyl" 여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 서로 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents of substituent group (a) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of: (i) "할로겐, F, Cl, Br, I"(i) "halogen, F, Cl, Br, I" Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체.A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항 또는 제6항에 있어서, The method according to claim 1 or 6, (C)에서,In (C), Z1 라디칼은 독립적으로 "NHC(O)NH에틸"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl", Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "페닐에티닐, 티오펜-3-일에티닐, 사이클로프로필에티닐, N-디메틸아미노프로프-1-이닐, 2-사이클로헥실비닐, 3-메톡시프로페닐, 벤질, 2-(4-플루오로페닐)에틸, 2-(4-플루오로페닐)비닐"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently "phenylethynyl, thiophen-3-ylethynyl, cyclopropylethynyl, N-dimethylaminoprop-1-ynyl, 2-cyclohexylvinyl, 3-methoxypropenyl, benzyl, 2- (4-fluorophenyl) ethyl, 2- (4-fluorophenyl) vinyl ", and Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체. A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항에 있어서, The method of claim 1, (D)에서,In (D), Z1 라디칼은 독립적으로 "NZ14Z15"이고, 여기서, Z14는 수소이고, Z15는 "C(O)NH알킬"이고;The Z1 radicals are independently "NZ14Z15", wherein Z14 is hydrogen and Z15 is "C (O) NHalkyl"; Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z3 radicals are independently selected from the group consisting of: (1) "NZ10Z11"(1) "NZ10Z11" 여기서, Z10, Z11 라디칼은 각각 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Wherein the Z10 and Z11 radicals are each independently selected from the group consisting of: (a) "수소, 아릴"(a) "hydrogen, aryl" 단, 치환체 그룹(a)의 상기한 치환체는, 이들이 수소가 아닌 경우, 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents of substituent group (a) are further substituted by one or more substituents, each of which is independently the same or differently selected from the group consisting of: (i) "사이클로알킬, 헤테로아릴, 헤테로사이클릴알킬, S(O)2알킬, NHS(O)2알킬, C(O)NH알킬, NHC(O)알킬, C(O)O알킬"(i) "cycloalkyl, heteroaryl, heterocyclylalkyl, S (O) 2 alkyl, NHS (O) 2 alkyl, C (O) NHalkyl, NHC (O) alkyl, C (O) Oalkyl" (b) "C(O)아릴"(b) "C (O) aryl" 여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 및/또는 치환체 그룹(b)은 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (a) and / or substituent group (b) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of: (i) "알킬"(i) "alkyl" Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체.A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항 또는 제8항에 있어서. The method of claim 1 or 8. (D)에서,In (D), Z1 라디칼은 독립적으로 "NHC(O)NH에틸"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl", Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "4-메틸벤즈아미드, 4-사이클로헥실페닐아미노, 4-메탄설포닐페닐아미노, 3-(N-메탄설폰아미드)-4-메틸페닐아미노, 3-N-메틸벤즈아미드아미노, 4-피페리딘-1-일메틸페닐아미노, 4-티오펜-3-일페닐아미노, 4-N-아세트아미도페닐아미노, 3-(에틸 벤조에이트)아미노"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently "4-methylbenzamide, 4-cyclohexylphenylamino, 4-methanesulfonylphenylamino, 3- (N-methanesulfonamide) -4-methylphenylamino, 3-N-methylbenzamideamino , 4-piperidin-1-ylmethylphenylamino, 4-thiophen-3-ylphenylamino, 4-N-acetamidophenylamino, 3- (ethyl benzoate) amino ", Z4 라디칼은 독립적으로 수소이고; Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체. A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항에 있어서, The method of claim 1, (E)에서,In (E), Z1 라디칼 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z 1 radical is independently selected from the group consisting of: (a) "NZ24Z25", 여기서, Z24는 수소이고, Z25는 "C(O)C(O)O알킬" 또는 "C(O)C(O)NH알킬" 또는 "C(O)NHO알킬"이고,(a) "NZ24Z25" wherein Z24 is hydrogen and Z25 is "C (O) C (O) Oalkyl" or "C (O) C (O) NHalkyl" or "C (O) NHOalkyl" ego, 여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents in substituent group (a) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of: (i) "OSi(알킬)3, OC(O)NH알킬, OC(O)O알킬, P(O)(O알킬)2, P(O)(OH)2, O알킬"(i) "OSi (alkyl) 3 , OC (O) NHalkyl, OC (O) Oalkyl, P (O) (Oalkyl) 2 , P (O) (OH) 2 , Oalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of: (ii) "헤테로사이클릴, OH, N(알킬)2, OC(O)알킬"(ii) “heterocyclyl, OH, N (alkyl) 2 , OC (O) alkyl” 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (ii) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of: (iii) "알킬"(iii) "alkyl" (b) "NZ26Z27", 여기서, Z26은 수소이고, Z27은 "C(O)NH알킬"이고,(b) "NZ26Z27", wherein Z26 is hydrogen, Z27 is "C (O) NHalkyl", 단, 치환체 그룹(b)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환되고:Provided that the substituents of substituent group (b) are each independently further substituted by one or more substituents selected the same or differently from the group consisting of: (i) "OSi(알킬)3, OC(O)NH알킬, OC(O)O알킬, P(O)(O알킬)2, P(O)(OH)2, O알킬"(i) "OSi (alkyl) 3 , OC (O) NHalkyl, OC (O) Oalkyl, P (O) (Oalkyl) 2 , P (O) (OH) 2 , Oalkyl" 여기서, 임의로, 치환체 그룹(i)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체 에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (i) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of: (ii) "헤테로사이클릴, OH, N(알킬)2, OC(O)알킬"(ii) “heterocyclyl, OH, N (alkyl) 2 , OC (O) alkyl” 여기서, 임의로, 치환체 그룹(ii)의 상기한 치환체는 또한 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 추가로 치환될 수 있고:Here, optionally, the aforementioned substituents of substituent group (ii) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of: (iii) "알킬"(iii) "alkyl" Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼 독립적으로 다음으로 이루어진 그룹으로부터 선택되고:Z3 radicals are independently selected from the group consisting of: (a) "아릴"(a) "aryl" 여기서, 임의로, 치환체 그룹(a)의 상기한 치환체는 각각 독립적으로 다음으로 이루어진 그룹으로부터 동일하거나 상이하게 선택된 하나 이상의 치환체에 의해 치환될 수 있고:Wherein, optionally, the aforementioned substituents in substituent group (a) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of: (i) "O알킬, OH"(i) "Oalkyl, OH" Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체. A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 제1항 또는 제10항에 있어서, The method according to claim 1 or 10, (E)에서,In (E), Z1 라디칼은 독립적으로 "3-메톡시-1-일우레아, 3-(프로프-1-인-3-일)-1-일 우레아, 3-[4-(3급-부틸디메틸실라닐옥시)부틸]-1-일우레아, 4-(N-에틸 카바메이트)부틸-1-일우레아, 4-(메틸 카보네이트)-부틸-1-일우레아, 4-(2,3-디하이드록시프로필 카보네이트)부틸-1-일우레아, 4-(2,2-디메틸-[1,3]디옥솔란-4-일메틸 카보네이트)부틸-1-일우레아, 4-(디에틸 포스페이트)부틸-1-일우레아, 4-(부틸 포스페이트)-1-일우레아, N-옥살산 모노아미드 에틸 에스테르, N-에틸-N'-옥살아미드, 2-(디에틸 포스페이트)에틸-1-일우레아, 2-(에틸 포스페이트)-1-일우레아, 3-(2-디에틸아미노-에톡시)프로필-1-일우레아, 4-[(2,2-디메틸프로피오닐옥시메톡시)포스피노일옥시메틸 2,2-디메틸프로파노에이트]부틸-1-일우레아, 4-[1-(1-아세톡시에톡시)에톡시포스피노일옥시 아세테이트]부틸-1-일우레아"로 이루어진 그룹으로부터 선택되고,Z1 radicals are independently "3-methoxy-1-ylurea, 3- (prop-1-yn-3-yl) -1-yl urea, 3- [4- (tert-butyldimethylsilanyloxy ) Butyl] -1-ylurea, 4- (N-ethyl carbamate) butyl-1-ylurea, 4- (methyl carbonate) -butyl-1-ylurea, 4- (2,3-dihydroxypropyl Carbonate) butyl-1-ylurea, 4- (2,2-dimethyl- [1,3] dioxolan-4-ylmethyl carbonate) butyl-1-ylurea, 4- (diethyl phosphate) butyl-1- Ilurea, 4- (butyl phosphate) -1-ylurea, N-oxalic acid monoamide ethyl ester, N-ethyl-N'-oxalamide, 2- (diethyl phosphate) ethyl-1-ylurea, 2- (Ethyl phosphate) -1-ylurea, 3- (2-diethylamino-ethoxy) propyl-1-ylurea, 4-[(2,2-dimethylpropionyloxymethoxy) phosphinoyloxymethyl 2 , 2-dimethylpropanoate] butyl-1-ylurea, 4- [1- (1-acetoxyethoxy) ethoxyphosphinoyloxy acetate] butyl-1-ylurea Eojin is selected from the group, Z2 라디칼은 독립적으로 수소이고;Z 2 radicals are independently hydrogen; Z3 라디칼은 독립적으로 "페닐, 4-하이드록시-3-메톡시페닐"로 이루어진 그룹으로부터 선택되고,Z3 radicals are independently selected from the group consisting of "phenyl, 4-hydroxy-3-methoxyphenyl", Z4 라디칼은 독립적으로 수소이고;Z 4 radicals are independently hydrogen; Z5 라디칼은 독립적으로 수소인 화학식 I의 신규한 피리도[2,3-b]피라진 유도체. A novel pyrido [2,3-b] pyrazine derivative of formula I wherein the Z5 radicals are independently hydrogen. 신규한 화학식 II의 피리도[2,3-b]피라진 유도체 및 생리학적으로 허용되는 염, 화학식 I의 화합물의 유도체 또는 유사체, 및 이의 용매화물, 수화물, 다형태 및 프로드러그, 이의 라세미체 형태, 순수한 에난티오머 및/또는 부분입체이성체 형태 또는 이들 에난티오머 및/또는 부분입체이성체의 혼합물 형태 또는 호변체 형태로 존재하는 화학식 I의 화합물 및 이의 염, 유도체 또는 유사체, 이의 용매화물, 수화물, 다형태 및 프로드러그. Novel pyrido [2,3-b] pyrazine derivatives and physiologically acceptable salts of compounds of formula (II), derivatives or analogues of compounds of formula (I), and solvates, hydrates, polymorphs and prodrugs thereof, racemates thereof In the form, pure enantiomers and / or diastereomeric forms or mixtures of these enantiomers and / or diastereomers or tautomeric forms thereof, and salts, derivatives or analogs thereof, solvates thereof, Hydrates, polymorphs and prodrugs. 화학식 IIFormula II
Figure 112008041801646-PCT00107
Figure 112008041801646-PCT00107
상기 화학식 II에서, In Chemical Formula II, 치환체 R1-R4는 각각 다음에 정의된 바와 같다:Substituents R1-R4 are each as defined below: R1 및 R2는 각각 독립적으로 수소 또는 NR5R6일 수 있고, 단, R1 = NR5R6인 경우, R2 = H이고, R2 = NR5R6인 경우, R1 = H이고,R1 and R2 may each independently be hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H, 여기서, R5는 수소, 알킬, R38, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2 ,CHO, C(O)OH, C(O)OR12, C(O)NH2, C(O)NHR12, C(O)NR12R13, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있 고, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R12 및 R13 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있거나, R12 및 R13은 함께 헤테로사이클릴 환일 수 있고,Wherein R 5 may be hydrogen, alkyl, R 38, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, Aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents are themselves each of F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (Alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) OR12, C (O) NH 2 , C (O) NHR12, C (O) NR12R13, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl , Mono- or polysubstituted identically or differently by heteroaryl, p can be a value of 0, 1, 2, 3, 4 or 5, and R12 and R13 radicals are each Neutral to either be an alkyl, aryl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl cycloalkyl, alkyl, heterocyclyl, alkylaryl, or heteroaryl alkyl, R12 and R13 may be heterocyclyl with a sun dog, R6은 -C(Y)NR7R8일 수 있고, 여기서, Y는 독립적으로 O 또는 S일 수 있고, R7 및 R8은 각각 독립적으로 다음과 같을 수 있다: R 6 may be —C (Y) NR 7 R 8, wherein Y may be independently O or S, and R 7 and R 8 may each independently be: 수소, Hydrogen, 치환되지 않거나 치환된 알킬, 여기서, 알킬 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-사이클로알킬, S-헤테로사이클릴, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고,Unsubstituted or substituted alkyl, wherein the alkyl radical is F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-hetero Aryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O ) -Heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylheteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O)- Interrogating heterocyclyl, OC (O) - aryl, OC (O) - heteroaryl, OC (O) - alkyl aryl, OC (O) - alkyl-heteroaryl, OSO 3 H, OSO 2 - alkyl, OSO 2 - cycloalkyl, , OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkylaryl, OSO 2 -alkylheteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C ( O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl Cycloalkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O ) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O ) N (heteroaryl) 2, SO- alkyl, SO- aryl, SO 2 - alkyl, SO 2 - aryl, SO 2 NH 2, SO 2 NH- alkyl, SO 2 NH- aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, cycloalkyl, heterocyclyl, aryl or hetero Mono- or polysubstituted identically or differently by aryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5, 치환되지 않거나 치환된 사이클로알킬, 여기서, 사이클로알킬 라디칼은 F, Cl, Br, I, NH2, NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클 릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, OH, O(-알킬O)p-알킬, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, CO2H, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, 알킬, 또는 아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고,Unsubstituted or substituted cycloalkyl, wherein the cycloalkyl radical is F, Cl, Br, I, NH 2, NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH- Alkylaryl, NH-alkylheteroaryl, N (alkyl) 2, NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -Heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylheteroaryl, OH, O (-alkylO) p-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O)- alkylaryl, OC (O) - alkyl-heteroaryl, OSO 3 H, OSO 2 - alkyl, OSO 2 - cycloalkyl, OSO 2 - heterocyclyl, OSO 2 - aryl, OSO 2 - hete Aryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, CO 2 H, CO 2 - alkyl, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl , CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 - alkyl-heteroaryl, C (O) -NH 2, C (O) NH- alkyl , C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O ) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C ( Mono- or polysubstituted identically or differently by O) N (aryl) 2 , C (O) N (heteroaryl) 2 , alkyl, or aryl, wherein p is 0, 1, 2, 3, Can be a value of 4 or 5, 치환되지 않거나 치환된 헤테로사이클릴, 여기서, 헤테로사이클릴 라디칼은 OH, O-알킬, O-아릴, NH2, NH-알킬, NH-아릴, 알킬, 알킬아릴 또는 아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, Unsubstituted or substituted heterocyclyl, wherein the heterocyclyl radical is the same or differently selected by OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkylaryl or aryl Substituted or polysubstituted, 치환되지 않거나 치환된 아릴, 여기서, 아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-사이클로알킬, S-헤테로사이클릴, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, O-알킬OH, O-(CH2)n-O, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이 클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, n은 1, 2 또는 3의 값이고,Unsubstituted or substituted aryl, wherein the aryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl , NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O ) -Alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl , NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylhetero Aryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylhetero Aryl, O-alkylOH, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocycle Reel, OSO 2 - aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, C (O) - alkyl, C (O) - aryl, C (O) - heteroaryl, CO 2 H, CO 2 - alkyl, CO 2 -R38, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl, cycloalkyl Alkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O ) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH- Alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (Aryl) 2 , C ( O) N (heteroaryl) 2, SO- alkyl, SO- aryl, SO 2 - alkyl, SO 2 - aryl, SO 2 NH 2, SO 2 NH- alkyl, NH- SO 2 aryl, SO 2 NH- heteroaryl Same as, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl Or differently mono- or polysubstituted, where p can be a value of 0, 1, 2, 3, 4 or 5, n is a value of 1, 2 or 3, 치환되지 않거나 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬,O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고,Unsubstituted or substituted heteroaryl, wherein the heteroaryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH -Aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O)- Alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2- Alkylheteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocycle Reel, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -R3 8, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl , OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkylaryl, OSO 2 -alkylheteroaryl, OP (O ) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 - alkyl-heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH -Heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N ( Alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 N H-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, hetero Mono- or polysubstituted identically or differently by cyclyl, aryl or heteroaryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5, C(O)-R39, 여기서, R39는 알킬, 아릴 또는 헤테로아릴일 수 있고, 알킬, 아릴 및 헤테로아릴 치환체는 자체로 서로 치환될 수 있고,C (O) -R39, wherein R39 may be alkyl, aryl or heteroaryl, the alkyl, aryl and heteroaryl substituents may themselves be substituted for one another, 또는 R7 및 R8은 함께 헤테로사이클릴 환을 형성할 수 있고,Or R7 and R8 may together form a heterocyclyl ring, R3 및 R4는 각각 독립적으로 다음과 같을 수 있다: R3 and R4 may each independently be as follows: 수소, 여기서, R3 및 R4는 수소가 아니고, Hydrogen, where R3 and R4 are not hydrogen, 치환된 알킬, 여기서, 알킬 라디칼은 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OH, C(O)OR14, C(O)NH2, C(O)NHR14, C(O)NR14R15, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R14 및 R15 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R14 및 R15는 함께 헤테로사이클릴 환을 형성할 수 있고,Substituted alkyl, wherein the alkyl radical is F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O ) OH, C (O) OR14, C (O) NH 2 , C (O) NHR14, C (O) NR14R15, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P Mono- or polysubstituted identically or differently by (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein p is 0 Can be a value of 1, 2, 3, 4 or 5, and the R14 and R15 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkyl Heteroaryl, or R14 and R15 together may form a heterocyclyl ring, 치환된 아릴, 여기서, 아릴 라디칼은 NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, S-알킬, S-아릴, S-헤테로아릴, O-알킬, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO2-알킬, OSO2-사이 클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)NH-알킬, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 O(-알킬O)p-알킬, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OR16, C(O)NH2, C(O)NHR16, C(O)NR16R17, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환되고, 여기서, p는 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고, R16 및 R17 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또 는 알킬헤테로아릴일 수 있거나, R16 및 R17은 함께 헤테로사이클릴 환을 형성할 수 있고, Substituted aryl, wherein the aryl radical is NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl , NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2-alkyl aryl, NHSO 2-alkyl-heteroaryl, S- alkyl, S- aryl, S- heteroaryl, O- alkyl, O- cycloalkyl, O- heterocyclyl, O- aryl, O -Heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocycle Reel, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO2-alkyl, OSO2 -Cycloalkyl, OSO2-heterocyclyl, OSO2-aryl, OSO2-heteroaryl, OSO2-alkylaryl, OSO2-alkylheteroaryl, C (O) -alkyl, C (O) -aryl, C (O)- heteroaryl, CO2- alkyl, CO2- cycloalkyl, CO2- heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl aryl, CO 2 -alkylheteroaryl, C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl , C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO2-alkyl, SO2-aryl, SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cyclo In groups of alkyl, heterocyclyl, aryl, heteroaryl and alkyl Di- or poly-substituted identically or differently by a substituent selected from cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are each O (-) AlkylO) p-alkyl, OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) OR16, C (O) NH2, C (O) NHR16, C (O) NR16R17 , SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl or alkyl Substituted by aryl, wherein p is wherein p is a value of 0, 1, 2, 3, 4 or 5, and the R16 and R17 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, Heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R16 and R17 may together form a heterocyclyl ring, 단, R3 또는 R4가 알킬헤테로사이클릴-치환된 아릴인 경우, R4 또는 R3은 상응하는 아릴이고, Provided that when R 3 or R 4 is alkylheterocyclyl-substituted aryl, then R 4 or R 3 is the corresponding aryl, 여기서, 아릴 라디칼은 NR20-알킬, NH-R38, NHC(O)-R38, NR19C(O)-알킬, NR19C(O)-사이클로알킬, NR19C(O)-헤테로사이클릴, NR19C(O)-아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NR19C(O)-알킬아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, O-R38, OC(O)-R38, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴, OC(O)O-R19, OC(O)NR18R18, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)O-R38, C(O)NH-R38, C(O)NR20-알킬, C(O)NR19-알킬R21, C(O)NR18-O-R18, C(O)NR18NR18R18 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R22 및 R23 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R22 및 R23은 함께 헤테로사이클릴 환을 형성할 수 있고, Wherein the aryl radical is NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O) -aryl , NR19C (O) -heteroaryl, NR18C (O) -alkylcycloalkyl, NR18C (O) -alkylheterocyclyl, NR19C (O) -alkylaryl, NR19C (O) -alkylheteroaryl, NR18C (O) O -R19, NR18C (O) NR18R18, O-R38, OC (O) -R38, OC (O) -alkylcycloalkyl, OC (O) -alkylheterocyclyl, OC (O) O-R19, OC (O ) NR18R18, OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) O-R38, C (O) NH-R38, C (O) NR20-alkyl, C (O ) NR 19 -alkylR 21, C (O) NR 18 -O-R 18, C (O) NR 18 NR 18 R 18 and the same or differently substituted or substituted by a substituent selected from the group of alkyl, cycloalkyl, heterocyclyl, aryl, hetero The aryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO , C (O) OH, C (O) OR22, C (O) NH2, C (O) NHR22, C (O) NR22R23, SO3H, SO2 -alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, wherein p is 0, 1, Can have a value of 2, 3, 4 or 5, and the R22 and R23 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroarylyl Or R22 and R23 together may form a heterocyclyl ring, 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 NH-알킬, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NHC(O)-알킬, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, S-알킬, S-아릴, S-헤테로아릴, O-알킬, O-사이클로알킬, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2-알킬, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)NH-알킬, C(O)NH-사이클로알 킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 O(-알킬O)p-알킬, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OR16, C(O)NH2, C(O)NHR16, C(O)NR16R17, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환되고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고, R16 및 R17 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로 아릴일 수 있거나, R16 및 R17은 함께 헤테로사이클릴 환을 형성할 수 있고,Substituted heteroaryl, wherein the heteroaryl radical is NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH- Alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O)- Aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 - heteroaryl, NHSO 2 - alkyl aryl, NHSO 2 - heteroaryl-alkyl, S- alkyl, S- aryl, heteroaryl, S-, O- alkyl, O- cycloalkyl, O- aryl, O- heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO2-alkyl, OSO2-between Chloalkyl, OSO2-heterocyclyl, OSO2-aryl, OSO2-heteroaryl, OSO2-alkylaryl, OSO2-alkylheteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl , CO2- alkyl, CO2- cycloalkyl, CO2- heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 -Alkylheteroaryl, C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl , SO 2 NH-alkylaryl, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and alkyl Identical by substituent Differently disubstituted or polysubstituted, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves O (-alkylO) p-alkyl, OP (O) (O-alkyl) 2, OP (O) ( O aryl) 2, C (O) OR16 , C (O) NH2, C (O) NHR16, C (O) NR16R17, SO2 -alkyl, SO 2 aryl , P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, wherein , p can be a value of 0, 1, 2, 3, 4 or 5, and R16 and R17 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl , Alkylaryl or alkylhetero aryl, or R16 and R17 together may form a heterocyclyl ring, 여기서, 헤테로아릴 라디칼은 NR20-알킬, NH-R38, NHC(O)-R38, NR19C(O)-알킬, NR19C(O)-사이클로알킬, NR19C(O)-헤테로사이클릴, NR19C(O)-아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NR19C(O)-알킬아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-알킬 헤테로사이클릴, O-R38, O-헤테로사이클릴, OC(O)-R38, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴, OC(O)O-R19, OC(O)NR18R18, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)O-R38, C(O)NH-R38, C(O)NR20-알킬, C(O)NR19-알킬R21, C(O)NR18-O-R18, C(O)NR18NR18R18, 및 알킬의 그룹으로부터 선택된 치환체에 의해 동일하거나 상이하게 이치환 또는 다치환되고, 사이클로알킬,헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴 또는 알킬아릴에 의해 치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고, R22 및 R23 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 또는 R22 및 R23은 함께 헤테로사이클릴 환을 형성할 수 있고, Wherein the heteroaryl radical is NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O)- Aryl, NR 19 C (O) -heteroaryl, NR 18 C (O) -alkylcycloalkyl, NR 18 C (O) -alkylheterocyclyl, NR 19 C (O) -alkylaryl, NR 19 C (O) -alkylheteroaryl, NR 18 C (O) O-R19, NR18C (O) NR18R18, NHSO2-alkyl heterocyclyl, O-R38, O-heterocyclyl, OC (O) -R38, OC (O) -alkylcycloalkyl, OC (O) -alkylhetero Cyclyl, OC (O) O-R19, OC (O) NR18R18, OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) O-R38, C (O) NH Disubstituted the same or differently by a substituent selected from the group of —R 38, C (O) NR 20 -alkyl, C (O) NR 19 -alkylR 21, C (O) NR 18 -O-R 18, C (O) NR 18 NR 18 R 18, and alkyl Or polysubstituted, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents are themselves each other F, Cl, Br, I, CN, CF 3 , N H 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) OR22, C (O) NH2, C ( O) NHR 22, C (O) NR 22 R 23, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, May be substituted by cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can be a value of 0, 1, 2, 3, 4 or 5, and the R22 and R23 radicals are each independently Alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R22 and R23 together can form a heterocyclyl ring, NR24R25, 여기서, R24는 -C(O)-R26, SO2R26, C(O)OR26 또는 C(O)-NR27R28일 수 있고, 여기서, R25는 수소, 알킬, 사이클로알킬, 아릴 또는 헤테로아릴일 수 있고, 여기서, R26은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬 사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, R27 및 R28은 각각 독립적으로 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, 또는 R27 및 R28은 함께 헤테로사이클릴 환을 형성할 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,NR24R25, wherein R24 can be -C (O) -R26, SO2R26, C (O) OR26 or C (O) -NR27R28, wherein R25 can be hydrogen, alkyl, cycloalkyl, aryl or heteroaryl , Wherein R 26 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl cycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, and R27 and R28 are each independently hydrogen, alkyl, cyclo Alkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, or R27 and R28 together may form a heterocyclyl ring, alkyl, cycloalkyl , Heterocyclyl, aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for each other, R18은 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R18 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, R19는 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R 19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, R20은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R20 may be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, R21은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴일 수 있고,R21 may be cycloalkyl, heterocyclyl, aryl, heteroaryl, R38은 알킬일 수 있고, 여기서, 알킬 라디칼은 9 내지 30개의 탄소원자를 갖는 포화되거나 불포화된, 직쇄 또는 측쇄일 수 있고, C9 -30-알케닐은 하나 이상의 C-C 이중결합을 갖고, C9-30-알키닐은 하나 이상의 C-C 삼중결합을 갖고, 여기서, 알케닐은 (E)- 또는 (Z)-배치로 존재할 수 있다. R38 may be an alkyl, where the alkyl radical may be a saturated or unsaturated, straight or branched chain having from 9 to 30 carbon atoms, C 9 -30 - alkenyl has at least one CC double bond, C 9- 30 -alkynyl has one or more CC triple bonds, where alkenyl may be present in (E)-or (Z) -configuration.
제12항에 있어서, The method of claim 12, R1 및 R2는 각각 독립적으로 수소 또는 NR5R6일 수 있고, 단, R1 = NR5R6인 경우, R2 = H이고, R2 = NR5R6인 경우, R1 = H이고,R1 and R2 may each independently be hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H, 여기서, R5는 수소, 알킬, R38, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, NO2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, CHO, C(O)OH, C(O)NH2, C(O)OR12, C(O)NHR12, C(O)NR12R13, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R12 및 R13 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있거나, R12 및 R13은 함께 헤테로사이클릴 환일 수 있고,Wherein R 5 may be hydrogen, alkyl, R 38, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, Aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents are themselves each of F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (Alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , CHO, C (O) OH, C (O) NH 2 , C (O) OR12, C (O) NHR12, C (O) NR12R13, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl , Mono- or polysubstituted identically or differently by heteroaryl, p may be a value of 0, 1, 2, 3, 4 or 5, and R12 and R13 radicals are each Neutral to either be an alkyl, aryl, cycloalkyl, heterocyclyl, aryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl aryl or alkyl heteroaryl, R12 and R13 may sun dog with heterocyclyl, R6은 -C(O)NR9-Y-R10일 수 있고, 여기서, Y는 독립적으로 O 또는 NR11일 수 있고, R 6 may be —C (O) NR 9 -Y-R 10, wherein Y may be independently O or NR 11, R9는 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, 알킬, 사 이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 치환될 수 있고,R9 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl and Heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may be substituted by themselves, R10 및 R11은 각각 독립적으로 R10 and R11 are each independently 수소, Hydrogen, 치환되지 않거나 치환된 알킬,Unsubstituted or substituted alkyl, 치환되지 않거나 치환된 사이클로알킬,Unsubstituted or substituted cycloalkyl, 치환되지 않거나 치환된 헤테로사이클릴, 여기서, 헤테로사이클릴 라디칼은 OH, O-알킬, O-아릴, NH2, NH-알킬, NH-아릴, 알킬, 알킬아릴 또는 아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, Unsubstituted or substituted heterocyclyl, wherein the heterocyclyl radical is the same or differently selected by OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkylaryl or aryl Substituted or polysubstituted, 치환되지 않거나 치환된 아릴, 여기서, 아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-사이클로알킬, S-헤테로사이클릴, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아 릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, O-알킬OH, O-(CH2)n-O, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, n은 1, 2 또는 3의 값이고,Unsubstituted or substituted aryl, wherein the aryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl , NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O ) -Alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkylaryl , NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2 -alkylhetero Aryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylhete Aryl, O- alkyl, OH, O- (CH 2) n -O, OC (O) - alkyl, OC (O) -R38, OC (O) - cycloalkyl, OC (O) - heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocycle Reel, OSO 2 - aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, C (O) - alkyl, C (O) - aryl, C (O) - heteroaryl, CO 2 H, CO 2 - alkyl, CO 2 -R38, CO 2 - cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl, cycloalkyl Alkyl, CO 2 -alkylheterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O ) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkyl Heterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N ( Aryl) 2 , C ( O) N (heteroaryl) 2, SO- alkyl, SO- aryl, SO 2 - alkyl, SO 2 - aryl, SO 2 NH 2, SO 2 NH- alkyl, NH- SO 2 aryl, SO 2 NH- heteroaryl Same as, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl Or differently mono- or polysubstituted, where p can be a value of 0, 1, 2, 3, 4 or 5, n is a value of 1, 2 or 3, 치환되지 않거나 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, NH-알킬NH2, NH-알킬OH, N(알킬)2, NHC(O)-알킬, NHC(O)-R38, NHC(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NHC(O)-아릴, NHC(O)-헤테로아릴, NHC(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O(-알킬O)p-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값 일 수 있고,Unsubstituted or substituted heteroaryl, wherein the heteroaryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH -Aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, NH-alkylNH 2 , NH-alkylOH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O)- Alkylaryl, NHC (O) -alkylheteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylaryl, NHSO 2- Alkylheteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkylO) p -alkyl, O-R38, O-cycloalkyl, O-heterocycle Reel, O-aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -R 38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylaryl, OC (O) -alkylheteroaryl , OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkylaryl, OSO 2 -alkylheteroaryl, OP (O ) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 - alkyl, aryl, CO 2 - alkyl-heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH -Heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N ( Alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, cycloalkyl, hetero Mono- or polysubstituted identically or differently by cyclyl, aryl or heteroaryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5, 또는 R10 및 R11은 함께 헤테로사이클릴 환을 형성할 수 있고,Or R10 and R11 may together form a heterocyclyl ring, R3 및 R4는 각각 독립적으로,R3 and R4 are each independently, 수소Hydrogen 하이드록실Hydroxyl 할로겐, 예를 들면, 불소, 염소, 브롬, 요오드Halogen, for example fluorine, chlorine, bromine, iodine 치환되지 않거나 치환된 알킬, 여기서, 알킬 라디칼은 F, Cl, Br, I, CN, CF3, NH2, NH-알킬, NH-아릴, N(알킬)2, SH, S-알킬, OH, OCF3, O(-알킬O)p-알킬, O-아릴, OSO3H, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)OH, C(O)OR14, C(O)NH2, C(O)NHR14, C(O)NR14R15, SO3H, SO2알킬, SO2아릴, P(O)(OH)2, P(O)(O알킬)2, P(O)(O아릴)2, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 여기서, p는 0, 1, 2, 3, 4 또는 5의 값일 수 있고, R14 및 R15 라디칼은 각각 독립적으로 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬 아릴 또는 알킬헤테로아릴일 수 있고, 또는 R14 및 R15는 함께 헤테로사이클릴 환을 형성할 수 있고,Unsubstituted or substituted alkyl, wherein the alkyl radical is selected from F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkylO) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (Oalkyl) 2 , OP (O) (Oaryl) 2 , C (O) OH, C (O) OR14, C (O) NH 2 , C (O) NHR14, C (O) NR14R15, SO 3 H, SO 2 Alkyl, SO 2 Aryl, P (O) (OH) Mono- or polysubstituted identically or differently by 2 , P (O) (Oalkyl) 2 , P (O) (Oaryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein p can be a value of 0, 1, 2, 3, 4 or 5, and R14 and R15 radicals are each independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkyl Aryl or alkylheteroaryl, or R 14 and R 15 together may form a heterocyclyl ring, 치환되지 않거나 치환된 아릴, 여기서, 아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH-아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NR20-알킬, NHC(O)-알킬, NHC(O)-R38, NR19(O)-알킬, NHC(O)-사이클로알킬, NR19C(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NR19C(O)-헤테로사이클릴, NHC(O)-아릴, NR19C(O)-아릴, NHC(O)-헤테로아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NHC(O)-알킬아릴, NR19C(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬헤테로사이클릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, O-(CH2)n-O, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴 OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OC(O)O-R19, OC(O)NR18R18, OSO3H, OSO2-알킬, OSO2-사이클 로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴,C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, C(O)NR20-알킬, C(O)NR19-알킬R21, -C(O)NR18-O-R18, -C(O)NR18NR18R18, SO-알킬, SO-아릴, SO2-알킬, SO2-아릴, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, n은 1, 2 또는 3의 값으로 추정될 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,Unsubstituted or substituted aryl, wherein the aryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl , NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NR 20 -alkyl, NHC (O) -Alkyl, NHC (O) -R38, NR19 (O) -alkyl, NHC (O) -cycloalkyl, NR19C (O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -heterocyclyl , NHC (O) -aryl, NR19C (O) -aryl, NHC (O) -heteroaryl, NR19C (O) -heteroaryl, NR18C (O) -alkylcycloalkyl, NR18C (O) -alkylheterocyclyl, NHC (O) -alkylaryl, NR19C (O) -alkylaryl, NHC (O) -alkylheteroaryl, NR19C (O) -alkylheteroaryl, NR18C (O) O-R19, NR18C (O) NR18R18, NHSO 2 -alkyl, NHSO 2-cycloalkyl, NHSO 2-heterocyclyl, NHSO 2-aryl, NHSO 2 - heteroaryl, NHSO 2 -alkyl-heterocyclyl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl Aryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O- Heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38 , OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylcycloalkyl, OC (O) -alkylheterocycle Reel OC (O) -alkylaryl, OC (O) -alkylheteroaryl, OC (O) O-R19, OC (O) NR18R18, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 - heterocyclyl, OSO 2-aryl, OSO 2-heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, OP (O) (O -alkyl) 2, OP ( O) (Oaryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 - heterocyclyl, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 -alkylaryl, CO 2 -alkylheteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH- Alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N ( Heteroaryl) 2 , C (O) NR 20 -alkyl, C (O) NR 19 -alkylR 21, -C (O) NR 18 -O-R 18, -C (O) NR 18 NR 18 R 18, SO-alkyl, SO-aryl, SO 2 -Alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, Same or differently by SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl Mono- or polysubstituted, n can be estimated to be 1, 2 or 3, alkyl, cyclo Alkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl substituents may themselves be substituted for one another, 치환되지 않거나 치환된 헤테로아릴, 여기서, 헤테로아릴 라디칼은 F, Cl, Br, I, CF3, CN, NH2, NH-알킬, NH-R38, NH-사이클로알킬, NH-헤테로사이클릴, NH- 아릴, NH-헤테로아릴, NH-알킬사이클로알킬, NH-알킬헤테로사이클릴, NH-알킬아릴, NH-알킬헤테로아릴, N(알킬)2, N(아릴)2, NR20-알킬, NHC(O)-알킬, NHC(O)-R38, NR19C(O)-알킬, NHC(O)-사이클로알킬, NR19C(O)-사이클로알킬, NHC(O)-헤테로사이클릴, NR19C(O)-헤테로사이클릴, NHC(O)-아릴, NR19C(O)-아릴, NHC(O)-헤테로아릴, NR19C(O)-헤테로아릴, NR18C(O)-알킬사이클로알킬, NR18C(O)-알킬헤테로사이클릴, NHC(O)-알킬아릴, NR19C(O)-알킬아릴, NHC(O)-알킬헤테로아릴, NR19C(O)-알킬헤테로아릴, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-알킬, NHSO2-사이클로알킬, NHSO2-헤테로사이클릴, NHSO2-아릴, NHSO2-헤테로아릴, NHSO2-알킬헤테로사이클릴, NHSO2-알킬아릴, NHSO2-알킬헤테로아릴, NO2, SH, S-알킬, S-아릴, S-헤테로아릴, OH, OCF3, O-알킬, O-R38, O-사이클로알킬, O-헤테로사이클릴, O-아릴, O-헤테로아릴, O-알킬사이클로알킬, O-알킬헤테로사이클릴, O-알킬아릴, O-알킬헤테로아릴, OC(O)-알킬, OC(O)-R38, OC(O)-사이클로알킬, OC(O)-헤테로사이클릴, OC(O)-아릴, OC(O)-헤테로아릴, OC(O)-알킬사이클로알킬, OC(O)-알킬헤테로사이클릴 OC(O)-알킬아릴, OC(O)-알킬헤테로아릴, OC(O)O-R19, OC(O)NR18R18, OSO3H, OSO2-알킬, OSO2-사이클로알킬, OSO2-헤테로사이클릴, OSO2-아릴, OSO2-헤테로아릴, OSO2-알킬아릴, OSO2-알킬헤테로아릴, OP(O)(OH)2, OP(O)(O알킬)2, OP(O)(O아릴)2, C(O)-알킬, C(O)-아릴, C(O)-헤테로아릴, CO2H, CO2-알킬, CO2-R38, CO2-사이클로알킬, CO2-헤테로사 이클릴, CO2-아릴, CO2-헤테로아릴, CO2-알킬사이클로알킬, CO2-알킬헤테로사이클릴, CO2-알킬아릴, CO2-알킬헤테로아릴, C(O)-NH2, C(O)NH-알킬, C(O)NH-R38, C(O)NH-사이클로알킬, C(O)NH-헤테로사이클릴, C(O)NH-아릴, C(O)NH-헤테로아릴, C(O)NH-알킬사이클로알킬, C(O)NH-알킬헤테로사이클릴, C(O)NH-알킬아릴, C(O)NH-알킬헤테로아릴, C(O)N(알킬)2, C(O)N(사이클로알킬)2, C(O)N(아릴)2, C(O)N(헤테로아릴)2, C(O)NR20-알킬, C(O)NR19-알킬R21, -C(O)NR18-O-R18, -C(O)NR18NR18R18, SO2NH2, SO2NH-알킬, SO2NH-아릴, SO2NH-헤테로아릴, SO2NH-알킬아릴, SO3H, SO2-O-알킬, SO2-O-아릴, SO2-O-알킬아릴, 알킬, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴, 사이클로알킬, 헤테로사이클릴, 아릴 또는 헤테로아릴에 의해 동일하거나 상이하게 일치환 또는 다치환될 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 및 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,Unsubstituted or substituted heteroaryl, wherein the heteroaryl radical is selected from F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH Aryl, NH-heteroaryl, NH-alkylcycloalkyl, NH-alkylheterocyclyl, NH-alkylaryl, NH-alkylheteroaryl, N (alkyl) 2 , N (aryl) 2 , NR 20 -alkyl, NHC ( O) -alkyl, NHC (O) -R38, NR19C (O) -alkyl, NHC (O) -cycloalkyl, NR19C (O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -hetero Cyclyl, NHC (O) -aryl, NR19C (O) -aryl, NHC (O) -heteroaryl, NR19C (O) -heteroaryl, NR18C (O) -alkylcycloalkyl, NR18C (O) -alkylheterocycle Reel, NHC (O) -alkylaryl, NR19C (O) -alkylaryl, NHC (O) -alkylheteroaryl, NR19C (O) -alkylheteroaryl, NR18C (O) O-R19, NR18C (O) NR18R18, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkylheterocyclyl, NHSO 2 -alkylaryl, NHS O 2 -alkylheteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O -Aryl, O-heteroaryl, O-alkylcycloalkyl, O-alkylheterocyclyl, O-alkylaryl, O-alkylheteroaryl, OC (O) -alkyl, OC (O) -R38, OC (O) -Cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkylcycloalkyl, OC (O) -alkylheterocyclyl OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OC (O) O-R19, OC (O) NR18R18, OSO 3 H, OSO 2 -alkyl, OSO 2 - cycloalkyl, OSO 2 - heterocyclyl, OSO 2 -aryl, OSO 2 - heteroaryl, OSO 2 - alkyl aryl, OSO 2 - alkyl-heteroaryl, OP (O) (OH) 2, OP (O) (O -alkyl) 2, OP (O) ( O aryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocycle Reel, CO 2 - aryl, CO 2 - heteroaryl, CO 2 - alkyl-cycloalkyl, CO 2 - alkyl heterocyclic Reel, CO 2 - alkyl, aryl, CO 2 - alkyl-heteroaryl, C (O) -NH 2, C (O) NH- alkyl, C (O) NH-R38, C (O) NH- cycloalkyl, C ( O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH-alkylaryl, C (O) NH-alkylheteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , C (O) NR 20 -alkyl, C (O) NR 19 -alkylR 21, -C (O) NR 18 -O-R 18, -C (O) NR 18 NR 18 R 18, SO 2 NH 2 , SO 2 NH -Alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkylaryl, SO 3 H, SO 2 -O-alkyl, SO 2 -O-aryl, SO 2 -O-alkylaryl, alkyl Mono- or polysubstituted identically or differently by alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, alkyl, cycloalkyl, heterocycle Aryl, aryl, heteroaryl, alkylcycloalkyl, alkylhetero Cycle reel, alkyl aryl and alkyl-heteroaryl substituents may be substituted with one another per se, OR29, 여기서, R29는 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,OR29, wherein R29 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl, Heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for one another, SR30, 여기서, R30은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아 릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,SR30, wherein R30 can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, alkyl, cycloalkyl, heterocyclyl, aryl And heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted with each other, NR31R32, 여기서, R31 및 R32는 각각 독립적으로 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴, -C(O)-R33, SO2R33, C(O)OR33 및 C(O)-NR34R35일 수 있고, 여기서, R33은 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, NR31R32, wherein R31 and R32 are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, -C (O) -R33 , SO2R33, C (O) OR33 and C (O) -NR34R35, wherein R33 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkyl May be heteroaryl, R34 및 R35는 각각 독립적으로 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴, 알킬헤테로아릴일 수 있고, 또는 R34 및 R35는 함께 헤테로사이클릴 환을 형성할 수 있고, R34 and R35 may each independently be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, or R34 and R35 together may be heterocycle Can form a reel ring, 또는 R31 및 R32는 함께 헤테로사이클릴 환을 형성할 수 있고, Or R31 and R32 may together form a heterocyclyl ring, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴 및 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴 치환체는 자체로 서로 치환될 수 있고,Alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl substituents may themselves be substituted for one another, R18은 수소, 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R18 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, R19는 알킬, 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R 19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, R20은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴, 알킬사이클로알킬, 알킬헤테로사이클릴, 알킬아릴 또는 알킬헤테로아릴일 수 있고,R20 may be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, R21은 사이클로알킬, 헤테로사이클릴, 아릴, 헤테로아릴일 수 있고,R21 may be cycloalkyl, heterocyclyl, aryl, heteroaryl, R38은 알킬일 수 있고, 여기서, 알킬 라디칼은 9 내지 30개의 탄소원자를 갖는 포화되거나 불포화된, 직쇄 또는 측쇄일 수 있고, C9-30-알케닐은 하나 이상의 C-C 이중결합을 갖고, C9-30-알키닐은 하나 이상의 C-C 삼중결합을 갖고, 여기서, 알케닐은 (E)- 또는 (Z)-배치로 존재할 수 있는, 신규한 화학식 II의 피리도[2,3-b]피라진 유도체, 및 생리학적으로 허용되는 염, 화학식 I의 화합물의 유도체 또는 유사체, 및 이의 용매화물, 수화물, 다형태 및 프로드러그, 이의 라세미체 형태, 순수한 에난티오머 및/또는 부분입체이성체 형태 또는 이들 에난티오머 및/또는 부분입체이성체의 혼합물 형태 또는 호변체 형태로 존재하는 화학식 I의 화합물 및 이의 염, 유도체 또는 유사체, 이의 용매화물, 수화물, 다형태 및 프로드러그.R 38 may be alkyl, wherein the alkyl radical may be saturated or unsaturated, straight or branched chain having 9 to 30 carbon atoms, C 9-30 -alkenyl has one or more CC double bonds, and C 9- 30 -alkynyl has one or more CC triple bonds, wherein the alkenyl may be present in (E)-or (Z) -configuration, novel pyrido [2,3-b] pyrazine derivatives of Formula II, And physiologically acceptable salts, derivatives or analogues of the compounds of formula (I), and solvates, hydrates, polymorphs and prodrugs thereof, racemic forms thereof, pure enantiomers and / or diastereomeric forms or their enanties Compounds of formula (I) and salts, derivatives or analogs thereof, solvates, hydrates, polymorphs and prodrugs thereof, present in the form of mixtures or tautomers of thiomers and / or diastereomers. 제12항 또는 제13항에 있어서, R2 = H인 화학식 II의 피리도[2,3-b]피라진 유도체.14. The pyrido [2,3-b] pyrazine derivative of formula II according to claim 12 or 13, wherein R2 = H. 제12항 또는 제13항에 있어서, R2 및 R4 = H인 화학식 II의 피리도[2,3-b]피라진 유도체.14. The pyrido [2,3-b] pyrazine derivative of formula II according to claim 12 or 13, wherein R2 and R4 = H. 제12항에 있어서, R2 및 R4 = H이고, R6 = -C(Y)NR7R8이고, 여기서, Y는 독립적으로 O 또는 S일 수 있고, R7 및 R8은 각각 제12항에 정의된 바와 같은 화학식 II의 피리도[2,3-b]피라진 유도체. The compound of claim 12, wherein R 2 and R 4 = H and R 6 = —C (Y) NR 7 R 8, wherein Y may be independently O or S, and R 7 and R 8 are each as defined in claim 12. Pyrido [2,3-b] pyrazine derivatives of II. 제12항 또는 제13항에 있어서, 알킬 라디칼이 메틸, 에틸, n-프로필, 2-프로필, n-부틸, 2급-부틸, 3급-부틸, n-펜틸, 이소-펜틸, 네오-펜틸, n-헥실, 2-헥실, n-옥틸, 에틸레닐 (비닐), 에티닐, 프로페닐 (-CH2CH=CH2; -CH=CH-CH3; -C(=CH2)-CH3), 프로피닐 (-CH2-C≡CH, -CC≡CH3), 부테닐, 부티닐, 펜테닐, 펜티닐, 헥세닐, 헥시닐, 헵테닐, 헵티닐, 옥테닐 및 옥티닐일 수 있는 것을 특징으로 하는 화학식 II의 피리도[2,3-b]피라진 유도체.The process according to claim 12 or 13, wherein the alkyl radical is methyl, ethyl, n -propyl, 2-propyl, n -butyl, secondary -butyl, tert-butyl, n -pentyl, iso-pentyl, neo-pentyl , n -hexyl, 2-hexyl, n -octyl, ethylenyl (vinyl), ethynyl, propenyl (-CH 2 CH = CH 2 ; -CH = CH-CH 3 ; -C (= CH 2 ) -CH 3 ), propynyl (-CH2-C≡CH, -CC≡CH 3 ), butenyl, butynyl, pentenyl, pentynyl, hexenyl, hexynyl, heptenyl, heptynyl, octenyl and octinyl A pyrido [2,3-b] pyrazine derivative of formula (II). 제12항 또는 제13항에 있어서, 헤테로사이클릴 라디칼이 테트라하이드로푸릴, 피롤리디닐, 이미다졸리디닐, 티아졸리디닐, 테트라하이드로피라닐, 피페리디닐, 피페라지닐 및 모르폴리닐일 수 있는 것을 특징으로 하는 화학식 II의 피리도[2,3-b]피라진 유도체.14. The heterocyclyl radical of claim 12 or 13, wherein the heterocyclyl radical may be tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl. A pyrido [2,3-b] pyrazine derivative of formula (II). 제12항 또는 제13항에 있어서, 헤테로아릴 라디칼이 피롤릴, 푸릴, 티에닐, 티아졸릴, 옥사졸릴, 옥사디아졸릴, 이속사졸릴, 피라졸릴, 이미다졸릴, 트리아졸, 테트라졸, 피리디닐, 피리미디닐, 피리다지닐, 피라지닐, 트리아진, 프탈라지닐, 인돌릴, 인다졸릴, 인돌리지닐, 퀴놀리닐, 이소퀴놀리닐, 퀴녹살리닐, 퀴나졸리닐, 프테리디닐, 카바졸릴, 페나지닐, 페녹사지닐, 페노티아지닐, 아크리디닐일 수 있는 것을 특징으로 하는 화학식 II의 피리도[2,3-b]피라진 유도체.14. The heteroaryl radical according to claim 12 or 13, wherein the heteroaryl radical is pyrrolyl, furyl, thienyl, thiazolyl, oxazolyl, oxadizolyl, isoxazolyl, pyrazolyl, imidazolyl, triazole, tetrazole, pyri Dinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazine, phthalazinyl, indolyl, indazolyl, indolinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pterridinyl Pycardo [2,3-b] pyrazine derivatives of formula (II) which may be carbazolyl, phenazinyl, phenoxazinyl, phenothiazinyl, acridinyl. 제1항 내지 제19항 중의 어느 한 항에 있어서, 다음으로 이루어진 그룹으로부터 선택된 화학식 I 및 II의 피리도[2,3-b]피라진 유도체:20. The pyrido [2,3-b] pyrazine derivatives of formulas I and II selected from the group consisting of: 화합물 1 1-에틸-3-(3-페닐에티닐피리도[2,3-b]피라진-6-일)우레아Compound 1 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea
Figure 112008041801646-PCT00108
Figure 112008041801646-PCT00108
화합물 2 1-에틸-3-(3-티오펜-3-일에티닐피리도[2,3-b]피라진-6-일)우레아Compound 2 1-ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazin-6-yl) urea
Figure 112008041801646-PCT00109
Figure 112008041801646-PCT00109
화합물 3 1-(3-사이클로프로필에티닐피리도[2,3-b]피라진-6-일)-3-에틸우레아Compound 3 1- (3-cyclopropylethynylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea
Figure 112008041801646-PCT00110
Figure 112008041801646-PCT00110
화합물 4 1-[3-(3-디메틸아미노프로프-1-이닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 4 1- [3- (3-dimethylaminoprop-1-ynyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea
Figure 112008041801646-PCT00111
Figure 112008041801646-PCT00111
화합물 5 1-[3-((E)-2-사이클로헥실비닐)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 5 1- [3-((E) -2-cyclohexylvinyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea
Figure 112008041801646-PCT00112
Figure 112008041801646-PCT00112
화합물 6 1-에틸-3-[3-((E)-3-메톡시프로페닐)피리도[2,3-b]피라진-6-일]우레아Compound 6 1-ethyl-3- [3-((E) -3-methoxypropenyl) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00113
Figure 112008041801646-PCT00113
화합물 7Compound 7
Figure 112008041801646-PCT00114
Figure 112008041801646-PCT00114
화합물 8Compound 8
Figure 112008041801646-PCT00115
Figure 112008041801646-PCT00115
화합물 9 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 메틸 카보네이트Compound 9 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate
Figure 112008041801646-PCT00116
Figure 112008041801646-PCT00116
화합물 10 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트Compound 10 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate
Figure 112008041801646-PCT00117
Figure 112008041801646-PCT00117
화합물 11 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 페닐 카보네이트Compound 11 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl phenyl carbonate
Figure 112008041801646-PCT00118
Figure 112008041801646-PCT00118
화합물 12 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 디에틸카바메이트Compound 12 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl diethylcarbamate
Figure 112008041801646-PCT00119
Figure 112008041801646-PCT00119
화합물 13 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 (E)-3-페닐아크릴레이트Compound 13 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate
Figure 112008041801646-PCT00120
Figure 112008041801646-PCT00120
화합물 14 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 노나데카노에이트Compound 14 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate
Figure 112008041801646-PCT00121
Figure 112008041801646-PCT00121
화합물 15 1-(3-벤질피리도[2,3-b]피라진-6-일)-3-에틸우레아Compound 15 1- (3-benzylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea
Figure 112008041801646-PCT00122
Figure 112008041801646-PCT00122
화합물 16 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트Compound 16 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate
Figure 112008041801646-PCT00123
Figure 112008041801646-PCT00123
화합물 17 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 이소부틸 카보네이트Compound 17 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl isobutyl carbonate
Figure 112008041801646-PCT00124
Figure 112008041801646-PCT00124
화합물 18 부트-2-이닐 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트Compound 18 But-2-ynyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate
Figure 112008041801646-PCT00125
Figure 112008041801646-PCT00125
화합물 19 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 디메틸카바메이트Compound 19 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl dimethylcarbamate
Figure 112008041801646-PCT00126
Figure 112008041801646-PCT00126
화합물 20 4-[6-(3-에틸-1-페닐우레아)피리도[2,3-b]피라진-3-일]페닐 에틸카바메이트Compound 20 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl ethylcarbamate
Figure 112008041801646-PCT00127
Figure 112008041801646-PCT00127
화합물 21 3급-부틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-카바메이트 Compound 21 tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate
Figure 112008041801646-PCT00128
Figure 112008041801646-PCT00128
화합물 22 2-메톡시에틸 {4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-카바메이트Compound 22 2-methoxyethyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate
Figure 112008041801646-PCT00129
Figure 112008041801646-PCT00129
화합물 23 1-에틸-3-{3-[4-(3-에틸우레아)페닐]피리도[2,3-b]피라진-6-일}우레아Compound 23 1-ethyl-3- {3- [4- (3-ethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} urea
Figure 112008041801646-PCT00130
Figure 112008041801646-PCT00130
화합물 24 1-{3-[4-(3,3-디메틸우레아)페닐]피리도[2,3-b]피라진-6-일}-3-에틸우레아Compound 24 1- {3- [4- (3,3-dimethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea
Figure 112008041801646-PCT00131
Figure 112008041801646-PCT00131
화합물 25 1-에틸-3-{3-[6-(3-에틸우레아)피리딘-3-일]피리도[2,3-b]피라진-6-일}우레아Compound 25 1-ethyl-3- {3- [6- (3-ethylurea) pyridin-3-yl] pyrido [2,3-b] pyrazin-6-yl} urea
Figure 112008041801646-PCT00132
Figure 112008041801646-PCT00132
화합물 26 1-에틸-3-{3-[2-(4-플루오로페닐)에틸]피리도[2,3-b]피라진-6-일}우레아Compound 26 1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea
Figure 112008041801646-PCT00133
Figure 112008041801646-PCT00133
화합물 27 1-에틸-3-{3-[(E)-2-(4-플루오로페닐)비닐]피리도[2,3-b]피라진-6-일}-우레아Compound 27 1-ethyl-3- {3-[(E) -2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-yl} -urea
Figure 112008041801646-PCT00134
Figure 112008041801646-PCT00134
화합물 28 1-에틸-3-[3-(4-모르폴린-4-일메틸페닐)피리도[2,3-b]피라진-6-일]우레아Compound 28 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00135
Figure 112008041801646-PCT00135
화합물 29 1-에틸-3-(3-{4-[2-(2-메톡시에톡시)에톡시]페닐}피리도[2,3-b]피라진-6-일)우레아Compound 29 1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea
Figure 112008041801646-PCT00136
Figure 112008041801646-PCT00136
화합물 30 N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-2-(2-메톡시에톡시)아세트아미드Compound 30 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -2- (2-methoxyethoxy) acetamide
Figure 112008041801646-PCT00137
Figure 112008041801646-PCT00137
화합물 31 N-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-4-메틸벤즈아미드Compound 31 N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide
Figure 112008041801646-PCT00138
Figure 112008041801646-PCT00138
화합물 32 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 2-메톡시에틸 카보네이트Compound 32 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2-methoxyethyl carbonate
Figure 112008041801646-PCT00139
Figure 112008041801646-PCT00139
화합물 33 2-벤질옥시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트Compound 33 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate
Figure 112008041801646-PCT00140
Figure 112008041801646-PCT00140
화합물 34 2-벤질옥시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 카보네이트Compound 34 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl carbonate
Figure 112008041801646-PCT00141
Figure 112008041801646-PCT00141
화합물 35 2-벤질옥시-N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐}-아세트아미드Compound 35 2-benzyloxy-N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -acetamide
Figure 112008041801646-PCT00142
Figure 112008041801646-PCT00142
화합물 36 1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-(3-페닐피리도[2,3-b]-피라진-6-일)우레아Compound 36 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3-b] -pyrazin-6-yl) urea
Figure 112008041801646-PCT00143
Figure 112008041801646-PCT00143
화합물 37 1-[4-(3급-부틸디메틸실라닐옥시)부틸]-3-[3-(4-하이드록시-3-메 톡시페닐)피리도[2,3-b]피라진-6-일]우레아Compound 37 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine-6- Urea
Figure 112008041801646-PCT00144
Figure 112008041801646-PCT00144
화합물 38 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 에틸카바메이트Compound 38 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate
Figure 112008041801646-PCT00145
Figure 112008041801646-PCT00145
화합물 39 메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트Compound 39 Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate
Figure 112008041801646-PCT00146
Figure 112008041801646-PCT00146
화합물 40 2,2-디메틸[1,3]디옥솔란-4-일메틸 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸 카보네이트Compound 40 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate
Figure 112008041801646-PCT00147
Figure 112008041801646-PCT00147
화합물 41 2,3-디하이드록시프로필 4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]-부틸 카보네이트Compound 41 2,3-dihydroxypropyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] -butyl carbonate
Figure 112008041801646-PCT00148
Figure 112008041801646-PCT00148
화합물 42 디에틸 {4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}-포스페이트 Compound 42 diethyl {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} -phosphate
Figure 112008041801646-PCT00149
Figure 112008041801646-PCT00149
화합물 43 {4-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]부틸}인산Compound 43 {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphate
Figure 112008041801646-PCT00150
Figure 112008041801646-PCT00150
화합물 44 디에틸 (4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스페이트 Compound 44 diethyl (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate
Figure 112008041801646-PCT00151
Figure 112008041801646-PCT00151
화합물 45 (4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)인산Compound 45 (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate
Figure 112008041801646-PCT00152
Figure 112008041801646-PCT00152
화합물 46 1-에틸-3-[3-(3-트리메틸실라닐페닐)피리도[2,3-b]피라진-6-일]우레아Compound 46 1-ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00153
Figure 112008041801646-PCT00153
화합물 47 1-[3-(4-사이클로헥실페닐아미노)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 47 1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea
Figure 112008041801646-PCT00154
Figure 112008041801646-PCT00154
화합물 48 1-에틸-3-[3-(4-메탄설포닐페닐아미노)피리도[2,3-b]-피라진-6-일]우레아Compound 48 1-ethyl-3- [3- (4-methanesulfonylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea
Figure 112008041801646-PCT00155
Figure 112008041801646-PCT00155
화합물 49 N-{5-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]-2-메틸-페닐}메탄설폰아미드Compound 49 N- {5- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -2-methyl-phenyl} methanesulfonamide
Figure 112008041801646-PCT00156
Figure 112008041801646-PCT00156
화합물 50 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]-N-메틸-벤즈아미드Compound 50 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -N-methyl-benzamide
Figure 112008041801646-PCT00157
Figure 112008041801646-PCT00157
화합물 51 1-에틸-3-[3-(4-피페리딘-1-일메틸페닐아미노)피리도[2,3-b]-피라진-6-일]우레아Compound 51 1-ethyl-3- [3- (4-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea
Figure 112008041801646-PCT00158
Figure 112008041801646-PCT00158
화합물 52 1-에틸-3-[3-(4-티오펜-3-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 52 1-ethyl-3- [3- (4-thiophen-3-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00159
Figure 112008041801646-PCT00159
화합물 53 N-{4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]페닐}-아세트아미드Compound 53 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] phenyl} -acetamide
Figure 112008041801646-PCT00160
Figure 112008041801646-PCT00160
화합물 54 에틸 3-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일아미노]벤조에이트 Compound 54 ethyl 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] benzoate
Figure 112008041801646-PCT00161
Figure 112008041801646-PCT00161
화합물 55 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 2-메톡시에틸 카보네이트 하이드로클로라이드Compound 55 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride
Figure 112008041801646-PCT00162
Figure 112008041801646-PCT00162
화합물 56 2-메톡시에틸 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]페닐 카보네이트 p-톨루엔설포네이트Compound 56 2-methoxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate p-toluenesulfonate
Figure 112008041801646-PCT00163
Figure 112008041801646-PCT00163
화합물 57 4-{6-[3-(4-하이드록시부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트Compound 57 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate
Figure 112008041801646-PCT00164
Figure 112008041801646-PCT00164
화합물 58 4-{6-[3-(4-하이드록시부틸)우레아]피리도[2,3-b]피라진-3-일}페닐 2-메톡시에틸 카보네이트 하이드로클로라이드Compound 58 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride
Figure 112008041801646-PCT00165
Figure 112008041801646-PCT00165
화합물 59 N-(3-페닐피리도[2,3-b]피라진-6-일)옥살산 모노아미드 에틸 에스테르Compound 59 N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalic acid monoamide ethyl ester
Figure 112008041801646-PCT00166
Figure 112008041801646-PCT00166
화합물 60 N-에틸-N'-(3-페닐피리도[2,3-b]피라진-6-일)옥살아미드Compound 60 N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide
Figure 112008041801646-PCT00167
Figure 112008041801646-PCT00167
화합물 61Compound 61
Figure 112008041801646-PCT00168
Figure 112008041801646-PCT00168
화합물 62 디에틸 {2-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]에틸}-포스페이트 Compound 62 Diethyl {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} -phosphate
Figure 112008041801646-PCT00169
Figure 112008041801646-PCT00169
화합물 63 {2-[3-(3-페닐피리도[2,3-b]피라진-6-일)우레아]에틸}인산Compound 63 {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} phosphate
Figure 112008041801646-PCT00170
Figure 112008041801646-PCT00170
화합물 64 1-[3-(2-디에틸아미노에톡시)프로필]-3-[3-(4-하이드록시-3-메톡시-페닐)피리도[2,3-b]피라진-6-일]우레아Compound 64 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea
Figure 112008041801646-PCT00171
Figure 112008041801646-PCT00171
화합물 65 (2,2-디메틸프로피오닐옥시메톡시)-(4-{3-[3-(4-하이드록시-3-메톡시-페닐)피리도[2,3-b]피라진-6-일]우레아}부틸)포스피노일옥시메틸 2,2-디메틸-프로파노에이트Compound 65 (2,2-dimethylpropionyloxymethoxy)-(4- {3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea} butyl) phosphinoyloxymethyl 2,2-dimethyl-propanoate
Figure 112008041801646-PCT00172
Figure 112008041801646-PCT00172
화합물 66 1-[(1-아세톡시에톡시)-(4-{3-[3-(4-하이드록시-3-메톡시페닐)-피리도[2,3-b]피라진-6-일]우레아}부틸)포스피노일옥시]에틸 아세테이트Compound 66 1-[(1-acetoxyethoxy)-(4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazin-6-yl ] Urea} butyl) phosphinoyloxy] ethyl acetate
Figure 112008041801646-PCT00173
Figure 112008041801646-PCT00173
화합물 67 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]2-메톡시페닐 디에틸카바메이트Compound 67 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] 2-methoxyphenyl diethylcarbamate
Figure 112008041801646-PCT00174
Figure 112008041801646-PCT00174
화합물 68 2-클로로-4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-6-메톡시-페닐 디에틸카바메이트Compound 68 2-chloro-4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl diethylcarbamate
Figure 112008041801646-PCT00175
Figure 112008041801646-PCT00175
화합물 69 4-[6-(3-에틸우레아)피리도[2,3-b]피라진-3-일]-2-메톡시페닐 2-[2-(2-메톡시에톡시)에톡시]에틸 카보네이트Compound 69 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2- [2- (2-methoxyethoxy) ethoxy] Ethyl carbonate
Figure 112008041801646-PCT00176
Figure 112008041801646-PCT00176
화합물 70 1-에틸-3-[4-(모르폴린-4-설포닐)페닐아미노]피리도[2,3- b]피라진-6-일우레아Compound 70 1-ethyl-3- [4- (morpholin-4-sulfonyl) phenylamino] pyrido [2,3-b] pyrazin-6-ylurea
Figure 112008041801646-PCT00177
Figure 112008041801646-PCT00177
화합물 71 에틸 5-[6-(3-에틸우레이도)피리도[2,3-b]피라진-3-일아미노]-2-하이드록시-벤조에이트Compound 71 Ethyl 5- [6- (3-ethylureido) pyrido [2,3-b] pyrazin-3-ylamino] -2-hydroxy-benzoate
Figure 112008041801646-PCT00178
Figure 112008041801646-PCT00178
화합물 72 1-[3-(3-디에틸아미노메틸-4-하이드록시페닐아미노)피리도[2,3-b]피라진-6-일]-3-에틸우레아Compound 72 1- [3- (3-diethylaminomethyl-4-hydroxyphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea
Figure 112008041801646-PCT00179
Figure 112008041801646-PCT00179
화합물 73 1-에틸-3-[3-(6-모르폴린-4-일피리딘-3-일아미노)피리도[2,3-b]피라진-6-일]우레아Compound 73 1-ethyl-3- [3- (6-morpholin-4-ylpyridin-3-ylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00180
Figure 112008041801646-PCT00180
화합물 74 1-에틸-3-{3-[3-(1H-테트라졸-5-일)페닐아미노]피리도[2,3-b]피라 진-6-일}우레아Compound 74 1-ethyl-3- {3- [3- (1H-tetrazol-5-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea
Figure 112008041801646-PCT00181
Figure 112008041801646-PCT00181
화합물 75 1-에틸-3-[3-(3-모르폴린-4-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 75 1-ethyl-3- [3- (3-morpholin-4-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00182
Figure 112008041801646-PCT00182
화합물 76 1-에틸-3-[3-(4-이미다졸-1-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 76 1-ethyl-3- [3- (4-imidazol-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00183
Figure 112008041801646-PCT00183
화합물 77 1-에틸-3-[3-(4-피롤리딘-1-일페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 77 1-ethyl-3- [3- (4-pyrrolidin-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00184
Figure 112008041801646-PCT00184
화합물 78 1-에틸-3-{3-[4-(4-메틸피페라진-1-일)페닐아미노]피리도[2,3-b]피라진-6-일}우레아Compound 78 1-ethyl-3- {3- [4- (4-methylpiperazin-1-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea
Figure 112008041801646-PCT00185
Figure 112008041801646-PCT00185
화합물 79 1-에틸-3-[3-(3-피페리딘-1-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 79 1-ethyl-3- [3- (3-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00186
Figure 112008041801646-PCT00186
화합물 80 1-에틸-3-[3-(4-모르폴린-4-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 80 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00187
Figure 112008041801646-PCT00187
화합물 81 1-{3-[3-(2-사이클로헥실에톡시)페닐아미노]피리도[2,3-b]피라진-6-일}-3-에틸우레아Compound 81 1- {3- [3- (2-cyclohexylethoxy) phenylamino] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea
Figure 112008041801646-PCT00188
Figure 112008041801646-PCT00188
화합물 82 1-에틸-3-[3-(3-[1,2,4]트리아졸-1-일메틸페닐아미노)피리도[2,3-b]피라진-6-일]우레아Compound 82 1-ethyl-3- [3- (3- [1,2,4] triazol-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea
Figure 112008041801646-PCT00189
Figure 112008041801646-PCT00189
화합물 83 2,2-디메틸[1,3]디옥솔란-4-일메틸 4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레이도}부틸 카보네이트Compound 83 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine- 6-yl] ureido} butyl carbonate
Figure 112008041801646-PCT00190
Figure 112008041801646-PCT00190
화합물 84 2,3-디하이드록시프로필 4-{3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레이도}부틸 카보네이트Compound 84 2,3-dihydroxypropyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] ureido} butyl carbonate
Figure 112008041801646-PCT00191
Figure 112008041801646-PCT00191
화합물 85 1-[3-(2-디에틸아미노에톡시)프로필]-3-[3-(4-하이드록시-3-메톡시페닐)피리도[2,3-b]피라진-6-일]우레아Compound 85 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl Urea
Figure 112008041801646-PCT00192
Figure 112008041801646-PCT00192
제1항 내지 제20항 중의 어느 한 항에 따른 하나 이상의 피리도[2,3-b]피라진 유도체를 포함하는 약제. A medicament comprising at least one pyrido [2,3-b] pyrazine derivative according to any one of claims 1 to 20. 제21항에 있어서, 하나 이상의 추가의 약제학적 활성 성분 및/또는 약제학적으로 허용되는 담체 및/또는 부형제와 배합된 피리도[2,3-b]피라진 유도체를 포함하는 약제.The pharmaceutical agent of claim 21 comprising a pyrido [2,3-b] pyrazine derivative in combination with one or more additional pharmaceutically active ingredients and / or pharmaceutically acceptable carriers and / or excipients. 제1항 내지 제20항 중의 어느 한 항에 따른 하나 이상의 피리도[2,3-b]피라진 유도체를 약제학적으로 허용되는 담체 및/또는 부형제와 함께 가공하여 약제학 적 제형을 제공하고 치료학적으로 유용한 형태로 만드는 것을 특징으로 하는, 제21항 또는 제22항에 따른 약제의 제조방법. 21. The at least one pyrido [2,3-b] pyrazine derivative according to any one of claims 1 to 20 can be processed with a pharmaceutically acceptable carrier and / or excipient to provide a pharmaceutical formulation and to provide a therapeutic 23. A method of making a medicament according to claim 21 or 22, characterized in that it is made in a useful form. 약제학적 제제로서 사용되는 제1항 내지 제20항 중의 어느 한 항에 따른 화합물. A compound according to any one of claims 1 to 20 for use as a pharmaceutical preparation. 잘못 지시된 세포 신호전달 프로세스를 조절하기 위한, 특히 활성 및 불활성 수용체 티로신 키나제, 및 또한 세포질 티로신, 세린/트레오닌 및 지질 키나제, 예를 들면, c-Raf, B-Raf, Mek, MAPKs, PDGFR베타, Flt-3, IGF1R, PI3K, PKB/Akt1, c-Kit, c-Abl, FGFR1 및 KDR의 작용에 영향을 주기 위한 약제 제조용 제1항 내지 제20항 중의 어느 한 항에 따른 화합물의 용도. Active and inactive receptor tyrosine kinases, and also cytoplasmic tyrosine, serine / threonine and lipid kinases, such as c-Raf, B-Raf, Mek, MAPKs, PDGFRbeta, for modulating misdirected cellular signaling processes Use of a compound according to any one of claims 1 to 20 for the manufacture of a medicament for affecting the action of Flt-3, IGF1R, PI3K, PKB / Akt1, c-Kit, c-Abl, FGFR1 and KDR. 포유 동물에서 "ras-Raf-Mek-Erk 신호전달경로, PI3K-Akt 신호전달경로 및/또는 SAPK 신호전달경로"로 이루어진 그룹으로부터 선택된 신호전달경로에 의해 매개된 생리학적 및/또는 병태생리학적 상태의 치료 또는 예방용 약제를 제조하기 위한 제1항 내지 제20항 중의 어느 한 항에 따른 화합물의 용도. Physiological and / or pathophysiological conditions mediated by signaling pathways selected from the group consisting of "ras-Raf-Mek-Erk signaling pathway, PI3K-Akt signaling pathway and / or SAPK signaling pathway" in mammals. Use of a compound according to any one of claims 1 to 20 for the manufacture of a medicament for the treatment or prophylaxis. 치료 또는 예방이 "ras-Raf-Mek-Erk 신호전달경로, PI3K-Akt 신호전달경로 및/또는 SAPK 신호전달경로"로 이루어진 그룹으로부터 선택된 신호전달경로(들)를 조절함에 의해 야기되는, 제1항 내지 제20항 또는 제26항 중의 어느 한 항에 따른 화합물의 용도. A first, wherein the treatment or prevention is caused by adjusting a signaling pathway (s) selected from the group consisting of "ras-Raf-Mek-Erk signaling pathway, PI3K-Akt signaling pathway and / or SAPK signaling pathway" Use of a compound according to any one of claims 20 to 26. 제1항 내지 제20항 또는 제26항 중의 어느 한 항에 있어서, 생리학적 및/또는 병태생리학적 상태가 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택된 효소에 의해 매개된 용도.27. The enzyme according to any one of claims 1 to 20 or 26, wherein the physiological and / or pathophysiological condition is selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1". Use mediated by. 제1항 내지 제20항, 제26항 또는 제28항 중의 어느 한 항에 있어서, 치료 또는 예방이 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택된 하나 이상의 효소의 조절에 의해 야기되는 용도. The method according to any one of claims 1 to 20, 26 or 28, wherein the treatment or prophylaxis is carried out of one or more enzymes selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1". Use caused by regulation. 제1항 내지 제20항, 제26항 또는 제27항 중의 어느 한 항에 있어서, 매개 및/또는 조절되는 신호전달경로가 ras-Raf-Mek-Erk 신호전달경로 및 PI3K-Akt 신호전달경로인 용도.28. The method according to any one of claims 1 to 20, 26 or 27, wherein the signaling pathways mediated and / or regulated are ras-Raf-Mek-Erk signaling pathways and PI3K-Akt signaling pathways. Usage. 제1항 내지 제20항, 제26항 또는 제27항 중의 어느 한 항에 있어서, 매개 및/또는 조절되는 신호전달경로가 Raf-Mek-Erk 신호전달경로인 용도.28. The use according to any one of claims 1 to 20, 26 or 27, wherein the signaling pathway mediated and / or regulated is Raf-Mek-Erk signaling pathway. 제1항 내지 제20항, 제26항 또는 제27항 중의 어느 한 항에 있어서, 매개 및/또는 조절되는 신호전달경로가 PI3K-Akt 신호전달경로인 용도.28. The use according to any one of claims 1 to 20, 26 or 27, wherein the signaling pathway mediated and / or regulated is a PI3K-Akt signaling pathway. 제1항 내지 제20항, 제26항 또는 제27항 중의 어느 한 항에 있어서, 매개 및/또는 조절되는 신호전달경로가 SAPK 신호전달경로 및 PI3K-Akt 신호전달경로인 용도.28. The use according to any one of claims 1 to 20, 26 or 27, wherein the signaling pathways mediated and / or regulated are SAPK signaling pathways and PI3K-Akt signaling pathways. 제1항 내지 제20항, 제26항 또는 제27항 중의 어느 한 항에 있어서, 매개 및/또는 조절되는 신호전달경로가 SAPK 신호전달경로인 용도.28. The use according to any of claims 1 to 20, 26 or 27, wherein the signaling pathway mediated and / or regulated is an SAPK signaling pathway. 제1항 내지 제20항, 제26항, 제27항, 제30항 또는 제31항 중의 어느 한 항에 있어서, ras-Raf-Mek-Erk 신호전달경로의 조절이 "티로신 키나제, 세린/트레오닌 키나제, 수용체-티로신 키나제, 세포질 티로신 키나제, 세포질 세린/트레오닌 키나제"로 이루어진 그룹으로부터 선택되는 하나 이상의 효소의 조절에 의해 야기되는 용도. 32. The method of any one of claims 1-20, 26, 27, 30, or 31, wherein the regulation of ras-Raf-Mek-Erk signaling pathway is "tyrosine kinase, serine / threonine." Kinase, receptor-tyrosine kinase, cytoplasmic tyrosine kinase, cytoplasmic serine / threonine kinase ". 제35항에 있어서, 효소가 "Erk, Erk1, Erk2"로 이루어진 그룹으로부터 선택되는 용도. 36. The use of claim 35, wherein the enzyme is selected from the group consisting of "Erk, Erk1, Erk2". 제1항 내지 제20항, 제26항, 제27항, 제30항, 제32항 또는 제33항 중의 어느 한 항에 있어서, PI3K-Akt 신호전달경로의 조절이 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택된 하나 이상의 효소의 조절에 의해 야기되는 용도.34. The method according to any one of claims 1 to 20, 26, 27, 30, 32 or 33, wherein the regulation of the PI3K-Akt signaling pathway is "PI3K, PI3K alpha, PI3K. Use caused by the modulation of one or more enzymes selected from the group consisting of beta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p ". 제1항 내지 제20항, 제26항, 제27항, 제33항 또는 제34항 중의 어느 한 항에 있어서, SAPK 신호전달경로의 조절이 티로신 키나제, 세린/트레오닌 키나제, 수용체-티로신 키나제, 세포질 티로신 키나제, 세포질 세린/트레오닌 키나제"로 이루어진 그룹으로부터 선택된 하나 이상의 효소의 조절에 의해 야기되는 용도. 35. The method of any one of claims 1-20, 26, 27, 33, or 34, wherein the regulation of SAPK signaling pathways comprises tyrosine kinases, serine / threonine kinases, receptor-tyrosine kinases, And cytoplasmic tyrosine kinases, cytoplasmic serine / threonine kinases. 제38항에 있어서, 효소가 "Jnk, Jnk1, Jnk2, Jnk3, p38, p38알파, p38베타, p38감마, p38델타"로 이루어진 그룹으로부터 선택되는 용도.The use according to claim 38, wherein the enzyme is selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38 alpha, p38 beta, p38 gamma, p38 delta". 제1항 내지 제20항 및 제25항 내지 제39항 중의 어느 한 항에 있어서, 2개 이상의 효소가 조절되는 용도.40. The use of any one of claims 1-20 and 25-39, wherein at least two enzymes are regulated. 제40항에 있어서, 하나 이상의 효소가 "Erk, Erk1, Erk2"로 이루어진 그룹으로부터 선택되고, 하나 이상의 효소가 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되는 용도.The method of claim 40, wherein the one or more enzymes are selected from the group consisting of “Erk, Erk1, Erk2” and the one or more enzymes are “PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K- C2beta, PI3K-Vps34p ". 제40항에 있어서, 하나 이상의 효소가 "Jnk, Jnk1, Jnk2, Jnk3, p38, p38알파, p38베타, p38감마, p38델타"로 이루어진 그룹으로부터 선택되고, 하나 이상의 효소가 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베 타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되는 용도.The method of claim 40, wherein the one or more enzymes are selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta", and the one or more enzymes are selected from "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p ". 제40항에 있어서, 하나 이상의 효소가 "Erk, Erk1, Erk2"로 이루어진 그룹으로부터 선택되고, 하나 이상의 효소가 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 용도.41. The use of claim 40, wherein at least one enzyme is selected from the group consisting of "Erk, Erk1, Erk2" and at least one enzyme is selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1" . 제40항에 있어서, 하나 이상의 효소가 "Jnk, Jnk1, Jnk2, Jnk3, p38, p38알파, p38베타, p38감마, p38델타"로 이루어진 그룹으로부터 선택되고, 하나 이상의 효소가 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 용도.The method of claim 40, wherein the one or more enzymes are selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta", wherein the one or more enzymes are "ATM, ATR, mTOR" , DNA-PK, hSMG-1 ″. 제40항에 있어서, 하나 이상의 효소가 "PI3K, PI3K알파, PI3K베타, PI3K감마, PI3K델타, PI3K-C2알파, PI3K-C2베타, PI3K-Vps34p"로 이루어진 그룹으로부터 선택되고, 하나 이상의 효소가 "ATM, ATR, mTOR, DNA-PK, hSMG-1"로 이루어진 그룹으로부터 선택되는 용도.The method of claim 40, wherein the one or more enzymes are selected from the group consisting of "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p", and the one or more enzymes are Use selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1". 제1항 내지 제20항 및 제25항 내지 제45항 중의 어느 한 항에 있어서, 조절이 억제인 용도. 46. The use of any one of claims 1-20 and 25-45, wherein the regulation is inhibition. 제1항 내지 제20항 및 제26항 내지 제46항 중의 어느 한 항에 있어서, 포유 동물이 "사람, 유용한 동물, 가축, 가정용 애완동물, 육우, 소, 양, 돼지, 염소, 말, 조랑말, 당나귀, 버새, 노새, 산토끼, 토끼, 고양이, 개, 기니아피그, 햄스터, 래트, 마우스"로 이루어진 그룹으로부터 선택되고, 바람직하게는 사람인 용도. 47. The method of any of claims 1-20 and 26-46, wherein the mammal is a "human, useful animal, livestock, domestic pet, beef, cow, sheep, pig, goat, horse, pony. , Donkey, burrow, mule, hare, rabbit, cat, dog, guinea pig, hamster, rat, mouse ". 제1항 내지 제20항 및 제26항 내지 제47항 중의 어느 한 항에 있어서, 생리학적 및/또는 병태생리학적 상태가 "악성 종양, 양성 종양, 염증성 장애, 염증, 통증, 류마티스 장애, 관절염 장애, HIV 감염, 신경계 또는 신경변성 장애, 류마티스, 관절염, AIDS, ARC (AIDS 관련 복합증), 카포시 육종, 뇌 및/또는 신경계 및/또는 뇌척수막으로부터 퍼지는 종양, 치매, 알츠하이머질환, 과다증식성 장애, 건선, 자궁내막증, 흉터 형성, 전립샘비대 (BPH), 면역계 장애, 자가면역 장애, 면역결핍 장애, 결장 종양, 위 종양, 장 종양, 폐 종양, 췌장 종양, 난소 종양, 전립샘 종양, 백혈병, 흑색종, 간 종양, 신장 종양, 두부 종양, 인후 종양, 신경아교종, 유방 종양, 자궁 암, 자궁내막 암, 자궁경부 암, 뇌 종양, 선극세포종, 방광 암, 위 종양, 결장 종양, 식도 암, 부인과 종양, 난소 종양, 갑상샘 암, 림프종, 만성 백혈병, 급성 백혈병, 재협착, 당뇨병, 당뇨병성 신병증, 섬유성 장애, 낭성섬유증, 악성 신장경화증, 혈전미세혈관병증 증후군, 기관이식거부, 사구체병증, 대사 장애, 고형 종양, 류마티스관절염, 당뇨병성 망막병증, 천식, 알레르기, 알레르기 장애, 만성 폐색성폐질환, 염증성 장질환, 섬유증, 아테롬성 동맥경화증, 심장 장애, 심혈관 장애, 심장근육의 장애, 혈관 장애, 혈관신생 장애, 신장 장애, 비염, 그레이브 질환, 국소 허혈, 심부전증, 허혈, 심장 비대, 신장 부전, 심장 근세포 기능장애, 고혈압, 혈관 협착, 뇌졸중, 과민성 쇼크, 혈소판 응집, 골격근 위축, 비만, 과체중, 글루코스 항상성, 울혈심부전증, 협심증, 심장 발작, 심근경색증, 과혈당, 저혈당, 고혈압"으로 이루어진 그룹으로부터 선택되는 용도. The method according to any one of claims 1 to 20 and 26 to 47, wherein the physiological and / or pathophysiological condition is "malignant tumor, benign tumor, inflammatory disorder, inflammation, pain, rheumatic disorder, arthritis" Disorders, HIV infection, neurological or neurodegenerative disorders, rheumatism, arthritis, AIDS, ARC (AIDS related complications), Kaposi's sarcoma, tumors spreading from the brain and / or nervous system and / or meninges, dementia, Alzheimer's disease, hyperproliferative disorders, Psoriasis, endometriosis, scar formation, prostatic hypertrophy (BPH), immune system disorders, autoimmune disorders, immunodeficiency disorders, colon tumors, gastric tumors, intestinal tumors, lung tumors, pancreatic tumors, ovarian tumors, prostate tumors, leukemias, melanoma , Liver tumor, kidney tumor, head tumor, throat tumor, glioma, breast tumor, uterine cancer, endometrial cancer, cervical cancer, brain tumor, adenocytoma, bladder cancer, stomach tumor, colon tumor, esophageal cancer, gynecological tumor Ovarian tumor , Thyroid cancer, lymphoma, chronic leukemia, acute leukemia, restenosis, diabetes, diabetic nephropathy, fibrotic disorder, cystic fibrosis, malignant nephropathy, thrombotic microangiopathy syndrome, tracheal rejection, glomerulopathy, metabolic disorders, solid Tumors, rheumatoid arthritis, diabetic retinopathy, asthma, allergies, allergic disorders, chronic obstructive pulmonary disease, inflammatory bowel disease, fibrosis, atherosclerosis, heart disorders, cardiovascular disorders, heart muscle disorders, vascular disorders, angiogenic disorders, Kidney disorders, rhinitis, Grave disease, focal ischemia, heart failure, ischemia, cardiac hypertrophy, kidney failure, cardiomyocyte dysfunction, hypertension, vascular narrowing, stroke, hypersensitivity shock, platelet aggregation, skeletal muscle atrophy, obesity, overweight, glucose homeostasis, congestion Heart failure, angina pectoris, heart attack, myocardial infarction, hyperglycemia, hypoglycemia, hypertension ". 제1항 내지 제22항, 제24항 또는 제26항 내지 제48항 중의 어느 한 항에 있어서, 약제가 하나 이상의 추가의 약리학적 활성 물질을 포함하는 용도.49. The use of any one of claims 1 to 22, 24 or 26 to 48, wherein the medicament comprises one or more additional pharmacologically active substances. 제1항 내지 제22항, 제24항 또는 제26항 내지 제48항 중의 어느 한 항에 있어서, 약제가 치료 전 및/또는 치료 동안 및/또는 치료 후 하나 이상의 추가의 약리학적 활성 물질과 함께 투여되는 용도. 49. The method of any one of claims 1 to 22, 24 or 26 to 48, wherein the medicament is combined with one or more additional pharmacologically active substances before and / or during and / or after treatment. Use administered. 제1항 내지 제22항, 제24항 또는 제26항 내지 제48항 중의 어느 한 항에 있어서, 약제가 방사선요법 및/또는 수술에 의한 치료 전 및/또는 치료 동안 및/또는 치료 후 투여되는 용도.49. The method according to any one of claims 1 to 22, 24 or 26 to 48, wherein the medicament is administered before and / or during and / or after treatment by radiotherapy and / or surgery. Usage. 제49항 또는 제50항에 있어서, 추가의 약리학적 활성 물질이 "DNA 국소이성화효소 I 및/또는 II 억제제, DNA 삽입제(intercalator), 알킬화제, 미세관 탈안정화제, 호르몬 및/또는 성장 인자 수용체 작용제 및/또는 길항제, 성장 인자 및 이의 수용체에 대한 항체, 키나제 억제제, 항대사물질"로 이루어진 그룹으로부터 선택되는 용도. 51. The method of claim 49 or 50, wherein the additional pharmacologically active agent is selected from the group consisting of "DNA isomerase I and / or II inhibitors, DNA intercalators, alkylating agents, microtubule destabilizing agents, hormones and / or growth factors. Receptor agonists and / or antagonists, growth factors and antibodies to the receptors thereof, kinases inhibitors, anti-metabolites. 제49항, 제50항 또는 제52항 중의 어느 한 항에 있어서, 추가의 약리학적 활성 물질이 "아스파라기나제, 블레오마이신, 카보플라틴, 카르무스틴, 클로르암부실, 시스플라틴, 콜라스파제, 사이클로포스파미드, 시타라빈, 다카바진, 다크티노마이신, 다우노루비신, 독소루비신 (아드리아마이신), 에피루비신, 에토포사이드, 5-플루오로우라실, 헥사메틸멜라민, 하이드록시우레아, 이포스파미드, 이리노테칸, 류코보린, 로무스틴 메클로르에타민, 6-머캅토푸린, 메스나, 메토트렉세이트, 미토마이신 C, 미톡산트론, 프레드니솔론, 프레드니손, 프로카바진, 랄록시펜, 스트렙토조신, 타목시펜, 티오구아닌, 토포테칸, 빈블라스틴, 빈크리스틴, 빈데신, 아미노글루테티미드, L-아스파라기나제, 아자티오프린, 5-아자시티딘 클라드리빈, 부설판, 디에틸스틸베스트롤, 2',2'-디플루오로데옥시시티딘, 독세탁셀, 에리트로하이드록시노닐아데닌, 에티닐에스트라디올, 5-플루오로데옥시우리딘, 5-플루오로데옥시우리딘 모노포스페이트, 플루다라빈 포스페이트, 플루옥시메스테론, 플루타미드, 하이드록시프로게스테론 카프로에이트, 이다루비신, 인터페론, 메드록시프로게스테론 아세테이트, 메게스트롤 아세테이트, 메팔란, 미토탄, 파클리탁셀, 옥살리플라틴, 펜토스타틴, N-포스포노아세틸-L-아스파르테이트 (PALA), 플리카마이신, 세무스틴, 테니포사이드, 테스토스테론 프로피오네이트, 티오테파, 트리메틸멜라민, 우리딘, 비노렐빈, 에포틸론, 겜시타빈, 탁소테레, BCNU, CCNU, DTIC, 5-플루오로우라실, 헤르셉틴, 아바스틴, 에르비툭스, 소라페니브, 글리벡, 이레사, 타르세바, 라파마이신, 아크티노마이신 D"로 이루어진 그룹으로부터 선택되는 용도.53. The method according to any one of claims 49, 50 or 52, wherein the additional pharmacologically active substance is "asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase. , Cyclophosphamide, cytarabine, dacarbazine, darktinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide , Irinotecan, leucovorin, lomustine mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifene, streptozosin, tamoxifen, thioguanine, Topotecan, vinblastine, vincristine, vindesine, aminoglutetimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2 ' , 2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyl adenine, ethynylestradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine Phosphate, Fluoxymesterone, Flutamide, Hydroxyprogesterone caproate, Idarubicin, Interferon, Medroxyprogesterone acetate, Megestrol acetate, Mephalan, Mitotan, Paclitaxel, Oxaliplatin, Pentostatin, N-phosphono Acetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, vinorelbine, epothilone, gemcitabine, taxotere, BCNU, CCNU , DTIC, 5-Fluorouracil, Herceptin, Avastin, Erbitux, Sorafenib, Gleevec, Iresa, Tarceva, Rapamycin, Actinomycin D " Applications are selected from. 하나 이상의 제1항 내지 제20항 중의 어느 한 항에 따른 화합물의 약리학적 활성 양을 포함하는 약제학적 조성물.A pharmaceutical composition comprising at least one pharmacologically active amount of a compound according to any one of claims 1 to 20. 제54항에 있어서, 활성 성분이 환자 체중 1kg당 0.001mg 내지 100mg의 단위 용량으로 존재하는 약제학적 조성물.The pharmaceutical composition of claim 54, wherein the active ingredient is present in unit doses from 0.001 mg to 100 mg per kg body weight of the patient. 제54항 또는 제55항에 있어서, 하나 이상의 약제학적으로 허용되는 담체 및/또는 부형제를 추가로 포함하는 약제학적 조성물. The pharmaceutical composition of claim 54 or 55, further comprising one or more pharmaceutically acceptable carriers and / or excipients. 제54항 내지 제56항 중의 어느 한 항에 있어서, 하나 이상의 추가의 약리학적 활성 성분을 포함하는 약제학적 조성물. The pharmaceutical composition of any one of claims 54-56, wherein the pharmaceutical composition comprises one or more additional pharmacologically active ingredients. 제57항에 있어서, 추가의 약리학적 활성 물질이 "DNA 국소이성화효소 I 및/또는 II 억제제, DNA 삽입제(intercalator), 알킬화제, 미세관 탈안정화제, 호르몬 및/또는 성장 인자 수용체 작용제 및/또는 길항제, 성장 인자 및 이의 수용체에 대한 항체, 키나제 억제제, 항대사물질"로 이루어진 그룹으로부터 선택되는 약제학적 조성물. 58. The method according to claim 57, wherein the additional pharmacologically active substance is a "DNA isomerase I and / or II inhibitor, DNA intercalator, alkylating agent, microtubule destabilizing agent, hormone and / or growth factor receptor agonist and / or Or an antibody against an antagonist, a growth factor and a receptor thereof, a kinase inhibitor, an anti-metabolic agent. 제57항 또는 제58항에 있어서, 추가의 약리학적 활성 성분이 "아스파라기나 제, 블레오마이신, 카보플라틴, 카르무스틴, 클로르암부실, 시스플라틴, 콜라스파제, 사이클로포스파미드, 시타라빈, 다카바진, 다크티노마이신, 다우노루비신, 독소루비신 (아드리아마이신), 에피루비신, 에토포사이드, 5-플루오로우라실, 헥사메틸멜라민, 하이드록시우레아, 이포스파미드, 이리노테칸, 류코보린, 로무스틴 메클로르에타민, 6머캅토푸린, 메스나, 메토트렉세이트, 미토마이신 C, 미톡산트론, 프레드니솔론, 프레드니손, 프로카바진, 랄록시펜, 스트렙토조신, 타목시펜, 티오구아닌, 토포테칸, 빈블라스틴, 빈크리스틴, 빈데신, 아미노글루테티미드, L-아스파라기나제, 아자티오프린, 5-아자시티딘 클라드리빈, 부설판, 디에틸스틸베스트롤, 2',2'-디플루오로데옥시시티딘, 독세탁셀, 에리트로하이드록시노닐아데닌, 에티닐에스트라디올, 5-플루오로데옥시우리딘, 5-플루오로데옥시우리딘 모노포스페이트, 플루다라빈 포스페이트, 플루옥시메스테론, 플루타미드, 하이드록시프로게스테론 카프로에이트, 이다루비신, 인터페론, 메드록시프로게스테론 아세테이트, 메게스트롤 아세테이트, 메팔란, 미토탄, 파클리탁셀, 옥살리플라틴, 펜토스타틴, N-포스포노아세틸-L-아스파르테이트 (PALA), 플리카마이신, 세무스틴, 테니포사이드, 테스토스테론 프로피오네이트, 티오테파, 트리메틸멜라민, 우리딘, 비노렐빈, 에포틸론, 겜시타빈, 탁소테레, BCNU, CCNU, DTIC, 5-플루오로우라실, 헤르셉틴, 아바스틴, 에르비툭스, 소라페니브, 글리벡, 이레사, 타르세바, 라파마이신, 아크티노마이신 D"로 이루어진 그룹으로부터 선택된 약제학적 조성물.59. The method according to claim 57 or 58, wherein the additional pharmacologically active ingredient is "asparagine, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, cholaspase, cyclophosphamide, cita Lavigne, dacarbazine, darktinomycin, daunorubicin, doxorubicin (Adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomu Sten mechlorethamine, 6 mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifene, streptozosin, tamoxifen, thioguanine, topotecan, vinblastine, vinblastine Christine, Bindesin, Aminoglutetimide, L-Asparaginase, Azathioprine, 5-Azacytidine Cladribine, Busulfan, Diethylstilbestrol, 2 ', 2'-difluorodeoxysi Dean, docetaxel, erythrohydroxynonyladenine, ethynylestradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide , Hydroxyprogesterone caproate, idarubicin, interferon, hydroxyprogesterone acetate, megestrol acetate, mephalan, mitotan, paclitaxel, oxaliplatin, pentostatin, N-phosphonoacetyl-L-aspartate (PALA) , Plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, vinorelbine, epothilone, gemcitabine, taxotere, BCNU, CCNU, DTIC, 5-fluorouracil, her Pharmaceuticals selected from the group consisting of Septin, Avastin, Erbitux, Sorafenib, Gleevec, Iresa, Tarceva, Rapamycin, Actinomycin D " Dangerous. 약리학적 활성 양의 제1항 내지 제20항 중의 어느 한 항에 따른 화합물 하나 이상 및 약리학적 활성 양의 제57항 내지 제59항 중의 어느 한 항에 따른 추가의 약리학적 활성 성분 하나 이상을 포함하는 키트. 60. A pharmacologically active amount comprising at least one compound according to claim 1 and at least one additional pharmacologically active ingredient according to any one of claims 57 to 59. Kit.
KR1020087014068A 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases KR101400905B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US73569805P 2005-11-11 2005-11-11
EP05024693A EP1785423A1 (en) 2005-11-11 2005-11-11 Pyridopyrazine derivatives and their use as kinase modulators
US60/735,698 2005-11-11
EP05024693.3 2005-11-11
US84976106P 2006-10-06 2006-10-06
US60/849,761 2006-10-06
PCT/EP2006/068322 WO2007054556A1 (en) 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases

Publications (2)

Publication Number Publication Date
KR20080068117A true KR20080068117A (en) 2008-07-22
KR101400905B1 KR101400905B1 (en) 2014-05-29

Family

ID=37654792

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087014068A KR101400905B1 (en) 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases

Country Status (10)

Country Link
EP (1) EP1957487A1 (en)
JP (1) JP5527972B2 (en)
KR (1) KR101400905B1 (en)
AR (1) AR060010A1 (en)
AU (1) AU2006313701B2 (en)
CA (1) CA2628039A1 (en)
HK (1) HK1126474A1 (en)
IL (1) IL191139A0 (en)
NO (1) NO20082511L (en)
WO (1) WO2007054556A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790342A1 (en) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
PT3122358T (en) 2014-03-26 2021-03-04 Astex Therapeutics Ltd Combinations
DK3122359T3 (en) 2014-03-26 2021-03-08 Astex Therapeutics Ltd COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2996989C (en) 2015-09-23 2023-10-03 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
LT3353177T (en) 2015-09-23 2020-08-25 Janssen Pharmaceutica Nv Tricyclic heterocycles for the treatment of cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809695A (en) 1967-04-19 1974-05-07 Degussa 2,6-dichloro-3-nitro-pyridine
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
EP0735025B1 (en) 1995-03-28 1998-07-01 Sumitomo Chemical Company Limited Process for producing aminonitropyridines
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
MXPA00006233A (en) 1997-12-22 2002-09-18 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS.
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
SK8712001A3 (en) 1998-12-22 2002-02-05 Warner Lambert Co Combination chemotherapy
AU5566701A (en) 2000-04-25 2001-11-07 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
EP1301472B1 (en) 2000-07-19 2014-03-26 Warner-Lambert Company LLC Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
BR0212510A (en) 2001-09-14 2004-08-24 Methylgene Inc Histone Deacetylase Inhibitor, Compound and Composition
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
AU2003226301A1 (en) 2002-04-08 2003-10-20 Merck And Co., Inc. Method of treating cancer
JP4451136B2 (en) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Akt activity inhibitor
CA2491680C (en) 2002-07-02 2012-04-17 Southern Research Institute Inhibitors of ftsz and uses thereof
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
PL1636228T3 (en) * 2003-05-23 2009-04-30 Aeterna Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
DE10323345A1 (en) * 2003-05-23 2004-12-16 Zentaris Gmbh New pyridopyrazines and their use as kinase inhibitors
RU2327696C2 (en) * 2003-06-05 2008-06-27 Центарис Гмбх Indole derivatives, with stimulating apoptosis effect (alternatives), pharmaceutical compositions based on these derivatives
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
EP1694671A2 (en) 2003-12-04 2006-08-30 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
EP1790342A1 (en) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators

Also Published As

Publication number Publication date
KR101400905B1 (en) 2014-05-29
AU2006313701A1 (en) 2007-05-18
AU2006313701B2 (en) 2012-05-31
NO20082511L (en) 2008-06-24
AR060010A1 (en) 2008-05-21
HK1126474A1 (en) 2009-09-04
EP1957487A1 (en) 2008-08-20
CA2628039A1 (en) 2007-05-18
JP2009515853A (en) 2009-04-16
WO2007054556A1 (en) 2007-05-18
IL191139A0 (en) 2008-12-29
JP5527972B2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
KR101400905B1 (en) Novel pyridopyrazines and their use as modulators of kinases
US8217042B2 (en) Pyridopyrazines and their use as modulators of kinases
US11655246B2 (en) Aminothiazole compounds as inhibitors of CTPS1
JP7157791B2 (en) (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide as dipeptidyl peptidase 1 inhibitors
JP6997766B2 (en) Modulator of integrated stress pathway
JP6145179B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of Janus related kinase (JAK)
JP7337790B2 (en) Modulators of integrated stress pathways
JP6585158B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives useful for the inhibition of Janus kinase
JP2023078341A (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP2504336B1 (en) Novel naphthyridine derivatives and the use thereof as kinase inhibitors
JP2021523226A (en) RIP1 inhibitor compound and methods for producing and using it
JP2021523225A (en) RIP1 inhibitor compound and methods for producing and using it
CN101356173B (en) Novel pyridopyrazines and their use as modulators of kinases
JPWO2005047286A1 (en) Spiro heterocyclic compounds
JP2013533317A (en) Hepatitis C virus inhibitor
RU2009120229A (en) Quinuclidinol derivatives as antagonists of muscarinic receptors
CA2587360A1 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
JP2013515733A (en) Indolyl-piperidinylbenzylamine as a β-tryptase inhibitor
WO2021212039A1 (en) Inhibitors of cysteine proteases and methods of use thereof
RU2515944C2 (en) PYRIDOPYRAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING OR PREVENTING PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS BY INHIBITION OF ENZYMES ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34P (VERSIONS)
TWI392675B (en) Novel pyridopyrazines and the use thereof as kinase modulators
MX2008006066A (en) Novel pyridopyrazines and their use as modulators of kinases
KR20240038996A (en) Compounds and compositions for the treatment of coronavirus-related diseases
EA045207B1 (en) COMPOUNDS INHIBITING RIP1, AS WELL AS METHODS OF THEIR PREPARATION AND APPLICATION

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee